

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
17 October 2002 (17.10.2002)

PCT

(10) International Publication Number  
WO 02/081625 A2

(51) International Patent Classification <sup>7</sup> :	C12N	US	60/283,512 (CIP)
(21) International Application Number:	PCT/US02/10366	Filed on	12 April 2001 (12.04.2001)
(22) International Filing Date:	3 April 2002 (03.04.2002)	US	60/283,444 (CIP)
(25) Filing Language:	English	Filed on	12 April 2001 (12.04.2001)
(26) Publication Language:	English	US	60/283,657 (CIP)
(30) Priority Data:		Filed on	13 April 2001 (13.04.2001)
60/281,086	3 April 2001 (03.04.2001)	US	60/283,710 (CIP)
60/281,906	5 April 2001 (05.04.2001)	Filed on	13 April 2001 (13.04.2001)
60/282,020	6 April 2001 (06.04.2001)	US	60/283,678 (CIP)
60/282,930	10 April 2001 (10.04.2001)	Filed on	13 April 2001 (13.04.2001)
60/283,512	12 April 2001 (12.04.2001)	US	60/284,234 (CIP)
60/283,444	12 April 2001 (12.04.2001)	Filed on	17 April 2001 (17.04.2001)
60/283,657	13 April 2001 (13.04.2001)	US	60/285,325 (CIP)
60/283,710	13 April 2001 (13.04.2001)	Filed on	19 April 2001 (19.04.2001)
60/283,678	13 April 2001 (13.04.2001)	US	60/285,381 (CIP)
60/284,234	17 April 2001 (17.04.2001)	Filed on	20 April 2001 (20.04.2001)
60/285,325	19 April 2001 (19.04.2001)	US	60/286,068 (CIP)
60/285,381	20 April 2001 (20.04.2001)	Filed on	24 April 2001 (24.04.2001)
60/286,068	24 April 2001 (24.04.2001)	US	60/286,292 (CIP)
60/286,292	25 April 2001 (25.04.2001)	Filed on	25 April 2001 (25.04.2001)
60/296,692	7 June 2001 (07.06.2001)	US	60/296,692 (CIP)
60/300,883	26 June 2001 (26.06.2001)	Filed on	7 June 2001 (07.06.2001)
60/311,003	8 August 2001 (08.08.2001)	US	60/300,883 (CIP)
60/311,973	13 August 2001 (13.08.2001)	Filed on	26 June 2001 (26.06.2001)
60/312,901	16 August 2001 (16.08.2001)	US	60/311,003 (CIP)
60/322,283	14 September 2001 (14.09.2001)	Filed on	8 August 2001 (08.08.2001)
60/327,448	5 October 2001 (05.10.2001)	US	60/311,973 (CIP)
60/345,734	31 December 2001 (31.12.2001)	Filed on	13 August 2001 (13.08.2001)
60/345,755	3 January 2002 (03.01.2002)	US	60/312,901 (CIP)
60/354,391	4 February 2002 (04.02.2002)	Filed on	16 August 2001 (16.08.2001)
10/114,153	2 April 2002 (02.04.2002)	US	60/322,283 (CIP)
(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:		Filed on	14 September 2001 (14.09.2001)
US	60/281,086 (CIP)	US	60/327,448 (CIP)
Filed on	3 April 2001 (03.04.2001)	Filed on	5 October 2001 (05.10.2001)
US	60/281,906 (CIP)	US	60/345,755 (CIP)
Filed on	5 April 2001 (05.04.2001)	Filed on	3 January 2002 (03.01.2002)
US	60/282,020 (CIP)	US	60/354,391 (CIP)
Filed on	6 April 2001 (06.04.2001)	Filed on	2 February 2002 (02.02.2002)
US	60/282,930 (CIP)	US	Not furnished (CIP)
Filed on	10 April 2001 (10.04.2001)	Filed on	31 December 2001 (31.12.2001)
			Not furnished (CIP)
			2 April 2002 (02.04.2002)
(71) Applicant (for all designated States except US):	CURA-GEN CORPORATION [US/US]; 11th Floor, 555 Long Wharf Drive, New Haven, CT 06511 (US).		

[Continued on next page]

(54) Title: NOVEL ANTIBODIES THAT BIND TO ANTIGENIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING THE ANTIGENS, AND METHODS OF USE

(57) Abstract: Disclosed herein are nucleic acid sequences that encode polypeptides. Also disclosed are antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids, polypeptides, or antibodies, or fragments thereof.

WO 02/081625 A2



## (72) Inventors; and

(75) Inventors/Applicants (for US only): **PADIGARU, Muralidhara** [IN/US]; 71 Hampton Park, Branford, CT 06405 (US). **SHENOY, Suresh, G.** [IN/US]; 15 Millwood Drive, Branford, CT 06405 (US). **KEKUDA, Ramesh** [IN/US]; 1213 Avalon Valley Drive, Danbury, CT 06810 (US). **RASTELLI, Luca** [IT/US]; 52 Pepperbush Lane, Guilford, CT 06437 (US). **MEZES, Peter, D.** [CA/US]; 7 Clark's lane, Old Lyme, CT 06371 (US). **SMITHSON, Glenda** [US/US]; 125 Michael Drive, Guildford, CT 06435 (US). **GUO, Xiaojia** [CN/US]; 713 Robert Frost Drive, Branford, CT 06405 (US). **GERLACH, Valerie** [US/US]; 18 Rock Pasture Road, Branford, CT 06405 (US). **CASMAN, Stacie, J.** [US/US]; 17 Peck Street, North Haven, CT 06473 (US). **BOLDOG, Ferenc, L.** [HU/US]; 1687 Hartford Turnpike, North Haven, CT 06473 (US). **LI, Li** [CN/US]; 56 Jerimoth Drive, Branford, CT 06405 (US). **ZERHUSEN, Bryan, D.** [US/US]; 337 Monticello Drive, Branford, CT 06405 (US). **TCHERNEV, Velizar, T.** [BG/US]; 45 Jefferson Road #3-12, Branford, CT 06405 (US). **GANGOLLI, Esha, A.** [IN/US]; 31 Strawberry Hill Road, Madison, CT 06443 (US). **VERNET, Corine, A., M.** [FR/US]; 1739 Foxon Road, Apartment L6, Branford, CT 06471 (US). **SPYTEK, Kimberly, A.** [US/US]; 28 Court Street, Number 1, New Haven, CT 06511 (US). **MALYANKAR, Uriel, M.** [IN/US]; 229 Branford Road, Number 330, Branford, CT 06405 (US). **PATTURAJAN, Meera** [IN/US]; 45 Harrison Avenue, Apartment 1C, Branford, CT 06405 (US). **MILLER, Charles, E.** [US/US]; 98 Saddle Hill Drive, Guilford, CT 06437 (US). **TAUPIER, Raymond, J., Jr.** [US/US]; 34 Pardec Place Extension, East Haven, CT 06512 (US). **HEYES, Melvyn, P.** [GB/US]; 183 Townsend Avenue, Number 3, New Haven, CT 06512 (US). **JU, Jingfang** [US/US]; 391 Rosebud Lane, Orange, CT 06477 (US). **PEYMAN, John, A.** [US/US]; 336 West Rock Avenue, New Haven, CT 06515 (US). **CATTERTON, Elina** [FI/US]; 584 Boston Post Road, Madison, CT 06443 (US). **MACDOUGALL,**

**John, R.** [CA/US]; 117 Russell Street, Hamden, CT 06517 (US). **EDINGER, Shlomit, R.** [US/US]; 766 Edgewood Avenue, New Haven, CT 06515 (US). **STONE, David, J.** [US/US]; 223 Whitehorn Drive, Guilford, CT 06437 (US). **MAZUR, Ann** [US/US]; 35 Burr Road, Bloomfield, CT 06002 (US).

(74) Agent: **ELRIFI, Ivor, R.**; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GI, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

# **NOVEL ANTIBODIES THAT BIND TO ANTIGENIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING THE ANTIGENS, AND METHODS OF USE**

## **FIELD OF THE INVENTION**

5           The present invention relates to novel antibodies that bind immunospecifically to antigenic polypeptides, wherein the polypeptides have characteristic properties related to biochemical or physiological responses in a cell, a tissue, an organ or an organism. The novel polypeptides are gene products of novel genes, or are specified biologically active fragments or derivatives thereof. Methods of use of the antibodies encompass procedures for  
10   diagnostic and prognostic assay of the polypeptides, as well as methods of treating diverse pathological conditions.

## **BACKGROUND OF THE INVENTION**

          Eukaryotic cells are characterized by biochemical and physiological processes which under normal conditions are exquisitely balanced to achieve the preservation and propagation  
15   of the cells. When such cells are components of multicellular organisms such as vertebrates, or more particularly organisms such as mammals, the regulation of the biochemical and physiological processes involves intricate signaling pathways. Frequently, such signaling pathways involve extracellular signaling proteins, cellular receptors that bind the signaling proteins, and signal transducing components located within the cells.

20           Signaling proteins may be classified as endocrine effectors, paracrine effectors or autocrine effectors. Endocrine effectors are signaling molecules secreted by a given organ into the circulatory system, which are then transported to a distant target organ or tissue. The target cells include the receptors for the endocrine effector, and when the endocrine effector binds, a signaling cascade is induced. Paracrine effectors involve secreting cells and receptor  
25   cells in close proximity to each other, for example two different classes of cells in the same tissue or organ. One class of cells secretes the paracrine effector, which then reaches the second class of cells, for example by diffusion through the extracellular fluid. The second class of cells contains the receptors for the paracrine effector; binding of the effector results in induction of the signaling cascade that elicits the corresponding biochemical or  
30   physiological effect. Autocrine effectors are highly analogous to paracrine effectors, except that the same cell type that secretes the autocrine effector also contains the receptor. Thus the autocrine effector binds to receptors on the same cell, or on identical neighboring cells. The binding process then elicits the characteristic biochemical or physiological effect.

          Signaling processes may elicit a variety of effects on cells and tissues including by  
35   way of nonlimiting example induction of cell or tissue proliferation, suppression of growth or

proliferation, induction of differentiation or maturation of a cell or tissue, and suppression of differentiation or maturation of a cell or tissue.

Many pathological conditions involve dysregulation of expression of important effector proteins. In certain classes of pathologies the dysregulation is manifested as elevated or excessive synthesis and secretion of protein effectors. In a clinical setting a subject may be suspected of suffering from a condition brought on by elevated or excessive levels of a protein effector of interest.

Antibodies are multichain proteins that bind specifically to a given antigen, and bind poorly, or not at all, to substances deemed not to be cognate antigens. Antibodies are comprised of two short chains termed light chains and two long chains termed heavy chains. These chains are constituted of immunoglobulin domains, of which generally there are two classes: one variable domain per chain, one constant domain in light chains, and three or more constant domains in heavy chains. The antigen-specific portion of the immunoglobulin molecules resides in the variable domains; the variable domains of one light chain and one heavy chain associate with each other to generate the antigen-binding moiety. Antibodies that bind immunospecifically to a cognate or target antigen bind with high affinities. Accordingly, they are useful in assaying specifically for the presence of the antigen in a sample. In addition, they have the potential of inactivating the activity of the antigen.

Therefore there is a need to assay for the level of a protein effector of interest in a biological sample from such a subject, and to compare this level with that characteristic of a nonpathological condition. In particular, there is a need for such an assay based on the use of an antibody that binds immunospecifically to the antigen. There further is a need to inhibit the activity of the protein effector in cases where a pathological condition arises from elevated or excessive levels of the effector based on the use of an antibody that binds immunospecifically to the effector. Thus, there is a need for the antibody as a product of manufacture. There further is a need for a method of treatment of a pathological condition brought on by an elevated or excessive level of the protein effector of interest based on administering the antibody to the subject.

30

## SUMMARY OF THE INVENTION

The invention is based in part upon the discovery of nucleic acid sequences encoding novel polypeptides. The novel nucleic acids and polypeptides are referred to herein as NOVX, or NOV1, NOV2, NOV3, *etc.*, nucleic acids and polypeptides. These nucleic acids



and polypeptides, as well as derivatives, homologs, analogs and fragments thereof, will hereinafter be collectively designated as "NOVX" nucleic acid or polypeptide sequences.

In one aspect, the invention provides an isolated polypeptide comprising a mature form of a NOVX amino acid. The polypeptide can be, for example, a NOVX amino acid  
5 sequence or a variant of a NOVX amino acid sequence, wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed. The invention also includes fragments of any of NOVX polypeptides. In another aspect, the invention also includes an isolated nucleic acid that encodes a NOVX polypeptide, or a fragment, homolog, analog or  
10 derivative thereof.

Also included in the invention is a NOVX polypeptide that is a naturally occurring variant of a NOVX sequence. In one embodiment, the variant includes an amino acid sequence that is the translation of a nucleic acid sequence differing by a single nucleotide from a NOVX nucleic acid sequence. In another embodiment, the NOVX polypeptide is a  
15 variant polypeptide described therein, wherein any amino acid specified in the chosen sequence is changed to provide a conservative substitution.

In another aspect, invention provides a method for determining the presence or amount of the NOVX polypeptide in a sample by providing a sample; introducing the sample to an antibody that binds immunospecifically to the polypeptide; and determining the  
20 presence or amount of antibody bound to the NOVX polypeptide, thereby determining the presence or amount of the NOVX polypeptide in the sample.

In yet another aspect, the invention includes a method for determining the presence of or predisposition to a disease associated with altered levels of a NOVX polypeptide in a mammalian subject by measuring the level of expression of the polypeptide in a sample from  
25 the first mammalian subject; and comparing the amount of the polypeptide in the sample of the first step to the amount of the polypeptide present in a control sample from a second mammalian subject known not to have, or not to be predisposed to, the disease. An alteration in the expression level of the polypeptide in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.

30 In another aspect, the invention includes pharmaceutical compositions that include therapeutically- or prophylactically-effective amounts of a therapeutic and a pharmaceutically-acceptable carrier. The therapeutic can be, e.g., a NOVX nucleic acid, a NOVX polypeptide, or an antibody specific for a NOVX polypeptide. In a further aspect, the

invention includes, in one or more containers, a therapeutically- or prophylactically-effective amount of this pharmaceutical composition.

In still another aspect, the invention provides the use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a human disease that is associated with a NOVX polypeptide.

In a further aspect, the invention provides a method for modulating the activity of a NOVX polypeptide by contacting a cell sample expressing the NOVX polypeptide with antibody that binds the NOVX polypeptide in an amount sufficient to modulate the activity of the polypeptide.

The invention also includes an isolated nucleic acid that encodes a NOVX polypeptide, or a fragment, homolog, analog or derivative thereof. In a preferred embodiment, the nucleic acid molecule comprises the nucleotide sequence of a naturally occurring allelic nucleic acid variant. In another embodiment, the nucleic acid encodes a variant polypeptide, wherein the variant polypeptide has the polypeptide sequence of a naturally occurring polypeptide variant. In another embodiment, the nucleic acid molecule differs by a single nucleotide from a NOVX nucleic acid sequence. In one embodiment, the NOVX nucleic acid molecule hybridizes under stringent conditions to the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 46, or a complement of the nucleotide sequence. In one embodiment, the invention provides a nucleic acid molecule wherein the nucleic acid includes the nucleotide sequence of a naturally occurring allelic nucleic acid variant.

Also included in the invention is a vector containing one or more of the nucleic acids described herein, and a cell containing the vectors or nucleic acids described herein. The invention is also directed to host cells transformed with a vector comprising any of the nucleic acid molecules described above.

In yet another aspect, the invention provides for a method for determining the presence or amount of a nucleic acid molecule in a sample by contacting a sample with a probe that binds a NOVX nucleic acid and determining the amount of the probe that is bound to the NOVX nucleic acid. For example the NOVX nucleic may be a marker for cell or tissue type such as a cell or tissue type that is cancerous.

In yet a further aspect, the invention provides a method for determining the presence of or predisposition to a disease associated with altered levels of a nucleic acid molecule in a first mammalian subject, wherein an alteration in the level of the nucleic acid in the first

subject as compared to the control sample indicates the presence of or predisposition to the disease.

The invention further provides an antibody that binds immunospecifically to a NOVX polypeptide. The NOVX antibody may be monoclonal, humanized, or a fully human  
5 antibody. Preferably, the antibody has a dissociation constant for the binding of the NOVX polypeptide to the antibody less than  $1 \times 10^{-9}$  M. More preferably, the NOVX antibody neutralizes the activity of the NOVX polypeptide.

In a further aspect, the invention provides for the use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a human disease,  
10 associated with a NOVX polypeptide. Preferably the therapeutic is a NOVX antibody.

In yet a further aspect, the invention provides a method of treating or preventing a NOVX-associated disorder, a method of treating a pathological state in a mammal, and a method of treating or preventing a pathology associated with a polypeptide by administering a NOVX antibody to a subject in an amount sufficient to treat or prevent the disorder.

15 Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references  
20 mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

25

### DETAILED DESCRIPTION OF THE INVENTION

The present invention provides novel nucleotides and polypeptides encoded thereby. Included in the invention are the novel nucleic acid sequences, their encoded polypeptides, antibodies, and other related compounds. The sequences are collectively referred to herein as  
30 "NOVX nucleic acids" or "NOVX polynucleotides" and the corresponding encoded polypeptides are referred to as "NOVX polypeptides" or "NOVX proteins." Unless indicated otherwise, "NOVX" is meant to refer to any of the novel sequences disclosed herein. Table 1 provides a summary of the NOVX nucleic acids and their encoded polypeptides.

**TABLE 1. NOVX Polynucleotide and Polypeptide Sequences and Corresponding  
SEQ ID Numbers**

<b>NOVX Assignment</b>	<b>Internal Identification</b>	<b>SEQ ID NO (nucleic acid)</b>	<b>SEQ ID NO (polypeptide)</b>	<b>Homology</b>
1a	CG56258-01	1	2	Sodium/Calcium Exchanger
1b	CG56258-02	3	4	Sodium/Calcium Exchanger
1c	248057963	5	6	Sodium/Calcium Exchanger
2a	CG59843-01	7	8	Fibropellin III
3a	CG59845-01	9	10	Butyrophilin
4a	CG59871-01	11	12	CVB3 Binding Protein
5a	CG59883-01	13	14	CVB3 Binding Protein
6a	CG59901-01	15	16	Scavenger receptor
7a	CG88748-01	17	18	Cyclic Nucleotide-gated Channel Protein
8a	CG90021-01	19	20	Testicular Metalloprotease (Disintegrin)
9a	CG90709-01	21	22	Ion Transport Protein
9b	CG90709-02	23	24	Ion Transport Protein
9c	CG90709-03	25	26	Ion Transport Protein
9d	CG90709-04	27	28	Ion Transport Protein
10a	CG90739-01	29	30	Neuronal Thread Protein
10b	172390256	31	32	Neuronal Thread Protein
10c	172390440	33	34	Neuronal Thread Protein
10d	172390569	35	36	Neuronal Thread Protein
10e	172390587	37	38	Neuronal Thread Protein
10f	172390603	39	40	Neuronal Thread Protein
10g	172390624	41	42	Neuronal Thread Protein
10h	172390644	43	44	Neuronal Thread Protein
11a	CG91667-01	45	46	Delta-like Homology (dlk1)
11b	CG91667-02	47	48	Delta-like Homology (dlk1)
12a	CG92293-01	49	50	Polyprotein (ovochymase)
12b	CG92293-02	51	52	Polyprotein (ovochymase)
13a	CG92384-01	53	54	Long type PB-Cadherin
14a	CG92455-01	55	56	IGFBP
15a	CG92531-01	57	58	Leucine Rich
16a	CG92715-01	59	60	KIAA0918
16b	CG92715-02	61	62	Leucine Rich Repeat
17a	CG92813-01	63	64	Cadherin Related Tumor Suppressor Precursor
18a	CG92844-01	65	66	Thyroid Hormone Induced Protein B Precursor
18b	174308357	67	68	Thyroid Hormone Induced Protein B Precursor
19a	CG93088-01	69	70	Monocarboxylate Transporter
20a	CG93335-01	71	72	Putative Type II Membrane
21a	CG93345-01	73	74	GPCR
22a	CG93400-01	75	76	GPCR
23a	CG93410-01	77	78	Glutamate Receptor 5 Precursor
23b	188822752	79	80	Glutamate Receptor 5 Precursor
24a	CG93722-01	81	82	Hepsin
25a	CG93858-01	83	84	Fibullin
25b	CG93858-02	85	86	Fibullin
25c	CG56914-03	87	88	Fibullin
26a	CG93871-01	89	90	Fibullin

27a	CG93884-01	91	92	Monocyte Inhibitory Receptor
-----	------------	----	----	------------------------------

Table 1 indicates the homology of NOVX polypeptides to known protein families. Thus, the nucleic acids and polypeptides, antibodies and related compounds according to the invention corresponding to a NOVX as identified in column 1 of Table 1 will be useful in  
5 therapeutic and diagnostic applications implicated in, for example, pathologies and disorders associated with the known protein families identified in column 5 of Table 1.

NOVX nucleic acids and their encoded polypeptides are useful in a variety of applications and contexts. The various NOVX nucleic acids and polypeptides according to the invention are useful as novel members of the protein families according to the presence of  
10 domains and sequence relatedness to previously described proteins. Additionally, NOVX nucleic acids and polypeptides can also be used to identify proteins that are members of the family to which the NOVX polypeptides belong.

Consistent with other known members of the family of proteins, identified in column 5 of Table 1, the NOVX polypeptides of the present invention show homology to, and  
15 contain domains that are characteristic of, other members of such protein families. Details of the sequence relatedness and domain analysis for each NOVX are presented in Example A.

The NOVX nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOVX activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small  
20 molecules that modulate or inhibit diseases associated with the protein families listed in Table 1.

The NOVX nucleic acids and polypeptides are also useful for detecting specific cell types. Details of the expression analysis for each NOVX are presented in Example B. Accordingly, the NOVX nucleic acids, polypeptides, antibodies and related compounds  
25 according to the invention will have diagnostic and therapeutic applications in the detection of a variety of diseases with differential expression in normal vs. diseased tissues, *e.g.* detection of a variety of cancers.

Additional utilities for NOVX nucleic acids and polypeptides according to the invention are disclosed herein.

**NOVX clones**

NOVX nucleic acids and their encoded polypeptides are useful in a variety of applications and contexts. The various NOVX nucleic acids and polypeptides according to the invention are useful as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. Additionally, NOVX nucleic acids and polypeptides can also be used to identify proteins that are members of the family to which the NOVX polypeptides belong.

The NOVX genes and their corresponding encoded proteins are useful for preventing, treating or ameliorating medical conditions, *e.g.*, by protein or gene therapy. Pathological conditions can be diagnosed by determining the amount of the new protein in a sample or by determining the presence of mutations in the new genes. Specific uses are described for each of the NOVX genes, based on the tissues in which they are most highly expressed. Uses include developing products for the diagnosis or treatment of a variety of diseases and disorders.

The NOVX nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications and as research tools. These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration *in vitro* and *in vivo* (vi) a biological defense weapon.

In one specific embodiment, the invention includes an isolated polypeptide comprising an amino acid sequence selected from the group consisting of: (a) a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 46; (b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 46, wherein any amino acid in the mature form is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed; (c) an amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 46; (d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 46

wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; and (e) a fragment of any of (a) through (d).

In another specific embodiment, the invention includes an isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of: (a) a mature form of the amino acid sequence given SEQ ID NO: 2n, wherein n is an integer between 1 and 46; (b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 46 wherein any amino acid in the mature form of the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed; (c) the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 46; (d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 46, in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; (e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 46 or any variant of said polypeptide wherein any amino acid of the chosen sequence is changed to a different amino acid, provided that no more than 10% of the amino acid residues in the sequence are so changed; and (f) the complement of any of said nucleic acid molecules.

In yet another specific embodiment, the invention includes an isolated nucleic acid molecule, wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of: (a) the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 46; (b) a nucleotide sequence wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 46 is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed; (c) a nucleic acid fragment of the sequence selected from the group consisting of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 46; and (d) a nucleic acid fragment wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 101 is changed from that selected from the

group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed.

### NOVX Nucleic Acids and Polypeptides

One aspect of the invention pertains to isolated nucleic acid molecules that encode NOVX polypeptides or biologically active portions thereof. Also included in the invention are nucleic acid fragments sufficient for use as hybridization probes to identify NOVX-encoding nucleic acids (*e.g.*, NOVX mRNA's) and fragments for use as PCR primers for the amplification and/or mutation of NOVX nucleic acid molecules. As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (*e.g.*, cDNA or genomic DNA), RNA molecules (*e.g.*, mRNA), analogs of the DNA or RNA generated using nucleotide analogs, and derivatives, fragments and homologs thereof. The nucleic acid molecule may be single-stranded or double-stranded, but preferably is comprised double-stranded DNA.

A NOVX nucleic acid can encode a mature NOVX polypeptide. As used herein, a "mature" form of a polypeptide or protein disclosed in the present invention is the product of a naturally occurring polypeptide or precursor form or proprotein. The naturally occurring polypeptide, precursor or proprotein includes, by way of nonlimiting example, the full-length gene product encoded by the corresponding gene. Alternatively, it may be defined as the polypeptide, precursor or proprotein encoded by an ORF described herein. The product "mature" form arises, again by way of nonlimiting example, as a result of one or more naturally occurring processing steps as they may take place within the cell, or host cell, in which the gene product arises. Examples of such processing steps leading to a "mature" form of a polypeptide or protein include the cleavage of the N-terminal methionine residue encoded by the initiation codon of an ORF, or the proteolytic cleavage of a signal peptide or leader sequence. Thus a mature form arising from a precursor polypeptide or protein that has residues 1 to N, where residue 1 is the N-terminal methionine, would have residues 2 through N remaining after removal of the N-terminal methionine. Alternatively, a mature form arising from a precursor polypeptide or protein having residues 1 to N, in which an N-terminal signal sequence from residue 1 to residue M is cleaved, would have the residues from residue M+1 to residue N remaining. Further as used herein, a "mature" form of a polypeptide or protein may arise from a step of post-translational modification other than a proteolytic cleavage event. Such additional processes include, by way of non-limiting example, glycosylation, myristylation or phosphorylation. In general, a mature polypeptide



or protein may result from the operation of only one of these processes, or a combination of any of them.

The term "probes", as utilized herein, refers to nucleic acid sequences of variable length, preferably between at least about 10 nucleotides (nt), 100 nt, or as many as approximately, *e.g.*, 6,000 nt, depending upon the specific use. Probes are used in the detection of identical, similar, or complementary nucleic acid sequences. Longer length probes are generally obtained from a natural or recombinant source, are highly specific, and much slower to hybridize than shorter-length oligomer probes. Probes may be single- or double-stranded and designed to have specificity in PCR, membrane-based hybridization technologies, or ELISA-like technologies.

The term "isolated" nucleic acid molecule, as utilized herein, is one, which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (*i.e.*, sequences located at the 5'- and 3'-termini of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated NOVX nucleic acid molecules can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell/tissue from which the nucleic acid is derived (*e.g.*, brain, heart, liver, spleen, *etc.*). Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material or culture medium when produced by recombinant techniques, or of chemical precursors or other chemicals when chemically synthesized.

A nucleic acid molecule of the invention, *e.g.*, a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:2*n*-1, wherein *n* is an integer between 1-46, or a complement of this aforementioned nucleotide sequence, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or a portion of the nucleic acid sequence of SEQ ID NO:2*n*-1, wherein *n* is an integer between 1-46, as a hybridization probe, NOVX molecules can be isolated using standard hybridization and cloning techniques (*e.g.*, as described in Sambrook, *et al.*, (eds.), MOLECULAR CLONING: A LABORATORY MANUAL 2<sup>nd</sup> Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989; and Ausubel, *et al.*, (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993.)

A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard

PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to NOVX nucleotide sequences can be prepared by standard synthetic techniques, *e.g.*, using an automated DNA synthesizer.

- 5 As used herein, the term "oligonucleotide" refers to a series of linked nucleotide residues, which oligonucleotide has a sufficient number of nucleotide bases to be used in a PCR reaction. A short oligonucleotide sequence may be based on, or designed from, a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue.
- 10 Oligonucleotides comprise portions of a nucleic acid sequence having about 10 nt, 50 nt, or 100 nt in length, preferably about 15 nt to 30 nt in length. In one embodiment of the invention, an oligonucleotide comprising a nucleic acid molecule less than 100 nt in length would further comprise at least 6 contiguous nucleotides of SEQ ID NO:2*n*-1, wherein *n* is an integer between 1-46, or a complement thereof. Oligonucleotides may be chemically
- 15 synthesized and may also be used as probes.

- In another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide sequence SEQ ID NO:2*n*-1, wherein *n* is an integer between 1-46, or a portion of this nucleotide sequence (*e.g.*, a fragment that can be used as a probe or primer or a fragment encoding a biologically-active
- 20 portion of a NOVX polypeptide). A nucleic acid molecule that is complementary to the nucleotide sequence of SEQ ID NO:2*n*-1, wherein *n* is an integer between 1-46, is one that is sufficiently complementary to the nucleotide sequence of SEQ ID NO:2*n*-1, wherein *n* is an integer between 1-46, that it can hydrogen bond with little or no mismatches to the nucleotide sequence of SEQ ID NO:2*n*-1, wherein *n* is an integer between 1-46, thereby forming a stable
- 25 duplex.

- As used herein, the term "complementary" refers to Watson-Crick or Hoogsteen base pairing between nucleotides units of a nucleic acid molecule, and the term "binding" means the physical or chemical interaction between two polypeptides or compounds or associated
- 30 polypeptides or compounds or combinations thereof. Binding includes ionic, non-ionic, van der Waals, hydrophobic interactions, and the like. A physical interaction can be either direct or indirect. Indirect interactions may be through or due to the effects of another polypeptide or compound. Direct binding refers to interactions that do not take place through, or due to, the effect of another polypeptide or compound, but instead are without other substantial chemical intermediates.

Fragments provided herein are defined as sequences of at least 6 (contiguous) nucleic acids or at least 4 (contiguous) amino acids, a length sufficient to allow for specific hybridization in the case of nucleic acids or for specific recognition of an epitope in the case of amino acids, respectively, and are at most some portion less than a full length sequence.

- 5 Fragments may be derived from any contiguous portion of a nucleic acid or amino acid sequence of choice. Derivatives are nucleic acid sequences or amino acid sequences formed from the native compounds either directly or by modification or partial substitution. Analogs are nucleic acid sequences or amino acid sequences that have a structure similar to, but not identical to, the native compound but differs from it in respect to certain components or side
- 10 chains. Analogs may be synthetic or from a different evolutionary origin and may have a similar or opposite metabolic activity compared to wild type. Homologs are nucleic acid sequences or amino acid sequences of a particular gene that are derived from different species.

- A full-length NOVX clone is identified as containing an ATG translation start codon
- 15 and an in-frame stop codon. Any disclosed NOVX nucleotide sequence lacking an ATG start codon therefore encodes a truncated C-terminal fragment of the respective NOVX polypeptide, and requires that the corresponding full-length cDNA extend in the 5' direction of the disclosed sequence. Any disclosed NOVX nucleotide sequence lacking an in-frame stop codon similarly encodes a truncated N-terminal fragment of the respective NOVX
- 20 polypeptide, and requires that the corresponding full-length cDNA extend in the 3' direction of the disclosed sequence.

- Derivatives and analogs may be full length or other than full length, if the derivative or analog contains a modified nucleic acid or amino acid, as described below. Derivatives or analogs of the nucleic acids or proteins of the invention include, but are not limited to,
- 25 molecules comprising regions that are substantially homologous to the nucleic acids or proteins of the invention, in various embodiments, by at least about 70%, 80%, or 95% identity (with a preferred identity of 80-95%) over a nucleic acid or amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art, or whose encoding nucleic acid is capable of
- 30 hybridizing to the complement of a sequence encoding the aforementioned proteins under stringent, moderately stringent, or low stringent conditions. *See e.g.* Ausubel, *et al.*, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993, and below.

A "homologous nucleic acid sequence" or "homologous amino acid sequence," or variations thereof, refer to sequences characterized by a homology at the nucleotide level or amino acid level as discussed above. Homologous nucleotide sequences encode those sequences coding for isoforms of NOVX polypeptides. Isoforms can be expressed in  
5 different tissues of the same organism as a result of, for example, alternative splicing of RNA. Alternatively, isoforms can be encoded by different genes. In the invention, homologous nucleotide sequences include nucleotide sequences encoding for a NOVX polypeptide of species other than humans, including, but not limited to: vertebrates, and thus can include, *e.g.*, frog, mouse, rat, rabbit, dog, cat, cow, horse, and other organisms.  
10 Homologous nucleotide sequences also include, but are not limited to, naturally occurring allelic variations and mutations of the nucleotide sequences set forth herein. A homologous nucleotide sequence does not, however, include the exact nucleotide sequence encoding human NOVX protein. Homologous nucleic acid sequences include those nucleic acid sequences that encode conservative amino acid substitutions (see below) in SEQ ID NO:2*n*-1,  
15 wherein *n* is an integer between 1-46, as well as a polypeptide possessing NOVX biological activity. Various biological activities of the NOVX proteins are described below.

A NOVX polypeptide is encoded by the open reading frame ("ORF") of a NOVX nucleic acid. An ORF corresponds to a nucleotide sequence that could potentially be translated into a polypeptide. A stretch of nucleic acids comprising an ORF is uninterrupted  
20 by a stop codon. An ORF that represents the coding sequence for a full protein begins with an ATG "start" codon and terminates with one of the three "stop" codons, namely, TAA, TAG, or TGA. For the purposes of this invention, an ORF may be any part of a coding sequence, with or without a start codon, a stop codon, or both. For an ORF to be considered as a good candidate for coding for a *bona fide* cellular protein, a minimum size requirement is  
25 often set, *e.g.*, a stretch of DNA that would encode a protein of 50 amino acids or more.

The nucleotide sequences determined from the cloning of the human NOVX genes allows for the generation of probes and primers designed for use in identifying and/or cloning NOVX homologues in other cell types, *e.g.* from other tissues, as well as NOVX homologues from other vertebrates. The probe/primer typically comprises substantially purified  
30 oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 25, 50, 100, 150, 200, 250, 300, 350 or 400 consecutive sense strand nucleotide sequence of SEQ ID NO:2*n*-1, wherein *n* is an integer between 1-46; or an anti-sense strand nucleotide sequence of SEQ ID NO:2*n*-1;

wherein  $n$  is an integer between 1-46; or of a naturally occurring mutant of SEQ ID NO:2 $n$ -1, wherein  $n$  is an integer between 1-46.

Probes based on the human NOVX nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In various  
5       embodiments, the probe further comprises a label group attached thereto, *e.g.* the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissues which mis-express a NOVX protein, such as by measuring a level of a NOVX-encoding nucleic acid in a sample of cells from a subject *e.g.*, detecting NOVX mRNA levels or determining whether a  
10       genomic NOVX gene has been mutated or deleted.

"A polypeptide having a biologically-active portion of a NOVX polypeptide" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. A nucleic acid fragment encoding a "biologically-  
15       active portion of NOVX" can be prepared by isolating a portion of SEQ ID NO:2 $n$ -1, wherein  $n$  is an integer between 1-46, that encodes a polypeptide having a NOVX biological activity (the biological activities of the NOVX proteins are described below), expressing the encoded portion of NOVX protein (*e.g.*, by recombinant expression *in vitro*) and assessing the activity of the encoded portion of NOVX.

## 20       NOVX Nucleic Acid and Polypeptide Variants

The invention further encompasses nucleic acid molecules that differ from the nucleotide sequences of SEQ ID NO:2 $n$ -1, wherein  $n$  is an integer between 1-46, due to degeneracy of the genetic code and thus encode the same NOVX proteins as that encoded by the nucleotide sequences of SEQ ID NO:2 $n$ -1, wherein  $n$  is an integer between 1-46. In  
25       another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence of SEQ ID NO:2 $n$ , wherein  $n$  is an integer between 1-46.

In addition to the human NOVX nucleotide sequences of SEQ ID NO:2 $n$ -1, wherein  $n$  is an integer between 1-46, it will be appreciated by those skilled in the art that DNA  
30       sequence polymorphisms that lead to changes in the amino acid sequences of the NOVX polypeptides may exist within a population (*e.g.*, the human population). Such genetic polymorphism in the NOVX genes may exist among individuals within a population due to natural allelic variation. As used herein, the terms "gene" and "recombinant gene" refer to

nucleic acid molecules comprising an open reading frame (ORF) encoding a NOVX protein, preferably a vertebrate NOVX protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the NOVX genes. Any and all such nucleotide variations and resulting amino acid polymorphisms in the NOVX polypeptides, which are the result of natural allelic variation and that do not alter the functional activity of the NOVX polypeptides, are intended to be within the scope of the invention.

Moreover, nucleic acid molecules encoding NOVX proteins from other species, and thus that have a nucleotide sequence that differs from any one of the human SEQ ID NO:2 $n$ -1, wherein  $n$  is an integer between 1-46, are intended to be within the scope of the invention.

Nucleic acid molecules corresponding to natural allelic variants and homologues of the NOVX cDNAs of the invention can be isolated based on their homology to the human NOVX nucleic acids disclosed herein using the human cDNAs, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.

Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 6 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:2 $n$ -1, wherein  $n$  is an integer between 1-46. In another embodiment, the nucleic acid is at least 10, 25, 50, 100, 250, 500, 750, 1000, 1500, or 2000 or more nucleotides in length. In yet another embodiment, an isolated nucleic acid molecule of the invention hybridizes to the coding region. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other.

Homologs (*i.e.*, nucleic acids encoding NOVX proteins derived from species other than human) or other related sequences (*e.g.*, paralogs) can be obtained by low, moderate or high stringency hybridization with all or a portion of the particular human sequence as a probe using methods well known in the art for nucleic acid hybridization and cloning.

As used herein, the phrase "stringent hybridization conditions" refers to conditions under which a probe, primer or oligonucleotide will hybridize to its target sequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter sequences. Generally, stringent conditions are selected to be about 5 °C lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength and pH. The  $T_m$  is the temperature (under defined ionic strength, pH and nucleic acid concentration) at

which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present at excess, at  $T_m$ , 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30 °C for short probes, primers or oligonucleotides (*e.g.*, 10 nt to 50 nt) and at least about 60 °C for longer probes, primers and oligonucleotides. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.

Stringent conditions are known to those skilled in the art and can be found in Ausubel, *et al.*, (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. Preferably, the conditions are such that sequences at least about 65%, 70%, 75%, 85%, 90%, 95%, 98%, or 99% homologous to each other typically remain hybridized to each other. A non-limiting example of stringent hybridization conditions are hybridization in a high salt buffer comprising 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65 °C, followed by one or more washes in 0.2X SSC, 0.01% BSA at 50 °C. An isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to any one of the sequences of SEQ ID NO:2*n*-1, wherein *n* is an integer between 1-46, corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (*e.g.*, encodes a natural protein).

In a second embodiment, a nucleic acid sequence that is hybridizable to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:2*n*-1, wherein *n* is an integer between 1-46, or fragments, analogs or derivatives thereof, under conditions of moderate stringency is provided. A non-limiting example of moderate stringency hybridization conditions are hybridization in 6X SSC, 5X Reinhardt's solution, 0.5% SDS and 100 mg/ml denatured salmon sperm DNA at 55 °C, followed by one or more washes in 1X SSC, 0.1% SDS at 37 °C. Other conditions of moderate stringency that may be used are well-known within the art. *See, e.g.*, Ausubel, *et al.* (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Krieger, 1990; GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY.

In a third embodiment, a nucleic acid that is hybridizable to the nucleic acid molecule comprising the nucleotide sequences of SEQ ID NO:2*n*-1, wherein *n* is an integer between 1-46, or fragments, analogs or derivatives thereof, under conditions of low stringency, is

provided. A non-limiting example of low stringency hybridization conditions are hybridization in 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 mg/ml denatured salmon sperm DNA, 10% (wt/vol) dextran sulfate at 40 °C, followed by one or more washes in 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS at 50 °C. Other conditions of low stringency that may be used are well known in the art (e.g., as employed for cross-species hybridizations). See, e.g., Ausubel, *et al.* (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY; Shilo and Weinberg, 1981. *Proc Natl Acad Sci USA* 78: 6789-6792.

10

### Conservative Mutations

In addition to naturally-occurring allelic variants of NOVX sequences that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences of SEQ ID NO:2*n*-1, wherein *n* is an integer between 1-46, thereby leading to changes in the amino acid sequences of the encoded NOVX proteins, without altering the functional ability of said NOVX proteins. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequence of SEQ ID NO:2*n*, wherein *n* is an integer between 1-46. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequences of the NOVX proteins without altering their biological activity, whereas an "essential" amino acid residue is required for such biological activity. For example, amino acid residues that are conserved among the NOVX proteins of the invention are particularly non-amenable to alteration. Amino acids for which conservative substitutions can be made are well-known within the art.

25

Another aspect of the invention pertains to nucleic acid molecules encoding NOVX proteins that contain changes in amino acid residues that are not essential for activity. Such NOVX proteins differ in amino acid sequence from any one of SEQ ID NO:2*n*-1, wherein *n* is an integer between 1-46, yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 45% homologous to the amino acid sequences of SEQ ID NO:2*n*, wherein *n* is an integer between 1-46. Preferably, the protein encoded by the nucleic acid molecule is at least about 60% homologous to SEQ ID NO:2*n*, wherein *n* is an integer between 1-46; more preferably at least about 70% homologous to SEQ ID NO:2*n*, wherein *n* is an integer between 1-46; still more preferably at least about

30



80% homologous to SEQ ID NO:2 $n$ , wherein  $n$  is an integer between 1-46; even more preferably at least about 90% homologous to SEQ ID NO:2 $n$ , wherein  $n$  is an integer between 1-46; and most preferably at least about 95% homologous to SEQ ID NO:2 $n$ , wherein  $n$  is an integer between 1-46.

5        An isolated nucleic acid molecule encoding a NOVX protein homologous to the protein of SEQ ID NO:2 $n$ , wherein  $n$  is an integer between 1-46, can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO:2 $n$ -1, wherein  $n$  is an integer between 1-46, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein.

10        Mutations can be introduced into any of SEQ ID NO:2 $n$ -1, wherein  $n$  is an integer between 1-46, by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted, non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side  
15 chain. Families of amino acid residues having similar side chains have been defined within the art. These families include amino acids with basic side chains (*e.g.*, lysine, arginine, histidine), acidic side chains (*e.g.*, aspartic acid, glutamic acid), uncharged polar side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (*e.g.*, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine,  
20 tryptophan), beta-branched side chains (*e.g.*, threonine, valine, isoleucine) and aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted non-essential amino acid residue in the NOVX protein is replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a NOVX coding sequence, such as by saturation mutagenesis,  
25 and the resultant mutants can be screened for NOVX biological activity to identify mutants that retain activity. Following mutagenesis of any one of SEQ ID NO:2 $n$ -1, wherein  $n$  is an integer between 1-46, the encoded protein can be expressed by any recombinant technology known in the art and the activity of the protein can be determined.

30        The relatedness of amino acid families may also be determined based on side chain interactions. Substituted amino acids may be fully conserved "strong" residues or fully conserved "weak" residues. The "strong" group of conserved amino acid residues may be any one of the following groups: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW, wherein the single letter amino acid codes are grouped by those amino acids that may be substituted for each other. Likewise, the "weak" group of conserved residues may be any

one of the following: CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK, NDEQHK, NEQHRK, HFY, wherein the letters within each group represent the single letter amino acid code.

5 In one embodiment, a mutant NOVX protein can be assayed for (i) the ability to form protein:protein interactions with other NOVX proteins, other cell-surface proteins, or biologically-active portions thereof, (ii) complex formation between a mutant NOVX protein and a NOVX ligand; or (iii) the ability of a mutant NOVX protein to bind to an intracellular target protein or biologically-active portion thereof; (*e.g.* avidin proteins).

10 In yet another embodiment, a mutant NOVX protein can be assayed for the ability to regulate a specific biological function (*e.g.*, regulation of insulin release).

#### Antisense Nucleic Acids

Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:2*n*-1, wherein *n* is an integer between 1-46, or fragments, 15 analogs or derivatives thereof. An "antisense" nucleic acid comprises a nucleotide sequence that is complementary to a "sense" nucleic acid encoding a protein (*e.g.*, complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence). In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire 20 NOVX coding strand, or to only a portion thereof. Nucleic acid molecules encoding fragments, homologs, derivatives and analogs of a NOVX protein of SEQ ID NO:2*n*, wherein *n* is an integer between 1-46, or antisense nucleic acids complementary to a NOVX nucleic acid sequence of SEQ ID NO:2*n*-1, wherein *n* is an integer between 1-46, are additionally provided.

25 In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding a NOVX protein. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues. In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence 30 encoding the NOVX protein. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (*i.e.*, also referred to as 5' and 3' untranslated regions).

Given the coding strand sequences encoding the NOVX protein disclosed herein, antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of NOVX mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of NOVX mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of NOVX mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally-occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids (e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used).

Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (*i.e.*, RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a NOVX protein to thereby inhibit expression of the protein (e.g., by

inhibiting transcription and/or translation). The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface (e.g., by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens). The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient nucleic acid molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an  $\alpha$ -anomeric nucleic acid molecule. An  $\alpha$ -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual  $\beta$ -units, the strands run parallel to each other. See, e.g., Gaultier, *et al.*, 1987. *Nucl. Acids Res.* **15**: 6625-6641. The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (See, e.g., Inoue, *et al.* 1987. *Nucl. Acids Res.* **15**: 6131-6148) or a chimeric RNA-DNA analogue (See, e.g., Inoue, *et al.*, 1987. *FEBS Lett.* **215**: 327-330).

### **Ribozymes and PNA Moieties**

Nucleic acid modifications include, by way of non-limiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject.

In one embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes as described in Haselhoff and Gerlach 1988. *Nature* **334**: 585-591) can be used to catalytically cleave NOVX mRNA transcripts to thereby inhibit translation of NOVX mRNA. A ribozyme having

specificity for a NOVX-encoding nucleic acid can be designed based upon the nucleotide sequence of a NOVX cDNA disclosed herein (*i.e.*, any one of SEQ ID NO:2*n*-1, wherein *n* is an integer between 1-46). For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a NOVX-encoding mRNA. *See, e.g.*, U.S. Patent 4,987,071 to Cech, *et al.* and U.S. Patent 5,116,742 to Cech, *et al.* NOVX mRNA can also be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. *See, e.g.*, Bartel *et al.*, (1993) *Science* 261:1411-1418.

Alternatively, NOVX gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the NOVX nucleic acid (*e.g.*, the NOVX promoter and/or enhancers) to form triple helical structures that prevent transcription of the NOVX gene in target cells. *See, e.g.*, Helene, 1991. *Anticancer Drug Des.* 6: 569-84; Helene, *et al.* 1992. *Ann. N.Y. Acad. Sci.* 660: 27-36; Maher, 1992. *Bioassays* 14: 807-15.

In various embodiments, the NOVX nucleic acids can be modified at the base moiety, sugar moiety or phosphate backbone to improve, *e.g.*, the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids. *See, e.g.*, Hyrup, *et al.*, 1996. *Bioorg Med Chem* 4: 5-23. As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics (*e.g.*, DNA mimics) in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleotide bases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomer can be performed using standard solid phase peptide synthesis protocols as described in Hyrup, *et al.*, 1996. *supra*; Perry-O'Keefe, *et al.*, 1996. *Proc. Natl. Acad. Sci. USA* 93: 14670-14675.

PNAs of NOVX can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, *e.g.*, inducing transcription or translation arrest or inhibiting replication. PNAs of NOVX can also be used, for example, in the analysis of single base pair mutations in a gene (*e.g.*, PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, *e.g.*, S<sub>1</sub> nucleases (*See*, Hyrup, *et al.*, 1996. *supra*); or as probes or primers for DNA sequence and hybridization (*See*, Hyrup, *et al.*, 1996, *supra*; Perry-O'Keefe, *et al.*, 1996. *supra*).

In another embodiment, PNAs of NOVX can be modified, *e.g.*, to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the

formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of NOVX can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes (e.g., RNase H and DNA polymerases) to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleotide bases, and orientation (see, Hyrup, et al., 1996. *supra*). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup, et al., 1996. *supra* and Finn, et al., 1996. *Nucl Acids Res* 24: 3357-3363. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, e.g., 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5' end of DNA. See, e.g., Mag, et al., 1989. *Nucl Acid Res* 17: 5973-5988. PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment. See, e.g., Finn, et al., 1996. *supra*. Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment. See, e.g., Petersen, et al., 1975. *Bioorg. Med. Chem. Lett.* 5: 1119-11124.

In other embodiments, the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, e.g., Letsinger, et al., 1989. *Proc. Natl. Acad. Sci. U.S.A.* 86: 6553-6556; Lemaitre, et al., 1987. *Proc. Natl. Acad. Sci.* 84: 648-652; PCT Publication No. WO88/09810) or the blood-brain barrier (see, e.g., PCT Publication No. WO 89/10134). In addition, oligonucleotides can be modified with hybridization triggered cleavage agents (see, e.g., Krol, et al., 1988. *BioTechniques* 6:958-976) or intercalating agents (see, e.g., Zon, 1988. *Pharm. Res.* 5: 539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, and the like.

### NOVX Polypeptides

A polypeptide according to the invention includes a polypeptide including the amino acid sequence of NOVX polypeptides whose sequences are provided in any one of SEQ ID NO:2*n*, wherein *n* is an integer between 1-46. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residues shown in any one of SEQ ID NO:2*n*, wherein *n* is an integer between 1-46, while still encoding a protein

that maintains its NOVX activities and physiological functions, or a functional fragment thereof.

In general, a NOVX variant that preserves NOVX-like function includes any variant in which residues at a particular position in the sequence have been substituted by other amino acids, and further include the possibility of inserting an additional residue or residues between two residues of the parent protein as well as the possibility of deleting one or more residues from the parent sequence. Any amino acid substitution, insertion, or deletion is encompassed by the invention. In favorable circumstances, the substitution is a conservative substitution as defined above.

One aspect of the invention pertains to isolated NOVX proteins, and biologically-active portions thereof, or derivatives, fragments, analogs or homologs thereof. Also provided are polypeptide fragments suitable for use as immunogens to raise anti-NOVX antibodies. In one embodiment, native NOVX proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, NOVX proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, a NOVX protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

An "isolated" or "purified" polypeptide or protein or biologically-active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the NOVX protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of NOVX proteins in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly-produced. In one embodiment, the language "substantially free of cellular material" includes preparations of NOVX proteins having less than about 30% (by dry weight) of non-NOVX proteins (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-NOVX proteins, still more preferably less than about 10% of non-NOVX proteins, and most preferably less than about 5% of non-NOVX proteins. When the NOVX protein or biologically-active portion thereof is recombinantly-produced, it is also preferably substantially free of culture medium, *i.e.*, culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the NOVX protein preparation.

The language "substantially free of chemical precursors or other chemicals" includes preparations of NOVX proteins in which the protein is separated from chemical precursors or

other chemicals that are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of NOVX proteins having less than about 30% (by dry weight) of chemical precursors or non-NOVX chemicals, more preferably less than about 20% chemical precursors or non-NOVX chemicals, still more preferably less than about 10% chemical precursors or non-NOVX chemicals, and most preferably less than about 5% chemical precursors or non-NOVX chemicals.

Biologically-active portions of NOVX proteins include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequences of the NOVX proteins (*e.g.*, the amino acid sequence of SEQ ID NO:2*n*, wherein *n* is an integer between 1-46) that include fewer amino acids than the full-length NOVX proteins, and exhibit at least one activity of a NOVX protein. Typically, biologically-active portions comprise a domain or motif with at least one activity of the NOVX protein. A biologically-active portion of a NOVX protein can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acid residues in length.

Moreover, other biologically-active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native NOVX protein.

In an embodiment, the NOVX protein has an amino acid sequence of SEQ ID NO:2*n*, wherein *n* is an integer between 1-46. In other embodiments, the NOVX protein is substantially homologous to SEQ ID NO:2*n*, wherein *n* is an integer between 1-46, and retains the functional activity of the protein of SEQ ID NO:2*n*, wherein *n* is an integer between 1-46, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail, below. Accordingly, in another embodiment, the NOVX protein is a protein that comprises an amino acid sequence at least about 45% homologous to the amino acid sequence of SEQ ID NO:2*n*, wherein *n* is an integer between 1-46, and retains the functional activity of the NOVX proteins of SEQ ID NO:2*n*, wherein *n* is an integer between 1-46.

### **Determining Homology Between Two or More Sequences**

To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or



nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (*i.e.*, as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity").

The nucleic acid sequence homology may be determined as the degree of identity between two sequences. The homology may be determined using computer programs known in the art, such as GAP software provided in the GCG program package. *See*, Needleman and Wunsch, 1970. *J Mol Biol* 48: 443-453. Using GCG GAP software with the following settings for nucleic acid sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the analogous nucleic acid sequences referred to above exhibits a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, with the CDS (encoding) part of the DNA sequence of SEQ ID NO:2*n*-1, wherein *n* is an integer between 1-46.

The term "sequence identity" refers to the degree to which two polynucleotide or polypeptide sequences are identical on a residue-by-residue basis over a particular region of comparison. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over that region of comparison, determining the number of positions at which the identical nucleic acid base (*e.g.*, A, T, C, G, U, or I, in the case of nucleic acids) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (*i.e.*, the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The term "substantial identity" as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 80 percent sequence identity, preferably at least 85 percent identity and often 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison region.

#### **Chimeric and Fusion Proteins**

The invention also provides NOVX chimeric or fusion proteins. As used herein, a NOVX "chimeric protein" or "fusion protein" comprises a NOVX polypeptide operatively-linked to a non-NOVX polypeptide. An "NOVX polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a NOVX protein of SEQ ID NO:2*n*, wherein *n* is an integer between 1-46, whereas a "non-NOVX polypeptide" refers to a polypeptide having an

amino acid sequence corresponding to a protein that is not substantially homologous to the NOVX protein, *e.g.*, a protein that is different from the NOVX protein and that is derived from the same or a different organism. Within a NOVX fusion protein the NOVX polypeptide can correspond to all or a portion of a NOVX protein. In one embodiment, a NOVX fusion protein comprises at least one biologically-active portion of a NOVX protein. In another embodiment, a NOVX fusion protein comprises at least two biologically-active portions of a NOVX protein. In yet another embodiment, a NOVX fusion protein comprises at least three biologically-active portions of a NOVX protein. Within the fusion protein, the term "operatively-linked" is intended to indicate that the NOVX polypeptide and the non-NOVX polypeptide are fused in-frame with one another. The non-NOVX polypeptide can be fused to the N-terminus or C-terminus of the NOVX polypeptide.

In one embodiment, the fusion protein is a GST-NOVX fusion protein in which the NOVX sequences are fused to the C-terminus of the GST (glutathione S-transferase) sequences. Such fusion proteins can facilitate the purification of recombinant NOVX polypeptides.

In another embodiment, the fusion protein is a NOVX protein containing a heterologous signal sequence at its N-terminus. In certain host cells (*e.g.*, mammalian host cells), expression and/or secretion of NOVX can be increased through use of a heterologous signal sequence.

In yet another embodiment, the fusion protein is a NOVX-immunoglobulin fusion protein in which the NOVX sequences are fused to sequences derived from a member of the immunoglobulin protein family. The NOVX-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a NOVX ligand and a NOVX protein on the surface of a cell, to thereby suppress NOVX-mediated signal transduction *in vivo*. The NOVX-immunoglobulin fusion proteins can be used to affect the bioavailability of a NOVX cognate ligand. Inhibition of the NOVX ligand/NOVX interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, as well as modulating (*e.g.* promoting or inhibiting) cell survival. Moreover, the NOVX-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-NOVX antibodies in a subject, to purify NOVX ligands, and in screening assays to identify molecules that inhibit the interaction of NOVX with a NOVX ligand.

A NOVX chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different

polypeptide sequences are ligated together in-frame in accordance with conventional techniques, *e.g.*, by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic

5 ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (*see, e.g.*, Ausubel, *et al.* (eds.) CURRENT PROTOCOLS IN

10 MOLECULAR BIOLOGY, John Wiley & Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (*e.g.*, a GST polypeptide). A NOVX-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the NOVX protein.

#### 15 NOVX Agonists and Antagonists

The invention also pertains to variants of the NOVX proteins that function as either NOVX agonists (*i.e.*, mimetics) or as NOVX antagonists. Variants of the NOVX protein can be generated by mutagenesis (*e.g.*, discrete point mutation or truncation of the NOVX protein). An agonist of the NOVX protein can retain substantially the same, or a subset of,

20 the biological activities of the naturally occurring form of the NOVX protein. An antagonist of the NOVX protein can inhibit one or more of the activities of the naturally occurring form of the NOVX protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the NOVX protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one

25 embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the NOVX proteins.

Variants of the NOVX proteins that function as either NOVX agonists (*i.e.*, mimetics) or as NOVX antagonists can be identified by screening combinatorial libraries of mutants

30 (*e.g.*, truncation mutants) of the NOVX proteins for NOVX protein agonist or antagonist activity. In one embodiment, a variegated library of NOVX variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of NOVX variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a

degenerate set of potential NOVX sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (*e.g.*, for phage display) containing the set of NOVX sequences therein. There are a variety of methods which can be used to produce libraries of potential NOVX variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential NOVX sequences. Methods for synthesizing degenerate oligonucleotides are well-known within the art. *See, e.g.*, Narang, 1983. *Tetrahedron* 39: 3; Itakura, *et al.*, 1984. *Annu. Rev. Biochem.* 53: 323; Itakura, *et al.*, 1984. *Science* 198: 1056; Ike, *et al.*, 1983. *Nucl. Acids Res.* 11: 477.

### Polypeptide Libraries

In addition, libraries of fragments of the NOVX protein coding sequences can be used to generate a variegated population of NOVX fragments for screening and subsequent selection of variants of a NOVX protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of a NOVX coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double-stranded DNA that can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with  $S_1$  nuclease, and ligating the resulting fragment library into an expression vector. By this method, expression libraries can be derived which encodes N-terminal and internal fragments of various sizes of the NOVX proteins.

Various techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of NOVX proteins. The most widely used techniques, which are amenable to high throughput analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique that enhances the frequency of functional mutants in

the libraries, can be used in combination with the screening assays to identify NOVX variants. See, e.g., Arkin and Yourvan, 1992. *Proc. Natl. Acad. Sci. USA* 89: 7811-7815; Delgrave, et al., 1993. *Protein Engineering* 6:327-331.

### NOVX Antibodies

5           The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, *i.e.*, molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, F<sub>ab</sub>, F<sub>ab'</sub> and F<sub>(ab)2</sub> fragments, and an F<sub>ab</sub> expression library. In general, antibody molecules  
10       obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgG<sub>1</sub>, IgG<sub>2</sub>, and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all such classes, subclasses and types of human antibody species.

15           An isolated protein of the invention intended to serve as an antigen, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that immunospecifically bind the antigen, using standard techniques for polyclonal and monoclonal antibody preparation. The full-length protein can be used or, alternatively, the invention provides antigenic peptide fragments of the antigen for use as immunogens. An  
20       antigenic peptide fragment comprises at least 6 amino acid residues of the amino acid sequence of the full length protein, such as an amino acid sequence of SEQ ID NO:2*n*, wherein *n* is an integer between 1-46, and encompasses an epitope thereof such that an antibody raised against the peptide forms a specific immune complex with the full length protein or with any fragment that contains the epitope. Preferably, the antigenic peptide  
25       comprises at least 10 amino acid residues, or at least 15 amino acid residues, or at least 20 amino acid residues, or at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of the protein that are located on its surface; commonly these are hydrophilic regions.

          In certain embodiments of the invention, at least one epitope encompassed by the  
30       antigenic peptide is a region of NOVX that is located on the surface of the protein, *e.g.*, a hydrophilic region. A hydrophobicity analysis of the human NOVX protein sequence will indicate which regions of a NOVX polypeptide are particularly hydrophilic and, therefore,

encode surface residues useful for targeting antibody production. As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art, including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation. See, 5 e.g., Hopp and Woods, 1981, *Proc. Nat. Acad. Sci. USA* 78: 3824-3828; Kyte and Doolittle 1982, *J. Mol. Biol.* 157: 105-142, each incorporated herein by reference in their entirety. Antibodies that are specific for one or more domains within an antigenic protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

The term "epitope" includes any protein determinant capable of specific binding to an 10 immunoglobulin or T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. A NOVX polypeptide or a fragment thereof comprises at least one antigenic epitope. An anti-NOVX antibody of the present invention is said to specifically bind to 15 antigen NOVX when the equilibrium binding constant ( $K_D$ ) is  $\leq 1 \mu\text{M}$ , preferably  $\leq 100 \text{ nM}$ , more preferably  $\leq 10 \text{ nM}$ , and most preferably  $\leq 100 \text{ pM}$  to about  $1 \text{ pM}$ , as measured by assays such as radioligand binding assays or similar assays known to those skilled in the art.

A protein of the invention, or a derivative, fragment, analog, homolog or ortholog thereof, may be utilized as an immunogen in the generation of antibodies that 20 immunospecifically bind these protein components.

Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof (see, for example, *Antibodies: A Laboratory Manual*, Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, 25 Cold Spring Harbor, NY, incorporated herein by reference). Some of these antibodies are discussed below.

#### **Polyclonal Antibodies**

For the production of polyclonal antibodies, various suitable host animals (e.g., rabbit, goat, mouse or other mammal) may be immunized by one or more injections with the native 30 protein, a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, the naturally occurring immunogenic protein, a chemically synthesized polypeptide representing the immunogenic protein, or a recombinantly expressed immunogenic protein. Furthermore, the protein may be conjugated

to a second protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (*e.g.*, aluminum hydroxide), surface active substances (*e.g.*, lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, *etc.*), adjuvants usable in humans such as Bacille Calmette-Guerin and *Corynebacterium parvum*, or similar immunostimulatory agents. Additional examples of adjuvants which can be employed include MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).

The polyclonal antibody molecules directed against the immunogenic protein can be isolated from the mammal (*e.g.*, from the blood) and further purified by well known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (*The Scientist*, published by The Scientist, Inc., Philadelphia PA, Vol. 14, No. 8 (April 17, 2000), pp. 25-28).

20

### Monoclonal Antibodies

The term "monoclonal antibody" (MAb) or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MAbs thus contain an antigen binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding affinity for it.

Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, *Nature*, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will

specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro.

The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell [Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103]. Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies [Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63].

The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980). It is an objective, especially important in therapeutic applications of monoclonal antibodies, to



identify antibodies having a high degree of specificity and a high binding affinity for the target antigen.

After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods (Goding, 1986). Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal.

The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

The monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (*e.g.*, by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Patent No. 4,816,567; Morrison, *Nature* 368, 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

### **Humanized Antibodies**

The antibodies directed against the protein antigens of the invention can further comprise humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered immunoglobulin. Humanized forms of antibodies are chimeric

immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')<sub>2</sub> or other antigen-binding subsequences of antibodies) that are principally comprised of the sequence of a human immunoglobulin, and contain minimal sequence derived from a non-human immunoglobulin. Humanization can be performed following the method of Winter and co-workers (Jones et al., *Nature*, 321:522-525 (1986); Riechmann et al., *Nature*, 332:323-327 (1988); Verhoeven et al., *Science*, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. (See also U.S. Patent No. 5,225,539.) In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies can also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., 1986; Riechmann et al., 1988; and Presta, *Curr. Op. Struct. Biol.*, 2:593-596 (1992)).

### Human Antibodies

Fully human antibodies essentially relate to antibody molecules in which the entire sequence of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed "human antibodies", or "fully human antibodies" herein. Human monoclonal antibodies can be prepared by the trioma technique; the human B-cell hybridoma technique (see Kozbor, et al., 1983 *Immunol Today* 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al., 1985 In: *MONOCLONAL ANTIBODIES AND CANCER THERAPY*, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by using human hybridomas (see Cote, et al., 1983. *Proc Natl Acad Sci USA* 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In: *MONOCLONAL ANTIBODIES AND CANCER THERAPY*, Alan R. Liss, Inc., pp. 77-96).

In addition, human antibodies can also be produced using additional techniques, including phage display libraries (Hoogenboom and Winter, *J. Mol. Biol.*, 227:381 (1991);

Marks et al., J. Mol. Biol., 222:581 (1991)). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al. (Bio/Technology 10, 779-783 (1992)); Lonberg et al. (Nature 368 856-859 (1994)); Morrison (Nature 368, 812-13 (1994)); Fishwild et al. (Nature Biotechnology 14, 845-51 (1996)); Neuberger (Nature Biotechnology 14, 826 (1996)); and Lonberg and Huszar (Intern. Rev. Immunol. 13 65-93 (1995)).

Human antibodies may additionally be produced using transgenic nonhuman animals which are modified so as to produce fully human antibodies rather than the animal's endogenous antibodies in response to challenge by an antigen. (See PCT publication WO94/02602). The endogenous genes encoding the heavy and light immunoglobulin chains in the nonhuman host have been incapacitated, and active loci encoding human heavy and light chain immunoglobulins are inserted into the host's genome. The human genes are incorporated, for example, using yeast artificial chromosomes containing the requisite human DNA segments. An animal which provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full complement of the modifications. The preferred embodiment of such a nonhuman animal is a mouse, and is termed the Xenomouse<sup>TM</sup> as disclosed in PCT publications WO 96/33735 and WO 96/34096. This animal produces B cells which secrete fully human immunoglobulins. The antibodies can be obtained directly from the animal after immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. Additionally, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly, or can be further modified to obtain analogs of antibodies such as, for example, single chain Fv molecules.

An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Patent No. 5,939,598. It can be obtained by a method including deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent

rearrangement of the locus and to prevent formation of a transcript of a rearranged immunoglobulin heavy chain locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable marker.

A method for producing an antibody of interest, such as a human antibody, is disclosed in U.S. Patent No. 5,916,771. It includes introducing an expression vector that contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain.

In a further improvement on this procedure, a method for identifying a clinically relevant epitope on an immunogen, and a correlative method for selecting an antibody that binds immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO 99/53049.

#### **F<sub>ab</sub> Fragments and Single Chain Antibodies**

According to the invention, techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (see *e.g.*, U.S. Patent No. 4,946,778). In addition, methods can be adapted for the construction of F<sub>ab</sub> expression libraries (see *e.g.*, Huse, et al., 1989 Science 246: 1275-1281) to allow rapid and effective identification of monoclonal F<sub>ab</sub> fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the idiotypes to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an F<sub>(ab)<sub>2</sub></sub> fragment produced by pepsin digestion of an antibody molecule; (ii) an F<sub>ab</sub> fragment generated by reducing the disulfide bridges of an F<sub>(ab)<sub>2</sub></sub> fragment; (iii) an F<sub>ab</sub> fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) F<sub>v</sub> fragments.

#### **Bispecific Antibodies**

Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the

binding specificities is for an antigenic protein of the invention. The second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.

Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, *Nature*, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker et al., *EMBO J.*, 10:3655-3659 (1991).

Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., *Methods in Enzymology*, 121:210 (1986).

According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (*e.g.* tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (*e.g.* alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

Bispecific antibodies can be prepared as full length antibodies or antibody fragments (*e.g.* F(ab')<sub>2</sub> bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies

can be prepared using chemical linkage. Brennan et al., Science 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate  $F(ab')_2$  fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The  $Fab'$  fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the  $Fab'$ -TNB derivatives is then reconverted to the  $Fab'$ -thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other  $Fab'$ -TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

- 10        Additionally,  $Fab'$  fragments can be directly recovered from *E. coli* and chemically coupled to form bispecific antibodies. Shalaby et al., J. Exp. Med. 175:217-225 (1992) describe the production of a fully humanized bispecific antibody  $F(ab')_2$  molecule. Each  $Fab'$  fragment was separately secreted from *E. coli* and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

- Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., J. Immunol. 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the  $Fab'$  portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain ( $V_H$ ) connected to a light-chain variable domain ( $V_L$ ) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the  $V_H$  and  $V_L$  domains of one fragment are forced to pair with the complementary  $V_L$  and  $V_H$  domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al., J. Immunol. 152:5368 (1994).

Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al., J. Immunol. 147:60 (1991).

- Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (*e.g.* CD2, CD3, CD28, or B7), or
- 5 Fc receptors for IgG (FcγR), such as FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen.
- Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA.
- 10 Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF).

#### **Heteroconjugate Antibodies**

- Heteroconjugate antibodies are also within the scope of the present invention.
- 15 Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Patent No. 4,676,980), and for treatment of HIV infection (WO 91/00360; WO 92/200373; EP 03089). It is contemplated that the antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents.
- 20 For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

#### **Effector Function Engineering**

- It can be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, *e.g.*, the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have
- 30 improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med., 176: 1191-1195 (1992) and Shopes, J. Immunol., 148: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity can also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research, 53: 2560-2565 (1993). Alternatively, an antibody

can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., *Anti-Cancer Drug Design*, 3: 219-230 (1989).

### Immunoconjugates

5       The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (*e.g.*, an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (*i.e.*, a radioconjugate).

Chemotherapeutic agents useful in the generation of such immunoconjugates have  
10   been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, *Phytolacca americana* proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis  
15   inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include  $^{212}\text{Bi}$ ,  $^{131}\text{I}$ ,  $^{131}\text{In}$ ,  $^{90}\text{Y}$ , and  $^{186}\text{Re}$ .

Conjugates of the antibody and cytotoxic agent are made using a variety of  
bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate  
20   (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-  
25   2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., *Science*, 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.

In another embodiment, the antibody can be conjugated to a "receptor" (such  
30   streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (*e.g.*, avidin) that is in turn conjugated to a cytotoxic agent.



### Immunoliposomes

The antibodies disclosed herein can also be formulated as immunoliposomes.

Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA, 82: 3688 (1985); Hwang et al., Proc.

5 Natl. Acad. Sci. USA, 77: 4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545.

Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556.

Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of  
10 defined pore size to yield liposomes with the desired diameter. Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al., J. Biol. Chem., 257: 286-288 (1982) via a disulfide-interchange reaction. A chemotherapeutic agent (such as Doxorubicin) is optionally contained within the liposome. See Gabizon et al., J. National Cancer Inst., 81(19): 1484 (1989).

15

### Diagnostic Applications of Antibodies Directed Against the Proteins of the Invention

Antibodies directed against a protein of the invention may be used in methods known within the art relating to the localization and/or quantitation of the protein (*e.g.*, for use in  
20 measuring levels of the protein within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like). In a given embodiment, antibodies against the proteins, or derivatives, fragments, analogs or homologs thereof, that contain the antigen binding domain, are utilized as pharmacologically-active compounds (see below).

25 An antibody specific for a protein of the invention can be used to isolate the protein by standard techniques, such as immunoaffinity chromatography or immunoprecipitation. Such an antibody can facilitate the purification of the natural protein antigen from cells and of recombinantly produced antigen expressed in host cells. Moreover, such an antibody can be used to detect the antigenic protein (*e.g.*, in a cellular lysate or cell supernatant) in order to  
30 evaluate the abundance and pattern of expression of the antigenic protein. Antibodies directed against the protein can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, *e.g.*, to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (*i.e.*, physically linking) the

antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase,  $\beta$ -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{35}\text{S}$  or  $^3\text{H}$ .

### Antibody Therapeutics

Antibodies of the invention, including polyclonal, monoclonal, humanized and fully human antibodies, may be used as therapeutic agents. Such agents will generally be employed to treat or prevent a disease or pathology in a subject. An antibody preparation, preferably one having high specificity and high affinity for its target antigen, is administered to the subject and will generally have an effect due to its binding with the target. Such an effect may be one of two kinds, depending on the specific nature of the interaction between the given antibody molecule and the target antigen in question. In the first instance, administration of the antibody may abrogate or inhibit the binding of the target with an endogenous ligand to which it naturally binds. In this case, the antibody binds to the target and masks a binding site of the naturally occurring ligand, wherein the ligand serves as an effector molecule. Thus the receptor mediates a signal transduction pathway for which ligand is responsible.

Alternatively, the effect may be one in which the antibody elicits a physiological result by virtue of binding to an effector binding site on the target molecule. In this case the target, a receptor having an endogenous ligand which may be absent or defective in the disease or pathology, binds the antibody as a surrogate effector ligand, initiating a receptor-based signal transduction event by the receptor.

A therapeutically effective amount of an antibody of the invention relates generally to the amount needed to achieve a therapeutic objective. As noted above, this may be a binding interaction between the antibody and its target antigen that, in certain cases, interferes with

the functioning of the target, and in other cases, promotes a physiological response. The amount required to be administered will furthermore depend on the binding affinity of the antibody for its specific antigen, and will also depend on the rate at which an administered antibody is depleted from the free volume other subject to which it is administered. Common  
5 ranges for therapeutically effective dosing of an antibody or antibody fragment of the invention may be, by way of nonlimiting example, from about 0.1 mg/kg body weight to about 50 mg/kg body weight. Common dosing frequencies may range, for example, from twice daily to once a week.

#### 10           **Pharmaceutical Compositions of Antibodies**

Antibodies specifically binding a protein of the invention, as well as other molecules identified by the screening assays disclosed herein, can be administered for the treatment of various disorders in the form of pharmaceutical compositions. Principles and considerations involved in preparing such compositions, as well as guidance in the choice of components are  
15 provided, for example, in Remington : The Science And Practice Of Pharmacy 19th ed. (Alfonso R. Gennaro, et al., editors) Mack Pub. Co., Easton, Pa. : 1995; Drug Absorption Enhancement : Concepts, Possibilities, Limitations, And Trends, Harwood Academic Publishers, Langhorne, Pa., 1994; and Peptide And Protein Drug Delivery (Advances In Parenteral Sciences, Vol. 4), 1991, M. Dekker, New York.

20           If the antigenic protein is intracellular and whole antibodies are used as inhibitors, internalizing antibodies are preferred. However, liposomes can also be used to deliver the antibody, or an antibody fragment, into cells. Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred. For example, based upon the variable-region sequences of an antibody, peptide  
25 molecules can be designed that retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced by recombinant DNA technology. See, e.g., Marasco et al., Proc. Natl. Acad. Sci. USA, 90: 7889-7893 (1993). The formulation herein can also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not  
30 adversely affect each other. Alternatively, or in addition, the composition can comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.

The active ingredients can also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, 5 albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in macroemulsions.

The formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.

Sustained-release preparations can be prepared. Suitable examples of sustained-  
10 release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, *e.g.*, films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and  $\gamma$  ethyl-L-glutamate, non-degradable  
15 ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT<sup>TM</sup> (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.

20

### ELISA Assay

An agent for detecting an analyte protein is an antibody capable of binding to an analyte protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (*e.g.*, F<sub>ab</sub> or F<sub>(ab)2</sub>)  
25 can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (*i.e.*, physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary  
30 antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. Included within the usage of the term "biological sample", therefore, is blood and a fraction or component of blood including blood serum, blood

plasma, or lymph. That is, the detection method of the invention can be used to detect an analyte mRNA, protein, or genomic DNA in a biological sample *in vitro* as well as *in vivo*. For example, *in vitro* techniques for detection of an analyte mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detection of an analyte protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. *In vitro* techniques for detection of an analyte genomic DNA include Southern hybridizations. Procedures for conducting immunoassays are described, for example in "ELISA: Theory and Practice: Methods in Molecular Biology", Vol. 42, J. R. Crowther (Ed.) Human Press, Totowa, NJ, 1995; "Immunoassay", E. Diamandis and T. Christopoulos, Academic Press, Inc., San Diego, CA, 1996; and "Practice and Theory of Enzyme Immunoassays", P. Tijssen, Elsevier Science Publishers, Amsterdam, 1985. Furthermore, *in vivo* techniques for detection of an analyte protein include introducing into a subject a labeled anti-analyte protein antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

#### NOVX Recombinant Expression Vectors and Host Cells

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding a NOVX protein, or derivatives, fragments, analogs or homologs thereof. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (*e.g.*, non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended

to include such other forms of expression vectors, such as viral vectors (*e.g.*, replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

5 The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably-linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory  
10 sequence(s) in a manner that allows for expression of the nucleotide sequence (*e.g.*, in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell).

The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (*e.g.*, polyadenylation signals). Such regulatory sequences  
15 are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (*e.g.*, tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the  
20 design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, *etc.*. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (*e.g.*, NOVX proteins, mutant forms of NOVX proteins, fusion proteins, *etc.*).

25 The recombinant expression vectors of the invention can be designed for expression of NOVX proteins in prokaryotic or eukaryotic cells. For example, NOVX proteins can be expressed in bacterial cells such as *Escherichia coli*, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press,  
30 San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out in *Escherichia coli* with vectors containing constitutive or inducible promoters directing the expression of either

fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988. *Gene* 67: 31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) that fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amrann *et al.*, (1988) *Gene* 69:301-315) and pET 11d (Studier *et al.*, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).

One strategy to maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein. See, e.g., Gottesman, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 119-128. Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (see, e.g., Wada, *et al.*, 1992. *Nucl. Acids Res.* 20: 2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

In another embodiment, the NOVX expression vector is a yeast expression vector. Examples of vectors for expression in yeast *Saccharomyces cerevisiae* include pYepSec1 (Baldari, *et al.*, 1987. *EMBO J.* 6: 229-234), pMFa (Kurjan and Herskowitz, 1982. *Cell* 30: 933-943), pJRY88 (Schultz *et al.*, 1987. *Gene* 54: 113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (Invitrogen Corp, San Diego, Calif.).

Alternatively, NOVX can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., SF9 cells) include the pAc series (Smith, *et al.*, 1983. *Mol. Cell. Biol.* 3: 2156-2165) and the pVL series (Lucklow and Summers, 1989. *Virology* 170: 31-39).

In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, 1987. *Nature* 329: 840) and pMT2PC (Kaufman, *et al.*, 1987. *EMBO J.* 6: 187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, and simian virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see, *e.g.*, Chapters 16 and 17 of Sambrook, *et al.*, MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (*e.g.*, tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, *et al.*, 1987. *Genes Dev.* 1: 268-277), lymphoid-specific promoters (Calame and Eaton, 1988. *Adv. Immunol.* 43: 235-275), in particular promoters of T cell receptors (Winoto and Baltimore, 1989. *EMBO J.* 8: 729-733) and immunoglobulins (Banerji, *et al.*, 1983. *Cell* 33: 729-740; Queen and Baltimore, 1983. *Cell* 33: 741-748), neuron-specific promoters (*e.g.*, the neurofilament promoter; Byrne and Ruddle, 1989. *Proc. Natl. Acad. Sci. USA* 86: 5473-5477), pancreas-specific promoters (Edlund, *et al.*, 1985. *Science* 230: 912-916), and mammary gland-specific promoters (*e.g.*, milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, *e.g.*, the murine hox promoters (Kessel and Gruss, 1990. *Science* 249: 374-379) and the  $\alpha$ -fetoprotein promoter (Campes and Tilghman, 1989. *Genes Dev.* 3: 537-546).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively-linked to a regulatory sequence in a manner that allows for expression (by transcription of the DNA molecule) of an RNA molecule that is antisense to NOVX mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen that direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen that direct constitutive, tissue specific or cell type



specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes *see, e.g.,* Weintraub, *et al.*, "Antisense RNA as a molecular tool for genetic analysis," *Reviews-Trends in Genetics*, Vol. 1(1) 1986.

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, NOVX protein can be expressed in bacterial cells such as *E. coli*, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (*e.g.*, DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, *et al.* (MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (*e.g.*, resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Various selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding NOVX or can be introduced on a separate vector. Cells stably transfected with the

introduced nucleic acid can be identified by drug selection (*e.g.*, cells that have incorporated the selectable marker gene will survive, while the other cells die).

A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (*i.e.*, express) NOVX protein. Accordingly, the invention further provides methods for producing NOVX protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding NOVX protein has been introduced) in a suitable medium such that NOVX protein is produced. In another embodiment, the method further comprises isolating NOVX protein from the medium or the host cell.

## 10 Transgenic NOVX Animals

The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which NOVX protein-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous NOVX sequences have been introduced into their genome or homologous recombinant animals in which endogenous NOVX sequences have been altered. Such animals are useful for studying the function and/or activity of NOVX protein and for identifying and/or evaluating modulators of NOVX protein activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, *etc.* A transgene is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and that remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous NOVX gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, *e.g.*, an embryonic cell of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing NOVX-encoding nucleic acid into the male pronuclei of a fertilized oocyte (*e.g.*, by microinjection, retroviral infection) and allowing the oocyte to develop in a pseudopregnant female foster animal. The human NOVX cDNA sequences, *i.e.*, any one of SEQ ID NO:2*n*-1, wherein *n* is an integer

between 1-46, can be introduced as a transgene into the genome of a non-human animal. Alternatively, a non-human homologue of the human NOVX gene, such as a mouse NOVX gene, can be isolated based on hybridization to the human NOVX cDNA (described further *supra*) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably-linked to the NOVX transgene to direct expression of NOVX protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866; 4,870,009; and 4,873,191; and Hogan, 1986. In: MANIPULATING THE MOUSE EMBRYO, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the NOVX transgene in its genome and/or expression of NOVX mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene-encoding NOVX protein can further be bred to other transgenic animals carrying other transgenes.

To create a homologous recombinant animal, a vector is prepared which contains at least a portion of a NOVX gene into which a deletion, addition or substitution has been introduced to thereby alter, *e.g.*, functionally disrupt, the NOVX gene. The NOVX gene can be a human gene (*e.g.*, the cDNA of any one of SEQ ID NO:2*n*-1, wherein *n* is an integer between 1-46), but more preferably, is a non-human homologue of a human NOVX gene. For example, a mouse homologue of human NOVX gene of SEQ ID NO:2*n*-1, wherein *n* is an integer between 1-46, can be used to construct a homologous recombination vector suitable for altering an endogenous NOVX gene in the mouse genome. In one embodiment, the vector is designed such that, upon homologous recombination, the endogenous NOVX gene is functionally disrupted (*i.e.*, no longer encodes a functional protein; also referred to as a "knock out" vector).

Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous NOVX gene is mutated or otherwise altered but still encodes functional protein (*e.g.*, the upstream regulatory region can be altered to thereby alter the expression of the endogenous NOVX protein). In the homologous recombination vector, the altered portion of the NOVX gene is flanked at its 5'- and 3'-termini by additional nucleic acid of the NOVX gene to allow for homologous recombination to occur between the exogenous NOVX

gene carried by the vector and an endogenous NOVX gene in an embryonic stem cell. The additional flanking NOVX nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5'- and 3'-termini) are included in the vector. *See, e.g., Thomas, et al., 1987. Cell* 51: 503 for a description of homologous recombination vectors. The vector is then introduced into an embryonic stem cell line (*e.g., by electroporation*) and cells in which the introduced NOVX gene has homologously-recombined with the endogenous NOVX gene are selected. *See, e.g., Li, et al., 1992. Cell* 69: 915.

The selected cells are then injected into a blastocyst of an animal (*e.g., a mouse*) to form aggregation chimeras. *See, e.g., Bradley, 1987. In: TERATOCARCINOMAS AND EMBRYONIC STEM CELLS: A PRACTICAL APPROACH, Robertson, ed. IRL, Oxford, pp. 113-152.* A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously-recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously-recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, 1991. *Curr. Opin. Biotechnol.* 2: 823-829; PCT International Publication Nos.: WO 90/11354; WO 91/01140; WO 92/0968; and WO 93/04169.

In another embodiment, transgenic non-humans animals can be produced that contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, *See, e.g., Lakso, et al., 1992. Proc. Natl. Acad. Sci. USA* 89: 6232-6236. Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae*. *See, O'Gorman, et al., 1991. Science* 251:1351-1355. If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, *e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.*

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, *et al., 1997. Nature* 385: 810-813. In brief, a cell (*e.g., a somatic cell*) from the transgenic animal can be isolated and induced to exit the growth cycle and enter G<sub>0</sub> phase. The quiescent cell can then be fused, *e.g., through the use*

of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell  
5 (e.g., the somatic cell) is isolated.

### Pharmaceutical Compositions

The NOVX nucleic acid molecules, NOVX proteins, and anti-NOVX antibodies (also referred to herein as "active compounds") of the invention, and derivatives, fragments, analogs and homologs thereof, can be incorporated into pharmaceutical compositions suitable  
10 for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most  
15 recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, finger's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well  
20 known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral,  
25 e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (i.e., topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or  
30 methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral

preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a NOVX protein or anti-NOVX antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier

for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

10 For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, *e.g.*, a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

20 The compounds can also be prepared in the form of suppositories (*e.g.*, with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (*see, e.g.*, U.S. Patent No. 5,328,470) or by stereotactic injection (*see, e.g.*, Chen, *et al.*, 1994. *Proc. Natl. Acad. Sci. USA* 91: 3054-3057). The pharmaceutical preparation of the gene therapy vector can include the therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, *e.g.*, retroviral vectors, the pharmaceutical preparation can include one or more cells that produce the gene delivery system.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

#### Screening and Detection Methods

The isolated nucleic acid molecules of the invention can be used to express NOVX protein (*e.g.*, via a recombinant expression vector in a host cell in gene therapy applications), to detect NOVX mRNA (*e.g.*, in a biological sample) or a genetic lesion in a NOVX gene, and to modulate NOVX activity, as described further, below. In addition, the NOVX proteins can be used to screen drugs or compounds that modulate the NOVX protein activity or expression as well as to treat disorders characterized by insufficient or excessive production of NOVX protein or production of NOVX protein forms that have decreased or aberrant activity compared to NOVX wild-type protein (*e.g.*; diabetes (regulates insulin release); obesity (binds and transport lipids); metabolic disturbances associated with obesity, the metabolic syndrome X as well as anorexia and wasting disorders associated with chronic diseases and various cancers, and infectious disease (possesses anti-microbial activity) and the various dyslipidemias. In addition, the anti-NOVX antibodies of the invention can be used to



detect and isolate NOVX proteins and modulate NOVX activity. In yet a further aspect, the invention can be used in methods to influence appetite, absorption of nutrients and the disposition of metabolic substrates in both a positive and negative fashion.

The invention further pertains to novel agents identified by the screening assays  
5 described herein and uses thereof for treatments as described, *supra*.

### Screening Assays

The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, *i.e.*, candidate or test compounds or agents (*e.g.*, peptides,  
10 peptidomimetics, small molecules or other drugs) that bind to NOVX proteins or have a stimulatory or inhibitory effect on, *e.g.*, NOVX protein expression or NOVX protein activity. The invention also includes compounds identified in the screening assays described herein.

In one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of the membrane-bound form of a NOVX  
15 protein or polypeptide or biologically-active portion thereof. The test compounds of the invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead one-compound" library method; and synthetic library methods using affinity  
20 chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds. *See, e.g.*, Lam, 1997. *Anticancer Drug Design* 12: 145.

A "small molecule" as used herein, is meant to refer to a composition that has a molecular weight of less than about 5 kD and most preferably less than about 4 kD. Small  
25 molecules can be, *e.g.*, nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids or other organic or inorganic molecules. Libraries of chemical and/or biological mixtures, such as fungal, bacterial, or algal extracts, are known in the art and can be screened with any of the assays of the invention.

Examples of methods for the synthesis of molecular libraries can be found in the art,  
30 for example in: DeWitt, *et al.*, 1993. *Proc. Natl. Acad. Sci. U.S.A.* 90: 6909; Erb, *et al.*, 1994. *Proc. Natl. Acad. Sci. U.S.A.* 91: 11422; Zuckermann, *et al.*, 1994. *J. Med. Chem.* 37: 2678; Cho, *et al.*, 1993. *Science* 261: 1303; Carrell, *et al.*, 1994. *Angew. Chem. Int. Ed. Engl.* 33: 2059; Carell, *et al.*, 1994. *Angew. Chem. Int. Ed. Engl.* 33: 2061; and Gallop, *et al.*, 1994. *J. Med. Chem.* 37: 1233.

Libraries of compounds may be presented in solution (*e.g.*, Houghten, 1992. *Biotechniques* 13: 412-421), or on beads (Lam, 1991. *Nature* 354: 82-84), on chips (Fodor, 1993. *Nature* 364: 555-556), bacteria (Ladner, U.S. Patent No. 5,223,409), spores (Ladner, U.S. Patent 5,233,409), plasmids (Cull, *et al.*, 1992. *Proc. Natl. Acad. Sci. USA* 89: 1865-1869) or on phage (Scott and Smith, 1990. *Science* 249: 386-390; Devlin, 1990. *Science* 249: 404-406; Cwirla, *et al.*, 1990. *Proc. Natl. Acad. Sci. U.S.A.* 87: 6378-6382; Felici, 1991. *J. Mol. Biol.* 222: 301-310; Ladner, U.S. Patent No. 5,233,409.).

In one embodiment, an assay is a cell-based assay in which a cell which expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface is contacted with a test compound and the ability of the test compound to bind to a NOVX protein determined. The cell, for example, can be of mammalian origin or a yeast cell. Determining the ability of the test compound to bind to the NOVX protein can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the NOVX protein or biologically-active portion thereof can be determined by detecting the labeled compound in a complex. For example, test compounds can be labeled with  $^{125}\text{I}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ , or  $^3\text{H}$ , either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. Alternatively, test compounds can be enzymatically-labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product. In one embodiment, the assay comprises contacting a cell which expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a NOVX protein, wherein determining the ability of the test compound to interact with a NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX protein or a biologically-active portion thereof as compared to the known compound.

In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a test compound and determining the ability of the test compound to modulate (*e.g.*, stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX or a biologically-active portion thereof can be accomplished, for example, by determining the ability of the NOVX protein to bind to or interact with a NOVX

target molecule. As used herein, a "target molecule" is a molecule with which a NOVX protein binds or interacts in nature, for example, a molecule on the surface of a cell which expresses a NOVX interacting protein, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. A NOVX target molecule can be a non-NOVX molecule or a NOVX protein or polypeptide of the invention. In one embodiment, a NOVX target molecule is a component of a signal transduction pathway that facilitates transduction of an extracellular signal (*e.g.* a signal generated by binding of a compound to a membrane-bound NOVX molecule) through the cell membrane and into the cell. The target, for example, can be a second intercellular protein that has catalytic activity or a protein that facilitates the association of downstream signaling molecules with NOVX.

Determining the ability of the NOVX protein to bind to or interact with a NOVX target molecule can be accomplished by one of the methods described above for determining direct binding. In one embodiment, determining the ability of the NOVX protein to bind to or interact with a NOVX target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (*i.e.* intracellular  $\text{Ca}^{2+}$ , diacylglycerol,  $\text{IP}_3$ , *etc.*), detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising a NOVX-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, *e.g.*, luciferase), or detecting a cellular response, for example, cell survival, cellular differentiation, or cell proliferation.

In yet another embodiment, an assay of the invention is a cell-free assay comprising contacting a NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to bind to the NOVX protein or biologically-active portion thereof. Binding of the test compound to the NOVX protein can be determined either directly or indirectly as described above. In one such embodiment, the assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a NOVX protein, wherein determining the ability of the test compound to interact with a NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX or biologically-active portion thereof as compared to the known compound.

In still another embodiment, an assay is a cell-free assay comprising contacting NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to modulate (*e.g.* stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX can be accomplished, for example, by determining the ability of the NOVX protein to bind to a NOVX target molecule by one of the methods described above for determining direct binding. In an alternative embodiment, determining the ability of the test compound to modulate the activity of NOVX protein can be accomplished by determining the ability of the NOVX protein further modulate a NOVX target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be determined as described, *supra*.

In yet another embodiment, the cell-free assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a NOVX protein, wherein determining the ability of the test compound to interact with a NOVX protein comprises determining the ability of the NOVX protein to preferentially bind to or modulate the activity of a NOVX target molecule.

The cell-free assays of the invention are amenable to use of both the soluble form or the membrane-bound form of NOVX protein. In the case of cell-free assays comprising the membrane-bound form of NOVX protein, it may be desirable to utilize a solubilizing agent such that the membrane-bound form of NOVX protein is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton<sup>®</sup> X-100, Triton<sup>®</sup> X-114, Thesit<sup>®</sup>, Isotridecypoly(ethylene glycol ether)<sub>n</sub>, N-dodecyl--N,N-dimethyl-3-ammonio-1-propane sulfonate, 3-(3-cholamidopropyl) dimethylamminiol-1-propane sulfonate (CHAPS), or 3-(3-cholamidopropyl)dimethylamminiol-2-hydroxy-1-propane sulfonate (CHAPSO).

In more than one embodiment of the above assay methods of the invention, it may be desirable to immobilize either NOVX protein or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to NOVX protein, or interaction of NOVX protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants.

Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided that adds a domain that allows one or both of the proteins to be bound to a matrix. For example, GST-NOVX fusion proteins or GST-target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtiter plates, that are then combined with the test compound or the test compound and either the non-adsorbed target protein or NOVX protein, and the mixture is incubated under conditions conducive to complex formation (*e.g.*, at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described, *supra*. Alternatively, the complexes can be dissociated from the matrix, and the level of NOVX protein binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either the NOVX protein or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated NOVX protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well-known within the art (*e.g.*, biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with NOVX protein or target molecules, but which do not interfere with binding of the NOVX protein to its target molecule, can be derivatized to the wells of the plate, and unbound target or NOVX protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the NOVX protein or target molecule, as well as enzyme-linked assays that rely on detecting an enzymatic activity associated with the NOVX protein or target molecule.

In another embodiment, modulators of NOVX protein expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of NOVX mRNA or protein in the cell is determined. The level of expression of NOVX mRNA or protein in the presence of the candidate compound is compared to the level of expression of NOVX mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of NOVX mRNA or protein expression based upon this comparison. For example, when expression of NOVX mRNA or protein is greater (*i.e.*, statistically significantly greater) in the presence of the candidate compound than

in its absence, the candidate compound is identified as a stimulator of NOVX mRNA or protein expression. Alternatively, when expression of NOVX mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of NOVX mRNA or protein expression.

- 5 The level of NOVX mRNA or protein expression in the cells can be determined by methods described herein for detecting NOVX mRNA or protein.

- In yet another aspect of the invention, the NOVX proteins can be used as "bait proteins" in a two-hybrid assay or three hybrid assay (*see, e.g.*, U.S. Patent No. 5,283,317; Zervos, *et al.*, 1993. *Cell* 72: 223-232; Madura, *et al.*, 1993. *J. Biol. Chem.* 268: 12046-12054; Bartel, *et al.*, 1993. *Biotechniques* 14: 920-924; Iwabuchi, *et al.*, 1993. *Oncogene* 8: 1693-1696; and Brent WO 94/10300), to identify other proteins that bind to or interact with NOVX ("NOVX-binding proteins" or "NOVX-bp") and modulate NOVX activity. Such NOVX-binding proteins are also involved in the propagation of signals by the NOVX proteins as, for example, upstream or downstream elements of the NOVX pathway.
- 15 The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for NOVX is fused to a gene encoding the DNA binding domain of a known transcription factor (*e.g.*, GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming a NOVX-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (*e.g.*, LacZ) that is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene that encodes the protein which interacts with NOVX.
- 20 25

The invention further pertains to novel agents identified by the aforementioned screening assays and uses thereof for treatments as described herein.

### 30 Detection Assays

Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. By way of example, and not of limitation, these sequences can be used to: (i) map

their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. Some of these applications are described in the subsections, below.

5

### Chromosome Mapping

Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of the NOVX sequences of  
10 SEQ ID NO:2*n*-1, wherein *n* is an integer between 1-46, or fragments or derivatives thereof, can be used to map the location of the NOVX genes, respectively, on a chromosome. The mapping of the NOVX sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.

Briefly, NOVX genes can be mapped to chromosomes by preparing PCR primers  
15 (preferably 15-25 bp in length) from the NOVX sequences. Computer analysis of the NOVX sequences can be used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the NOVX sequences will  
20 yield an amplified fragment.

Somatic cell hybrids are prepared by fusing somatic cells from different mammals (e.g., human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but retain the mouse chromosomes. By using media in which mouse cells cannot grow, because they lack a particular enzyme, but in  
25 which human cells can, the one human chromosome that contains the gene encoding the needed enzyme will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. See, e.g., D'Eustachio, *et al.*,  
30 1983. *Science* 220: 919-924. Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and deletions.

PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day

using a single thermal cycler. Using the NOVX sequences to design oligonucleotide primers, sub-localization can be achieved with panels of fragments from specific chromosomes.

- Fluorescence *in situ* hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one
- 5 step. Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical like colcemid that disrupts the mitotic spindle. The chromosomes can be treated briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA sequence as short as 500 or 600 bases.
- 10 However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases, will suffice to get good results at a reasonable amount of time. For a review of this technique, *see*, Verma, *et al.*, HUMAN CHROMOSOMES: A MANUAL OF BASIC TECHNIQUES (Pergamon Press, New York 1988).

- 15 Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations
- 20 during chromosomal mapping.

- Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, *e.g.*, in McKusick, MENDELIAN INHERITANCE IN MAN, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes
- 25 and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, *e.g.*, Egeland, *et al.*, 1987. *Nature*, 325: 783-787.

- Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the NOVX gene, can be determined. If a mutation
- 30 is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete



sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

### Tissue Typing

5       The NOVX sequences of the invention can also be used to identify individuals from minute biological samples. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. The sequences of the invention are useful as additional DNA markers for RFLP ("restriction fragment length polymorphisms," described in U.S. Patent No.  
10   5,272,057).

Furthermore, the sequences of the invention can be used to provide an alternative technique that determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the NOVX sequences described herein can be used to prepare two PCR primers from the 5'- and 3'-termini of the sequences. These primers can then be  
15   used to amplify an individual's DNA and subsequently sequence it.

Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the invention can be used to obtain such identification sequences from individuals and from tissue. The NOVX  
20   sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Much of the allelic variation is due to single nucleotide polymorphisms (SNPs), which include restriction  
25   fragment length polymorphisms (RFLPs).

Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences can comfortably provide  
30   positive individual identification with a panel of perhaps 10 to 1,000 primers that each yield a noncoding amplified sequence of 100 bases. If coding sequences, such as those of SEQ ID NO:2*n*-1, wherein *n* is an integer between 1-46, are used, a more appropriate number of primers for positive individual identification would be 500-2,000.

### Predictive Medicine

The invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for

5 prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the invention relates to diagnostic assays for determining NOVX protein and/or nucleic acid expression as well as NOVX activity, in the context of a biological sample (*e.g.*, blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant NOVX

10 expression or activity. The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers. The

15 invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. For example, mutations in a NOVX gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or

20 associated with NOVX protein, nucleic acid expression, or biological activity.

Another aspect of the invention provides methods for determining NOVX protein, nucleic acid expression or activity in an individual to thereby select appropriate therapeutic or prophylactic agents for that individual (referred to herein as "pharmacogenomics"). Pharmacogenomics allows for the selection of agents (*e.g.*, drugs) for therapeutic or

25 prophylactic treatment of an individual based on the genotype of the individual (*e.g.*, the genotype of the individual examined to determine the ability of the individual to respond to a particular agent.)

Yet another aspect of the invention pertains to monitoring the influence of agents (*e.g.*, drugs, compounds) on the expression or activity of NOVX in clinical trials.

30 These and other agents are described in further detail in the following sections.

### Diagnostic Assays

An exemplary method for detecting the presence or absence of NOVX in a biological sample involves obtaining a biological sample from a test subject and contacting the

biological sample with a compound or an agent capable of detecting NOVX protein or nucleic acid (e.g., mRNA, genomic DNA) that encodes NOVX protein such that the presence of NOVX is detected in the biological sample. An agent for detecting NOVX mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to NOVX mRNA or  
5 genomic DNA. The nucleic acid probe can be, for example, a full-length NOVX nucleic acid, such as the nucleic acid of SEQ ID NO:2n-1, wherein *n* is an integer between 1-46, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to NOVX mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are  
10 described herein.

An agent for detecting NOVX protein is an antibody capable of binding to NOVX protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')<sub>2</sub>) can be used. The term "labeled", with regard to the probe or antibody, is intended to  
15 encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with  
20 fluorescently-labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect NOVX mRNA, protein, or genomic DNA in a biological sample *in vitro* as well as *in vivo*. For example, *in vitro* techniques for detection of NOVX mRNA include Northern  
25 hybridizations and *in situ* hybridizations. *In vitro* techniques for detection of NOVX protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. *In vitro* techniques for detection of NOVX genomic DNA include Southern hybridizations. Furthermore, *in vivo* techniques for detection of NOVX protein include introducing into a subject a labeled anti-NOVX antibody.  
30 For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test

subject or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.

In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent  
5 capable of detecting NOVX protein, mRNA, or genomic DNA, such that the presence of NOVX protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of NOVX protein, mRNA or genomic DNA in the control sample with the presence of NOVX protein, mRNA or genomic DNA in the test sample.

The invention also encompasses kits for detecting the presence of NOVX in a  
10 biological sample. For example, the kit can comprise: a labeled compound or agent capable of detecting NOVX protein or mRNA in a biological sample; means for determining the amount of NOVX in the sample; and means for comparing the amount of NOVX in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect NOVX protein or nucleic  
15 acid.

### Prognostic Assays

The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant NOVX  
20 expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disease or disorder. Thus, the invention provides a method for  
25 identifying a disease or disorder associated with aberrant NOVX expression or activity in which a test sample is obtained from a subject and NOVX protein or nucleic acid (*e.g.*, mRNA, genomic DNA) is detected, wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant NOVX expression or activity. As used herein, a "test sample" refers to a biological  
30 sample obtained from a subject of interest. For example, a test sample can be a biological fluid (*e.g.*, serum), cell sample, or tissue.

Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (*e.g.*, an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder

associated with aberrant NOVX expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for a disorder. Thus, the invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant NOVX expression or activity in which a test sample is obtained and NOVX protein or nucleic acid is detected (*e.g.*, wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant NOVX expression or activity).

The methods of the invention can also be used to detect genetic lesions in a NOVX gene, thereby determining if a subject with the lesioned gene is at risk for a disorder characterized by aberrant cell proliferation and/or differentiation. In various embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by at least one of an alteration affecting the integrity of a gene encoding a NOVX-protein, or the misexpression of the NOVX gene. For example, such genetic lesions can be detected by ascertaining the existence of at least one of: (i) a deletion of one or more nucleotides from a NOVX gene; (ii) an addition of one or more nucleotides to a NOVX gene; (iii) a substitution of one or more nucleotides of a NOVX gene, (iv) a chromosomal rearrangement of a NOVX gene; (v) an alteration in the level of a messenger RNA transcript of a NOVX gene, (vi) aberrant modification of a NOVX gene, such as of the methylation pattern of the genomic DNA, (vii) the presence of a non-wild-type splicing pattern of a messenger RNA transcript of a NOVX gene, (viii) a non-wild-type level of a NOVX protein, (ix) allelic loss of a NOVX gene, and (x) inappropriate post-translational modification of a NOVX protein. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in a NOVX gene. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (*see, e.g.*, U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (*see, e.g.*, Landegran, *et al.*, 1988. *Science* 241: 1077-1080; and Nakazawa, *et al.*, 1994. *Proc. Natl. Acad. Sci. USA* 91: 360-364), the latter of which can be particularly useful for detecting point mutations in the NOVX-gene (*see*, Abravaya, *et al.*, 1995. *Nucl. Acids Res.* 23: 675-682). This method can include the steps of collecting a sample of cells from a patient, isolating

nucleic acid (*e.g.*, genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers that specifically hybridize to a NOVX gene under conditions such that hybridization and amplification of the NOVX gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

Alternative amplification methods include: self sustained sequence replication (*see*, Guatelli, *et al.*, 1990. *Proc. Natl. Acad. Sci. USA* 87: 1874-1878), transcriptional amplification system (*see*, Kwok, *et al.*, 1989. *Proc. Natl. Acad. Sci. USA* 86: 1173-1177); Q $\beta$  Replicase (*see*, Lizardi, *et al.*, 1988. *BioTechnology* 6: 1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

In an alternative embodiment, mutations in a NOVX gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (*see, e.g.*, U.S. Patent No. 5,493,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

In other embodiments, genetic mutations in NOVX can be identified by hybridizing a sample and control nucleic acids, *e.g.*, DNA or RNA, to high-density arrays containing hundreds or thousands of oligonucleotides probes. *See, e.g.*, Cronin, *et al.*, 1996. *Human Mutation* 7: 244-255; Kozal, *et al.*, 1996. *Nat. Med.* 2: 753-759. For example, genetic mutations in NOVX can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin, *et al.*, *supra*. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation

array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.

In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the NOVX gene and detect mutations by comparing the sequence of the sample NOVX with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert, 1977. *Proc. Natl. Acad. Sci. USA* 74: 560 or Sanger, 1977. *Proc. Natl. Acad. Sci. USA* 74: 5463. It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays (*see, e.g.,* Naeve, *et al.*, 1995. *Biotechniques* 19: 448), including sequencing by mass spectrometry (*see, e.g.,* PCT International Publication No. WO 94/16101; Cohen, *et al.*, 1996. *Adv. Chromatography* 36: 127-162; and Griffin, *et al.*, 1993. *Appl. Biochem. Biotechnol.* 38: 147-159).

Other methods for detecting mutations in the NOVX gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes. *See, e.g.,* Myers, *et al.*, 1985. *Science* 230: 1242. In general, the art technique of "mismatch cleavage" starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type NOVX sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent that cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S<sub>1</sub> nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. *See, e.g.,* Cotton, *et al.*, 1988. *Proc. Natl. Acad. Sci. USA* 85: 4397; Saleeba, *et al.*, 1992. *Methods Enzymol.* 217: 286-295. In an embodiment, the control DNA or RNA can be labeled for detection.

In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in NOVX cDNAs obtained from samples of cells. For example, the mutY enzyme of *E. coli* cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches. *See, e.g.,* Hsu, *et al.*, 1994. *Carcinogenesis* 15: 1657-1662. According to

an exemplary embodiment, a probe based on a NOVX sequence, e.g., a wild-type NOVX sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, e.g., U.S. Patent No. 5,459,039.

- 5 In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in NOVX genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids. See, e.g., Orita, *et al.*, 1989. *Proc. Natl. Acad. Sci. USA*: 86: 2766; Cotton, 1993. *Mutat. Res.* 285: 125-144; Hayashi, 1992. *Genet. Anal. Tech. Appl.* 9: 73-79.
- 10 Single-stranded DNA fragments of sample and control NOVX nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than
- 15 DNA), in which the secondary structure is more sensitive to a change in sequence. In one embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility. See, e.g., Keen, *et al.*, 1991. *Trends Genet.* 7: 5.

- In yet another embodiment, the movement of mutant or wild-type fragments in
- 20 polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE). See, e.g., Myers, *et al.*, 1985. *Nature* 313: 495. When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a
- 25 denaturing gradient to identify differences in the mobility of control and sample DNA. See, e.g., Rosenbaum and Reissner, 1987. *Biophys. Chem.* 265: 12753.

- Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known
- 30 mutation is placed centrally and then hybridized to target DNA under conditions that permit hybridization only if a perfect match is found. See, e.g., Saiki, *et al.*, 1986. *Nature* 324: 163; Saiki, *et al.*, 1989. *Proc. Natl. Acad. Sci. USA* 86: 6230. Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the



oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

Alternatively, allele specific amplification technology that depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization; *see, e.g.,* Gibbs, *et al.*, 1989. *Nucl. Acids Res.* 17: 2437-2448) or at the extreme 3'-terminus of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (*see, e.g.,* Prossner, 1993. *Tibtech.* 11: 238). In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection. *See, e.g.,* Gasparini, *et al.*, 1992. *Mol. Cell Probes* 6: 1. It is anticipated that in certain embodiments amplification may also be performed using *Taq* ligase for amplification. *See, e.g.,* Barany, 1991. *Proc. Natl. Acad. Sci. USA* 88: 189. In such cases, ligation will occur only if there is a perfect match at the 3'-terminus of the 5' sequence, making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, *e.g.,* in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a NOVX gene.

Furthermore, any cell type or tissue, preferably peripheral blood leukocytes, in which NOVX is expressed may be utilized in the prognostic assays described herein. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

25

### Pharmacogenomics

Agents, or modulators that have a stimulatory or inhibitory effect on NOVX activity (*e.g.,* NOVX gene expression), as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders (The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers.) In conjunction with such

treatment, the pharmacogenomics (*i.e.*, the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (*e.g.*, drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.

Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See *e.g.*, Eichelbaum, 1996. *Clin. Exp. Pharmacol. Physiol.*, 23: 983-985; Linder, 1997. *Clin. Chem.*, 43: 254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is hemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (*e.g.*, N-acetyltransferase 2 (NAT 2) and cytochrome pregnancy zone protein precursor enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a

metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. At the other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been  
5 identified to be due to CYP2D6 gene amplification.

Thus, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding  
10 drug-metabolizing enzymes to the identification of an individual's drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a NOVX modulator, such as a modulator identified by one of the exemplary screening assays described herein.

15

#### **Monitoring of Effects During Clinical Trials**

Monitoring the influence of agents (*e.g.*, drugs, compounds) on the expression or activity of NOVX (*e.g.*, the ability to modulate aberrant cell proliferation and/or differentiation) can be applied not only in basic drug screening, but also in clinical trials. For  
20 example, the effectiveness of an agent determined by a screening assay as described herein to increase NOVX gene expression, protein levels, or upregulate NOVX activity, can be monitored in clinical trails of subjects exhibiting decreased NOVX gene expression, protein levels, or downregulated NOVX activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease NOVX gene expression, protein levels, or  
25 downregulate NOVX activity, can be monitored in clinical trails of subjects exhibiting increased NOVX gene expression, protein levels, or upregulated NOVX activity. In such clinical trials, the expression or activity of NOVX and, preferably, other genes that have been implicated in, for example, a cellular proliferation or immune disorder can be used as a "read out" or markers of the immune responsiveness of a particular cell.

30 By way of example, and not of limitation, genes, including NOVX, that are modulated in cells by treatment with an agent (*e.g.*, compound, drug or small molecule) that modulates NOVX activity (*e.g.*, identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of

expression of NOVX and other genes implicated in the disorder. The levels of gene expression (*i.e.*, a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of NOVX or other genes. In this manner, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.

In one embodiment, the invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (*e.g.*, an agonist, antagonist, protein, peptide, peptidomimetic, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of a NOVX protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the pre-administration sample with the NOVX protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of NOVX to higher levels than detected, *i.e.*, to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of NOVX to lower levels than detected, *i.e.*, to decrease the effectiveness of the agent.

#### Methods of Treatment

The invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant NOVX expression or activity. The disorders include cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, obesity, transplantation, adrenoleukodystrophy, congenital adrenal hyperplasia, prostate cancer, neoplasm; adenocarcinoma, lymphoma, uterus cancer, fertility, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, immunodeficiencies, graft versus

host disease, AIDS, bronchial asthma, Crohn's disease; multiple sclerosis, treatment of Albright Hereditary Osteodystrophy, and other diseases, disorders and conditions of the like.

These methods of treatment will be discussed more fully, below.

## 5            **Disease and Disorders**

Diseases and disorders that are characterized by increased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that antagonize (*i.e.*, reduce or inhibit) activity. Therapeutics that antagonize activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may  
10 be utilized include, but are not limited to: (i) an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; (ii) antibodies to an aforementioned peptide; (iii) nucleic acids encoding an aforementioned peptide; (iv) administration of antisense nucleic acid and nucleic acids that are "dysfunctional" (*i.e.*, due to a heterologous insertion within the coding sequences of coding sequences to an aforementioned peptide) that are utilized to  
15 "knockout" endogenous function of an aforementioned peptide by homologous recombination (*see, e.g.*, Capecchi, 1989. *Science* 244: 1288-1292); or (v) modulators (*i.e.*, inhibitors, agonists and antagonists, including additional peptide mimetic of the invention or antibodies specific to a peptide of the invention) that alter the interaction between an aforementioned peptide and its binding partner.

20 Diseases and disorders that are characterized by decreased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that increase (*i.e.*, are agonists to) activity. Therapeutics that upregulate activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to, an aforementioned peptide, or analogs, derivatives,  
25 fragments or homologs thereof; or an agonist that increases bioavailability.

Increased or decreased levels can be readily detected by quantifying peptide and/or RNA, by obtaining a patient tissue sample (*e.g.*, from biopsy tissue) and assaying it *in vitro* for RNA or peptide levels, structure and/or activity of the expressed peptides (or mRNAs of an aforementioned peptide). Methods that are well-known within the art include, but are not  
30 limited to, immunoassays (*e.g.*, by Western blot analysis, immunoprecipitation followed by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, immunocytochemistry, *etc.*) and/or hybridization assays to detect expression of mRNAs (*e.g.*, Northern assays, dot blots, *in situ* hybridization, and the like).

### Prophylactic Methods

In one aspect, the invention provides a method for preventing, in a subject, a disease or condition associated with an aberrant NOVX expression or activity, by administering to  
5 the subject an agent that modulates NOVX expression or at least one NOVX activity. Subjects at risk for a disease that is caused or contributed to by aberrant NOVX expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the  
10 manifestation of symptoms characteristic of the NOVX aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending upon the type of NOVX aberrancy, for example, a NOVX agonist or NOVX antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein. The prophylactic methods of the invention are further discussed in the  
15 following subsections.

### Therapeutic Methods

Another aspect of the invention pertains to methods of modulating NOVX expression or activity for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of NOVX protein  
20 activity associated with the cell. An agent that modulates NOVX protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of a NOVX protein, a peptide, a NOVX peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more NOVX protein activity. Examples of such stimulatory agents include active NOVX protein and a nucleic acid molecule encoding  
25 NOVX that has been introduced into the cell. In another embodiment, the agent inhibits one or more NOVX protein activity. Examples of such inhibitory agents include antisense NOVX nucleic acid molecules and anti-NOVX antibodies. These modulatory methods can be performed *in vitro* (e.g., by culturing the cell with the agent) or, alternatively, *in vivo* (e.g., by administering the agent to a subject). As such, the invention provides methods of treating  
30 an individual afflicted with a disease or disorder characterized by aberrant expression or activity of a NOVX protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., up-regulates or down-regulates) NOVX expression or activity. In another embodiment, the method involves administering a

NOVX protein or nucleic acid molecule as therapy to compensate for reduced or aberrant NOVX expression or activity.

- Stimulation of NOVX activity is desirable *in situations* in which NOVX is abnormally downregulated and/or in which increased NOVX activity has a beneficial effect. One
- 5 example of such a situation is where a subject has a disorder characterized by aberrant cell proliferation and/or differentiation (*e.g.*, cancer or immune associated disorders). Another example of such a situation is where the subject has a gestational disease (*e.g.*, preclampsia).

#### **Determination of the Biological Effect of the Therapeutic**

- In various embodiments of the invention, suitable *in vitro* or *in vivo* assays are
- 10 performed to determine the effect of a specific Therapeutic and whether its administration is indicated for treatment of the affected tissue.

- In various specific embodiments, *in vitro* assays may be performed with representative cells of the type(s) involved in the patient's disorder, to determine if a given Therapeutic exerts the desired effect upon the cell type(s). Compounds for use in therapy
- 15 may be tested in suitable animal model systems including, but not limited to rats, mice, chicken, cows, monkeys, rabbits, and the like, prior to testing in human subjects. Similarly, for *in vivo* testing, any of the animal model system known in the art may be used prior to administration to human subjects.

#### **Prophylactic and Therapeutic Uses of the Compositions of the Invention**

- The NOVX nucleic acids and proteins of the invention are useful in potential
- 20 prophylactic and therapeutic applications implicated in a variety of disorders including, but not limited to: metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias, metabolic
- 25 disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers.

- As an example, a cDNA encoding the NOVX protein of the invention may be useful in gene therapy, and the protein may be useful when administered to a subject in need thereof. By way of non-limiting example, the compositions of the invention will have
- 30 efficacy for treatment of patients suffering from: metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders,

Alzheimer's Disease, Parkinson's Disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias.

Both the novel nucleic acid encoding the NOVX protein, and the NOVX protein of the invention, or fragments thereof, may also be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. A further use could be as an anti-bacterial molecule (*i.e.*, some peptides have been found to possess anti-bacterial properties). These materials are further useful in the generation of antibodies, which immunospecifically-bind to the novel substances of the invention for use in therapeutic or diagnostic methods.

10



## EXAMPLES

## Example A: Polynucleotide and Polypeptide Sequences, and Homology Data

## Example 1.

- 5 The NOV1 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 1A.

Table 1A. NOV1 Sequence Analysis		
	SEQ ID NO: 1	2813 bp
NOV1a, CG56258-01 DNA Sequence	TCTCGTGTATGGCGTGGTTAAGGTTGCAGCCTCTCACCTCTGCCTTCTCCATTTGG GCTGGTTACCTTTGTGCTCTTCTGAATGGTCTTCGAGCAGAGGCTGGTGGCTCAGGG GACGTGCCAAGCACAGGGCAGAACATGAGTCTGTTCAGGGTCATCGGACTGCAAGG AGGGTGTCTATCTGCAATCTGGTACCCGGAGAACCTTCCCTTGGGGACAAGATTGC CAGGGTCATTGTCTATTTTGTGGCCCTGATATACATGTTCTTGGGGTGTCCATCATT GCTGACCGCTTCATGGCATCTATTGAAGTCATCACCTCTCAAGAGAGGGAGGTGACAA TTAAGAAACCAATGGAGAAACCAGCACAACTATTTCGGGTCTGGAATGAACTGT CTCCAACTGACCTTATGGCCCTGGGTCTCTGCTCTGAGATACTCTCTCTTTA ATTGAGGTGTGTGGTCATGGGTTCATTGCTGGTGATCTGGGACCTTCTACCATTTAG GGAGTGCAGCCTTCAACATGTTTCATCATCATTGGCATCTGTGTCTACGTGATCCAGA CGGAGAGACTCGCAAGATCAAGCATCTACGAGTCTTCTTCATCACCGCTGCTTGGAGT ATCTTTGCCTACATCTGGCTCTATATGATTCTGGCAGTCTTCTCCCCTGGTGTGGTCC AGGTTTGGGAAGGCCTCCTCACTCTCTTCTTCTTCCAGTGTGTGCTCTTGGCCCTG GGTGGCAGATAAACGACTGCTCTTCTACAAATACATGCACAAAAGTACCGCACAGAC AAACACCGAGGAATTATCATAGAGACAGAGGGTGACCACCCTAAGGGCATTGAGATGG ATGGGAAAATGATGAATCCCATTTTCTAGATGGGAACCTGGTGCCCTGGAAGGGAA GGAAGTGGATGAGTCCCGCAGAGAGATGATCCGGATTCTCAAGGATCTGAAGCAAAAA CACCCAGAGAAGGACTTAGATCAGCTGGTGGAGATGGCCAATTACTATGCTCTTTCCC ACCAACAGAAGACCGGTGCTTCTACCGTATCCAAGCCACTCGTATGATGACTGGTGC AGGCAATATCCTGAAGAAACATGCAGCAGAACCAAGCAAGAGGCTCCAGCATGAGC GAGGTGCACACCGATGAGCCTGAGGACTTTATTTCCAAGGTCTTCTTTGACCCATGTT CTTACCAGTGCCTGGAGAACTGTGGGGCTGTACTCTGACAGTGGTGAGGAAAGGGGG AGACATGTCAAAGACCATGTATGTGGACTACAAACAGAGGATGGTTCTGCCAATGCA GGGGCTGACTATGAGTTACAGAGGGCAGCGTGGTTCTGAAGCCAGGAGAGACCCAGA AGGAGTTCTCCGTGGGCATAATTGATGACGACATTTTGAAGGAGGATGAACACTTCTT TGTAAGGTTGAGCAATGTCCGCATAGAGGAGGAGCAGCCAGAGGAGGGGATGCCTCCA GCAATATTCAACAGTCTTCCCTTGCCTCGGGCTGTCTAGCCTCCCCTTGTGTGGCCA CAGTTACCATCTTGGATGATGACCATGCAGGCATCTTCACTTTGAATGTGATACTAT TCATGTCACTGAGAGTATTGGTGTATGGAGGTCAAGGTTCTGCGGACATCAGGTGCC CGGGGTACAGTCATCGTCCCTTTAGGACAGTAGAAGGGACAGCCAAGGGTGGCGGTG AGGACTTTGAAGACACATATGGGGAGTTGGAATTCAAGAATGATGAACTGTGAAAAC TCTTCAGGTGAAGATAGTTGATGACGAGGAATATGAGAAAAAGGATAATTTCTTCATT GAGCTGGGCCAGCCCCAGTGGCTTAAGCGAGGGATTTCAGCTCTGCTACTCAATCAAG GGGATGGGGACAGGAAGCTAACAGCCGAGGAGGAGGAGGCTCGGAGGATAGCAGAGAT GGGCAAGCCAGTTCTTGGGGAGAACTGCCGGCTGGAGGTCTCATCGAGGAGTCATAT GATTTTAAGAACACGGTGGATAAACTCATCAAGAAAACGAACCTTGGCCTTGGTAATTG GGACCCATTTCATGGAGGGAGCAGTTTTTAGAGGCAATTACGGTGAGCGCAGGGGACGA GGAGGAGGAGGAGGACGGGTCCCGGAGGAGCGGCTGCCGTCGTGCTTTGACTACGTG ATGCACTTCTGACGGTGTCTTGAAGGTGCTCTTCGCTGTGTGCCCCCACCAGGT ACTGCCACGGCTGGGCCTGCTTGGTGTCTCCATCTGGTCACTCGGCCTGCTCACCGC CCTCATTTGGGGACCTCGCCTCCCACTTCGGCTGCACCGTTGGCCTCAAGGACTCTGTC AATGCTGTGTCTTCTGCTGGCCTGGGCACCTCCATCCCTGACACGTTTCGCCAGCAAGG TGGCGGCGCTGCAGGACAGTGCGCCGACGCGTCCATCGGCAACGTGACCGGCTCCAA CGCGGTGAACGTGTTCTTGGCCTGGGCGTGCCTGGTCTGTGGCCGCGGTGACTGG GCGGTGCAGGGCCGCCCTTCGAGGTGCGCACTGGCAGCTGGCCTTCTCCGTACGCG	

	TCTTCACCGTCTTCGCCTTCGTGGGCATTGCCGTGCTGCTGTACCGGCGCCGGCCGCA CATCGGCGGCGAGCTGGGCGGCGCCGCGCGGACCCAAGCTCGCCACCACCGCGCTCTTC CTGGGCCTCTGGCTCCTGTACATCCTCTTCGCCAGCCTGGAGGCGTACTGCCACATCC GGGGCTTCTAGGGCCTCGCGCAGAGACTC		
	ORF Start: ATG at 9	ORF Stop: TAG at 2793	
	SEQ ID NO: 2	928 aa	MW at 102900.1kD
NOV1a, CG56258-01 Protein Sequence	MAWLRLQPLTSAFLHFLVTFVLFLNGLRAEAGSGDVPSTGQNNESCSGSSDCKEGLV ILPIWYPENPSLGDKIARVIVYFVALIYMFLGVSIADRFMASIEVITSQEREVTIKK PNGETSTTTIRVWNETVSNLTLMALGSSAPEILLSLIEVCGHGFAGDLGPSTIVGSA AFNMFIIIGICVYVIPDGETRKIKHLRVFFITAAWSIFAYIWLYMILAVFSPGVVQVW EGLLTLLFFFPVCVLLAWVADKRLLFYKYMHHKRYTDKHRGIIETEGDHPKGIEMDGK MMNSHFLDGNLVPLEGKEVDESRREMIRILKDLKQKHPEKDLQVLVEMANYALSHQQ KSRAFYRIQATRMMTGAGNILLKHAEEQAKKASSMSEVHTDEPEDFISKVFFDPCSQY CLENCGAVLLTVVRKGGDMSKTMYVDYKTEDGSANAGADYEFTEGTVVLKPGETQKEF SVGIIDDDIFEDEHFFVRLSNVRIEEQPEEGMPAIFNSLPLPRAVLASPCVATVT ILDDDHAGIFTFECDTIHVSESIGVMEVKVLRVTSARGTIVVPFRVTEGTAKGGGEDF EDTYGELEFKNDET VKTLQVKIVDDEEYKKNDFIELGQPQLKRGISALLNQGDG DRKLTABEEEEARRIAEMGKPVLGENCRLVIIIEESYDFKNTVDKLIKKTNLALVIGTH SWREQFLEAITVSAGDEEEEDGSREERLPSCFDYVMHFLT VFWKVL FACVPPT EYCH GWACFGVSILVIGLLTALIGDLASHFGCTVGLKDSVNAVVFVALGTSI PDTFASKVAA LQDQCADASIGNVTGSNAVNVFLGLGVAVSVAAVYVAVQGRPFVVRTGT LAFSVTLFT VFAFVGIAVLLYRRRPHIGGELGGPRGPKLATTALFLGLWLLYILFASLEAYCHIRGF		
	SEQ ID NO: 3	2840 bp	
NOV1b, CG56258-02 DNA Sequence	GTCTCTGGCCTATCAGGAGGACAACTGGTGCTGCAATAGAAGCCAGTGGCTAAGTCTC GTGTATGGCGTGGTTAAGGTTGCAGCCTCTCACCTCTGCCTTCTCCATTTGGGCTG GTTACCTTTGTGCTCTTCTCTGAATGGTCTTCGAGCAGAGGCTGGTGGCTCAGGGGACG TGCCAAGCACAGGGCAGAACAATGAGTCCTGTTCAAGGTCATCGGACTGCAAGGAGGG TGT CATCTGCCAATCTGGTACCCGGAGAACCCTTCCCTTGGGGACAAGATTGCCAGG GTCATTGTCTATTTTGTGGCCCTGATATACATGTTCTTGGGGTGTCATCATTGCTG ACCGCTTCATGGCATCTATTGAAGTCATCACCTCTCAAGAGAGGGAGGTGACAATTA GAAACCCAATGGAGAAACAGCACAACTACTATTCGGGTCTGGAATGAACTGTCTCC AACCTGACCCTTATGGCCTGGGTTCTCTGCTCCTGAGATACTCTCTCTTTAATTG AGGTGTGTGGTCATGGGTTTATTGCTGGTGATCTGGGACCTTCTACCATTGTAGGGAG TGCAGCCTTCAACATGTTTCATCATCATTGGCATCTGTGTCTACGTGATCCCAGACGGA GAGACTCGAAGATCAAGCATCTACGAGTCTTCTTCATCACCGCTGCTTGGAGTATCT TTGCCTACATCTGGCTCTATATGATTCTGGCAGTCTTCTCCCTGGTGTGGTCCAGGT TTGGGAAGGCCTCCTCACTCTCTTCTTCTTCCAGTGTGTGCTTCTGGCCTGGGTG GCAGATAAACGACTGCTCTTCTACAAATACATGCACAAAAAGTACCGCACAGACAAAC ACCGAGGAATTATCATAGAGACAGAGGGTGACCACCTAAGGGCATTGAGATGGATGG GAAAATGATGAATCCCATTTTCTAGATGGGAACCTGGTGCCCTGGAAGGGAAGGAA GTGGATGAGTCCCGCAGAGAGATGATCCGATTCTCAAGGATCTGAAGCAAAAACACC CAGAGAAGGACTTAGATCAGCTGGTGGAGATGGCCAATTACTATGCTCTTCCCACCA ACAGAAGAGCCGTGCCTTCTACCGTATCCAAGCCACTCGTATGATGACTGGTGCAGGC AATATCCTGAAGAAACATGCAGCAGAACAAGCCAAGAAGGCCTCCAGCATGAGCGAGG TGCACACCGATGAGCCTGAGGACTTTATTTCCAAGGTCTTCTTTGACCCATGTTCTTA CCAGTGCTGTGAGAACTGTGGGCTGTACTCTGTGACAGTGGTGAGGAAAGGGGAGAC ATGTCAAAGACCATGTATGTGGACTACAAAACAGAGGATGGTTCTGCCAATGCAGGGG CTGACTATGAGTTCACAGAGGGCACGGTGGTCTGAAGCCAGGAGAGACCCAGAAGGA GTTCTCCGTGGGCATAATTGATGACGACATTTTGAAGGAGGATGAACACTTCTTTGTA AGGTTGAGCAATGTCCGCATAGAGGAGGAGCAGCCAGAGGAGGGGATGCCTCCAGCAA TATTCAACAGTCTTCCCTTGCCTCGGGCTGTCTAGCCTCCCCTTGTGTGGCCACAGT TACCATCTTGGATGATGACCATGCAGGCATCTTCACTTTTGAATGTGATACTATTTCAT GTCAGTGAGAGTATTGGTGTATGGAGGTCAAGGTTCTGCGGACATCAGGTGCCCGGG GTACAGTCATCGTCCCCTTTAGGACAGTAGAAGGGACAGCCAAGGGTGGCGGTGAGGA CTTTGAAGACACATATGGGGAGTTGGAATTCAAGAATGATGAAACTGTCAAACAATT CACATCAAGGTAATTGATGATGAGGCATATGAGAAAAACAAGAATTACTTCATTGAGA TGATGGGCCCCCGCATGGTGGATAGTGTTCAGAAAGCGCTCTGTTATCTCCAGA CAGGAAGCTGACTATGGAAGAAGAGGAGGCCAAGAGGATAGCAGAGATGGGAAGGCCA		

	GTATTGGGTGAACACCCCAAAGTAGAAGTCATCATTGAAGAGTCCTATGAGTTCAAGA CTACGGTGGACAACTGATCAAGAAGACAAACCTGGCCTTGGTTGTGGGGACCCATT CTGGAGGGACCAAGTTCATGGAGGCCATCACCGTCAGTGCAGCAGGGGATGAGGATGAG GATGAATCCGGGGAGGAGAGGCTGCCCTCCTGCTTTGACTACGTCATGCACCTTCCTGA CTGTCTTCTGGAAGGTGCTGTTTGCCTGTGTGCCCCCACAGAGTACTGCCACGGCTG GGCCTGCTTCGCCCTCTCCATCCTCATCATTGGCATGCTACCGCCATCATTGGGGAC CTGGCCTCGCACTTCGGCTGCACCATTTGGTCTCAAAGATTCAAGTCACAGCTGTTGTTT TCGTGGCATTGGCACCTCTGTCCCAGATACGTTTGCCAGCAAAGCTGCTGCCCTCCA GGATGTATATGCAGACGCCTCCATTGGCAACGTGACGGGCAGCAACGCCGTCATATGTC TTCCTGGGCATCGGCCTGGCCTGGTCCGTGGCCGCCATCTACTGGGCTCTGCAGGGAC AGGAGTTCCACGTGTCGGCCGGCACACTGGCCTTCTCCGTCACCCCTCTTACCACCTTT TGCATTGTCTGCATCAGCGTGCTCTTGACCGAAGGCGCCGACCTGGGAGGGGAG CTTGGTGGCCCCGTGGCTGCAAGCTCGCCACAACATGGCTCTTTGTGAGCCTGTGGC TCCTCTACATACTCTTTGCCACACTAGAGGCCTATTGCTACATCAAGGGGTTCTAA		
	ORF Start: ATG at 63	ORF Stop: TAA at 2838	
	SEQ ID NO: 4	925 aa	MW at 102802.3kD
NOV1b, CG56258-02 Protein Sequence	MAWLRLQPLTSAFLHFLVTFVLFLNGLRAEAGSGDVPSTGQNNESCSGSSDCKE ILPIWYPENPSLDKRIARVIVYFVALIYMFLGVSIADRFMASIEVITSQEREVTIKK PNGETSTTIRVWNETVSNLTLMALGSSAPEILLSLIEVCHGFIAGDLGPSTIVGSA AFNMFIIIGICVYVIPDGETRKIKHLRVFFITAAWSIFAYIWLYMILAVFSPGVQVW EGLLTLEFFPVCVLLAWADKRLLFYKYMHHKYRTDKHRGIIETEGDHPKGIEMDGK MMNSHFLDGNLVPLEGKEVDESRRMIRILKDLKQKHPEKDLQVEMANYALSHQQ KSRAFYRIQATRMMTGAGNILKHAEEQAKKASSMSEVHTDEPEDFISKVFFDPCSYQ CLENCGAVLLTVVRKGGDSKTMVVDYKTEDGSANAGADYEFTEGTVVLKPGETQKEF SVGIIDDDIFEDEHFFVRLSNVRIEEQPEEGMPAIFNSLPLPRAVLASPCVATVT ILDDDHAGIFTFECDTIHVSESIGVMEVKVLRVTSARGTVIIVPFRTEGTAKGGGEDF EDTYGELEFKNDET VKTIHKVIDDEAYEKNKNYFIEMMGPRMVDMSFQKALLSPDR KLTMEEEBAKRIAEMGKPVLGHPKLEVIIEESYEFKTTVDKLIKKTNLALVVGTHSW RDQFMEAITVSAAGDEDEDESGEERLPSCFDYVMHFLT VFWKLVFACVPPEYCHGWA CFAVSILIIIGMLTAIIGDLASHFGCTIGLKDSVTAVVFVAFGTSVPDTFASKAALQD VYADASIGNVTGSNAVNVFLGIGLAWSVAAIYWALQGEFHVSAAGTLPFVTLFTIFA FVCISVLLYRRRPHLGGELGGPRGCKLATTWLFVSLWLLYILFATLEAYCYIKGF		
	SEQ ID NO: 5	2685 bp	
NOV1c, 248057963 DNA Sequence	GGATCCGAGGCTGGTGGCTCAGGGGACGTGCCAAGCACAGGGCAGAACAATGAGTCCT GTTACGGGTTCATCGGACTGCAAGGAGGTGTCTCCTGCCAATCTGGTACCCGGAGAA CCCTTCCCTTGGGGACAAGATTGCCAGGGTCATTGTCTATTTGTGGCCCTGATATAC ATGTTCTTGGGGTGTCCATCATTGCTGACCGCTTCATGGCATCTATTGAAGTCATCA CCTCTCAAGAGAGGGAGGTGACAATTAAGAAACCAATGGAGAAACCAGCACAAACCAC TATTCGGGTCTGGAATGAAACTGTCTCCAACCTGACCCCTATGGCCCTGGGTTCCTCT GCTCCTGAGATACTCTCTCTTTAATTGAGGTGTGTGGTCATGGGTTTCATTGCTGGTG ATCTGGGACCTTCTACCATTTGATAGGGAGTGCAGCCTTCAACATGTTTCATCATCATTGG CATCTGTGTCTACGTGATCCAGACGGAGAGACTCGCAAGATCAAACATCTACGAGTC TTCTTCATCACCGCTGCTTGGAGTATCTTGCCTACATCTGGCTCTATATGATTCTGG CAGTCTTCTCCCTGGTGTGGTCCAGGTTTGGGAAGGCCTCCTCACTCTCTTCTCTT TCCAGTGTGTGCTCTTCTGGCCTGGGTGGCAGATAAACGACTGCTCTTCTACAATAAC ATGCACAAAAAGTACCGCACAGACAAACACCGAGGAATTATCATAGAGACAGAGGGTG ACCACCCTAAGGGCATTGAGATGGATGGGAAAATGATGAATCCCATTTTCTAGATGG GAACCTGGTGCCCTGGAAGGGAAGGAAGTGGATGAGTCCCGCAGAGAGATGATCCGG ATTCTCAAGGATCTGAAGCAAAAACCCAGAGAAGGACTTAGATCAGCTGGTGGAGA TGGCCAATTACTATGCTCTTTCACCAACAGAAGAGCCGCGCTTCTACCGTATCCA AGCCACTCGTATGATGACTGGTGCAGGCAATATCCTGAAGAAACATGCAGCAGAACAA GCCAAGAAGGCCTCCAGCATGAGCGAGGTGCACACCGATGAGCCTGAGGACTTTATTT CCAAGGTCTTCTTTGACCATGTTCTTACCAGTGCCTGGAGAAGTGTGGGGCTGTACT CCTGACAGTGGTGAGGAAAGGGGAGACATGTCAAAGACCATGTATGTGGACTACAAA ACAGAGGATGGTCTGCCAATGCAGGGGCTGACTATGAGTTCACAGAGGGCACGGTGG TTCTGAAGCCAGGAGAGACCCAGAAGGAGTCTCCGTGGGCATAATTGATGACGACAT TTTGTAGGAGGATGAACACTTCTTTGTAAGGTTGAGCAATGTCCGCATAGAGGAGGAG CAGCCAGAGGAGGGGATGCCTCCAGCAATATTCAACAGTCTTCCCTTGCTCGGGCTG		

	TCCTAGCCTCCCTTGTGTGGCCACAGTTACCATCTTGGATGATGACCATGCAGGCAT CTTCACTTTTGAATGTGATACTATTTCATGTGAGAGTATTGGTGTATGGAGGTC AAGGTTCTGCGGACATCAGGTGCCCGGGGTACAGTCATCGTCCCCTTTAGGACAGTAG AAGGGACAGCCAAGGGTGGCGGTGAGGACTTTGAAGACACATATGGGGAGTTGGAATT CAAGATGATGAACTGTGAAAACCATAAGGGTTAAAATAGTAGATGAGGAGGAATAC GAAAGGCAAGAGAATTTCTTCATTGCCCTTGGTGAACCGAAATGGATGGAACGTGGAA TATCAGATGTGACAGACAGGAAGCTGACTATGGAAGAAGAGGAGGCCAAGAGGATAGC AGAGATGGGAAAAGCCAGTATTGGGTGAACACCCCAAAGTGAAGTCATCATTGAAGAG TCCTATGAGTTCAAGACTACGGTGGACAACTGATCAAGAAGACAAACCTGGCCTTGG TTGTGGGGACCCATTCTTGGAGGGACAGTTTCATGGAGGCCATCACCGTCAGTGCAGC AGGGGATGAGGATGAGGATGAATCCGGGGAGGAGAGGCTGCCCTCCTGCTTTGACTAC GTCATGCACTTCCTGACTGTCTTCTGGAAGGTGCTGTTTGCTGTGTGCCCCACAG AGTACTGCCACGGCTGGGCTGCTTCCGCGTCTCCATCCTCATCATTGGCATGCTCAC CGCCATCATTGGGGACCTGGCCTCGCACTTCGGCTGCACCATTTGGTCTCAAAGATTCA GTCACAGCTGTTGTTTTCTGGCATTTCGACCTCTGTCCAGATACGTTTGCCAGCA AAGCTGCTGCCCTCCAGGATGTATATGCAGACGCTCCATTGGCAACGTGACGGGCAG CAACGCCGTCAATGTCTTCTGGGCATCGGCCTGGCCTGGTCCGTGGCCGCCATCTAC TGGGCTCTGCAGGACAGGAGTTCCACGTGTCGGCCGGCAGCACTGGCCTTCTCCGTCA CCCTCTTCAACATCTTTGCAATTTGTCTGCATCAGCGTGCTCTGTACCGAAGGCGGCC GCACCTGGGAGGGAGCTTGGTGGCCCCCGTGGCTGCAAGCTCGCCACAACATGGCTC TTTGTGAGCCTGTGGCTCCTCTACATACTCTTTGCCACACTAGAGGCCTATTGCTACA TCAAGGGGTTCTCGAG		
	ORF Start: at 1	ORF Stop: end of sequence	
	SEQ ID NO: 6	895 aa	MW at 99385.0kD
NOV1c, 248057963 Protein Sequence	GSEAGGSGDVPSTGQNNESCSSDCKEGVILPIWYPENPSLGDKIARVIVYFVALIY MFLGVSIIADRFMASIEVITSQEREVTIKKPNGETSTTTIRVWNETVSNLTLMALGSS APEILLSLIEVCGHGFIAAGLGPSTIVGSAAFNMFIIGICVYVIPDGETRKIKHLRV FFITAAWSIFAYIWLYMILAVFSPGVVQVWEGLLTLFFFPVCVLLAWVADKRLLFYKY MHKKYRTDKHRGIIETEGDHPKGIEMDGKMMNSHFLDGNLVPLEGKEVDESRRMIR ILKDLKQKHPEKDLQLVEMANYALSHQKSRIFYRIQATRMGTAGNLIKHAEEQ AKKASSMSEVHTDEPEDFISKVFFDPCSYQCLENCGAVLLTVVRKGGDMSKTMVVDYK TEDGSANAGADYEFTEGTIVLKPGETQKEFSVGIIDDDIFEEDHEFFVRLSNVRIEE QPEEGMPPAIFNSLPLPRAVLASPCVATVTILDDHAGIFTFECDTIHVSESIGVMEV KVLRTSGARGTVIVPFRTEGTAKGGGEDFEDTYGELEFKNDET VKTIRVKIVDEEY ERQENFFIALGEPKWMERGISDVTDRKLTMEEEEAERIAEMGKPVLGEPKLEVIIE SYEFKTTVDKLIKTNLALVVGTHSWRQFMEAITVSAAGDEDESGEERLPSCFDY VMHFLTVEWKVLFACVPPTEYCHGWACFAVSILIGMLTAIGDLASHFGCTIGLKDS VTAVVFVAFGTSVPDTFASKAAALQDVYADASIGNVTGSNAVNVFLGIGLAWSVAIY WALQGQEFHVSAGTLAFSVTLFTIFAFVCI SVLLYRRRPHLGELGGPRGCKLATTWL FVSLWLLYILFATLEAYCYIKGFLE		

Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 1B.

Table 1B. Comparison of NOV1a against NOV1b and NOV1c.		
Protein Sequence	NOV1a Residues/ Match Residues	Identities/ Similarities for the Matched Region
NOV1b	1..928	833/929 (89%)
	1..925	866/929 (92%)
NOV1c	30..928	808/899 (89%)
	2..893	844/899 (93%)

Further analysis of the NOV1a protein yielded the following properties shown in Table 1C.

<b>Table 1C. Protein Sequence Properties NOV1a</b>	
PSort analysis:	0.6400 probability located in plasma membrane; 0.4600 probability located in Golgi body; 0.3700 probability located in endoplasmic reticulum (membrane); 0.1000 probability located in endoplasmic reticulum (lumen)
SignalP analysis:	Cleavage site between residues 31 and 32

- A search of the NOV1a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 1D.

<b>Table 1D. Geneseq Results for NOV1a</b>				
<b>Geneseq Identifier</b>	<b>Protein/Organism/Length [Patent #, Date]</b>	<b>NOV1a Residues/ Match Residues</b>	<b>Identities/ Similarities for the Matched Region</b>	<b>Expect Value</b>
AAM47745	Human natrium(+)-calcium(2+) exchanger form 3 protein, HNCX3 - Homo sapiens, 927 aa. [WO200183744-A2, 08-NOV-2001]	1..928 1..927	862/929 (92%) 900/929 (96%)	0.0
AAB41497	Human ORFX ORF1261 polypeptide sequence SEQ ID NO:2522 - Homo sapiens, 952 aa. [WO200058473-A2, 05-OCT-2000]	48..928 74..952	701/890 (78%) 788/890 (87%)	0.0
AAM26102	Peptide #139 encoded by probe for measuring placental gene expression - Homo sapiens, 609 aa. [WO200157272-A2, 09-AUG-2001]	1..593 11..608	420/606 (69%) 496/606 (81%)	0.0
AAM13701	Peptide #135 encoded by probe for measuring cervical gene expression - Homo sapiens, 609 aa. [WO200157278-A2, 09-AUG-2001]	1..593 11..608	420/606 (69%) 496/606 (81%)	0.0
AAM53461	Human brain expressed single exon probe encoded protein SEQ ID NO: 25566 - Homo sapiens, 609 aa. [WO200157275-A2, 09-AUG-2001]	1..593 11..608	420/606 (69%) 496/606 (81%)	0.0

- In a BLAST search of public sequence databases, the NOV1a protein was found to have homology to the proteins shown in the BLASTP data in Table 1E.

Table 1E. Public BLASTP Results for NOV1a				
Protein Accession Number	Protein/Organism/Length	NOV1a Residues/ Match Residues	Identities/ Similarities for the Matched Portion	Expect Value
Q96QG1	SODIUM/CALCIUM EXCHANGER SCL8A3 - Homo sapiens (Human), 924 aa.	1..928 1..924	866/929 (93%) 903/929 (96%)	0.0
Q96QG2	SODIUM/CALCIUM EXCHANGER SCL8A3 - Homo sapiens (Human), 925 aa.	1..928 1..925	857/930 (92%) 892/930 (95%)	0.0
P70549	Sodium/calcium exchanger 3 precursor (Na(+)/Ca(2+)-exchange protein 3) - Rattus norvegicus (Rat), 927 aa.	1..928 1..927	848/929 (91%) 895/929 (96%)	0.0
AAL39160	SODIUM/CALCIUM EXCHANGER - Mus musculus (Mouse), 928 aa.	1..928 1..928	837/929 (90%) 879/929 (94%)	0.0
Q9UPR5	Sodium/calcium exchanger 2 precursor (Na(+)/Ca(2+)-exchange protein 2) - Homo sapiens (Human), 921 aa.	48..928 43..921	701/890 (78%) 788/890 (87%)	0.0

Pfam analysis indicates that the NOV1a protein contains the domains shown in Table 1F.

Table 1F. Domain Analysis of NOV1a			
Pfam Domain	NOV1a Match Region	Identities/ Similarities for the Matched Region	Expect Value
Filo_VP35: domain 1 of 1	184..199	7/16 (44%) 10/16 (62%)	6.1
Na_Ca_Ex: domain 1 of 2	110..257	35/153 (23%) 120/153 (78%)	1.2e-32
Glycos_transf_4: domain 1 of 1	760..910	33/215 (15%) 95/215 (44%)	5.7
Na_Ca_Ex: domain 2 of 2	764..912	55/152 (36%) 130/152 (86%)	2.1e-48

**Example 2.**

The NOV2 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 2A.

5

Table 2A. NOV2 Sequence Analysis			
	SEQ ID NO: 7	2277 bp	
NOV2a, CG59843-01 DNA Sequence	CCGGCTCCCGCGCCCTCCCGGCCGGCCATGCAGCCCCGCCGCGCCAGGCGCCCGGTG CGCAGCTGCTGCCCGCGCTGGCCCTGCTGCTGCTGCTCGGAGCGGGGCCCCGAGG CAGCTCCCTGGCCAACCCGGTGCCCGCCGCGCCCTGTCTGCGCCCGGGCCGTGCGCC GCGCAGCCCTGCCGAATGGGGGTGTGTGCACCTCGCGCCCTGAGCCGGAACCCGAGC ACCCGGCCCCCGCGGCGAGCCTGGCTACAGCTGCACCTGCCCGCGGGATCTCCGG CGCCAAC TGCCAGCTTGTGTCAGATCCTTGTGCCAGCAACCCCTGTGACCATGGCAAC TGCAGCAGCAGCAGCAGCAGCAGCAGCGATGGCTACCTCTGCATTTGCAATGAAGGCT ATGAAGGTCCCAACTGTGAACAGGCACTTCCCAGTCTCCCAGCCACTGGCTGGACCGA ATCCATGGCACC CGACAGCTT CAGCCTGTTCTGCTACTCAGGAGCCTGACAAAATC CTGCCCTCGCTCTCAGGCAACGGTGACACTGCCTACCTGGCAGCCGAAAACAGGGCAGA AAGTTGTAGAAATGAAATGGGATCAAGTGGAGGTGATCCCAGATATTGCTGTGGGAA TGCCAGTTCTAACAGCTCTGCGGGTGGCCGCTGGTATCCTTTGAAGTGCCACAGAAC ACCTCAGTCAAGATTTCGGAAGATGCCACTGCCTCACTGATTTTGCTCTGGAAGGTCA CGGCCACAGGATTCCAACAGTGCTCCCTCATAGATGGACGAAGTGTGACCCCCCTTCA GGCTTCAGGGGACTGGTCTCTGGAGGAGATGCTCGCCTTGGGGAATAATCACTTT ATTGGTTTTGTGAATGATTCTGTGACTAAGTCTATTGTGGCTTTCGCTTAACCTGCG TGGTGAAGGTCAGCACCTGTGTGCCGGGGAGAGTCACGCAAATGACTTGGAGTGTTC AGGAAAAGGAAAATGCACCACGAAGCCGTGAGAGGCAACTTTTCTGTACCTGTGAG GAGCAGTACGTGGGTACTTCTGTGAAGAATACGATGCTTGCCAGAGGAAACCTTGCC AAAACAACGCGAGCTGTATTGATGCAAATGAAAAGCAAGATGGGAGCAATTTACCTG TGTTTGCTTCTCGTGTATCTGAGAGCTTTGCCAGTCCAGATTGATTACTGCATC CTAGACCCATGCAGAAATGGAGCAACATGCATTTCCAGTCTCAGTGGATTACCTGCC AGTGTCCAGAAGGATACTTCGGATCTGCTTGTGAAGAAAAGGTGGACCCCTGCGCCTC GTCTCCGTGCCAGAAACACGGCACCTGCTATGTGGACGGGGTACACTTTACCTGCAAC TGCAGCCCGGGCTTACAGGGCCGACCTGTGCCAGCTTATTGACTTCTGTGCCCTCA GCCCTGTGCTCATGGCACGTGCCGCGAGCGTGGGCACCAAGCTACAAATGCCCTCTGTGA TCCAGGTTACCATGGCCTCTACTGTGAGGAGGAATATAATGAGTGCCTCTCCGCTCCA TGCTGAATGCAGCCACCTGCAGGGACCTCGTTAATGGCTATGAGTGTGTGTGCCTGG CAGAATACAAAGGAACACACTGTGAATTGTACAAGGATCCCTGCGCTAACGTGAGCTG TCTGAACGAGCCACCTGTGACAGCGACGGCCTGAATGGCACGTGCATCTGTGCACCC GGGTTTACAGGTGAAGAGTGGCAGATTGACATAAATGAATGTGACAGTAACCCCTGCC ACCATGGTGGGAGCTGCCTGGACCAAGCCCAATGGTTATAACTGCCACTGCCCGCATGG TTGGGTGGGAGCAAACTGTGAGATCCACCTCCAATGGAAGTCCGGGCACATGGCGGAG AGCCTCACCAACATGCCACGGCACTCCCTCTACATCATATTGGAGCCCTCTGCGTGG CCTTCATCCTTATGCTGATCATCCTGATCGTGGGGATTGCGGCATCAGCCGATTGA ATACCAGGGTTCTTCCAGGCCAGCCTATGAGGAGTTCTACAACTGCCGAGCATCGAC AGCGAGTTCAGCAATGCCATTGCATCCATCCGGCATGCCAGGTTTGGAAAGAAATCCC GGCCTGCAATGTATGTGAGCCCCATCGCCTATGAAGATTACAGTCTGTATGACAA ACCCTTGGTCACACTGATTAATAAAGATTGTAAATCTTTTTTTGGATTATTTTTTC AAAAAGATGAGATAC		
	ORF Start: ATG at 28	ORF Stop: TAA at 2239	
	SEQ ID NO: 8	737 aa	MW at 78473.7kD
NOV2a, CG59843-01 Protein Sequence	MQPRRAQAPGAQLLPALALLLLGAGPRGSSSLANPVPAAPLSAPGPCAAQPCRNGGV CTSRPEPDPQHPAPAGEPGYSCTCPAGISGANCLVADPCASNPCHHGNCSSSSSSSS DGYLCICNEGYEGPNCEQALPFLPATGWTESMAPRQLQVPATQEPDKILPRSQATVT LPTWQPKTGQKVVEMKWDQVEVPIPIACGNASSNSSAGRLVSEVPQNTSVKIRQDA TASLILLWKVTATGFQQCSLIDGRSVTPLQASGGLVLLEMLALGNHFI GFVNDSVT		

	KSI VALRLTLVVKVSTCVPGESHANDLECSGKGKCTTKPSEATFSC TCEEQYVGTFC E EYDACQRKPCQNNASCIDANEKQDGSNFTCVCLPGYTGELCQSKIDY CILDPCRNGAT CISSLSGFTQCCEGYFGSACEEKVDPCASSPCQNGTCYVDGVHFTCNCS PGFTGPT CAQLIDFCALSPCAHGTCRSVGT SYKCLCDPGYHGLYCEEYNECL SAPCLNAATCRD LVNGYECVCLAEYKGTHCELYKDP CANVSCLNGATCDS DGLNGTCTICAPGFTGEECDI DINECDSNPCHHGGSCLDQPNGYNCHCPHG WVGANCEIHLQWKSGHMAESLTNMPRHS LYIIIGALCVAFILMLIILIVGICRISRIEYQGSSRPAYEEFYNCRSIDSEFSNAIAS IRHARFGKKS RPAMYDVSPIAYEDYSPDDKPLVTLIKTKDL
--	--

Further analysis of the NOV2a protein yielded the following properties shown in Table 2B.

Table 2B. Protein Sequence Properties NOV2a	
PSort analysis:	0.4600 probability located in plasma membrane; 0.1000 probability located in endoplasmic reticulum (membrane); 0.1000 probability located in endoplasmic reticulum (lumen); 0.1000 probability located in outside
SignalP analysis:	Cleavage site between residues 35 and 36

- 5 A search of the NOV2a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 2C.

Table 2C. Geneseq Results for NOV2a				
Geneseq Identifier	Protein/Organism/Length [Patent #, Date]	NOV2a Residues/ Match Residues	Identities/ Similarities for the Matched Region	Expect Value
AAU29042	Human PRO polypeptide sequence #19 - Homo sapiens, 737 aa. [WO200168848-A2, 20-SEP-2001]	1..737 1..737	737/737 (100%) 737/737 (100%)	0.0
AAB01313	Human PRO299 polypeptide - Homo sapiens, 737 aa. [WO200032776-A2, 08-JUN-2000]	1..737 1..737	737/737 (100%) 737/737 (100%)	0.0
AAY17822	Human PRO299 protein sequence - Homo sapiens, 737 aa. [WO9928462-A2, 10-JUN-1999]	1..737 1..737	737/737 (100%) 737/737 (100%)	0.0
AAW39257	Human membrane protein - Homo sapiens, 737 aa. [JP10036395-A, 10-FEB-1998]	1..737 1..737	737/737 (100%) 737/737 (100%)	0.0
AAW39256	Human partial mature membrane protein - Homo sapiens, 612 aa. [JP10036395-A, 10-FEB-1998]	27..638 1..612	612/612 (100%) 612/612 (100%)	0.0



In a BLAST search of public sequence databases, the NOV2a protein was found to have homology to the proteins shown in the BLASTP data in Table 2D.

Table 2D. Public BLASTP Results for NOV2a				
Protein Accession Number	Protein/Organism/Length	NOV2a Residues/ Match Residues	Identities/ Similarities for the Matched Portion	Expect Value
BAB72175	TRANSMEMBRANE PROTEIN BET - Mus musculus (Mouse), 737 aa.	1..737 1..737	666/737 (90%) 694/737 (93%)	0.0
AAH24766	HYPOTHETICAL 49.8 KDA PROTEIN - Homo sapiens (Human), 459 aa (fragment).	279..737 1..459	459/459 (100%) 459/459 (100%)	0.0
AAH22636	HYPOTHETICAL 42.4 KDA PROTEIN - Mus musculus (Mouse), 389 aa (fragment).	349..737 1..389	371/389 (95%) 382/389 (97%)	0.0
Q9NTF1	HYPOTHETICAL 27.8 KDA PROTEIN - Homo sapiens (Human), 252 aa (fragment).	486..737 1..252	252/252 (100%) 252/252 (100%)	e-158
Q9UDM2	WUGSC:H_NH015002.1 PROTEIN - Homo sapiens (Human), 192 aa (fragment).	384..575 1..192	192/192 (100%) 192/192 (100%)	e-123

- 5 Pfam analysis indicates that the NOV2a protein contains the domains shown in Table 2E.

Table 2E. Domain Analysis of NOV2a			
Pfam Domain	NOV2a Match Region	Identities/ Similarities for the Matched Region	Expect Value
EGF: domain 1 of 10	48..91	17/50 (34%) 34/50 (68%)	0.038
EGF: domain 2 of 10	98..132	16/47 (34%) 27/47 (57%)	1.5e-05
Vinculin: domain 1 of 1	225..248	11/29 (38%) 17/29 (59%)	6.5
EGF: domain 3 of 10	307..347	12/51 (24%) 28/51 (55%)	1.1
EGF: domain 4 of 10	353..389	14/47 (30%) 28/47 (60%)	5.9e-07

EGF: domain 5 of 10	396..427	16/47 (34%) 26/47 (55%)	2.8e-07
metalthio: domain 1 of 1	398..458	17/70 (24%) 29/70 (41%)	5.7
EGF: domain 6 of 10	434..465	16/47 (34%) 25/47 (53%)	2.2e-06
Keratin_B2: domain 1 of 1	343..496	39/194 (20%) 80/194 (41%)	0.72
EGF: domain 7 of 10	472..502	15/47 (32%) 25/47 (53%)	3.2e-07
EGF: domain 8 of 10	509..540	13/47 (28%) 23/47 (49%)	2.2e-06
EGF: domain 9 of 10	547..578	15/47 (32%) 23/47 (49%)	0.00048
DSL: domain 1 of 1	509..578	17/73 (23%) 44/73 (60%)	3.4
EGF: domain 10 of 10	585..616	16/47 (34%) 27/47 (57%)	2.7e-07
Rhabd_glycop: domain 1 of 1	638..684	9/50 (18%) 31/50 (62%)	1.5

**Example 3.**

The NOV3 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 3A.

5

Table 3A. NOV3 Sequence Analysis			
	SEQ ID NO: 9	813 bp	
NOV3a, CG59845-01 DNA Sequence	TTGGGGAGAAGATTAAAAAATGCTAGAGCATGCCAACATATAAAATTCGAAGTCAAT GGTCAAACAGTGCCTCGCATCTCTCACATCACCCACTTGGCCCTCTTCCAAATGTAC TTTACTTCCTCTTCTCATCTCTTCGTTGCTGTCTCCCTTCACAGAACAAATTCATAGTG AATAGCTTAAAGAGGCCAATCTTGGCTCCACTGGGTGGAAGTTGAGCTCAGTTGCC AGCTGTCTCCACCACAAAGCGCAGAACACATGGAAATACGCTGGTTCAGAGTCACTA CACACGACCTGTTTACCTGTATAAGGATGGTAAAGACCTGTATGGAGAACTATCTCC AAGTATGTGGAGCGGACAGAGCTCCTGAAAGAAGCCATTGGAGAAGGTAAAGTGACCC TCAGGATCCTTAATGTCACTGCTGATGATGACGGGCAGTACCACTGCTTCTCAAAGT CAGAAATGTCTATGAAGAGTCCATCACAGAAGTGAAGGTCTCAGATAAACTGTTTCCA TGGAATTCATCTGGATACTGATTCTGGTTGCAATCTTGGCTGTTCTGCTATTCTTCA TTATGTTGGGAAGTGTGTTTCTTTGGAGGAGGAGAGGCACTCTGCGTTTTAGAGTTTC CAGTTTTTCTGTTCTGTTTTTCCCCATCTTTGTGGTTTTATCTACCGACTTGCATGT ACAAAGCTTCAACTCATCTCCTGTCTGGGCCCCCACTTTTAATTCTCATTCTTTGTT ATGCATACAGTCTCAAGCCTTTCTAGGATATTACCAGGGCAGTTGACTGCCTTTAACT G		
	ORF Start: ATG at 31	ORF Stop: TAG at 778	
	SEQ ID NO: 10	249 aa	MW at 28550.3kD

NOV3a, CG59845-01 Protein Sequence	MPTYKIPSQWSNSALASLTSPWPSSKCTLLPLLILSLLSPFTEQFIVNSLKRPI LAP LGGKVELSCQLSPQSAEHMEIRWFQSHYTRPVLYKDGKDL YGETISKYVERTELLK EAIGEGKVTLRILNVSADDDGQYHCFKDRNVYEESITEVKVSDKLFWNISIWILILV AILAVLLFFIMLGTVFLWRRRGT LRFRVSSFSVLFFPHLCGFIYRLACTKLQLILLSG PPLLILILCYAYSLKPF
--	--

Further analysis of the NOV3a protein yielded the following properties shown in Table 3B.

Table 3B. Protein Sequence Properties NOV3a	
PSort analysis:	0.8000 probability located in mitochondrial inner membrane; 0.6000 probability located in plasma membrane; 0.4000 probability located in Golgi body; 0.3000 probability located in endoplasmic reticulum (membrane)
SignalP analysis:	Cleavage site between residues 46 and 47

- 5 A search of the NOV3a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 3C.

Table 3C. Geneseq Results for NOV3a				
Geneseq Identifier	Protein/Organism/Length [Patent #, Date]	NOV3a Residues/ Match Residues	Identities/ Similarities for the Matched Region	Expect Value
AAY44236	Human myelin oligodendrocyte glycoprotein - Homo sapiens, 247 aa. [WO9960021-A2, 25-NOV-1999]	15..242 1..228	103/233 (44%) 147/233 (62%)	5e-45
AAW37543	Human myelin oligodendrocyte glycoprotein - Homo sapiens, 247 aa. [WO9735879-A1, 02-OCT-1997]	15..242 1..228	102/233 (43%) 147/233 (62%)	1e-44
AAR71360	Human MOG - Homo sapiens, 247 aa. [WO9507096-A, 16-MAR-1995]	15..242 1..228	102/233 (43%) 147/233 (62%)	1e-44
AAR70182	Human myelin oligonucleotide glycoprotein (MOG) - Homo sapiens, 247 aa. [WO9506727-A, 09-MAR-1995]	15..242 1..228	102/233 (43%) 147/233 (62%)	1e-44
AAR71361	Human truncated MOG - Homo sapiens, 203 aa. [WO9507096-A, 16-MAR-1995]	15..209 1..197	90/198 (45%) 129/198 (64%)	4e-40

10

In a BLAST search of public sequence databases, the NOV3a protein was found to have homology to the proteins shown in the BLASTP data in Table 3D.

Table 3D. Public BLASTP Results for NOV3a				
Protein Accession Number	Protein/Organism/Length	NOV3a Residues/ Match Residues	Identities/ Similarities for the Matched Portion	Expect Value
Q9BGS7	HYPOTHETICAL 28.2 KDA PROTEIN - Macaca fascicularis (Crab eating macaque) (Cynomolgus monkey), 247 aa.	15..242 1..228	102/233 (43%) 148/233 (62%)	3e-44
Q96KU9	BA145L22.1.1 (MYELIN/OLIGODENDROCYTE GLYCOPROTEIN (MOG) BETA 1 (ISOFORM 1)) - Homo sapiens (Human), 252 aa.	15..242 1..228	102/233 (43%) 147/233 (62%)	3e-44
Q16653	Myelin-oligodendrocyte glycoprotein precursor - Homo sapiens (Human), 247 aa.	15..242 1..228	102/233 (43%) 147/233 (62%)	3e-44
A55717	myelin/oligodendrocyte glycoprotein precursor - mouse, 247 aa.	15..242 1..228	98/233 (42%) 139/233 (59%)	8e-40
CAB89269	BA145L22.1.6 (MYELIN/OLIGODENDROCYTE GLYCOPROTEIN (MOG), ISOFORM 6) - Homo sapiens (Human), 208 aa.	15..209 1..197	90/198 (45%) 129/198 (64%)	1e-39

PFam analysis indicates that the NOV3a protein contains the domains shown in Table 3E.

Table 3E. Domain Analysis of NOV3a			
Pfam Domain	NOV3a Match Region	Identities/ Similarities for the Matched Region	Expect Value
ig: domain 1 of 1	60..143	13/85 (15%) 54/85 (64%)	0.00063
ATP-synt_B: domain 1 of 1	162..177	7/16 (44%) 14/16 (88%)	8.6

5

#### Example 4.

The NOV4 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 4A.

Table 4A. NOV4 Sequence Analysis			
	SEQ ID NO: 11	1536 bp	
NOV4a, CG59871-01 DNA Sequence	TATGTGGGAGGACGGGCTGCCACCCCGCGCGCAGGAACCCTGGTTAGCTTAAGG GATGGAGGCGGGGACCCCTGCGCAGGCTTGC GCGGTGGGAGGCGGGCCGCCGCGACCT ACGACGCCGCGCGCCGGAGGCTGAGAGTTCGGCGCCGGGAGGGTCCCGGGGACAGAA GAGCGCCTCGCCCGGTTGCCAAGGCAACCCACGCGGCTGGAGAAGCGGCGCTCGCA GCCCGGCCGGGCGCGTGCCGGAAGTGACGCGAGTTCACTTCCGCGAGCGGGGCTGGG AGGAGGGGCGGAGGGTGACAGAGGTGCCGCCGCCCGCGAGCCAGTCGGGAGCGCGCG AGGCGCGGGGAGCCTGGGCACCAGGAGCGAGAGCCGCTACCTGCAGCCGCCGCCAC GGCACGGCAGCCACCATGGCGCTCCTGCTGTGCTTCGTGCTCCTGTGCGGAGTAGTGG ATTTCCGCAAGAAGTTTGAGTATCACTACTCCTGAAGAGATGATTGAAAAAGCCAAAGG GGAACTGCCTATCTGCCATGCAAAATTTACGCTTAGTCCCGAAGACCAGGGACCGCTG GACATCGAGTGGCTGATATCACCAGCTGATAATCAGAAGGTGGATCAAGTGATTATTT TATATTCTGGAGACAAAATTTATGATGACTACTATCCAGATCTGAAAGGCCGAGTACA TTTTACGAGTAATGATCTCAAATCTGGTGATGCATCAATAAATGTAAACGAATTTACAA CTGTGCAGATATTGGCACATATCAGTGCAAAGTGAAAAAGCTCCTGGTGTGCAATAA AGAAGATTCACTGGTAGTTCTTGTTAAGCCTTCAGGTGCGAGATGTTACGTTGATGG ATCTGAAGAAATTGGAAGTGACTTTAAGATAAAATGTGAACCAAAAGAAGGTTCACTT CCATTACAGTATGAGTGGCAAAAATGTCTGACTCACAGAAAATGCCCACTTCATGGT TAGCAGAAATGACTTCATCTGTTATATCTGTAAAAATGCCTCTTCTGAGTACTCTGG GACATACAGCTGTACAGTCAGAAACAGAGTGGGCTCTGATCAGTGCCTGTTGCGCTCA AACGTTGTCCCTCCTTCAAATAAAGCTGGACTAATTGCAGGAGCCATTATAGGAAGCTT TGCTTGCTCTAGCGCTCATTGGTCTTATCATCTTTTGCTGTGCGTAAAAAGCGCAGAGA AGAAAAATATGAAAAGGAAGTTCATCACGATATCAGGGAAGATGTGCCACCTCCAAAG AGCCGTACGTCCACTGCCAGAAGCTACATCGGCAGTAATCATTCCTCTGGGGTCCA TGCTCTCCTTCCAACATGGAAGGATATTCGAAGACTCAGTATAACAAGTACCAAGTGA AGACTTTGAACGCACTCCTCAGAGTCCGACTCTCCCACTGTCTAAGGTAGCTGCCCT AATCTAAGTCGAATGGGCGGATTCTGTGATGATTCCCGCACAGAGCAAGGATGGGT CTATAGTATAGAGCCTCCATACATCTCA		
	ORF Start: ATG at 2	ORF Stop: TAG at 1517	
	SEQ ID NO: 12	505 aa	MW at 54859.8kD
NOV4a, CG59871-01 Protein Sequence	MWEDGLPHPRAQEPWFSLRDGGGDPCAGLRRGRPPATYDAARREAESSAPGSGRGQK SASPGCQGNPTRLKXPALAAPGPLEVTRVHLPSGWEEGRRVQRCRRRRREPVGSR GAGSLGTRSESRLPAAAAHGTAATMALLLCFVLLCGVDFARSLSITTPPEEMIEKAKG ETAYLPCKFTLSPEDQGPLDIEWLISPADNQKVDQVILYSGDKIYDDYYPDLKGRVH FTSNDLKSGDASINVTNLQLSDIGTYQCKVKKAPGVANKKIHLVVLVKPSGARCYVDG SEEIGSDFKIKCEPKESLPLQYEWQKLSDSQKMPTSWLAEMTSSVISVKNASSEYSG TYSCTVRNRVGSQCLLRNLNVPPSNKAGLIAGAIIGTLLALALIGLII FCCRKKRRE EKYEKEVHHDIREDVPPPKSRTSTARSYIGSNHSSLGSMSPSNMEGYSKTQYKQVPSE DFERTPQSPTLPPAKVAAPNLSRMGAIPVMI PAQSKDGSIV		

Further analysis of the NOV4a protein yielded the following properties shown in Table 4B.

Table 4B. Protein Sequence Properties NOV4a	
PSort analysis:	0.6000 probability located in plasma membrane; 0.4000 probability located in Golgi body; 0.3000 probability located in endoplasmic reticulum (membrane); 0.3000 probability located in microbody (peroxisome)
SignalP analysis:	No Known Signal Sequence

A search of the NOV4a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 4C.

<b>Table 4C. Geneseq Results for NOV4a</b>				
<b>Geneseq Identifier</b>	<b>Protein/Organism/Length [Patent #, Date]</b>	<b>NOV4a Residues/ Match Residues</b>	<b>Identities/ Similarities for the Matched Region</b>	<b>Expect Value</b>
AAB47270	Human CAR - Homo sapiens, 365 aa. [US6245966-B1, 12-JUN-2001]	141..505 1..365	364/365 (99%) 364/365 (99%)	0.0
AAW57212	Human coxsackievirus and adenovirus receptor - Homo sapiens, 365 aa. [WO9811221-A2, 19-MAR-1998]	141..505 1..365	364/365 (99%) 364/365 (99%)	0.0
AAW69697	Human coxsackievirus and Ad2 and Ad5 receptor HCAR protein - Homo sapiens, 365 aa. [WO9833819-A1, 06-AUG-1998]	141..505 1..365	364/365 (99%) 364/365 (99%)	0.0
AAB50930	Human PRO5723 protein - Homo sapiens, 352 aa. [WO200073452-A2, 07-DEC-2000]	141..483 1..343	339/343 (98%) 339/343 (98%)	0.0
AAB65294	Human PRO5723 protein sequence SEQ ID NO:505 - Homo sapiens, 352 aa. [WO200073454-A1, 07-DEC-2000]	141..483 1..343	339/343 (98%) 339/343 (98%)	0.0

5

In a BLAST search of public sequence databases, the NOV4a protein was found to have homology to the proteins shown in the BLASTP data in Table 4D.

Table 4D. Public BLASTP Results for NOV4a				
Protein Accession Number	Protein/Organism/Length	NOV4a Residues/ Match Residues	Identities/ Similarities for the Matched Portion	Expect Value
P78310	Coxsackievirus and adenovirus receptor precursor (Coxsackievirus B-adenovirus receptor) (hCAR) (CVB3 binding protein) - Homo sapiens (Human), 365 aa.	141..505 1..365	364/365 (99%) 364/365 (99%)	0.0
Q9UKV4	COXSACKIE AND ADENOVIRUS RECEPTOR PROTEIN - Homo sapiens (Human), 344 aa (fragment).	141..479 1..339	338/339 (99%) 338/339 (99%)	0.0
AAK57804	COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR BCAR - Bos taurus (Bovine), 365 aa.	141..505 1..365	331/365 (90%) 345/365 (93%)	0.0
P97792	Coxsackievirus and adenovirus receptor homolog precursor (mCAR) - Mus musculus (Mouse), 365 aa.	141..505 1..365	327/365 (89%) 344/365 (93%)	0.0
Q9DBJ8	COXSACKIEVIRUS AND ADENOVIRUS RECEPTOR - Mus musculus (Mouse), 366 aa.	141..505 1..366	327/366 (89%) 344/366 (93%)	0.0

Pfam analysis indicates that the NOV4a protein contains the domains shown in Table 4E.

Table 4E. Domain Analysis of NOV4a			
Pfam Domain	NOV4a Match Region	Identities/ Similarities for the Matched Region	Expect Value
ig: domain 1 of 2	174..262	13/90 (14%) 62/90 (69%)	0.0054
ig: domain 2 of 2	295..354	11/62 (18%) 46/62 (74%)	1.5e-05
Adeno_E3_CR2: domain 1 of 1	372..417	15/50 (30%) 24/50 (48%)	4.9

5

#### Example 5.

The NOV5 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 5A.

Table 5A. NOV5 Sequence Analysis			
	SEQ ID NO: 13	1302 bp	
NOV5a, CG59883-01 DNA Sequence	ATGAACATGAAATTGCAGATGTCTGTTTTTGACATACTGATTAAAATTCCTTTGGAC CGTATCCAGAAGTGGGATTGATGGATCATAGGTGCGCCAGGCGCGGGGAGCCTAGGAC CTGGAGCGAGAGCCGCCTACCTGCAGCCGCCGCCACGGCACGGCAGCCACCGTGGCC CTCCTGCTGCGCTTCGTGCTCCTGTGCAGAGTCGCGGATTTTCATCAGAGGTTGGAGTA TCACTACTCTGAGCAGATGATTGAAAAAGCCAAAGGGGAAATGCCTATCTGCCATG CAAATTTACGCTTAGTCTGAAGACCAGGGACCACTGGACATCGAGTGGCTGATATCA CCAGCTGATAATCAGAAGGTGGATCAAGTGATTATTTTATATTCTGGAGACAAAAAT ATGATGACTACTATCCAGATCTGAAAGGCCGAGTACATTTTAAGAGTAATGATCTCAA ATCTGGTGATGCATCAATAAATGTAAACGAATTTTCAGCTGTGAGATATTGGCACAGAT CAGTGCAAAGTGAAAAGAGCTCCTGGTGTTGCAAATAGGAAGATTTCAGCTGGTAGTT TTGGTAAGCCTTCAGGTACAAGATGTTACGTTGATGGATCAGAAGAAATTGGAAGTGA CTTTAAATTAAAAATGTGAACCAAAAGAAGGTTCACTTCCATTACAGTATGAGTGGCAA AAATTGTCTGACTCACAGAAAATGCCCACTTCATGGTTAGCAGAAATGACTTCATCTG TTATATCTGTAAAAAAAATGCTTCTTCTGAGTACTCTGGGACATACAGCTGTACAAT CAGAAACAGAGTGGGCTCTGATCAGTGCCTGTTGCGTGTAACGTTGTCCCTCCTTCA AATAAAGCTGGACTAATTGCAGGAGCCATTATAGGAACTTTGCTTGCTCTAGTGCTCA TTGGTCTTATCATCTTTTGTCTGCTAAAAAGCGCAGAGAAGAAAAATATGAAAAGGA AGTTCATCACGATATCAAGGAAGATGTGCCGCTCCAAAGAGCCACACGTCCACTGCC AGAAGCTACATAGGCAGTAATCATTATCCCTGGGATCCATATCTCCTTCCAACATGC AAGGATATTCCAAGACTCAGTATAAACAAGTACCAAGTGAAGACTTTGAACGCACTCC TCAGAGTCCGACTCTCCCACCTGCTAAGGTAGCTGCCCTAATCTAAGTCGAATGGGC GCGATTCTGTGATGATTCCCGCACAGAGCAAGGATGGGTCTATAGTATAGAGCCTCC ATACATCTCATCTGTGCTCTCCGTGT		
	ORF Start: ATG at 1	ORF Stop: TAG at 1267	
	SEQ ID NO: 14	422 aa	MW at 46596.9kD
NOV5a, CG59883-01 Protein Sequence	MNMKLQMSVFDILIKIPLDTPYEVGLMDHRCARRGEPRTWSESRLPAAAAHGTAATVA LLLRFVLLCRVADFIRGWSITTPQMIKAKGETAYLPCKFTLSPEDQGPLDIEWLIS PADNQKVDQVILYSGDKNYDDYYPDLKGRVHFKSNDLKSGDASINVTNQLSDIGTD QCKVKRAPGVANRKIQLVVLGKPSGTRCYVDGSEEIGSDFKLKCEPKESLPLQYEWQ KLSDSQKMPTSWLAEMTSSVISVKKNASSEYSGTYSCTIRNRVGSQCLLRNVVPPS NKAGLIAGAIIGTLLALVLIGLIIFCCRKKRREEKYEKEVHHDIKEDVPPPKSHTSTA RSYIGSNHSSLGSISPSNMEGYSKTQYKQVPSEDFERTPQSPTLPPAKVAAPNLSRMG AIPVMIPAQSKDGSIV		

Further analysis of the NOV5a protein yielded the following properties shown in Table 5B.

Table 5B. Protein Sequence Properties NOV5a	
PSort analysis:	0.6000 probability located in plasma membrane; 0.4000 probability located in Golgi body; 0.3000 probability located in endoplasmic reticulum (membrane); 0.3000 probability located in microbody (peroxisome)
SignalP analysis:	Cleavage site between residues 23 and 24

5

A search of the NOV5a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 5C.



Table 5C. Geneseq Results for NOV5a				
Geneseq Identifier	Protein/Organism/Length [Patent #, Date]	NOV5a Residues/ Match Residues	Identities/ Similarities for the Matched Region	Expect Value
AAB47270	Human CAR - Homo sapiens, 365 aa. [US6245966-B1, 12-JUN-2001]	57..422 1..365	340/366 (92%) 349/366 (94%)	0.0
AAW57212	Human coxsackievirus and adenovirus receptor - Homo sapiens, 365 aa. [WO9811221-A2, 19-MAR-1998]	57..422 1..365	340/366 (92%) 349/366 (94%)	0.0
AAW69697	Human coxsackievirus and Ad2 and Ad5 receptor HCAR protein - Homo sapiens, 365 aa. [WO9833819-A1, 06-AUG-1998]	57..422 1..365	340/366 (92%) 349/366 (94%)	0.0
AAW57213	Mouse coxsackievirus and adenovirus receptor - Mus sp, 376 aa. [WO9811221-A2, 19-MAR-1998]	57..422 1..365	316/366 (86%) 338/366 (92%)	0.0
AAB50930	Human PRO5723 protein - Homo sapiens, 352 aa. [WO200073452-A2, 07-DEC-2000]	57..400 1..343	315/344 (91%) 324/344 (93%)	0.0

In a BLAST search of public sequence databases, the NOV5a protein was found to have homology to the proteins shown in the BLASTP data in Table 5D.

Table 5D. Public BLASTP Results for NOV5a				
Protein Accession Number	Protein/Organism/Length	NOV5a Residues/ Match Residues	Identities/ Similarities for the Matched Portion	Expect Value
P78310	Coxsackievirus and adenovirus receptor precursor (Coxsackievirus B-adenovirus receptor) (hCAR) (CVB3 binding protein) - Homo sapiens (Human), 365 aa.	57..422 1..365	340/366 (92%) 349/366 (94%)	0.0
AAK57804	COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR BCAR - Bos taurus (Bovine), 365 aa.	59..422 3..365	323/364 (88%) 341/364 (92%)	0.0
P97792	Coxsackievirus and adenovirus receptor homolog precursor (mCAR) - Mus musculus (Mouse), 365 aa.	57..422 1..365	317/366 (86%) 339/366 (92%)	0.0

Q9DBJ8	COXSACKIEVIRUS AND ADENOVIRUS RECEPTOR - Mus musculus (Mouse), 366 aa.	57..422 1..366	317/367 (86%) 339/367 (91%)	0.0
Q9R066	COXSACKIE-ADENOVIRUS- RECEPTOR HOMOLOG - Rattus norvegicus (Rat), 358 aa (fragment).	57..415 1..358	314/359 (87%) 332/359 (92%)	0.0

PFam analysis indicates that the NOV5a protein contains the domains shown in Table 5E.

5

Table 5E. Domain Analysis of NOV5a			
Pfam Domain	NOV5a Match Region	Identities/ Similarities for the Matched Region	Expect Value
ig: domain 1 of 2	90..178	12/90 (13%) 62/90 (69%)	37
ig: domain 2 of 2	211..271	11/63 (17%) 43/63 (68%)	0.014
Adeno_E3_CR2: domain 1 of 1	289..334	15/50 (30%) 24/50 (48%)	3.2

#### Example 6.

The NOV6 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 6A.

10

Table 6A. NOV6 Sequence Analysis		
	SEQ ID NO: 15	2412 bp
NOV6a, CG59901-01 DNA Sequence	<p>ATGGCCCGGGCCAGGGCCGGGGCGCTGCTGGCGCTTTGGGTGCTCGGGGCGCGCGC  ATCCCGAGTGCCCTGGACTTCAGGCCGCCCTTCCGGCCGACGCAGCCGCTGCGCCTCTG  CGCGCAGTACTCGGACTTCGGCTGCTGCGATGAGGGGCGCGACGCCGAGCTGACCCGC  CGCTTCTGGGCCCTGGCGAGCCGCTGGACGCCGCCGAGTGGGCGCGTGGCCGGCT  ACGCGAGGGACCTGCTGTGCCAGTCCGTGGAGTGGACAGACATGCAAAGAGATAATGA  AGTCCTAGCCAAGCTGACTGGCTGGAGCGCCCTGGCGACGGAGCAGTACTGCTGTA  GAGAACTCACCCTCTCTGGACTACCCTGGTCTGGGCACCACATTACGTCGTGTGAAT  GCTCGCCGTATGCAGCCACCTCTATGACGCCGAGGACCCATTACGCCCTGCGCAC  GGTGCCCGGGCTCTGCCAGGATTACTGCCTGGACATGTGGCATAAGTGCCGGGGCTG  TTCCGTACCTGTCAACTGACCAGGAGCTCTGGGCGCTGGAGGGCAACCTTGCCAGGT  TCTGCCGCTACCTGTCCCTGGATGACACGGACTACTGCTTCCCTTACCTGCTGGTCAA  CAAGAACCTCAACTCAAACCTGGGCCACGTGGTAGCCGATGCCAAGGGTGCCCTGCAG  CTGTGCCCTGGAGGAGGTGGCCAAACGGGCTGCGCAACCCCGTGGCCATGGTCCATGCCA  GGGATGGCAACCCACCGCTTCTTCGTGGCCGAGCAGGTGGGGCTGGTGTGGGCTACCT  GCCCGACCGCTCGAGGCTGGGAAGCCTTCTCTGAACATCAGCCGGGTGGTGTCTCACC  TCGCCCTGGGAGGTGACGAGCGTGGCTTCTGGGCATTGCCTTCCACCCAGCTTCC  AGCACAAACCGCAGGCTCTACGTCTACTACTCAGTGGGTATCCGACGAGTGAAGTGGAT</p>	

	CCGCATCAGCGAGTTGAGAGTCTCCGAGGATGACGAGAACGCGTGGACCACAGCTCT GAGAGGATAATCCTGGAGGTCAAAGAACCAGCCTCAAACCACAACGGGGGCCAGCTGC TTTTCGGGGATGACGGGTACCTCTACATCTTCACTGGAGATGGCGGGATGGCCGGAGA CCCCTTTGGGACATTTGGAAATGCCCAAACAAGTATGTTTCACTTTTATTGGCTTG TGGGTTGGTCTCCATATCCCTGGGCTTCTCATACTCTTCCAGAGGTGCGCGCTGCTGG GCAAGGTGCTGCGCATCGACGTGGACCCCGAGGTCTACGCCCTAGGCGTGCGCAACAT GTGGCGCTGCTCCTTCGACCGTGCGGACCCCTCCTCGGGCACTGGCCGCGGCGCCTC TTCTGCGGCGACGTGGGCCAGAACAAGTTCGAGGAGGTGGACGTGGTGGAGCGCGGCG GCAACTATGGCTGGCGCGCGCGGAAGGGTTCGAGTGCTACGACCGCAGCCTGTGCGC CAACACCTCTCTCAATGACTTGCTGCCGATTTTCGCCTACCCGCACACGGTTGGCAAG TCGGTCACAGGGGGCTACGTGTACCGGGGCTGCGAGTACCCCAACCTGAACGGCCTCT ACATTTTGGGGATTTTATGAGCGGGCGTCTGATGTCCCTCCAAGAGAACCAGGGAC AGGCCAGTGGCAGTACAGTGAGATCTGCATGGGCCACGGCCAGACCTGTGAGTCCCA GGCCTCATCAACAATACTACCCGTACATCATCTCCTTCGGGGAGGACGAGGCCGGGG AGCTGTACTTCAATGTCGACAGGGGAGCCGAGTGCCACAGCTCCACGCGAGTTGTCTA CAAAATAATTGACGCATCCAGAGTTCATCCCGAAGACACGGAGCACCCCGCGGCCTAC AGCGCGGGCGCCACGCGGGCGCCCGGAGGGCGCCACGCGCGCTCCCCCGCGCGC CAACCCCGCGGCCAGCGCGGCCACCCAGCAGCCAGGGAGCCGGAGGGCGCGGGCG GCGGGCGGGGGCGGTGAACCTCGGCGAGCCGGCGTTCCGGGATGGCGAGGTGCGCCTG GTGCGGCCCGCGGGCCTGAGCTCTGGCAGCGGGCGGTGGAGGTGTTCTGTGGGCGGAC GCTGGGCGACCGTGTGCGACGACTCCTGGAACATCAGCGCGCGCCCGCTGCTGTGTCG CCAGCTGGGGTTTGCTACGCCGTGCGCGCGCTCAAGAGAGCCGAGTTTCGGCCAGGGC GGCTCGCTGCGCATTTCTGCTGGACGATGTGCGCTGCGCGGGCTGGGAGCGGAACCTGC TGGAGTGCCAGCACACGCGGTGGGCACCCACAACCTGCGAGCAGCAGGAGTGGCGG CGTCGTGTGCAGCCACCAGAACCCCGACCTGTAG		
	ORF Start: ATG at 1	ORF Stop: TAG at 2410	
	SEQ ID NO: 16	803 aa	MW at 88653.7kD
NOV6a, CG59901-01 Protein Sequence	MARARAGALLALWVLGAAHPQCLDFRPPFRPTQPLRLCAQYSDFGCCDEGRDAELTR RFWALASRVDAEWAACAGYARDLLCQSVETDMQRDNEVLAKLTGWSAPGDGAVTAV ENSPSLDYPGLGTTFTSCECSPYAAHLYDAEDPFTPLRTVPLCQDYCLDMWHKCRGL FRHLSTDQELWALEGNLARFCRYLSLDDTDYCFPYLLVNKNLNSNLGHVVADAKGLQ LCLEEVANGLRNPVAMVHARDGTHRFVAEQVGLVWAYLPDRSRLGKPFNLISRVVLT SPWEGDERGFLGIAFHPSFQHNRLYVYYSVGIRSEWIRISEFRVSEDDENAVHSS ERIILEVKEPASNHNGQLLFDDGYLYIFTGDGGMAGDPFGTFGNAQNKYVQLLIGL WVGLHIPGLLILFORSALLGKVLRIDVDPEVYALGVRNMWRCSFDRGDPSSGTGRGL PCGDVGQNKFEEDVVERGGNYGWRAREGFECYDRSLCANTSLNDLLPIFAYPHTVGK SVTGGYVYRGCEYPNLNGLYIFGDFMSGRLMSLQENPGTGQWQYSEICMHGQTCFEP GLINNYYPYIISFGEDEAGELYFMSTGEPSATAPRGVVYKIIDASRVHPEDTEHPAAY SAGAHAGARRGRPTAAPPTPRPARPTQQPGSRRGGRRRRLNSASRAFRDGEVRL VRPAGLSSSGRVEVFVGGRWGTVCDDSWNISGAAVVCRQLGFAYAVRAVKRAEFGQG GSLPILDDVRCAGWERNLLECQHNGVGTHNCEHDEDAGVVCSHQNPDL		

Further analysis of the NOV6a protein yielded the following properties shown in Table 6B.

Table 6B. Protein Sequence Properties NOV6a	
PSort analysis:	0.4600 probability located in plasma membrane; 0.2073 probability located in microbody (peroxisome); 0.1000 probability located in endoplasmic reticulum (membrane); 0.1000 probability located in endoplasmic reticulum (lumen)
SignalP analysis:	Cleavage site between residues 20 and 21

A search of the NOV6a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 6C.

Table 6C. Geneseq Results for NOV6a				
Geneseq Identifier	Protein/Organism/Length [Patent #, Date]	NOV6a Residues/ Match Residues	Identities/ Similarities for the Matched Region	Expect Value
AAU12201	Human PRO1779 polypeptide sequence - Homo sapiens, 724 aa. [WO200140466-A2, 07-JUN-2001]	20..629 42..605	343/636 (53%) 410/636 (63%)	0.0
AAB25594	Protein encoded by human secreted protein gene #1 - Homo sapiens, 724 aa. [WO200029435-A1, 25-MAY-2000]	20..629 42..605	343/636 (53%) 410/636 (63%)	0.0
AAB94773	Human protein sequence SEQ ID NO:15860 - Homo sapiens, 529 aa. [EP1074617-A2, 07-FEB-2001]	223..629 2..410	269/432 (62%) 319/432 (73%)	e-159
AAB25576	Protein encoded by human secreted protein gene #1 - Homo sapiens, 529 aa. [WO200029435-A1, 25-MAY-2000]	223..629 2..410	269/432 (62%) 319/432 (73%)	e-159
AA Y97561	Mouse Hedgehog interacting protein sequence - Mus musculus, 700 aa. [WO200074706-A1, 14-DEC-2000]	93..631 50..593	183/615 (29%) 272/615 (43%)	5e-59

5

In a BLAST search of public sequence databases, the NOV6a protein was found to have homology to the proteins shown in the BLASTP data in Table 6D.

Table 6D. Public BLASTP Results for NOV6a				
Protein Accession Number	Protein/Organism/Length	NOV6a Residues/ Match Residues	Identities/ Similarities for the Matched Portion	Expect Value
Q96JK4	KIAA1822 PROTEIN - Homo sapiens (Human), 533 aa (fragment).	299..803 1..533	464/556 (83%) 466/556 (83%)	0.0
Q91638	GENE 5 PROTEIN - Xenopus laevis (African clawed frog), 995 aa.	5..626 39..606	346/648 (53%) 419/648 (64%)	0.0

Q9H8A0	CDNA FLJ13840 FIS, CLONE THYRO1000783, MODERATELY SIMILAR TO XENOPUS LAEVIS TAIL-SPECIFIC THYROID HORMONE UP-REGULATED (GENE 5) MRNA - Homo sapiens (Human), 529 aa.	223..629 2..410	269/432 (62%) 319/432 (73%)	e-159
Q9D2G9	4930507C10RIK PROTEIN - Mus musculus (Mouse), 497 aa.	248..629 1..383	260/407 (63%) 299/407 (72%)	e-148
Q96BT4	SIMILAR TO HYPOTHETICAL PROTEIN FLJ13840 - Homo sapiens (Human), 256 aa.	223..475 2..256	168/278 (60%) 195/278 (69%)	1e-91

PFam analysis indicates that the NOV6a protein contains the domains shown in Table 6E.

Table 6E. Domain Analysis of NOV6a			
Pfam Domain	NOV6a Match Region	Identities/ Similarities for the Matched Region	Expect Value
SRCR: domain 1 of 1	699..797	49/115 (43%) 73/115 (63%)	6.2e-25

5

#### Example 7.

The NOV7 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 7A.

Table 7A. NOV7 Sequence Analysis		
	SEQ ID NO: 17	2111 bp
NOV7a, CG88748-01 DNA Sequence	GTCCTCTGTGACCTTCTTCTTGGCCCTCTTCTGGCAGATAAGTGCTCTGGTTGTACA TGGAGGATGACCGAAAAAACC AATGGTGTGAAGAGCTCCCCAGCCAATAATCACAAACC ATCATGCACCTCCTGCCATCAAGGCCAATGGCAAAGATGACCACAGGACAAGCAGCAG GCCACACTCTGCAGCTGACGATGACACCTCCTCAGAACTGCAGAGGCTGGCAGACGTG GATGCCCCACAGCAGGGAAGGAGTGGCTTCCGCAGGATAGTTTCGCCTGGTGGGGATCA TCAGAGAATGGGCCAACAAGAATTTCCGAGAGGAGGAACCTAGGCCTGACTATTTCCT CGAGCGTTTTCGTGGGCCTGAACTCCAGACTGTGACCACACAGGAGGGGGATGGCAA GGCGACAAGGATGGCGAGGACAAAGGCACCAAGAAGAAATTTGAACTATTGTCTTGG ACCCAGCTGGGGATTGGTACTACTGCTGGCTATTTGTCATTGCCATGCCCGTCCCTTTA CAACTGGTGCCTGCTGGTGGCCAGAGCCTGCTTCAGTGACCTACAGAAAGGCTACTAC CTGGTGTGGCTGGTGTGGATTATGTCTCAGATGTGGTCTACATTGCCGACCTCTTCA TCCGATTGGCAGCAGGTTTCTGGAGCAGGGGCTGCTGGTCAAAGATACCAAGAACT GCGAGACAACTACATCCACACCTGCAGTTCAAGCTGGATGTGGCTTCCATCATCCCC ACTGACCTGATCTATTTGCTGTGGACATCCACAGCCCTGAGGTGCGCTTCAACCGCC TGCTGCACCTTGCCCCATGTTTGAGTTCTTTGACCGACAGAGACACGCACCAACTA CCCTAACATCTTCCGCATCAGCAACCTTGTCCTCTACATCTTGGTCATCATCCACTGG AATGCCTGCATCTATTATGCCATCTCCAAATCCATAGGCTTTGGGTCGACACCTGGG	

	TTTACCCAAACATCACTGACCCTGAGTATGGCTACCTGGCTAGGGAATACATCTATTG CCTTTACTGGTCCACACTGACTCTCACTACCATTTGGGGAGACACCACCCCTGTAAAG GATGAGGAGTACCTATTGTGCATCTTTGACTTCCTGATTGGCGTCTCATCTTTGCCA CCATCGTGGGAAATGTGGGCTCCATGATCTCCAACATGAATGCCACCCGGGCAGAGTT CCAGGCTAAGATCGATGCCGTGAAACACTACATGCAGTTCGAAAGGTGAGCAAGGGG ATGGAAGCCAAGGTCATTAGGTGGTTTGAATACTTGTGGACCAATAAGAAGACAGTGG ATGAGCGAGAAATTTCAAGAATCTGCCAGCCAAGCTCAGGGCTGAGATAGCCATCAA TGTCCACTTGTCCACACTCAAGAAAGTGCGCATCTTCCATGATTGTGAGGCTGGCCTG CTGGTAGAGCTGGTACTGAAACTCCGTCTCAGGTCTTCAGTCTCTGGGATTACATTT GCCGCAAAGGGGACATCGGCAAGGAGATGTACATCATTAAAGGAGGGCAAAGTGGCAGT GGTGGCTGATGATGGTGTGACTCAGTATGCTCTGCTGTCTGGCTGGAAGCTGCTTTGGC GAGATCAGTATCCTTAACATTAAGGGCAGTAAAATGGGCAATCGACGCACAGCTAATA TCCGCAGCCTGGGCTACTCAGATCTCTTCTGCTTGTCCAAGGATGATCTTATGGAAGC TGTGACTGAGTACCCTGATGCCAAGAAAGTCTAGAAGAGAGGGGTGCGGAGATCCTC ATGAAGGAGGGACTGCTGGATGAGAACGAAGTGGCAACCAGCATGGAGGTGCGAGTGC AGGAGAAGCTAGGGCAGCTGGAGACCAACATGGAACCTTGTACACTCGCTTTGGCCG CCTGCTGGCTGAGTACACGGGGGCCAGCAGAAGCTCAAGCAGCGCATCACAGTTCTG GAAACCAAGATGAAACAGAACAAATGAAGATGACTACTGTCTGATGGGATGAACAGCC CTGAGCTGGCTGCTGCTGACGAGCCATAAGACCTGGGGCCCACTGCCTCTCCAGCAT TGGCCTTGGCCTTGATCCAGAA		
	ORF Start: ATG at 65	ORF Stop: TAA at 2057	
	SEQ ID NO: 18	664 aa	MW at 76047.3kD
NOV7a, CG88748-01 Protein Sequence	MTEKTNGVKSSPANNHNHAPPAIKANGKDDHRTSSRPSSAADDDTSSELQRLADVDA PQQRSGFRIRIVRLVGIIREWANKNFREEPRPDSFLERFRGPELQTVTTQEGDGKGD KDGEDKGTKKKFELFVLDPAWDWYICWLFVIAMPVLYNWCLLVARACFSDLQKGYLLV WLVLVYVSDVYIADLFIRLRTGTFLEQGLLVKDTKKLRDNYIHTLQFKLDVASIIPD LIYFAVDIHSPEVRFNRLLHFARMFEFFDRTETRTNYPNIFRISNLVLYILVLIHWN CIYYAISKSIGFVDTWVYPNITDPEYGYLAREYIYCLYWSLTLLTTIGETPPPVKDE EYLFVIFDFLIGVLIFATIVGNVSGMISNMNATRAEFQAKIDAVKHYMQFRKVSKGME AKVIRWFDYLTWNKKTVDEREILKNLPAKLRAEIAINVHLSTLKKVRI FHDCEAGLLV ELVLKLRPQVFS PGDYICRKGDIGKEMYIIKEGKLAVVADDGVTQYALLSAGSCFGEI SILNIKSGMKGNRRTANIRSLGYSDFCLSKDDLMEAVTEYPDAAKVLLEERGRI LMK EGLDENEVATSMEDVDQEKLGQLETNMETLYTRFGRLLAEYTGAAQQLKQRITVLET KMKQNNEDDYLSDGMNSPELAAADEP		

Further analysis of the NOV7a protein yielded the following properties shown in Table 7B.

Table 7B. Protein Sequence Properties NOV7a	
PSort analysis:	0.6000 probability located in plasma membrane; 0.4000 probability located in Golgi body; 0.3000 probability located in endoplasmic reticulum (membrane); 0.3000 probability located in microbody (peroxisome)
SignalP analysis:	No Known Signal Sequence

- 5 A search of the NOV7a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 7C.

Table 7C. Geneseq Results for NOV7a				
Geneseq Identifier	Protein/Organism/Length [Patent #, Date]	NOV7a Residues/ Match Residues	Identities/ Similarities for the Matched Region	Expect Value
AAE04894	Human transporter and ion channel-7 (TRICH-7) protein - Homo sapiens, 664 aa. [WO200146258-A2, 28-JUN-2001]	1..664 1..664	664/664 (100%) 664/664 (100%)	0.0
AAM47673	MOL10b protein sequence - Homo sapiens, 575 aa. [WO200181578-A2, 01-NOV-2001]	124..657 18..555	290/540 (53%) 394/540 (72%)	e-170
AAM47672	MOL10a protein sequence - Unidentified, 578 aa. [WO200181578-A2, 01-NOV-2001]	132..657 27..558	290/534 (54%) 391/534 (72%)	e-168
ABG27071	Novel human diagnostic protein #27062 - Homo sapiens, 259 aa. [WO200175067-A2, 11-OCT-2001]	198..399 57..258	151/202 (74%) 176/202 (86%)	3e-88
ABG27071	Novel human diagnostic protein #27062 - Homo sapiens, 259 aa. [WO200175067-A2, 11-OCT-2001]	198..399 57..258	151/202 (74%) 176/202 (86%)	3e-88

In a BLAST search of public sequence databases, the NOV7a protein was found to have homology to the proteins shown in the BLASTP data in Table 7D.

5

Table 7D. Public BLASTP Results for NOV7a				
Protein Accession Number	Protein/Organism/Length	NOV7a Residues/ Match Residues	Identities/ Similarities for the Matched Portion	Expect Value
S35691	cyclic nucleotide-gated channel protein - rabbit, 732 aa.	1..664 69..732	624/664 (93%) 643/664 (95%)	0.0
Q28718	Cyclic-nucleotide-gated olfactory channel (Cyclic-nucleotide-gated cation channel 2) (CNG channel 2) (CNG-2) (CNG2) (Aorta CNG channel) (RACNG) - Oryctolagus cuniculus (Rabbit), 664 aa.	1..664 1..664	624/664 (93%) 643/664 (95%)	0.0

Q03041	Cyclic-nucleotide-gated olfactory channel (Cyclic-nucleotide-gated cation channel 2) (CNG channel 2) (CNG-2) (CNG2) - Bos taurus (Bovine), 663 aa.	1..657 1..657	618/657 (94%) 639/657 (97%)	0.0
Q62398	Cyclic-nucleotide-gated olfactory channel (Cyclic-nucleotide-gated cation channel 2) (CNG channel 2) (CNG-2) (CNG2) - Mus musculus (Mouse), 664 aa.	1..662 2..664	618/663 (93%) 636/663 (95%)	0.0
Q00195	Cyclic-nucleotide-gated olfactory channel (Cyclic-nucleotide-gated cation channel 2) (CNG channel 2) (CNG2) (CNG-2) (OCNC1) - Rattus norvegicus (Rat), 664 aa.	1..662 2..664	615/663 (92%) 636/663 (95%)	0.0

PFam analysis indicates that the NOV7a protein contains the domains shown in Table 7E.

Table 7E. Domain Analysis of NOV7a			
Pfam Domain	NOV7a Match Region	Identities/ Similarities for the Matched Region	Expect Value
ion_trans: domain 1 of 1	174..371	35/236 (15%) 152/236 (64%)	5.1e-22
cNMP_binding: domain 1 of 1	469..565	34/120 (28%) 81/120 (68%)	1.4e-25

5

#### Example 8.

The NOV8 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 8A.

Table 8A. NOV8 Sequence Analysis		
	SEQ ID NO: 19	2273 bp
NOV8a, CG90021-01 DNA Sequence	TCCTTTCCTTCCCATGTCTTTGGATGACTATCGCTGGGCTGGGACATGAGGCGGGC AGAGGCGCGGGTCACCTTAGGACCCCCCTCTTGCTGCTGGGGCTCTGGGCGCTCCTG GCTCCGGTCCGGTGTCTCAAGGCCGTCCCTTGTGGCACTATGCCTCCTCCGAGGTGG TGATTCCCAGGAAGGAGACACCATAGCAAAGGCCTTCAGTTTCCCAGGCTGGCTGTC CTACAGCCTGTGTTTGGGTTTGGGGTCAAAGACACGTCATTACATGCGGAGGAAA CACCTTCTTTGGCCTAGACATCTGCTGGTGACAACCTCAGGATGACCAAGGAGTCTTGC AGATGGGTGACCCCTACATCCCTCCAGACTGCTACTACCTCGGCTACCTGGAGGAGGT GCCTCTGTCCATGGTCACCGTCGACACGTGCTATGGGGACCTCAGAGGCATCATGAGG CTGGACGACCTTGCGTACGAAATCAAACCCCTCCAGGATTCGCGCAGGTTTGAACATG TTGTTTTTCAGATAGTGGCCGAGCCCAACGCAACAGGGCCACATTTAGAGATGATGA CAATGAGACAGACCCCTGTTCTCTGAAGCAAATGACAGCATGAATCCAGGATATCT	



	AATTCGCTGTATAGTTCTCATAGAGGCAATATAAAAGGCCACGTTCAATGTTCCAATT CATATTATCGCATATATGGCAATATTACAACCTTGTTCCAAAGAGGTGGTCCAGATGTT CAGTCTCATTGACAGCATTGCTCAAAATATTGATCTGCGGTACTATATTTATCTTTTG ACCATATATAAATCGTGACCCAGCCCCTGTGAATGAATATCGAATTCAGAGTGCAA TGTTTACCTATTTTAAACAACCTTTTGTGATACTTTTCATGTTTCATCCACACT ACTTATTAATAACGTGCCACATGAATCTAATCTGAACCTGAAAGGTATAACTTCTGT TCCCGTATAGCCCTGTTACACATTGGTACTCCAGGCAGACATTATTTATTGGTAGCCG TCATAATAACCCAGACACAGATGAGAAGTATTGGTCTGGAGTATGATGATAACTACTG CACATGTCAGAGAAGGGCCTCCTGCATTATGCAGCGATTTCTGGGATGACAGATGCG TTCAGTAACTGTTCTTATGGACATGCACAAAATGTTTTATACATTAGGCCGCTGTG TTTTTGAAACACTTGCTCCTGTGTATAACGAAACCATGACAACGGTTCGCTGTGGAAA CCTCATAGTGGAGGGGAGGGAGGAATGTGACTGTGGCTCCTTCAAGCAGTGTATGCC AGTTATTGCTGCCAAAGTGACTGTCACTTAACACCGGGGAGCATCTGCCATATAGGAG AGTGCTGTACAACTGCAGCTTCTCCCCACCAGGGACTCTCTGCAGACCTATCCAAAA TATATGTGACCTTCAGAGTACTGTACGGGACCACCGTGACATGTCCCGCAAAGTT TATATGCAAGATGGAACCCCGTGCACTGAAGAAGGCTACTGCTATCGTGGGAATGCA CTGATCGCAATGTGCTCTGCAAGGCGATCTTTGGTGTGCTGCTGAGGATGCTCCCGA GGTCTGCTATGACATAAATCTTGAAGCTACCGATTGGACATTGTATTAGACAACAA ACATATCTCAGCTACCAGGCTTGTGCAGGAATAGATAAGTTTGTGGAAGACTGCAGT GTACCAATGTGACCCATCTTCCCGGCTGCAGGAACGTGTTTCATTCCATCACTCAGT GAGAGGAGGGTTTCAGTGTGTTGGACTGGATGAACACCATGCAACAGACACGACTGAT GTTGGGCGTGTGATAGATGGCACTCCTTGTGTTTCATGAAACTTCTGTAATAACACCC AGTGCAATGTGACTATCACTTCACTGGGCTACAACCTGCCACCTCAGAAGTCCGGTCA TAGAGGAGTCTGCAACAACAGAAAGGAAGTCCATTGCCATATAGGCTGGGATCTCCCA CTGTGCCAAGAAGAGGTGCTGGTGGGAGTGTCAACAGCGGGCCACCTCCAAAAAGAA CACGTTCCGTCAAACAAAGCCAGCAATCAGTGATGTATCTGAGAGTGGTCTTTGGTCG TATTTACGCCTTCATAATTGCACTGCTCTTTGGGACAGCCAAAAATGTGCGAATATC AGGACCACACCGTTAAGGAAGGGACAGTTACTAACCTGAATAACACTAATTACGCC TCCCGATCCCT		
	ORF Start: ATG at 48	ORF Stop: TAA at 2247	
	SEQ ID NO: 20	733 aa	MW at 83206.8kD
NOV8a, CG90021-01 Protein Sequence	MRRAEARVTLRTPLLLLGLWALLAPVRCSQGRPLWHYASSEVVI PRKETHHSGKGLQFP GWLSSYSLCFGWQQRHVHMRKHLLWPRHLLVTTQDDQGLVQMGPDI PPDCYVLYG LEEVPLSMVTVDTCYDLRGIMRLDDLAYEIKPLQDSRRFEHVVFQIVAEPNATGPTF RDDDNETDPLFSEANDSMNPRISNSLYSSHRGNIKGHVQCSNSYYRIYGNITTSKEV VQMFSLIDSIAQNIDLRYYIYLLTIYNNRDPAPVNEYRIQSAMFTYFKTTFFDTFHVH SSTLLIKYVPHESNYEPERYNFCSRILLHIGTPGRHYLLVAVIITQTQMRSIGLEYD DNYCTCQRRASCIMQRFPGMTDAFSNCSYGHANCFIHSGRVCFETLAPVYNETMTTV RCGNLIVEGREEDCGSFKQCYASYCCQSDCHLTPGSI CHIGECCTNCSFSPPGTLCR PIQNICDLPEYCHGTTVTCPANVYMQDGTPTTEGYCYRGNCTDRNVLCALFVSAE DAPEVCYDINLESYRFGHCIRQQTYSYQACAGIDKFCGRLQCTNVTHLPRLQERVSF HHSVRGGFQCFGLDEHHTDITDVGVRVIDGTPCVHGNFCNNTQCNVITSLGYNCHPQ KCGHRGVCNNRRNCHCHIGWDPPLCLRRGAGGSVNSGPPPKRTRSVKQSQSVMYLRV VFGRIYAFIALLFGTAKNVRTIRTTTVKEGTVTNPE		

Further analysis of the NOV8a protein yielded the following properties shown in Table 8B.

Table 8B. Protein Sequence Properties NOV8a	
PSort analysis:	0.4600 probability located in plasma membrane; 0.3000 probability located in lysosome (membrane); 0.2800 probability located in endoplasmic reticulum (membrane); 0.1000 probability located in endoplasmic reticulum (lumen)
SignalP analysis:	Cleavage site between residues 32 and 33

A search of the NOV8a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 8C.

Table 8C. Geneseq Results for NOV8a				
Geneseq Identifier	Protein/Organism/Length [Patent #, Date]	NOV8a Residues/ Match Residues	Identities/ Similarities for the Matched Region	Expect Value
AAU72892	Human metalloprotease partial protein sequence #4 - Homo sapiens, 731 aa. [WO200183782-A2, 08-NOV-2001]	1..733 1..731	639/734 (87%) 669/734 (91%)	0.0
AAE15652	Human disintegrin-like protein, NOV3 - Homo sapiens, 737 aa. [WO200194416-A2, 13-DEC-2001]	1..733 1..737	609/740 (82%) 645/740 (86%)	0.0
AAE14340	Human protease PRPS-5 protein - Homo sapiens, 576 aa. [WO200183775-A2, 08-NOV-2001]	447..733 294..576	253/287 (88%) 263/287 (91%)	e-157
AAB47561	Protease PRPS-3 - Homo sapiens, 559 aa. [WO200171004-A2, 27-SEP-2001]	1..329 1..332	270/335 (80%) 283/335 (83%)	e-153
AAV28655	Human SVPH1-8 protease - Homo sapiens, 722 aa. [WO9936549-A1, 22-JUL-1999]	8..676 8..675	243/692 (35%) 365/692 (52%)	e-123

5

In a BLAST search of public sequence databases, the NOV8a protein was found to have homology to the proteins shown in the BLASTP data in Table 8D.

Table 8D. Public BLASTP Results for NOV8a				
Protein Accession Number	Protein/Organism/Length	NOV8a Residues/ Match Residues	Identities/ Similarities for the Matched Portion	Expect Value
Q28484	TESTICULAR METALLOPROTEASE-LIKE, DISINTEGRIN-LIKE, CYSTEINE-RICH PROTEIN IVA - Macaca fascicularis (Crab eating macaque) (Cynomolgus monkey), 732 aa.	1..733 1..732	622/734 (84%) 666/734 (89%)	0.0

Q28485	TESTICULAR METALLOPROTEASE-LIKE, DISINTEGRIN-LIKE, CYSTEINE-RICH PROTEIN IVB - <i>Macaca fascicularis</i> (Crab eating macaque) ( <i>Cynomolgus</i> monkey), 713 aa (fragment).	20..733 1..713	603/715 (84%) 651/715 (90%)	0.0
O19050	CELLULAR DISINTEGRIN ADAM 6D - <i>Oryctolagus cuniculus</i> (Rabbit), 731 aa.	4..733 4..731	424/736 (57%) 526/736 (70%)	0.0
O19051	CELLULAR DISINTEGRIN ADAM 6E - <i>Oryctolagus cuniculus</i> (Rabbit), 730 aa.	14..733 10..730	415/724 (57%) 518/724 (71%)	0.0
P70535	TMDC IV PROTEIN - <i>Rattus norvegicus</i> (Rat), 751 aa.	1..720 8..732	385/728 (52%) 487/728 (66%)	0.0

Pfam analysis indicates that the NOV8a protein contains the domains shown in Table 8E.

5

Table 8E. Domain Analysis of NOV8a			
Pfam Domain	NOV8a Match Region	Identities/ Similarities for the Matched Region	Expect Value
Pep_M12B_propep: domain 1 of 1	77..192	42/119 (35%) 102/119 (86%)	1.3e-44
Reprolysin: domain 1 of 1	216..395	45/210 (21%) 108/210 (51%)	0.00095
metalthio: domain 1 of 1	395..458	14/67 (21%) 32/67 (48%)	7
disintegrin: domain 1 of 1	414..489	32/76 (42%) 44/76 (58%)	2.2e-18

#### Example 9.

The NOV9 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 9A.

10

Table 9A. NOV9 Sequence Analysis		
	SEQ ID NO: 21	1677 bp

NOV9a, CG90709-01 DNA Sequence	TTAATCTTCTGTGGCAGAAATGCAATGGCACATCGTGATTCTGAGATGAAAGAAGAAT GTCTAAGGGAAGACCTGAAGTTTTACTTTCATGAGCCCTTGTGAAAAATACCGAGCCAG ACGCCAGATTCCGTGGAAGCTGGGTTTGAGATTGTTGAAGATAGTCATGGTCACCACA CAGCTTGTTCGTTTTGGTTAAGTAACCAGCTGGTGGTTGCTTTCAAAGAAGATAACA CTGTTGCTTTTAAAGCACTGTTTTTGAAGGATATTCTGGTACAGATGAAGATGACTA CAGCTGCAGTGTATATACTCAAGAGGATGCCTATGAGAGCATCTTTTTGCTATTAAAT CAGTATCATCAGCTAAAGGACATTACCCTGGGGACCCCTTGGTTATGGAGAAAAATGAAG ACAATAGAATTGGCTTAAAGTCTGTAAGCAGCATTACAAGAAAGGGACCATGTTTCC TTCTAATGAGACACTGAATATTGACAACGACGTTGAGCTCAACTGTGGGGTTGTGGCG ATATACATTTTAAAGTGTTATTCCCTAAGAGATATTATGACAATTTATACCTTTCAAT ATATTTTATTACAGGCTCTTACAGGTTGAAATCTCCTTTTCATCTTAAAGGCATTGACCT ACAGACAATTCATCCCGTGAGTTACCAGACTGTTATGTCTTTTACAATACGATTATC TTTGACAATAAAGCTCACAGTGGCAAAATCAAAATCTATTTTGACAGTGATGCCAAAA TTGAAGAATGTAAAGACTTGAACATATTTGGATCTAGTAAGTATGCTCTGGTGTGTTGA TGCATTTGTCTATTGTGATTTGCTTGGCATCTCTTATTCTGTGTACAAGATCCATTGTT CTTGCTCTAAGGTTACGGAGATTTCTAAATTTCTTCTGGAGAAGTACAAGCGGCCTG TGTGTGACACCGACAGTGGGAGTTTCATCAACGGCTGGTATGTCCTGGTGATTATCAG CGACTAATGACAATCATTGGCTCCATATTAAAAATGGAATCAAAGCAAAGAAATCTC ACAACTATGATCTCTGCAGCATTTTTCTTGGAACTCTACGCTCTTGGTTTGGGTTG GAGTCATCAGATACCTGGGTTATTTCCAGGCATATAATGTACTGATTTTAAACATGCA GGCCTCACTGCCAAAAGTTCTTCGGTTTGTGCTTGTGCTGGTATGATTATCTGGGT TACACATTCTGTGGCTGGATTGTCTTAGGACCATACCATCTACAGTTTGAAGAACTGA ACACAGTTGCTGAGTGTCTGTTTTCTCTGGTCAACGGTGATGACATGTTTGAACCTT TGCCCAAATCCAGCAGAAGAGCATCTTGGTGTGGCTGTTCAAGTCTGTATTTATAT TCCTTCATCAGCCTTTTTATATATATGATTCTCAGTCTTTTTATTGCACTTATTACAG ATTCTTATGACACCATTAAAGAAATCCAACAGAATGGGTTTCTGAAACGGATTTGCA GGAATTCCTGAAGGAATGCAGTAGCAAGAAGAGTATCAGAAAGAGTCTCAGCCTTC CTGTCTGCATCTGCTGTGCGAGGAGGTCAATATCATGTTTATTCTCCATGCTCCTGA GATGGGCTGTTCTGTTGTCTTAAAGAAGAGCCCCCTCCAAGATTACCATTACAT		
	ORF Start: ATG at 25	ORF Stop: TAA at 1645	
	SEQ ID NO: 22	540 aa	MW at 62760.5kD
NOV9a, CG90709-01 Protein Sequence	MAHRDSEMKEECLREDLKIFYFMSPEKYRARRQIPWKLGLQILKIVMVTQLVRFGLS NQLVFAFKEDNTVAFKHLFLKGYSGTDEDDYSCSVYTQEDAYESIFFAINQYHQLKDI TLGTLGYGENEDNRIGLKVCKQHYKKGTMFSPNETLNIDNDVELNCGVVAIYILKCY LRDIMTIYTFQYILFRLLQVEISFHLKIDLQTIHSRELPCYVFQNTIIFDNKAHSG KIKIYFSDAKIEECKDLNIFGSSKYALVFDAFVIVICLASLILCTRISIVLALRLRRF LNFFLEKYKRPVCDTDQWEFINGWYVLVIISDLMTIIGSILKMEIKAKNLNTYDLCSI FLGTSTLLVWVGVIYRILGYFQAYNVLILTMQASLPKVLRFACAGMIYLYGTFCGWIV LGPYHLQFENLNTVAECLFSLVNGDDMFATFAQIQKSIILVWLFSLYLYSFIISLFIY MILSLFIALITDSYDIKKFQONGFPETDLQEFLEKCSSKEEYQKESSAFLSCICRR RSVSCLFSMILLRWAVLLS		
	SEQ ID NO: 23	1671 bp	
NOV9b, CG90709-02 DNA Sequence	TTAAATTAATCTTCTGTGGCAGAAATGCAATGGCACATCGTGATTCTGAGATGAAAG AAGAATGTCTAAGGGAAGACCTGAAGTTTTACTTTCATGAGCCCTTGTGAAAAATACCG AGCCAGACGCCAGATTCCGTGGAAGCTGGGTTTGAGATTGTTGAAGATAGTCATGGTC ACCACAGCTTGTTCGTTTTGGTTAAGTAACCAGCTGGTGGTTGCTTTCAAAGAAG ATAACACTGTTGCTTTAAGCACTGTTTTTGAAGGATATTCTGGTACAGATGAAGA TGACTACAGCTGCAGTGTATATACTCAAGAGGATGCCTATGAGAGCATCTTTTTGCT ATTAATCAGTATCATCAGCTAAAGGACATTACCCTGGGGACCCCTGGTTATGGAGAAA ATGAAGACAATAGAATTGGCTTAAAGTCTGTAAGCAGCATTACAAGAAAGGGACCAT GTTTCCTTCAATGAGACACTGAATATTGACAACGACGTTGAGCTAGATTGTGTTCAA TTAGACCTTCAGGACCTCTCCAAGAAGCCTCCGGACTGGAAGAACTCATCATTCTTCA GACTGGAATTTTATCGGCTCTTACAGGTTGAAATCTCCTTTTCATCTTAAAGGCATTGA CCTACAGACAATTCATCCCGTGAGTTACCAGACTGTTATGTCTTTCAGAATACGATT ATCTTTGACAATAAAGCTCACAGTGGCAAAATCAAAATCTATTTGACAGTGATGCCA AAATTGAAGAATGTAAAGACTTGAACATATTTGGATCAGCTCAGAAATGCTCAGTA TGTCCTGGTGTGTTGATGCATTTGTCTGTTGATTGCTTGGCATCTCTTATTCTGTGT ACAAGATCCATTGTTCTGCTCTAAGGTTACGGAAGAGATTTCTAAATTTCTTCTGCTG		

	AGAAGTACAAGCGGCCTGTGTGTGACACCGACCAGTGGGAGTTCATCAACGGCTGGTA TGTCCTGGTGATTATCAGCGACCTAATGACAATCATTGGCTCCATATTAATAATGGAA ATCAAAGCAAAGAATCTCACAACCTATGATCTCTGCAGCATTTTTCTTGGAACTCTA CGCTCTTGGTTTGGGTTGGAGTCATCAGATACCTGGGTTATTTCCAGGCATATAATGT ACTGATTTTAACAATGCAGGCCTCACTGCCAAAAGTCTCTCGGTTTTGTGCTTGTGCT GGTATGATTTATCTGGGTTACACATTCTGTGGCTGGATTGTCTTAGGACCATAACATG ACAAGTTTGAAAATCTGAACACAGTTGCTGAGTGTCTGTTTTCTCTGGTCAACGGTGA TGACATGTTTGCAACCTTTGCCCAAATCCAGCAGAAGAGCATCTTGGTGTGGCTGTTC AGTCGTCTGTATTTATATTCCCTTCATCAGCCTTTTTATATATATGATTCTCAGTCTTT TTATTGCACCTATTACAGATTCTTATGACACCATTAAAGAAATCCAACAGAATGGGTT TCCTGAAACGGATTTCAGGAATTCCTGAAGGAATGCAGTAGCAAAGAAGAGATCAG AAAGAGTCTCAGCCTTCCTGTCTGCATCTGCTGTGCGGAGGAGGTGAGTATCATGTT TATTCTCCATGCTCCTGAGATGGGCTGTTCTGTGTCTTAAGAAAGA		
	ORF Start: ATG at 31	ORF Stop: TAA at 1663	
	SEQ ID NO: 24	544 aa	MW at 63298.8kD
NOV9b, CG90709-02 Protein Sequence	MAHRDSEMKEECLREDLKIFYMSPCEKYRARRQIPWKLGLQILKIVMVTQLVRFGLS NQLVVAFKEDNTVAFKHLFLKGYSGTDEDDYSVYTQEDAYESIFFAINQYHQLKDI TLGTLGYGENEDNRIGLKVKQHYKKGTMPSPNETLNIDNDVELDCVQLDLQDLSKKP PDWKNSFFRLEFYRLQVEISFHLKGIDLQTIHSRELPCYVFQNTIIFDNKAHSGK IKIYFSDAKIECKDLNIFGSAQKNAQYVLFDAFVIVICLASLILCTRSIVLALRL RKRFLNFFLEKYKRPVCDTDQWEFINGWYVLVIISDLMTIIGSILKMEIKAKNLTNYD LCSIFLGTSTLLVWVGIVIRYLGYPQAYNVLIITMQASLPKVLRFACAGMIYLGYPFC GWIVLGPYHDKFENLNTVAECLFSLVNGDDMFATFAQIQKKSILVWLFRLYLYSPIS LFIYMILSLFIALITDSYDTIKKFQNGFPETDLQEFLEKCSKSEYQKESSAFLSCI CRRRSVSCLFSMLLRWAVLLS		
	SEQ ID NO: 25	2130 bp	
NOV9c, CG90709-03 DNA Sequence	TTAAATTAATCTTCTGTGGCAGAAATGCAATGGCACATCGTGATTCTGAGATGAAAG AAGAATGTCTAAGGGAAGACCTGAAGTTTTACTTCATGAGCCCTTGTGAAAAATACCG AGCCAGACGCCAGATTCCGTGGAACCTGGGTTGCAGATTTTGAAGATAGTCATGGTC ACCACACAGCTTGTTCGTTTTGGTTTAAAGTAACCAGCTGGTGGTTGCTTCAAAGAAG ATAACACTGTTGCTTTTAAAGCACTTGTTTTTGAAGGATATTCTGGTACAGATGAAGA TGACTACAGCTGCAGTGTATATACTCAAGAGGATGCCTATGAGAGCATCTTTTTTGCT ATTAATCAGTATCATCAGCTAAAGGACATTACCCTGGGGACCCTTGGTTATGGAGAAA ATGAAGACAATAGAATTGGCTTAAAAGTCTGTAAGCAGCATTACAAGAAAGGACCAT GTTTCCTTCTAATGAGACACTGAATATTGACAACGACGTTGAGCTAGATTGTGTTCAA TTAGACCTTCAGGACCTCTCCAAGAAGCCTCCGGACTGGAAGAACTCATCATTCTTCA GACTGGAATTTTATCGGCTCTTACAGGTTGAAATCTCCTTTTCATCTTAAAGGCATTGA CCTACAGACAATTCATTCCCCTGAGTTACCAGACTGTTATGTCTTTCAGAATACGATT ATCTTTGACAATAAAGCTCACAGTGGCAAAATCAAATCTATTTGACAGTGATGCCA AAATTGAAGAATGTAAGACTTGAACATATTTGGATCAGCTCAGAAAAATGCTCAGTA TGTCTTGGTGTGTTGATGCAATTGTGTCATTGTGATTGCTTGGCATCTCTTATTCTGTGT ACAAGATCCATTGTTCTTGCTCTAAGGTTACGGAAGAGATTTCTAAATTTCTTCTCTGG AGAAGTACAAGCGGCCTGTGTGTGACACCGACCAGTGGGAGTTTCATCAACGGCTGGTA TGTCTTGGTGATTATCAGCGACCTAATGACAATCATTGGCTCCATATTAATAATGGAA ATCAAAGCAAAGAATCTCACAACCTATGATCTCTGCAGCATTCTTCTTGGAACTCTA CGCTCTTGGTTTGGGTTGGAGTCATCAGATACCTGGGTTATTTCCAGGCATATAATGT ACTGATTTTAACAATGCAGGCCTCACTGCCAAAAGTCTCTCGGTTTTGTGCTTGTGCT GGTATGATTTATCTGGGTTACACATTCTGTGGCTGGATTGTCTTAGGACCATAACATG ACAAGTTTGAAAATCTGAACACAGTTGCTGAGTGTCTGTTTTCTCTGGTCAACGGTGA TGACATGTTTGCAACCTTTGCCCAAATCCAGCAGAAGAGCATCTTGGTGTGGCTGTTC AGTCGTCTGTATTTATATTCCCTTCATCAGCCTTTTTATATATATGATTCTCAGTCTTT TTATTGCACTTATTACAGATTCTTATGACACCATTAAAGAAATCCAACAGAATGGGTT TCCTGAAACGGATTTCAGGAATTCCTGAAGGAATGCAGTAGCAAAGAAGAGTATCAG AAAGAGTCTCAGCCTTCCTGTCTGCATCTGCTGTGCGAGGAGGAAAAGAGTGATG ATCACTTGATACCTATTAGCTAAAGTCTGCTAAAGATGATTAAAGTTCAGGCATCCT TATCCAGCAGCTGAGCAGAGGAACCCAAATGACTTGGACAAGCAGTTCCAAAATGAC TCTCTTATTTAATGTGGAGTGGGAAAGAGGACTCACAGTTAGCCAGCTGACCATGACT GAAGTTCAGCTTTACTTGTATATAAACTTGAATGATAAAGAATAGACCATGGGCTAC		

	TACTGGGCATTAGTGCAATATAACCAGCCGATAATAAAATTTCTCTATTAGTCTGTTA CTTTATGACATGATCTCGGAATGGCAAAGATTCATTTCAGAAAGTGTGCGAAATAATA GTTCTTACCCTGTTAATTACACATTGTGCGTCCTCGGCCCCAAGGGACTGGCACAAG GGAAGTGGGTGGAAACATTGTTTAATACCGGGCTCGGTACAAAAGACCCGGTGGG GCATCCATTTAAGAGTCACGGGCGAACTACACGGGCAAGACC		
	ORF Start: ATG at 31	ORF Stop: TAA at 1645	
	SEQ ID NO: 26	538 aa	MW at 62653.9kD
NOV9c, CG90709-03 Protein Sequence	MAHRDSEMKEECLREDLKIFYFMSPEKYRARRQIPWKLGLQILKIVMVTQLVRFGLS NQLVAVFKEDNTVAFKHLFLKGYSGTDEDDYSCSVYTQEDAYESIFFAINQYHQLKD TLGTLGYGENEDNRIGLKVKQKHKKGTMPSPNETLNIDNDVELDCVQLDLQDLSKKP PDWKNSSFFRLEFYRLQVEISFHLKGIDLQTIHSRELPCDYVFQNTIIFDNKAHSGK IKIYFSDAKIEECKDLNIFGSAQKNAQYVLVDFDAFVIVICLASLILCTRSIVLALRL RKRFLNFFLEKYKRPVCDTDQWEFINGWYVLVIISDLMTIIGSILKMEIKAKNLNTYD LCSIFLGTSTLLVWGVIRYLGYPQAYNVILITMQASLPKVLRFACAGMIYLGYTFC GWIVLGPYHDKFENLNTVAECLFSLVNGDDMFATFAQIQKSLVWLFSLYLYSFIS LFIYMILSLFIALITDSYDTIKKFQNGFPETDLQEFLEKCSSEKEYQKESSAFLSCI CCRRRKRSDHLLIPIS		
	SEQ ID NO: 27	2067 bp	
NOV9d, CG90709-04 DNA Sequence	ACGCGTTACGGGGAGGGGCGAAATGAGTCGGCCGTGAACGGTGTTCCTGTTCCGAAT CCCCAGACCCCTGGAAGTTTGAAGGAGGAGGCATGGCCCCGAGCCTTATCGTTTT CCCCAGGCAAGGATTCCGGAGAGAGGATCAGGTGTTTTAGGTAAACCGTCAGAAATG CAATGGCACATCGTGATTCTGAGATGAAGAAGATGTCTAAGGGAAGACCTGAAGTT TACTGCATGAGCCCTTGTGAAAAATACCGAGCCAGACGCCAGATTCCGTGGAAACTG GGTTTGACAGATTTTGAAGATAGTCATGGTCACCACACAGCTTGTTCGTTTTGGTTTAA GTAACCAGCTGGTGGTGTCTTTCAAAGAAGATAACACTGTTGCTTTTAAAGCACTTGT TTTGAAGGATATTTCTGGTACAGATGAAGATGACTACAGCTGCAGTGTATATACTCAA GAGGATGCCTATGAGAGCATCTTTTTTGCTATTAATCAGTATCATCAGTAAAGGACA TTACCCCTGGGACCTTGGTTATGGAGAAAATGAAGACAATAGAATTGGCTTAAAGT CTGTAAGCAGCATTACAAGAAAGGGACCATGTTTCCTTCTAATGAGACACTGAATATT GACAACGACGTTGAGCTAGATTGTGTTCAATTAGACCTTCAGGACCTCTCCAAGAAGC CTCCGACTGGAAGAACTCATCTTCTCAGACTGGAATTTTATCGGCTCTTACAGGT TGAAATCTCCTTTCATCTTAAAGGCATTGACCTACAGACAATTCATCCCGTGAGTTA CCAGACTGTTATGTCTTTCAGAATACGATTATCTTTGACAATAAAGCTCACAGTGGCA AAATCAAATCTATTTTACAGTGATGCCAAAATGAAGAATGTAAAGACTTGAACAT ATTTGGATCAGCTCAGAAAAATGCTCAGTATGTCCTGGTGTGTTGATGCATTGTGATT GTGATTTGCTTGGCATCTCTTATCTGTGTACAAGATCCATTGTTCTTGCTCTAAGGT TACGGAAGAGATTTCTAAATTTCTTCTGGAGAAGTACAAGCGGCCTGTGTGTGACAC CGACCAGTGGGAGTTCATCAACGGCTGGTATGTCCTGGTGATTATCAGGCACCTAATG ACAATCATTTGGCTCCATATTAATAATGGAATCAAAGCAAAGAACTCAACAACTATG ATCTCTGCAGCATTTTTCTTGAACCTCTACGCTCTTGGTTTGGGTTGGAGTCATCAG ATACCTGGGTATTTCCAGGCATATAATGTACTGATTTTAAACAATGCAGGCCTCACTG CCAAAAGTTCTTCGGTTTTGTGCTTGTGCTGGTATGATTTATCTGGGTTACACATTCT GTGGCTGGATTGTCTTAGGACCATACCATGACAAGTTTGAAAATCTGAACACAGTTGCT TGAGTGTCTGTTTTCTCTGGTCAACGGTGATGACATGTTTGCAACCTTTGCCCAAATC CAGCAGAAGAGCATCTGGTGTGGCTGTTTCAGTCGCTGTATTTATATCTCTTCATCA GCCTTTTTATATATATGATTCTCAGTCTTTTTATTGCACTTATTACAGATTCTTATGA CACCATTAAAGAAATCCAACAGAATGGGTTTCTGAAACGGATTTCAGGAATTTCTGTG AAGGAATGCAGTAGCAAAGAAGAGTATCAGAAAGAGTCTCAGCCTTCTGTCTCTGCA TCTGCTGTCGGAGGAGGAAAAGAAGTGATGATCACTTGATACCTATTAGCTAAAGTTC TGCTAAAGATGATTAAAGTTCAGGCATCCTTATCCAGCAGCTGAGCAGAGGAACCCCA AATGACTTGGACAAGCAGTTCAAAATGACTCTCTTATTTAATTGTGGAGTGGGAAAG AGGACTCACAGTTAGCCAGCTGACCATGACTGAAGTTCAGCTTACTTTTTATAAAC TTGAATGATAAAGAATAGACCATGGGCTACTACTGGGCATTAGTGCAATATAACAGCG ATAATAAAATCTCTATTAGTCTGTTAATTTATGAAA		
	ORF Start: ATG at 93	ORF Stop: TAA at 1791	
	SEQ ID NO: 28	566 aa	MW at 65866.6kD

NOV9d, CG90709-04 Protein Sequence	MARQPYRFPQARIPERGSGVFRLLTVRNAMAHRDSEMKEECLREDLKFCMSPEKYRA RRQIPWKLGLQILKIVMVTTLQVRFGLSNQLVVAFKEDNTVAFKHLFLKGYSGTDEDD YSCSVYTQEDAYESIFFAINQYHQLKDITLGTLYGENEDNRIGLVCKQHYKKGTMF PSNETLNIDNDVELDCVQLDQLSKKPPDWKNSFFRLEFYRLLQVEISFHLKGIDL QTIHSRELPDCYVFQNTIIFDNKAHSGKIKIYFSDAKIEECKDLNIFGSAQKNAQYV LVFDAFVIVICLASLILCTRSIVLALRLRKRFLNFFLEKYKRPVCDTDQWEFINGWYV LVIISDLMTIIGSILKMEIKAKNLNTNYDLCSIFLGTSTLLVWVGVIKRYLGYFQAYNVL ILTMQASLPKVLRFACAGMIYLGTYFCGWIVLGPYHDKFENLNTVAECLFSLVNGDD MFATFAQIQQKSILVWLFSLRYLYSFISLFIYMLSLFIALITDSYDTIKKFQONGFP ETDLQEFLKECSSKEEYQKESSAFLSCICRRRRKRSDHLLIPIS
--	---

Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 9B.

Table 9B. Comparison of NOV9a against NOV9b through NOV9d.		
Protein Sequence	NOV9a Residues/ Match Residues	Identities/ Similarities for the Matched Region
NOV9b	1..540	485/545 (88%)
	1..544	493/545 (89%)
NOV9c	1..526	481/531 (90%)
	1..530	489/531 (91%)
NOV9d	1..526	480/531 (90%)
	29..558	488/531 (91%)

5

Further analysis of the NOV9a protein yielded the following properties shown in Table 9C.

Table 9C. Protein Sequence Properties NOV9a	
PSort analysis:	0.6000 probability located in plasma membrane; 0.4000 probability located in Golgi body; 0.3000 probability located in endoplasmic reticulum (membrane); 0.3000 probability located in microbody (peroxisome)
SignalP analysis:	Cleavage site between residues 65 and 66

- 10 A search of the NOV9a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 9D.

Table 9D. Geneseq Results for NOV9a				
Geneseq Identifier	Protein/Organism/Length [Patent #, Date]	NOV9a Residues/ Match Residues	Identities/ Similarities for the Matched Region	Expect Value
AAM51858	Human TRP-like calcium channel TLCC-2 - Homo sapiens, 580 aa. [WO200177331-A1, 18-OCT-2001]	9..533 37..579	262/550 (47%) 374/550 (67%)	e-142
AAB74707	Human membrane associated protein MEMAP-13 - Homo sapiens, 580 aa. [WO200112662-A2, 22-FEB-2001]	9..533 37..579	262/550 (47%) 374/550 (67%)	e-142
AAB93412	Human protein sequence SEQ ID NO:12616 - Homo sapiens, 497 aa. [EP1074617-A2, 07-FEB-2001]	109..523 76..497	241/426 (56%) 318/426 (74%)	e-139
AAB08906	Human secreted protein sequence encoded by gene 16 SEQ ID NO:63 - Homo sapiens, 511 aa. [WO200017222-A1, 30-MAR-2000]	42..533 1..510	244/517 (47%) 349/517 (67%)	e-131
ABB11279	Human secreted protein homologue, SEQ ID NO:1649 - Homo sapiens, 164 aa. [WO200157188-A2, 09-AUG-2001]	334..497 1..164	161/164 (98%) 163/164 (99%)	3e-90

In a BLAST search of public sequence databases, the NOV9a protein was found to have homology to the proteins shown in the BLASTP data in Table 9E.

5

Table 9E. Public BLASTP Results for NOV9a				
Protein Accession Number	Protein/Organism/Length	NOV9a Residues/ Match Residues	Identities/ Similarities for the Matched Portion	Expect Value
Q9CQD3	3300002C04RIK PROTEIN - Mus musculus (Mouse), 538 aa.	1..523 1..527	426/528 (80%) 466/528 (87%)	0.0



AAL84622	MUCOLIPIN-3 - Homo sapiens (Human), 553 aa.	10..523 35..553	304/525 (57%) 396/525 (74%)	e-177
AAL84623	MUCOLIPIN-3 - Mus musculus (Mouse), 553 aa.	3..523 23..553	306/534 (57%) 398/534 (74%)	e-176
Q9H4B3	MUCOLIPIDIN - Homo sapiens (Human), 580 aa.	9..533 37..579	262/550 (47%) 374/550 (67%)	e-142
Q9GZU1	CDNA: FLJ22449 FIS, CLONE HRC09609 (MUCOLIPIN) (MUCOLIPIDOSIS TYPE IV PROTEIN) (MUCOLIPIN 1) - Homo sapiens (Human), 580 aa.	9..533 37..579	262/550 (47%) 374/550 (67%)	e-142

PFam analysis indicates that the NOV9a protein contains the domains shown in Table 9F.

Table 9F. Domain Analysis of NOV9a			
Pfam Domain	NOV9a Match Region	Identities/ Similarities for the Matched Region	Expect Value
DUF214: domain 1 of 1	231..407	30/267 (11%) 117/267 (44%)	9.2
ion_trans: domain 1 of 1	314..474	31/236 (13%) 117/236 (50%)	0.01

5

#### Example 10.

The NOV10 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 10A.

Table 10A. NOV10 Sequence Analysis			
	SEQ ID NO: 29	642 bp	
NOV10a, CG90739-01 DNA Sequence	CACCAAGGGCCTGGCACCAGGTGCCAGTCTTCCAGTTGCGAGGGCAAGCAAACCCGT CATGAGCAACTCCCTTCCCCATCTCTGCTCACCATGTGGACGCTGAAATCGTCCCTGG TCCTGCTTCTGTGCCTCACCTGCAGCTATGCCTTTATGTTCTCTTCTCTGAGACAGAA AACTAGCGAACCCAGGGGAAGGTGCCGTGTGGAGAGCACTTTCGGATTTCGGCAGAA CTACCAGAGCACACCCAAGGCTGGCTTGGGAGCAAATGGCTCTGGCTTTTGTGTTGCT TTGTGCCGTTTGTGATACTGCAGTGTCAAAGAGACAGTGAGAAGAATAAGGAGCAGAG TCCTCCTGGCCTTCGAGGCTTCCCATTTTCGCACTCCACTAAAGAAAAATCAAATGCT TCTCTTTACAAAGACTGTGTATTCAATACCTTAAACGAACCTGAAGTGGAGCTTTTGA AATTTGTGTCCGAAGTGCAGAATCTTAAAGGTGCCATGGCAACAGGCAGTGGCAGTAA CCTCAAGCTTCGAAGGTGCAGAGATGCCTGCAGATCCATACCATGTCACAATCTGTAA ATATGGGGAGAAGAAAGCTCTAGCTGAATGGATTGTGTGTCTCAGGAGAGAAAAAGT GAGT		
	ORF Start: ATG at 92	ORF Stop: TGA at 605	
	SEQ ID NO: 30	171 aa	MW at 19498.4kD

NOV10a, CG90739-01 Protein Sequence	MWTLLKSSLVLLCLTCSYAFMFSSLRQKTSEPQGVPCGEHFRIRQNLPEHTQGWLGSKWLWLLFAVVPFVILQCQRDSEKNKEQSPGLRGFPFRTPLKKNQNASLYKDCVFNTLNELEVELLKVFSEVQNLKGAMATGSGSNLKLRRSEMPADPYHVTICKIWGESSS		
	SEQ ID NO: 31	141 bp	
NOV10b, 172390256 DNA Sequence	GGATCCTTTATGTTCTTCTCTCTGAGACAGAAAAGTACGGAACCCAGGGGAAGGTGCGTGTGGAGAGCACTTTCGGATTTCGGCAGAACCTACCAGAGCACACCCAAGGCTGGCTTGGGAGCAAATGGCTCTGGCTCGAG		
	ORF Start: at 1	ORF Stop: end of sequence	
	SEQ ID NO: 32	47 aa	MW at 5515.2kD
NOV10b, 172390256 Protein Sequence	GSFMFSSLRQKTSEPQGVPCGEHFRIRQNLPEHTQGWLGSKWLWLE		
	SEQ ID NO: 33	141 bp	
NOV10c, 172390440 DNA Sequence	GGATCCTTTATGTTCTTCTCTCTGAGACAGAAAAGTACGGAACCCAGGGGAAGGTGCAATACGGAGAGCACTTTCGGATTTCGGCAGAACTACCAGAGCACACCCAAGGCTGGCTTGGGAGCAAATGGCTCTGGCTCGAG		
	ORF Start: at 1	ORF Stop: end of sequence	
	SEQ ID NO: 34	47 aa	MW at 5606.3kD
NOV10c, 172390440 Protein Sequence	GSFMFSSLRQKTSEPQGVQYGEHFRIRQNLPEHTQGWLGSKWLWLE		
	SEQ ID NO: 35	468 bp	
NOV10d, 172390569 DNA Sequence	GGATCCTTTATGTTCTTCTCTCTGAGACAGAAAAGTACGGAACCCAGGGGAAGGTGCGTGTGGAGAGCACTTTCGGATTTCGGCAGAACCTACCAGAGCACACCCAAGGCTGGCTTGGGAGCAAATGGCTCTGGCTTTTGTGTTGCTGTTGTGCCGTTTGTGATACTGAAGTGTCAAAGAGACAGTGAGAAGAATAAGGAGCAGAGTCCTCCTGGCCTTCGAGGCTTCCCATTTCGCACTCCACTAAAGAAAAATCAAATGCTTCTTTACAAAGACTGTGTATTCAAATACCTTAAACGAACTTGAAGTGGAGCTTTTGAAATTTGTGTCCGAAGTGCAGAACTCTTAAAGGTGCCATGGCAACAGGCAGTGGCAGTAACCTCAAGCTTCGAAGGTGCAGAGATGCTGCAGATCCATACCATGTCACAATCTGTAAAATATGGGGAGAAGAAAGCTCTAGCCTCGAG		
	ORF Start: at 1	ORF Stop: end of sequence	
	SEQ ID NO: 36	156 aa	MW at 17757.3kD
NOV10d, 172390569 Protein Sequence	GSFMFSSLRQKTSEPQGVPCGEHFRIRQNLPEHTQGWLGSKWLWLLFAVVPFVILKCQRDSEKNKEQSPGLRGFPFRTPLKKNQNASLYKDCVFNTLNELEVELLKVFSEVQNLKGAMATGSGSNLKLRRSEMPADPYHVTICKIWGESSSLE		
	SEQ ID NO: 37	468 bp	
NOV10e, 172390587 DNA Sequence	GGATCCTTTATGTTCTTCTCTCTGAGACAGAAAAGTACGGAACCCAGGGGAAGGTGCGTGTGGAGAGCACTTTCGGATTTCGGCAGAACCTACCAGAGCACACCCAAGGCTGGCTTGGGAGCAAATGGCTCTGGCTTTTGTGTTGCTGTTGTGCCGTTTGTGATACTGCAGTGTCAAAGAGACAGTGAGAAGAATAAGGAGCAGAGTCCTCCTGGCCTTCGAGGCTTCCCATTTCGCACTCCACTAAAGAAAAATCAAATGCTTCTTTACAAAGACTGTGTATTCAAATACCTTAAACGAACTTGAAGTGGAGCTTTTGAAATTTGTGTCCGAAGTGCAGAACTCTTAAAGGTGCCATGGCAACAGGCAGTGGCAGTAACCTCAAGCTTCGAAGGTGCAGAGATGCTGCAGATCCATACCATGTCACAATCTGTAAAATATGGGGAGAAGAAAGCTCTAGCCTCGAG		
	ORF Start: at 1	ORF Stop: end of sequence	

	SEQ ID NO: 38	156 aa	MW at 17757.2kD
NOV10e, 172390587 Protein Sequence	GSFMFSSLRQKTSEPQGVPCGEHFRIRQNLPEHTQGWLGSKWLWLLFAVVPFVILQC QRDSEKNKEQSPPLRGFPFRTPCLKKNQNASLYKDCVFNTLNELEVELLKVFSEVQNL KGAMATGSGSNLKLRRSEMPADPYHVTICKIWGEESSSLE		
	SEQ ID NO: 39	468 bp	
NOV10f, 172390603 DNA Sequence	GGATCCTTTATGTTCTCTTCTCTGAGACAGAAAAGTACGGAACCCAGGGGAAGGTGC CGTGTGGAGAGCACTTTCGGATTTCGGCAGAACCTACCAGAGCACACCCAAGGCTGGCT TGGGAGCAAATGGCTCTGGCTTTTGTGTTGCTGTTGTGCCGTTTGTGATACTGAAGTGT CAAAGAGACAGTGAGAAGAATAAGGAGCAGAGTCCTCTGGCCTTCGAGGCTTCCCAT TTCGCACTCCACTAAAGAAAAATCAAAATGCTTCTCTTTACAAAGACTGTGTATTCAA TACCTTAAACGAACCTGAAGTGGAGCTTTTGAAATTTGTGTCCGAAGTCGAGAACCCT AAAGGTGCCATGGCAACAGGCAGTGGCAGTAACCTCAAGCTTCGAAGGTCAGAGATGC CTGCAGATCCATACCATGTACAATCTGTAAAATATGGGGAGAAGAAAGCTCTAGCCT CGAG		
	ORF Start: at 1	ORF Stop: end of sequence	
	SEQ ID NO: 40	156 aa	MW at 17757.3kD
NOV10f, 172390603 Protein Sequence	GSFMFSSLRQKTSEPQGVPCGEHFRIRQNLPEHTQGWLGSKWLWLLFAVVPFVILKC QRDSEKNKEQSPPLRGFPFRTPCLKKNQNASLYKDCVFNTLNELEVELLKVFSEVQNL KGAMATGSGSNLKLRRSEMPADPYHVTICKIWGEESSSLE		
	SEQ ID NO: 41	468 bp	
NOV10g, 172390624 DNA Sequence	GGATCCTTTATGTTCTCTTCTCTGAGACAGAAAAGTACGGAACCCAGGGGAAGGTGC CGTGTGGAGAGCACTTTCGGATTTCGGCAGAACCTACCAGAGCACACCCAAGGCTGGCT TGGGAGCAAATGGCTCTGGCTTTTGTGTTGCTGTTGTGCCGTTTGTGATACTGAAGTGT CAAAGAGACAGTGAGAAGAATAAGGAGCAGAGTCCTCTGGCCTTCGAGGCTTCCCAT TTCGCACTCCACTAAAGAAAAATCAAAATGCTTCTCTTTACAAAGACTGTGTATTCAA TACCTTAAACGAACCTGAAGTGGAGCTTTTGAAATTTGTGTCCGAAGTGCAAAATCTT AAAGGTGCCATGGCAACAGGCAGTGGCAGTAACCTCAAGCTTCGAAGGTCAGAGATGC CTGCAGATCCATACCATGTACAATCTGTAAAATATGGGGAGAAGAAAGCTCTAGCCT CGAG		
	ORF Start: at 1	ORF Stop: end of sequence	
	SEQ ID NO: 42	156 aa	MW at 17769.3kD
NOV10g, 172390624 Protein Sequence	GSFMFSSLRQKTSEPQGVPCGEHFRIRQNLPEHTQGWLGSKWLWLLFAVVPFVILKC QRDSEKNKEQSPPLRGFPFRTPCLKKNQNASLYKDCVFNTLNELEVELLKVFSEVQNL KGAMATGSGSNLKLRRSEMPADPYHVTICKIWGEESSSLE		
	SEQ ID NO: 43	468 bp	
NOV10h, 172390644 DNA Sequence	GGATCCTTTATGTTCTCTTCTCTGAGACAGAAAAGTACGGAACCCAGGGGAAGGTGC AATACGGAGAGCACTTTCGGATTTCGGCAGAACCTACCAGAGCACACCCAAGGCTGGCT TGGGAGCAAATGGCTCTGGCTTTTGTGTTGCTGTTGTGCCGTTTGTGATACTGAAGTGT CAAAGAGACAGTGAGAAGAATAAGGAGCAGAGTCCTCTGGCCTTCGAGGCTTCCCAT TTCGCACTCCACTAAAGAAAAATCAAAATGCTTCTCTTTACAAAGACTGTGTATTCAA TACCTTAAACGAACCTGAAGTGGAGCTTTTGAAATTTGTGTCCGAAGTGCAAAATCTT AAAGGTGCCATGGCAACAGGCAGTGGCAGTAACCTCAAGCTTCGAAGGTCAGAGATGC CTGCAGATCCATACCATGTACAATCTGTAAAATATGGGGAGAAGAAAGCTCTAGCCT CGAG		
	ORF Start: at 1	ORF Stop: end of sequence	
	SEQ ID NO: 44	156 aa	MW at 17848.3kD
NOV10h, 172390644 Protein Sequence	GSFMFSSLRQKTSEPQGVQYGEHFRIRQNLPEHTQGWLGSKWLWLLFAVVPFVILKC QRDSEKNKEQSPPLRGFPFRTPCLKKNQNASLYKDCVFNTLNELEVELLKVFSEVQNL KGAMATGSGSNLKLRRSEMPADPYHVTICKIWGEESSSLE		

Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 10B.

<b>Table 10B. Comparison of NOV10a against NOV10b through NOV10h.</b>		
<b>Protein Sequence</b>	<b>NOV10a Residues/ Match Residues</b>	<b>Identities/ Similarities for the Matched Region</b>
NOV10b	19..63 2..46	44/45 (97%) 45/45 (99%)
NOV10c	19..63 2..46	42/45 (93%) 43/45 (95%)
NOV10d	19..171 2..154	151/153 (98%) 153/153 (99%)
NOV10e	19..171 2..154	152/153 (99%) 153/153 (99%)
NOV10f	19..171 2..154	151/153 (98%) 153/153 (99%)
NOV10g	19..171 2..154	150/153 (98%) 152/153 (99%)
NOV10h	19..171 2..154	149/153 (97%) 151/153 (98%)

5

Further analysis of the NOV10a protein yielded the following properties shown in Table 10C.

<b>Table 10C. Protein Sequence Properties NOV10a</b>	
<b>PSort analysis:</b>	0.4600 probability located in plasma membrane; 0.1031 probability located in microbody (peroxisome); 0.1000 probability located in endoplasmic reticulum (membrane); 0.1000 probability located in endoplasmic reticulum (lumen)
<b>SignalP analysis:</b>	Cleavage site between residues 20 and 21

- 10 A search of the NOV10a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 10D.

Table 10D. Geneseq Results for NOV10a				
Geneseq Identifier	Protein/Organism/Length [Patent #, Date]	NOV10a Residues/ Match Residues	Identities/ Similarities for the Matched Region	Expect Value
AAU68550	Human novel cytokine encoded by cDNA 790CIP2D_11 #1 - Homo sapiens, 239 aa. [WO200175093-A1, 11-OCT-2001]	1..171 69..239	150/171 (87%) 158/171 (91%)	5e-85
AAV53032	Human secreted protein clone di393_2 protein sequence SEQ ID NO:70 - Homo sapiens, 171 aa. [WO9957132-A1, 11-NOV-1999]	1..171 1..171	150/171 (87%) 158/171 (91%)	5e-85
AAG00463	Human secreted protein, SEQ ID NO: 4544 - Homo sapiens, 101 aa. [EP1033401-A2, 06-SEP-2000]	1..101 1..101	92/101 (91%) 93/101 (91%)	2e-49
AAV12683	Human 5' EST secreted protein SEQ ID NO:273 - Homo sapiens, 101 aa. [WO9906549-A2, 11-FEB-1999]	1..101 1..101	92/101 (91%) 93/101 (91%)	2e-49
AAM87953	Human immune/haematopoietic antigen SEQ ID NO:15546 - Homo sapiens, 89 aa. [WO200157182-A2, 09-AUG-2001]	83..171 1..89	70/89 (78%) 79/89 (88%)	1e-34

In a BLAST search of public sequence databases, the NOV10a protein was found to have homology to the proteins shown in the BLASTP data in Table 10E.

5

Table 10E. Public BLASTP Results for NOV10a				
Protein Accession Number	Protein/Organism/Length	NOV10a Residues/ Match Residues	Identities/ Similarities for the Matched Portion	Expect Value
Q9HCV6	DJ1153D9.4 (NOVEL PROTEIN) - Homo sapiens (Human), 138 aa (fragment).	34..171 1..138	138/138 (100%) 138/138 (100%)	7e-79

Q9D9T2	1700029J11RIK PROTEIN - Mus musculus (Mouse), 170 aa.	4..170 5..169	99/168 (58%) 122/168 (71%)	2e-46
Q96C09	SIMILAR TO NEURONAL THREAD PROTEIN - Homo sapiens (Human), 106 aa.	1..88 1..88	83/88 (94%) 85/88 (96%)	9e-45
Q9HCV7	DJ1153D9.3 (NOVEL PROTEIN) - Homo sapiens (Human), 94 aa.	1..86 1..86	81/86 (94%) 81/86 (94%)	4e-42
Q9CRL6	2810426N06RIK PROTEIN - Mus musculus (Mouse), 300 aa (fragment).	13..51 188..232	17/45 (37%) 24/45 (52%)	4.4

No significant matches were found in a PFam analysis of the NOV10a protein.

#### 5 Example 11.

The NOV11 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 11A.

Table 11A. NOV11 Sequence Analysis			
	SEQ ID NO: 45	1152 bp	
NOV11a, CG91667-01 DNA Sequence	ATGACCGCGACCGAAGCCCTCCTGCGCGTCCTCTTGCTCCTGCTGGCTTTCGGCCACA GCACCTATGGGGCTGAATGCTTCCCGGCCTGCAACCCCCAAAATGGATTCTGCGAGGA TGACAATGTTTGCAGGTGCCATGTGCGCTGGCAGGGTCCCCCTTTGTGACCAGTGCGTG ACCTCTCCCGGCTGCCTTCACGGACTCTGTGGAGAACCCGGGCAGTGCATTGACACCG ACGGCTGGGACGGGAGCTCTGTGATAGAGATGTTGCGGCCTGCTCCTCGGCCCTTG TGCCAAACACGGGACCTGCGTGAGCCTGGACGGTGGCCTCTATGAATGCTCCTGTGCC CCCGGGTACTCGGGAAAGGACTGCCAGAAAAGGACGGGCCCTGTGTGATCAACGGCT CCCCCTGCCAGCACGGAGGCACCTGCGTGGATGATGAGGGCCGGGCCTCCCATGCCTC CTGCCTGTGCCCCCTGGCTTCTCAGGCAATTTCTGCGAGATCGTGGCCAACAGCTGC ACCCCAACCATGCGAGAACGACGGCGTCTGCACTGACATTGGGGCGCACTTCCGCT GCCGGTGGCCAGCCGGCTTCATCGACAAGACCTGCAGCCGCCCGGTGACCAACTGCGC CAGCAGCCCGTGCCAGAACGGGGGCACCTGCCTGCAGCACACCCAGGTGAGCTACGAG TGTCTGTGCAAGCCCGAGTTACAGGTCTCACCTGTGTCAAGAAGCGCGCGCTGAGCC CCCAGCAGGTACCCGCTCTGCCCAGCGGTATGGGCTGGCCTACCGCCTGACCCCTGG GGTGACAGAGCTGCCGGTGCAGCAGCCGGAGCACCGCATCCTGAAGGTGTCCATGAAA GAGCTCAACAAGAAAACCCCTCTCCTCACCGAGGGCCAGGCCATCTGCTTACCATCC TGGGCGTGCTCACCAGCCTGGTGGTGTGGGCACTGTGGGTATCGTCTTCTCAACAA GTGCGAGACCTGGGTGTCCAACCTGCGCTACAACCACATGCTGCGGAAGAAGAAGAAC CTGCTGCTTCAGTACAACAGCGGGAGGACCTGGCCGTCAACATCATCTTCCCCGAGA AGATCGACATGACCACCTTCAGCAAGGAGGCCGGCGACGAGGAGATCTAA		
	ORF Start: ATG at 1	ORF Stop: TAA at 1150	
	SEQ ID NO: 46	383 aa	MW at 41153.6kD
NOV11a, CG91667-01 Protein Sequence	MTATEALLRVLLLLLAFGHSTYGAECPACNPQNGFCEDDNVCRCHVGWQGPLCDQCV TSPGCLHGLCGEPGQCICTDGDWDELCDRDVRACSSAPCANNGTCVSLDGGLYECSCA PGYSGKDCQKKDGPVINGSPCQHGGTCVDDEGRASHASCLPPGFGSGNFCEIVANSC TPNPCENDGVCTDIGDFRCRCFAGFIDKTCRSPVTNCASSPCQNGGTCLQHTQVSYE CLCKPEFTGLTCVKKRALSPQVTRLPSGYGLAYRLTPGVHELVPQQPEHRLKVSMSK ELNKKTPLLTEGQAICTILGLVLTSLVVLGTGVI FLNKCETWVSNLRNHLRKKKN LLLQYNSGEDLAVNIIFPEKIDMTTFSKEAGDEEI		

	SEQ ID NO: 47	1299 bp
NOV11b, CG91667-02 DNA Sequence	TCCGCAACCAGAAGCCAGTGC GCGCGCCAGGAGCCG GACCCGCGCCCGCACC GCTCCC GGGACCGCGACCCCGGCGCCCGCAGAGATGACCGGACCGAAGCCCTCCTGCGCGTCCT CTTGCTCCTGCTGGCTTTTCGGCCACAGCACCTATGGGGCTGAATGCTTCCCGGCTGC AACCCCAAAATGGATTCTGCGAGGATGACAATGTTTGAGGTGCCAGCCTGGCTGGC AGGGTCCCCTTTGTGACCAGTGCGTGACCTCTCCCGGCTGCCTTCACGGA CTCTGTGG AGAACC CGGGCAGTGCAATTG CACCGACGGCTGGGACGGGAGCTCTGTGATAGAGAT GTTTCGGGCTGCTCCTCGGCCCCCTGTGCCAACACGGGACCTGCGTGAGCCTGGACG ATGGCCTCTATGAATGCTCCTGTGCCCCCGGTACTCGGGAAGGACTGCCAGAAAA GGACGGGCCCTGTGTGATCAACGGCTCCCCCTGCCAGCACGGAGGCACCTGCGTGGAT GATGAGGGCCGGGCTCCCATGCCTCCTGCCTGTGCCCCCTGGCTTCTCAGGCAATT TCTGCGAGATCGTGGCCAACAGCTGCACCCCAACCCATGCGAGAACGACGGCGTCTG CACTGACATCGGGGGGAGCTTCCGCTGCCGGTGCCAGCCGGCTTACATCGACAAGACC TGCAGCCGCGCGGTGACCAACTGCGCCAGCAGCCCGTGCCAGAACGGGGGCACCTGCC TGCAGCACACCCAGGTGAGCTACGAGTGTCTGTGCAAGCCGAGTTACAGGTCTCAC CTGTGTCAAGAAGCGCGCGCTGAGCCCCAGCAGGTACCCGTCTGCCAGCGGCTAT GGGCTGGCTACCGCCTGACCCCTGGGGTGACGAGCTGCCGGTGACGAGCCGGAGC ACCGCATCCTGAAGGTGTCCATGAAAGAGCTCAACAAGAAACCCCTCTCCTACCGA GGGCCAGGCCATCTGCTTACCATCCTGGGCGTGCTACCAAGCCTGGTGGTGCTGGGC ACTGTGGGTATCGTCTTCTCAACAAGTCCGAGACCTGGGTGTCCAACCTGCGCTACA ACCACATGCTGCGGAAGAAGAAGAACCTGCTGCTTCAGTACAACAGCGGGAGGACCT GGCCGTCAACATCATCTTCCCGAGAAGATCGACATGACCACCTTCAGCAAGGAGGCC GGCGACGAGGAGATCTAAGCAGCGTTCCACAGCCCCCTCTAGATTCTTGGAGTTCCT CAGAGCTTACTATACGCGGTCTG	
	ORF Start: ATG at 85	ORF Stop: TAA at 1234
	SEQ ID NO: 48	383 aa      MW at 41200.6kD
NOV11b, CG91667-02 Protein Sequence	MTATEALLRVL LLLAFGHSTYGAECFPACNPQNGFCEDDNVCRCPGWQGPLCDQCV TSPGCLHGLCGEPGQCICTDGDWDELCDRDVRCSSAPCANNGTCVSLDDGLYECSCA PGYSGKDCQKKDGPVINGSPQHGGTCVDDEGRASHASCLPPGFSGNFCEIVANSC TPNPCENDGVCTDIGGDFRCRCPAGFIDKTC SRPVTNCASSPCQNGGTCLOHTQVSYE CLCKPEFTGLTCVKKRALSPQQVTRLPSGYGLAYRLTPGVHELFPVQQPEHRILKVMK ELNKKTPLLTEGQAICFTILGVLTSLVVLGTGVI FLNKCETWVSNLRYNHMLRKKKN LLLQYNSGEDLAVNIIFPEKIDMTTFSKEAGDEEI	

Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 11B.

Table 11B. Comparison of NOV11a against NOV11b.		
Protein Sequence	NOV11a Residues/ Match Residues	Identities/ Similarities for the Matched Region
NOV11b	1..383	353/383 (92%)
	1..383	353/383 (92%)

5

Further analysis of the NOV11a protein yielded the following properties shown in Table 11C.

Table 11C. Protein Sequence Properties NOV11a	
PSort analysis:	0.4600 probability located in plasma membrane; 0.1000 probability located in endoplasmic reticulum (membrane); 0.1000 probability located in endoplasmic reticulum (lumen); 0.1000 probability located in outside

SignalP analysis:	Cleavage site between residues 24 and 25
-------------------	--

A search of the NOV11a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 11D.

5

Table 11D. Geneseq Results for NOV11a				
Geneseq Identifier	Protein/Organism/Length [Patent #, Date]	NOV11a Residues/ Match Residues	Identities/ Similarities for the Matched Region	Expect Value
AAR56166	Neuroendocrine tumor dlk - Homo sapiens, 383 aa. [WO9413701-A, 23-JUN-1994]	1..383 1..383	380/383 (99%) 380/383 (99%)	0.0
AAR56167	Neuroendocrine tumor dlk - Mus sp, 385 aa. [WO9413701-A, 23- JUN-1994]	1..383 1..385	330/385 (85%) 348/385 (89%)	0.0
AAY77124	Human neurotransmission- associated protein (NTAP) 1296451 - Homo sapiens, 272 aa. [WO200001821-A2, 13-JAN- 2000]	1..185 1..163	157/185 (84%) 159/185 (85%)	2e-95
AAE13632	Human preadipocyte factor-1- like protein - Homo sapiens, 383 aa. [WO200157233-A2, 09- AUG-2001]	7..322 10..325	120/319 (37%) 168/319 (52%)	1e-63
AAG67516	Amino acid sequence of a human secreted polypeptide - Homo sapiens, 383 aa. [WO200166690- A2, 13-SEP-2001]	7..322 10..325	120/319 (37%) 167/319 (51%)	2e-63

In a BLAST search of public sequence databases, the NOV11a protein was found to have homology to the proteins shown in the BLASTP data in Table 11E.

10



Table 11E. Public BLASTP Results for NOV11a				
Protein Accession Number	Protein/Organism/Length	NOV11a Residues/ Match Residues	Identities/ Similarities for the Matched Portion	Expect Value
P80370	Delta-like protein precursor (DLK) (pG2) [Contains: Fetal antigen 1 (FA1)] - Homo sapiens (Human), 383 aa.	1..383 1..383	381/383 (99%) 381/383 (99%)	0.0
Q96DW5	UNKNOWN (PROTEIN FOR MGC:17291) - Homo sapiens (Human), 383 aa.	1..383 1..383	380/383 (99%) 380/383 (99%)	0.0
Q969Y6	HYPOTHETICAL 41.2 KDA PROTEIN (SIMILAR TO DELTA-LIKE HOMOLOG) (DROSOPHILA) - Homo sapiens (Human), 383 aa.	1..383 1..383	379/383 (98%) 380/383 (98%)	0.0
Q925U3	DLK (DELTA LIKE) - Mus musculus (Mouse), 385 aa.	1..383 1..385	332/385 (86%) 350/385 (90%)	0.0
A54785	preadipocyte factor 1 precursor, long form - mouse, 385 aa.	1..383 1..385	331/385 (85%) 349/385 (89%)	0.0

PFam analysis indicates that the NOV11a protein contains the domains shown in Table 11F.

Table 11F. Domain Analysis of NOV11a			
Pfam Domain	NOV11a Match Region	Identities/ Similarities for the Matched Region	Expect Value
EGF: domain 1 of 6	26..54	10/47 (21%) 20/47 (43%)	2.6
Bowman-Birk_leg: domain 1 of 1	70..85	8/22 (36%) 13/22 (59%)	3.3
EGF: domain 2 of 6	57..85	9/47 (19%) 21/47 (45%)	0.1
metalthio: domain 1 of 1	61..117	14/67 (21%) 33/67 (49%)	5.9
EGF: domain 3 of 6	92..124	19/47 (40%) 28/47 (60%)	8.2e-09
EGF: domain 4 of 6	131..167	17/47 (36%) 28/47 (60%)	5.4e-08

EGF: domain 5 of 6	174..205	15/47 (32%) 28/47 (60%)	7.4e-09
EGF: domain 6 of 6	212..244	16/47 (34%) 25/47 (53%)	1.2e-07
Keratin_B2: domain 1 of 1	134..253	29/183 (16%) 58/183 (32%)	2.4

**Example 12.**

The NOV12 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 12A.

Table 12A. NOV12 Sequence Analysis		
	SEQ ID NO: 49	3121 bp
NOV12a, CG92293-01 DNA Sequence	AATTCGATGGTCAACATGAAAGTAAGGAACCTGCCGTGGGATCTAGATTCTTCTCT AGAATTAGTAGTTGGAGAAATTCAACAGTGAAGTGGACATCCATGGCAGGTCTCCCTAA AATCAGATGAGCACCATTCTGTGGAGGAAGCTTGATTCAAGAAGATCGGTTGTTAC AGCAGCAGACTGCCTGGACAGCCTCAGTGAGAAGCAGCTGAAGAATATAACTGTGACT TCTGGGGAGTACAGCCTCTTTCAGAAGGATAAGCAAGAACAGAATATTCCTGTCTCAA AAATTATTACCCATCCTGAATACAACAGCCGTGAATATATGAGTCTGATATTGCACT GCTGTATCTAAACACAAAGTCAAGTTTGGAAATGCTGTTTCAGCCAATCTGTCTTCCT GACAGCGATGATAAAGTTGAACCAGGAATCTTTGCTTATCCAGTGGATGGGGCAAGA TTTCCAAAACATCAGAATATTCAAATGTCCTACAAGAAATGGAACCTTCCCATCATGGA TGACAGAGCGTGAATACTGTGCTCAAGAGCATGAACCTCCCTCCCTGGGAAGGACC ATGCTGTGTGCTGGCTTCCCTGATGGGGGAATGGACGCTGCCAGGGGGACTCTGGAG GACCACTGGTTTGTAGAAGAGGTGGTGGAACTCTGGATTCTTGCTGGGATAAATTCTG GGTAGCTGGTTGTGCTGGAGGTTCAAGTTCCCGTAAGAAACAACCATGTGAAGGCATCA CTTGGCATTTTCTCCAAAGTGTCTGAGTTGATGGATTTTATCACTCAAAACCTGTTCA CAGGTTCCATTTATTACATTTTCTTCACTTCCCTACCCAGCTTATATGTTTGGAA AATAATGGTACCAGAAGATAAAATAATCCTGATAAAATTTACAAGTTTAGACATGGAA AAGCAAGTTGGATGTGATCATGACTATGTATCTTTACGATCAAGCAGTGGAGTGCTTT TTAGTAAGGTCTGTGGAAAAATATTGCCTTCACCATTTGCTGGCAGAGACCAGTGAGGC CATGGTTCCATTTGTTTCTGATACAGAAGACAGTGGCAGTGGCTTTGAGCTTACCGTT ACTGCTGTACAGAAGTCAGAAGCAGGGTCAGGTTGTGGGAGTCTGGCTATATTGGTAG AAGAAGGGACAAATCACTCTGCCAAGTATCCTGATTGTATCCAGTAACACAAGGTG TCATTGGTTCATTTGTGCTCCAGAGAAGCACATTATAAAGTTGACATTTGAGGACTTT GCTGTCAAATTTAGTCCAACTGTATTTATGATGCTGTTGTGATTTACGGTGATTCTG AAGAAAAGCACAAAGTTAGCTAACTTTGTGGAATGCTGACCATCACTTCAATATTCAG TTCTAGTAACATGACGGTGATATACTTTAAAAGTGATGGTAAAAATCGTTTACAAGGC TTCAAGGCCAGATTTACATTTTGCCCTCAGAGTCTTTAAACAAATTTGAACCAAAGT TACCTCCCCAAACAATCCTGTATCTACCGTAAAAGCTATTCTGCATGATGTCTGTGG CATCCCTCCATTTAGTCCCCAGTGGCTTCCAGAAGAATCGCAGGAGGGGAAGAAGCC TGCCCCCACTGTTGGCCATGGCAGGTGGGTCTGAGGTTTCTAGGCGATTACCAATGTG GAGGTGCCATCATCAACCAAGTGTGGATTCTGACCGCAGCCCACTGTGTGCAATTGAA GAATAATCCACTCTCCTGGACTATTATTGCTGGGGACCATGACAGAACTGAAGGAA TCAACAGAGCAGGTGAGAAGGGCCAAACACATAATAGTGCATGAAGACTTTAACACAC TAAGTTATGACTCTGACATTGCCCTAATAACAATAAGCTCTCTCTGGAGTACAACCTC GGTGGTGAGGCCAGTATGTCTCCACACAGCGCAGAGCCTCTATTTCTCTGGAGATC TGTGCTGTGACCGGATGGGAAGCATCAGTGCAGATGGTGGCTAGCAAGTCCGCTAC AGCAGATTCAAGTGCATGTGTTAGAAAGAGAGGTCTGTGAACACACTTACTATTCTGC CCATCCAGGAGGGATCACAGAGAAGATGATCTGTGCTGGCTTTGCAGCATCTGGAGAG AAAGATTTCTGCCAGGGAGACTCTGGTGGGCCACTAGTATGTAGACATGAAATGGTC	

	CCTTTGTCTCTATGGCATTGTGACGTGGGGAGCTGGTGTTCCAGCCATGGAAGCC GGGTGTATTGGCCAGAGTGATGATCTTCTTGGACTGGATCCAATCAAAAATCAATGGT CCTGCTTCACTTCAGACAAATAATAAATGCAAAACCTTAAAAACAACAATTGCCACCAC CCACACCTTCACCAGACAGTGCATCTTGGCCAGGTTGTTGCTCTGAAGCAGAGCTAGA AAAGCCTAGAGGCTTTTTTCCACACCACGGTATCTACTGGATTATAGAGGAAGACTG GAATGTTCTTGGGTGCTCAGAGTTTACCAAGCAGTATGGCAAAATTTACCATTGAGT ATCTGTCACTCCTGGGGTCTCCTGTGTGTCAAGACTCAGTTCTAATTATTATGAAGA AAGACACAGTAAGAGAAAGACGGCAGGTGGATTACATGGAAGAAGACTTTACTCAATG ACTTTCATGAGTCTCGACCGCTGGTGAGGGTGACATTCCATGCCCTTGTACGAGGTG CATTTGGTATAAGCTATATTTGCTTGAAGTCTTAGGTCCAAAGGACAGTAAATAAC CAGACTTTCCCAAAGTTCAAACAGAGAGCACTTGGTCCCTTGTGAGGATGTTCTTCTG ACCAAGCCAGAAGGGATCATGCGGATCCCAAGAAATTCACAGAACTACTATGGGCT CATTTACATGGCTCCAAGAAAGAGTTTATCTTGATATCCAGTGCTGCTTACCTGACTG TGCAATTTAAGACTGATGAGTCTGAGAGAAAGAGGTTTTAAGCTTATTTAGAAGAGA TGATTGAGGAGCAATCACAGAAGAGCAATATTGAGACCAATTTCTATCAGTGGAGA GTTTTCACTACTAATCTGGTGCCAGACTCCCAACCTGACCCTGCT		
	ORF Start: ATG at 8	ORF Stop: TAA at 2966	
	SEQ ID NO: 50	986 aa	MW at 109103.2kD
NOV12a, CG92293-01 Protein Sequence	MVNMKSKEPAVGSRFFSRISSWRNSTVTGHPWQVSLKSDEHHFCGSLIQEDRVVTA HCLDSLSEKQLKNIITVTSGEYSLFQDKQEQNIPVSKIIITHEPNSREYMSPDIALY LKHKVKFNGNAVQPICLPDSDDKVEPGILCLSSGWGKISKTSYNSVLQEMELPIMDDR ACNTVLKSMNLPPLGRTMLCAGFPDGM DACQDSSGGLVCRGGGIWLAGITSWA GCAGGSVPVRNNHVKASLGFISKVSELMDFITQNLFTGSIYYIFFTFPYPVSLYVWKIM VPEDKIIILKFTSLDMEKQVGCDDHYVSLRSSSGVLFKVCGLILPSPLLAETSEAMV PFVSDTEDSGSGFELTVTAVQKSEAGSGGSLAILVEEGTNHSAKYPDLYPSNTRCHW FICAPEKHIIKLTFEDFAVKFSPNCIYDAVVIYGDSEKHLAKLCLGMLTITSIFSS NMTVIYFKSDGKNRLQGFARFTILPSESLNKFEPKLPPQNNPVSTVKAILHDVCGIP PFSPQWLSRRIAGGEEACPHCWVQVGLRFLGDYQCGGAIINPVWILTAAHCVQLKNN PLSWTIAGDHRNLKESTEQVRRAKHIIIVHEDFNTLSYDSIALIQLSSPLEYNSV RPVCLPHSAEPLFSSEICAVTGWGSIADGGLASRLQIQVHVFLREVCEHTYSAHP GGITEKMICAGFAASGEKDFCQDSSGGLVCRHENGPFVLYGIVSWGAGCVQPKPGV FARVMIFLDWIQSKINGPASLQTNKCKTLKQQLPPPTSPDSASWPGCCSEAELEKP RGFFPTPRYLLDYRGRLECSWVLRVSPSSMAKFTIEYLSLLGSPVCQDSVLIIEEERH SKRKTAGGLHGRRLYSMTFSPGPLVRVTFHALVRGAFGISYIVLVKVLGPKDSKITRL SQSSNREHLVPCEDVLLTKPEGIMRIPRNSHRTTMSFTWLQERVYLDIQCLLPDCAF		
	SEQ ID NO: 51	2929 bp	
NOV12b, CG92293-02 DNA Sequence	AATTCGATGGTCAACATGAAAAGTAAGGAACCTGCCGTGGGATCTAGATTCTTCTCT AGAATTAGTAGTTGGAGAAATTCACAGTGACTGGACATCCATGGCAGGTCTCCCTAA AATCAGATGAGCACCCTTCTGTGGAGGAAGCTTGATTCAAGAAGATCGGGTGTGTAC AGCAGCACACTGCCGTGGACAGCCTCAGTGAGAAGCAGCTGAAGAATATAACTGTGACT TCTGGGGAGTACAGCCTCTTTTCAAGAGGATAAGCAAGAACAGAATATTCTGTCTCAA AAATTATTACCCATCCTGAATACAACAGCCGTGAATATATGAGTCTGTATATGCACT GCTGTATCTAAACACAAAGTCAAGTTTGGAAATGCTGTTTCAGCCAATCTGTCTTCTCT GACAGCGATGATAAAGTTGAACCAGGAATCTTTGCTTATCCAGTGGATGGGGCAAGA TTTCCAAAACATCAGAATATTCAAATGTCTACAAGAAATGGAACCTCCCATCATGGA TGACAGAGCGGTGTAATACTGTGCTCAAGAGCATGAACCTCCCTCCCTGGGAAGGACC ATGCTGTGTGCTGGCTTCCCTGATGGGGGAATGGACGCTGCCAGGGGGACTCTGGAG GACCACTGGTTGTAGAAGAGGTGGTGAATCTGGATTCTTGCTGGGATAACTTCTCTG GGTAGCTGGTTGTGCTGGAGGTTGAGTTCCCGTAAGAAACAACCATGTGAAGGCATCA CTTGGCATTTTCTCAAAGTGTCTGAGTTGATGAGTTTATCACTCAAAACCTGTTTCA CAGGTTCCATTTATTACATTTCTTCACTTCCCTACCCAGCTTATATGTTTGGAA AATAATGGTACCAGAAGATAAAATAATCCTGATAAAATTTACAAGTTTAGACATGGAA AAGCAAGTTGGATGTGATCATGACTATGTATCTTTACGATCAAGCAGTGGAGTGCTTT TTAGTAAGGTCTGTGGAAAAATATTGCCTTCAACATTGCTGGCAGAGACCACTGAGGC CATGGTTCCATTTGTTTCTGATACAGAAGCAGTGGCAGTGGCTTTGAGCTTACCGTT ACTGCTGTACAGAAGTCAGAAGCAGGGTCAGGTTGTGGAGTCTGGCTATATTTGGTAG AAGAAGGGACAAATCACTCTGCCAAGTATCCTGATTGTATCCCAAGTAACACAAGGTG TCATTGGTTCAATTTGTGCTCCAGAGAAGCACATTATAAAGTTGACATTGAGGACTTT		

	GCTGTCAAATTTAGTCCAACTGTATTTATGATGCTGTTGTGATTTACGGTGATTCTG AAGAAAAGCACAAAGTTAGCTAAACTTTGTGGAATGCTGACCATCAATATTTCAG TTCTAGTAACATGACGGTGATATACTTTAAAAGTGATGGTAAAAATCGTTTACAAGGC TTCAAGGCCAGATTTACCATTTTGCCTCAGAGTCTTTAAACAAATTTGAACCAAAGT TACCTCCCCAAAACAATCCTGTATCTACCGTAAAAGCTATTCTGCATGATGTCTGTGG CATCCCTCCATTTAGTCCCCAGTGGCTTTCCAGAAGAATCGCAGGAGGGGAAGAAGCC TGCCCCACTGTTGGCCATGGCAGGTGGGTCTGAGGTTTCTAGGCGATTACCAATGTG GAGGTGCCATCATCAACCCAGTGTGGATTCTGACCGCAGCCCACTGTGTGCAATTGAA GAATAATCCACTCTCCTGGACTATTATTGCTGGGGACCATGACAGAAACCTGAAGGAA TCAACAGAGCAGGCAGATGGTGGCCTAGCAAGTCGCTACAGCAGATTCAAGTGCATG TGTTAGAAAGAGAGGTCTGTGAACACACTTACTATTCTGCCCATCCAGGAGGGATCAC AGAGAAGATGATCTGTGCTGGCTTTGCAGCATCTGGAGAGAAAGATTTCTGCCAGGGA GACTCTGGTGGGCCACTAGTATGTAGACATGAAAATGGTCCCTTTGTCTCTATGGCA TTGTGAGCTGGGGAGCTGGCTGTGTCCAGCCATGGAAGCCGGGTGTATTGTCAGAGT GATGATCTTCTTGGACTGGATCCAATCAAAAATCAATGGTCCGTCTCACTTCAGACA AATAATAAATGCAAAACCTTAAAACAACAATTGCCACCACCCACACCTTCACCAGACA GTGCATCTTGGCCAGGTGTTGTCTCTGAAGCAGAGCTAGAAAAGCCTAGAGGCTTTT TCCCACACCACGGTATCTACTGGATTATAGAGGAAGACTGGAATGCTTGGGTGGCTC AGAGTTTACCAAGCAGTATGGCAAAATTTACCATTGAGTATCTGTCACTCCTGGGGT CTCCTGTGTGTCAAGACTCAGTTCTAATTATTTATGAAGAAAGACACAGTAAGAGAAA GACGGCAGGTGGATTACATGGAAGAAGACTTTACTCAATGACTTTCATGAGTCTTGGGA CCGCTGGTGAGGGTGACATTCATGCCCCTGTACGAGGTGCATTGTTGATAAGCTATA TTGTCTTGAAAGTCTAGGTCCAAAGGACAGTAAAATAACAGACTTTCCCAAAGTTC AAACAGAGAGCACTTGGTCCCTTGTGAGGATGTTCTTCTGACCAAGCCAGAAGGGATC ATGCGGATCCCAAGAAATTCTCACAGAACTACTATGGGCTCATTACATGGCTCCAAG AAAGAGTTTATCTTGATATCCAGTGCTGCTTACCTGACTGTGCAATTTTAAAGACTGATG AGTCTGAGAGAAAGAGGTTTTAAGCTTATTTAGAAGAGATGATTACAGGAGCAATCAC AGAAGAGCAATATTGAGACCCAATTTCTATCAGTGGAGAGTTTTCACTACTAATCTG GTGCCAGACTCCCAACCTGACCCTGCT		
	ORF Start: ATG at 8	ORF Stop: TAA at 2774	
	SEQ ID NO: 52	922 aa	MW at 102051.3kD
NOV12b, CG92293-02 Protein Sequence	MVNMKSKEPAVGSRRFSSRISSWRNSTVTGHPWQVSLKSDHEHFCGSLIQEDRVVTAA HCLDSLSEKQLKNITVTSGEYSLFQKDKQEQNIPVSKIITHPEYNSREYMSPDIALLY LKHVKVFGNAVQPICLPDSDDKVEPGILCLSSGWGKISKTSSEYNSVLQEMELPIMDDR ACNTVLKSMNLPLPLGRMLCAGFPDGGMDACQGDSSGGLVCRRGGGIWLIGITSWVA GCAGGSVPVRNNHVKASLGIFSKVSELMDFITQNLFTGSIYYIFFTFPYPPLVVKIM VPEDKIILIKFTSLDMEKQVQGDHDYVSLRSSSGVLFSKVCGLPSPLLAETSEAMV PFVSDTEDSGSGFELTVTAQKSEAGSGGSLAILVEEGTNHSAKYPDLYPNTRCHW FICAPEKHIIKLTFFEDFAVKFSPNCIYDAVVIYGDSEKHKLAKLCGLMTITSIFSSS NMTVIYFKSDGKNRLQGFKARFTILPSES LNKFEPKLPQNNPVSTVKAILHDVCGIP PFSPQWLSRRIAGGEEACPHCWQVGLRFLGDYQCGGAIINPVWILTAHCVQLKNN PLSWTIIAGDHDRLNKESTEQADGGLASRLQQIQVHVLEREVECHTYSAHPGGITEK MICAGFAASGEKDFCQGDSSGGLVCRHENGPFVLYGIVSWGAGCVQPKPGVFARVMI FLDWIQSKINGPASLQTNKCKTLKQQLPPPTSPDSASWPGCCSEAELEKPRGFPT PRYLLDYRGRLECSWVLRVSPSSMAKFTIEYLSLLGSPVCQDSVLIYEERHSKRKTA GGLHGRRLYSMTFMSPGLVVRVTFHALVRGAFGISYIVLKVLPKDSKITRLSQSSNR EHLVPCEDVLLTKPEGIMRIPRNSHRTTMSFTWLQERVYLDIQCLPDCAF		

Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 12B.

<b>Table 12B. Comparison of NOV12a against NOV12b.</b>		
<b>Protein Sequence</b>	<b>NOV12a Residues/ Match Residues</b>	<b>Identities/ Similarities for the Matched Region</b>
NOV12b	1..986	894/988 (90%)
	1..922	903/988 (90%)

Further analysis of the NOV12a protein yielded the following properties shown in Table 12C.

<b>Table 12C. Protein Sequence Properties NOV12a</b>	
<b>PSort analysis:</b>	0.4820 probability located in mitochondrial matrix space; 0.4298 probability located in microbody (peroxisome); 0.1907 probability located in mitochondrial inner membrane; 0.1907 probability located in mitochondrial intermembrane space
<b>SignalP analysis:</b>	No Known Signal Sequence

5

A search of the NOV12a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 12D.

<b>Table 12D. Geneseq Results for NOV12a</b>				
<b>Geneseq Identifier</b>	<b>Protein/Organism/Length [Patent #, Date]</b>	<b>NOV12a Residues/ Match Residues</b>	<b>Identities/ Similarities for the Matched Region</b>	<b>Expect Value</b>
ABG24246	Novel human diagnostic protein #24237 - Homo sapiens, 913 aa. [WO200175067-A2, 11-OCT- 2001]	1..771 13..738	660/771 (85%) 670/771 (86%)	0.0
ABG24246	Novel human diagnostic protein #24237 - Homo sapiens, 913 aa. [WO200175067-A2, 11-OCT- 2001]	1..771 13..738	660/771 (85%) 670/771 (86%)	0.0
ABG19887	Novel human diagnostic protein #19878 - Homo sapiens, 1576 aa. [WO200175067-A2, 11- OCT-2001]	1..770 852..1576	659/770 (85%) 669/770 (86%)	0.0

10

ABG14588	Novel human diagnostic protein #14579 - Homo sapiens, 1576 aa. [WO200175067-A2, 11-OCT-2001]	1..770 852..1576	659/770 (85%) 669/770 (86%)	0.0
ABG10218	Novel human diagnostic protein #10209 - Homo sapiens, 1576 aa. [WO200175067-A2, 11-OCT-2001]	1..770 852..1576	659/770 (85%) 669/770 (86%)	0.0

In a BLAST search of public sequence databases, the NOV12a protein was found to have homology to the proteins shown in the BLASTP data in Table 12E.

5

Table 12E. Public BLASTP Results for NOV12a				
Protein Accession Number	Protein/Organism/Length	NOV12a Residues/ Match Residues	Identities/ Similarities for the Matched Portion	Expect Value
Q91674	POLYPROTEIN - Xenopus laevis (African clawed frog), 1524 aa.	15..955 53..995	413/969 (42%) 567/969 (57%)	0.0
P79953	OVIDUCTIN - Xenopus laevis (African clawed frog), 1004 aa.	15..778 42..828	291/798 (36%) 430/798 (53%)	e-146
Q90WD8	OVIDUCTIN - Bufo japonicus (Japanese toad), 974 aa.	10..801 41..849	284/829 (34%) 436/829 (52%)	e-141
Q9BK47	SEA STAR REGENERATION-ASSOCIATED PROTEASE SRAP - Luidia foliolata, 267 aa.	513..769 12..264	111/264 (42%) 156/264 (59%)	2e-51
O96899	PLASMINOGEN ACTIVATOR SPA - Scolopendra subspinipes, 277 aa.	532..767 33..264	104/241 (43%) 148/241 (61%)	8e-49

PFam analysis indicates that the NOV12a protein contains the domains shown in Table 12F.

Table 12F. Domain Analysis of NOV12a			
Pfam Domain	NOV12a Match Region	Identities/ Similarities for the Matched Region	Expect Value
trypsin: domain 1 of 2	19..263	100/275 (36%) 186/275 (68%)	2.5e-76
CUB: domain 1 of 3	266..365	31/116 (27%) 64/116 (55%)	7.5e-06

CUB: domain 2 of 3	377..486	40/116 (34%) 73/116 (63%)	1.8e-22
trypsin: domain 2 of 2	533..765	109/264 (41%) 182/264 (69%)	2.5e-82
CUB: domain 3 of 3	804..912	23/118 (19%) 70/118 (59%)	7.3e-05

**Example 13.**

The NOV13 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 13A.

5

Table 13A. NOV13 Sequence Analysis		
	SEQ ID NO: 53	2544 bp
NOV13a, CG92384-01 DNA Sequence	TCCTGGGCCCCAGCCCCGCGCAGGCCAAGGATGAGGCCGAGGCCCGAAGGTAGGGGGC TCCGGGCGGGAGTCGCGCTGTCCCCGCGCTACTGCTGCTGCTGCTGCTGCCGCCGCC GCCGACGCTGCTGGGGCGCTGTGGGCAGCGGGCACACCCTCGCCGTGGCGCCCCGA GCTCGGCAGGACGGCGCGCTGGGAGCCGGCCGCGTCAAACGCGGCTGGGTGTGGAACC AGTTCTTCGTGGTAGAGGAGTACACGGGCACGGAGCCCCCTGTATGTGGGCAAGATCCA CTCCGACTCAGACGAGGGTGACGGGGCCATCAAGTACACCATCTCAGGCGAGGGTGCT GGGACCATCTTCCTGATCGACGAGCTGACAGGCGACATTTCATGCCATGGAGCGCCTGG ACCGCGAGCAGAAAACCTTCTACACGCTGCGGGCCCAGGCTCGGGATCGCGCCACCAA CCGCTACTGGAGCCCGAGTCGGAGTTCATCATCAAGGTGCAGGACATCAATGACAGT GAGCCCCGCTTCCTGCACGGCCCCCTATATTGGCAGCGTGGCCGAGCTCTCACCTACAG GTACGTCGGTGATGCAGGTGATGGCCTCGGATGCGGATGACCCACGTACGGCAGCAG CGCTCGGCTGGTGACAGCGTGTGGACGGCGAGCACCACTTCACCGTGGACCCCAAG ACCGGTGTAATCCGGACGGCTGTGCCTGACCTTGACCGCAGAGCCAGGAGCGCTACG AGGTGGTGATCCAGGCCACAGACATGGCGGGTCAGCTGGGTGGCCTCTCGGGCTCCAC TACCGTCACCATCGTAGTCACCGACGTCAATGACAACCCGCCCCGTTTCCCGCAGGAG ATGTACCAGTTCAGCATCCAGGAGTCAGCCCCCATTGGAACGGCTGTGGGACGTGTGA AGGCTGAGGACTCAGACGTGGGAGAGAACAACAGACATGACTTACCACCTTAAGGACGA GAGCAGCAGCGCGCGGATGTGTTCAAGGTCACCACAGACAGCAGACTCAGGAGGCC ATCATCGTAGTGCAGAAGCGCCTGGACTTCGAATCCAGCCCGTGCACACCGTGATCC TGGAGGCCCTCAACAAGTTCGTGGACCCCCGCTTCGCCGACCTGGGCACGTTCCGCGA CCAGGCGATCGTGCGCGTGGCCGTGACCGACGTGGACGAGCCCCCGAGTTCCGGCCG CCCTCCGGCCTCCTGGAGGTGCAGGAGGACGCGCAGGTGGGCTCCCTGGTCGGCGTGG TGACGCGCGGGACCCCGACGCGCCCAACCGGCCGTCCGGTACGCCATTGACCGCGA ATCAGATTGGACCAGATCTTCGATATCGATGCGGACACAGGCGCCATCGTGAATGGC AAGGGGTGGACCGCGAGACGGCCGGCTGGCACAACATCAGTGTGGCCATGGAGG CGGACAATCATGCACAGCTATCCCGGGCATCCCTAAGGATCCGAATCCTGGATGTGAA CGACAATCCCCAGAAGTGGCCACACCCTACGAGGCAGCTGTATGCGAGGATGCCAAG CCAGGCCAGCTCATCCAGACCATCAGCGTGGTGGACAGAGACGAGCCCCAAGGCGGGC ACCGCTTCTATTTCGCGCTGGTGCCTGAAGCTCCAGCAACCCCTATTCTCTCTGCT TGACATCCAAGACAACACCGCTGCAGTGCACACGCAGCACGTGGGCTTCAACCGGCAG GAGCAGGACGTGTCTTCCTGCCCATCCTGGTGGTAGACAGTGGGCCGCCCACTGA GCAGCACAGGCACGCTCACCATCCGCATCTGTGGCTGCGACAGCTCCGGCACCATCCA GTCCTGCAACACACGCGCTTTGTCTATGGCCGCTCCCTCAGCCCCGCGCCCTTTG GTCTGCGTTCTCATCCTGTTGTGTGCTGGTGTCTGATCCTCACCTCAGGCGCCACC ACAAGAGCCACCTGAGCTCGGACGAGGATGAAGACATGCGGGACAACGTCATCATATA CAACGACGAAGGCGGCGGCGAGCAGACACCGAAGCCTACGACATGTGGCGCTGCGG AGCCTCTACGACTTCGGCGAGCTCAAGGGCGGCGACGGGGCGGCGAGCGCGGGCAGCC CCCCGAGGCCCACTGCCCTCCGAGCGCCACTCGCTGCCGAGGGGCCGCGAGCCC	

	CGAGCCAGACTTCTCAGTGTTTCAGGGACTTCATCAGCCGCAAGGTGGCACTGGCGGAC GGGGACCTGTGCGTGCCGCCCTACGACGCCCTCCAGACCTACGCCCTCGAGGGCGCGG ACTCGCCGGCCGCTCGCTCAGCTCCCTGCACAGCGGCTCGTGGGGCTCCGAGCAGGA CTTCGCCTATTTAGCATGTGGGGTCATTGCGGCTCCGAGCAGGACTTCGCCTATCTC AGCAGCTGGGGTCCGCGCTTCCGGCCCCCTGGCCGCGCTCTACGCCGCCACCGCGGGG ACGACGAGGCCAGGCCCTCTAGCCCCCTCGCCCTGCCGTGGGGGCGCGGC		
	ORF Start: ATG at 31	ORF Stop: TAG at 2515	
	SEQ ID NO: 54	828 aa	MW at 89732.6kD
NOV13a, CG92384-01 Protein Sequence	MRPRPEGRGLRAGVALSPALLLLLLPPPTLLGRLWAAGTSPSPAPGARQDGA LGAG RVKRGVWNQFFVVEEYTGTEPLYVGKIHSDESDGAIKYTISGEGAGTIFLIDELT GDIHAMERLDREQKTFYTLRAQARDRATNRLLEPESEFIKQVDINDSEPRFLHGPYI GSVAELSPTGTSVMQVMASDADDPYTGSSARLVYSVLDGEHFTVDPKTGVIRTAVPD LDRESQERYEVVIQATDMAGQLGGLSGSTTVTIVVTDVNDNPPRFPQEMYQFSIQESA PIGTAVGRVKAEDSDVGENTDMTYHLKDESSGGDVFKVTTSDTQEAIIVVQKRLDF ESQPVHTVILEALNKFVDPFRFADLGTFRDQAIVRVAVTDVDEPPEFRPPSGLLEVQED AQVGSVLGVVTARDPDAANRPVRYAIDRESLDQIFDIDADTGAIVTGKGLDRETAGW HNITVLAMEADNHAQLSRASLRIRILDVNDNPPELATPYEAAVCEDAKPGQLIQTISV VDRDEPQGGHRYFRLVPEAPSNPHFSLLDIQDNTAAVHTQHVGFNREQQDVFFLPIL VDSGPPTLSSTGTLTIRICGCDSSGTIQSCNTTAFVMAASLSPGALLVCVLILVVLV LLILTLRRHHKSHLSSDEDEMRDNVIIYNDEGGGEQDTEAYDMSALRSLYDFGELKG GDGGGSAGSPQAHLPSEHSLPQGPSPPEPDFSVFRDFISRKVALADGDLSPVPPYDA FQTYALEGADSPAASLSSLHSGSGSEQDFAYFSMWGHSQDFAYLSSWGPRFRPL AALYAGHRGDDEAQAAS		

Further analysis of the NOV13a protein yielded the following properties shown in Table 13B.

Table 13B. Protein Sequence Properties NOV13a	
PSort analysis:	0.4600 probability located in plasma membrane; 0.1561 probability located in microbody (peroxisome); 0.1000 probability located in endoplasmic reticulum (membrane); 0.1000 probability located in endoplasmic reticulum (lumen)
SignalP analysis:	Cleavage site between residues 34 and 35

5

A search of the NOV13a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 13C.

Table 13C. Geneseq Results for NOV13a				
Geneseq Identifier	Protein/Organism/Length [Patent #, Date]	NOV13a Residues/ Match Residues	Identities/ Similarities for the Matched Region	Expect Value
AAU09864	Novel human secreted protein #5 - Homo sapiens, 801 aa. [WO200179454-A1, 25-OCT-2001]	41..821 38..796	412/784 (52%) 540/784 (68%)	0.0

10



AAM78375	Human protein SEQ ID NO 1037 - Homo sapiens, 788 aa. [WO200157190-A2, 09-AUG-2001]	50..825 43..788	393/779 (50%) 546/779 (69%)	0.0
AAW13132	Full length human cadherin-8 - Homo sapiens, 793 aa. [US5597725-A, 28-JAN-1997]	17..824 7..792	394/816 (48%) 560/816 (68%)	0.0
AAW25635	Human cadherin-8 - Homo sapiens, 793 aa. [US5646250-A, 08-JUL-1997]	17..824 7..792	394/816 (48%) 560/816 (68%)	0.0
AAW13126	Full length rat cadherin-8 - Rattus rattus, 799 aa. [US5597725-A, 28-JAN-1997]	17..824 14..798	390/813 (47%) 557/813 (67%)	0.0

In a BLAST search of public sequence databases, the NOV13a protein was found to have homology to the proteins shown in the BLASTP data in Table 13D.

5

Table 13D. Public BLASTP Results for NOV13a				
Protein Accession Number	Protein/Organism/Length	NOV13a Residues/ Match Residues	Identities/ Similarities for the Matched Portion	Expect Value
Q9UJ99	DJ998H6.1 (ORTHOLOG OF RAT PB-CADHERIN) - Homo sapiens (Human), 828 aa.	1..828 1..828	810/843 (96%) 811/843 (96%)	0.0
Q9WTP5	PB-CADHERIN - Mus musculus (Mouse), 813 aa.	1..828 1..813	762/833 (91%) 777/833 (92%)	0.0
Q63315	LONG TYPE PB-CADHERIN - Rattus norvegicus (Rat), 813 aa.	1..828 1..813	761/833 (91%) 775/833 (92%)	0.0
Q63561	SHORT TYPE PB-CADHERIN - Rattus norvegicus (Rat), 694 aa.	1..688 1..690	637/695 (91%) 649/695 (92%)	0.0
Q9ULB5	Cadherin-7 precursor - Homo sapiens (Human), 785 aa.	56..816 41..776	420/764 (54%) 552/764 (71%)	0.0

PFam analysis indicates that the NOV13a protein contains the domains shown in Table 13E.

Table 13E. Domain Analysis of NOV13a			
Pfam Domain	NOV13a Match Region	Identities/ Similarities for the Matched Region	Expect Value
cadherin: domain 1 of 5	68..159	32/107 (30%) 60/107 (56%)	2.4e-12
FBPase: domain 1 of 1	200..225	12/28 (43%) 20/28 (71%)	2.9
cadherin: domain 2 of 5	173..268	46/109 (42%) 80/109 (73%)	1.3e-29
cadherin: domain 3 of 5	282..386	30/111 (27%) 75/111 (68%)	6.5e-14
cadherin: domain 4 of 5	399..490	37/108 (34%) 69/108 (64%)	1.2e-17
cadherin: domain 5 of 5	503..600	27/113 (24%) 71/113 (63%)	1.3e-10
Cadherin_C_term: domain 1 of 1	646..819	75/179 (42%) 147/179 (82%)	1.3e-65

**Example 14.**

The NOV14 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 14A.

Table 14A. NOV14 Sequence Analysis		
	SEQ ID NO: 55	1170 bp
NOV14a, CG92455-01 DNA Sequence	TAAGCTTCTCTGAACATGCAGAGCAGTGGTAACTATGAGGAGGCACAGTCTCTCCTGA GCATGACTCTGGCTGTTGGTGTGGCTTTGCTGCAGCTGCCGTGTGCCATTGATGATCC TGCTCCTCTTCCCTCGGGAAGCTGCCTGATGGAGTCTGGCTCCTGGAGCTGAGCCAC AATAATCTCAGCCATCTGCCGGCTGGCGCCTTCCAGGGCTTTTGGGGACTGCGGGTGT TGCTGCTTTCTCTCAATATCCTGCGGGATCTGTCTGATGGGGCCCTAGGGGGCCTCAG TTTCCTGGAGCAGCTGAACCTCAGCCATAACCAGCTGGCCCATCTGCCACAGACTTC TCGGCTACCCTGGGCTCTCTGCTCTGCTGACCTCTCTCACAACCTACTCACTTCCC TGGACCCACAGCCTGTGGCGCCTGGGGGGCCTGGAGCAGCTCAACCTGAGCCACAA CCAGCTGGCTGAACTGGCCGCAGGGGTCTTTGGGGGCCTCTTCCACCTACACTGGCTC TCGCTGGCTGGGAACCAGCTGCAGCGGGTGAAGGGTGCTGCCCTGACCACTGTGCCGG GCTTGGGAAGTCTCTCTGTAGCTGGGAATGACATCAGTGCCTTCGGAAAGTTGGGTCA CCTGCGGCACTTGAGTGTCGTAGACCTGGGCATCCTGACTTGCCTGGGCCCCGAAAGG CTGTCAGGGGCAGTGTGAGTGGTGTGGAGGCCAGCTTTGCCTGGCTGAGACTGCCA CTGTGCTGGGCATCACAGGCACCGTGCTGCTCACAGTGGCTGTGGCTGTGCTGATGGC TGAGCGCAAGCGAAGACAGGGCCCGCAAGAAGCCGGGAGCTGGGGAGCTTTCTGGAG AGGCTATTTAATCAGCAGGCAGATCAACAGGCCAAAATTTCCACCATAACTGCAAAC TGAATGCGGATGAATGGATTACAACATGGTCAAACCTTGCAATGAGAGGCATTATAAT GTATGGTGCTATAATTGATAGTGATTACCGGGGAGAGTTAAAGGTCAATTTATACAAT	

	ACCACTCCAGATTCTTTTGTATATAAAACCGCAGATGCAGGTTGCTCAATTGTTAGTGG TATCTTGTCAACAACCCCCGAGGAAATTTCCACCCAATAGAAACAACATATAGAACG GAACATTCAG		
	ORF Start: ATG at 16	ORF Stop: TAG at 1141	
	SEQ ID NO: 56	375 aa	MW at 40138.8kD
NOV14a, CG92455-01 Protein Sequence	MQSSGNYEEAQSLLSMTLAVGVALLQLPCAIDDPAPLPSGKLPDGVWLELSHNNLSH LPAGAFQGFVGLRVLLLSLNLRLDSDGALGGLSFLEQLNLSHNQLAHLPTDFSATLG SLLCLDLSHNLLTSLDPTSLWRLGGLEQLNLSHNQLAELAAGVFGLFHLHWLSLAGN QLQRVKGAALTTPGLEVLVAGNDISAFGKLGLRHLSSVDLGIITCAGPERLSGAV LSGVEAQLCLAETATVLGITGTVLLTVAVAVLMAERKRRQGPQEGELGSFLERLFNQ QADQQAISTITANLNADEWITTSNLMARGIIMYGAIIDSDYRGELKVILYNTTPDS FAIKPQMVAQLLVVSCQQPPRKFPQ		

Further analysis of the NOV14a protein yielded the following properties shown in Table 14B.

Table 14B. Protein Sequence Properties NOV14a	
PSort analysis:	0.4600 probability located in plasma membrane; 0.1285 probability located in microbody (peroxisome); 0.1000 probability located in endoplasmic reticulum (membrane); 0.1000 probability located in endoplasmic reticulum (lumen)
SignalP analysis:	Cleavage site between residues 31 and 32

- 5 A search of the NOV14a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 14C.

Table 14C. Geneseq Results for NOV14a				
Geneseq Identifier	Protein/Organism/Length [Patent #, Date]	NOV14a Residues/ Match Residues	Identities/ Similarities for the Matched Region	Expect Value
ABG16717	Novel human diagnostic protein #16708 - Homo sapiens, 550 aa. [WO200175067-A2, 11-OCT-2001]	287..375 182..268	73/89 (82%) 78/89 (87%)	5e-33
ABG16717	Novel human diagnostic protein #16708 - Homo sapiens, 550 aa. [WO200175067-A2, 11-OCT-2001]	287..375 182..268	73/89 (82%) 78/89 (87%)	5e-33
ABG05979	Novel human diagnostic protein #5970 - Homo sapiens, 258 aa. [WO200175067-A2, 11-OCT-2001]	272..367 55..152	69/98 (70%) 78/98 (79%)	2e-30

ABG05979	Novel human diagnostic protein #5970 - Homo sapiens, 258 aa. [WO200175067-A2, 11-OCT-2001]	272..367 55..152	69/98 (70%) 78/98 (79%)	2e-30
AAB82352	Protein sequence SEQ ID NO.2 - Homo sapiens, 794 aa. [WO200138357-A2, 31-MAY-2001]	42..250 93..303	79/213 (37%) 103/213 (48%)	8e-20

In a BLAST search of public sequence databases, the NOV14a protein was found to have homology to the proteins shown in the BLASTP data in Table 14D.

5

Table 14D. Public BLASTP Results for NOV14a				
Protein Accession Number	Protein/Organism/Length	NOV14a Residues/ Match Residues	Identities/ Similarities for the Matched Portion	Expect Value
Q9N4G6	Y71F9B.8 PROTEIN (1D304) - Caenorhabditis elegans, 542 aa.	45..271 190..436	80/248 (32%) 127/248 (50%)	6e-20
CAC42683	SEQUENCE 1 FROM PATENT WO0142286 - Homo sapiens (Human), 794 aa.	42..250 93..303	79/213 (37%) 103/213 (48%)	2e-19
Q9UGS3	DJ756G23.1 (NOVEL LEUCINE RICH PROTEIN) - Homo sapiens (Human), 797 aa (fragment).	42..250 101..311	79/213 (37%) 103/213 (48%)	2e-19
O70211	INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN COMPLEX ACID-LABILE SUBUNIT - Rattus norvegicus (Rat), 603 aa.	44..236 386..595	74/215 (34%) 99/215 (45%)	1e-18
P70193	MEMBRANE GLYCOPROTEIN - Mus musculus (Mouse), 1091 aa.	44..214 237..415	67/179 (37%) 92/179 (50%)	3e-18

PFam analysis indicates that the NOV14a protein contains the domains shown in Table 14E.

Table 14E. Domain Analysis of NOV14a			
Pfam Domain	NOV14a Match Region	Identities/ Similarities for the Matched Region	Expect Value
LRR: domain 1 of 7	45..68	10/25 (40%) 17/25 (68%)	1
LRR: domain 2 of 7	69..92	9/25 (36%) 20/25 (80%)	4.2

LRR: domain 3 of 7	93..115	10/25 (40%) 16/25 (64%)	0.39
LRR: domain 4 of 7	117..140	12/25 (48%) 16/25 (64%)	0.057
LRR: domain 5 of 7	141..164	11/25 (44%) 19/25 (76%)	0.0059
LRR: domain 6 of 7	165..188	6/25 (24%) 15/25 (60%)	39
LRR: domain 7 of 7	189..210	7/25 (28%) 16/25 (64%)	44
dUTPase: domain 1 of 1	269..375	28/139 (20%) 75/139 (54%)	0.00014

**Example 15.**

The NOV15 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 15A.

5

Table 15A. NOV15 Sequence Analysis		
	SEQ ID NO: 57	2328 bp
NOV15a, CG92531-01 DNA Sequence	<p>ATGCCCGGCTACAGTGCTCTTTCTAATAAACCCATGCTGGAAACAACCCAAATGTCTA TCACTAGAGGAATGGGTAAGTACTTGTGGTACGGTGTGGTACCGAGAAGGCTGGACC AGCAGTTCCAGGCGGCATGGAGGGGCCCCGGAGCTCCACCCATGTCCCCCTGGTGCTG CCGCTTCTGTACTTCTGCTGCTGGCCCCGGCTAGGCAGGCCCGCCGCCAGCGTGCC CACAGGCCCTGCATCTGTGACAACCTCCAGGCGACACGTTGCCTGCCGGTACCAGAACCT CACTGAGGTGCCAGACGCCATCCCTGAGCTGACCCAGCGGCTGGACCTGCAGGGCAAT TTGCTGAAGGTGATCCCCGCAGCCGCTTCCAGGGCGTGCTCACCTCACACACCTGG ACCTGCGCCACTGCGAGGTGGAGCTGGTGGCCGAGGGCGCCTTCCGTGGCTGGGCCG CCTGCTCCTGCTCAACCTGGCCTCCAACACCTGCGTGAGCTGCCCCAGGAGGCGTG GACGGGCTGGGCTCGTTGCGGCGGCTGGAGCTGGAGGGGAACGCACTGGAGGAGCTGC GGCCGGGACGTTCCGGGCACTGGGTGCGCTGGCCACGCTAAACCTGGGCCACAACGC CCTGGTTTACCTGCCCGCCATGGCCTTCCAGGGGCTACTGCGCGTCCGTGGCTGCGG CTGTGCGACAACGCGCTCAGCGTGCTGGCCCCCGAGGCCCTGGCTGGCCTGCCCGCC TGAGACGGCTCAGCCTACACCACAACGAGCTCCAGGCTCTGCCCGGGCCTGTCTTGTC CCAGGCCCGCGGCCTGGCCCGCTGAGAGCTGGGCCACAACCCGCTCACCTACGCGGGC GAGGAGGACGGGCTGGCGCTGCCCGGCTGCGGGAGCTGTGCTGGACCGCGGGGCC TGCAGGCCCTGGGTCCAGGGCCTTCGCACACTGTCCGCGCCTGCACACCTCGACCT CCGCGGGAACAGCTAGACACCTGCCCGGCTGCAGGGCCCGGGCCAGCTGCGCCGG CTGCGGCTGCAGGGGAATCCGCTGTGGTGCAGGCTGCCAGGCGCGGCCCTACTCGAGT GGCTGGCGCGGGCGCGCTGCGCTCGGACGGCGCGTGCCAGGGGCCGCGCGCCTGCG GGCGAGGCTCTGGACGCCCTGCGGCCCTGGGACCTGCGCTGCCCTGGGACGCGGCG CAGGAAGAGGAAGAGCTGGAAGAGCGGGCTGTGGCCGGGCCCCGCGCCCTCCGCGCG GCCCTCCGCGCGGCCCGGGGAGGAGCGGGCAGTCGCGCCTTGCCCTCGCGCCTGCGT GTGCGTCCCCGAGTCCCGGCACAGCAGCTGCGAGGGCTGCGGCTGCAGGCGGTGCC CGCGGCTTCCCCAGCGACACCCAGCTCCTGGACCTGAGGCGGAACCACTTCCCCCTCGG TGCCCCGAGCGGCCTTCCCCGGCCTGGGCCACCTGGTGTGCTGCACCTGCAGCACTG CGGCATCGCGGAGCTGGAAGCGGGCGCCTGGCCGGGCTGGGCGGCTGATCTACCTG TACCTCTCGACAACAGCTCGCAGGCCTCAGCGTGCTGCCCTTGAAGGGGCTCCCC GCCTCGGCTACCTGTACCTAGAACGCAACCGTTTCTGTCAGGTGCCAGGGGCTGCCCT GCGCGCCTGCCAGCCTCTTCTCCCTGCACCTGCAGGACAACGCTGTGGACCGCCTG</p>	

	GCACCTGGGGACCTGGGGAGAACACGGGCCTTGCGCTGGGTCTACCTGAGTGGAACC GCATCACCGAAGTGTCCCTTGGGGCGCTGGGCCAGCTCGGGAGCTGGAGAAGCTGCA CCTGGACAGGAATCAGCTGCGAGAGGTGCCACTGGGGCCTTGGAGGGGCTGCCTGCC CTCCTGGAGCTGCAGCTCTCGGGCAACCCACTCAGGGCCTTGCGTGACGGAGCCTTCC AGCCTGTGGGCAGGTGCGTGCAGCACCTCTTCTGAACAGCAGTGGCCTGGAGCAGGT GGGCACTGGGCATCTGGCGGGGTGGTGACAGGAGGCGGCACAAGGCCACAGGCAGCGT GCATTCACTCAACAAGCATTGCCAGCCCCTTGGTGCCAGGCCTGGGGCCCGGGCTCC AGAGCCTGCACCTGCAGAAGAACCAGCTTCGGGCCCTGCCTGCCCTGCCAGTCTCAG CCAGCTGGAGCTCATCGACCTCAGCAGCAATCCCTTCCACTGTGACTGCCAGTGCTT CCGCTGCACAGGCACACCATGTCCATGCCATCCGAGCAGCTTGTGGGAGGGGCGGG TCCTGTGA		
	ORF Start: ATG at 1	ORF Stop: TGA at 2326	
	SEQ ID NO: 58	775 aa	MW at 83600.4kD
NOV15a, CG92531-01 Protein Sequence	MPGYSALSNKPMLETTQMSITRGMGKLLVVRGTEKAGPAVPGMEGPRSSTHVPLVL PLLVLVLLAPARQAAAQRCPQACICDNSRRHVACRYQNLTEVPDAIPELTQRLDLQGN LLKVI PAAAFQGVPHLTHDLRHCEVELVAEGAFRGLGRLLLLNLASNHLREL PQEAL DGLGSLRRLELEGNAL EELRPGTFGALGALATLNLAHNALVYLPAMAFQGLLRVWLRL LSHNALSVLAPEALAGLPALRRLSLHHNELQALPGPVLSQARGLARLELGHNPITYAG EEDGLALPGLRELLLDGGALQALGPRAFAHCPRLHTLDRGNQLDTPPLQGPGLRR LRLQGNPLWCGCQARPLLEWLARARVSDGACQGPRLRGEALDALRPWDLRCPGDAA QEEEELEERAVAGPRAPPRGPPRGPEERAVAPCPACVCVPESRHSSCEGCGLQAVP RGFPSDTQLDLRRNHFPSPRAAFPLGHLVSLHLQHCGIAELEAGALAGLRLIYL YLSDNQLAGLSAAALEGAPRLGYLYLERNRFLQVPGAALRALPSLFSLHLQDNAVDR APGDLGRTRALRWVYLSGNRI TEVSLGALGPARELEKLHLDRNQLREVPTGALEGLPA LLELQLSGNPLRALRDGA FQPVGRSLQHLFLNSSGLEQVGTGHLAGLVQEAQAQHRQR AFTQAFASPLVPGLPGQLSLHLQKNQLRALPALPSLSQLELIDLSSNPFHCDQCQLL PLHRHTMSMPIRAACGEGRVL		

Further analysis of the NOV15a protein yielded the following properties shown in Table 15B.

Table 15B. Protein Sequence Properties NOV15a	
PSort analysis:	0.7900 probability located in plasma membrane; 0.3000 probability located in microbody (peroxisome); 0.3000 probability located in Golgi body; 0.2000 probability located in endoplasmic reticulum (membrane)
SignalP analysis:	Cleavage site between residues 70 and 71

5

A search of the NOV15a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 15C.

10

Table 15C. Geneseq Results for NOV15a				
Geneseq Identifier	Protein/Organism/Length [Patent #, Date]	NOV15a Residues/ Match Residues	Identities/ Similarities for the Matched Region	Expect Value
AAB82352	Protein sequence SEQ ID NO.2 - Homo sapiens, 794 aa. [WO200138357-A2, 31-MAY-2001]	12..766 1..728	696/756 (92%) 703/756 (92%)	0.0
AAE03600	Human leucine-rich repeat-containing protein, AZAD - Homo sapiens, 794 aa. [WO200142286-A2, 14-JUN-2001]	12..766 1..728	696/756 (92%) 703/756 (92%)	0.0
AAB99488	Human chondroadherin protein sequence - Homo sapiens, 381 aa. [WO200137861-A1, 31-MAY-2001]	436..758 41..335	124/323 (38%) 178/323 (54%)	2e-56
AAR85888	WD-40 domain-contg. insulin-like growth factor binding protein - Synthetic, 605 aa. [WO9521252-A2, 10-AUG-1995]	71..541 35..537	166/556 (29%) 209/556 (36%)	8e-37
AAB38400	Fragment of human secreted protein encoded by gene 3 clone HSYAV50 - Homo sapiens, 723 aa. [WO200061623-A1, 19-OCT-2000]	39..450 36..464	137/441 (31%) 180/441 (40%)	3e-31

In a BLAST search of public sequence databases, the NOV15a protein was found to have homology to the proteins shown in the BLASTP data in Table 15D.

5

Table 15D. Public BLASTP Results for NOV15a				
Protein Accession Number	Protein/Organism/Length	NOV15a Residues/ Match Residues	Identities/ Similarities for the Matched Portion	Expect Value
Q9UGS3	DJ756G23.1 (NOVEL LEUCINE RICH PROTEIN) - Homo sapiens (Human), 797 aa (fragment).	43..766 40..737	684/724 (94%) 689/724 (94%)	0.0
CAC42683	SEQUENCE 1 FROM PATENT WO0142286 - Homo sapiens (Human), 794 aa.	12..766 1..728	696/756 (92%) 703/756 (92%)	0.0

O70210	CHONDROADHERIN PRECURSOR - Rattus norvegicus (Rat), 358 aa.	436..758 18..312	125/323 (38%) 178/323 (54%)	3e-56
Q96RJ5	CHONDROADHERIN - Homo sapiens (Human), 359 aa.	436..758 19..313	124/323 (38%) 178/323 (54%)	6e-56
A53860	chondroadherin precursor - bovine, 361 aa.	436..758 21..315	124/323 (38%) 178/323 (54%)	1e-55

PFam analysis indicates that the NOV15a protein contains the domains shown in Table 15E.

Table 15E. Domain Analysis of NOV15a			
Pfam Domain	NOV15a Match Region	Identities/ Similarities for the Matched Region	Expect Value
Trypan_glycop: domain 1 of 1	56..76	10/21 (48%) 20/21 (95%)	2.7
GASA: domain 1 of 1	51..100	16/109 (15%) 33/109 (30%)	9.8
LRRNT: domain 1 of 2	76..105	12/31 (39%) 21/31 (68%)	1.9e-05
LRR: domain 1 of 19	107..130	8/25 (32%) 18/25 (72%)	1.8
LRR: domain 2 of 19	131..154	6/25 (24%) 19/25 (76%)	2.8
LRR: domain 3 of 19	155..178	9/25 (36%) 19/25 (76%)	0.087
LRR: domain 4 of 19	179..202	10/25 (40%) 18/25 (72%)	0.082
LRR: domain 5 of 19	203..226	9/25 (36%) 16/25 (64%)	0.71
LRR: domain 6 of 19	227..250	11/25 (44%) 19/25 (76%)	0.017
LRR: domain 7 of 19	251..274	7/25 (28%) 18/25 (72%)	4.5
LRR: domain 8 of 19	299..322	9/25 (36%) 17/25 (68%)	68
LRR: domain 9 of 19	323..344	9/25 (36%) 18/25 (72%)	0.25



LRRCT: domain 1 of 1	354..402	20/55 (36%) 34/55 (62%)	0.0078
LRRNT: domain 2 of 2	439..468	14/31 (45%) 20/31 (65%)	0.047
LRR: domain 10 of 19	470..493	8/25 (32%) 16/25 (64%)	41
LRR: domain 11 of 19	494..517	5/25 (20%) 20/25 (80%)	0.35
LRR: domain 12 of 19	518..541	8/25 (32%) 20/25 (80%)	0.22
LRR: domain 13 of 19	542..565	7/25 (28%) 18/25 (72%)	11
LRR: domain 14 of 19	566..589	7/25 (28%) 15/25 (60%)	1.4e+02
LRR: domain 15 of 19	590..613	5/25 (20%) 19/25 (76%)	1.8
LRR: domain 16 of 19	614..637	9/25 (36%) 21/25 (84%)	0.0028
LRR: domain 17 of 19	638..661	9/25 (36%) 15/25 (60%)	38
LRR: domain 18 of 19	663..686	5/25 (20%) 17/25 (68%)	84
LRR: domain 19 of 19	714..735	8/25 (32%) 18/25 (72%)	0.91

**Example 16.**

The NOV16 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 16A.

5

Table 16A. NOV16 Sequence Analysis		
	SEQ ID NO: 59	2800 bp
NOV16a, CG92715-01 DNA Sequence	TAGACGCGGAGCCCAAGGAGGTAAAATGCACACTTGCTGCCCCAGTAACCTTTGGAA CAGGACCTTCACAGAAAAATGCATAGCTGGATGCTGCAGACTCTAGCGTTTGCTGTAA CATCTCTCGTCCTTTCGTGTGCAGAAACCATCGATTATTACGGGGAAATCTGTGACAA TGCATGTCCTTGTGAGGAAAAGGACGGCATTTTAACTGTGAGCTGTGAAAACCGGGGG ATCATCAGTCTCTCTGAAATTAGCCCTCCCCGTTTCCCAATCTACCACCTCTGTGTGT CCGGAAACCTTTTGAACCGTCTCTATCCCAATGAGTTTGTCAATTACACTGGGGCTTC AATTTTGCATCTAGGTAGCAATGTTATCCAGGACATTGAGACCGGGGCTTCCATGGG CTACGGGGTTTGAGGAGATTGCATCTAAACAATAATAAACTGGAACCTCTGCGAGATG ATACCTTCCTTGGCTTGGAGAACCTGGAGTACCTACAGGTCGATTACAACCTACATCAG CGTCATTGAACCCAATGCTTTTGGGAACTGCATTTGTTGCAGGTGCTTATCCTCAAT GACAATCTTTGTCCAGTTTACCCAACAATCTTTCCGTTTTGTGCCCTTAACGCACT TGGACCTCCGGGGGAACCGGCTGAAACTTCTGCCCTACGTGGGGCTCTTGACGACAT	

GGATAAAGTTGTGGAGCTACAGCTGGAGGAAAAACCCCTTGGAAATTTGTTCTTTGTAGCTG ATCTCTCTAAAGGATTGGTTGGACAGCATCTCCTATTACGCCCTGGTGGGGGATGTAG TTTGTGAGACCCCCTTCCGCTTACACGGAAGGGACTTGGACGAGGTATCCAAGCAGGA ACTTTGCCCAAGGAGACTTATTTCTGACTACGAGATGAGGCCGACAGCGCTTTGAGC ACCACGGGGTATTTACACACCACCCCGGCGTCAGTGAATTCTGTGGCCACTTCTTCCT CTGCTGTTTACAAACCCCTTTGAAGCCCCCTAAGGGGACTCGCCAAACCAACAGCC CAGGGTCGCGCCACCTCTCGGCAGCCCTCTAAGGACTTTGGGCTACAGCAACTATGGC CCACGATCGCCTATCAGACCAAATCCCCGGTGCCTTTGGAGTGTCCACCGCGTGCT CTTGCAACCTGCAGATCTCTGATCTGGGCCTCAACGTAACTGCCAGGAGCGAAAGAT CGAGAGCATCGCTGAAGTGCAGCCCCAAGCCCTACAATCCCAAGAAAATGTATCTGACA GAGAATACATCGTGTCTGTGCGCAGGACAGACTTCTTGAGGCCACCGGGCTGGACC TCTGTCACTTGGGGAATAACCGCATCTCGATGATCCAGGACCGCGCTTTGGGGATCT ACCAACCTGAGGCCCTCTACCTGAATGGCAACAGGATCGAGAGGCTGAGCCCGGAG TTATTCTATGGCCTGCAGAGCCTGCAGTATCTTCTCTCCAGTACAATCTCATCCGCG AGATTCACTGTGGAATTTTGAACCCGCTCCCAAACCTCCAGCTGTATTCTTGAATAA CAACCTCCTGCAGGCCATGCCTCAGGCGTCTTCTGTGGCTTGACCTCCTCAGGCTA AACCTGAGGAGTAACCACTTCACTCCTTGCCAGTGAGGAGTTTGGACAGCTGA AGTCACTCATCCAAATCGACCTGCATGACAATCCTTGGGATTGTACCTGTGACATTGT GGGCATGAAGCTGTGGGTGGAGCAGCTCAAAGTGGGCGTCTAGTGGACGAGGTGATC TGTAAGCGCCCCAAAAAATTCGCTGAGACCGACATGCGCTCCATTAGTCGGAGCTGC TGTGCCCTGACTATTAGATGTAGTAGTTTCCACGCCCCACACCTCCTCTATCCAGGT CCCTGCGGAGGACGAGCCCGTGACTCCTGCGGTCGGGTGAATAGACCGGGGCCCC CGCAGCTTGGGCGCAGCGCGGAGGGCGCTCGTGGTGCCTTGTCTGTGTTAATTCTCA GCCTCCTGTGTTTTTCATCATGTCCGCTCTTCTGTGGCGCGGGGCTCTTCTGTCTGGT CATGAAGCGCAGGAAGAAGAACAGAGCGACACACCAGACCAACAACTCCGACGTG AGCTCCTTTAATCATGAGTACAGCGTGTACGGCGCGCGGCGGCGGACGGGCGGCCAC CACAGCGCACGTGCATCACCAGCGGCGCGCGCTGCCCAAGGTGAAGACGCGCGGG CCAGCTGTATGAATACATCCCCACCCACTGGGCCATGTGTGCAAAAAACCCATCTAC CGCTCCCGAGAGGGCAACTCCGTAGAGGATTACAAAGACCTGCACGAGCTCAAGGTCA CCTACAGCAGCAACCAACACCTGCAGCAGCAGCAGCAGCCGCCGCCACCAGCAGCA GCCACAGCAGCAGCCCCCGCGCAGCTGCAGCTGCAGCTTGGGGAGGAGGAGGGCGG GAAAGCCACCACTTGTGGGAGCCCCGCTACAGCGTCAGCACCATCGAGCCCCGGGAG ACCTGCTGTGCGCGGTGCGGAGCGCGGACCGCTTTACAGGGGCAATTTAGAACCCAGA CAAACTGCTTCCACCACCCCGCGGCAATAGCTTCCCGGAATATCCCAAATTCCTG TGCAGCCCCGCTGCTTACACTTTCTCCCCAACTATGACCTGAGACGCCCCCATCAGT ATTTGCACCCGGGGGAGGGGACAGCAGGCTACGGGAACCGGTGCTCTACAGCCCCC GAGTGTCTGTTTGTGA			
ORF Start: ATG at 26		ORF Stop: end of sequence	
SEQ ID NO: 60		925 aa	MW at 103516.1kD
NOV16a, CG92715-01 Protein Sequence	MHTCCPPVLTLEQDLHRKMHSMWLQTLFAVTSVLVLSCAETIDYYGEICDNAPCEEKD GILTVCENRGIISLSEISPPRFPIYHLLLSGNLNLRLYPNEFVNYTGASILHLGSNV IQDIETGAFHGLRGLRRLHLNKNLELLRDDTFLGLENLEYLQVDYNYISVIEPNAFG KLHLQLVLILNDNLLSSLPNNLFRFVPLTHDLRGNRLKLLPYVGLLQHMCKVVELQL EENPNWNCSEILSKDWLDSISYSALVGDVVCETPFRLLHGRDLDEVSQKELCPRLIS DYEMRPQTPLSTTGAYLHTTPASVNSVATSSSAVYKPLKPPKTRQPNKPRVPTSRQ PSKDLGYSNYGPSIATYQTKSPVPLECPTACSCNLQISDLGLNVNCQERKIESIAELQP KPYNPKKMYLTENYIAVVRRTDFLEATGLDLLHLGNNRISMTQDRAFDLTNLRRLYL NGNRIERLSPELFYGLQSLQYLFQYNLIREIQSFTFDPVPLQLLFLNNNLLQAMPS GVFSGLTLLRLNLRSHFTSLPVSGLVDQLKSLIQIDLHNDPWCCTDIDVGMKLWVEQ LKVGLVLDVEICKAPKKFAETDMRSIKSELLCPDYSDVVSTPTSSIQVPARTSAVT PAVRNLSTGAPASLGAGGGASSVPLSVLILSLLVFIMSVFAAGFLVLMKRRKKNQ SDHTSTNNSDVSSFNMQYSVYGGGGGTGGHPHAHVHHRGPALPKVKTAPGHVYIEIPH PLGHMCKNPIYRSREGNSVEDYKDLHELKVYSSNHLQQQQQPPPPPPQPPQPPQ LQLQPGEERESHHLRSPAYSVSTIEPREDLLSPVQDADRFYRGILEPDKHCSTTPA GNSLPEYPKPCSPAAYTFSPNYDLRRPHQYLHPGAGDSRLREPVLVSFPPSAVF		
SEQ ID NO: 61		4500 bp	
NOV16b, CG92715-02 DNA	CGGAACCCGCGGTGCGCACCGCGCGCGGCGGCCAGGCTGGAGGCGTCCGGGCGCCTC TTTCTCTCAGCCTCTGGGACTCGCTGCTCGCAGTCTCCTCGCCTGCTGGGCTTGA		

Sequence	GAAACCTAGTGCATACCCCAAAGAGGGTTTTTGTGTATGTGTGTGTTTTTAAAGGGTG GCTATGATGACTGGGCCTTGGAGACGCGGAGACCAAGGAGGTAAATGCACACTTGCT GCCCCCAGTAACTTTGGAACAGGACCTTCACAGAAAAATGCATAGCTGGATGCTGCA GACTCTAGCGTTTGTGTAACATCTCTCGTCTTTCGTGTGCAGAAACCATCGATTAT TACGGGGAAATCTGTGACAATGCATGTCTTGTGTAGGAAAAGGACGGCATTTTAACTG TGAGCTGTGAAAACCGGGGATCATCAGTCTCTGAAATTAGCCCTCCCGTTTCCC AATCTACCACCTCTTGTGTCCGAAACCTTTGAACCGTCTCTATCCCAATGAGTTT GTCAATTACACTGGGGCTTCAATTTTGCATCTAGGTAGCAATGTTATCCAGGACATTG AGACCGGGGCTTCCATGGGCTACGGGGTTTGTAGGAGATTGCATCTAAACAATAATAA ACTGGAACCTTCTGCGAGATGATACCTTCTTGGCTTGGAGAACCTGGAGTACCTACAG GTCGATTACAACATACATCAGCGTCATTGAACCCAATGCTTTTGGGAACTGCATTGT TGCAGGTGCTTATCCTCAATGACAATCTTTTGTCCAGTTTACCCAAACATCTTTCCG TTTTGTGCCCTTAACGCCTTGGACCTCCGGGGGAACCGGCTGAAACTTCTGCCCTAC GTGGGGCTCTTGCAGCACATGGATAAAGTTGTGGAGCTACAGCTGGAGGAAAACCTT GGAATTGTTCTTGTGAGCTGATCTCTTAAAGGATTGGTTGGACAGCATCTCCTATT AGCCCTGGTGGGGGATGTAGTTTGTGAGACCCCTTCCGCTTACACGGAAGGGACTTG GACGAGGTATCCAAGCAGGAACCTTGCCCAAGGAGACTTATTTCTGACTACGAGATGA GGCCGACAGCGCTTGTAGCACCACGGGGTATTACACACCACCCCGCGCTCAGTGAA TTCTGTGGCCACTTCTTCTCTGCTGTTTACAAACCCCTTGAAGCCCCCTAAGGGG ACTCGCCAACCCAACAAGCCAGGGTGCGCCACCTCTCGGCAGCCCTCTAAGGACT TGGGCTACAGCAACTATGGCCCCAGCATCGCCTATCAGACCAATCCCGGTGCTTT GGAGTGTCCACCGCGTCTTGTCAACCTGCAGATCTCTGATCTGGGCTCAACGTA AACTGCCAGGAGCGAAAGATCGAGAGCATCGCTGAACCTGCAGCCGACGCCCTACATC CCAAGAAAATGTATCTGACAGAGAACTACATCGCTGTCTGCGCAGGACAGACTTCT GGAGGCCACGGGGCTGGACCTCTGCACCTGGGGAATAACCGCATCTGATGATCCAG GACCGCGCTTTCGGGGATCTCACCACCTGAGGCGCCTCTACCTGAATGGCAACAGGA TCGAGAGGCTGAGCCCGGAGTTATTCTATGGCCTGCAGAGCTGCAGTATCTTCTCT CCAGTACAATCTCATCCGCGAGATTCACTGTGAACCTTTGACCCGTCCTCAACCTC CAGCTGCTATTCTTGAATAACAACCTCTGCAGGCCATGCCCTCAGGCGTCTTCTCTG GCTTGACCCCTCTCAGGCTAAACCTGAGGAGTAACCACTTCACTCCTTGCCAGTGAG TGGAGTTTGGACCAGCTGAAGTCACTCATCCAAATCGACCTGCATGACAATCCTTGG GATTGTACCTGTGACATTGTGGGCATGAAGCTGTGGGTGGAGCAGCTCAAAGTGGGCG TCCTAGTGGACGAGGTGATCTGTAAGGCGCCCAAAAATTCTGCTGAGACCGACATGCG CTCCATTAAAGTCGAGCTGTGTGCCCTGACTATTGAGATGTAGTATTCCACGCCC ACACCCCTCTCTATCCAGGTCCCTGCGAGGACCAGCGCCGTGACTCTGCGGTCCGGT TGAATAGCACCGGGGCCCCCGGAGCTTGGGCGCAGGCGGAGGGGCGTCTGCGTGCC CTTGTCTGTGTTAATTCTCAGCCTCCTGCTGGTTTTCATCATGTCCGTCTTCTGCGC GCCGGGCTCTTCTGTCTGGTCATGAAGCGCAGGAAGAAGAACGAGCGACCAACCA GCACCAACAACCTCCGAGCTGAGCTCCTTTAACATGCAGTACAGCGTGTACGGCGCGG CGGCGGCACGGGCGGCCACCCACAGCGCACGTGCATCACCGGGGCGCGCTGCCCC AAGGTGAAGACGCCCGGGGCCAGTGTATGAATACATCCCCACCACTGGGGCCACA TGTGCAAAAACCCATCTACCGCTCCCGAGAGGGCAACTCCGTAGAGGATTACAAAGA CCTGCACGAGCTCAAGGTACCTACAGCAGCAACCACCACTGCAGCAGCAGCAGCAG CCGCCGCGCCACCGCAGCAGCCACAGCAGCAGCCCCCGCGCAGCTGCAGCTGCAGC CCGGGGAGGAGGAGAGGCGGGAAAGCCACCACTTGCAGGAGCCCCGCTACAGCGTCAG CACCATCGAGCCCCGGGAGGACCTGCTGTGCGCGGTGCAGGACGCCGACCGCTTTTAC AGGGGCATTTTAGAACAGACAAACACTGCTCCACCACCCCCCGCGCAATAGCCTCC CGGAATATCCCAAATTCCTGTCAGCCCCGCTGCTTACACTTTCTCCCCAACTATGA CCTGAGACGCCCCATCAGTATTGACCCGGGGGCGAGGACAGCAGGCTACGGGAA CCGGTGCTCTACAGCCCCCGAGTGCTGCTTTGTAGAACCACCGGAACGAATATC TGGAGTTAAAAGCAAACTAAACGTTGAGCCGACTACCTCGAAGTGCTGGA AAAACA GACCACGTTTAGCCAGTTCTAAAAGCAAAGAACTCTCTTGGAGCTTTTGCATTTAAA ACAAACAAGCAAGCAGACACACACAGTGAAACACTTTGATTAAATGTGTGTTTCAAC GTTTAGGGTGAAGTGCTTGGCACGGGATTTCTCAGCTTCGGTGGAAGATACGAAAAG GGTGTGCAATTTCTTTAAAATTTACAGTGGGAAACATTTGTGTAACTGGGCACAT CACTTTCTCTTCTTGGTGTGGGGCAGGTGTGGAGAAGGGCTTAAAGGAGGCCAATTT GCTGCGCGGGTGACCTGTGAAGGTACAGTCATTTTGTAGTGGTTGGAAGTGCTAA GAATGGTGGATGATGGCAGAGCATAGATTCTACTCTCTCTTCTTCTCTCTCTCTCT CCAACGAAACCTGCCCCAACCTCTAAATATCCACCAGATAAGACATGGAATGAGGTCT AAATGACACAAAGTGAAGAAATCAACACAACACAACTTTACAGCTAACACAAATGA TCAACAAAACCGAACCAACAGACAACCATCGAACCTCACCCTCACCCTCACAAC
----------	---

	AACTCATATCAAGACAACAACACAATGACGTTAAAGGAAACGAAATCAATGCAAAAAT AGACATTTGACAAATACAAAAAACAAAGAACCGTGATCACACTACAACCGAAGCAACCA TAGATGTGAGAAAAACAACAAACAAACACCGAGCTATATGATCCATAATTGATTAG TCAAAATAACTTATTGATGAAATATACAAATATTTTATTGTAGCACCTATTTTTATAT GCACATTTAGCATTCCTCTTTCTTCACTATTTAGCCTATGATTTTGAGAGGTGTCA CACTGTATTAGGATCTGCATTTCTAAACTGACGTGGTATCAGGAAGGCATTTTCAAT CATTCAAAATGTGGAGAATTTAATGGCTAAATCTTAAAGCCAATGCAACCCACCCA ATTGAATCTGCATTTTCTTTAAGAAAACAGAGCTGATTGTATCCCAATGTATTTTAA AAAATAGGGCAATTGATTGGGCCATTCCGAGAGAATTGTTTGAAGTTTGGGTTTAA TTAGAAAATATTGAAAGTATTTTTATTAATGAACCAAAATGACATGTTCAATTGACT ACTATTGTAGCCGATTTTCGATTGTTTAAACCAACCCAGTTGCATTTGTACAGATCCA CGTGTACTGGCACTCAGAAGACCAATCATGGACTGTACAAGTCTCTATACAATGTC TTTATCCCTGTGGGCAGCAAGCAATGATGATAATGACAAACAGGATATCTGTAAGATG GGGCTACTGTTGTACAGTCTCATATGTATCCAGCACATGTAATTTTTTAAATAGTT TCTGAATAAACTTGATAACTATGTCAAAAAA		
	ORF Start: ATG at 178	ORF Stop: TAA at 3094	
	SEQ ID NO: 62	972 aa	MW at 109043.3kD
NOV16b, CG92715-02 Protein Sequence	MMTGPPWRGDQGGKMHTCCPPVTLEQDLHRKMHSWMLQTLFAVTSVLSCAETIDYY GEICDNACPCEEKDGILTVSCENRGIISLSEISPPRFPIYHLLLSGNLLNRLYPNEFV NYTGASILHLGNSVIQDIETGAFHGLRGLRRLHLNKKLELLRDDTFLGLENLEYLQV DYNYSVIEPNFAGKLHLLQVLILNDNLLSSLPNNLFRFVPLTHDLRGNRLKLLPYV GLLQHMDKVVELQLEENPWNCSELI SLKDWLDSISYSALVGDDVVCETPFRHGRDL EVSKQELCFRRLISDYEMRPTPLSTTGYLHTTPASVNSVATSSSAVYKPLKPKPGT RQPNKPRVRPTSRQPSKDLGYSNYGPSIAYQTKSPVPLECPTACSCNLQISDLGLNVN CQERKIESIAELQPKYPNPKMYLTENYIAVVRTDFLEATGLDLLHLGNRISMIQD RAFGLTNLRLRYLNGNRIERLSPELFYGLQSLQYLFLQYNLIREIQSGTFDPVPLN LLFLNLLQAMP SGVFSGLTLLRLNLSNHFTSLPVSGVLDQLKSLIQIDLHDNPWD CTCDIVGMKLWVEQLKVGVLVDEVICKAPKKFAETDMRSIKSELLCPDYSDVVSTPT PSSIQVPARTSAVTPAVRLNSTGAPASLGAGGGASSVPLSVLILSLLLVFIMSVFVAA GLFVLVMKRRKKNQSDHTSTNNSDVSSFMQYSVYGGGGTGGHAPHVHHRGPALPK VKTPAGHVYEYI PPHLGHMCKNPIYRSREGNSVEDYKDLHELKVITYSSNHLQQQQQP PPPPQQPQQPPQLQLPGEERESHHLRSPAYSVSTIEPREDLSPVQDADRFRYR GILEPDKHCSTTPAGNSLPEYKFPKCPAAYTFSPNYDLRRPHQYLHPGAGDSRLREP VLYSPPSAVFVEPNRNEYLELKAKLNVEPDYLEVLEKQTTFSQF		

Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 16B.

Table 16B. Comparison of NOV16a against NOV16b.		
Protein Sequence	NOV16a Residues/ Match Residues	Identities/ Similarities for the Matched Region
NOV16b	1..925 15..939	752/925 (81%) 752/925 (81%)

5

Further analysis of the NOV16a protein yielded the following properties shown in Table 16C.

Table 16C. Protein Sequence Properties NOV16a	
PSort analysis:	0.8500 probability located in endoplasmic reticulum (membrane); 0.4400

	microbody (peroxisome); 0.3000 probability located in nucleus
SignalP analysis:	Cleavage site between residues 41 and 42

A search of the NOV16a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 16D.

5

Table 16D. Geneseq Results for NOV16a				
Geneseq Identifier	Protein/Organism/Length [Patent #, Date]	NOV16a Residues/ Match Residues	Identities/ Similarities for the Matched Region	Expect Value
AAB95753	Human protein sequence SEQ ID NO:18665 - Homo sapiens, 958 aa. [EP1074617-A2, 07-FEB-2001]	1..925 1..925	925/925 (100%) 925/925 (100%)	0.0
ABB12025	Human IGFALS homologue, SEQ ID NO:2395 - Homo sapiens, 977 aa. [WO200157188-A2, 09-AUG-2001]	1..925 20..944	924/925 (99%) 924/925 (99%)	0.0
AAG67524	Amino acid sequence of a human secreted polypeptide - Homo sapiens, 845 aa. [WO200166690-A2, 13-SEP-2001]	46..925 27..812	423/886 (47%) 563/886 (62%)	0.0
AAE01232	Human gene 1 encoded secreted protein HMIAJ30, SEQ ID NO:94 - Homo sapiens, 845 aa. [WO200134769-A2, 17-MAY-2001]	46..925 27..812	422/886 (47%) 562/886 (62%)	0.0
AAE01312	Human gene 1 encoded secreted protein fragment, SEQ ID NO:177 - Homo sapiens, 596 aa. [WO200134769-A2, 17-MAY-2001]	46..630 6..583	336/594 (56%) 436/594 (72%)	0.0

10 In a BLAST search of public sequence databases, the NOV16a protein was found to have homology to the proteins shown in the BLASTP data in Table 16E.

Table 16E. Public BLASTP Results for NOV16a				
Protein Accession Number	Protein/Organism/Length	NOV16a Residues/ Match Residues	Identities/ Similarities for the Matched Portion	Expect Value
O94991	Hypothetical protein KIAA0918 - Homo sapiens (Human), 966 aa (fragment).	1..925 9..933	925/925 (100%) 925/925 (100%)	0.0
Q9H156	BG115M3.1 (NOVEL PROTEIN) - Homo sapiens (Human), 845 aa.	46..925 27..812	423/886 (47%) 563/886 (62%)	0.0
O94933	Hypothetical protein KIAA0848 - Homo sapiens (Human), 977 aa.	9..773 4..764	370/787 (47%) 511/787 (64%)	0.0
Q96JH3	KIAA1854 PROTEIN - Homo sapiens (Human), 572 aa (fragment).	46..599 33..571	325/555 (58%) 419/555 (74%)	0.0
CAB65788	BG256O22.1 (SIMILAR TO IGFALS (INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN, ACID LABILE SUBUNIT)) - Homo sapiens (Human), 853 aa (fragment).	16..713 15..683	348/703 (49%) 468/703 (66%)	0.0

Pfam analysis indicates that the NOV16a protein contains the domains shown in Table 16F.

Table 16F. Domain Analysis of NOV16a			
Pfam Domain	NOV16a Match Region	Identities/ Similarities for the Matched Region	Expect Value
LRRNT: domain 1 of 2	47..82	12/37 (32%) 23/37 (62%)	23
LRR: domain 1 of 10	82..105	9/25 (36%) 13/25 (52%)	4.8e+02
LRR: domain 2 of 10	106..129	5/25 (20%) 16/25 (64%)	80
LRR: domain 3 of 10	130..153	9/25 (36%) 19/25 (76%)	1.6
LRR: domain 4 of 10	154..177	10/25 (40%) 21/25 (84%)	0.0061
LRR: domain 5 of 10	178..200	9/25 (36%) 16/25 (64%)	43
LRR: domain 6 of 10	201..222	10/25 (40%) 17/25 (68%)	48

LRRCT: domain 1 of 2	235..285	18/54 (33%) 34/54 (63%)	3e-08
LRRNT: domain 2 of 2	373..406	10/35 (29%) 19/35 (54%)	0.049
LRR: domain 7 of 10	434..457	9/25 (36%) 17/25 (68%)	0.17
LRR: domain 8 of 10	458..481	10/25 (40%) 22/25 (88%)	0.00064
LRR: domain 9 of 10	482..505	6/25 (24%) 18/25 (72%)	0.096
LRR: domain 10 of 10	506..529	10/25 (40%) 19/25 (76%)	0.0085
LRRCT: domain 2 of 2	563..613	12/54 (22%) 38/54 (70%)	5.6e-05

**Example 17.**

The NOV17 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 17A.

5

Table 17A. NOV17 Sequence Analysis		
	SEQ ID NO: 63	15603 bp
NOV17a, CG92813-01 DNA Sequence	CTAATAGAATTACAGCGGCCGCTTTCCCGGTGCGCAGTTGTGCTTGGACGTTTGTGCC TCCCTCTTCACGCTCTTCGCTGCGGGTAAGTTCTAAAGTTTCTGAAGGCCGTTCTTTG CAATGATTCCTCATATACCTTAGATACAGGCAACTTCTCCCAACTCTCATCCACCCGG GTGAAAACGCTCAGACTATCTGGATTCAAAAACAAAGTAAAAGGGGGCATATATAAGA GGCTTGAGAACTTTTCTGGGAACTCAGCTCACAGGAGTGTCCCGCGGAATGCCCTGC CGCTTTTCGCCACAGCATCTCTTTCGCACTCCGCGTTCAACTGGCTACCTAGAGTCTT TTGCTGATGCTACTTGCTTTTGCCGGACTGGAGGTCTTTTGAAATAGCAGAGGTCTCA GACCAAGCCGTCAGCTGAATCTTTGCTGGCGCTCCTTAATCCCTGTAATATCATTGC GTTTGCTTCACCCCTCCTTCTCTTTATCACATCGTTTATAGGAGCCAGGACCATGGA CTTAGCACACAGACAGGGCTACTGGCCGCCGTTGGCTCCCGTTGCACACTCTATCAGTA TCTCAGCTCCTTCGAGTGTTTGGCTACTGTCTTCCGGGGCAGGCTGGGTCC ACGGGGCCGAGCCGCGCCAGGTGTTCCAAGTGCTGGAAGAGCAACCTCCAGGCACTCT GGTAGGCACCATCCAGACGCGCCCGGCTTACCTACAGGCTCAGCGAAAGCCACGCC CTGTTTGCCATAAACAGTAGCACCAGGAGCCCTGTACACCACTCCACCATCGACCCGG AGAGCCTGCCAGCGACGTGATCAACCTGGTGGTCTTTCCAGCGCGCCACCTACCC CACCGAAGTGCGAGTGCTGGTGCGGGACCTCAATGACAACGCCCCGTTTTCCCGGAC CCCTCTATCGTGGTCACTTTCAAGGAAGACAGTAGCAGCGGACGCCAAGTCATCTTAG ACACCGCCACCGACTCGGACATCGGCTCAAACGGTGTGGACCACCGCTCCTACCGCAT CATCCGCGGCAATGAGGCGGGGCGCTTCCGTCTGGACATCAACCTGAACCCGAGCGGC GAGGGAGCGTTCTGTCATCTGGTGTTCAAGGGCGGACTGGACCGTGAGGTCACTCCGC AGTACCAGCTCCTGGTTGAGGTGGAGGACAAGGGTGAGCCTAAGCGCGGGGTACCT TCAGGTAAACGTGACTGTGCAAGACATTAATGACAACCCCCCGTTTTTGGCAGTTCT CACTACCAGGCGGGGTGCTGAGGACGCGGTTGTGGGTTCCAGCGTCTCCAGGTGG CGGCGGCGGACGCGGACGAGGGACCAACGCGGACATCCGCTATCGCTGCAGGACGA GGGGACCCCTTCCAAATGGACCCTGAGACGGGACTTATCACGGTGCGGGAGCCCTG GACTTCGAAGCTCGGCGCCAATACTCGCTTACGGTGACGGGATGGACAGAGGCGTGC CTTCCTCACTGGGCGCGCGAGGCGCTGATTAGCTGCTGGACGTGAATGACAATGA	

CCCGGTAGTGAAGTTCCGCTACTTCCCGGCCACCTCGCGCTACGCCCTCGGTAGATGAG  
 AATGCTCAAGTGGGACACCGTGGTGGCTCTGCTCACCGTGACGGACGACAGATTCTCCCG  
 CGGCCAACGGGAACATCTCCGTGCAAAATCTCGGGGGCAATGAGCAGCGCCACTTTGA  
 AGTGCAAAGCAGCAAAGTGCCGAACCTGAGCCTAATCAAGGTGGCCAGCGCCTTGGAC  
 CGCGAGCGCATCCCTTCTACAACCTCAGAGTTTCCGTCTCTGATAACTACGGGGCGC  
 CCCCTGGCGCAGCAGTCCAGGCGCGCTCTTCTGTGGCAAGCCTGGTGATTTTGTAA  
 TGACATCAATGACCATCCTCCTGTCTTTTACAGCAAGTGTACAGAGTGAACCTGAGC  
 GAGGAGCGCCTCCGGGAAGCTATGTGAGTGGGATATCTGCCACTGATGGCGACTCTG  
 GTCTCAATGCTAATCTGCGTTACAGCATTGTCTCTGGCAATGGACTGGGATGGTTCCA  
 TATCAGTGAACATAGCGGCCTCGTGACCACTGGGTCTCTGGGGGCCTGGACCGTGAA  
 CTGTGCTTCCAGATTGTTCTGAATATAAGTGCCCCGGGACAGGGAGTTACCCCAAGG  
 TGTCCTATGCCCAGCTTGTAGTAACTCTCTAGATGTGAATGATGAAAAGCCAGTATT  
 TAGCCAGCCAGAAGGGTATGATGTGTCTGTGGTTGAGAATGCCCAACAGGGACAGAA  
 CTGTTGATGCTCAGGGCAACTGACGGGGACCTGGGTGACAACGGAACAGTGCCTTCT  
 CCTTACAAGAGGCAGAGACTGACCGGAGGTCTTCCGTCTGGATCCTGTGTCTGGGAG  
 GTTGAGTACTATTTCTCTCTTGACAGAGAAGAGCAAGCCTTCTACTCCCTGTTGGTT  
 CTGGCCACAGATCTGGGCTCCCTCCCCAGTCATCAATGGCTCGCATAAATGTGAGTC  
 TTCTGGATATAAATGATAACAGCCCTGTCTTCTACCCGGTCCAATACTTTGCTCACAT  
 TAAGGAGAATGAGCCTGGAGGTAGCTACATCACCACGTGTCTGTCCACTGACCCAGAC  
 TTGGGTACCAATGGTACTGTCAAATATAGCATATCTGCTGGGGACAGGTCTCGGTTTC  
 AGGTCAATGCTCAGAGTGGGGTTATTTCTACAAGAAATGGCCCTAGACAGAGAAGAAAA  
 AACAGCTTATCAGTTGCAAATAGTAGCTACTGATGGTGGCAATTTACAATCTCCCAAC  
 CAGGCAATAGTAACCATCACTGTATTGGACACTCAAGACAACCCACCTGTATTCACTC  
 AGGTTGCCCTACAGCTTTGTGGTTTGTGAGAACGTGGCGCTGGGATATCATGTGGGTAG  
 TGTGTCTGCATCCACCATGGATCTCAATTCCAACATCAGTTATCTCATTACTACTGGG  
 GATCAGAAAGGTATGTTTGCTATCAACCAGGTCACTGGGCAGCTTACCACAGCAAATG  
 TGATTGATAGAGAAGAGCAATCCTTTTATCAGCTGAAGGTAGTGCCAGTGGGGGCAC  
 AGTGACTGGAGACACTATGGTTAACATAACAGTTAAGGATTTGAATGACAACTCTCCC  
 CATTTCTTTCAGGCAATAGAGAGTGTAAATGTGGTGGAGAATTTGGCAGGCAGGTACAC  
 GCATTTTCCAGGCCAAAGCTGTGGACCCTGATGAAGGTGTCAATGGCATGGTACTCTA  
 TAGTCTGAAGCAAAACCCCAAGAACCTGTTTGCTATCAATGAAAAGAAATGGCACTATT  
 AGTCTGCTTGGGCCCTGGATGTTTATGCTGGCTCCTACCAATAGAGATCTTGGCAT  
 CTGACATGGGTGTCCACAGCTCTCCTCTAGTGTATCCTAACAGTTTATGTCCATGA  
 TGTAAATGACAATTCACAGTGTGTTGACCAACTCTCTTATGAAGTACCCCTTCTGAG  
 TCAGAACCCTGTGAATTTCTCGATTCTTTAAAGTACAAGCTTCTGATAAGGATTGAGGAG  
 CAAATGATGGTCAATTGTATATAAAAAGTGAACCTGGACCGTGAACCTCAAGACAGATA  
 TGTTTTAAATGGTTGTTGCTTCTGACAGAGCAGTGGAACCCCTTAGTGCTACTGTGAAT  
 GTTACTGTAAATTTAGAAGATGTAAATGATAACAGACCTCTTTTAAACAGTACCAATT  
 ACACATTTTACTTCGAAGAAGAGCAGAGGGCTGGGTCTGTTGTGGGCAAGTAAGTGC  
 TGTAGATAAAGACTTTGGGCCAAATGGAGAAGTAAGGTATTCTTTTGAATGGTGACG  
 CCAGATTTTGAGTTGCATGCCATCAGTGGGGAAATTACAAATACTCATCAGTTTGACA  
 GGGAGTCTCTTATGAGGCGGAGAGGGACTGCTGTGTTTAGCTTTACAGTCATAGCAAC  
 AGATCAGGGGATCCCTCAGCCTCTCAAGGATCAGGCCACTGTACATGTTTACATGAAG  
 GATATAAATGATAATGCTCCCAAATTTTAAAAGACTTTTACCAAGCTACAATATCAG  
 AATCAGCAGCCAATCTGACACAAGTGTTAAGAGTATCTGCCTCAGATGTTGATGAAGG  
 TAATAATGGACTTATTCATATTCTATAATAAAAGGAAATGAAGAAAGACAGTTTGCT  
 ATAGACAGTACCTCTGGTCAGGTAACACTAATTGGCAAATTAGACTATGAAGCAACAC  
 CTGCCTATTTCCCTTGAATTCAGCAGTGGATTGAGGACAATCCCCCTCAATTCAAC  
 GTGTACTTTAAATATTGATATTTTAGATGAAAATGACAATACCCCTTCTTCTCTTAA  
 TCAACACTGTTTGTGATGTTTTGGAAAACATGAGAATGGTGAACTCGTGTCTCTG  
 TTACTGCAACTGATTCCGATTCAAGGTGACAATGTTGATTATATTACAGTATTACTGG  
 GACTAACAACCCAGGAACCTTTAGCATTAGCCCAACACTGGGAGTATTTTCTTGCC  
 AAAAACTGGACTTTGAAACACAGTCTTTGTATAAATTAATATAACAGCAAAAGACC  
 AAGGAAGACCTCTCCTTCTCATCTACAATGTAGTGGTTATTACAGTGAGGGACTTTAA  
 TGACAACTCCTCTAGCTTTCTCCTGGAGATATTTTCAAGTCTATTGTTGAGAACATT  
 CCCATTGGTACATCTGTCAATTCAGTGACTGCACATGACCCTGATGCAGACATTAAATG  
 GTCAACTATCCTACACAATCATTCAACAGATGCCAAGAGGCAACCACTTTACCATAGA  
 TGAAGTCAAAGGGACTATATATACTAATGCTGAAATAGATCGGGAATTTGCTAATCTC  
 TTTGAGTTGACTGTAAAGCCAATGATCAAGCTGTGCCAATAGAACTAGACGGTATG  
 CTTTGAAGAACGTGACCATTTTGGTTACAGACCTCAATGACAATGTCCCAATGTTTAT  
 ATCACAACCGCCCTTGCTGCAGACCCATCAGCTGTGATTGGTTCCGTTCTGACAACA



ATTATGGCTGCTGACCCAGATGAAGGTGCTAATGGAGAAATAGAGTATGAGATCATCA  
 ATGGGGACACAGACACCTTCATTGTTGATCGTTATAGTGGAGACCTGAGAGTGGCTTC  
 AGCGTTGGTGCCTTCACAGTTGATCTACAATCTCATAGTTTCAGCAACAGACCTTGGG  
 CCTGAAAGGAGGAAATCGACCACTGAATTGACCATCATTCTTCAGGGCCTTGATGGAC  
 CTGTTTTTACTCAACCCAAATATATACTATTTTGAAGGAAGGAGAACCATTGGCAC  
 AAACGTGATATCAATAGAAGCAGCTAGCCCCAGAGGATCTGAGGCCCCAGTGGAGTAT  
 TATATTGTTTCAGTTCGTTGTGAAGAAAAAACTGTTGGACGCCTCTTTACTATTGGAC  
 GACATACTGGTATAATTGACACCGCAGCCATTCTGGACCGGAGCAAGGAGCATGTCT  
 TTACCTGGTGGATGTTTATGCCATAGAAAAATCAACTGCTTTTCCAGAACACAGAGA  
 GCAGAGGTAGAAACAACACTTCAGGATATCAATGACAATCCACCAGTATTTCCAACGG  
 ACATGCTGGATCTCACGGTAGAGGAGAACATTGGAGATGGCTCTAAGATTATGCAGCT  
 GACAGCCATGGATGCTGACGAGGTGCAAATGCTCTCGTCACATACACTATCATTAGTG  
 GGTCTTTGGTAGCAGCCATTTAGCCACGGATGATGACTCTGGTGTGAATGGAGAAA  
 TTACATATATTGTGAATGAAGATGATGAAGATGGCATCTTTTCTGAATCCTATTAC  
 TGGGGTCTTTAATTGACTCGATTATTAGATTATGAAGTACAGCAATATTATATCCTC  
 ACTGTTTCGAGCAGAAGATGGTGGGGACAATTTACTACCATCAGAGTTTATTTCAATA  
 TTCTAGATGTAATGATAATCCACCTATTTTCAGCTTGAATTCATACAGCACATCTTT  
 AATGGAGAATCTACCTGTGGGATCTACTGTTCTTGTGTTTAAATGTTACTGATGCAGAT  
 ATGATGAAGGCAGAAATAAAGATGTTCTTTGAAACCAAGTGAAGAACAAAGACACAACAT  
 ACCAGAATCTCTGGGACACATTCAAAGCAGTGTGTAGAGGGAAATTTATAGCACTAAA  
 TGCCCAACAGAGAAGCAGGAAAGATCCAAAATTGACACCCTAACATCACAATTAAAA  
 GAACTAGAAAAGCAAGAGCAAAACACATTCAAAGCTAGCAGAAAGCAAGAAATACTA  
 AAATCAGAGCAGAACTGAAGGATATAGAGACACAAAAAACCTTCAAAAAATTAATGA  
 ATCCAGGAGCTGGTTTTTTGAAGGATCAACAAAATTGATAGACCGCTAGCAAGACTA  
 ATAAAGAAGAAAACAGAGAAGAAATCAAATAGACGCAATAAAAAATGATAAAGGGGATA  
 TCACCATCGATCCACAGAAATACAACTACCATCAGAGAATACTGCAAAACACCTCTA  
 TGCAATAAACTAGAAAATCTAGAAGAAATGGATAAATTCCTCGACACATACACCCTC  
 CCAAGACTAAACAGGAAGAAGTTGAATCTCTGAATAGACCAATAACAGACTCTGAAA  
 CTGTGGCAATAATCAATAGCTTACCAACCAAAAAGAGTCCAGGACAGATGGATTAC  
 AGCCGAATTCTACCAGATGATAACAACCCAGTCTTGCACAAGCTTTGTATAAAGTG  
 GAGATTAATGAAAACACACTTACTGGAACAGATATAATACAAGTGTTCGCAGCAGATG  
 GAGATGAAGGCACAAATGGACAGGTTTCGCTATGGCATGTGTAATGGTAATACCAATCA  
 GGAATTTTCGGATAGACTCTGTGACAGGTGCCATCACTGTGCTAAACCTTTGGATAGA  
 GAAAAGACCCCTACCTACCATTAACTGTTTCAAGCAACAGATCGAGGCAGCACACCCA  
 GAACTGATACTCCACGGTCAGCATTGTTCTACTGGATATTAAATGACTTGTTCCTGT  
 ATTTGAGCTATCTCCATATTCTGTAAATGTCCCTGAGAATTTAGGGACACTACCAGA  
 ACAATTCTTCAGACTGCTTCGCCTTGCCTGAGGTTTGCCAGCGCCAGTAAAGCGTATT  
 TCACAACAATTCTTGAGGATGCACCAACTGGAACAGATGTTTTATTGGTAAATGCCTC  
 AGATGCTGATGCTTCAAAGAATGCAGTTATAAGTTATAGGATCATCGGTGGAACTCT  
 CAGTTCACGATCAACCATCGACAGGACAAATCATCACCAGCGATTGTTAGATAGGG  
 AAACAAAAGATAATTATACTTTGGTAGTGGTCTGCAGTGATGCGGGATCCCCAGAGCC  
 TCTTTCCAGTTCACCAAGTGTGCTTGTCACTGTGACTGATGTCCATGACAAATCCACCA  
 AGATTTTCAGCATCACCATATGTCACTCACATCCCATCTCTCTACTCTTCCAGGTTCCCT  
 TTGTCTTTGCGGTTACAGTCACAGATGCTGATATTGGACCAAATCTGAACTGCATTA  
 TTCTCTTTGCGGTAGAAATCTGAAAAATTTACATTGACCCACTGAGGGGAGCCATT  
 ATGGCCGCGGACCACTAAACGGAGCTTCAGAAGTGACATTTCTGTGATGTAAAG  
 ATGGTGGCTCATTTCCAAAGACAGATTCTACAACAGTGACTGTTAGATTCTGTGAATAA  
 GGCCGATTTCCCTAAAGTCAGAGCCAAAGAACAAACGTTTCATGTTTCTGAAAACCAA  
 CCAGTCAGCTCTCTTGTCAACCATCACAGGATCCTCTTAAAGAGGAGAACCTATGT  
 CATATTATATCGCAAGTGGGAATCTTGGCAATACTTTCCAGATTGATCAGTTAACAGG  
 GCAGGTGTCTATTAGTCAACCTCTGGATTGTGAAAAGATACAAAAATATGTGTATGG  
 ATAGAGGCCAGAGACGGTGGTTTCCCTCCTTTCTCCTCTTACGAGAACTTGATATAA  
 CAGTATTAGATGTCAATGATAATGCCCCAATTTTTAAGGAAGACCCATTTATATCTGA  
 AATATTGGAAAACCTTTCCCTCGAAAAATACTTACTGTTTCGGCAATGGACAAGGAC  
 AGTGGACCCCAATGGACAGTTAGATTATGAAATTGTTAATGGCAACATGGAAAAATGTT  
 TCAGTATCAATCATGCTACTGGTGAATTAGAAGCGTTAGACCTTTGGACAGGGAAAA  
 AGTATCTCATTATGTCTAACCATAAAATCATCAGACAAAGGTCCTCCGTCTCAGAGT  
 ACTTCAGTAAAGTCATGATTAAACATTTTAGATGAAAATGATAATGCCCTAGGTTTT  
 CTCAGATATTTAGTGCCCATGTTCTGAAAATTTCCCTTAGGATACACAGTTACCCG  
 TGTCACAACTCTGATGAAGACATTGGGATCAATGCAATTAGTAGATATTTATAATG  
 GATGCAAGTCTTCATTTACAATTAATCCAGCACAGGGGATATTGTCTAAGCAGAC

CTTTAAATAGGGAAGATACAGACCGTTACAGAATTCGAGTTTCCGCACATGATTCTGG  
GTGGACTGTAAGTACAGATGT CACAATATTTGTGACAGACATCAATGACAATGCTCCA  
AGATTTAGCAGAACTTCTTATTATTAGATTGCCCTGAACCTTACTGAGATTGGCTCCA  
AAGTAACTCAGGTATTTGCAACAGATCCTGATGAGGGATCAAATGGACAAGTGTTTTA  
TTTCATAAAATCCCAATCAGAATATTTAGGATTAATGCCACCACTGGAGAGATTTTC  
AATAAACAGATCTTAAATACCAAAATGTCACTGGCTTCAGTAATGTGAATATCAACA  
GGCATAGTTTTATAGTGACATCTTCAGATCGAGGTAAACCTTCCTTAATTAGTGAGAC  
AACAGTTACCATCAATATAGTGGACAGTAATGACAATGCACCTCAATTTCTTAAAGT  
AAATATTTCACTCCAGTCACCAAAATGTTAAGGTTGGTACGAAGTTAATCAGAGTTA  
CAGCAATAGATGACAAAGATTTTGGACTGAATTCAGAAGTGGAGTATTTCAATTTCTAA  
TGATAACCATTTAGGAAAATTTAAGTTGGACAATGATACGGGGTGGATTTCAGTAGCA  
TCCTCCCTGATTCTGACTTGAACCAAACTTTTTATCACAGTCACTGCAAAGGATA  
AGGGAAACCCCTCCACTTCTTCCCAAGCAACTGTTCAATAACTGTCACTGAGGAAAA  
CTACCATACACCTGAATTCCTCAAAGCCACATGAGTGCAACCATCCCTGAGAGCCAT  
AGCATTTGGGTCCATTGT CAGAACTGTTTCTGCAAGAGATAGAGATGCAGCGATGAATG  
GCTTGATTAAGTACAGCATTTCTTCAGGAAATGAAGAAGGCATTTTTGCAATCAATTC  
TTCTACAGGTATATTAACACTAGCCAAAGCTCTTGATTATGAGCTATGCCAGAAACAC  
GAAATGACGATTAGTGCTATAGATGGAGGATGGGTTGCAAGAAGTGGTTACTGCAATG  
TGACCGTAAATGTGATTGATGTGAATGATAATTCTCAGTATTCCTCTCTGATGACTA  
TTTCCCTACTGTTTTGGAATAATGCCCAAGTGAACAACAGTTATCCACCTAAATGCA  
ACAGATGCTGACTCTGGAACAAATGCTGTGATTGCGTATACTGTACAGTCATCTGACA  
GTGACCTCTTTGTCAATTGACCCTAACACAGGAGTCATAACCACTCAAGGCTTCTTGGA  
TTTTGAAACCAAGCAGAGCTACCATCTTACTGTGAAAGCCTTCAATGTCCTCCAGTGA  
GAAAGGTGTAGCTTTGCCACTGTTAATATACAATTAAGGAGCAAAATGATATGTGC  
CCCGTTTTGTTTTCAAACCTTACTATTTTGAATCTCAGAAGCAGCTCTAAAGGTAC  
TATTGTTGGAGAAGTGTGTTGCTAGCGACCGTGATTGGGCACTGATGGGGAGGTACAC  
TATTTGATTTTTGGTAATAGTCGAAAGAAGGGTTCCAGATCAATAAGAAGACTGGAC  
AGATTTATGTTTCTGGAATCTTGATCGAAAAAAGAAGAAAGGGTGTCTTTGAAGGT  
ATTGGCCAAGAACTTTGGCAGCATTAGAGGTGCAGATATAGATGAGGTCACTGTAAT  
GTCACCGTGCTTGATGCAATGACCCACCCATTTTACTCTAAACATCTACAGTGTC  
AGATCAGTGAAGGGGTCCCAATAGGAACTCATGTGACCTTTGT CAGTGCCTTTGACTC  
AGACTCCATCCCCAGCTGGAGCAGGTTTCTTACTTCATCGGATCAGGGAATGAAAT  
GGTGCCTTTTCTATTAATCCGCAGACAGGACAGATCACCGTTACTGCAGAATTAGATC  
GAGAAACCTTCCCCTCTATAATCTCTCAGTTTTGGCTGTTGATTACGGGACCCCTC  
AGCTACAGGTAGTGCCTCTTTATTAGTCACCCCTGGAAGATATAAATGATAACGGGCCC  
ATGCTGACTGT CAGTGAAGGAGAAGTCATGGAAAAACAACGGCCAGGCACTTTGGTGA  
TGACCCTTCAGTCCACTGACCTGATCTCCCTCCAAATCAAGGTCCCTTTACTTATTA  
CTTGCTGAGCACAGGTCTTGCACACAGTTATTTCACTGCTGAGCACTGCTGGAGTTCTG  
AGCACAACCAGAGAGATTGACAGAGAGCAGATTGCAGACTTCTATCTGTCTGTGGTTA  
CCAAGGATTTCTGGTGTCTCTCAAATGTCTTCCACAGGAAGTGTGCATATCAGATTAT  
AGACCAAAATGACAATCTTCCAGTCTCGGACGGTGGAGATATTTGTTAATTATTAT  
GGTAACCTGTTTCCCGGTGGGATTTTAGGCTCTGTGAAGCCACAGGATCCAGATGTGT  
TAGACAGCTTCCACTGCTCCCTTACTTCAGGAGTTACCAGCCTCTTCAGTATTCAGG  
GGGTACTTGTGATCTGAATCCCAGCCAAGGTCCACAGATGGCAGCTTTGATCTGACT  
GTCCTTAGCAATGATGGAGTTCACAGCACAGTCACGAGCAACATCCGAGTTTTCTTTG  
CTGGATTTTCCAATGCCACAGTGGATAACAGCATCTTACTTCGTCTCGGCGTACCAAC  
AGTAAAGGACTTCTTGACCAACCACTATCTTCATTTTTTACGCATTGCCAGCTCACAG  
CTGACAGGCTTAGGCACTGCTGTGCAACTGTACAGTGCAATGAAGAGAACAATAGAA  
CGTTTCTTTTGGCAGCTGTGAAGCGAAATCATAATCAGTATGTGAATCCCAGTGGCGT  
AGCCACCTTCTTTGAAAGCATCAAAGAGATCCTTCTCCGGCAGAGTGGAGTAAAGGTG  
GAATCTGTGGATCATGACTCTGTGTGTCATGGCCCATGT CAGAATGGAGGGAGCTGTC  
TACGAAGATTGGCTGTGAGCTCCGTATTAAGGCGGTGAGAGTCTTCCAGTCATCAT  
CGTGGCAAATGAACCTCTGCAGCCTTTCTTATGCAAGTGTCTGCCAGGATATGCCGGT  
AGCTGGTGTGAATAGATATAGATGAATGTCTTCCATCACCTTGCCACAGTGGTGGAA  
CCTGT CACAATTTAGTGGGAGGATTTTCATGCAGCTGCCAGATGGCTTCACTGGTAG  
GGCGTGTGAGAGAGATATCAATGAGTGCCTGCAGAGTCCTTGAAGAATGGTGCCATC  
TGCCAGAATTTTCCAGGAAGCTTCAACTGTGTTTGCAAACTGGATACACAGGTATGA  
CAACGTTTGTACTTTTCTCACTAAGACTTGGAATGTGTGAATCTTCAGTCAATTAC  
TGTGAATGCAACCCCTGCTTTAATGGTGGTTCCTGCCAAAGTGGTGTGGATTCTTATT  
ATTGTCATTGTCCATTGGTGTCTTTGGAACACTGCGAGTTGAACAGTTATGGATTG  
AGGAGTTATCATACATGGAATTTCCAAGCTTGACCCCAATAACAACATATTTATGT

CAAAATTGCCACGATTAAAAGTCATGCCTTATTGCTTTACAACATATGACAACCAGACA  
GGCGACCGGGCTGAGTTTTTGGCCCTTGAAATTGCCGAAGAAAGACTAAGATTCTCTT  
ATAATTAGGCAGTGGTACATATAAGCTCACCACCATGAAGAAGGTGTCAGATGGACA  
TTTTCACTGTGATTGCCAGGAGAGCAGGAATGGCAGCCTCCTTAACTGTGGACTCC  
TGTTCTGAGAACCAAGAGCCAGGATATTGTACTGTGAGTAATGTGGCAGTTTCAGATG  
ACTGGACTCTTGATGTTTACGCCAAATAGAGTTACAGTTGGAGGTATCAGATCTCTAGA  
ACCAATCCTTCAGAGAAGAGGACACGTGGAAGCCATGATTTTGTGGGTGTATAATG  
GAGTTTGCAGTCAATGGAAGGCCTCTGGAACCCAGCCAAGCTTTGGCAGCACAAAGGCA  
TCCTAGATCAGTATGGCGATTTTATTTCTTACTGTTTTAAAGAAAAAAATGCAAAAA  
AGTATGCTTCACTGTTACTCTGACACTGCCTTATCATTAGAAGGCAAGGGCGCTTG  
GACTACCACATGAGTCAGAAATGAGAAGCGGGAATATTTGTTAAGGCAAGCTTACGAG  
GTGCCATGTTGGAGCCTTTTGGTGTGAACAGTCTGGAAGTAAAAATTTAGGACCAGAAG  
CGAGAATGGCGTTTTAATCCATATCCAAGAAAGCAGCAATTACACTACTGTGAAGGGA  
ATGTGTGAATCTTCAGTCAATTACTGTGAATGCAACCCCTGCTTTAATGGTGGTTCCT  
GCCAAAGTGGTGTGGATTCTTATTATTGTGATTGTCCATTGGTGTCTTTGGAAAAACA  
CTGCGAGTTGAACAGTTATGGATTGTAGGAGTTATCATACATGGAATTTCCAAGCTTG  
GACCCCAATAACAACTATATTTATGTCAAATTTGCCACGATTAAGTATGCTCTTAT  
TGCTTTACAACATGACAACCAGACAGGCGACCGGCTGAGTTTTTGGCCCTTGAAT  
TGCCGAAGAAAGACTAAGATTCTCTTATAATTTAGGCAGTGGTACATATAAGCTCACC  
ACCATGAAGAAGGTGTCAGATGGACATTTTCACTGTGATTGCCAGGAGAGCAGGAA  
TGACTCTTGATGTTTCAAGCAATAGAGTTACAGTTGGAGGTATCAGATCTCTAGAACC  
AATCCTTCAGAGAAGAGGACACGTGGAAGCCATGATTTTGTGGGTGTATAATGGAG  
TTTGCAGTCAATGGAAGGCCTCTGGAACCCAGCCAAGCTTTGGCAGCAAGGCATCC  
TAGATCAGTATGGCGATTTTATTTCTTACTGTTTTAAAGAAAAAAATGCAAAAAGTA  
TGCTTCACTTGGCCTCCATCTCGGGAAGCATAGCTTGGCCTCCATCTCAAAAACAGAT  
CCCTCAGTGAAGATTGGCTGGCGTGGCCGAACATTTGTGCCAGCAACCCCTGCTGGG  
GTGATTTGCTGTGCATTAATCAGTGGTATGCCTACAGGTGTGTCCTCTGGGGACTG  
TGCTCCCAACCCGTGCCAGATGGTGGCAGCTGTGAGCCAGGCTGCATCCGGCTTC  
ACCTGTAGCTGCCAGACTCGCACACGGGAAGGACCTGTGAGATGGTGTGGCCTGTC  
TTGGCGTCTCTGTCTCAGGGGAAGGTGTGCAAGCTGGAAGTCTGCGGGGCATGT  
CTGTGTTCTGAGTCAGGGCCCTGAAGAGATCTCTGCTGCTTTGTGGGTGTGCTGCTGCC  
ATCGTGGGCGAGCTGCGCAACCGTCTTGGCCCTCCTGGTCTTAGCCTGATCCTGTGTA  
ACCAAGTGCAGGGGGAAGAGGCCAAAAATCCCAAGAGGAGAAGAAACCGAAGGAGAA  
GAAGAAAAAGGGAAGTGAGAACGTTGCTTTTGATGACCTGACAATATCCCTCCCTAT  
GGGGATGACATGACTGTGAGGAAGCAGCCTGAAGGGAACCCAAAACAGATATCATTG  
AAAGGGAACCCCTACCTTATCTATGATGAAACTGATATTCCTCACAACCTCAGAAAC  
CATCCCCAGCGCCCTTTGGCATCTCCAGAGCAGGAGATAGAGCACTATGACATTGAC  
AACGCCAGCAGCATCGCCCTTCGGATGCAGACATCATTCAACACTACAAGCAGTTCC  
GCAGCCACACACCAAAATTTCAATCCAGAGGCACAGTCCCTTAGGCTTTGCAAGGCA  
ATCCCCATGCCCTTAGGAGCAAGCAGTTGACTTACCAGCCTTCATATGGTCAAGGT  
TTGAGAACCAGCTCCCTAAGCCACTCAGCATGCCCAACTCCCAACCCCTGTGTCTCGAC  
ACAGTCCAGCCCTTTCTCCAATCTTCTACGTTCTATAGAAAACAGCCAGCAAGGGA  
ATTGCATCTTCTTATAAGGGATGGTAATACTTTGGAAATGCATGGTGACACCTGCCAA  
CCTGGCATTTTCAACTATGCCACAAGGCTGGGAAGGAGAAGCAAGAGTCTCAGGCCA  
TGGCATCACATGGTTCTAGACCAGGGAGTGCCTAAAGCAGCCGATTTGGCAGATTCC  
ACTGGAATCTTCTCTCCAGTCGGACTTTCTATTGAAGAAGTGAGAGGCTCAACACA  
CCTCGCCCTAGAAACCCAAGTATCTGCAGTGCAGACCATGGGAGGTCTTCTTCAGAGG  
AGGACTGCAGAAGGCCACTGTCTAGAACAAAGGAATCCAGCGGATGGCATTCAGCTCC  
AGAATCCTCTTCTGATAGTGACTCCCATGAATCTTCACTTGCTCAGAAATGGAATAT  
GACAGGGAGAAGCCAATGGTATATACTTCCAGAATGCCAAATTATCTCAAGTCAATG  
AATCTGATGCAGATGATGAAGATAATTATGGAGCCAGACTGAAGCCTCGAAGGTACCA  
CGGTGCGAGGGCCGAGGGAGGACCTGTGGGCACCCAGGCAGCAGCACCAGGCACTGCT  
GACAACACACTGCCCATGAAGCTAGGGCAGCAAGCAGGGACTTTCAACTGGGACAACC  
TTTTGAAGTGGGGCCCTGGCTTTGGCCATTATGTAGATGTTTTTAAAGATTGGCATC  
TCTTCCAGAAAAAGCAGCAGCAATGAAGAAGGCAAGCTGGGACAACTAAACCAAGTC  
CCCAAGATGGGGAAGCAGAACAGTATGTGTGAAGTTTATGTACTGGCACTATAAAAT  
ATAAAAACAAGAAATAATACTCAAACCATTGTAAAGTTGCTGACTAGGTTGGGTCA  
TTTGAAAAACAGGCCAGTATGACTAGTGGTGGAGGGAAACTTTAAAAATAATAACC  
ACAATGCTGCTGAAACAGACTCAACAACCTCTTAATTTAAACATGTGTGGTTGAATT  
C

	ORF Start: ATG at 518	ORF Stop: TGA at 15401	
	SEQ ID NO: 64	4961 aa	MW at 543673.9kD
NOV17a, CG92813-01 Protein Sequence	MDLAPDRATGRPWLPLHTLSVSQLLRVFWLLSLLPGQAWVHGAEPQVQVLEEQPPG TLVGTIQTRPGFTYRLSESHALFAINSSTGALYTTSTIDRESLPSDVINLVVLSAPT YPTEVRVLVRDLNDNAPVFPDPSIVVTFKEDSSSGRQVILDTATSDSIGSNGVDHRSY RIIRGNEAGRFRLLDINLNPSEGAFHLHLSVSKGGLDREVTPQYQLLVEVEDKGEKPRRG YLQVNVTVQDINDNPPVFGSSHYQAGVPEDAVVGSSVLQVAAADADEGTNADIRYRLQ DEGTFPFQMDPETGLITVREPLDFEARQYSLTVQAMDRGVPSLTGRAEALIQLLDVND NDPVVKFRYFPATSRYASVDENAQVGTVVALLTVTDADSPAANGNISVQILGGNEQRH FEVQSSKVPNLSLIKVASALDRERIPSYNLTVSVSDNYGAPPGAQVARSVASLVIF VNDINDHPPVFSQQVYRVNLSEEAPPGSYVSGISATDGDGSGLNANLRYISVSGNLGW FHISEHSLVTTGSSGGLDRELASQIVLNIARDQGVHPKVSQAQLVVTLLDVNDEKP VFSQPEGYDVSUVENAPTGTLLMLRATDGDLDGNGTVRFSLQEAETDRRSFRLDPVS GRLSTISSLDREEQAFYSLLVLATDLGSPQSSMARINVSLLDINDNSPVFPYQYFA HIKENEPGGSYITTVSATDPDLGTNGTVKYSISAGDRSRFQVNAQSGVISTRMALDRE EKTAYQLQIVATDGGNLQSPNQAIVTITVLDTQDNPPVFSQVAYSFVVFENVALGYHV GSVSASTMDLNSNTSYLITGTDQKGMFAINQVTGQLTTANVIDREEQSFYQLKVVASG GTVTGDITMVNITVKDLNDSNPHFLQAIESVNVVENWQAGHSIFQAKAVDPDEGVNGMV LYSLKQNPKNLFAINEKNGTISLLGPLDVHAGSYQIEILASDMGVPQLSSSVILTIVYV HDVNDNSPVFDQLSYEVLSESEPVNSRFFKVQASDKDSGANDGQLYIKSELDRQLD RYVLMVVASDRAVEPLSATVNVTVILEDVNDNRPLFNSTNYTFYFEEQGRAGSFVGKV SAVDKDFGPNGEVRYSEFEMVQPDFELHAISGEITNTHQFDRESLMRRRGTAVFSTVI ATDQGIPOPLKQDQATVHVYMKDINDNAPKFLKDFYQATISEAANLTQVLRVSASVD EGNGLIHYSIIKGNERQFAIDSTSGQVTLIGKLDYEATPAYSLVIAQVDSGTIPLN STCTLNIDILDENDNTPSFLKSTLFVDVLENMRIGELVSSVTATSDSGDNVDLYYSI TGTNNHGTFSISPNTGSI FLAKKLDFTQSLYKLNITAKDQGRPPRSSTMSVVIHVVD FNDNPPSFPPGDI FKSIVENIPIGTSVISVTAHDPDADINGQLSYTIIQQMPRGNHFT IDEVKGTIYTNAEIDREFANLFELTVKANDQAVPIETRRYALKNVITLVDLNDNVPM FISQNALAADPSAVIGSVLTTIMAADPDEGANGEIEYEIINGDTDTFIVDRYSGDLRV ASALVPSQLIYNLIVSATDLGPERRKSTTELTII LQGLDGPVFTQPKYITILKEGEPI GTNVISIEAASPRGSEAPVEYYIVSVRCEEKTVGRLFITGRHTGIIQTAAILDREQGA CLYLVDVYAEKSTAFPRTQRAEVETTLQDINDNPPVFPDMLDLTVEENIGDGSKIM QLTAMDADEVQMLSSHTLSLVGSLVAAILATDDDSGVNGEITYIVNEDDEDGIFFLNP ITGVFNLTRLLDYEVOQYYIILTVRAEDGGQFTTIRVYFNILDVNDNPPIFSLNSYST SLMENLPVGSTVLVFNVTADMMKAEIKMFFETSENKDTTYQNLWDTFKAVCRGKFIA LNAHKRKQERSKIDTLTSQLEKEKQEQTHSKASRRQEITKIRAEKDIETQKTLQKI NESRSWFFERINKIDRPLARLIKKEKQIDAIKNDKGDITIDPTEIQTIREYCKH LYANKLENLEEMDKFLDTYTLPRNLQBEVESLNRPIITDSETVAIINSLPTKKSPGPDG FTAIFYQMITYPFAQALYKEVINENTLTGTDIIQVFAADGDEGTNGQVRYGIVNGNT NQEFRIDSVTGAITVAKPLDREKTPYHLTVQATDRGSTPRDTSVSVILLDINDFV PVFELSPPSVNVNENLGTLPRTILQTASPCVRFASASKAYFTTIPEDAPTGTVDLLVN ASDADASKNAVISYRIIGNSQFTINPSTGQIITSALLDRETNDNYTLVVVCS DAGSP EPLSSSTSVLVTVDVHDNPPRFQHPYVTHIPSPTLPGSFVFAVTVTDADIGPNSEL HYSLSGRNSEKFHIDPLRGAIMAAGPLNGASEVTFVHVVDGGSFPKTDSTVTVRVFV NKADFPKVRKEQTFMFPENQPVSSLVTTITGSSLRGEPMSYIIASGNLGNFTFQIDQL TGQVSI SQPLDFEKIQKYVWIEARDGGFPFSSYEKLDITVLDVNDNAPIFKEDPFI SEILENLSPRKILTVSAMDKDSGPNQGLDYEIVNGNMENSFSINHATGEIRSVRPLDR EKVSHYVLTIKSSDKGSPSQSTSVKVMINILDENDNAPRFSQIFSAHVPENSPLGYTV TRVTTSDDEDIGINAISRYSIMDASLPFTINPSTGDIVISRPLNREDTDRYRIRVSAHD SGWTVSTDVTIFVTDINDNAPRFSRTSYLDCPELTEIGSKVTQVFATDPDEGSNGQV FYFIKSQSEYFRINATTGEIFNKQILKYQNVTFGSNVNINRHSFIVTSSDRGKPSLIS ETTVTINIVDSNDNAPQLFSKYFTPVTKNVKVGTKLIRVTAIDDKDFGLNSEVEYFI SNDNHLGKFKLDNDTGWISVASSLISDLNQNFFITVTAKDKGNPPLSSQATVHITVTE ENYHTPEFSQSHMSATIPESHISGSIVRTVSARDRAAMNGLIKYISSGNEEGIFAI NSSTGILTLAKALDYELCQKHEMTISAIDGGWVARTGYCSVTNVNVDVNDNSPVFLSD DYFPTVLENAPSGTTVIHLNATDADSGTNAVIAYTVQSSDSDLFVIDPNTGVITTQGF LDFETKQSYHLTVKAFNVPDEERCSFATVNIQLKGTNEYVPRFVSKLYYFEISEAAPK GTIVGEVFASDRDLGTDGEVHYLIFGNSRKKGFQINKKTQGIYVSGILDRKKEERVSL KVLAKNFGSIRGADIDEVTNVTVLDANDPPIFTLNIYSVQISEGVPIGHTVFVSFAF		

	DSDSIPSWSRFSYFIGSGNENGAFSINPQTGQITVTAELDRETLPIYNLSVLAVDSGT PSATGSASLLVLTLEDINDNGPMLTVSEGEVMENKRPGLVMTLQSTDPDLPPNQGPFT YYLLSTGPATSYFSLSTAGVLSTTREIDREQIADFYL SVVT KD SGVPQMSSTGT V HIT VIDQNDNPSQSRTVEIFVNYG NLFPGGILGSVKPQDPDVLDSFHCSLTSGVTSLSFSI PGGTCDLNSQPRSTDGTFDLTVLSNDGVHSTVTSNIRVFFAGFSNATVDNSILLRLGV PTVKDFLTNHYLHFLRIASSQLTGLGTAVQLYSAYEENNR TFLA AVKRHNHNYVNP S GVATFFESIKEILLRQSGVKVESVDHDS CVHG PCQNGGSC LRLAVSSVLKSRESLPV IIVANEPLQPFLCKCLPGYAGSWCEIDI DECLPSPCHSGGTCHNLVGGFSCSCP DGFT GRACERDINECLQSPCKNGAICQNFPGSFNCVCKTGYTGMTTFVLFSRLRGKCVNLQS ITVNATPALMVVPAKVWILIIVIVHLVSL EHC ELSYGFEELSYMEFSPSLDPNNNYI YVKFATIKSHALLLYNDNQTDRAEFLALEIAEERLRFSYNL GSGTYKLT TMKKVSD GHFHTVIARRAGMAASLTVDSCSENPQEPGYCTVSNVAVSDDWTL DVQPNRVTVGGIRS LEPILQRRGHVESHD FVG CIMEFAVNGRPLEPSQALAAQ GILDQY GDFISYCFKEKKC KKVCFTVTPDTALSLEGKGRLDYHMSQNEKREYLLRQSLRGAMLEPFGVNSLEV KFR T RSENGVLIHIQESSNYTTVKGMCESSVNYCECNPCFN GSGSCQSGVDSYCHC PFGVFG KHCELNSYGFEELSYMEFSPSLDPNNNYIYVKFATIKSHALLLYNDNQTDRAEFLAL ETAEERLRFSYNL GSGTYKLT TMKKVSDGHFHTVIARRAGMTLDVQPNRVTVGGIRSL EPILQRRGHVESHD FVG CIMEFAVNGRPLEPSQALAAQ GILDQY GDFISYCFKEKKC KYASLGLHLGKHSASISKTDPSVKIGCRGPNICASNPCWGDLLCINQWYAYRCVPPG DCASHPCQNGGSCPEGLHSGFTCS CPDSHTGRTCEMVVACLGVLC PQGKVKAGSPAG HVCVLSQGPEEISLPLWAVPAIVGSCATVLALLVLSLILCNQCRGKKAKNPKEEKKPK EKKKKGSENVAFDDPDNIPPYGDDMTVRKQPEGNPKPDI IERENPYLIYDETDIPHNS ETIPSAPLASPEQEIEHYDIDNASSIAPSDADI IQHYKQFRSHTPKFSIQRHSP LGFA RQSPMPLGASSLTYQPSYQGLRTSSL SHSACPTPNPLSRHSPAPFSKSSTFYRNSPA RELHLPIRDGNTLEMHGDTCPQGI FNYATRLGRRSKSPQAMASHGSRPGSRLKQPIGQ IPLESSPPVGLSIEEVERLNTPRPRNPSICSADHGRSSSEEDCRRPLSRTRN PADGIP APESSSDSDSHESFTCSEMEYDREKPMVYTSRMPKLSQVNESADDEDNYGARLKPRR YHGRRAEGGPVGTQAAAPGTADNTLPMKLGQQAGTFNWDNLLNWGPFGFHYVDVFKDL ASLPEKAAANEKGAGTTKPVPKDGEAEQYV
--	---

Further analysis of the NOV17a protein yielded the following properties shown in Table 17B.

Table 17B. Protein Sequence Properties NOV17a	
PSort analysis:	0.8000 probability located in nucleus; 0.6000 probability located in plasma membrane; 0.4000 probability located in Golgi body; 0.3000 probability located in endoplasmic reticulum (membrane)
SignalP analysis:	Cleavage site between residues 43 and 44

5

A search of the NOV17a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 17C.

10

Table 17C. Geneseq Results for NOV17a				
Geneseq Identifier	Protein/Organism/Length [Patent #, Date]	NOV17a Residues/ Match Residues	Identities/ Similarities for the Matched Region	Expect Value
ABG22977	Novel human diagnostic protein #22968 - Homo sapiens, 4591 aa. [WO200175067-A2, 11-OCT- 2001]	119..4188 134..4099	1159/4320 (26%) 1853/4320 (42%)	0.0
ABG22977	Novel human diagnostic protein #22968 - Homo sapiens, 4591 aa. [WO200175067-A2, 11-OCT- 2001]	119..4188 134..4099	1159/4320 (26%) 1853/4320 (42%)	0.0
AAM52106	Rat fat 3 protein SEQ ID NO 3 - Rattus norvegicus, 4555 aa. [JP2001258573-A, 25-SEP-2001]	70..3771 192..3829	1054/3877 (27%) 1742/3877 (44%)	0.0
AAU07054	Human Flamingo protein encoded by cDNA splice variant - Homo sapiens, 2923 aa. [WO200161003- A1, 23-AUG-2001]	2627..4042 162..1566	427/1490 (28%) 665/1490 (43%)	e-137
AAU07053	Human Flamingo polypeptide - Homo sapiens, 2956 aa. [WO200161003-A1, 23-AUG- 2001]	2627..4042 162..1566	427/1490 (28%) 665/1490 (43%)	e-137

In a BLAST search of public sequence databases, the NOV17a protein was found to have homology to the proteins shown in the BLASTP data in Table 17D.

5

Table 17D. Public BLASTP Results for NOV17a				
Protein Accession Number	Protein/Organism/Length	NOV17a Residues/ Match Residues	Identities/ Similarities for the Matched Portion	Expect Value
P33450	Cadherin-related tumor suppressor precursor (Fat protein) - Drosophila melanogaster (Fruit fly), 5147 aa.	49..1878 71..1951	748/1932 (38%) 1066/1932 (54%)	0.0
IJFFTM	cadherin-related tumor suppressor precursor - fruit fly (Drosophila melanogaster), 5147 aa.	49..1878 71..1951	744/1932 (38%) 1065/1932 (54%)	0.0

Q96JQ0	Protocadherin 16 precursor (Cadherin 19) (Cadherin fibroblast 1) - Homo sapiens (Human), 3298 aa.	5..1877 12..1883	621/1950 (31%) 925/1950 (46%)	0.0
Q99PF4	Cadherin 23 precursor (Otocadherin) - Mus musculus (Mouse), 3354 aa.	53..1877 588..2430	606/1927 (31%) 896/1927 (46%)	0.0
P58365	Cadherin 23 precursor (Otocadherin) - Rattus norvegicus (Rat), 3317 aa.	53..1877 586..2428	613/1928 (31%) 897/1928 (45%)	0.0

Pfam analysis indicates that the NOV17a protein contains the domains shown in Table 17E.

Table 17E. Domain Analysis of NOV17a			
Pfam Domain	NOV17a Match Region	Identities/ Similarities for the Matched Region	Expect Value
cadherin: domain 1 of 30	47..126	19/107 (18%) 59/107 (55%)	0.012
cadherin: domain 2 of 30	140..241	36/113 (32%) 76/113 (67%)	4.6e-15
cadherin: domain 3 of 30	255..344	43/107 (40%) 75/107 (70%)	1.3e-27
cadherin: domain 4 of 30	363..466	43/113 (38%) 79/113 (70%)	2.9e-23
cadherin: domain 5 of 30	480..573	36/109 (33%) 75/109 (69%)	3.5e-24
cadherin: domain 6 of 30	588..680	46/108 (43%) 76/108 (70%)	5.3e-27
cadherin: domain 7 of 30	694..784	43/107 (40%) 67/107 (63%)	7.2e-27
cadherin: domain 8 of 30	798..884	34/107 (32%) 66/107 (62%)	4.2e-18
cadherin: domain 9 of 30	898..987	31/107 (29%) 66/107 (62%)	1.3e-18
cadherin: domain 10 of 30	1001..1071	26/107 (24%) 59/107 (55%)	1.6e-08
cadherin: domain 11 of 30	1085..1181	34/111 (31%) 72/111 (65%)	1.6e-14
Isochorismatase: domain 1 of 1	1038..1206	27/213 (13%) 112/213 (53%)	8.8

cadherin: domain 12 of 30	1195..1286	38/107 (36%) 76/107 (71%)	3.2e-27
cadherin: domain 13 of 30	1300..1391	41/107 (38%) 70/107 (65%)	7.3e-27
cadherin: domain 14 of 30	1405..1500	38/108 (35%) 73/108 (68%)	5.3e-19
cadherin: domain 15 of 30	1506..1602	29/114 (25%) 70/114 (61%)	6.8e-12
cadherin: domain 16 of 30	1614..1711	28/112 (25%) 63/112 (56%)	0.014
S-AdoMet_syntD2: domain 1 of 1	1789..1803	8/15 (53%) 12/15 (80%)	3.8
cadherin: domain 17 of 30	1754..1840	31/107 (29%) 64/107 (60%)	2.2e-14
cadherin: domain 18 of 30	2107..2198	45/107 (42%) 76/107 (71%)	6.4e-31
cadherin: domain 19 of 30	2244..2334	44/107 (41%) 72/107 (67%)	2.2e-28
cadherin: domain 20 of 30	2348..2436	34/107 (32%) 66/107 (62%)	1.8e-12
cadherin: domain 21 of 30	2449..2537	36/107 (34%) 65/107 (61%)	1.2e-11
cadherin: domain 22 of 30	2551..2641	37/107 (35%) 72/107 (67%)	9.7e-26
cadherin: domain 23 of 30	2654..2740	38/107 (36%) 63/107 (59%)	3.2e-17
cadherin: domain 24 of 30	2754..2851	31/116 (27%) 74/116 (64%)	5.3e-16
cadherin: domain 25 of 30	2865..2957	40/107 (37%) 68/107 (64%)	4.3e-16
cadherin: domain 26 of 30	2971..3062	37/107 (35%) 74/107 (69%)	3.2e-26
cadherin: domain 27 of 30	3076..3164	36/108 (33%) 67/108 (62%)	4.2e-21
cadherin: domain 28 of 30	3180..3273	33/107 (31%) 71/107 (66%)	1.8e-16
cadherin: domain 29 of 30	3286..3378	38/107 (36%) 78/107 (73%)	2e-27



PEP-utilizers: domain 1 of 1	3326..3392	17/107 (16%) 43/107 (40%)	5.2
cadherin: domain 30 of 30	3390..3482	37/109 (34%) 75/109 (69%)	1e-21
EGF: domain 1 of 5	3683..3736	14/64 (22%) 33/64 (52%)	7.1
EGF: domain 2 of 5	3743..3774	18/47 (38%) 25/47 (53%)	2.1e-08
metalthio: domain 1 of 1	3745..3805	16/70 (23%) 29/70 (41%)	7.8
EGF: domain 3 of 5	3781..3812	15/47 (32%) 25/47 (53%)	8.9e-05
EB: domain 1 of 1	3765..3823	16/70 (23%) 41/70 (59%)	3.7
laminin_G: domain 1 of 4	3890..4033	48/163 (29%) 99/163 (61%)	5.8e-19
laminin_G: domain 2 of 4	4116..4125	5/10 (50%) 10/10 (100%)	5.6
EGF: domain 4 of 5	4148..4179	16/47 (34%) 24/47 (51%)	0.013
laminin_EGF: domain 1 of 1	4148..4195	15/64 (23%) 33/64 (52%)	2
laminin_G: domain 3 of 4	4208..4272	26/77 (34%) 48/77 (62%)	4.5e-09
laminin_G: domain 4 of 4	4286..4322	14/37 (38%) 27/37 (73%)	0.0066
EGF: domain 5 of 5	4410..4442	16/47 (34%) 26/47 (55%)	3e-06

**Example 18.**

The NOV18 clone was analyzed, and the nucleotide and encoded polypeptide sequences are  
5 shown in Table 18A.

Table 18A. NOV18 Sequence Analysis		
	SEQ ID NO: 65	2118 bp
NOV18a, CG92844-01 DNA Sequence	GGAGTGAAC TAACACAAAGTTAGGAATTCTTATTGGTTTACAAAAACAATGTTGATTA GTGATTGGCTATATACATTGTTAAGGTATAGGGTGTGGCTCGCCGGTGCCCTCGACCT GCCCGCTGGGTCCTGTGCCTTTGAAGAGAGCACTTGGCGCTTTGACTCCGTGTTGGCC TCTCTGCCGTGGATTTTAAATGAGGAAGGCCATTACATTTATGTGGATACCTCCTTTG	

	GCAAGCAGGGGGAGAAAGCTGTGCTGCTAAGTCTTGACTTACAGGCTGAGGAATGGAG CTGCCTCCGTTTGGTCTACAGATAACCATCTTCGGAGTCTCTGTGAGATCCCAGC CAGCTGAACCTCTACATGAGATTTGAAGATGAAAGCTTTGATCGCTTGCTTTGGTCAG CTAAGGAACCTTCAGACAGCTGGCTCATAGCCAGCTTGGATTTGCAAAACAGTTCCAA GAAATTCAGATTTTAATAGAAGGTGTACTAGGACAGGGAAAACACAGCCAGCATCGCA CTATTTGAAATCAAGATGACAACCGGCTACTGTATTGAATGTGACTTTGAAGAAAATC ATCTCTGTGGCTTTGTGAACCGCTGGAATCCCAATGTGAAGTGGTTTGGTGGAGGAGG AAGTATTCGGAATGTCCAATCCATTCTCCACAGGATCACACCTTCAAGAGTGAAGTGTG GGTCACTACATGTACGTGGACTCAGTTTATGTGAAGCACTTCCAGGAGGTGGCACAGC TCATCTCCCCGTTGACCACGGCCCCCATGGCTGGCTGCCTGTCAATTTATTACCAGAT CCAGCAGGGGAATGACAATGTCTTTTCCCTTTACACTCGGGATGTGGCTGGCCTTTAC GAGGAAATCTGGAAGCAGACAGGCCAGGGAATGCTGCCTGGAACCTTGCAGAGGTGCG AGTTCACTGCTCAATTTTCTCTGCAGGTTATTTTGAAGTTGCTTTCAATGGTCCCAA GGGAGGTTATGTTGCCCTGGATGATATTTCAATCTCTCCTGTTCACTGCCAGAATCAG ACAGGTCTTCTGTTCACTGCCGTGGAAGCCAGCTGCAATTTTGAGCAAGATCTCTGCA ACTTTTACCAAGATAAAGAAGGTCCAGGTTGGACCCGAGTGAAAGTAAAACCAACAT GTATCGGGCTGGAGACCACACTACAGGCTTAGGTTATTACCTGCTAGCCAACACAAAG TTCACATCTCAGCCTGGCTACATTGGAAGGCTCTATGGGCCCTCCCTACCAGGAACT TGCAGTATTGTCTGCGTTTTTCATTATGCCATCTATGGATTTTAAAAATGAGTGACAC CCTAGCAGTTTACATCTTTGAAGAGAACCATGTGGTTCAAGAGAAGATCTGGTCTGTG TTGGAGTCCCCAAGGGGTGTTTGGATGCAAGCTGAAATCACCTTTAAGAAGCCCATGC CTTTTCAGGTGGTTTTTCATGAGCCTATGCAAAAGTTTCTGGGACTGTGGGCTGTAGC CCTGGATGACATTACAATACAATTGGGAAGCTGCTCATCTTCAGAGAACTTCCACCT CCACCTGGAGAGTGTACTTTTCGAGCAAGATGAATGTACATTTACTCAGGAGAAAAGAA ACCGGAGCAGCTGGCACAGGAGGAGGGGAGAACTCCCACTTCTACACAGGACCAAA GGGAGATCACACTACTGGGGTAGGCTACTACATGTACATTGAGGCCTCCCATATGGTG TATGGACAAAAGCAGCCTCTTGTCCAGGCCTCTGCGAGGAGTCTCTGAAAACACT GCTTGACCTTTTCTACCATGTATGGAGGGGGCACTGGCCTGTGAGTGTTTATCT GAAAAAGGAAGAAGACAGTGAAGAGTCCCTCTTATGGAGGAGAAGAGGTGAACAGAGC ATTTCTGGCTACGAGCACTGATTGAATACAGCTGTGAGAGGCAACACCAGATAATTT TTGAAGCCATTGAGGAGTATCAATAAGAAGTGATATTGCCATTGATGATGTTAAATT TCAGGCAGGACCCTGTCAATCATCAGGATATTCTGAGGACTTAAATGAAATTGAGTAT TAAGAAATGATCTGCATTGGATTTACTAGA		
	ORF Start: ATG at 49	ORF Stop: TAA at 2089	
	SEQ ID NO: 66	680 aa	MW at 77231.5kD
NOV18a, CG92844-01 Protein Sequence	MLISDWLYTLRLRYRVWLAGALDLPAGSCAFEESTCGFDSVLASLPWILNEEGHYIYVD TSFGKQGEKAVLLSPDLQAEWSCLRLVYQITTSSESLSDPSQLNLYMRFEDSFDR LWSAKEPSDSWLIASLDLQNSKKFKILIEGVLGQNTASIALFEIKMTTGICYIECDF EENHLCGFVNRWNPVNWVFGGGSIRNVHSILPDHTFKSELGHMYVDSVYVKHFQE VAQLISPLTTAPMAGCLSFYQIQQGNNDNVFSLYTRDVAGLYEEIWKADRPNGAAWN AEVEFSAHFPLQVIFEVAFNGPKGGYVALDDISFSPVHCQNQTGLLFSAVEASCNFEQ DLNCFYQDKEGPGWTRVKVKPNMYRAGDHTTGLGYLLANTKFTSQPGYIGRLYGPSL PGNLQYCLRFHYAIYGLKMSDTLAVYIFEENHVQEKIWSVLES PRGVWMAEITFK KPMFPQVVFMSLCKSFWDCLVALDDITIQLGSCSSSEKLPPPPGECTFEQDECTFTQ EKRNRSWHRRTPTSTYTPGPKGDHTTGVGYMYIEASHMVYQKARLLSRPLRGVS GKHCLTFFYHMYGGGTGLLSVYLKKEEDSEESLLWRRRGEQSIWLRALIEYSCERQH QIIFEAIRGVSIRSDIAIDVVKFQAGPCQSSGYSIEDLNEIEY		
	SEQ ID NO: 67	2023 bp	
NOV18b, 174308357 DNA Sequence	GGATCCTTTGAAGAGAGCACTTGCGGCTTGAAGTCCGTTGGCTCTCTGCCGTGGA TTTTAAATGAGGAAGGCCATTACATTTATGTGGATACCTCCTTTGGCAAGCAGGGGA GAAAGCTGTGCTGCTAAGTCTGACTTACAGGCTGAGGAATGAGCTGCCTCCGTTTG GTCTACCAGATAAACCACATCTTCGGAGTCTCTGTGAGATCCCAGCCAGCTGAACCTCT ACATGAGATTTGAAGATGAAAGCTTTGATCGCTTGCTTTGGTCAGCTAAGGAACCTTC AGACAGCTGGCTCATAGCCAGCTTGGATTTGCAAAACAGTTCCAAGAAATTCAGATT TTAATAGAAGGTGTACTAGGACAGGGAACACAGCCAGCATCGCACTATTTGAAATCA AGATGACAACCGGCTACTGTATTGAATGTGACTTTGAAGAAAATCATCTCTGTGGCTT TGTGAACCGCTGGAATCCCAATGTGAAGTGGTTTGTGGAGGAGGAAGTATTCGGAAT GTCCACTCCATTCTCCACAGGATCACACCTTCAAGAGTGAAGTGGGCACTACATGT		

	ACGTGGACTCAGTTTATGTGAAGCACTTCCAGGAGGTGGCAGCTCATCTCCCCGTT GACCACGGCCCCCATGGCTGGCTGCCCGTCATTTTATTACCAGATCCAGCAGGGGAAT GACAATGTCTTTTCCCTTTTACACTCGGGATGTGGCTGGCCTTTACGAGGAAATCTGGA AAGCAGACAGGCCAGGGAATGCTGCCTGGAACCTTGCGGAGGTGCGAGTTCAATGCTCC TTACCCCATGGAGGTTATTTTGAAGTTGCTTTCAATGGTCCCAAGGGAGGTTATGTT GCCCTGGATGATATTTTCTCTCTCTGTTCACTGCCAGAATCAGACAGAACTTCTGT TCAGTGCCGTGGAAGCCAGCTGCAATTTTGAGCAAGATCTCTGCAACTTTTACCAAGA TAAAGAAGGTCCAGGTTGGACCCGAGTGAAAGTAAACCAAAATGTATCGGGCTGGA GACCACACTACAGGCTTAGGGTATTACCTGCTAGCCAACACAAAGTTCACATCTCAGC CTGGCTACATTGGAAGGCTCTATGGGCCCTCCCTACCAGGAACTTGCAAGTATTGTCT GCGTTTTTCAATTATGCCATCTATGGATTTTAAAAATGAGTGACACCCTAGCAGTTTAC ATCTTTGAAGAGAACCATGTGGTTCAAGAGAAGATCTGGTCTGTGTTGGAGTCCCAA GGGGTGTGTTGGATGCAAGCTGAAATCACCTTTAAGAAGCCCATGCCTACCAAGTGGT TTTCATGAGCCTATGCAAAAGTTTCTGGGACTGTGGGCTTGTAGCCCTGGATGACATT ACAATACAATTGGGAAGCTGCTCATCTTCAGAGAACTTCCACCTCCACCTGGAGAGT GTACTTTTCGAGCAAGATGAATGTACATTTACTCAGGAGAAAAGAAACCGGAGCAGCTG GCACAGGAGGAGGGGAGAACTCCCACTTCTACACAGGACCAAGGGAGATCACACT ACTGGGGTAGGCTACTACATGTACATTGAGGCCCTCCCATATGGTGTATGGACAAAAAG CACGCCTCTGTCCAGGCCTCTGCGAGGAGTCTCTGGAACCACTGCTTGACCTTTTT CTACCACATGTATGGAGGGGGCACTGGCCTGCTGAGTGTTTATCTGAAAAGGAAGAA GACAGTGAAGAGTCCCTCTTATGGAGGAGAAGAGGTGAACAGAGCATTTCTGGCTAC GAGCACTGATTGAATACAGCTGTGAGAGGCAACACCAGATGATTTTGAAGCCATTG AGGAGTATCAATAAGAAGTGATATTGCCATTGATGATGTTAAATTTTCAGGCAGGACCC TGTGGAGAAATGGAAGATACAACCTCAACAATCATCAGGATATTCTGAGGACTTAAATG AAATTGAGTATCTCGAGGAGTCAAAGCCGCAAGTGCTCTCTTCAAAGGTCC		
	ORF Start: at 1	ORF Stop: at 2023	
	SEQ ID NO: 68	674 aa	MW at 76492.5kD
NOV18b, 174308357 Protein Sequence	GSFEESTCGFDSVLASLPWILNEEGHYIYVDTSFQKQGEKAVLLSPDLQAEWESCLRL VYQITTSSESLSDPSQLNLVYMRFEDESFDRLLSAKEPSDSWLIASLDLQNSSKKFKI LIEGVLGQGNATASIALFEIKMTTGYSIECDFEENHLCGFVNRWNPVNVWFVGGGSIRN VHSILPQDHTFKSELGHYMYVDSVYVKHFQEVQQLISPLTTPMAGCPSFYQIQGN DNVFSLYTRDVAGLYEEIWKADRPNGNAAWNLAEEFNPAPYMEVIFEVAFNGPKGGYV ALDDISFSFVHCNQTELLFSAVEASCNFEQDLNCFYQDKEGPGWTRVKVKNMYRAG DHTTGLGYLLANTKFTSQPGYIGRLYGPSLPGNLQYCLRFHYAIYGFLLKMSDTLAVY IFEENHVQEKIWSVLESFPRGVWMAEITFKKPMPTKVVFMSLCKSFWDGGLVALDDI TIQLGSCSSSEKLPPPPGECTFEQDECTFTQEKRNRSWHRRRGETPTSYTGPKGDHT TGVGYMYIEASHMVYQKARLLSRPLRGVSGKHCLTFFYHMYGGGTGLLSVYLKKEE DSEESLLWRRRGEQSI SWLRALIEYSCERQHQMF EAIRGVSIRSDIAIDVVKFQAGP CGEMEDTTQQSSGYSEDLNEIYLEESKPQVLSSKV		

Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 18B.

Table 18B. Comparison of NOV18a against NOV18b.		
Protein Sequence	NOV18a Residues/ Match Residues	Identities/ Similarities for the Matched Region
NOV18b	29..680 2..661	629/660 (95%) 636/660 (96%)

5

Further analysis of the NOV18a protein yielded the following properties shown in Table 18C.

<b>Table 18C. Protein Sequence Properties NOV18a</b>	
<b>PSort analysis:</b>	0.7480 probability located in microbody (peroxisome); 0.6736 probability located in nucleus; 0.6415 probability located in mitochondrial matrix space; 0.3377 probability located in mitochondrial inner membrane
<b>SignalP analysis:</b>	Cleavage site between residues 30 and 31

A search of the NOV18a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 18D.

<b>Table 18D. Geneseq Results for NOV18a</b>				
<b>Geneseq Identifier</b>	<b>Protein/Organism/Length [Patent #, Date]</b>	<b>NOV18a Residues/ Match Residues</b>	<b>Identities/ Similarities for the Matched Region</b>	<b>Expect Value</b>
ABB53298	Human polypeptide #38 - Homo sapiens, 686 aa. [WO200181363-A1, 01-NOV-2001]	17..680 15..686	659/672 (98%) 661/672 (98%)	0.0
AAB01432	Human TANGO 239 (form 2) - Homo sapiens, 686 aa. [WO200039284-A1, 06-JUL-2000]	17..680 15..686	655/672 (97%) 660/672 (97%)	0.0
ABB53297	Human polypeptide #37 - Homo sapiens, 640 aa. [WO200181363-A1, 01-NOV-2001]	52..680 4..640	624/637 (97%) 626/637 (97%)	0.0
AAB01426	Human TANGO 239 - Homo sapiens, 549 aa. [WO200039284-A1, 06-JUL-2000]	17..506 15..504	482/490 (98%) 487/490 (99%)	0.0
AAB00036	Human TANGO 239 partial sequence - Homo sapiens, 465 aa. [WO200039284-A1, 06-JUL-2000]	26..500 1..465	456/475 (96%) 461/475 (97%)	0.0

10 In a BLAST search of public sequence databases, the NOV18a protein was found to have homology to the proteins shown in the BLASTP data in Table 18E.

Table 18E. Public BLASTP Results for NOV18a				
Protein Accession Number	Protein/Organism/Length	NOV18a Residues/ Match Residues	Identities/ Similarities for the Matched Portion	Expect Value
Q91641	Thyroid hormone-induced protein B precursor - <i>Xenopus laevis</i> (African clawed frog), 688 aa.	1..680 1..688	438/689 (63%) 547/689 (78%)	0.0
Q96BM4	HYPOTHETICAL 26.4 KDA PROTEIN - <i>Homo sapiens</i> (Human), 232 aa.	457..680 1..232	222/232 (95%) 223/232 (95%)	e-129
CAD13324	BA373A9.2 (NOVEL PROTEIN (ORTHOLOG OF X.LAEVIS THYROID HORMONE-INDUCED PROTEIN B)) - <i>Homo sapiens</i> (Human), 135 aa (fragment).	554..680 1..135	127/135 (94%) 127/135 (94%)	4e-67
Q63191	Apical endosomal glycoprotein precursor - <i>Rattus norvegicus</i> (Rat), 1216 aa.	272..670 587..975	108/412 (26%) 182/412 (43%)	5e-29
Q9GMT4	HYPOTHETICAL 51.2 KDA PROTEIN - <i>Macaca fascicularis</i> (Crab eating macaque) ( <i>Cynomolgus</i> monkey), 448 aa.	511..666 240..411	66/172 (38%) 87/172 (50%)	1e-20

PFam analysis indicates that the NOV18a protein contains the domains shown in Table 18F.

Table 18F. Domain Analysis of NOV18a			
Pfam Domain	NOV18a Match Region	Identities/ Similarities for the Matched Region	Expect Value
MAM: domain 1 of 4	28..171	54/176 (31%) 123/176 (70%)	1.3e-34
MAM: domain 2 of 4	172..331	49/175 (28%) 115/175 (66%)	3.5e-35
TonB_boxC: domain 1 of 1	448..463	2/16 (12%) 14/16 (88%)	5
MAM: domain 3 of 4	344..500	59/174 (34%) 120/174 (69%)	7.3e-43

pili_assembly_C: domain 1 of 1	607..623	5/17 (29%) 15/17 (88%)	6.8
MAM: domain 4 of 4	511..668	68/174 (39%) 129/174 (74%)	6.8e-59

**Example 19.**

The NOV19 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 19A.

Table 19A. NOV19 Sequence Analysis		
	SEQ ID NO: 69	3815 bp
NOV19a, CG93088-01 DNA Sequence	CGGCCGCGATCCCCACCAACCAGCCCGGCCGCGACGGGGCACTGAGCCGGGTGCT GAGCACCGGAGGCCCGCGAGGCCGGGACTCAGATGTTGAAAGTTAATTTGTGTAAA GACTTATGCACGTGGTGACATGAGTTCTGCCAGTGCTCTGAAATCAAAGTGAAGAAA TAAATCCATGGAAGCCAGGCAATGATGGGTGTAGCTATGACTCTCTGAAGGACCTG CAGAGAAACGCCTCCTGATTTTGTCTTACAATGGAAGTTAAAAAGTGCCTGACGGTG GATGGGGCTGGGTGATGTGTTTGTCTCCTTCTTACTCAGTTTGTGTGTACGGATC CCACTAGCTGTTGGAGTCTGTACATAGAATGGCTGGATGCCTTTGGTGAAGGAAAA GGAAAAACAGCCTGGGTTGGATCCCTGGCAAGTGGAGTTGGCTTGCTTGCAAGTCCTG TCTGCAGTCTCTGTGTCTCATCTTTGGAGCAAGACCTGTACAAATCTTCACTGGCTT CATGGTGGCTGGAGGCTGATGTTGAGCAGTTTGTCTCCCAATATCTACTTTCTGTTT TTTTCTTATGGCATTGTTGTAGGTCTTGGATGTGGTTTATTATACACTGCAACAGTA CCATTACGTGCCAGTATTTTGACGATCGCCGAGGCCTAGCGCTTGGCCTGATTTCAAC AGGTTCAAGCGTTGGCCTTTTCATATATGCTGCTCTGCAGAGGATGCTGGTTGAGTTC TATGGACTGGATGGATGCTTGCTGATTGTGGGTGCTTTAGCTTTAAATATATTAGCCT GTGGCAGTCTGATGAGACCCCTCCAATCTTCTGATTGTCTTTGCTTAAAAAATAGC TCCAGAAGATCTACCAGATAAACTCCATTACAATGAAAAAGGAAAGAACTCTGGAA GAAAAACATAAACATTTCTGACAAGAGCTACAGTAGTGAGGAAAAATGCAGGATCACGT TAGCCAATGGTGACTGGAAACAAGACAGCCTACTTCATAAAAACCCACAGTGACACA CACAAAAGAGCCTGAAACGTACAAAAGAAAGTTGCAGAACAGACATATTTTGTCAAA CAGCTTGCCAAAGAGGAAGTGGCAGTTATATAAAAACCTACTGTGGTGAACTGTGGCTC TTTTTAAAAACAAAGTATTTTTCAGCCCTTTTCATTGCTATCTTACTCTTTGACATCGG AGGTTTTCACCTTCACTTATGGAAGATGTAGCAAGAAGTTCAAAAGTGAAAGAA GAAGAGTTTATTATGCCACTTATTTCCATTATAGGCATTATGACAGCAGTTGGTAAAC TGCTTTTAGGGATACTGGCTGACTTCAAGTGGATTAATACCTTGATCTTTATGTTGC TACCTTAATCATCATGGGCCTAGCCTTGTGTGCAATTCCATTTGCCAAAAGCTATGTC ACATTGGCGTTGCTTTCTGGGATCCTAGGGTTTCTTACTGGTAATTGGTCCATCTTTC CATATGTGACCACGAAGACTGTGGGAATTGAAAAATTAGCCCATGCCATGGGATATT AATGTTCTTTGCTGGACTTGGAATAGCCTAGGACCACCATCGTTGGGTGGTTTTAT GACTGGACCCAGACCTATGATATTGCATTTTATTTTAGTGGCTTCTGCGTCTGCTGG GAGGTTTTATTCTGCTGCTGGCAGCCTTGCCCTCTTGGGATACATGCAACAAGCAACT CCCAAGCCAGCTCCAACAACCTTCTTGTAACAAGTTGCCTCTAATGTTTAGAAGAAT ATTGGAAGACACTATTTTGTCTATTTATACCATATAGCAACGATATTTTAACAGATT CTCAAGCAAATTTTCTAGAGTCAAGACTATTTTCTCATAGCAAATTTCACAATGACT GACTCTGAATGAATTATTTTTTTTATATATCCTATTTTTTATGAGTGTATGCGTAG CCTCTATCTCGTATTTTTTCTATTTCTCCTCCCCACACCATCAATGGGACTATTCTG TTTGCTGTATTCTACTAGTTCTTAACATTGTAAAAAGTTTGACCAGCCTCAGAAGGC TTTCTCTGTGTAAAGAAGTATAATTTCTCTGCTGACTCCATTTAATCCACTGCAAGGC ACCTAGAGAGACTGCTCCTATTTTAAAGTGATGCAAGCATCATGATAAGATATGTGT GAAGCCCACTAGGAAATAAATCATTTCTTCTCTATGTTGACTTGCTAGTAAACAGA AGACTTCAAGCCAGCCAGGAAATTAAAGTGGCGACTAAAACAGCCTTAAGAATTGCAG TGGAGCAAATTGGTCAATTTTTTAAAAAATATATTTTAACCTACAGTCACCAAGTTTTC	

	ATTATTCTATTTACCTCACTGAAGTACTCGCATGTTGTTTGGTACCACTGAGCAACT GTTTCAGTTCCTAAGGTATTTGCTGAGATGTGGGTGAACTCCAAATGGAGAAGTAGTC ACTGTAGACTTTCTTCATGGTTGACCACTCCAACCTTGCTCACTTTTGCTTCTTGGCC ATCCACTCAGCTGATGTTTCTGGAAGTGCTAATTTACCTGTTTCCAAATGGAAAC ACATTTCTCAATCATTCGGTTCTGGCAAATGGGAAACATCCATTGCTTTGGGCACAG TGGGGATGGGCTGCAAGTTCCTGCATATCCTCCCAGTGAAGCATTTATTTGCTACTAT CAGATTTTACCACTATCAAATATAATTCAAGGGCAGAATTAAACGTGAGTGTGTGTGT GT AGGGCAATAAGAAATTAATACCCCTTATGCAGTTGCATTTAACCTTAAGAAAAATGTCC TTGGGATAAACTCCAATGTTTAATACATGATTTTTTTTCTAAAGAAATGGGTTTTAA ACTTTGGTATGCATCAGAATTCCTATAGATCTTTTGAATAATAGGTACCTGGGTA TCACACATAGAATTTTAATCTGCTGGTGTAGGCTGTTGCCAAACATCTATAATTT TACTGAGCTCTTCAAGTGATTCTGATAACACAGCCTGGATTGAGAATTTTATAAGAT TGGCAATGGAAAAACATTTATTCTTTTAAATAATAATTTTTTAAACCCAAGAGGTC AGGGGATTTTATAACCAATAGCCAAGTGTCTTTAAATAGGAGGCACCTTCCCATT GTGCCAAATCATCTTTTCATTTATTTTGAATTTGTATGATTATTTTATACTTGTAT GTTGCCTTTCTTGAAGGCGCTGAAGCACTTTATAAACACAAATCCTCACAATACCT CTGTGAGGTAGGTAAATAGTACTTTTCTATGTAGTAAACCTGGAATATGGAGAATTTT ATAACAGTTCATTCTACTTAATAATGCAATAATGGAGCTCCAAGTTGTCTTGGACTTC TACACCACACTCAGACTTCTGAAAGTTTCTGTACCTCATTCTTAGTCCCTGTCAA GGTTAGTAAATAAAATAAGTGACATAAAAAAAAAAAAAAACTAAACTACTTGTGTGT TTGAAAGTTCCTTTTGGCAGTTATGTTTCAAGAAACCAATAACCTGAAAAAGTTTGA CTTTGATGTGACATCTTCATATTCATCAATGCTGATAATTGTCCAAAGGCATCTTCAC TATGCTCTGCTAAATAACATCCAATGTGGGCGTTATCTGTTGTCTAGGGGATGAATTTT AAGTTACAATAAAATATTTTTCTTTGTTTGCATCAAAAAAAAAA		
	ORF Start: ATG at 263	ORF Stop: TAG at 1790	
	SEQ ID NO: 70	509 aa	MW at 55780.8kD
NOV19a, CG93088-01 Protein Sequence	MELKKSPDGGWGWVIVFVSFLTQFLCYGSPLAVGVLYIEWLDAFEGEGKGTAWVGS SGVGLLASPVCSLVCSSFGARPVTFISGFMVAGGLMLSSFPAPNIYFLFFSYGIVVGLG CGLLYTATVTITCQYFDDRGLALGLISTGSSVGLFIYAALQRLMVEFYGLDGCLLIV GALALNILACGSLMRPLQSSDCPLPKKIAPEDLPDKYSIYNEKGKNLEENINILDKSY SSEKCRITLANGDWKQDSLHKNPTVHTKEPETYKKKVAEQTYFCKQLAKRKKWQLY KNYCGETVALFKNKVSALFIAILLFDIGGFPPSLMEDVARSSNVKEEFIMPLISI IGIMTAVGKLLGLADFKWINTLYLYVATLIIMGLALCAIPFAKSYVTLALLSGILG FLTGNWSIFPYVTTKTGIEKLAHAYGILMFFAGLGNLGPPLGWFYDWTQTYDIAF YFSGFCVLLGGFILLALP SWDT CNKQLPKPAPTTFLYKVASNV		

Further analysis of the NOV19a protein yielded the following properties shown in Table 19B.

Table 19B. Protein Sequence Properties NOV19a	
PSort analysis:	0.6400 probability located in plasma membrane; 0.4600 probability located in Golgi body; 0.3700 probability located in endoplasmic reticulum (membrane); 0.1000 probability located in endoplasmic reticulum (lumen)
SignalP analysis:	Cleavage site between residues 29 and 30

5

A search of the NOV19a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 19C.

Table 19C. Geneseq Results for NOV19a				
Geneseq Identifier	Protein/Organism/Length [Patent #, Date]	NOV19a Residues/ Match Residues	Identities/ Similarities for the Matched Region	Expect Value
AAY31642	Human transport-associated protein-4 (TRANP-4) - Homo sapiens, 465 aa. [WO9941373-A2, 19-AUG-1999]	5..218 14..227	75/214 (35%) 116/214 (54%)	1e-33
AAM93737	Human polypeptide, SEQ ID NO: 3705 - Homo sapiens, 471 aa. [EP1130094-A2, 05-SEP-2001]	7..201 33..228	67/196 (34%) 109/196 (55%)	5e-30
AAB88570	Human hydrophobic domain containing protein clone HP03612 #34 - Homo sapiens, 375 aa. [WO200112660-A2, 22-FEB-2001]	7..201 9..204	67/196 (34%) 108/196 (54%)	6e-30
AAE06594	Human protein having hydrophobic domain, HP03949 - Homo sapiens, 390 aa. [WO200149728-A2, 12-JUL-2001]	67..451 13..384	95/403 (23%) 175/403 (42%)	3e-25
AAO07132	Human polypeptide SEQ ID NO 21024 - Homo sapiens, 107 aa. [WO200164835-A2, 07-SEP-2001]	398..480 5..87	38/83 (45%) 51/83 (60%)	1e-14

In a BLAST search of public sequence databases, the NOV19a protein was found to have homology to the proteins shown in the BLASTP data in Table 19D.

Table 19D. Public BLASTP Results for NOV19a				
Protein Accession Number	Protein/Organism/Length	NOV19a Residues/ Match Residues	Identities/ Similarities for the Matched Portion	Expect Value
Q9UFH8	HYPOTHETICAL 17.1 KDA PROTEIN - Homo sapiens (Human), 157 aa (fragment).	353..509 1..157	155/157 (98%) 156/157 (98%)	2e-87
Q9CPZ7	4930425B13RIK PROTEIN (1200003C15RIK PROTEIN) - Mus musculus (Mouse), 159 aa.	352..509 1..159	148/159 (93%) 152/159 (95%)	2e-82
O15374	Monocarboxylate transporter 5 (MCT 5) (MCT 4) - Homo sapiens (Human), 487 aa.	5..473 13..468	128/487 (26%) 222/487 (45%)	7e-47



O15403	Monocarboxylate transporter 7 (MCT 7) (MCT 6) - Homo sapiens (Human), 523 aa.	7..491 19..481	124/490 (25%) 223/490 (45%)	3e-40
Q9W509	MCT1 PROTEIN - Drosophila melanogaster (Fruit fly), 626 aa.	7..230 29..255	85/227 (37%) 124/227 (54%)	1e-38

PFam analysis indicates that the NOV19a protein contains the domains shown in Table 19E.

Table 19E. Domain Analysis of NOV19a			
Pfam Domain	NOV19a Match Region	Identities/ Similarities for the Matched Region	Expect Value
sugar_tr: domain 1 of 1	11..456	74/547 (14%) 276/547 (50%)	0.27

5

#### Example 20.

The NOV20 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 20A.

Table 20A. NOV20 Sequence Analysis			
	SEQ ID NO: 71	724 bp	
NOV20a, CG93335-01 DNA Sequence	CAGGAGGCGGGTGGGTCAAGGTAACCTCTGGGCTACAGAGTCCTTGCTGGGGGTTCCGGG GAGCGCTTGGACCCCGGCTTCTGGGACGCGTCAGAATATTATCCAGCAATGCAAAATGA ACAAACTATAACTACACACAGCTGCATGGATAAATGTCAGAAACATGACGTTGAGTGT GAGAAGCCAGATGCAACGAGGACTCACTGTGCAATTCTGTGCATGTACAGTGGCCAG GAGAAGGGAGCACTGGCTTTGCTTTTCATCAGGCCAAAGATGCCTTTCTTTGGGAATAC GTTCAGTCCGAAGAAGACACCTCCTCGGAAGTCGGCATCTCTCTCCAACCTGCATTCT TTGGATCGATCAACCCGGGAGGTGGAGCTGGGCTTGAATACGGATCCCCGACTATGA ACCTGGCAGGGCAAAGCCTGAAGTTTGAAAATGGCCAGTGGATAGCAGAGACAGGGGT TAGTGGCGGTGTGGACCGGAGGGAGGTTTCAGCGCCTTCGCAGGCGGAACAGCAGTTG GAGGAAGAGAACAATCTCTTGGCGCTGAAAGTGGACATCTTATTAGACATGCTTTTCAG AGTCCACTGCTGAATCCCACTTAATGGAGAAGGAAGTGGATGAAGTGAAGATCAGCCC GAAGAGAAAATGAAGACCCAGAGACATTTATTGGGGAGTAGGATGTGGCTGAGTGTCT TTTTTTTGGCCAGACTAGCGGATTTCAG		
	ORF Start: ATG at 142	ORF Stop: TGA at 649	
	SEQ ID NO: 72	169 aa	MW at 19286.6kD
NOV20a, CG93335-01 Protein Sequence	MDKCQKHDVECEKPDANEDSLCNSVHVQWPGEGSTGFAFIRPKMPFFGNTFSPKKTPI RKSASLSNLHSLDRSTREVELGLEYGSPMTNLAGQSLKFENGQWIAETGVSGGVDRRE VQRLRRRNQQLLEENLLRLKVDILLDMLSESTAESHLMKELDELIRISRRK		

10

Further analysis of the NOV20a protein yielded the following properties shown in Table 20B.

Table 20B. Protein Sequence Properties NOV20a	
PSort analysis:	0.4600 probability located in nucleus; 0.3000 probability located in microbody (peroxisome); 0.1000 probability located in mitochondrial matrix space; 0.1000 probability located in lysosome (lumen)
SignalP analysis:	No Known Signal Sequence

A search of the NOV20a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 20C.

5

Table 20C. Geneseq Results for NOV20a				
Geneseq Identifier	Protein/Organism/Length [Patent #, Date]	NOV20a Residues/ Match Residues	Identities/ Similarities for the Matched Region	Expect Value
AAM00955	Human bone marrow protein, SEQ ID NO: 431 - Homo sapiens, 175 aa. [WO200153453-A2, 26-JUL-2001]	31..169 37..175	139/139 (100%) 139/139 (100%)	1e-74
AAY86201	Nuclear transport protein clone hfb2025 protein sequence - Homo sapiens, 67 aa. [WO9964455-A1, 16-DEC-1999]	103..169 1..67	67/67 (100%) 67/67 (100%)	6e-30
ABB23535	Protein #5534 encoded by probe for measuring heart cell gene expression - Homo sapiens, 26 aa. [WO200157274-A2, 09-AUG-2001]	44..69 1..26	26/26 (100%) 26/26 (100%)	2e-08
AAB69070	Human male enhanced antigen-2 (MEA-2) protein sequence SEQ ID NO:2 - Homo sapiens, 1374 aa. [JP2000316580-A, 21-NOV-2000]	62..163 768..868	25/102 (24%) 45/102 (43%)	1.1
AAU36216	Pseudomonas aeruginosa cellular proliferation protein #206 - Pseudomonas aeruginosa, 874 aa. [WO200170955-A2, 27-SEP-2001]	104..163 683..749	22/67 (32%) 35/67 (51%)	1.9

In a BLAST search of public sequence databases, the NOV20a protein was found to have homology to the proteins shown in the BLASTP data in Table 20D.

10

Table 20D. Public BLASTP Results for NOV20a				
Protein Accession Number	Protein/Organism/Length	NOV20a Residues/ Match Residues	Identities/ Similarities for the Matched Portion	Expect Value
Q9Y3M2	HYPOTHETICAL 14.5 KDA PROTEIN (CHROMOSOME 22 OPEN READING FRAME 2) - Homo sapiens (Human), 126 aa.	44..169 1..126	126/126 (100%) 126/126 (100%)	4e-66
AAL56062	CYTOSOLIC LEUCINE-RICH PROTEIN - Homo sapiens (Human), 126 aa.	44..169 1..126	125/126 (99%) 126/126 (99%)	1e-65
Q9D1C2	1110014P06RIK PROTEIN (RIKEN CDNA 1110014P06 GENE) - Mus musculus (Mouse), 127 aa.	44..169 1..126	104/126 (82%) 120/126 (94%)	1e-56
Q9UIK9	HRIHFB2025 PROTEIN - Homo sapiens (Human), 67 aa (fragment).	103..169 1..67	67/67 (100%) 67/67 (100%)	1e-29
Q9CVN6	1700121K02RIK PROTEIN - Mus musculus (Mouse), 226 aa (fragment).	47..160 70..191	45/122 (36%) 69/122 (55%)	2e-15

PFam analysis indicates that the NOV20a protein contains the domains shown in Table 20E.

Table 20E. Domain Analysis of NOV20a			
Pfam Domain	NOV20a Match Region	Identities/ Similarities for the Matched Region	Expect Value
Transposase_8: domain 1 of 1	54..149	22/99 (22%) 64/99 (65%)	2.9

5

#### Example 21.

The NOV21 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 21A.

Table 21A. NOV21 Sequence Analysis		
	SEQ ID NO: 73	1310 bp
NOV21a, CG93345-01 DNA Sequence	GATTCCAGTTGAAGTCAGTTTGACTTAATGAGCTCTTCTCTATTTTCCTACTCAAACC TCTATTCCACCATGTCACCACTCAACCAAACCTACTGAGAACCACCAGAGCTTCTTCAC CCTGACTGGGATTCCAGGAATGCCAGAGAAAGACTTATGGATGGCCTTGCCCTCTGT CTTCTTTATAGCACCACGATCTTGGGAAATGTCACCATCCTTGTGTCATCAAAGTTG	

	AGCAAAGTCTCCATGAGCCCATGTATTTTTTCTAGCCATGTTAGCTGCCACTGACCT CAGCCTTTCAGTGTCTTCCATGCCTACCATGGTCAGTGTTCACTGGTTCAACTGGCGT TCAATAACTTTTAAATGGCTGCCTTATCCAGATGTTCTTCATCCACACATTTGGGGGAG TGGAATCAGGTGTTCTGGTGGCCATGGCCTTTGATCGCTTTGTGGCCATCCGCTTTCC TTTGCACTATGCTACAATTCTCACTCACAGTGTATCAGCAAGATTGCAGCAGCCATC CTGCTACGGAGTGTGGGGGCTGTGCTCCCTGTGCCTTTTCTCATCAAAGGTTACCTT TCTGTCACTCCAATGTCTCTCCCATGCATACTGCCTCCATCAGGATGCCATGAGGCT TGCCTGTGCTGACACTGGTGTCAATAGCATCTATGGCCTGTTGGCTGTGATCTTCATC ATTGTACTAGATGCCTTAATACTTTTGGCCTCTTACATTCTAATCCTGCAGGCAGTAT TGAGCATTGCTTCCAGGAAGACAGGCTCAAGGCTCTCAACACCTGTGTCTCTCTCAT ATCTGCAGTGTGCTTTTCTATGTGCCTCTCATTGGTATGACCCTAATTCATCGCTAT GGGAAGCATTGTGACCACATAACACACATTCATGGCCAATATCTACCTGCTTCTCC CTCCTGTGCTCAATCCCATTTGTGTACAGTGTTAGGACCAAGCAGATCTGATAGCAGAT TGTCCAGGCCCTTTGTGGGGCTAGGGTTAGCCCTTAATGGCATCTACTATTTCCAAGT AAATGCAATCAAGTTAGAGAAGAGTATCAAATACAGCACTATCCAATAGAAATTCCCA CAGAAGTGATATTTCTATTTCTCTGCTGTTTAGTAAGTAGTGTACATGGCTA TTAATTGCTTGAATTTTGCTAGTGCAAGCTGAGGAACTGAATTTTAAATGTACTTAA TTTTAATTGATTTAAATGTAATTTAAGTAGTCATATGTAAGTAGTGTGCCGTATC AAATAGTACAAATACAATGGGTAGTGATATGAAA		
	ORF Start: ATG at 28	ORF Stop: TGA at 976	
	SEQ ID NO: 74	316 aa	MW at 35115.4kD
NOV21a, CG93345-01 Protein Sequence	MSSSLFSYSLNLYSTMSPLNQTTENHQSFFTLTGIPGMPEKDLWMALPLCLLYSTTILG NVTILVVIKVEQSLHEPMTFFLAMLAATDLSLSLSMPTMVSVHWFNWRSTFNGCLI QMFFIHTFGGVESGLVMAFDRFVAIRFPLHYATILTHSVISKIAAAILLRSGAVL PVPFLIKRLPFCHSNVLSHAYCLHQDAMRLACADTGVNSIYGLLAVIFIIVLDALILL ASYILILQAVLSIASQEDRLKALNTCVSLISAVLLFYVPLIGMTLIHRYGKHLSPLIH TFMANIYLLLPPVLNPIVYSVRTKQI		

Further analysis of the NOV21a protein yielded the following properties shown in Table 21B.

Table 21B. Protein Sequence Properties NOV21a	
PSort analysis:	0.6000 probability located in plasma membrane; 0.4905 probability located in mitochondrial inner membrane; 0.4000 probability located in Golgi body; 0.3000 probability located in endoplasmic reticulum (membrane)
SignalP analysis:	Cleavage site between residues 59 and 60

5

A search of the NOV21a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 21C.

10

Table 21C. Geneseq Results for NOV21a				
Geneseq Identifier	Protein/Organism/Length [Patent #, Date]	NOV21a Residues/ Match Residues	Identities/ Similarities for the Matched Region	Expect Value
AAG71700	Human olfactory receptor polypeptide, SEQ ID NO: 1381 - Homo sapiens, 323 aa. [WO200127158-A2, 19-APR-2001]	15..316 1..302	298/302 (98%) 301/302 (98%)	e-169
AAG71602	Human olfactory receptor polypeptide, SEQ ID NO: 1283 - Homo sapiens, 302 aa. [WO200127158-A2, 19-APR-2001]	15..316 1..302	193/303 (63%) 244/303 (79%)	e-110
AAU24684	Human olfactory receptor AOLFR183 - Homo sapiens, 302 aa. [WO200168805-A2, 20-SEP-2001]	15..316 1..302	193/303 (63%) 244/303 (79%)	e-110
AAG71516	Human olfactory receptor polypeptide, SEQ ID NO: 1197 - Homo sapiens, 315 aa. [WO200127158-A2, 19-APR-2001]	26..316 11..301	170/291 (58%) 220/291 (75%)	9e-99
AAU24569	Human olfactory receptor AOLFR59 - Homo sapiens, 315 aa. [WO200168805-A2, 20-SEP-2001]	26..316 11..301	170/291 (58%) 220/291 (75%)	9e-99

In a BLAST search of public sequence databases, the NOV21a protein was found to have homology to the proteins shown in the BLASTP data in Table 21D.

5

Table 21D. Public BLASTP Results for NOV21a				
Protein Accession Number	Protein/Organism/Length	NOV21a Residues/ Match Residues	Identities/ Similarities for the Matched Portion	Expect Value
AAL60646	OLFACTORY RECEPTOR MOR10-1 - Mus musculus (Mouse), 315 aa.	19..316 4..300	210/298 (70%) 248/298 (82%)	e-119
AAL60660	OLFACTORY RECEPTOR MOR10-2 - Mus musculus (Mouse), 318 aa.	22..316 7..301	181/295 (61%) 228/295 (76%)	e-104

AAL60631	OLFACTORY RECEPTOR MOR5-2 - Mus musculus (Mouse), 321 aa.	13..316 5..307	172/304 (56%) 232/304 (75%)	2e-98
AAL60629	OLFACTORY RECEPTOR MOR5-1 - Mus musculus (Mouse), 321 aa.	13..316 5..307	173/304 (56%) 230/304 (74%)	2e-98
AAL60640	OLFACTORY RECEPTOR MOR7-2 - Mus musculus (Mouse), 312 aa.	27..316 13..302	170/290 (58%) 221/290 (75%)	1e-97

PFam analysis indicates that the NOV21a protein contains the domains shown in Table 21E.

Table 21E. Domain Analysis of NOV21a			
Pfam Domain	NOV21a Match Region	Identities/ Similarities for the Matched Region	Expect Value
7tm_1: domain 1 of 1	58..309	50/270 (19%) 169/270 (63%)	1.2e-22

5

### Example 22.

The NOV22 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 22A.

Table 22A. NOV22 Sequence Analysis			
	SEQ ID NO: 75	999 bp	
NOV22a, CG93400-01 DNA Sequence	ACGAGTGGATAAGCTAGTGACCTATCTGTGATGTTTCTGCTCAATACCTCAGAAGTTG AAGTCTCCACATTCTCTATTGATTGGGATACCAGGACTTGAGCATGCACACATTTGGAT CTCTATCCCCATCTGCCTTATGTACCTCATGGCCATCCTGGGCAACTGCACCATCCTA TTTGTATCAGAACAGAGCATTCCCTGCAAGAGCCCATGTACTATTTCTCTCCATGC TGGCCCTGTCCGACCTGGGCTGTCTTTCTCCTCCCTACCCACGATGCTGAGAATCTT CTTGTTCAACAACATGGGGATTCTGCTGATACATGCATTGCCCAGGAATTCTTCATC CATGGATTCACAGACATGGAGTCTTCAGTTCTCCTAATCATGTCCCTTGTGATCACTTA TAGCCATTTGCAACCCCTAAGATATAGCTCTATTCTCACCAGCTTCAGGGTTTTCGCA AATTGGACTGGCTTTTGCCATTAAAAGCATTCTCCTAGTGCTACCCCTTCTTTTACT TTAAAGAGACTCAGATACTGTAATAAACACCTTTTATCCCACTCCTACTGCCTTCAC AGGATGTAATGAAGCTGGCCTGCTCTGACAACAGGGTTAACTTTTACTATGGTTTGT CGTTGCACTCTGCATGATGTCAGACAGTTTTTATTGCTATTTTCTATATGTGTTTCAT CTGAAGACTGTGTTGGGTATTGCATCCCATGGGAGTGCTCGAAGCTCTTGACACCT GTGTGTCATATCTGTGCTGTACTCGTCTTCTATGTGCCCATCATCACCTTGGCTAC CATGCGTCGCTTTGCTAAGCATAAATCCCTTTAGCTATGATTCTGATAGCAGATGCA TTCTTGCTGGTACCACCCTTGATGAATCCCATTTGTGTATTGTGTAAAACTCGGCAG TTAGAGTAAAGGTCCTGGAAAAATTGGCTCTGAAGCCTAAATGATGGGGCAAGGTG AAATTCTATTTTT		
	ORF Start: ATG at 31	ORF Stop: TGA at 970	
	SEQ ID NO: 76	313 aa	MW at 35541.3kD

NOV22a, CG93400-01 Protein Sequence	MFLNTSEVEVSTFLLIGIPGLEHAHIWISIPICLMYLMAILGNCTILFVIRTEHSLO EPMYYFLSMLALSDLGLSFSSLPMLRIFLFNNMGISADTCIAQEFTIHGFTDMESSV LLIMSF DHLVAICNPLRYSSILTSFRVLQIGLAF AIKSILLVLPPLPFLKRLRYCNKH LLSHSYCLHQDVMKLACSDNRVNFYGLFVALCMMSDSFYCYFLYVFILKTVLGIASH GECLEALDTCVSHICAVLVFYVPIITLATMRRFAKHKSPLAMILIADAFLLVPPIMNP IVYCVKTRQIRVKVLEKLALPKK
---	--

Further analysis of the NOV22a protein yielded the following properties shown in Table 22B.

Table 22B. Protein Sequence Properties NOV22a	
PSort analysis:	0.6000 probability located in plasma membrane; 0.4000 probability located in Golgi body; 0.3000 probability located in endoplasmic reticulum (membrane); 0.2414 probability located in mitochondrial inner membrane
SignalP analysis:	Cleavage site between residues 44 and 45

- 5 A search of the NOV22a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 22C.

Table 22C. Geneseq Results for NOV22a				
Geneseq Identifier	Protein/Organism/Length [Patent #, Date]	NOV22a Residues/ Match Residues	Identities/ Similarities for the Matched Region	Expect Value
AAG71721	Human olfactory receptor polypeptide, SEQ ID NO: 1402 - Homo sapiens, 316 aa. [WO200127158-A2, 19-APR-2001]	1..313 1..313	305/314 (97%) 307/314 (97%)	e-172
AAG71564	Human olfactory receptor polypeptide, SEQ ID NO: 1245 - Homo sapiens, 322 aa. [WO200127158-A2, 19-APR-2001]	1..311 5..315	231/311 (74%) 264/311 (84%)	e-131
AAG71701	Human olfactory receptor polypeptide, SEQ ID NO: 1382 - Homo sapiens, 312 aa. [WO200127158-A2, 19-APR-2001]	1..308 1..306	230/308 (74%) 257/308 (82%)	e-129
AAU24682	Human olfactory receptor AOLFR181 - Homo sapiens, 312 aa. [WO200168805-A2, 20-SEP-2001]	1..308 1..306	230/308 (74%) 257/308 (82%)	e-129

AAG72486	Human OR-like polypeptide query sequence, SEQ ID NO: 2167 - Homo sapiens, 345 aa. [WO200127158-A2, 19-APR-2001]	1..313 1..338	234/338 (69%) 265/338 (78%)	e-127
----------	---	------------------	--------------------------------	-------

In a BLAST search of public sequence databases, the NOV22a protein was found to have homology to the proteins shown in the BLASTP data in Table 22D.

5

Table 22D. Public BLASTP Results for NOV22a				
Protein Accession Number	Protein/Organism/Length	NOV22a Residues/ Match Residues	Identities/ Similarities for the Matched Portion	Expect Value
AAL60639	OLFACTORY RECEPTOR MOR8-3 - Mus musculus (Mouse), 312 aa.	3..313 2..312	273/311 (87%) 286/311 (91%)	e-154
AAL60635	OLFACTORY RECEPTOR MOR8-1 - Mus musculus (Mouse), 318 aa.	1..311 8..318	248/311 (79%) 271/311 (86%)	e-141
AAL60638	OLFACTORY RECEPTOR MOR8-2 - Mus musculus (Mouse), 317 aa.	1..311 5..315	214/311 (68%) 252/311 (80%)	e-121
AAL60640	OLFACTORY RECEPTOR MOR7-2 - Mus musculus (Mouse), 312 aa.	12..304 13..306	175/294 (59%) 215/294 (72%)	1e-94
AAL60634	OLFACTORY RECEPTOR MOR7-1 - Mus musculus (Mouse), 313 aa.	1..307 1..308	171/308 (55%) 221/308 (71%)	4e-94

PFam analysis indicates that the NOV22a protein contains the domains shown in Table 22E.

Table 22E. Domain Analysis of NOV22a			
Pfam Domain	NOV22a Match Region	Identities/ Similarities for the Matched Region	Expect Value
7tm_1: domain 1 of 2	43..81	12/39 (31%) 30/39 (77%)	6e-09
7tm_1: domain 2 of 2	217..293	13/88 (15%) 51/88 (58%)	1.3



**Example 23.**

The NOV23 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 23A.

Table 23A. NOV23 Sequence Analysis			
	SEQ ID NO: 77	2715 bp	
NOV23a, CG93410-01 DNA Sequence	GATGGAGCACGGCACACTCCTCGCCAGCCGGGCTCTGGACCAGGGACACCAGCTGG GCACTCCTCTATTTCCTCTGCTATATCCTCCCTCAGACCGCCCGCAAGTACTCAGGA TCGGAGGGATTTTTGAAACAGTGGAATAATGAGCCTGTTAATGTTGAAGAATTAGCTTT CAAGTTTGCAGTCACCAGCATTAACAGAAACCGAACCTGATGCCTAACACCACATTA ACCTATGACATCCAGAGAATTAACCTTTTGTAGATTTTGAGGCCTCGCGGAGAGCAT GTGACCAGCTGGCTCTTGGTGTGGCTGCTCTCTTTGGCCCTTCCCATAGCTCCTCCGT CAGTGTGTGCAGTCTATTTGCAATGCTCTCGAAGTTCACACATACAGACCCGCTGG AAACACCCCTCGGTGGACAACAAAGATTGTTTTACATCAACCTTTACCCAGATTATG CAGCTATCAGCAGGGCGATCCTGGATCTGGTCTCTATTACAACCTGGAACAGTGGC AGTGGTGTATGAAGACAGCACAGGTCTAATTCGTCTACAAGAGCTCATCAAAGCTCCC TCCAGATATAATATTAATAATCAAAATCCGCCAGCTGCCCTCTGGGAATAAAGATGCCA AGCCTTTACTCAAGGAGATGAAGAAAGGCAAGGAGTCTATGTGATATTTGATTGTTT ACATGAAACAGCCGCTGAAATCCTTAAGCAGATTCTGTTTCATGGGCATGATGACCGAG TACTATCACTACTTTTTCAACCCCTGGACTTATTTGCTTTGGATCTGGAACTCTATA GGTACAGTGGCGTAAACATGACCGGGTTTCGGCTGCTTAACATTGACAACCCCTCACGT GTCATCCATCATTGAGAAGTGGTCCATGGAGAGACTGCAGGCCCCACCCAGGCCCGAG ACTGGCCTTTTGGATGGCATGATGACAACCTGAAGCGGCTCTGATGTACGATGCTGTGT ACATGGTGGCCATTGCCTCGCACCGGGCATCCCAGCTGACCGTCAGCTCCCTGCAGTG CCATAGACATAAGCCATGGCGCCTCGGACCCAGATTATGAACCTGATCAAAGAGGCC CGGTGGGATGGCTTGACTGGGCATATCACCTTTAATAAAACCAATGGCTTGAGGAAGG ATTTTGATCTGGATATTATTAGTCTCAAAGAGGAAGGAAGTGAAGAGTTGGGATTG GAATTCCAACAGTGGGCTTAACATGACGGACAGCAACAAAGACAAGTCCAGCAATATC ACTGATTCATTGGCCAACAGAACTCATTGTCAACACCATTCTGGAAGAACCCATATG TTATGTACAGGAAATCTGATAAGCCTCTATATGGAATGACAGATTGGAAGGATATTG CCTAGACCTGTTGAAAGAATTGTCAAACATCCTGGGTTTCATTTATGATGTTAACTA GTTCCCGATGGCAAATATGGGGCCAGAAATGACAAAGGGGAGTGAACGGGATGGTTA AAGAACCTCATAGATCACAGGGCTGACCTGGCAGTGGCTCCTCTTACCATCACCTACGT GCGGGAGAAAGTCATTGACTTCTCCAACCCCTTCATGACCCTAGGCATCAGCATTCTC TACCGGAAGCCCAATGGTACCAATCCAGGCGTTTTCTCCTTCTCAACCCCTGTCTC CAGATATTGGATGTATGTGCTCTTAGCCTGCTTGGGAGTCAGCTGTGTACTCTTTGT GATTGCAAGGTTTACACCCTACGAGTGGTATAACCCCCACCCATGCAACCTGACTCA GACGTGGTGGAAAAACAATTTTACTTTACTAAATAGTTTCTGGTTTGGAGTTGGAGCTT TCATGCAGCAAGGATCAGAGCTGATGCCAAAGCTCTATCGACCAGAATAGTTGGAGG GATATGGTGGTTTTTACCCTAATCATCATTTCATCCTACACGGCCAATCTGGCTGCC TTCTTGACAGTAGAGAGAATGGAATCCCCATAGATTTCGGCAGATGATCTGGCAAAGC AAACCAAGATAGAATATGGGGCGGTTAGAGATGGATCAACAATGACCTTCTTCAAGAA ATCAAAAATCTCCACCTATGAGAAGATGTGGGCTTTCATGAGCAGCAGGCAGCAGACC GCCCTGGCAAGAAACAGTGATGAGGGGATCCAGAGAGTGCTCACCACAGACTACGGCG TGCTGATGGAGTCCACCAGCATTGAGTATGTGACGCAGAGAACTGCAACCTCACTCA GATCGGGGGCCTCATTGACTCCTAAAGGTTACGGAGTGGGAACACCTATTGGTTCTCCT TACCGGGATAAAATTTACTATTGCTATTCTTCAACTCCAAGAAGAAGGGAAGCTGCATA TGATGAAAGAGAAGTGGTGGCGTGGGAATGGCTGCCCGAGGAAGACAACAAGAAGC CAGTGCCCTGGGAGTGGAAAATATTGGAGGCATCTTCATTGTTCTGGCTGCCGGACTG GTCCTTTCTGTATTGTAGCTATTGGAGAATTATATACAAATCAGGAAGAATAATG ATATTGAACAGGCTTTTTGTCTTTTATGGACTGCAATGTAAGCAAACCCATCCAAC CAACTCCACTTCTGGAACACTTTTATCTACGGATTGAGAATGTGGTAAATTAATTCGA GAGGAGAGAGGGATTGAAAAACAGTCCTCAGTTTCATACTGTGTAATC		
	ORF Start: ATG at 2	ORF Stop: TAA at 2711	
	SEQ ID NO: 78	903 aa	MW at 102229.3kD

NOV23a, CG93410-01 Protein Sequence	MEHGTLAQPGLWTRDTSWALLYFLCYILPQTAPQVLRIGGI FETVENEPVNVEELAF KFAVTSINRNRTLMPNTTLLTYDIQRINLFDSEASRRACDQLALGVAALFGPSHSSSV SAVQSI CNALEVPHIQTRWKHPVDNKDLFYINLYPDYAAISRAILDLVLYYNWKTVA VVYEDSTGLIRLQELIKAPSRYNIKIKIRQLPSGNKDAKPLLKEMKKGKEFYVIFDCS HETAABILKQILFMGMMTEYHYFFTTLDLFDLDELRYSGVNMTGFRLLNIDNPHV SSIIEKWSMERLQAPPRPETGLLDGMMTTEAALMYDAVYMAIASHRASQLTVSSSLQC HRHKPWRLGPRFMNLKEARWDGLTGHITFNKTNGLRKDFLDIIISLKEEGTEKIGIW NSNSGLNMTDSNKKSSNITDSLNRTLIVTTILEEPPYVMYRKSDKPLYGNDRFEGYC LDLLKELSNILGFIDVKLVDPGKYGAQNDKGEWNGMVKELIDHRADLAVAPLTIYV REKVIDFSKPFMTLGISILYRKPNGTNPVFSFLNPLSPDIWMYVLLACLGVSCVLFV IARFTPYEWINPHPCNPDSVVENNFTLLNSFWFGVGAFFMQQGSSELMKALSTRIVGG IWWFFTLIIISSYTANLAAFLTVERMESPIDSAADLAKQTKIEYGAVRDGSTMTEFFKK SKISTYEKMWAFMSSRQQTALARNSEDEGIQRVLTIDYALLMESTSIEYVTQRNCNLQ IGGLIDSKGYGVGTPIGSPYRDKITIAILQLQEEGKLHMMKEKWWRGNGCPPEEDNKEA SALGVENIGGIFIVLAAGLVLSVFVAIGEFYKSRKNNDIEQAFCCFFYGLQCKQTHPT NSTSGTTLSTDLECGKLIREBERGIRKQSSVHTV		
	SEQ ID NO: 79	1602 bp	
NOV23b, 188822752 DNA Sequence	AGATCTCAAGTACTCAGGATCGGAGGGATTTTTGAAACAGTGAAAATGAGCCTGTTA ATGTTGAAGAATTAGCTTTCAAGTTTGCAGTCACCAGCATTAAACAGAAACCGAACCT GATGCCTAACACCACATTAACCTATGACATCCAGAGAATTAACTTTTTGATAGTTTT GAGGCCTCGCGGAGAGCATGTGACCAGCTGGCTCTTGGTGTGGCTGCTCTCTTTGGCC CTTCCCATAGCTCCTCCGTCAGTGCTGTGCAGTCTATTGGCAATGCTCTCGAAGTTCC ACACATACAGACCCGCTGGAACACCCCTCGGTGGACAACAAAGATTTGTTTTACATC AACCTTTACCCAGATTATGCAGCTATCAGCAGGGCGATCCTGGATCTGGTCTCTATT ACAACTGGAACAGTGACAGTGGTGTATGAAGACAGCACAGGTCTAATTCGTCTACA AGAGCTCATCAAAGCTCCCTCCAGATATAATATTAATAAATCAAATCCGCCAGCTGCCC TCTGGGAATAAAGATGCCAAGCCTTTACTCAAGGAGATGAAGAAAGGCAAGGAGTTCT ATGTGATATTTGATTGTTACATGAAACAGCCGCTGAAATCCTTAAGCAGATTCTGTT CATGGGCATGATGACCGAGTACTATCACTACTTTTTCACAAACCTGGACTTATTGCT TTGGATCTGGAACCTCTATAGGTACAGTGGCGTAAACATGACCGGGTTTTCGGTGCTTA ACATTGACAACCCCTCACGTGTCATCCATCATTGAGAAGTGGTCCATGGAGAGACTGCA GGCCCCACCCAGGCCCCGAGACTGGCCTTTTGGATGGCATGATGACAACTGAAGCGGCT CTGATGTACGATGCTGTGTACATGGTGGCCATTGCCTCGCACCGGGCATCCAGCTGA CCGTGAGCTCCCTGCAGTGCCATAGACATAAGCCATGGCGCCTCGGACCCAGATTTAT GAACCTGATCAAAGAGGCCCGGTGGGATGGCTTGACTGGGCATATCACCTTTAATAAA ACCAATGGCTTGAGGAAGGATTTTGATCTGGATATTATTAGTCTCAAAGAGGAAGGAA CTGAAAAGATTGGGATTTGGAATCCAACAGTGGGCTTAACATGACGGACAGCAACAA AGACAAGTCCAGCAATATCACTGATTCAATGGCCAACAGAACACTCATTGTCAACACC ATTCTGGAAGAACCCTATGTTATGTACAGGAAATCTGATAAGCCTCTATATGGAATG ACAGATTTGAAGGATATTGCCTAGACCTGTTGAAAGAATTGTCAAACATCTGGGTTT CATTTATGATGTTAACTAGTTCCTCGATGGCAAATATGGGGCCAGAAATGACAAAGGG GAGTGGAAACGGGATGTTAAAGAACTCATAGATCAGAGGGCTGACCTGGCAGTGGCTC CTCTTACCATCACTAGTGCAGGAGAAAGTCAATGACTTCAACCTCCCTCATGAC CCTAGGCATCAGCATTCTCTACCGGAAGCCCAATGGTACCAATCCAGGCGTTTTCTCC TTCTCAACCCCTGTCTCCAGATATTTGGCTCGAG		
	ORF Start: at 1	ORF Stop: end of sequence	
	SEQ ID NO: 80	534 aa	MW at 60947.3kD
NOV23b, 188822752 Protein Sequence	RSQVLRIGGI FETVENEPVNVEELAFKFAVTSINRNRTLMPNTTLLTYDIQRINLFDSE EASRRACDQLALGVAALFGPSHSSSVSAVQSI CNALEVPHIQTRWKHPVDNKDLFYI NLYPDYAAISRAILDLVLYYNWKTVA VVYEDSTGLIRLQELIKAPSRYNIKIKIRQLP SGNKDAKPLLKEMKKGKEFYVIFDCSHETAABILKQILFMGMMTEYHYFFTTLDLFA LDLELYRYSGVNMTGFRLLNIDNPHVSSIIEKWSMERLQAPPRPETGLLDGMMTTEAA LMYDAVYMAIASHRASQLTVSSSLQCHRHKPWRLGPRFMNLKEARWDGLTGHITFNK TNGLRKDFLDIIISLKEEGTEKIGIWNNSNSGLNMTDSNKKSSNITDSLNRTLIVTT ILEEPPYVMYRKSDKPLYGNDRFEGYCLDLLKELSNILGFIDVKLVDPGKYGAQNDKG EWNMGVKEIDHRADLAVAPLTIYVREKVIDFSKPFMTLGISILYRKPNGTNPVFS FLNPLSPDIWLE		

Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 23B.

Table 23B. Comparison of NOV23a against NOV23b.		
Protein Sequence	NOV23a Residues/ Match Residues	Identities/ Similarities for the Matched Region
NOV23b	35..565	492/531 (92%)
	3..533	493/531 (92%)

5

Further analysis of the NOV23a protein yielded the following properties shown in Table 23C.

Table 23C. Protein Sequence Properties NOV23a	
PSort analysis:	0.6000 probability located in plasma membrane; 0.4000 probability located in Golgi body; 0.3000 probability located in endoplasmic reticulum (membrane); 0.1000 probability located in mitochondrial inner membrane
SignalP analysis:	Cleavage site between residues 35 and 36

10 A search of the NOV23a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 23D.

Table 23D. Geneseq Results for NOV23a				
Geneseq Identifier	Protein/Organism/Length [Patent #, Date]	NOV23a Residues/ Match Residues	Identities/ Similarities for the Matched Region	Expect Value
AAR63069	Human EAA3c excitatory amino acid receptor - Homo sapiens, 865 aa. [CA2110933-A, 12-JUN-1994]	1..862 1..862	853/862 (98%) 853/862 (98%)	0.0
AAB19496	The Q591 form of the human EAA3 receptor - Homo sapiens, 905 aa. [US6136544-A, 24-OCT-2000]	1..858 1..858	851/858 (99%) 851/858 (99%)	0.0
AAR75883	Human EAA3 receptor (Q-591) - Homo sapiens, 905 aa. [WO9517508-A2, 29-JUN-1995]	1..858 1..858	851/858 (99%) 851/858 (99%)	0.0

AAR60112	Human EAA3a excitatory amino acid receptor - Homo sapiens, 905 aa. [CA21 10933-A, 12-JUN-1994]	1..858 1..858	851/858 (99%) 851/858 (99%)	0.0
AAB19499	Amino acid sequence of the R591 form of the human EAA3 receptor - Homo sapiens, 905 aa. [US6136544-A, 24-OCT-2000]	1..858 1..858	850/858 (99%) 851/858 (99%)	0.0

In a BLAST search of public sequence databases, the NOV23a protein was found to have homology to the proteins shown in the BLASTP data in Table 23E.

5

Table 23E. Public BLASTP Results for NOV23a				
Protein Accession Number	Protein/Organism/Length	NOV23a Residues/ Match Residues	Identities/ Similarities for the Matched Portion	Expect Value
P39086	Glutamate receptor, ionotropic kainate 1 precursor (Glutamate receptor 5) (GLUR-5) (GluR5) (Excitatory amino acid receptor 3) (EAA3) - Homo sapiens (Human), 918 aa.	1..903 1..918	900/918 (98%) 900/918 (98%)	0.0
CAC80546	GLUTAMATE RECEPTOR SUBUNIT GLUR5 - Homo sapiens (Human), 905 aa.	1..858 1..858	852/858 (99%) 852/858 (99%)	0.0
P22756	Glutamate receptor, ionotropic kainate 1 precursor (Glutamate receptor 5) (GLUR-5) (GluR5) - Rattus norvegicus (Rat), 949 aa.	1..854 1..869	823/869 (94%) 838/869 (95%)	0.0
Q9DGM1	GLUTAMATE RECEPTOR 5 - Danio aequipinnatus (Giant danio) (Brachydanio aequipinnatus), 880 aa.	32..854 32..868	735/837 (87%) 789/837 (93%)	0.0
Q60934	Glutamate receptor, ionotropic kainate 1 precursor (Glutamate receptor 5) (GLUR-5) (GluR5) - Mus musculus (Mouse), 836 aa.	1..756 1..758	707/758 (93%) 727/758 (95%)	0.0

PFam analysis indicates that the NOV23a protein contains the domains shown in Table 23F.

Table 23F. Domain Analysis of NOV23a			
Pfam Domain	NOV23a Match Region	Identities/ Similarities for the Matched Region	Expect Value
ANF_receptor: domain 1 of 1	25..415	95/466 (20%) 351/466 (75%)	8.9e-114
SBP_bac_3: domain 1 of 1	434..801	46/425 (11%) 216/425 (51%)	0.79
lig_chan: domain 1 of 1	560..841	161/322 (50%) 272/322 (84%)	4.8e-161

**Example 24.**

The NOV24 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 24A.

Table 24A. NOV24 Sequence Analysis			
	SEQ ID NO: 81		1443 bp
NOV24a, CG93722-01 DNA Sequence	AGCATTACCCTACTCCTAGAGGGATTGTAGAGATTAGTGCCATCATCAAGGACTTCAA AGATGCCAGAGTGGCTAGATGCAATGGGTCTGCTCTGTAATCCCAACACTTTGGGAGG CCAAGGCAGGAGGATTGCTTGAGGTCAGGAGTTTGAGCTTGGGCAACATAGTGAGACT CTGCCTCTACAAAAAGTCTTTGAAAAAGATACCAGAGTGGTGATTCTCTAAAACATCC CCATTTAGTTTGCTATTTTGGCAGAAGACAGATGCATCTTGGAGAAGACTCCACTGCA CTTCCACCACCAGTGCACACACACATGGACCCAGCTGCACGTGCTGCCCTGCTACTGCT GGCACATGCACACGATTGTGGAACAGCACCGCTTAAGGATGTGTTGCAAGGGTCTCGG ATTATAGGGGGCACCAGAAGCACAAGCTGGCGCATGGCCGTGGGTGGTGAGCCTGCAGA TTAAATATGGCCGTGTTCTTGTTTCATGTATGTGGGGGAACCCTAGTGAGAGAGAGGTG GGTCTCTACAGCTGCCCACTGCACTAAAGACACTAGGTACGTATTCAGAACACAATA TTTAGCGCATCCTTTAATGTGGACAGCTGTGATTGGAACATAATAATACATGGACGCT ATCCTCATACCAAGAAGATAAAAAATTAAAGCAATCATTATTCATCCAACTTCATTTT GGAATCTTATGTAATGATATTGCACTTTTTCACTTAAAAAAGCAGTGAGGTATAAT GACTATATTCAGCCTATTTGCCTACCTTTTGATGTTTTCCAAATCCTGGACGGAAACA CAAAGTGTTTTATAAGTGGCTGGGGGAAGAACAAAGAAGAAGGTAATTTGCAGCCGCT TTGTTTACCTACTCAAGCCTCCGCAATGGTGTGCTCCAAGATAACTTACTGGTATTTT TTGTTAACAGGTACGCTACAAATATTTACAAGATGCAGAAGTGCATTATATTTCTC GAGAGATGTGTAATCTGAGAGGAGTTATGGGGGAATAATCCTAACACTTCATTTTG TGCAGGTGATGAAGATGGAGCTTTTGATACTTGCAGGGGTGACAGTGGGGGACCATT ATGTGCTACTTACCAGAATATAAAAGATTTTTTGTAAATGGGAATTACCAGTTACGGAC ATGGCTGTGGTGAAGAGGTTTTCTCTGGTGTCTATATTGGGCCATCCTTCTACCAAAA GTGGCTGACAGAGCATTTCTCCATGCAAGCACTCAAGGCATACTTACTATAAATATT TTACGTGGCCAGATCCTCATAGCTTTTATGTTTTGTGTCATCTTACTAGCAACAACATAAA GAAATTCTGAAGGCTTTCATATCTTTATTTGCATTGTGTCCCTTTCTATGTTCTATA TAATGAACATCATTTATTCTTCTAGCAATTAATTGCCTACATTAGAGATT		
	ORF Start: ATG at 77		ORF Stop: TAA at 1331
	SEQ ID NO: 82		418 aa      MW at 46709.8kD
NOV24a, CG93722-01	MQWVVPVIPTLWEAKAGGLLEVRSLSLGNIVRLCLYKSLKKDTRVVIPTSPFSLPI WQKTGSGWRRLLHCTSTTSAHTGPSCTAALLLLAHADCGTAPLKDVLQGSRIIGGTE		

Protein Sequence	AQAGAWPVVSLQIKYGRVLVHVCGGTLVRERWVLTAHCTKDTRYVFRTQLFSDPLM WTAVIGTNNIHGRYPHTKKIKIKAI I IHPNFILESYVNDIALFHLKAVRYNDYIQPI CLPFDVVFQILDGNTKCFISGWRTKEEGLQPLCLPTQASAMVCSKITWYFLLTGNA TNILQDAEVHYISREMCNSERSYGGII PNTSFCAGDEDEGAFDTCRGDSGGPLMCYLPE YKRFFVMGITSYGHGCGRRGFPVYIGPSFYQKWLTEHFFHASTQGILTINILRGQIL IALCFVILLATT
------------------	--

Further analysis of the NOV24a protein yielded the following properties shown in Table 24B.

Table 24B. Protein Sequence Properties NOV24a	
PSort analysis:	0.9325 probability located in endoplasmic reticulum (membrane); 0.6976 probability located in plasma membrane; 0.3200 probability located in microbody (peroxisome); 0.1900 probability located in Golgi body
SignalP analysis:	Cleavage site between residues 17 and 18

- 5 A search of the NOV24a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 24C.

Table 24C. Geneseq Results for NOV24a				
Geneseq Identifier	Protein/Organism/Length [Patent #, Date]	NOV24a Residues/ Match Residues	Identities/ Similarities for the Matched Region	Expect Value
AAU03900	Human protease-like polypeptide #2 - Homo sapiens, 348 aa. [WO200149864-A1, 12-JUL-2001]	92..418 59..348	288/327 (88%) 288/327 (88%)	e-168
AAU03901	Human protease-like polypeptide #3 - Homo sapiens, 288 aa. [WO200149864-A1, 12-JUL-2001]	96..418 3..288	284/323 (87%) 285/323 (87%)	e-166
AAU03899	Human protease-like polypeptide #1 - Homo sapiens, 217 aa. [WO200149864-A1, 12-JUL-2001]	174..418 1..217	217/245 (88%) 217/245 (88%)	e-126
AAW96812	A mouse serine protease called hepsin - Mus musculus, 416 aa. [WO9854307-A1, 03-DEC-1998]	56..397 62..414	119/398 (29%) 178/398 (43%)	4e-41
AAV43325	Mouse hepsin protein sequence - Mus musculus, 416 aa. [US5981830-A, 09-NOV-1999]	56..397 62..414	119/398 (29%) 178/398 (43%)	4e-41

- 10 In a BLAST search of public sequence databases, the NOV24a protein was found to have homology to the proteins shown in the BLASTP data in Table 24D.

Table 24D. Public BLASTP Results for NOV24a				
Protein Accession Number	Protein/Organism/Length	NOV24a Residues/ Match Residues	Identities/ Similarities for the Matched Portion	Expect Value
AAL50817	AIRWAY TRYPSIN-LIKE PROTEASE - Rattus norvegicus (Rat), 417 aa.	96..385 171..413	104/290 (35%) 146/290 (49%)	1e-42
Q29015	PREPROACROSIN - Sus sp, 415 aa.	85..383 4..283	116/318 (36%) 150/318 (46%)	2e-42
P08001	Acrosin precursor (EC 3.4.21.10) (53 kDa fucose-binding protein) - Sus scrofa (Pig), 415 aa.	85..383 4..283	116/318 (36%) 150/318 (46%)	2e-42
Q9QZ74	ADRENAL SECRETORY SERINE PROTEASE PRECURSOR - Rattus norvegicus (Rat), 279 aa.	96..385 33..275	104/290 (35%) 145/290 (49%)	3e-42
O35453	Serine protease hepsin (EC 3.4.21.-) - Mus musculus (Mouse), 416 aa.	84..397 139..414	104/324 (32%) 156/324 (48%)	2e-40

PFam analysis indicates that the NOV24a protein contains the domains shown in Table 24E.

Table 24E. Domain Analysis of NOV24a			
Pfam Domain	NOV24a Match Region	Identities/ Similarities for the Matched Region	Expect Value
trypsin: domain 1 of 2	111..263	67/174 (39%) 115/174 (66%)	1.2e-41
trypsin: domain 2 of 2	287..383	41/105 (39%) 72/105 (69%)	4.1e-25

5

#### Example 25.

The NOV25 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 25A.

Table 25A. NOV25 Sequence Analysis		
	SEQ ID NO: 83	2867 bp
NOV25a, CG93858-01 DNA Sequence	TCATTTTAGGGGCTCTGTTTTTCATCTCAGATTATTCTGTCTTGTAGCCCATGGTAACT GGAGTCCTTGGAGTGGCTGGGGAACATGCAGCCGGACGTGTAAACGGAGGGCAGATGCG GCGGTACCGCACATGTGATAACCTCCTCCCTCCAATGGGGGAAGAGCTTGTGGGGGA CCAGACTCCCAGATCCAGAGGTGCAACACTGACATGTGTCCTGTGGATGGAAGTTGGG GAAGCTGGCATAGTTGGAGCCAGTGCTCTGCCTCCTGTGGAGGAGGTGAAAAGACTCG	

	<p>GAAGCGGCTGTGCGACCATCCTGTGCCAGTTAAAGGTGGCCGTCCTTGTCCCGGAGAC  ACTACTCAGGTGACCAGGTGCAATGTACAAGCATGTCCAGGTGGGCCCCAGGAGCCA  GAGGAAGTGTTATTGGAAATATTAATGATGTTGAATTTGGAATTGCTTTCTTAATGC  CACAATACTGATAGCCCTAACTCTGATACTAGAATAATACGTGCCAAAATTACCAAT  GTACCTCGTAGTCCTGGTTTCAGCAATGAGAAAGATAGTTTCTATTCTAAATCCCATT  ATTGGACAACAGCAAAGGAAATAGGAGAAGCAGTCAATGGCTTTACCCTCACCAATGC  AGTCTTCAAAGAGAACTCAAGTGGAAATTTGCAACTGGAGAAATCTTGACAGATGAGT  CATATTGCCGGGGCTTGGATTCCGATGGTTCTTTGCTGCTAGATATCGTTGTGAGTG  GCTATGCTTACAGCTTCAGTCACCTGCTGAAGTCACTGTAAAGGATTACACAGAGGA  CTACATTCAAACAGGTCTGGGCGAGCTGTACGCCTACTCAACCCGGCTGTTACCATT  GATGGCATCAGCATCCCATACACATGGAACACACCGTTTTCTATGATCAGGCACAGG  GAAGAATGCCTTTCTGGTTGAAACACTTCATGCATCCTCTGTGGAATCTGACTATAA  CCAGATAGAAGAGACACTGGGTTTAAATTCATGCTTCAATATCCAAAGGAGATCGC  AGTAATCAGTGCCCTCCGGGTTTACCTTAGACTCAGTTGGACCTTTTTGTGCTGATG  AGGATGAATGTGCAGCAGGGAATCCCTGCTCCCATAGCTGCCACAATGCCATGGGGAC  TTACTACTGCTCCTGCCCTAAAGGCCTCACCATAGCTGCAGATGGAAGAACTTGTCAA  GATATTGATGAGTGTGCTTTGGGTAGGCATACCTGCCACGCTGGTCAGGACTGTGACA  ATACGATTGGATCTTATCGCTGTGTGGTCCGTTGTGGAAGTGGCTTTGGAAGAACCTC  TGATGGGCTGAGTTGTCAAGATATTAATGAATGTCAAGAATCCAGCCCCTGTCACCAG  CGCTGTTTCAATGCCATAGGAAGTTTCCATTGTGGATGTGAACCTGGGTATCAGCTCA  AAGGCAGAAAATGCATGGATGTGAACGAGTGTAGACAAAATGTATGCAGACCAGATCA  GCACTGTAAAGAACCCCGTGGTGGCTATAAGTGCATTGATCTTTGTCCAAATGGAATG  ACCAAGGCAGAAAATGGAACCTGTATTGATATTGATGAATGTAAGATGGGACCCATC  AGTGCAGATATAACAGATATGTGAGAATACAAGAGGCAGCTATCGTTGTGTATGCC  AAGAGGTTATCGGTCTCAAGGAGTTGGAAGACCCTGCATGGATATTGATGAATGTGAA  AATACAGATGCCTGCCAGCATGAGTGTGAAGAACCTTTGGAAGTTATCAGTGCATCT  GCCCACCTGGCTATCAACTCACACAAATGGAAAGACATGCCAAGATATCGATGAATG  TCTGGAGCAGAATGTGCACTGTGGACCCAATCGCATGTGCTTCAACATGAGAGGAAGC  TACCAGTGCATCGATACACCCTGTCCACCAACTACCAACGGGATCCTGTTTCAGGGT  TCTGCCCTCAAGAACTGTCCACCCAATGATTGGAATGTGCCTTGAGCCCATATGCCTT  GGAATACAACTCGTCTCCCTCCCATTGGAATAGCCACCAATCAAGATTTAATCCGG  CTGGTTGCATACACACAGGATGGAGTGTATGCCAGGACAACCTTTCCTCATGGTAG  ATGAGGAACAGACTGTTCTTTTGCCTTGAGGGATGAAAACCTGAAAGGAGTGGTGTA  TACAACAGGACCACTACGAGAAGCAGAGACCTACCGCATGAGGGTCCGAGCTCATCC  TACAGTGCCAATGGGACCAATTGAATATCAGACCACATTATAGTTTATATAGCTGTGT  CCGCCTATCCATACTAAGGAACCTCTCAAAGCCTATCCACATATTTAAACCGCATTA  ATCATGGCAATCAAGCCCCCTTCCAGATTACTGTCTCTTGAACAGTTGCAATCTTGGC  AGCTTGAATGTTGCTACACTCTGTTTGTGTGCCTTCTTGGTACTTCTGAGGTAT  TTTCATGATCCCACCATGGTCTATCTTGAAGTATGGTCTAGAAAAGTCCCTTATTAT  TTTATTTATTACACTGGAGCAGTTACTTCCCAAAGATTATTCTGAACATCTAAACAGGA  CATATCAGTGATGGTTTACAGTAGTGTAGTACCTAAGATCATTTTCTGAAAGCCAAA  CCAAACAACGAAAACAAGAACAATAATTGAGATCAAATAGAGTTTTTGTAGCATT  GACTATTTTGAATCATAAATTAGTTACTAAGTATTTGATCAAAGCTTATAAAAT  AACTTACGGAGATTTTGTAAAGTATTGATACATTATAATAGGACTTGCCTATTTTCAT  TTTTAAGAAGAAAAACCACTCAT</p>
	<div>ORF Start: ATG at 112</div> <div>ORF Stop: TAA at 2335</div>
	<div>SEQ ID NO: 84</div> <div>741 aa</div> <div>MW at 81868.0kD</div>
NOV25a, CG93858-01 Protein Sequence	<p>MRRYRTCDNPPPSNGGRACGGPDSQIQRCNTDMCPVDGWSGWSWSQCSASCGGGEK  TRKRLCDHPVPVKGRPCPGDITQVTRCNVQACPGGPQRARGSVIGNINDVEFGIAFL  NATITDSPNSDTRIIIRAKITNVPRSLGSAMRKIVSILNPIYWT TAKEIGEAVNGFTLT  NAVFKRETQVEFATGEILQMSHIARGLSDGSLLLDIVVSGYVLQLQSPAETVVKDYT  EDYIQTGPGQLYAYSTRIFTIDGISIPTYWNHTVFYDQAQGRMPFLVETLHASSVESD  YNQIEETLGFKIHASISKGRNSNQCPSGFTLDSVGPFCADEDECAAGNPCSHSCHNAM  GTYYCSCP KGLTIAADGRTCQDIDECALGRHTCHAGQDCDNTIGSYRCVVRCSGFRF  TSDGLSCQDINECQESSPCHQRCFNAIGSFHCGCEPGYQLKGRKCMDVNECRQNVCRP  DQHCKNTRGGYKCIDLCPNGMTKAENGTCIDIDECKDGHQCRYNQICENTRGSYRCV  CPRGYRSQGVGRPCMDIDECENTDACQHECKNTFGSYQCICPPGYQLTHNGKTCQDID  ECLEQNVHCGPNRMCFNMGRGSYQCIDTPCPNYQRDPVSGFCLKNCPNPLECALSPY  ALEYKLVSLPFGIATNQDLIRLVAYTQDGVMPRTTFLMVDEEQTVPFALRDENLKGV</p>



	VYTRPLREAETYRMRVRASSYSANGTIEYQTTFIVYIAVSAYPY	
	SEQ ID NO: 85	8243 bp
NOV25b, CG93858-02 DNA Sequence	GCAGAGTACAGTGGTTGGATTATATTTAGTAAATGGGAATATATGTTGATAACACCT GCTTTTCACTTTTAATATATTTACTATTATAGTTCCTCCAAGTGTCTATTGGTCTCTAAAT CTGAAAATCTTACCGTCGTGGTGAACAATTTTCATCTCTTTGACCTGTGAGGTCTCTGG TTTTCCACCTCCTGACCTCAGCTGGCTCAAGAATGAACAGCCCATCAAAGTGAACACA AATACTCTCATTTGTGCCTGGTGGTGAACCTCTACAGATTATTCGGGCCAAGGTATCAG ATGGTGGTGAATACACTTGTATAGCTATCAATCAAGCTGGCGAAAGCAAGAAAAAGTT TTCCCTGACTGTTATGTGCCCCAAGCATTAAAGACCATGACAGTGAATCTCTTTCT GTAGTTAATGTAAGAGAGGGAACTTCTGTGTCTTTGGAGTGTGAGTCGAACGCTGTGC CACCTCCAGTCATCACTTGGTATAAGAATGGGCGGATGATAACAGAGTCTACTCATGT GGAGATTTTAGCTGATGGACAAATGCTACACATTAAGAAAGCTGAGGTATCTGACACA GGCCAGTATGTATGTAGAGCTATAAATGTAGCAGGACGGGATGATAAAAATTTCCACC TCAATGTATATGTGCCACCCAGTATTGAAGGACCTGAAAGAGAAGTGATTGTGGAGAC GATCAGCAATCCTGTGACATTAACATGTGATGCCACTGGGATCCCACCTCCCACGATA GCATGGTTAAAGAACCACAAGCGCATAGAAAATTTCTGACTCACTGGAACTTCGTATTT TGTCTGGAGGTAGCAAACCTCCAGATTGCCCGGTCTCAGCATTGAGATGAGTGGAACTA TACATGTATTGCTTCAAATATGGAGGGAAAAGCCAGAAATATTACTTTCTTTCAATT CAAGTTCCTCCAAGTGTGCTGGTGTGAAATTCAGTGTATGTGAGTGTCTCTTAG GAGAAAATGTTGAGCTGGTCTGCAATGCAAATGGCATTCTCTACTCCACTTATTCATG GCTTAAAGATGGAAAGCCCATAGCTAGTGGTGAACAGAAAGAATCCGAGTGAAGTGA AATGGCAGCACATTAACATTTATGGAGCTCTTACATCTGACACGGGAAATACACAT GTGTTGCTACTAATCCCGCTGGAGAGAAGACCGAATTTTAACTTGAATGTCTATGT TACACCTACAATTAGGGGTAATAAGATGAAGCAGAGAACTAATGACTTTAGTGGAT ACTTCAATAAATATTGAATGCAGAGCCACAGGGACGCCTCCACCACAGATAAAGTGGC TGAAGAATGGACTTCCTCTGCCTCTCTCTCCCATATCCGGTTACTGGCAGCAGGACA AGTTATCAGGATTGTGAGAGCTCAGGTGTCTGATGTGCTGTATATCTGTGTGGCC TCCAACAGAGCTGGGGTGGATAAATAAGCATTACAATCTTCAAGTGTGTCACCACCAA ATATGGACAATTCAATGGGGACAGAGGAAATCACAGTTCTCAAAGGTAGTTCCACCTC TATGGCATGCATTACTGATGGAACCCAGCTCCAGTATGGCCTGGCTTAGAGATGGC CAGCCTCTGGGGCTTGATGCCCATCTGACAGTCAGCACCCATGGAATGGTCTGTCAGC TCCTCAAAGCAGAGACTGAAGATTCCGGAAAGTACACCTGCATTGCCTCAAATGAAGC TGGAGAAGTCAGCAAGCACTTTATCCTCAAGGTCTAGAACCACCTCAATTAATGGA TCTGAAGAACATGAAGAGATATCAGTAATTGTTAATAACCCACTTGAATTAACCTGCA TTGCTTCTGGAATCCCAGCCCTAAAATGACCTGGATGAAGATGGCCGGCCCCCTTCC ACAGACGGATCAAGTGCAACTCTAGGAGGAGGAGAGGTTCTTCAATTTCTACTGCT CAGGTGGAGGATACAGGAAGATATACATGTCTGGCATCCAGTCTGCAGGAGATGATG ATAAGGAATATCTAGTGAGAGTGCATGTACCTCCTAATATTGCTGGAACCTGATGAGCC CCGGGATATCACTGTGTTACGGAACAGACAAGTACATTGGAATGCAAGTCAGATGCA GTGCCCCACCTGTAATTACTTGGCTCAGAAATGGAGAACGGTTACAGGCAACACCTC GAGTGCGAATCCTATCTGGAGGGAGATACTTGCAATCAACAATGCTGACCTAGGTGA TACAGCCAATTATACCTGTGTTGCCAGCAACATTGCAGGAAAGACTACAAGAGAATTT ATTCTCACTGTAATGTTCTCCAAACATAAAGGGGGCCCCAGAGCCTTGTAATTC TTTTAAATAAGTCAACTGTATTGGAATGCATCGCTGAAGGTGTCCCAACTCCAAGGAT AACATGGAGAAAGGATGGAGCTGTTCTAGCTGGGAATCATGCAAGATATTCCATCTTG GAAAATGGATTCTTCATATTCAATCAGCACATGTCACTGACACTGGACGGTATTTGT GTATGGCCACCAATGCTGCTGGAACAGATCGCAGGCGAATAGATTTACAGGTCCATGT TCCTCCATCTATTGCTCCGGGTCTACCAACATGACTGTAATAGTAAATGTTCAAAC ACTCTGGCTGTGAGGCTACTGGGATACCAAAACCATCAATCAATTGGAGAAAAATG GGCATCTTCTTAATGTGGATCAAAATCAGAACTCATAAGGCTCCTTTCTCAGGTTT ACTAGTAATTATTTCCCTTCTGTGGATGACACTGCAACCTATGAATGTACTGTGACA AACGGTGTGGAGATGATAAAGAACTGTGGATCTCACTGTCCAAGTTCACCTTCCA TAGCTGATGAGCCTACAGATTTCTAGTAACCAACATGCCCCAGCAGTAATTACCTG CACTGCTTCGGGAGTTCATTTCCCTCAATTCAGTGGACCAAAATGGTATAAGACTG CTTCCCAGGGGAGATGGCTATAGAATTCTGTCTCAGGAGCAATTGAATACTTGCCA CCCAATTAAACCATGCTGGAAGATACACTTGTGTCGCTAGGAATGGGGTGGCTCTGC ACATCGACACGTGACCTTTCATGTTGATGAGCCTCAGTCATTGAGCCCCAACCAAGT GAACTACACGTCACTCTGAACAATCCTATTTTATTACCATGTGAAGCAACAGGGACAC CCAGTCTTTTCACTTGGCAAAAAGAGGCATCAATGTTAACAACCTTCAGGCAGAAA CCATGCGATTCTTCTAGTGGCGGCTTACAGATCTCCAGAGCTGTCGAGAGGATGCT	

GGCACCTTACATGTGTGTGGCCAGAACCCGGCTGGTACAGCCTTGGGCAAAATCAAGT  
 TAAATGTCCAAGTTCCTCCAGTCATTAGCCCTCATCTAAAGGAATATGTTATTGCTGT  
 GGACAAGCCCATCACGTTATCCTGTGAAGCAGATGGCCTCCCTCCGCTGACATTACA  
 TGGCATAAAGATGGGCGTGCAATTGTGGAATCTATCCGCCAGCGCTCCTCAGCTCTG  
 GCTCTCTGCAAATAACATTTGTCCAGCCTGGTGATGCTGGCCATTACAGTGCATGGC  
 AGCCAATGTAGCAGGATCAAGCAGCACAAAGCACCAGCTCACCCTCATGTACCACCC  
 AGGATCAGAAGTACAGAAGGACACTACACGGTCAATGAGAATTCACAAGCCATTCTTC  
 CATGCGTAGCTGATGGAATCCCCACACCAGCAATTAAGTGGAAAAAGACAATGTTCT  
 TTTAGCTAACTTGTTAGGAAAATACACTGCTGAACCATATGGAGAACTCATTTTAGAA  
 AATGTTGTGCTGGAGGATCTGGCTTCTATACCTGTGTGCTAACAAATGCTGCAGGTG  
 AAGATACACACACTGTGAGCCTGACTGTGCATGTTCTCCCCACTTTTACTGAACTTCC  
 TGGAGACGTGTCAATAATAAGGAGAACAGCTACGATTAAGCTGTAAAGCTACTGGT  
 ATTCCATTGCCCAAATTAACATGGACCTTCAATAACAATATTATTCAGCCCACTTTG  
 ACAGTGTGAATGGACACAGTGAAGTGTATTGAAAGAGTGTCAAAGAGGATTGAGG  
 TACTTATGTGTGCACCCGAGAGAACAGCGTTGGCTTTGTGAAGGCAATTGGATTGTG  
 TATGTGAAGAACCTCCAGTCTTCAAAGGTGATTATCCTTCTCACTGGATTGAACCA  
 TTGGTGGGAATGCAATCCTGAATTGTGAGGTGAAAGGAGACCCACCCCAACCATCCA  
 GTGGAACAGAAAGGAGTGGATATTGAAATTAGCCACAGAATCCGCAACTGGGCAAT  
 GGCTCCCTGGCCATCTATGGCACTGTTAATGAAGATGCCGGTGACTATACATGTGTAG  
 CTACCAATGAAGCTGGGGTGGTGGAGCGCAGCATGAGTCTGACTCTGCAAGTCTTCC  
 TATTATCACTCTTGAGCCAGTGGAACTGTTATTAATGCTGGTGGCAAAATCATATTG  
 AATTGTCAGGCAACTGGAGAGCCTCAACCAACCATTACATGGTCCCGTCAAGGGCACT  
 CTATTTCTGGGATGACCGGTTAAGCTGTTGTCCAACAACCTATTATATATTGCTGA  
 TGCTCAGAAAGAGATACCTCTGAATTTGAATGTGTTGCTCGAACTTAATGGGTTCT  
 GTCCTTGTGAGAGTGCCAGTCATAGTCCAGGTTGATGGTGGATTTTCCAGTGGTCTG  
 CATGGAGAGCCTGCAGTGTCACTGTGGAAGGCAATCCAAAAGAGGAGTCCGTCTGTG  
 CAACCAGCCCTTCCAGCAATGGTGGGAAGCCCTGCCAAGGTTGAGATTGGAAATG  
 CGAACTGTCAAATAAGCCTTGTCCAGTGGATGGTAGCTGGTGGGAATGGAGTCTTT  
 GGGAAAGATGCACAAGGAGCTGTGGACGCGGCAACCAACAGGACCAGGACTTGCAA  
 TAATCCATCAGTTCAGCATGGTGGGCGGCCATGTGAAGGAATGCTGTGGAATAATT  
 ATGTGCAACATTAGGCCTTGCCCAAGTTCATGGAGCATGGAGCGCTTGGCAGCCTTGGG  
 GAACATGCAGCGAAAGTTGTGGGAAGGTACTCAGACAAGAGCAAGACTTTGTAATAA  
 CCCACCACAGCGTTTGGTGGGTCTTACTGTGATGGAGCAGAAACAGATGCAAGTT  
 TGCAATGAAAGAAATTGTCCAGTTCATGGCAAGTGGGCGACTTGGGCGAGTGGAGTG  
 CCTGTTCTGTGTCATGTGGAGGAGTGCCAGACAGAGAACAAGGGGCTGCTCCGACCC  
 TGTGCCCCAGTATGGAGGAAGGAAATGCCAAGGAGTGTGTCAGAGTGAATTTTGC  
 AACAGTGACCTTGCCCAACCCATGGTAAGTGGAGTCTTGGAGTGGCTGGGGAACAT  
 GCAGCCGGACGTGTAACGGAGGGCAGATGCGGCGGTACCGCACATGTGATAACCTCC  
 TCCCTCCAATGGGGGAAGAGCTTGTGGGGGACCAGACTCCAGATCCAGAGGTGCAAC  
 ACTGACATGTGTCCTGTGGATGGAAGTTGGGGAGCTGGCATAGTTGGAGCCAGTGCT  
 CTGCCTCCTGTGGAGGAGGTGAAAGACTCGGAAGCGGCTGTGCGACCATCCTGTGCC  
 AGTTAAAGGTGGCGTCCCTGTCCCGGAGACACTACTCAGGTGACCAGGTGCAATGTA  
 CAAGCATGTCCAGTGGGCCCCAGCGAGCCAGAGGAAGTGTATTGGAAATATTAAATG  
 ATGTTGAATTTGGAATTGCTTTCCTTAATGCCACAATAACTGATAGCCCTAAGTCTGA  
 TACTAGAATAATACGTGCCAAAATTACCAATGTACCTCGTAGTCTTGGTTTCAAGATG  
 AGAAAGATAGTTTCTATTCTAAATCCCATTTATTGGACAACAGCAAAGGAAATAGGAG  
 AAGCAGTCAATGGCTTTACCTCACCATGCAGTCTTCAAAGAGAACTCAAGTGGAA  
 ATTTGCAACTGGAGAAATCTTGCAAGATGAGTCAATTTGCCCGGGGCTTGGATTCCGAT  
 GGTCTTTGCTGTAGATATCGTTGTGAGTGGCTATGTCTACAGCTTCACTCACCTG  
 CTGAAGTCACTGTAAAGGATTACACAGAGGACTACATTCAAACAGGTCTGGGCACT  
 GTACGCCTACTCAACCCGGCTGTTCAACATTGATGGCATCAGCATCCCATACACATGG  
 AACCACACCGTTTTCTATGATCAGGCACAGGGAAGAAATGCCTTTCTTGGTTGAAACAC  
 TTCATGCATCCTCTGTGGAATCTGACTATAACAGATAGAAGAGACACTGGGTTTTAA  
 AATTCAATGCTTCAATATCCAAAGGAGATCGCAGTAATCAGTGGCCCTCCGGGTTTACC  
 TTAGACTCAGTTGGACCTTTTGTGCTGATGAGGATGAATGTGCAGCAGGGAATCCCT  
 GCTCCCATAGCTGCCACAATGCCATGGGGACTTACTACTGCTCCTGCCCTAAAGGCCT  
 CACCATAGCTGCAGATGGAAGAACTGTCAAGATATTGATGAGTGTGCTTTGGGTAGG  
 CATACCTGCCACGCTGGTCAAGTGTGACAATACGATTGGATCTTATCGCTGTGTGG  
 TCCGTTGTGGAAGTGGCTTTGGAAGAACTCTGATGGGCTGAGTTGTCAAGATATTAA  
 TGAATGTCAAGAATCCAGCCCTGTCAACAGCGCTGTTTCAATGCCATAGGAAGTTTC  
 CATTGTGGATGTGAACCTGGGTATCAGCTCAAAGGCAGAAAATGCATGGATGTGAACG

	<p>AGTGTAGACAAAATGTATGCAGACCAGATCAGCACTGTAAGAACACCCGTGGTGGCTA  TAAGTGCATTGATCTTTGTCCAAATGGAATGACCAAGGCAGAAAATGGAACCTGTATT  GATATTGATGAATGTAAAGATGGGACCCATCAGTGCAGATATAACCAGATATGTGAGA  ATACAAGAGGCAGCTATCGTTGTGTATGCCCAGAGGTTATCGGTCTCAAGGAGTTGG  AAGACCCTGCATGGATATTGATGAATGTGAAAATACAGATGCCTGCCAGCATGAGTGT  AAGAATACCTTTGGAAGTTATCAGTGCATCTGCCCACCTGGCTATCAACTCACACACA  ATGGAAAGACATGCCAAGATATCGATGAATGTCTGGAGCAGAATGTGCACTGTGGACC  CAATCGCATGTGCTTCAACATGAGAGGAAGCTACCACTGCATCGATACACCCTGTCCA  CCCAACTACCAACGGGATCCTGTTTCAGGGTTCTGCCTCAAGAACTGCCACCAATG  ATTTGGAATGTGCCTTGAGCCCATATGCCTTGGAAATACAACTCGTCTCCCTCCATT  TGGAATAGCCACCAATCAAGATTTAATCCGGCTGGTTGCATACACACAGGATGGAGTG  ATGCATCCCAGGACAACCTTCTCATGGTAGATGAGGAACAGACTGTCCTTTTGCCT  TGAGGGATGAAAACCTGAAAGGAGTGGTGTATACAACACGACCACCTACGAGAAGCAGA  GACCTACCGCATGAGGGTCCGAGCCTCATCCTACAGTGCCAATGGGACCATTGAATAT  CAGACCACATTCATAGTTTATATAGCTGTGTCCGCCTATCCATACTAAGGAACTCTCC  AAAGCCTATTCCACATATTAAACCGCATTAAATCATGGCAATCAAGCCCCCTTCCAGA  TTACTGTCTCTTGAACAGTTGCAATCTTGGCAGCTTGAATGGTGTACACTCTGTT  TTGTGTGCCTTCTTGGTACTTCTGAGGTATTTTCATGATCCCACTGGTCATATCT  TGAAGTATGGTCTAGAAAAGTCCCTTATTATTTTATTATTACACTGGAGCAGTTACT  TCCCAAAGATTATTCTGAACATCTAACAGGACATATCAGTGATGGTTTACAGTAGTGT  AGTACCTAAGATCATTTTCTGAAAGCCAAACCAACCAACGAAAAACAGAACAATA  ATTGAGAATCAATAGAGTTTGTAGCATTTGACTATTTTGAATCATAAATTAGT  TACTAAGTATTTTGATCAAAGCTTATAAAATAACTTACGGAGAATTTTGAAGTATTG  ATACATT</p>
	<p>ORF Start: ATG at 44      ORF Stop: TAA at 7760</p>
	<p>SEQ ID NO: 86      2572 aa      MW at 279540.0kD</p>
<p>NOV25b, CG93858-02 Protein Sequence</p>	<p>MLITPAFTFNIFTIIVPPSVIGPKSENLTVVVNNFISLTCEVSGFPFPPDLISWLKNEQF  IKLNTNTLIVPGGRTLQIRAKVSDGGEYTCIAINQAGESKKKFSLVVPPPSIKDHD  SESLSVVNVREGTSVLECESNAVPPPVITWYKNGRMITESTHVEILADQMLHIKKA  EVSDTGQYVCRAINVAGRDDKNFHLNVVPPPSIEGPEREVIVETISNPVTLTCDATGI  PPPTIAWLKNHKRIENSLSLEVRILSGGSKLQIARSQHSQSDSGNYTCIASNMEGKAQKY  YFLSIQVPPSVAGAEIPSDVSVLLGENVELVCNANGIPTPLIQWLKDGKPIASGETER  IRVSANGSTLNIYALTSYTGKTCVATNPAGEEDRIFNLNVVYVPTIRGNKDEAEKL  MTLVDTISINIECRATGTPPQINWLKNGLPLPLSSHIRLLAAGQVIRIVRAQVSDVAV  YTCVASNRAGVDNKHYNLQVFAPPNMDNSMGTEETIVLKGSSSTSMACITDGTAPASMA  WLRDQPLGLDAHLTVSTHGMVLQLLKAETEDSGKYTCIASNEAGEVSKHFILKVLEP  PHINGSEEHEEISVIVNNPLELTCIASGIPAPKMTWMKDGRPLPQTDQVQTLGGGEVL  RISTAQVEDTGRTYCLASSPAGDDDDKEYLVVRVHVPVNIAGTDEPRDITVLRNRQVTLE  CKSDAVPPPVTWLRNGERLQATPRVRLSGGRYLQINNADLGDTANYTCVASNIAGK  TTREFILTVNVPVNIKGGPQSLVILLNKSTVLECIAEGVPTPRITWRKDGAVLAGNHA  RYSILENGFLHIQSAHVTDTGRYLCMATNAAGTDRRRIDLQVHVPPPSIAPGPTNMTVI  VNVQTLACEATGIPKPSINWRKNGHLLNVQDNQNSYRLLSSGSLVVISPSVDDTATY  ECTVTNGAGDDKRTVDLTQVPPPSIADEPTDFLVTKHAPAVITCTASGVFPFPIHWTK  NGIRLLPRGDGYRILSSGAIEILATQLNHAGRYTCVARNAAGSAHRHVLHVHEPPVI  QPQPSLHVILNPNILLPCEATGTPSPFITWQKEGINVNTSGRNHVLPSGGLQISRA  VREDAGTYMCVAQNPAAGTALGKIKLVQVPPVISPFLKEYVIAVDKPIITLSEADGLP  PPDITWHKDGRAIVESIRQVRLSSGSLQITFVQPGDAGHYTCMAANVAGSSSTSTKLT  VHVPPRIRSTEGHYTVNENSQAILPCVADGIPTPAINWKKDNVLLANLLGKYTAEPYG  ELILENVLEDSEGYTCVANNAAGEDTHTVSLTVHVLPTFTELPDVSLLNKGEQLRLS  CKATGIPLPKLTWTFNNNIIPAHFDVNGHSELVIERVSKEDSGTYVCTAENSVMGVK  AIGFVYVKEPPVFKGDYPHSHWIEPLGGNAILNCEVKGDPPTPIQWNRKGVDEIEISHRI  RQLGNGSLAIYGTVNEDAGDYTCVATNEAGVVERMSLTLSQSPPIITLEPVETVINAG  GKIILNCQATGEPQPTITWSRQGHISWDDRVNVLNNSLYIADAQKEDTSEFECVAR  NLMGSLVLRVPVIVQVHGGFSQWSAWRACSVTCGKGIQKRSRLCNQPLPANGGKPCQG  SDLEMRNCQNKPCPDGWSWSEWSLWEECTRSRGRNQTRTRTCNNPSVQHGGRPCGN  AVEIIMCNIRPCPVHGAWSAQWPWGTCSESCGKGTQTRARLCNNPPPAFGGSYCDGAE  TQMVCNERNCVHGKWATWASWSACSVSCGGGARQRTGCSDFVPVQYGGRKCEGSDV  QSDFCNSDPCPTHGNWSPWSGWGTCSTRTCNNGQMRRYRTCDNPPPSNGGRACGGPDSQ  IQRCDTMCVPDGSWSGWSHWSQCSASC GGGEKTRKRLCDHPVPVKGGRPCPGDTTQV</p>

	<p>TRCNVQACPGGPQRARSGVIGNINDVEFGIAFLNATITDSPNSDTRIIRAKITNVPRS  LGSAMRKIVSILNPIYWTTAKEIGEAVNGFTLTNAVFKRETQVEFATGEILQMSHIAR  GLDSDGSLLLDIVSGYVLQLQSPAETVKDYTEDYIQTGPGQLYAYSTRFLTIDGIS  IPYTNWHTVFYDQAQGRMPFLVETLHASSVESDYNQIEETLGFKIHASISKGDRSNQC  PSGFITLDSVGPFCADEDECAAGNPCSHSCHNAMGTYYCSCPGLTIAADGRTCCQDIDE  CALGRHTCHAGQDCDNTIGSYRCVVRCSGFRRTSDGLSCQDINEQESSPCHQRCFN  AIGSFHCGCEPGYQLKGRKCMDVNECRQNVCRPDQHCKNTRGGYKCIDLCPNGMTKAE  NGTCIDIDECKDGTQCRYNQICENTRGSYRCVCPRGYRSQGVGRPCMDIDECENTDA  CQHECKNTFGSYQCICPPGYQLTHNGKTCQDIDECLEQNVHCGPNRMCFNMGRGSYQCI  DTPCPPNYQRDPVSGFCLKNCPNDLECALSPYALEYKLVSLPFGIATNQDLIRLVAY  TQDGMVHPRTTFLMVDEEQVFPFALRDENLKGVVYTRPLREAETYMRVRASSYSAN  GTIEYQTTFIVYIAVSAYPY</p>	
	SEQ ID NO: 87	6343 bp
NOV25c, CG56914-03 DNA Sequence	<p>AACCACCTCACATTAATGGATCTGAAGAACATGAAGAGATATCAGTAATGTGTAATAA  CCCACTTGAACCTACCTGCATTGCTTCTGGAATCCAGCCCTAAATGACCTGGATG  AAAGATGGCCGGCCCCCTTCCACAGACGGATCAAGTGCAAACCTCTAGGAGGAGGAGAGG  TTCTTCGAATTTCTACTGCTCAGGTGGAGGATACAGGAAGATATACATGTCTGGCATC  CAGTCTCGCAGGAGATGATGATAAGGAATATCTAGTGAGAGTGATGTACCTCCTAAT  ATTGCTGGAACGTGATGAGCCCCGGGATATCACTGTGTTACGGAACAGACAAGTGACAT  TGGAATGCAAGTCAGATGCAGTGCCCCACCTGTAATTACTTGGCTCAGAAATGGAGA  ACGGTTACAGGCAACACCTCGAGTGCGAATCCTATCTGGAGGGAGATACTTGCAATC  AACAATGCTGACCTAGGTGATACAGCCAATTATACCTGTGTTGCCAGCAACATTCGAG  GAAAGACTACAAGAGAATTTATTCTCACTGTAAATGTTCCCTCAAACATAAAGGGGGG  CCCCCAGAGCCTTGTAATCTTTTAAATAAGTCAACTGTATTGGAATGCATCGCTGAA  GGTGTGCCAACTCCAAGGATAACATGGAGAAAGGATGGAGCTGTTCTAGCTGGGAATC  ATGCAAGATATTCCATCTTGGAATGGATTCCCTCATATTCAATCAGCACATGTAC  TGACACTGGACGGTATTTGTGTATGGCCACCAATGCTGCTGGAACAGATCGCAGGCGA  ATAGATTTACAGTCCATGGTTCACTAGTAATTTATTTCCCTTCTGTGGATGACACTG  CAACCTATGAATGTACTGTGACAAACGGTGCTGGAGATGATAAAAGAACTGTGGATCT  CACTGTCCAAGTTCACCTTCCATAGCTGATGAGCCTACAGATTTCTAGTAACCAAA  CATGCCCCAGCAGTAATTACTGCACTGCTTCGGGAGTTCCATTTCCCTCAATTCACT  GGACCAAAAATGGTATAAGACTGCTTCCAGGGGAGATGGCTATAGAATTCTGTCTC  AGGAGCAATTGAAATACTTGCCACCCAATTAAACCATGCTGGAAGATACACTTGTGTC  GCTAGGAATGCGGCTGGCTCTGCACATCGACACGTGACCTTCATGTTCTAGGCCTC  CAGTCATTGAGCCCCAACCAAGTGAACACACGTCATTCTGAACAATCCTATTTTATT  ACCATGTGAAGCAACAGGGACACCCAGTCTTTTCACTTACTTGCAAAAAGAGGCATC  AATGTTAACACTTCAGGCAGAAACCATGCACTTCTTCTAGTGGCGGCTTACAGATCT  CCAGAGCTGTCCGAGAGGATGCTGGCACTTACATGTGTGTGGCCAGAACCCGGCTGG  TACAGCCTTGCGCAAAATCAAGTTAAATGTCCAAGTTCTCCAGTCACTTAGCCCTCAT  CTAAAGGAATATGTTATTGTGTGGACAAGCCCATCAGTTATCCTGTGAAGCAGATG  GCCTCCCTCCGCTGACATTACATGGCATAAAGATGGCGTGCAATTGTGGAATCTAT  CCGCCAGCGCTCCTCAGCTCTGGCTCTCTGCAAATAGCATTGTCCAGCTGGTGAT  GCTGGCCATTACACGTGCATGGCAGCCAATGTAGCAGGATCAAGCAGCACAAAGCACA  AGCTCACCGTCCATGTACCAACCCAGGATCAGAAGTACAGAAGGACACTACACGGTCAA  TGAGAAATCACAAGCCATTCTTCCATGCGTAGCTGATGGAATCCCCACACCAGCAATT  AACTGGAAAAAGACAATGTTCTTTTAGCTAACTGTGTAGGAAAATACACTGCTGAAC  CATATGGAGAATCATTTTAGAAAATGTGTGCTGGAGGATTCTGGCTTCTATACCTG  TGTGTCTAAATGCTGCAAGTGAAGATACACACACTGTCAGCCTGACTGTGCATGTT  CTCCCCACTTTTACTGAACCTCTGGAGACGTGTCATTAAATAAAGGAGAACAGCTAC  GATTAAGCTGTAAAGCTACTGGTATTCCATTGCCCAAATTAACATGGACCTTCAATAA  CAATATTATTCCAGCCCACTTTGACAGTGTGAATGGACACAGTGAACCTGTTATTGAA  AGAGTGTCAAAGAGGATTACAGTACTTATGTGTGCACCGCAGAGAACAGCGTTGGCT  TTGTGAAGCAATTGGATTTGTTTATGTGAAAGAACCTCCAGTCTTCAAAGGTGATTA  TCCTTCTAACTGGATTGAACCACTTGGTGGGAATGCAATCCTGAATTGTGAGGTGAAA  GGAGACCCCAACCAACCATCCAGTGGAACAGAAAGGGAGTGGATTTGAAATTAGCC  ACAGAATCCGGCACTGGGCAATGGCTCCCTGGCCATCTATGGCACTGTTAATGAAGA  TGCCGGTGACTATACATGTGTAGCTACCAATGAAGCTGGGGTGGTGGAGCCGAGCATG  AGTCTGACTCTGCAAAGTCTCTATTATCACTCTTGAGCCAGTGGAACCTGTTATTA  ATGCTGGTGGCAAAATCATATTGAATTGTCAGGCACTGGAGAGCCTCAACCAACCAT  TACATGGTCCCGTCAAGGGCACTTATTCTGGGATGACCGGTTAACGTGTTGTCT</p>	

AACAACTCATTATATATTGCTGATGCTCAGAAAGAAGATACCTCTGAATTTGAATGCG  
 TTGCTCGAAACTTAATGGGTTCTGTCTTGTGAGAGTGCCAGTCATAGTCCAGGTTCA  
 TGGTGGATTTTCCAGTGGTCTGTCATGGAGAGCCTGCAGTGTACCTGTGGAAAAGGC  
 ATCCAAAAGAGGAGTCTGTGCAACCAGCCCTTCCAGCCAATGGTGGGAAGCCCT  
 GCCAAGGTTTCAGATTTGGAAATGCGAAACTGTCAAATAGCCTTGTCCAGTGGATGG  
 TAGCTGGTCGGAATGGAGTCTTTGGGAAGAATGCACAAGGAGCTGTGGACGCGGCAAC  
 CAAACCAGGACCAGGACTTGCAATAATCCATCAGTTCAGCATGGTGGGCGGCCATGTG  
 AAGGGAATGCTGTGGAAATAATTATGTGCAACATTAGGCCTTGCCCAAGTTCATGGAGC  
 ATGGAGCGCTTGGCAGCCTTGGGGAACATGCAGCGAAAGTTGTGGGAAGGTACTCAG  
 ACAAGAGCAAGACTTTGTAATAACCACCAGCAGCTTGGTGGGTCTACTGTGATG  
 GAGCAGAAACACAGATGCAAGTTTGCAATGAAAGAAATTTGCCAATTCATGGCAAGTG  
 GCGGACTTGGGCCAGTTGGAGTGCCTGTTCTGTGTCTGTGGAGGAGGTGCCAGACAG  
 AGAACAAAGGGGCTGCTCCGACCCTGTGCCCAAGTATGGAGGAAGGAAATGCGAAGGA  
 GTGATGTCCAGAGTGATTTTGCAACAGTGACCCTTGCCCAACCCATGGTAAGTGGAG  
 TCCTTGGAGTGGCTGGGGAACATGCAGCCGACGTGTAACGGAGGGCAGATGCGCGCG  
 TACCGCACATGTGATAACCCTCCTCCCTCCAATGGGGGAAGAGCTTGTGGGGGACCAG  
 ACTCCAGATCCAGAGGTGCAACACTGACATGTGTCTGTGGATGGAAGTTGGGGAAG  
 CTGGCATAGTTGGAGCCAGTGTCTGCCTCCTGTGGAGGAGGTGAAAGACTCGGAAG  
 CGGCTGTGCGACCATCCTGTGCCAGTTAAAGGTGGCCGTCTTGTCCCGGAGACACTA  
 CTCAGGTGACCAGGTGCAATGTACAAGCATGTCCAGGTGGGCCCCAGCGAGCCAGAGG  
 AAGTGTATTGGAAATATTAATGATGTTGAATTTGGAATTTGCTTTCTTAATGCCACA  
 ATAACGTATAGCCCTAACTCTGATACTAGAATAATACGTGCCAAAATTACCAATGTAC  
 CTCGTAGTCTTGGTTGAGCAATGAGAAAGATAGTTTCTATTCTAAATCCCATTTATTG  
 GACAAACAGCAAAGGAAATAGGAGAAGCAGTCAATGGCTTTACCCTCACCAATGCAGTC  
 TTCAAAAGAGAACTCAAGTGAATTTGCAACTGGAGAAATCTTGCAAGTGAATCATA  
 TTGCCCGGGGCTTGGATTCCGATGGTTCTTTGTCTGCTAGATATCGTTGTGAGTGGCTA  
 TGTCTTACAGCTTCAGTCACCTGCTGAAGTCACTGTAAAGGATTACACAGAGGACTAC  
 ATTCAAACAGGTCTTGGGAGCTGTACGCCTACTCAACCCGGCTGTTACCATTGATG  
 GCATCAGCATCCCATACATGGAACACACCCGTTTCTATGATCAGGCACAGGGAAG  
 AATGCCTTTCTTGGTTGAAACACTTCATGCATCCTCTGTGGAATCTGACTATAACCAG  
 ATAGAAGAGACACTGGGTTTTAAATTCATGCTTCAATATCCAAAGGAGATCGCAGTA  
 ATCAGTGCCCTCCGGGTTTACCTTAGACTCAGTTGGACCTTTTGTGCTGATGAGGA  
 TGAATGTGCAGCAGGGAATCCCTGCTCCCATAGCTGCCACAATGCCATGGGGACTTAC  
 TACTGCTCCTGCCCTAAAGGCCTCACCATAGCTGCAGATGGAAGAATCTGTCAAGATA  
 TTGATGAGTGTGCTTTGGGTAGGCATACCTGCCACGCTGGTCAGGACTGTGACAATAC  
 GATTGGATCTTATCGCTGTGTGGTCCGTTGTGGAAGTGGCTTTGGAAGACCTCTGAT  
 GGGCTGAGTTGTCAAGATATTAATGAATGTCAAGAATCCAGCCCCTGTACCAGCGCT  
 GTTTCAATGCCATAGGAAGTTTCATTGTGGATGTGAACCTGGGTATCAGCTCAAAGG  
 CAGAAAATGCATGGATGTGAACGAGTGTAGACAAAATGTATGCAGCCAGATCAGCAC  
 TGTAAGAACACCCGTTGGTGGCTATAAGTGCAATGATCTTTGTCCAAATGGAATGACCA  
 AGGCAGAAAATGGAACCTGTATTGATATTGATGAATGTAAAGATGGGACCCATCAGTG  
 CAGATATAACCAGATATGTGAGAATACAAGAGGCAGCTATCGTTGTGTATGCCCAAGA  
 GGTATCGGTCTCAAGGAGTTGGAAGACCTGTCATGGATATTGATGAATGTGAAAATA  
 CAGATGCCTGCCTGCATGAGTGTGAAGAATACCTTTGGAAGTTATCAGTGCATCTGCCC  
 ACCTGGCTATCAACTCACACACAATGGAAAGACATGCCAAGATATCGATGAATGTCTG  
 GAGCAGAATGTGCACTGTGGACCCAATCGCATGTGCTTCAACATGAGAGGAAGCTACC  
 AGTGCATCGATACACCTGTCCACCCAATACCAACGGGATCCTGCTCAGGGTTCTG  
 CCTCAAGAACTGTCCACCCAATGATTGGAATGTGCCTTGAGCCCATATGCCTTGGA  
 TACAACTCGTCTCCCTCCCATTTGGAATAGCCACCAATCAAGATTTAATCCGGCTGG  
 TTGCATACACACAGGATGGAGTGCATCCAGGACAACCTTCTCATGGTAGATGA  
 GGAACAGACTGTTCTTTTGCCTTGAGGGATGAAAACCTGAAAGGAGTGGTGTATACA  
 ACACGACCACTACGAGAAGCAGAGACCTACCGCATGAGGGTCCGAGCCTCATCTTACA  
 GTGCCAATGGGACCATTGAATATCAGACCACATTCATAGTTTATATAGCTGTGTCCGC  
 CTATCCATACTAAGGAACCTCCAAAGCCTATTCCACATATTTAAACCGCATTAATCA  
 TGGCAATCAAGCCCCCTTCCAGATTACTGTCTCTTGAACAGTTGCAATCTTGGCAGCT  
 TGAAAATGGTGCTACACTCTGTTTTGTGTGCTTCTTGGTACTTCTGAGGTATTTTC  
 ATGATCCCACTGGTCATATCTTGAAGTATGGTCTAGAAAAGTCCCTTATTATTTTA  
 TTTATTACACTGGAGCAGTTACTTCCCAAAGATTATTCTGAACATCTAACAGGACATA  
 TCAGTGATGGTTTACAGTAGTGTAGTACCTAAGATCATTTTCTGAAAGCCAAACCAA  
 ACAACGAAAAACAAGAACAATAATTGAGAATCAAATAGAGTTTTTGTAGCATTTGACT  
 ATTTTGAATCATAAAATTAGTTACTAAGTATTTGATCAAAGCTTATAAAATAACT

	TACGGAGATTTTGTAAAGTATTGATACATTATAATAGGACTTGCCATTTTCATTTT AAGAAGAAAAACACCACTCAT		
	ORF Start: ATG at 105	ORF Stop: TAA at 5811	
	SEQ ID NO: 88	1902 aa	MW at 207163.2kD
NOV25c, CG56914-03 Protein Sequence	MTWMKDGRLPQTDQVQTLGGGEVLRISTAQVEDTGRYTCLASSPAGDDKEYLVRVH VPPNIAGTDEPRDITVLRNRQVLTLECKSDAVPPPVITWLRNGERLQATPRVRILSGGR YLQINNADLGDTANYTCVASNIAGKTTREFILTVNPPNIKGGPQSLVILLNKSTVLE CIAEGVPTPRITWRKDGAVLAGNHARYSILENGFLHIQSAHVTDGTGRYLCMATNAAGT DRRRIDLQVHGLSVIISPSVDDTATYECTVTNGAGDDKRTVDLTQVPPSIADPTDF LVTKHAPAVITCTASGVPPFSIHWTKNIGIRLLPRGDGYRILSSGAIEIATQLNHAGR YTCVARNAAGSAHRHVTLHVHEPPVIQPPSELHVILNPNILLPCEATGTPSPFITWQ KEGINVNTSGRNHAVLPSSGGLQISRAVREDAGTYMCVAQNPAQTALGKIKLVQVPPV ISPHLKEYVIAVDKPITLSCADGLPPPDITWHKDGRAIVESIRQVRLSSGSLQIAFV QPGDAGHYTCMAANVAGSSSTSTKLTVHVPPRIRSTEGHYTVNENSQAILPCVADGIP TPAINWKKDNVLLANLLGKYTAEPYGEILILENVVLEDSGFYTCVANNAAGEDTHTVSL TVHVLPTFTELPGDVSLNKGEQLRLSCKATGIPLPKLTWTFNNNIIPAHFDSVNGHSE LVIERVSKEDSGTYVCTAENSVGFVKAIGFVYVKEPPVFKGDYPSNWIPEPLGGNAILN CEVKGDPPTPTIQWNRKGVDIETSHRIRQLGNGSLAIYGTVNEDAGDYTCVATNEAGVV ERSMSLTLSQSPPIITLEPVEVTINAGGKII LNCQATGEPQPTITWSRQHSISWDDRV NVLSNNSLYIADAQKEDTSEFECVARNLMGSLVLRVPVIVQVHGGFSQWSAWRACSVT CGKGIQKRSRLCNQPLPANGKPCQGS DLEMRNCQNKPCPVDGWSWESLWEECTRSC GRGNQTRTRTCNNPSVQHGGRPCEGNAVEIIMCNIRPCPVHGAWSAQWPWGTCSESCG KGTQTRARLCNNPPPAFGGSYCDGAETQMVCNERNCPIHGKWATWASWSACSVCSCG GARQTRRGCSDPVPQYGGRKCEGSDVQSDFCNSDPCPTHGNWSPWSWGTCSTCNGG QMRRYRTCNDPPPSNGGRACGGPDSQIQRCDTMCVPDGSWGSWSQCSASCSCGGE KTRKRLCDHPVPVKGGRPCPGD TTQVTRCNVQACPGGPQRARGSVIGNINDVEFGIAF LNATITDSPNSDTRIIRAKITNVPRSLGSAMRKIVSILNPIYWT TAKEIGEAVNGFTL TNAVFKRETQVEFATGEILQMSHIARGLDSDGSLLLDIVVSGYVLQLQSPA EVTVKDY TEDYIQTGPGQLYAYSTRFLTIDGISIPYTNHTVFDQAQGRMPFLVETLHASSVES DYNQIEETLGFKIHASISKDRSNQCPSGFTLDSVGFPCADEDECAAGNPCSHSCHNA MGTYYCSCPKGLTIAADGRTQDIDECALGRHTCHAGQDCDNTIGSYRCVVRCGSGFR RTSDGLSCQDINECQESSPCHQRCFNAIGSFHCGCEPGYQLKGRKCMDVNECRQNVCR PDQHCKNTRGGYKCIDLCPNGMTKAENGTCIDIDECKDGT HQCRYNQICENTRGSYRC VCPRGYSQGVGRPCMDIDECENTDACLHECKNTFGSYQCICPPGYQLTHNGKTCQDI DECLEQNVHCGPNRMCFNMRGSYQCIDTPCPPNYQRDPASGFC LKNCPPNDLECALSP YALEYKLVSLPFGIATNQDLIRLVAYTQDGMHPRTTFLMVDEEQTVFPALRDENLKG VVYTTTRPLREAETYRMRVRASSYSANGTIEYQTTFIVYIAVSAYPY		

Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 25B.

Table 25B. Comparison of NOV25a against NOV25b and NOV25c.		
Protein Sequence	NOV25a Residues/ Match Residues	Identities/ Similarities for the Matched Region
NOV25b	1..741 1832..2572	730/741 (98%) 730/741 (98%)
NOV25c	1..741 1162..1902	728/741 (98%) 728/741 (98%)

5

Further analysis of the NOV25a protein yielded the following properties shown in Table 25C.

<b>Table 25C. Protein Sequence Properties NOV25a</b>	
PSort analysis:	0.6500 probability located in cytoplasm; 0.1000 probability located in mitochondrial matrix space; 0.1000 probability located in lysosome (lumen); 0.0000 probability located in endoplasmic reticulum (membrane)
SignalP analysis:	No Known Signal Sequence

A search of the NOV25a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 25D.

5

<b>Table 25D. Geneseq Results for NOV25a</b>				
<b>Geneseq Identifier</b>	<b>Protein/Organism/Length [Patent #, Date]</b>	<b>NOV25a Residues/ Match Residues</b>	<b>Identities/ Similarities for the Matched Region</b>	<b>Expect Value</b>
AAB95002	Human protein sequence SEQ ID NO:16644 - Homo sapiens, 741 aa. [EP1074617-A2, 07-FEB-2001]	1..741 1..741	741/741 (100%) 741/741 (100%)	0.0
AAU16959	Human novel secreted protein, SEQ ID 200 - Homo sapiens, 877 aa. [WO200155441-A2, 02-AUG-2001]	1..741 137..877	741/741 (100%) 741/741 (100%)	0.0
AAG67241	Amino acid sequence of human thrombospondin 1-like protein - Homo sapiens, 780 aa. [WO200109321-A1, 08-FEB-2001]	1..741 40..780	741/741 (100%) 741/741 (100%)	0.0
AAG67244	Amino acid sequence of murine thrombospondin 1-like protein - Mus musculus, 1068 aa. [WO200109321-A1, 08-FEB-2001]	1..741 328..1068	673/741 (90%) 707/741 (94%)	0.0
AAG67243	Amino acid sequence of murine thrombospondin 1-like protein - Mus musculus, 744 aa. [WO200109321-A1, 08-FEB-2001]	1..741 4..744	673/741 (90%) 707/741 (94%)	0.0

In a BLAST search of public sequence databases, the NOV25a protein was found to have homology to the proteins shown in the BLASTP data in Table 25E.

10

Table 25E. Public BLASTP Results for NOV25a				
Protein Accession Number	Protein/Organism/Length	NOV25a Residues/ Match Residues	Identities/ Similarities for the Matched Portion	Expect Value
Q96K89	CDNA FLJ14438 FIS, CLONE HEMBB1000317, WEAKLY SIMILAR TO FIBULIN-1, ISOFORM D PRECURSOR - Homo sapiens (Human), 741 aa.	1..741 1..741	741/741 (100%) 741/741 (100%)	0.0
Q96SC3	FIBULIN-6 - Homo sapiens (Human), 2673 aa (fragment).	1..580 1816..2396	559/581 (96%) 567/581 (97%)	0.0
Q96RW7	HEMICENTIN - Homo sapiens (Human), 5636 aa.	1..580 4779..5359	559/581 (96%) 566/581 (97%)	0.0
Q95NZ3	F56H11.1B PROTEIN - Caenorhabditis elegans, 689 aa.	311..741 223..689	160/480 (33%) 224/480 (46%)	4e-62
Q9TZS1	FIBULIN-1D - Caenorhabditis elegans, 589 aa (fragment).	311..741 123..589	160/480 (33%) 224/480 (46%)	4e-62

Pfam analysis indicates that the NOV25a protein contains the domains shown in Table 25F.

Table 25F. Domain Analysis of NOV25a			
Pfam Domain	NOV25a Match Region	Identities/ Similarities for the Matched Region	Expect Value
tsp_1: domain 1 of 1	41..91	23/54 (43%) 39/54 (72%)	6.7e-13
EGF: domain 1 of 7	334..368	16/47 (34%) 25/47 (53%)	8.4e-06
granulin: domain 1 of 1	355..370	7/16 (44%) 11/16 (69%)	4.2
EGF: domain 2 of 7	374..413	14/48 (29%) 25/48 (52%)	2
EGF: domain 3 of 7	419..451	12/47 (26%) 24/47 (51%)	0.0045
EGF: domain 4 of 7	457..493	14/47 (30%) 24/47 (51%)	13
TILa: domain 1 of 1	467..522	20/62 (32%) 32/62 (52%)	7.7



Keratin_B2: domain 1 of 1	383..525	34/191 (18%) 70/191 (37%)	8.7
EGF: domain 5 of 7	499..536	14/47 (30%) 28/47 (60%)	0.0013
EGF: domain 6 of 7	542..576	17/47 (36%) 28/47 (60%)	1.3e-07
EGF: domain 7 of 7	582..622	13/49 (27%) 26/49 (53%)	17
fn2: domain 1 of 1	611..622	7/12 (58%) 8/12 (67%)	7.8
cadherin: domain 1 of 1	643..735	15/107 (14%) 54/107 (50%)	5.2

**Example 26.**

The NOV26 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 26A.

5

Table 26A. NOV26 Sequence Analysis		
	SEQ ID NO: 89	2018 bp
NOV26a, CG93871-01 DNA Sequence	CTCCTCACGGCGCCAGGAGAGGGGCGAGGGCCGGCAGCCCCCTCTCCCGCGCGCGGC GCAGGAGCCGAGCCAGCCCGGGGACCCGCGCGCGCGGTATGTGGGCGGACTGC TCCTTCGGGCGCCTGTGTGCGCTCCTGCTGCCGGGGGACAGCCCGAGGCTACAC CGGGAGGAAGCCCGCCGGGCACTTCGCGGCCGAGAGGCGCCGACTGGGCCCCACGTC TGCCTCTCTGGGTTTGGGAGTGGCTGCTGCCCTGGCTGGGCGCCCTCTATGGGTGGT GGCCTGACACCTGCGTCTCTGCTCCTTCGGCTGTGGGAGTGGCATCTGCATCGCTCC CAATGTCTGCTCCTGCCAGGATGGAGAGCAAGGGCCACCTGCCAGAAACCATGGA CCATGTGGGAGTACGGCTGTGACCTTACCTGCAACCATGGAGGCTGTGAGGAGTGG CCCGAGTGTGCCCGTGGGCTTCTCGATGACGGAGACAGCTGTTGGCATCAGGTGTGA CATTGACGAATGTGTAACCTCCTCCTGCGAGGGCCACTGTGTGAACACAGAAGTGGG TTTGTGTGCGAGTGTGGGCGGGCATGCAGCTGTCTGCCGACCGCCACAGCTGCCAAG ACACTGACGAATGCCTAGGACTCCCTGTGAGCAGAGATGTAAAAACAGCATTGGCAG CTACAAGTGTCTGTGCAACTGGCTTCCACCTTCATGGCAACCGGCACTCCTGTGTA GATGTAAACGAGTGTGCGAGGCCATTGGAGAGGCGAGTCTGTACCATTCTGCCACA ACACCGTGGGCAGCTTCTATGCACATGCCGACCTGGCTTCAGGCTCCGAGCTGACCG CGTGTCTGTGAAGCTTTCCCGAAAGCCGTGCTGGCCCCATCTGCCATCCTGCAACCC CGGCAACACCCGTCCAAGATGCTTCTGTGCTTCTGAGGCCGGCCGGCTGCCCTGT CCCCAGGACATAGCCCTCCTTCTGGGGCTCCAGGGCCCCAGCCGAGTCAGGACCAC CCGCCTGCCATCTCCACCCACGACTACCCACATCCTCCCTTCTGCCCTGTGTGG CTGCTGTCCACCTGCTGGCCACCCAGTGCCTACTGCCTCCCTGCTGGGGAACCTCA GACCCCTCTACTCCTTCAGGGGAGGTGATGGGGACCCCTTCTCACCAGGGGGCC TGAGTCCCCCGACTGGCAGCAGGGCCCTCTCCCTGCTGGCACCTGGGAGCCATGCAT GAATCAAGGAGTCGCTGGACAGAGCCTGGGTGTTCCAGTGTGGTGGCAGGATGGGA AGGTGACCTGTGAAAAGGTGAGGTGTGAAGCTGCTTGTTCACCCCAATTCCCTCCAG AGATGGTGGGTGCTGCCATCGTGCACAGGTTGTTTTCACAGTGGTGTCTGCCAGCT GAAGGGGATGTGTTTTACCTCCCAATGAGAACTGCACCGTCTGTGTCTGTCTGGCTG GAAACGTGTCGTGCATGTTTCGTGAGTGTCTTTTGGCCCGTGTGAGACCCCCATAA AGACAGATGCTATTCCACGGCCGGTGTACGCAGACGGGGCTGTGTTCAAGTGGGGT GGTGACGAGTGTACCACTGTGTTTGCCAGAATGGGAGGTGGAGTGCTCCTTCATGC CCTGCCCTGAGCTGGCCTGCCCCGAGAAGAGTGGCGGCTGGGCCCTGGGCAGTGTG	

	CTTCACCTGCCAGGAGCCACACCCTCGACAGGTTGCTCTCTTGACGACAACGGGGTT GAGTTTCCGATTGGACAGATCTGGTCGCCTGGTGACCCCTGTAGATGGCTCGGTGAGC TGCAAGAGGACAGACTGTGTGGACTCCTGCCCTACCCGATCCGGATCCCTGGACAGT GCTGCCCAGACTGTTTCAGCAGGTAATCCCCTGCCTCTGCCCAAGCCCCAGGGCAGG GCATCTCAGGCATCGGGCTCCTTAAGCCCTATACAGCCTTCATCTC		
	ORF Start: ATG at 101	ORF Stop: TAA at 1937	
	SEQ ID NO: 90	612 aa	MW at 65156.4kD
NOV26a, CG93871-01 Protein Sequence	MWAGLLRAACVALLLPAGAPARGYTGRKPPGHFAAERRRLGPHVCLSGFGSGCCPGWA PSMGGGHCTLR LCSFGCGSGICIAPNVSCQDGEQGATCPETHGPCGEYGC DLTCNHG GCQEVARVCPVGF SMTETAVGIRCDIDECVTSSCEGHCVNTEGGFVCECGPGMQLSAD RHSCQDTDECLGTPCQQRCKNSIGSYKSCRTGFHLHGNRHSCVDVNECRRPLERRVC HHSCHNTVGSFLCTCRPGFRLRADRVSCFAFPKAVLAPSAILQPRQHPSKMLLLLPEA GRPALSPGHSPSGAGPPAGVTRTLRPSPTPRLPSTSSPSAPVWLLSTLLATPVPTAS LLGNLRPPSLLQGEVMGTPSSPRGPESPRLAAGSPCWHLGAMHESRSRWTEPGCSQC WCEDGKVTCEKVRCEAACSHPIPSRDGGCCPSTGCFHSGVVRAEGDVFSPNENCTV CVCLAGNVSCMFPRECFPGCETPHKDRCYFHGRWYADGAVFSGGGDECTTCVCQNGEV ECSFMPCELACPREEWRLGPGQCCFTCQEPTPSTGCSLDDNGVEFFIGQIWSPGDPC RWLGELQEDRLCGLLPSPDPDPWTVLRLFSR		

Further analysis of the NOV26a protein yielded the following properties shown in Table 26B.

Table 26B. Protein Sequence Properties NOV26a	
PSort analysis:	0.5947 probability located in outside; 0.1900 probability located in lysosome (lumen); 0.1000 probability located in endoplasmic reticulum (membrane); 0.1000 probability located in endoplasmic reticulum (lumen)
SignalP analysis:	Cleavage site between residues 22 and 23

- 5 A search of the NOV26a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 26C.

Table 26C. Geneseq Results for NOV26a				
Geneseq Identifier	Protein/Organism/Length [Patent #, Date]	NOV26a Residues/ Match Residues	Identities/ Similarities for the Matched Region	Expect Value
AAB85364	Novel Von Willebrand/thrombosporin-like polypeptide - Homo sapiens, 235 aa. [WO200153485-A1, 26-JUL-2001]	283..490 1..208	201/208 (96%) 203/208 (96%)	e-124
AAM99920	Human polypeptide SEQ ID NO 36 - Homo sapiens, 272 aa. [WO200155173-A2, 02-AUG-2001]	388..580 5..205	185/201 (92%) 188/201 (93%)	e-120

AAM99933	Human polypeptide SEQ ID NO 49 - Homo sapiens, 212 aa. [WO200155173-A2, 02-AUG-2001]	388..580 5..205	181/201 (90%) 185/201 (91%)	e-117
AAB85365	Novel Von Willebrand/thrombosporin-like mature protein sequence - Homo sapiens, 217 aa. [WO200153485-A1, 26-JUL-2001]	301..490 1..190	183/190 (96%) 185/190 (97%)	e-113
ABG15393	Novel human diagnostic protein #15384 - Homo sapiens, 1028 aa. [WO200175067-A2, 11-OCT-2001]	70..138 959..1027	69/69 (100%) 69/69 (100%)	7e-39

In a BLAST search of public sequence databases, the NOV26a protein was found to have homology to the proteins shown in the BLASTP data in Table 26D.

5

Table 26D. Public BLASTP Results for NOV26a				
Protein Accession Number	Protein/Organism/Length	NOV26a Residues/ Match Residues	Identities/ Similarities for the Matched Portion	Expect Value
Q96DN2	CDNA FLJ32009 FIS, CLONE NT2RP7009498, WEAKLY SIMILAR TO FIBULIN-1, ISOFORM A PRECURSOR - Homo sapiens (Human), 955 aa.	1..580 1..589	570/589 (96%) 573/589 (96%)	0.0
Q9DBE2	1300015B04RIK PROTEIN - Mus musculus (Mouse), 608 aa.	1..606 1..607	507/615 (82%) 538/615 (87%)	0.0
O00274	C1QR(P) - Homo sapiens (Human), 652 aa.	80..375 300..566	104/300 (34%) 134/300 (44%)	5e-32
Q9NPY3	DJ737E23.1 (COMPLEMENT COMPONENT C1Q RECEPTOR) - Homo sapiens (Human), 652 aa.	80..375 300..566	104/300 (34%) 134/300 (44%)	7e-32
Q91V88	POEM (NEPHRONECTIN SHORT ISOFORM) - Mus musculus (Mouse), 561 aa.	44..372 35..383	103/363 (28%) 152/363 (41%)	5e-31

PFam analysis indicates that the NOV26a protein contains the domains shown in Table 26E.

Table 26E. Domain Analysis of NOV26a			
Pfam Domain	NOV26a Match Region	Identities/ Similarities for the Matched Region	Expect Value
EGF: domain 1 of 5	71..97	9/47 (19%) 16/47 (34%)	8.1
zf-NF-X1: domain 1 of 1	104..127	8/27 (30%) 13/27 (48%)	8
EGF: domain 2 of 5	109..140	10/47 (21%) 24/47 (51%)	25
EGF: domain 3 of 5	145..178	16/47 (34%) 23/47 (49%)	0.0045
EGF: domain 4 of 5	184..217	12/47 (26%) 25/47 (53%)	0.011
TIL: domain 1 of 1	165..223	13/70 (19%) 40/70 (57%)	0.53
EGF: domain 5 of 5	223..260	12/48 (25%) 26/48 (54%)	0.034
Keratin_B2: domain 1 of 1	93..271	39/213 (18%) 89/213 (42%)	6.2
TILa: domain 1 of 1	384..438	15/59 (25%) 28/59 (47%)	9.4
vwc: domain 1 of 3	385..439	21/84 (25%) 40/84 (48%)	7.8e-08
vwc: domain 2 of 3	442..492	18/84 (21%) 39/84 (46%)	0.00017
vwc: domain 3 of 3	493..550	21/84 (25%) 40/84 (48%)	1.8e-07

**Example 27.**

The NOV27 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 27A.

Table 27A. NOV27 Sequence Analysis		
	SEQ ID NO: 91	2173 bp
NOV27a, CG93884-01 DNA	CTGAGGGCTCATCCCTCTGCAGAGCGCGGGGTACCGGGAGGAGACGCCATGACGCC GCCCTCACAGCCCTGCTCTGCCTTGGGCTGAGTCTGGGCCCCAGGACCCGCGTGCAGG CAGGGCCCTTCCCAAAACCCACCCTCTGGGCTGAGCCAGGCTCTGTGATCAGCTGGGG	

Sequence	<p>GAGCCCCGTGACCATCTGGTGTCAAGGGGAGCCTGGAGGCCAGGAGTACCGACTGGAT  AAGAGGGGAAGCCAGAGCCCTTGGACAGAAATAACCCACTTGAACCCCAAGAACAAGG  CCAGATTCTCCATCCCATCCATGACAGAGCACCATTGCGGGGAGATACCGCTGCCACTA  TTACAGCTCTGCAGGCTGGTCAGAGCCCAGCGACCCCTGGAGCTGGTGATGACAGGA  TTCTACAACAAACCACCCTCTCAGCCCTGCCAGCCCTGTGGTGGCCTCAGGGGGGA  ATATGACCCCTCCGATGTGGCTCACAGAAGGGATATCACCATTTTGTCTGTATGAAGGA  AGGAGAACACCAGCTCCCCCGGACCCTGGACTCACAGAGCTCCACAGTGGGGGGTTTC  CAGGCCCTGTTCCCTGTGGGCCCCGTGAACCCAGCCACAGGTGGAGGTTACATGCT  ATTACTATTATATGAACACCCCCAGGTGTGGTCCCACCCAGTGACCCCTGGAGAT  TCTGCCCTCAGGCGTGTCTAGGAAGCCCTCCCTCCTGACCTGCAGGGCCCTGTCGTG  GCCCTGGGCAGAGCTGACCTCCAGTGTGGCTCTGTATGTCGGCTACGACAGATTTG  TTCTGTATAAGGAGGGGGAACGTGACTTCTCCAGCGCCCTGGCCAGACCCGAGG  TGGCTCTCCAGGCCAACTTACCCTGGGCCCTGTGAGCCCTCCACGGGGGCCAG  TACAGGTGCTATGGTGACACAACCTCTCCTCCGAGTGGTGGCCCCCAGCGACCCCT  TGAACATCTGATGGCAGGACAGATCTATGACACCGTCTCCTGTGACACAGCCGGG  CCCCACAGTGGCCTCAGGAGAGAACGTGACCCCTGCTGTGTAGTCATGGTGGCAGTTT  GACACTTTCCTTCTGACCAAGAAGGGGAGCCCATCCCCACTCGCTCTGAGATCAA  TGTACGGAGCTCATAAGTACCAGGCTGAATCCCCATGAGTCTGTGACCTCAGCCCA  CGCGGGGACCTACAGGTGCTACGGCTCATAAGCTCCAACCCCACTGCTGTCTTTC  CCCAGTGAGCCCTGGAACTCATGGTCTCAGGACACTCTGGAGGCTCCAGCCTCCAC  CCACAGGGCCGCCCTCCACACCTGGTCTGGGAAGATACCTGGAGGTTTGTATTGGGGT  CTCGGTGGCCTTCTGCTGCTGCTCTTCTCTCTCTCTCTCTCTCTCGACGTCAG  CGTCACAGCAAAACAGGACATCTGACCAGAGAAAGACTGCTTCTCCAGCGTCTGTGAG  GGGCTCGGAGACAGAGCCCAAGGACAGGGGCCCTGCTGAGGAGGTCCAGCCAGCTGC  TGACGTCCAGGAAGAAAACCTCTATGCTGCCGTGAAGGACACACAGTCTGAGGACAGG  GTGGAGCTGGACAGTCAGCAGAGCCACACGATGAAGACCCAGGAGTGAAGTATG  CCCCGGTGAACAACCTCAGTCTAGGAGAGAAATGGCCTCTCTCTCTCTCTCTCTGTC  TGGGGAATCTCTGGACAAAGGACAGACAGGTGGAAGGAGACAGACAGTGGACACT  GAGGCTGTGATCTGAAGCCTCCAGGATGTGACCTACGCCAGCTGCACAGCTTGA  CCCTTAGACGGAAGGCAACTGAGCCTCTCCATCCAGGAAGGGGAACCTCCAGCTGA  GCCCAGCATCTACGCCACTCTGGCCATCCACTAGCCCGGGGGGTACGCAGACCCACA  CTCAGCAGAAGGAGACTCAGGACTGCTGAAGGCACGGGAGCTGCCCCAGTGGACACC  AGTGAACCCAGCTCAGCCTGGACCCCTAACACAGACCATGAGGAGACGCTGGGAACCT  GTGGGACTACCTGACTCAAAGATGACTAATATCGTCCCATTTTGGAAATAAAGCAAC  AGACTTCTCAACAATAGTAAAT</p>		
	ORF Start: ATG at 50	ORF Stop: TAG at 1946	
	SEQ ID NO: 92	632 aa	MW at 69499.3kD
NOV27a, CG93884-01 Protein Sequence	<p>MTPALTALLCLGLSLGPRTRVQAGFPFKPTLWAEPSVSIWGSPTVIWCQSLEAQEY  RLDKEGSPEPLDRNNPLEPKNKARFSIPMSTEHHAGRYRCHYSSAGWSEPSDPLELV  MTGFYNKPTLSALPSPVVASGGNMTLRCSQKGYHHFVLMKEGHLPRTLDSQQLHS  GGFQALFPVGPVNPNSHRWFTCYYYIMNTQVWHSPSDPLEILPQVSRKPSLLTLQG  PVVAPGQSLTLQCGSDVGYDRFVLYKEGERDFLQRPQGQPQAGLSQANFTLGPVSPSH  GGQYRCYGAHNLSSEWSAPSDDLNLIMAGQIYDTVLSLAQPGPTVASGENVTLLCQSW  WQFDFTLLTKEGAHPLRLRSMYGAHKYQAEFPMPVPTSAHAGTYRCYGSYSNNPHL  LSFPSEPLELMVSGHSGGSSLPPTGPPSTPGLGRYLEVLIGVSVAFVLLFLLLFLLL  RRQRHSHKRTSDQRKTDQFQRPAGAAETPKDRGLLRSSPADVQEEENLYAAVKDTS  EDRVELDSQSPHEDPQAVTYAPVKHSPRREMASPPSSSGEFELDTKDRQVEEDRQ  MDTEAAASEASQDVTYAQLHSLTLRRKATEPPPSQEGEPPAEPSIYATLAIH</p>		

Further analysis of the NOV27a protein yielded the following properties shown in Table 27B.

Table 27B. Protein Sequence Properties NOV27a	
PSort analysis:	0.4600 probability located in plasma membrane; 0.1000 probability located in endoplasmic reticulum (membrane); 0.1000 probability located in endoplasmic reticulum (lumen); 0.1000 probability located in outside

SignalP analysis:	Cleavage site between residues 24 and 25
-------------------	--

A search of the NOV27a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 27C.

5

Table 27C. Geneseq Results for NOV27a				
Geneseq Identifier	Protein/Organism/Length [Patent #, Date]	NOV27a Residues/ Match Residues	Identities/ Similarities for the Matched Region	Expect Value
AAB61263	Human monocyte inhibitory receptor precursor - Homo sapiens, 631 aa. [WO200100810-A1, 04-JAN-2001]	1..632 1..631	629/632 (99%) 630/632 (99%)	0.0
AAB04177	Leukocyte immunoglobulin like receptor pbm17 - Homo sapiens, 631 aa. [WO200068383-A2, 16-NOV-2000]	1..632 1..631	615/632 (97%) 623/632 (98%)	0.0
AAW82552	Human LIR-pbm17 protein - Homo sapiens, 631 aa. [WO9848017-A1, 29-OCT-1998]	1..632 1..631	615/632 (97%) 623/632 (98%)	0.0
ABG11435	Novel human diagnostic protein #11426 - Homo sapiens, 656 aa. [WO200175067-A2, 11-OCT-2001]	1..632 16..656	603/641 (94%) 615/641 (95%)	0.0
ABG11435	Novel human diagnostic protein #11426 - Homo sapiens, 656 aa. [WO200175067-A2, 11-OCT-2001]	1..632 16..656	603/641 (94%) 615/641 (95%)	0.0

In a BLAST search of public sequence databases, the NOV27a protein was found to have homology to the proteins shown in the BLASTP data in Table 27D.

Table 27D. Public BLASTP Results for NOV27a				
Protein Accession Number	Protein/Organism/Length	NOV27a Residues/ Match Residues	Identities/ Similarities for the Matched Portion	Expect Value
O15471	MONOCYTE INHIBITORY RECEPTOR PRECURSOR - Homo sapiens (Human), 631 aa.	1..632 1..631	630/632 (99%) 631/632 (99%)	0.0

10

AAC51900	IMMUNOGLOBULIN-LIKE TRANSCRIPT 5 - Homo sapiens (Human), 631 aa.	1..632 1..631	629/632 (99%) 631/632 (99%)	0.0
AAC51887	IMMUNOGLOBULIN-LIKE TRANSCRIPT 5 PROTEIN - Homo sapiens (Human), 631 aa.	1..632 1..631	628/632 (99%) 629/632 (99%)	0.0
AAC51901	IMMUNOGLOBULIN-LIKE TRANSCRIPT 5 - Homo sapiens (Human), 632 aa.	1..632 1..632	623/632 (98%) 628/632 (98%)	0.0
AAC51896	IMMUNOGLOBULIN-LIKE TRANSCRIPT 5 PROTEIN - Homo sapiens (Human), 632 aa.	1..632 1..632	620/632 (98%) 626/632 (98%)	0.0

PFam analysis indicates that the NOV27a protein contains the domains shown in Table 27E.

Table 27E. Domain Analysis of NOV27a			
Pfam Domain	NOV27a Match Region	Identities/ Similarities for the Matched Region	Expect Value
ig: domain 1 of 4	42..100	12/63 (19%) 44/63 (70%)	0.00012
ig: domain 2 of 4	137..198	9/66 (14%) 41/66 (62%)	1.1e+02
ig: domain 3 of 4	238..298	12/65 (18%) 47/65 (72%)	7.7e-07
ig: domain 4 of 4	338..398	13/65 (20%) 39/65 (60%)	0.0043

**Example B: Identification of NOVX clones**

The novel NOVX target sequences identified in the present invention may have been subjected to the exon linking process to confirm the sequence. PCR primers were designed by starting at the most upstream sequence available, for the forward primer, and at the most downstream sequence available for the reverse primer. In each case, the sequence was examined, walking inward from the respective termini toward the coding sequence, until a suitable sequence that is either unique or highly selective was encountered, or, in the case of the reverse primer, until the stop codon was reached. Such primers were designed based on *in silico* predictions for the full length cDNA, part (one or more exons) of the DNA or protein sequence of the target sequence, or by translated homology of the predicted exons to closely related human sequences from other species. These primers were then employed in PCR amplification based on the following pool of human cDNAs: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain - whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, and uterus.

Usually the resulting amplicons were gel purified, cloned and sequenced to high redundancy. The PCR product derived from exon linking was cloned into the pCR2.1 vector from Invitrogen. The resulting bacterial clone has an insert covering the entire open reading frame cloned into the pCR2.1 vector. The resulting sequences from all clones were assembled with themselves, with other fragments in CuraGen Corporation's database and with public ESTs. Fragments and ESTs were included as components for an assembly when the extent of their identity with another component of the assembly was at least 95% over 50 bp. In addition, sequence traces were evaluated manually and edited for corrections if appropriate. These procedures provide the sequence reported herein.

**Example C: Quantitative expression analysis of clones in various cells and tissues**

The quantitative expression of various clones was assessed using microtiter plates containing RNA samples from a variety of normal and pathology-derived cells, cell lines and tissues using real time quantitative PCR (RTQ PCR). RTQ PCR was performed on an Applied Biosystems ABI PRISM® 7700 or an ABI PRISM® 7900 HT Sequence Detection System. Various collections of samples are assembled on the plates, and referred to as Panel



1 (containing normal tissues and cancer cell lines), Panel 2 (containing samples derived from tissues from normal and cancer sources), Panel 3 (containing cancer cell lines), Panel 4 (containing cells and cell lines from normal tissues and cells related to inflammatory conditions), Panel 5D/5I (containing human tissues and cell lines with an emphasis on metabolic diseases), AI\_comprehensive\_panel (containing normal tissue and samples from autoimmune diseases), Panel CNSD.01 (containing central nervous system samples from normal and diseased brains) and CNS\_neurodegeneration\_panel (containing samples from normal and Alzheimer's diseased brains).

RNA integrity from all samples is controlled for quality by visual assessment of agarose gel electropherograms using 28S and 18S ribosomal RNA staining intensity ratio as a guide (2:1 to 2.5:1 28s:18s) and the absence of low molecular weight RNAs that would be indicative of degradation products. Samples are controlled against genomic DNA contamination by RTQ PCR reactions run in the absence of reverse transcriptase using probe and primer sets designed to amplify across the span of a single exon.

First, the RNA samples were normalized to reference nucleic acids such as constitutively expressed genes (for example,  $\beta$ -actin and GAPDH). Normalized RNA (5  $\mu$ l) was converted to cDNA and analyzed by RTQ-PCR using One Step RT-PCR Master Mix Reagents (Applied Biosystems; Catalog No. 4309169) and gene-specific primers according to the manufacturer's instructions.

In other cases, non-normalized RNA samples were converted to single strand cDNA (sscDNA) using Superscript II (Invitrogen Corporation; Catalog No. 18064-147) and random hexamers according to the manufacturer's instructions. Reactions containing up to 10  $\mu$ g of total RNA were performed in a volume of 20  $\mu$ l and incubated for 60 minutes at 42 °C. This reaction can be scaled up to 50  $\mu$ g of total RNA in a final volume of 100  $\mu$ l. sscDNA samples are then normalized to reference nucleic acids as described previously, using 1X TaqMan® Universal Master mix (Applied Biosystems; catalog No. 4324020), following the manufacturer's instructions.

Probes and primers were designed for each assay according to Applied Biosystems Primer Express Software package (version I for Apple Computer's Macintosh Power PC) or a similar algorithm using the target sequence as input. Default settings were used for reaction conditions and the following parameters were set before selecting primers: primer

concentration = 250 nM, primer melting temperature ( $T_m$ ) range = 58 °-60 °C, primer optimal  $T_m$  = 59 °C, maximum primer difference = 2 °C, probe does not have 5'G, probe  $T_m$  must be 10 °C greater than primer  $T_m$ , amplicon size 75bp to 100bp. The probes and primers selected (see below) were synthesized by Synthegen (Houston, TX, USA). Probes were double  
5 purified by HPLC to remove uncoupled dye and evaluated by mass spectroscopy to verify coupling of reporter and quencher dyes to the 5' and 3' ends of the probe, respectively. Their final concentrations were: forward and reverse primers, 900nM each, and probe, 200nM.

PCR conditions: When working with RNA samples, normalized RNA from each tissue and each cell line was spotted in each well of either a 96 well or a 384-well PCR plate  
10 (Applied Biosystems). PCR cocktails included either a single gene specific probe and primers set, or two multiplexed probe and primers sets (a set specific for the target clone and another gene-specific set multiplexed with the target probe). PCR reactions were set up using TaqMan® One-Step RT-PCR Master Mix (Applied Biosystems, Catalog No. 4313803) following manufacturer's instructions. Reverse transcription was performed at 48 °C for 30  
15 minutes followed by amplification/PCR cycles as follows: 95°C 10 min, then 40 cycles of 95 °C for 15 seconds, 60 °C for 1 minute. Results were recorded as CT values (cycle at which a given sample crosses a threshold level of fluorescence) using a log scale, with the difference in RNA concentration between a given sample and the sample with the lowest CT value being represented as 2 to the power of delta CT. The percent relative expression is then  
20 obtained by taking the reciprocal of this RNA difference and multiplying by 100.

When working with sscDNA samples, normalized sscDNA was used as described previously for RNA samples. PCR reactions containing one or two sets of probe and primers were set up as described previously, using 1X TaqMan® Universal Master mix (Applied Biosystems; catalog No. 4324020), following the manufacturer's instructions. PCR  
25 amplification was performed as follows: 95 °C 10 min, then 40 cycles of 95 °C for 15 seconds, 60 °C for 1 minute. Results were analyzed and processed as described previously.

#### **Panels 1, 1.1, 1.2, and 1.3D**

The plates for Panels 1, 1.1, 1.2 and 1.3D include 2 control wells (genomic DNA control and chemistry control) and 94 wells containing cDNA from various samples. The  
30 samples in these panels are broken into 2 classes: samples derived from cultured cell lines and samples derived from primary normal tissues. The cell lines are derived from cancers of

the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell carcinoma, ovarian cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer. Cell lines used in these panels are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were  
5 cultured using the conditions recommended by the ATCC. The normal tissues found on these panels are comprised of samples derived from all major organ systems from single adult individuals or fetuses. These samples are derived from the following organs: adult skeletal muscle, fetal skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney, adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the spleen, bone marrow, lymph  
10 node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose.

In the results for Panels 1, 1.1, 1.2 and 1.3D, the following abbreviations are used:

15 ca. = carcinoma,  
\* = established from metastasis,  
met = metastasis,  
s cell var = small cell variant,  
non-s = non-sm = non-small,  
squam = squamous,  
20 pl. eff = pl effusion = pleural effusion,  
glio = glioma,  
astro = astrocytoma, and  
neuro = neuroblastoma.

#### **General\_screening\_panel\_v1.4**

25 The plates for Panel 1.4 include 2 control wells (genomic DNA control and chemistry control) and 94 wells containing cDNA from various samples. The samples in Panel 1.4 are broken into 2 classes: samples derived from cultured cell lines and samples derived from primary normal tissues. The cell lines are derived from cancers of the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell  
30 carcinoma, ovarian cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer. Cell lines used in Panel 1.4 are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured using the conditions recommended by the ATCC. The normal tissues found on Panel 1.4 are comprised of pools of samples derived from all major organ systems from 2 to 5 different adult  
35 individuals or fetuses. These samples are derived from the following organs: adult skeletal

muscle, fetal skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney, adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and  
5 adipose. Abbreviations are as described for Panels 1, 1.1, 1.2, and 1.3D.

### **Panels 2D and 2.2**

The plates for Panels 2D and 2.2 generally include 2 control wells and 94 test samples composed of RNA or cDNA isolated from human tissue procured by surgeons working in close cooperation with the National Cancer Institute's Cooperative Human Tissue Network  
10 (CHTN) or the National Disease Research Initiative (NDRI). The tissues are derived from human malignancies and in cases where indicated many malignant tissues have "matched margins" obtained from noncancerous tissue just adjacent to the tumor. These are termed normal adjacent tissues and are denoted "NAT" in the results below. The tumor tissue and the "matched margins" are evaluated by two independent pathologists (the surgical pathologists  
15 and again by a pathologist at NDRI or CHTN). This analysis provides a gross histopathological assessment of tumor differentiation grade. Moreover, most samples include the original surgical pathology report that provides information regarding the clinical stage of the patient. These matched margins are taken from the tissue surrounding (*i.e.* immediately proximal) to the zone of surgery (designated "NAT", for normal adjacent tissue, in Table  
20 RR). In addition, RNA and cDNA samples were obtained from various human tissues derived from autopsies performed on elderly people or sudden death victims (accidents, *etc.*). These tissues were ascertained to be free of disease and were purchased from various commercial sources such as Clontech (Palo Alto, CA), Research Genetics, and Invitrogen.

### **Panel 3D**

25 The plates of Panel 3D are comprised of 94 cDNA samples and two control samples. Specifically, 92 of these samples are derived from cultured human cancer cell lines, 2 samples of human primary cerebellar tissue and 2 controls. The human cell lines are generally obtained from ATCC (American Type Culture Collection), NCI or the German tumor cell bank and fall into the following tissue groups: Squamous cell carcinoma of the tongue, breast cancer, prostate cancer, melanoma, epidermoid carcinoma, sarcomas, bladder  
30 carcinomas, pancreatic cancers, kidney cancers, leukemias/lymphomas, ovarian/uterine/cervical, gastric, colon, lung and CNS cancer cell lines. In addition, there are

two independent samples of cerebellum. These cells are all cultured under standard recommended conditions and RNA extracted using the standard procedures. The cell lines in panel 3D and 1.3D are of the most common cell lines used in the scientific literature.

**Panels 4D, 4R, and 4.1D**

5 Panel 4 includes samples on a 96 well plate (2 control wells, 94 test samples) composed of RNA (Panel 4R) or cDNA (Panels 4D/4.1D) isolated from various human cell lines or tissues related to inflammatory conditions. Total RNA from control normal tissues such as colon and lung (Stratagene, La Jolla, CA) and thymus and kidney (Clontech) was employed. Total RNA from liver tissue from cirrhosis patients and kidney from lupus patients  
10 was obtained from BioChain (Biochain Institute, Inc., Hayward, CA). Intestinal tissue for RNA preparation from patients diagnosed as having Crohn's disease and ulcerative colitis was obtained from the National Disease Research Interchange (NDRI) (Philadelphia, PA).

Astrocytes, lung fibroblasts, dermal fibroblasts, coronary artery smooth muscle cells, small airway epithelium, bronchial epithelium, microvascular dermal endothelial cells,  
15 microvascular lung endothelial cells, human pulmonary aortic endothelial cells, human umbilical vein endothelial cells were all purchased from Clonetics (Walkersville, MD) and grown in the media supplied for these cell types by Clonetics. These primary cell types were activated with various cytokines or combinations of cytokines for 6 and/or 12-14 hours, as indicated. The following cytokines were used; IL-1 beta at approximately 1-5ng/ml, TNF  
20 alpha at approximately 5-10ng/ml, IFN gamma at approximately 20-50ng/ml, IL-4 at approximately 5-10ng/ml, IL-9 at approximately 5-10ng/ml, IL-13 at approximately 5-10ng/ml. Endothelial cells were sometimes starved for various times by culture in the basal media from Clonetics with 0.1% serum.

Mononuclear cells were prepared from blood of employees at CuraGen Corporation,  
25 using Ficoll. LAK cells were prepared from these cells by culture in DMEM 5% FCS (Hyclone), 100µM non essential amino acids (Gibco/Life Technologies, Rockville, MD), 1mM sodium pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5}$  M (Gibco), and 10mM Hepes (Gibco) and Interleukin 2 for 4-6 days. Cells were then either activated with 10-20ng/ml PMA and 1-2µg/ml ionomycin, IL-12 at 5-10ng/ml, IFN gamma at 20-50ng/ml and IL-18 at  
30 5-10ng/ml for 6 hours. In some cases, mononuclear cells were cultured for 4-5 days in DMEM 5% FCS (Hyclone), 100µM non essential amino acids (Gibco), 1mM sodium

pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5} \text{M}$  (Gibco), and 10mM Hepes (Gibco) with PHA (phytohemagglutinin) or PWM (pokeweed mitogen) at approximately  $5 \mu\text{g/ml}$ . Samples were taken at 24, 48 and 72 hours for RNA preparation. MLR (mixed lymphocyte reaction) samples were obtained by taking blood from two donors, isolating the mononuclear cells using Ficoll and mixing the isolated mononuclear cells 1:1 at a final concentration of approximately  $2 \times 10^6 \text{cells/ml}$  in DMEM 5% FCS (Hyclone),  $100 \mu\text{M}$  non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol ( $5.5 \times 10^{-5} \text{M}$ ) (Gibco), and 10mM Hepes (Gibco). The MLR was cultured and samples taken at various time points ranging from 1- 7 days for RNA preparation.

Monocytes were isolated from mononuclear cells using CD14 Miltenyi Beads, +ve VS selection columns and a Vario Magnet according to the manufacturer's instructions. Monocytes were differentiated into dendritic cells by culture in DMEM 5% fetal calf serum (FCS) (Hyclone, Logan, UT),  $100 \mu\text{M}$  non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5} \text{M}$  (Gibco), and 10mM Hepes (Gibco), 50ng/ml GMCSF and 5ng/ml IL-4 for 5-7 days. Macrophages were prepared by culture of monocytes for 5-7 days in DMEM 5% FCS (Hyclone),  $100 \mu\text{M}$  non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5} \text{M}$  (Gibco), 10mM Hepes (Gibco) and 10% AB Human Serum or MCSF at approximately 50ng/ml. Monocytes, macrophages and dendritic cells were stimulated for 6 and 12-14 hours with lipopolysaccharide (LPS) at 100ng/ml. Dendritic cells were also stimulated with anti-CD40 monoclonal antibody (Pharmingen) at  $10 \mu\text{g/ml}$  for 6 and 12-14 hours.

CD4 lymphocytes, CD8 lymphocytes and NK cells were also isolated from mononuclear cells using CD4, CD8 and CD56 Miltenyi beads, positive VS selection columns and a Vario Magnet according to the manufacturer's instructions. CD45RA and CD45RO CD4 lymphocytes were isolated by depleting mononuclear cells of CD8, CD56, CD14 and CD19 cells using CD8, CD56, CD14 and CD19 Miltenyi beads and positive selection. CD45RO beads were then used to isolate the CD45RO CD4 lymphocytes with the remaining cells being CD45RA CD4 lymphocytes. CD45RA CD4, CD45RO CD4 and CD8 lymphocytes were placed in DMEM 5% FCS (Hyclone),  $100 \mu\text{M}$  non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5} \text{M}$  (Gibco), and 10mM Hepes (Gibco) and plated at  $10^6 \text{cells/ml}$  onto Falcon 6 well tissue culture plates that had been coated overnight with  $0.5 \mu\text{g/ml}$  anti-CD28 (Pharmingen) and  $3 \mu\text{g/ml}$  anti-CD3 (OKT3,

ATCC) in PBS. After 6 and 24 hours, the cells were harvested for RNA preparation. To prepare chronically activated CD8 lymphocytes, we activated the isolated CD8 lymphocytes for 4 days on anti-CD28 and anti-CD3 coated plates and then harvested the cells and expanded them in DMEM 5% FCS (Hyclone), 100 $\mu$ M non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol 5.5x10<sup>-5</sup>M (Gibco), and 10mM Hepes (Gibco) and IL-2. The expanded CD8 cells were then activated again with plate bound anti-CD3 and anti-CD28 for 4 days and expanded as before. RNA was isolated 6 and 24 hours after the second activation and after 4 days of the second expansion culture. The isolated NK cells were cultured in DMEM 5% FCS (Hyclone), 100 $\mu$ M non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol 5.5x10<sup>-5</sup>M (Gibco), and 10mM Hepes (Gibco) and IL-2 for 4-6 days before RNA was prepared.

To obtain B cells, tonsils were procured from NDRI. The tonsil was cut up with sterile dissecting scissors and then passed through a sieve. Tonsil cells were then spun down and resuspended at 10<sup>6</sup> cells/ml in DMEM 5% FCS (Hyclone), 100 $\mu$ M non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol 5.5x10<sup>-5</sup>M (Gibco), and 10mM Hepes (Gibco). To activate the cells, we used PWM at 5 $\mu$ g/ml or anti-CD40 (Pharmingen) at approximately 10 $\mu$ g/ml and IL-4 at 5-10ng/ml. Cells were harvested for RNA preparation at 24, 48 and 72 hours.

To prepare the primary and secondary Th1/Th2 and Tr1 cells, six-well Falcon plates were coated overnight with 10 $\mu$ g/ml anti-CD28 (Pharmingen) and 2 $\mu$ g/ml OKT3 (ATCC), and then washed twice with PBS. Umbilical cord blood CD4 lymphocytes (Poietic Systems, German Town, MD) were cultured at 10<sup>5</sup>-10<sup>6</sup> cells/ml in DMEM 5% FCS (Hyclone), 100 $\mu$ M non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol 5.5x10<sup>-5</sup>M (Gibco), 10mM Hepes (Gibco) and IL-2 (4ng/ml). IL-12 (5ng/ml) and anti-IL4 (1 $\mu$ g/ml) were used to direct to Th1, while IL-4 (5ng/ml) and anti-IFN gamma (1 $\mu$ g/ml) were used to direct to Th2 and IL-10 at 5ng/ml was used to direct to Tr1. After 4-5 days, the activated Th1, Th2 and Tr1 lymphocytes were washed once in DMEM and expanded for 4-7 days in DMEM 5% FCS (Hyclone), 100 $\mu$ M non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol 5.5x10<sup>-5</sup>M (Gibco), 10mM Hepes (Gibco) and IL-2 (1ng/ml). Following this, the activated Th1, Th2 and Tr1 lymphocytes were re-stimulated for 5 days with anti-CD28/OKT3 and cytokines as described above, but with the addition of anti-CD95L (1 $\mu$ g/ml) to prevent apoptosis. After 4-5 days, the Th1, Th2 and Tr1 lymphocytes

were washed and then expanded again with IL-2 for 4-7 days. Activated Th1 and Th2 lymphocytes were maintained in this way for a maximum of three cycles. RNA was prepared from primary and secondary Th1, Th2 and Tr1 after 6 and 24 hours following the second and third activations with plate bound anti-CD3 and anti-CD28 mAbs and 4 days into the second and third expansion cultures in Interleukin 2.

The following leukocyte cells lines were obtained from the ATCC: Ramos, EOL-1, KU-812. EOL cells were further differentiated by culture in 0.1mM dbcAMP at  $5 \times 10^5$  cells/ml for 8 days, changing the media every 3 days and adjusting the cell concentration to  $5 \times 10^5$  cells/ml. For the culture of these cells, we used DMEM or RPMI (as recommended by the ATCC), with the addition of 5% FCS (Hyclone), 100 $\mu$ M non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5}$  M (Gibco), 10mM Hepes (Gibco). RNA was either prepared from resting cells or cells activated with PMA at 10ng/ml and ionomycin at 1 $\mu$ g/ml for 6 and 14 hours. Keratinocyte line CCD106 and an airway epithelial tumor line NCI-H292 were also obtained from the ATCC. Both were cultured in DMEM 5% FCS (Hyclone), 100 $\mu$ M non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5}$  M (Gibco), and 10mM Hepes (Gibco). CCD1106 cells were activated for 6 and 14 hours with approximately 5 ng/ml TNF alpha and 1ng/ml IL-1 beta, while NCI-H292 cells were activated for 6 and 14 hours with the following cytokines: 5ng/ml IL-4, 5ng/ml IL-9, 5ng/ml IL-13 and 25ng/ml IFN gamma.

For these cell lines and blood cells, RNA was prepared by lysing approximately  $10^7$  cells/ml using Trizol (Gibco BRL). Briefly, 1/10 volume of bromochloropropane (Molecular Research Corporation) was added to the RNA sample, vortexed and after 10 minutes at room temperature, the tubes were spun at 14,000 rpm in a Sorvall SS34 rotor. The aqueous phase was removed and placed in a 15ml Falcon Tube. An equal volume of isopropanol was added and left at  $-20^\circ\text{C}$  overnight. The precipitated RNA was spun down at 9,000 rpm for 15 min in a Sorvall SS34 rotor and washed in 70% ethanol. The pellet was redissolved in 300 $\mu$ l of RNase-free water and 35 $\mu$ l buffer (Promega) 5 $\mu$ l DTT, 7 $\mu$ l RNasin and 8 $\mu$ l DNase were added. The tube was incubated at  $37^\circ\text{C}$  for 30 minutes to remove contaminating genomic DNA, extracted once with phenol chloroform and re-precipitated with 1/10 volume of 3M sodium acetate and 2 volumes of 100% ethanol. The RNA was spun down and placed in RNase free water. RNA was stored at  $-80^\circ\text{C}$ .



The plates for AI\_comprehensive panel\_v1.0 include two control wells and 89 test samples comprised of cDNA isolated from surgical and postmortem human tissues obtained from the Backus Hospital and Clinomics (Frederick, MD). Total RNA was extracted from tissue samples from the Backus Hospital in the Facility at CuraGen. Total RNA from other  
5 tissues was obtained from Clinomics.

Joint tissues including synovial fluid, synovium, bone and cartilage were obtained from patients undergoing total knee or hip replacement surgery at the Backus Hospital. Tissue samples were immediately snap frozen in liquid nitrogen to ensure that isolated RNA was of optimal quality and not degraded. Additional samples of osteoarthritis and rheumatoid  
10 arthritis joint tissues were obtained from Clinomics. Normal control tissues were supplied by Clinomics and were obtained during autopsy of trauma victims.

Surgical specimens of psoriatic tissues and adjacent matched tissues were provided as total RNA by Clinomics. Two male and two female patients were selected between the ages of 25 and 47. None of the patients were taking prescription drugs at the time samples were  
15 isolated.

Surgical specimens of diseased colon from patients with ulcerative colitis and Crohns disease and adjacent matched tissues were obtained from Clinomics. Bowel tissue from three female and three male Crohn's patients between the ages of 41-69 were used. Two patients were not on prescription medication while the others were taking dexamethasone,  
20 phenobarbital, or tylenol. Ulcerative colitis tissue was from three male and four female patients. Four of the patients were taking lebid and two were on phenobarbital.

Total RNA from post mortem lung tissue from trauma victims with no disease or with emphysema, asthma or COPD was purchased from Clinomics. Emphysema patients ranged in age from 40-70 and all were smokers, this age range was chosen to focus on patients with  
25 cigarette-linked emphysema and to avoid those patients with alpha-1anti-trypsin deficiencies. Asthma patients ranged in age from 36-75, and excluded smokers to prevent those patients that could also have COPD. COPD patients ranged in age from 35-80 and included both smokers and non-smokers. Most patients were taking corticosteroids, and bronchodilators.

In the labels employed to identify tissues in the AI\_comprehensive panel\_v1.0 panel,  
30 the following abbreviations are used:

- 5        AI = Autoimmunity  
        Syn = Synovial  
        Normal = No apparent disease  
        Rep22 /Rep20 = individual patients  
        RA = Rheumatoid arthritis  
        Backus = From Backus Hospital  
        OA = Osteoarthritis  
        (SS) (BA) (MF) = Individual patients  
 10       Adj = Adjacent tissue  
        Match control = adjacent tissues  
        -M = Male  
        -F = Female  
        COPD = Chronic obstructive pulmonary disease

#### Panels 5D and 5I

- 15        The plates for Panel 5D and 5I include two control wells and a variety of cDNAs isolated from human tissues and cell lines with an emphasis on metabolic diseases. Metabolic tissues were obtained from patients enrolled in the Gestational Diabetes study. Cells were obtained during different stages in the differentiation of adipocytes from human mesenchymal stem cells. Human pancreatic islets were also obtained.

- 20        In the Gestational Diabetes study subjects are young (18 - 40 years), otherwise healthy women with and without gestational diabetes undergoing routine (elective) Caesarean section. After delivery of the infant, when the surgical incisions were being repaired/closed, the obstetrician removed a small sample (<1 cc) of the exposed metabolic tissues during the closure of each surgical level. The biopsy material was rinsed in sterile saline, blotted and
 25       fast frozen within 5 minutes from the time of removal. The tissue was then flash frozen in liquid nitrogen and stored, individually, in sterile screw-top tubes and kept on dry ice for shipment to or to be picked up by CuraGen. The metabolic tissues of interest include uterine wall (smooth muscle), visceral adipose, skeletal muscle (rectus) and subcutaneous adipose. Patient descriptions are as follows:

- 30                    Patient 2        Diabetic Hispanic, overweight, not on insulin  
                      Patient 7-9      Nondiabetic Caucasian and obese (BMI>30)  
                      Patient 10     Diabetic Hispanic, overweight, on insulin  
                      Patient 11     Nondiabetic African American and overweight  
 35                    Patient 12     Diabetic Hispanic on insulin

Adipocyte differentiation was induced in donor progenitor cells obtained from Osiris (a division of Clonetics/BioWhittaker) in triplicate, except for Donor 3U which had only two replicates. Scientists at Clonetics isolated, grew and differentiated human mesenchymal stem

cells (HuMSCs) for CuraGen based on the published protocol found in Mark F. Pittenger, et al., Multilineage Potential of Adult Human Mesenchymal Stem Cells Science Apr 2 1999: 143-147. Clonetics provided Trizol lysates or frozen pellets suitable for mRNA isolation and ds cDNA production. A general description of each donor is as follows:

- 5            Donor 2 and 3 U: Mesenchymal Stem cells, Undifferentiated Adipose  
             Donor 2 and 3 AM: Adipose, AdiposeMidway Differentiated  
             Donor 2 and 3 AD: Adipose, Adipose Differentiated

- Human cell lines were generally obtained from ATCC (American Type Culture Collection), NCI or the German tumor cell bank and fall into the following tissue groups:
- 10    kidney proximal convoluted tubule, uterine smooth muscle cells, small intestine, liver HepG2 cancer cells, heart primary stromal cells, and adrenal cortical adenoma cells. These cells are all cultured under standard recommended conditions and RNA extracted using the standard procedures. All samples were processed at CuraGen to produce single stranded cDNA.

- Panel 5I contains all samples previously described with the addition of pancreatic islets from a 58 year old female patient obtained from the Diabetes Research Institute at the University of Miami School of Medicine. Islet tissue was processed to total RNA at an outside source and delivered to CuraGen for addition to panel 5I.
- 15    islets from a 58 year old female patient obtained from the Diabetes Research Institute at the University of Miami School of Medicine. Islet tissue was processed to total RNA at an outside source and delivered to CuraGen for addition to panel 5I.

In the labels employed to identify tissues in the 5D and 5I panels, the following abbreviations are used:

- 20            GO Adipose = Greater Omentum Adipose  
             SK = Skeletal Muscle  
             UT = Uterus  
             PL = Placenta  
             AD = Adipose Differentiated  
25            AM = Adipose Midway Differentiated  
             U = Undifferentiated Stem Cells

#### **Panel CNSD.01**

- The plates for Panel CNSD.01 include two control wells and 94 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center. Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at -80°C in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.
- 30    Brain Tissue Resource Center. Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at -80°C in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.

Disease diagnoses are taken from patient records. The panel contains two brains from each of the following diagnoses: Alzheimer's disease, Parkinson's disease, Huntington's disease, Progressive Supranuclear Palsy, Depression, and "Normal controls". Within each of these brains, the following regions are represented: cingulate gyrus, temporal pole, globus palladus, substantia nigra, Brodman Area 4 (primary motor strip), Brodman Area 7 (parietal cortex), Brodman Area 9 (prefrontal cortex), and Brodman area 17 (occipital cortex). Not all brain regions are represented in all cases; e.g., Huntington's disease is characterized in part by neurodegeneration in the globus palladus, thus this region is impossible to obtain from confirmed Huntington's cases. Likewise Parkinson's disease is characterized by degeneration of the substantia nigra making this region more difficult to obtain. Normal control brains were examined for neuropathology and found to be free of any pathology consistent with neurodegeneration.

In the labels employed to identify tissues in the CNS panel, the following abbreviations are used:

- 15       PSP = Progressive supranuclear palsy
- Sub Nigra = Substantia nigra
- Glob Palladus= Globus palladus
- Temp Pole = Temporal pole
- Cing Gyr = Cingulate gyrus
- 20       BA 4 = Brodman Area 4

#### **Panel CNS\_Neurodegeneration\_V1.0**

The plates for Panel CNS\_Neurodegeneration\_V1.0 include two control wells and 47 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center (McLean Hospital) and the Human Brain and Spinal Fluid Resource Center (VA Greater Los Angeles Healthcare System). Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at -80°C in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.

Disease diagnoses are taken from patient records. The panel contains six brains from Alzheimer's disease (AD) patients, and eight brains from "Normal controls" who showed no evidence of dementia prior to death. The eight normal control brains are divided into two categories: Controls with no dementia and no Alzheimer's like pathology (Controls) and controls with no dementia but evidence of severe Alzheimer's like pathology, (specifically

senile plaque load rated as level 3 on a scale of 0-3; 0 = no evidence of plaques, 3 = severe AD senile plaque load). Within each of these brains, the following regions are represented: hippocampus, temporal cortex (Brodman Area 21), parietal cortex (Brodman area 7), and occipital cortex (Brodman area 17). These regions were chosen to encompass all levels of neurodegeneration in AD. The hippocampus is a region of early and severe neuronal loss in AD; the temporal cortex is known to show neurodegeneration in AD after the hippocampus; the parietal cortex shows moderate neuronal death in the late stages of the disease; the occipital cortex is spared in AD and therefore acts as a "control" region within AD patients. Not all brain regions are represented in all cases.

10 In the labels employed to identify tissues in the CNS\_Neurodegeneration\_V1.0 panel, the following abbreviations are used:

AD = Alzheimer's disease brain; patient was demented and showed AD-like pathology upon autopsy  
 Control = Control brains; patient not demented, showing no neuropathology  
 15 Control (Path) = Control brains; patient not demented but showing severe AD-like pathology  
 SupTemporal Ctx = Superior Temporal Cortex  
 Inf Temporal Ctx = Inferior Temporal Cortex

20 **A. NOV1a and NOV1b (CG56258-01 and CG56258-02: sodium/calcium exchanger)**

Expression of gene CG56258-021 and CG56258-02 was assessed using the primer-probe sets Ag2903, Ag5035 and Ag6163, described in Tables AA, AB and AC. Results of the RTQ-PCR runs are shown in Tables AD, AE, AF, AG, AH and AI.

25

Table AA. Probe Name Ag2903

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-gactcgcaagatcaagcatcta-3'	22	641	93
Probe	TET-5'-cttcttcacaccgctgcttgagta-3'-TAMRA	26	668	94
Reverse	5'-tagagccagatgtaggcaaaga-3'	22	694	95

**Table AB. Probe Name Ag5035**

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-gaaagccagtattgggtgaac-3'	21	2023	96
Probe	TET-5'-ccccaaactagaagtcattcattgaaga-3'-TAMRA	27	2045	97
Reverse	5'-tttgtccaccgtagtcttgaac-3'	22	2081	98

**Table AC. Probe Name Ag6163**

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-ggggagttggaattcaagaat-3'	21	1815	99
Probe	TET-5'-tgaaactgtcaaaacaattcacatcaag-3'-TAMRA	28	1838	100
Reverse	5'-tctcatatgcctcatcatcaattac-3'	25	1866	101

**Table AD. AI\_comprehensive panel\_v1.0**

Tissue Name	Rel. Exp.(%) Ag2903, Run 225410015	Rel. Exp.(%) Ag5035, Run 244570389	Tissue Name	Rel. Exp.(%) Ag2903, Run 225410015	Rel. Exp.(%) Ag5035, Run 244570389
110967 COPD-F	0.6	0.3	112427 Match Control Psoriasis-F	4.1	4.8
110980 COPD-F	0.4	0.6	112418 Psoriasis-M	0.8	0.5
110968 COPD-M	0.9	1.2	112723 Match Control Psoriasis-M	0.1	0.0
110977 COPD-M	0.9	0.8	112419 Psoriasis-M	1.3	0.9
110989 Emphysema-F	0.6	0.0	112424 Match Control Psoriasis-M	1.1	0.5
110992 Emphysema-F	0.4	0.7	112420 Psoriasis-M	2.1	2.2
110993 Emphysema-F	1.1	1.4	112425 Match Control Psoriasis-M	2.9	5.8
110994 Emphysema-F	1.0	0.7	104689 (MF) OA Bone- Backus	68.3	44.4
110995 Emphysema-F	1.1	0.8	104690 (MF) Adj "Normal" Bone-Backus	8.8	5.2

110996 Emphysema-F	0.0	0.0	104691 (MF) OA Synovium- Backus	2.1	1.7
110997 Asthma-M	1.5	0.6	104692 (BA) OA Cartilage- Backus	3.3	3.6
111001 Asthma-F	1.8	1.5	104694 (BA) OA Bone- Backus	100.0	100.0
111002 Asthma-F	1.9	1.9	104695 (BA) Adj "Normal" Bone-Backus	36.3	28.7
111003 Atopic Asthma-F	2.7	2.4	104696 (BA) OA Synovium- Backus	1.4	0.5
111004 Atopic Asthma-F	0.9	1.2	104700 (SS) OA Bone- Backus	54.0	37.6
111005 Atopic Asthma-F	0.9	1.1	104701 (SS) Adj "Normal" Bone-Backus	60.3	34.9
111006 Atopic Asthma-F	0.4	0.3	104702 (SS) OA Synovium- Backus	2.9	2.1
111417 Allergy-M	2.2	2.8	117093 OA Cartilage Rep7	1.4	0.4
112347 Allergy-M	0.6	0.0	112672 OA Bone5	4.8	3.3
112349 Normal Lung-F	0.9	0.0	112673 OA Synovium5	1.6	1.7
112357 Normal Lung-F	0.1	0.3	112674 OA Synovial Fluid cells5	2.6	2.6
112354 Normal Lung-M	0.0	0.3	117100 OA Cartilage Rep14	0.0	0.0
112374 Crohns-F	0.2	0.0	112756 OA Bone9	5.6	0.4
112389 Match Control Crohns-F	0.2	1.1	112757 OA Synovium9	32.3	37.4
112375 Crohns-F	0.0	0.0	112758 OA Synovial Fluid Cells9	1.1	0.6
112732 Match Control	0.8	0.8	117125 RA Cartilage Rep2	2.8	1.1

Crohns-F					
112725 Crohns-M	0.1	0.0	113492 Bone2 RA	3.0	1.2
112387 Match Control Crohns-M	1.6	1.1	113493 Synovium2 RA	1.6	0.8
112378 Crohns-M	0.6	0.0	113494 Syn Fluid Cells RA	1.8	0.8
112390 Match Control Crohns-M	1.0	0.8	113499 Cartilage4 RA	1.7	1.9
112726 Crohns-M	0.8	0.7	113500 Bone4 RA	2.6	2.2
112731 Match Control Crohns-M	0.9	0.3	113501 Synovium4 RA	2.0	0.7
112380 Ulcer Col-F	0.4	0.5	113502 Syn Fluid Cells4 RA	0.6	0.6
112734 Match Control Ulcer Col-F	3.5	1.8	113495 Cartilage3 RA	1.6	0.6
112384 Ulcer Col-F	2.7	1.9	113496 Bone3 RA	1.9	0.7
112737 Match Control Ulcer Col-F	0.5	0.6	113497 Synovium3 RA	1.4	0.8
112386 Ulcer Col-F	2.0	1.4	113498 Syn Fluid Cells3 RA	2.6	2.7
112738 Match Control Ulcer Col-F	0.1	0.3	117106 Normal Cartilage Rep20	0.4	0.0
112381 Ulcer Col-M	1.3	0.0	113663 Bone3 Normal	0.6	0.0
112735 Match Control Ulcer Col-M	3.3	1.2	113664 Synovium3 Normal	0.2	0.0
112382 Ulcer Col-M	1.2	0.6	113665 Syn Fluid Cells3 Normal	0.2	0.0
112394 Match Control Ulcer Col-M	0.9	0.8	117107 Normal Cartilage Rep22	2.9	0.4



112383 Ulcer Col-M	0.7	0.0	113667 Bone4 Normal	1.1	0.0
112736 Match Control Ulcer Col-M	0.7	0.3	113668 Synovium4 Normal	1.3	0.5
112423 Psoriasis-F	0.7	0.3	113669 Syn Fluid Cells4 Normal	1.1	0.5

Table AE. CNS\_neurodegeneration\_v1.0

Tissue Name	Rel. Exp.(%) Ag2903, Run 209735156	Rel. Exp.(%) Ag5035, Run 224062761	Tissue Name	Rel. Exp.(%) Ag2903, Run 209735156	Rel. Exp.(%) Ag5035, Run 224062761
AD 1 Hippo	9.1	8.1	Control (Path) 3 Temporal Ctx	3.9	3.2
AD 2 Hippo	24.1	35.6	Control (Path) 4 Temporal Ctx	32.8	89.5
AD 3 Hippo	8.2	4.5	AD 1 Occipital Ctx	15.4	8.8
AD 4 Hippo	7.7	9.7	AD 2 Occipital Ctx (Missing)	0.0	0.0
AD 5 Hippo	100.0	84.1	AD 3 Occipital Ctx	5.5	1.9
AD 6 Hippo	22.2	20.3	AD 4 Occipital Ctx	18.8	16.3
Control 2 Hippo	31.0	50.3	AD 5 Occipital Ctx	56.6	63.7
Control 4 Hippo	9.1	10.7	AD 6 Occipital Ctx	20.6	13.6
Control (Path) 3 Hippo	5.5	1.4	Control 1 Occipital Ctx	1.7	2.7
AD 1 Temporal Ctx	7.7	7.5	Control 2 Occipital Ctx	63.3	76.3

AD 2 Temporal Ctx	21.6	34.4	Control 3 Occipital Ctx	24.7	14.3
AD 3 Temporal Ctx	4.8	3.8	Control 4 Occipital Ctx	5.6	5.0
AD 4 Temporal Ctx	18.2	24.7	Control (Path) 1 Occipital Ctx	89.5	100.0
AD 5 Inf Temporal Ctx	82.9	97.3	Control (Path) 2 Occipital Ctx	15.6	8.8
AD 5 Sup Temporal Ctx	32.1	31.4	Control (Path) 3 Occipital Ctx	1.0	0.9
AD 6 Inf Temporal Ctx	26.6	21.2	Control (Path) 4 Occipital Ctx	19.2	21.0
AD 6 Sup Temporal Ctx	29.5	18.9	Control 1 Parietal Ctx	6.9	5.4
Control 1 Temporal Ctx	4.2	3.1	Control 2 Parietal Ctx	27.0	26.6
Control 2 Temporal Ctx	51.1	50.3	Control 3 Parietal Ctx	22.7	12.3
Control 3 Temporal Ctx	23.8	15.3	Control (Path) 1 Parietal Ctx	100.0	87.7
Control 3 Temporal Ctx	6.4	5.6	Control (Path) 2 Parietal Ctx	29.5	19.2
Control (Path) 1 Temporal Ctx	68.3	73.7	Control (Path) 3 Parietal Ctx	3.8	1.3
Control (Path) 2 Temporal Ctx	49.7	27.9	Control (Path) 4 Parietal Ctx	61.6	46.0

Table AF. General\_screening\_panel\_v1.5

Tissue Name	Rel. Exp.(%) Ag5035, Run 228967202	Rel. Exp.(%) Ag5035, Run 244373096	Tissue Name	Rel. Exp.(%) Ag5035, Run 228967202	Rel. Exp.(%) Ag5035, Run 244373096
Adipose	1.6	2.2	Renal ca. TK-10	0.0	0.0
Melanoma* Hs688(A).T	0.0	0.0	Bladder	0.6	0.3
Melanoma* Hs688(B).T	0.0	0.0	Gastric ca. (liver met.) NCI-N87	0.0	0.0
Melanoma* M14	0.0	0.0	Gastric ca. KATO III	0.0	0.0
Melanoma* LOXIMVI	0.0	0.0	Colon ca. SW- 948	0.0	0.0
Melanoma* SK-MEL-5	0.0	0.0	Colon ca. SW480	0.0	0.0
Squamous cell carcinoma SCC-4	0.0	0.0	Colon ca.* (SW480 met) SW620	0.0	0.0
Testis Pool	0.0	0.1	Colon ca. HT29	0.0	0.0
Prostate ca.* (bone met) PC-3	0.0	0.0	Colon ca. HCT- 116	0.0	0.0
Prostate Pool	1.4	2.0	Colon ca. CaCo- 2	0.2	0.2
Placenta	0.3	0.1	Colon cancer tissue	0.7	0.1
Uterus Pool	2.1	1.6	Colon ca. SW1116	0.0	0.0
Ovarian ca. OVCAR-3	0.0	0.0	Colon ca. Colo- 205	0.0	0.0
Ovarian ca. SK-OV-3	0.0	0.0	Colon ca. SW-48	0.0	0.0
Ovarian ca. OVCAR-4	0.3	0.0	Colon Pool	3.5	3.1
Ovarian ca. OVCAR-5	0.0	0.0	Small Intestine Pool	1.1	1.3
Ovarian ca. IGROV-1	0.0	0.0	Stomach Pool	0.2	1.4
Ovarian ca. OVCAR-8	0.0	0.0	Bone Marrow Pool	2.3	1.8
Ovary	0.3	0.3	Fetal Heart	0.3	0.6
Breast ca. MCF-7	0.0	0.0	Heart Pool	0.8	0.0
Breast ca. MDA-MB-	0.0	0.0	Lymph Node Pool	2.6	2.0

231					
Breast ca. BT 549	0.0	0.0	Fetal Skeletal Muscle	17.9	22.2
Breast ca. T47D	0.0	0.0	Skeletal Muscle Pool	100.0	83.5
Breast ca. MDA-N	0.0	0.0	Spleen Pool	0.6	0.0
Breast Pool	2.6	3.5	Thymus Pool	0.6	0.4
Trachea	0.8	1.1	CNS cancer (glio/astro) U87-MG	0.0	0.0
Lung	0.0	0.0	CNS cancer (glio/astro) U-118-MG	0.2	0.0
Fetal Lung	14.3	14.5	CNS cancer (neuro;met) SK-N-AS	0.0	0.0
Lung ca. NCI-N417	0.0	0.0	CNS cancer (astro) SF-539	0.0	0.0
Lung ca. LX-1	0.0	0.0	CNS cancer (astro) SNB-75	0.0	0.2
Lung ca. NCI-H146	0.0	0.0	CNS cancer (glio) SNB-19	0.0	0.0
Lung ca. SHP-77	9.3	12.7	CNS cancer (glio) SF-295	0.0	0.0
Lung ca. A549	0.0	0.0	Brain (Amygdala) Pool	32.8	31.0
Lung ca. NCI-H526	0.2	0.2	Brain (cerebellum)	69.7	76.3
Lung ca. NCI-H23	0.0	0.0	Brain (fetal)	90.1	100.0
Lung ca. NCI-H460	0.0	0.0	Brain (Hippocampus) Pool	27.9	31.0
Lung ca. HOP-62	0.0	0.0	Cerebral Cortex Pool	36.3	48.3
Lung ca. NCI-H522	0.0	0.0	Brain (Substantia nigra) Pool	31.0	32.1
Liver	0.0	0.0	Brain (Thalamus) Pool	50.0	50.3
Fetal Liver	2.1	2.0	Brain (whole)	46.0	38.2
Liver ca. HepG2	0.0	2.0	Spinal Cord Pool	17.6	18.4
Kidney Pool	1.8	0.0	Adrenal Gland	2.5	2.5
Fetal Kidney	0.8	0.7	Pituitary gland	1.3	1.2

			Pool		
Renal ca. 786-0	0.0	0.0	Salivary Gland	0.0	0.2
Renal ca. A498	0.0	0.0	Thyroid (female)	0.0	0.0
Renal ca. ACHN	0.0	0.0	Pancreatic ca. CAPAN2	0.0	0.0
Renal ca. UO-31	0.0	0.0	Pancreas Pool	1.6	7.9

Table AG. Panel 1.3D

Tissue Name	Rel. Exp.(%) Ag2903, Run 162556420	Tissue Name	Rel. Exp.(%) Ag2903, Run 162556420
Liver adenocarcinoma	0.0	Kidney (fetal)	0.3
Pancreas	0.0	Renal ca. 786-0	0.0
Pancreatic ca. CAPAN 2	0.0	Renal ca. A498	0.0
Adrenal gland	0.1	Renal ca. RXF 393	0.0
Thyroid	0.2	Renal ca. ACHN	0.0
Salivary gland	0.1	Renal ca. UO-31	0.1
Pituitary gland	0.4	Renal ca. TK-10	0.0
Brain (fetal)	2.0	Liver	0.0
Brain (whole)	3.9	Liver (fetal)	0.4
Brain (amygdala)	3.7	Liver ca. (hepatoblast) HepG2	0.0
Brain (cerebellum)	3.3	Lung	0.0
Brain (hippocampus)	5.6	Lung (fetal)	0.4
Brain (substantia nigra)	0.9	Lung ca. (small cell) LX-1	0.0
Brain (thalamus)	5.9	Lung ca. (small cell) NCI-H69	0.2
Cerebral Cortex	80.7	Lung ca. (s.cell var.) SHP-77	3.4
Spinal cord	1.7	Lung ca. (large cell) NCI-H460	0.0
glio/astro U87-MG	0.0	Lung ca. (non-sm. cell) A549	0.1
glio/astro U-118-MG	0.0	Lung ca. (non-s.cell) NCI-H23	0.0
astrocytoma SW1783	0.6	Lung ca. (non-s.cell) HOP-62	0.0
neuro*; met SK-N-AS	0.0	Lung ca. (non-s.cl)	0.0

		NCI-H522	
astrocytoma SF-539	0.0	Lung ca. (squam.) SW 900	0.0
astrocytoma SNB-75	0.0	Lung ca. (squam.) NCI-H596	0.2
glioma SNB-19	0.1	Mammary gland	0.1
glioma U251	0.0	Breast ca.* (pl.ef) MCF-7	0.0
glioma SF-295	0.0	Breast ca.* (pl.ef) MDA-MB-231	0.0
Heart (fetal)	5.2	Breast ca.* (pl.ef) T47D	0.0
Heart	0.3	Breast ca. BT-549	0.0
Skeletal muscle (fetal)	100.0	Breast ca. MDA-N	0.0
Skeletal muscle	21.2	Ovary	0.2
Bone marrow	0.2	Ovarian ca. OVCAR-3	0.0
Thymus	0.6	Ovarian ca. OVCAR-4	0.3
Spleen	0.0	Ovarian ca. OVCAR-5	0.0
Lymph node	0.3	Ovarian ca. OVCAR-8	0.0
Colorectal	1.1	Ovarian ca. IGROV- 1	0.0
Stomach	0.1	Ovarian ca.* (ascites) SK-OV-3	0.0
Small intestine	0.2	Uterus	0.1
Colon ca. SW480	0.0	Placenta	0.0
Colon ca.* SW620(SW480 met)	0.0	Prostate	0.0
Colon ca. HT29	0.0	Prostate ca.* (bone met)PC-3	0.0
Colon ca. HCT-116	0.0	Testis	0.3
Colon ca. CaCo-2	0.0	Melanoma Hs688(A).T	0.0
Colon ca. tissue(ODO3866)	0.5	Melanoma* (met) Hs688(B).T	0.0
Colon ca. HCC-2998	0.0	Melanoma UACC- 62	0.2
Gastric ca.* (liver met) NCI-N87	0.0	Melanoma M14	0.0
Bladder	0.2	Melanoma LOX IMVI	0.0

Trachea	0.3	Melanoma* (met) SK-MEL-5	0.0
Kidney	0.0	Adipose	0.3

Table AH. Panel 2D

Tissue Name	Rel. Exp.(%) Ag2903, Run 162345106	Tissue Name	Rel. Exp.(%) Ag2903, Run 162345106
Normal Colon	8.1	Kidney Margin 8120608	0.5
CC Well to Mod Diff (ODO3866)	0.3	Kidney Cancer 8120613	0.0
CC Margin (ODO3866)	0.3	Kidney Margin 8120614	0.1
CC Gr.2 rectosigmoid (ODO3868)	0.1	Kidney Cancer 9010320	0.5
CC Margin (ODO3868)	0.2	Kidney Margin 9010321	0.0
CC Mod Diff (ODO3920)	0.3	Normal Uterus	1.0
CC Margin (ODO3920)	0.4	Uterus Cancer 064011	0.5
CC Gr.2 ascend colon (ODO3921)	1.1	Normal Thyroid	1.0
CC Margin (ODO3921)	0.9	Thyroid Cancer 064010	0.0
CC from Partial Hepatectomy (ODO4309) Mets	0.4	Thyroid Cancer A302152	0.0
Liver Margin (ODO4309)	0.1	Thyroid Margin A302153	0.1
Colon mets to lung (OD04451-01)	0.1	Normal Breast	3.0
Lung Margin (OD04451- 02)	1.3	Breast Cancer (OD04566)	0.4
Normal Prostate 6546-1	2.3	Breast Cancer (OD04590-01)	0.8
Prostate Cancer (OD04410)	1.2	Breast Cancer Mets (OD04590-03)	1.5
Prostate Margin (OD04410)	4.2	Breast Cancer Metastasis (OD04655-05)	0.2
Prostate Cancer (OD04720-01)	1.2	Breast Cancer 064006	0.5

Prostate Margin (OD04720-02)	4.6	Breast Cancer 1024	1.2
Normal Lung 061010	5.8	Breast Cancer 9100266	1.8
Lung Met to Muscle (ODO4286)	0.0	Breast Margin 9100265	1.1
Muscle Margin (ODO4286)	100.0	Breast Cancer A209073	0.6
Lung Malignant Cancer (OD03126)	0.8	Breast Margin A209073	0.0
Lung Margin (OD03126)	7.7	Normal Liver	0.0
Lung Cancer (OD04404)	1.4	Liver Cancer 064003	0.0
Lung Margin (OD04404)	4.1	Liver Cancer 1025	0.0
Lung Cancer (OD04565)	0.3	Liver Cancer 1026	0.0
Lung Margin (OD04565)	1.2	Liver Cancer 6004-T	0.1
Lung Cancer (OD04237-01)	0.7	Liver Tissue 6004-N	0.5
Lung Margin (OD04237-02)	2.4	Liver Cancer 6005-T	0.0
Ocular Mel Met to Liver (ODO4310)	0.0	Liver Tissue 6005-N	0.0
Liver Margin (ODO4310)	0.1	Normal Bladder	0.6
Melanoma Mets to Lung (OD04321)	0.1	Bladder Cancer 1023	0.2
Lung Margin (OD04321)	2.4	Bladder Cancer A302173	1.4
Normal Kidney	1.5	Bladder Cancer (OD04718-01)	0.5
Kidney Ca, Nuclear grade 2 (OD04338)	0.5	Bladder Normal Adjacent (OD04718-03)	4.9
Kidney Margin (OD04338)	1.4	Normal Ovary	0.1
Kidney Ca Nuclear grade 1/2 (OD04339)	1.8	Ovarian Cancer 064008	1.9
Kidney Margin (OD04339)	0.6	Ovarian Cancer (OD04768-07)	0.0
Kidney Ca, Clear cell type (OD04340)	1.0	Ovary Margin (OD04768-08)	0.2
Kidney Margin (OD04340)	0.8	Normal Stomach	4.5
Kidney Ca, Nuclear grade 3 (OD04348)	1.3	Gastric Cancer 9060358	1.7
Kidney Margin	0.7	Stomach Margin	1.5



(OD04348)		9060359	
Kidney Cancer (OD04622-01)	0.7	Gastric Cancer 9060395	1.2
Kidney Margin (OD04622-03)	0.0	Stomach Margin 9060394	2.0
Kidney Cancer (OD04450-01)	0.0	Gastric Cancer 9060397	0.6
Kidney Margin (OD04450-03)	0.1	Stomach Margin 9060396	1.7
Kidney Cancer 8120607	0.1	Gastric Cancer 064005	2.9

Table AI. Panel 4.1D

Tissue Name	Rel. Exp.(%) Ag5035, Run 223740981	Tissue Name	Rel. Exp.(%) Ag5035, Run 223740981
Secondary Th1 act	0.0	HUVEC IL-1beta	2.0
Secondary Th2 act	0.0	HUVEC IFN gamma	0.0
Secondary Tr1 act	0.0	HUVEC TNF alpha + IFN gamma	1.9
Secondary Th1 rest	0.0	HUVEC TNF alpha + IL4	0.0
Secondary Th2 rest	0.0	HUVEC IL-11	0.0
Secondary Tr1 rest	0.0	Lung Microvascular EC none	0.0
Primary Th1 act	0.0	Lung Microvascular EC TNFalpha + IL-1beta	100.0
Primary Th2 act	0.0	Microvascular Dermal EC none	0.0
Primary Tr1 act	2.0	Microvascular Dermal EC TNFalpha + IL-1beta	55.5
Primary Th1 rest	0.0	Bronchial epithelium TNFalpha + IL1beta	2.2
Primary Th2 rest	0.0	Small airway epithelium none	4.2
Primary Tr1 rest	0.0	Small airway epithelium TNFalpha + IL-1beta	3.7
CD45RA CD4 lymphocyte act	0.0	Coronary artery SMC rest	2.3
CD45RO CD4 lymphocyte act	0.0	Coronary artery SMC TNFalpha + IL-1beta	0.0
CD8 lymphocyte act	0.0	Astrocytes rest	0.0
Secondary CD8 lymphocyte rest	0.0	Astrocytes TNFalpha + IL-1beta	0.0
Secondary CD8	0.0	KU-812 (Basophil) rest	10.6

lymphocyte act			
CD4 lymphocyte none	0.0	KU-812 (Basophil) PMA/ionomycin	13.6
2ry Th1/Th2/Tr1_anti- CD95 CH11	0.0	CCD1106 (Keratinocytes) none	0.0
LAK cells rest	0.0	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	0.0
LAK cells IL-2	0.0	Liver cirrhosis	0.0
LAK cells IL-2+IL-12	8.4	NCI-H292 none	0.0
LAK cells IL-2+IFN gamma	2.9	NCI-H292 IL-4	0.0
LAK cells IL-2+ IL-18	3.8	NCI-H292 IL-9	0.0
LAK cells PMA/ionomycin	2.3	NCI-H292 IL-13	2.5
NK Cells IL-2 rest	0.0	NCI-H292 IFN gamma	0.0
Two Way MLR 3 day	2.1	HPAEC none	0.0
Two Way MLR 5 day	2.3	HPAEC TNF alpha + IL-1 beta	8.8
Two Way MLR 7 day	1.8	Lung fibroblast none	0.0
PBMC rest	6.7	Lung fibroblast TNF alpha + IL-1 beta	0.0
PBMC PWM	0.0	Lung fibroblast IL-4	0.0
PBMC PHA-L	6.3	Lung fibroblast IL-9	0.0
Ramos (B cell) none	0.0	Lung fibroblast IL-13	0.0
Ramos (B cell) ionomycin	0.0	Lung fibroblast IFN gamma	0.0
B lymphocytes PWM	9.2	Dermal fibroblast CCD1070 rest	0.0
B lymphocytes CD40L and IL-4	1.9	Dermal fibroblast CCD1070 TNF alpha	0.0
EOL-1 dbcAMP	0.0	Dermal fibroblast CCD1070 IL-1 beta	0.0
EOL-1 dbcAMP PMA/ionomycin	0.0	Dermal fibroblast IFN gamma	0.0
Dendritic cells none	0.0	Dermal fibroblast IL-4	0.0
Dendritic cells LPS	2.4	Dermal Fibroblasts rest	2.0
Dendritic cells anti- CD40	0.0	Neutrophils TNFa+LPS	0.0
Monocytes rest	0.0	Neutrophils rest	0.0
Monocytes LPS	31.6	Colon	5.4
Macrophages rest	1.7	Lung	8.1
Macrophages LPS	6.5	Thymus	5.1
HUVEC none	0.0	Kidney	0.0

HUVEC starved	0.0		
---------------	-----	--	--

**AI\_comprehensive\_panel\_v1.0 Summary:** Ag2903/Ag5035 Two experiments with two different probe and primer sets produce results that are in very good agreement. Expression of the CG56258-01 gene appears to be more highly associated with synovium and bone samples from patients with osteoarthritis when compared to expression in the control samples. Thus, therapeutic modulation of the expression or function of this gene may be effective in the treatment of osteoarthritis. A third experiment with the probe and primer set Ag6163 shows low/undetectable levels of expression (CTs>35).

**CNS\_neurodegeneration\_v1.0 Summary:** Ag2903/Ag5035 Two experiments with two different probes and primers produce results that are in excellent agreement. This panel does not show differential expression of the CG56258-01 gene in Alzheimer's disease. However, this expression profile confirms the presence of this gene in the brain, with highest expression in the hippocampus of an Alzheimer's patient and the occipital cortex of a control patient (CTs=28-30). Please see Panel 1.3D for discussion of utility of this gene in the central nervous system.

**General\_screening\_panel\_v1.5 Summary:** Ag5035 Two experiments with the same probe and primer produce results that are in excellent agreement, with the CG56258-02 gene showing highly brain preferential expression (CTs=30-31). In addition, moderate levels of expression are seen in fetal and adult skeletal muscle (CTs=30-31). This expression profile is in excellent concordance with the results in Panel 1.3D. Please see Panel 1.3D for further discussion of utility of this gene in the central nervous system and metabolic disease.

**Panel 1.3D Summary:** Ag2903 Expression of the CG56258-01 gene is highest in fetal skeletal muscle (CT=26.8). In addition, significant levels of expression are also seen in adult skeletal muscle and fetal heart. Thus, expression of this gene could be used to differentiate skeletal muscle derived samples from other samples on this panel and as a marker of skeletal muscle. This gene encodes a putative sodium/calcium exchanger. Altered levels of intracellular calcium have been implicated in many diseases, including type 2 diabetes. Based on its expression profile and homology to a calcium transport protein, therapeutic modulation of the expression or function of this gene or gene product may be effective in the treatment of type 2 diabetes.

In addition, moderate to low levels of expression are seen in all regions of the CNS examined. Inhibition of calcium uptake has been shown to decrease neuronal death in response to cerebral ischemia. Therefore, this gene, a putative calcium transport protein, represents an excellent drug target for the treatment of stroke. Treatment with an antagonist immediately after stroke could decrease total infarct volume and lessen the overall stroke severity.

*See, generally,*

Balasubramanyam M, Balaji RA, Subashini B, Mohan V. Evidence for mechanistic alterations of  $\text{Ca}^{2+}$  homeostasis in Type 2 diabetes mellitus. *Int J Exp Diabetes Res* 2001;1(4):275-87. PMID: 11467418; and

Matsuda T, Arakawa N, Takuma K, Kishida Y, Kawasaki Y, Sakaue M, Takahashi K, Takahashi T, Suzuki T, Ota T, Hamano-Takahashi A, Onishi M, Tanaka Y, Kameo K, Baba A. SEA0400, a novel and selective inhibitor of the  $\text{Na}^{+}$ - $\text{Ca}^{2+}$  exchanger, attenuates reperfusion injury in the in vitro and in vivo cerebral ischemic models. *J Pharmacol Exp Ther* 2001 Jul;298(1):249-56.

**Panel 2D Summary:** Ag2903 The expression of the CG56258-01 gene in this panel is consistent with the profile seen in Panel 1.3D. Expression is highest and most prominent in a normal muscle sample (CT=28.7). Please see Panel 1.3D for discussion of utility of this gene in metabolic disease.

**Panel 4.1D Summary:** Ag5035 Expression of the CG56258-02 gene is restricted to TNF- $\alpha$  and IL-1  $\beta$  treated lung and dermal microvasculature (CTs=33-34). Endothelial cells are known to play important roles in inflammatory responses by altering the expression of surface proteins that are involved in activation and recruitment of effector inflammatory cells. The expression of this gene in dermal microvascular endothelial cells suggests that this protein product may be involved in inflammatory responses to skin disorders, including psoriasis. Expression in lung microvascular endothelial cells suggests that the protein encoded by this transcript may also be involved in lung disorders including asthma, allergies, chronic obstructive pulmonary disease, and emphysema. Therefore, therapeutic modulation of the protein encoded by this gene may lead to amelioration of symptoms associated with psoriasis, asthma, allergies, chronic obstructive pulmonary disease, and emphysema.

Ag5035 Results from one experiment with this gene are not included. The amp plot indicates that there were experimental difficulties with this run.

Ag6163 Expression of this gene is low/undetectable in all samples on this panel (CTs>35).

### B. NOV2a (CG59843-01: fibropellin III-like)

- 5 Expression of gene CG59843-01 was assessed using the primer-probe sets Ag2797, Ag3606 and Ag221, described in Tables BA, BB and BC. Results of the RTQ-PCR runs are shown in Tables BD, BE, BF, BG, BH, BI, BJ, BK and BL.

Table BA. Probe Name Ag2797

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5' -cagctacaaatgcctctgtgat-3'	22	1488	102
Probe	TET-5' -ccaggttaccatggcctctactgtga-3' - TAMRA	26	1510	103
Reverse	5' -agcggagaggcactcattatat-3'	22	1542	104

Table BB. Probe Name Ag3606

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5' -cagctacaaatgcctctgtgat-3'	22	1488	105
Probe	TET-5' -ccaggttaccatggcctctactgtga-3' - TAMRA	26	1510	106
Reverse	5' -agcggagaggcactcattatat-3'	22	1542	107

- 10 Table BC. Probe Name Ag221

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5' -ctgccaggtaggcagtgta-3'	20	545	108
Probe	TET-5' -aaaatcctgcctcgctctcaggcaa-3' - TAMRA	25	517	109
Reverse	5' -gcctggtcctgctactcagga-3'	21	489	110

Table BD. CNS\_neurodegeneration\_v1.0

Tissue Name	Rel. Exp.(%) Ag2797, Run 208699245	Rel. Exp.(%) Ag3606, Run 210997602	Tissue Name	Rel. Exp.(%) Ag2797, Run 208699245	Rel. Exp.(%) Ag3606, Run 210997602
AD 1 Hippo	8.0	14.9	Control	2.7	3.4

			(Path) 3 Temporal Ctx		
AD 2 Hippo	19.8	40.9	Control (Path) 4 Temporal Ctx	12.0	21.5
AD 3 Hippo	7.3	11.1	AD 1 Occipital Ctx	9.5	16.3
AD 4 Hippo	7.0	12.1	AD 2 Occipital Ctx (Missing)	92.7	0.0
AD 5 hippo	97.3	61.1	AD 3 Occipital Ctx	5.6	0.1
AD 6 Hippo	31.9	88.9	AD 4 Occipital Ctx	15.1	27.0
Control 2 Hippo	14.6	47.0	AD 5 Occipital Ctx	97.3	25.5
Control 4 Hippo	12.4	19.8	AD 6 Occipital Ctx	99.3	57.8
Control (Path) 3 Hippo	5.1	12.3	Control 1 Occipital Ctx	2.6	3.4
AD 1 Temporal Ctx	10.7	16.7	Control 2 Occipital Ctx	51.8	73.2
AD 2 Temporal Ctx	19.5	41.8	Control 3 Occipital Ctx	0.2	15.3
AD 3 Temporal Ctx	3.2	6.7	Control 4 Occipital Ctx	6.4	13.1
AD 4 Temporal Ctx	14.7	25.0	Control (Path) 1 Occipital Ctx	63.7	97.3
AD 5 Inf Temporal Ctx	100.0	100.0	Control (Path) 2 Occipital Ctx	7.9	10.9
AD 5	100.0	51.4	Control	4.1	2.8

SupTemporal Ctx			(Path) 3 Occipital Ctx		
AD 6 Inf Temporal Ctx	36.1	65.1	Control (Path) 4 Occipital Ctx	4.8	9.7
AD 6 Sup Temporal Ctx	26.2	50.0	Control 1 Parietal Ctx	7.3	7.6
Control 1 Temporal Ctx	6.1	6.9	Control 2 Parietal Ctx	95.9	36.6
Control 2 Temporal Ctx	25.2	54.0	Control 3 Parietal Ctx	10.4	19.8
Control 3 Temporal Ctx	6.0	14.9	Control (Path) 1 Parietal Ctx	34.9	70.2
Control 4 Temporal Ctx	4.3	8.9	Control (Path) 2 Parietal Ctx	12.9	22.7
Control (Path) 1 Temporal Ctx	33.4	50.3	Control (Path) 3 Parietal Ctx	2.2	3.5
Control (Path) 2 Temporal Ctx	12.6	27.0	Control (Path) 4 Parietal Ctx	16.7	28.5

Table BE. General\_screening\_panel\_v1.4

Tissue Name	Rel. Exp.(%) Ag3606, Run 217675868	Tissue Name	Rel. Exp.(%) Ag3606, Run 217675868
Adipose	0.0	Renal ca. TK-10	0.1
Melanoma* Hs688(A).T	0.1	Bladder	0.1
Melanoma* Hs688(B).T	2.9	Gastric ca. (liver met.) NCI-N87	0.3
Melanoma* M14	0.0	Gastric ca. KATO III	0.0
Melanoma* LOXIMVI	10.4	Colon ca. SW-948	0.0
Melanoma* SK-MEL-5	97.9	Colon ca. SW480	0.0
Squamous cell carcinoma SCC-4	1.4	Colon ca.* (SW480 met) SW620	0.0
Testis Pool	0.4	Colon ca. HT29	0.0
Prostate ca.* (bone met) PC-3	0.1	Colon ca. HCT-116	0.6
Prostate Pool	0.3	Colon ca. CaCo-2	0.0

Placenta	0.1	Colon cancer tissue	0.3
Uterus Pool	0.3	Colon ca. SW1116	0.0
Ovarian ca. OVCAR-3	0.1	Colon ca. Colo-205	0.0
Ovarian ca. SK-OV-3	0.2	Colon ca. SW-48	0.0
Ovarian ca. OVCAR-4	0.0	Colon Pool	0.2
Ovarian ca. OVCAR-5	0.7	Small Intestine Pool	0.3
Ovarian ca. IGROV-1	1.2	Stomach Pool	0.4
Ovarian ca. OVCAR-8	0.6	Bone Marrow Pool	0.2
Ovary	0.0	Fetal Heart	0.0
Breast ca. MCF-7	0.0	Heart Pool	0.2
Breast ca. MDA-MB-231	0.7	Lymph Node Pool	0.3
Breast ca. BT 549	2.9	Fetal Skeletal Muscle	0.0
Breast ca. T47D	1.0	Skeletal Muscle Pool	0.0
Breast ca. MDA-N	5.4	Spleen Pool	0.8
Breast Pool	0.2	Thymus Pool	0.1
Trachea	1.3	CNS cancer (glio/astro) U87-MG	100.0
Lung	0.0	CNS cancer (glio/astro) U-118-MG	42.0
Fetal Lung	0.4	CNS cancer (neuro;met) SK-N-AS	0.0
Lung ca. NCI-N417	0.0	CNS cancer (astro) SF-539	0.3
Lung ca. LX-1	0.0	CNS cancer (astro) SNB-75	1.2
Lung ca. NCI-H146	12.0	CNS cancer (glio) SNB-19	1.0
Lung ca. SHP-77	40.6	CNS cancer (glio) SF-295	23.7
Lung ca. A549	0.1	Brain (Amygdala) Pool	18.2
Lung ca. NCI-H526	0.0	Brain (cerebellum)	77.4
Lung ca. NCI-H23	2.2	Brain (fetal)	32.1
Lung ca. NCI-H460	34.2	Brain (Hippocampus) Pool	19.2
Lung ca. HOP-62	2.1	Cerebral Cortex Pool	20.2
Lung ca. NCI-H522	0.0	Brain (Substantia nigra) Pool	24.7



Liver	0.0	Brain (Thalamus) Pool	25.5
Fetal Liver	0.0	Brain (whole)	26.8
Liver ca. HepG2	0.0	Spinal Cord Pool	24.0
Kidney Pool	1.1	Adrenal Gland	26.4
Fetal Kidney	4.1	Pituitary gland Pool	5.0
Renal ca. 786-0	0.0	Salivary Gland	10.0
Renal ca. A498	0.1	Thyroid (female)	0.0
Renal ca. ACHN	0.0	Pancreatic ca. CAPAN2	0.3
Renal ca. UO-31	0.3	Pancreas Pool	0.7

Table BF. Panel 1

Tissue Name	Rel. Exp.(%) Ag221, Run 87987754	Tissue Name	Rel. Exp.(%) Ag221, Run 87987754
Endothelial cells	0.0	Renal ca. 786-0	0.0
Endothelial cells (treated)	0.0	Renal ca. A498	0.0
Pancreas	0.0	Renal ca. RXF 393	0.0
Pancreatic ca. CAPAN 2	0.0	Renal ca. ACHN	0.0
Adrenal gland	22.8	Renal ca. UO-31	0.0
Thyroid	0.0	Renal ca. TK-10	0.0
Salivary gland	6.7	Liver	0.0
Pituitary gland	0.0	Liver (fetal)	0.0
Brain (fetal)	15.3	Liver ca. (hepatoblast) HepG2	0.0
Brain (whole)	42.6	Lung	0.0
Brain (amygdala)	19.9	Lung (fetal)	0.0
Brain (cerebellum)	100.0	Lung ca. (small cell) LX-1	0.0
Brain (hippocampus)	17.9	Lung ca. (small cell) NCI-H69	0.0
Brain (substantia nigra)	40.9	Lung ca. (s.cell var.) SHP-77	0.0
Brain (thalamus)	39.5	Lung ca. (large cell) NCI-H460	0.0
Brain (hypothalamus)	7.9	Lung ca. (non-sm. cell) A549	0.0
Spinal cord	13.6	Lung ca. (non-s.cell) NCI-H23	0.6
glio/astro U87-MG	21.0	Lung ca. (non-s.cell) HOP-62	0.6
glio/astro U-118-MG	10.4	Lung ca. (non-s.cl)	0.0

		NCI-H522	
astrocytoma SW1783	1.8	Lung ca. (squam.) SW 900	0.0
neuro*; met SK-N-AS	0.0	Lung ca. (squam.) NCI-H596	0.0
astrocytoma SF-539	0.0	Mammary gland	0.0
astrocytoma SNB-75	0.0	Breast ca.* (pl.ef) MCF-7	0.0
glioma SNB-19	0.3	Breast ca.* (pl.ef) MDA-MB-231	0.0
glioma U251	0.0	Breast ca.* (pl. ef) T47D	0.0
glioma SF-295	3.5	Breast ca. BT-549	0.0
Heart	0.0	Breast ca. MDA-N	2.8
Skeletal muscle	0.0	Ovary	0.0
Bone marrow	0.0	Ovarian ca. OVCAR-3	0.0
Thymus	0.0	Ovarian ca. OVCAR-4	0.0
Spleen	0.0	Ovarian ca. OVCAR-5	0.0
Lymph node	0.0	Ovarian ca. OVCAR-8	0.2
Colon (ascending)	0.2	Ovarian ca. IGROV-1	0.0
Stomach	1.7	Ovarian ca. (ascites) SK-OV-3	0.0
Small intestine	0.3	Uterus	1.5
Colon ca. SW480	0.0	Placenta	0.0
Colon ca.* SW620 (SW480 met)	0.0	Prostate	0.9
Colon ca. HT29	0.0	Prostate ca.* (bone met) PC-3	0.0
Colon ca. HCT-116	0.0	Testis	0.2
Colon ca. CaCo-2	0.0	Melanoma Hs688(A).T	0.0
Colon ca. HCT-15	0.0	Melanoma* (met) Hs688(B).T	0.2
Colon ca. HCC-2998	0.0	Melanoma UACC-62	0.0
Gastric ca. * (liver met) NCI-N87	0.0	Melanoma M14	0.0
Bladder	0.2	Melanoma LOX IMVI	1.7
Trachea	3.1	Melanoma* (met) SK-MEL-5	21.3

Kidney	1.5	Melanoma SK-MEL-28	0.0
Kidney (fetal)	5.9		

Table BG. Panel 1.3D

Tissue Name	Rel. Exp.(%) Ag2797, Run 165643064	Rel. Exp.(%) Ag2797, Run 165693893	Tissue Name	Rel. Exp.(%) Ag2797, Run 165643064	Rel. Exp.(%) Ag2797, Run 165693893
Liver adenocarcinoma	0.5	0.9	Kidney (fetal)	2.1	4.5
Pancreas	0.0	0.0	Renal ca. 786-0	0.0	0.0
Pancreatic ca. CAPAN 2	0.3	0.2	Renal ca. A498	0.5	0.6
Adrenal gland	11.7	15.6	Renal ca. RXF 393	0.1	0.0
Thyroid	0.0	0.1	Renal ca. ACHN	0.0	0.0
Salivary gland	6.7	9.3	Renal ca. UO-31	3.5	0.4
Pituitary gland	13.7	12.2	Renal ca. TK-10	0.1	0.1
Brain (fetal)	27.9	31.2	Liver	0.0	0.0
Brain (whole)	59.0	66.9	Liver (fetal)	0.1	0.0
Brain (amygdala)	33.4	35.4	Liver ca. (hepatoblast) HepG2	0.0	0.1
Brain (cerebellum)	71.2	82.4	Lung	0.1	0.3
Brain (hippocampus)	29.7	37.4	Lung (fetal)	0.1	0.0
Brain (substantia nigra)	41.8	52.9	Lung ca. (small cell) LX-1	0.0	0.0
Brain (thalamus)	100.0	100.0	Lung ca. (small cell) NCI-H69	0.0	0.0
Cerebral Cortex	26.6	28.7	Lung ca. (s.cell var.) SHP-77	14.3	15.3
Spinal cord	27.7	38.2	Lung ca. (large cell) NCI-H460	28.3	29.1
glio/astro U87-MG	16.5	21.2	Lung ca. (non-sm. cell) A549	0.1	0.1

glio/astro U-118-MG	13.8	21.0	Lung ca. (non-s.cell) NCI-H23	0.6	1.0
astrocytoma SW1783	4.4	4.3	Lung ca. (non-s.cell) HOP-62	3.1	1.4
neuro*; met SK-N-AS	0.0	0.1	Lung ca. (non-s.cl) NCI-H522	0.7	0.0
astrocytoma SF-539	0.1	0.0	Lung ca. (squam.) SW 900	0.1	0.1
astrocytoma SNB-75	0.5	0.3	Lung ca. (squam.) NCI-H596	0.3	0.1
glioma SNB-19	1.0	0.6	Mammary gland	0.3	0.2
glioma U251	0.8	0.4	Breast ca.* (pl.ef) MCF-7	0.1	0.0
glioma SF-295	4.2	4.2	Breast ca.* (pl.ef) MDA-MB-231	0.3	0.5
Heart (fetal)	0.2	0.2	Breast ca.* (pl.ef) T47D	0.0	0.0
Heart	0.3	0.1	Breast ca. BT-549	1.3	2.0
Skeletal muscle (fetal)	0.1	3.5	Breast ca. MDA-N	0.6	1.2
Skeletal muscle	0.0	0.2	Ovary	0.0	0.1
Bone marrow	0.0	0.0	Ovarian ca. OVCAR-3	0.1	0.2
Thymus	0.1	0.1	Ovarian ca. OVCAR-4	0.0	0.1
Spleen	1.5	0.8	Ovarian ca. OVCAR-5	0.2	0.1
Lymph node	0.2	0.2	Ovarian ca. OVCAR-8	0.2	0.2
Colorectal	0.2	0.1	Ovarian ca. IGROV-1	0.1	0.0
Stomach	1.9	2.5	Ovarian ca.* (ascites) SK-OV-3	0.1	0.1
Small intestine	0.8	2.1	Uterus	0.5	1.1
Colon ca. SW480	0.0	0.0	Placenta	0.1	0.1
Colon ca.* SW620(SW480	0.0	0.1	Prostate	0.2	0.9

met)					
Colon ca. HT29	0.0	0.0	Prostate ca.* (bone met)PC-3	0.0	0.0
Colon ca. HCT-116	0.1	0.2	Testis	0.2	0.5
Colon ca. CaCo-2	0.0	0.0	Melanoma Hs688(A).T	0.1	0.1
Colon ca. tissue(ODO3866)	0.1	0.4	Melanoma* (met) Hs688(B).T	0.2	0.1
Colon ca. HCC-2998	0.0	0.0	Melanoma UACC-62	0.7	0.3
Gastric ca.* (liver met) NCI-N87	0.5	0.6	Melanoma M14	0.2	0.1
Bladder	0.0	0.0	Melanoma LOX IMVI	0.3	0.3
Trachea	1.0	1.2	Melanoma* (met) SK- MEL-5	18.6	16.2
Kidney	1.0	1.8	Adipose	0.1	0.1

Table BH. Panel 2D

Tissue Name	Rel. Exp.(%) Ag2797, Run 163577803	Rel. Exp.(%) Ag2797, Run 165910585	Tissue Name	Rel. Exp.(%) Ag2797, Run 163577803	Rel. Exp.(%) Ag2797, Run 165910585
Normal Colon	24.0	8.5	Kidney Margin 8120608	18.3	10.2
CC Well to Mod Diff (ODO3866)	0.4	0.4	Kidney Cancer 8120613	0.5	100.0
CC Margin (ODO3866)	6.3	2.1	Kidney Margin 8120614	15.8	8.4
CC Gr.2 rectosigmoid (ODO3868)	0.2	0.2	Kidney Cancer 9010320	36.6	24.3
CC Margin (ODO3868)	1.8	0.9	Kidney Margin 9010321	19.3	14.5
CC Mod Diff (ODO3920)	0.2	0.0	Normal Uterus	4.2	1.5
CC Margin (ODO3920)	6.8	5.7	Uterus Cancer 064011	4.9	2.3

CC Gr.2 ascend colon (ODO3921)	2.0	0.5	Normal Thyroid	1.7	0.1
CC Margin (ODO3921)	2.1	1.2	Thyroid Cancer 064010	0.0	0.0
CC from Partial Hepatectomy (ODO4309) Mets	0.0	0.0	Thyroid Cancer A302152	0.1	0.0
Liver Margin (ODO4309)	0.0	0.0	Thyroid Margin A302153	0.0	0.1
Colon mets to lung (OD04451- 01)	1.3	0.1	Normal Breast	3.3	1.5
Lung Margin (OD04451-02)	10.7	4.5	Breast Cancer (OD04566)	0.0	0.0
Normal Prostate 6546-1	98.6	16.2	Breast Cancer (OD04590-01)	0.0	0.7
Prostate Cancer (OD04410)	7.9	2.3	Breast Cancer Mets (OD04590-03)	1.1	0.0
Prostate Margin (OD04410)	8.4	4.4	Breast Cancer Metastasis (OD04655-05)	1.0	0.0
Prostate Cancer (OD04720-01)	3.2	2.6	Breast Cancer 064006	0.4	0.2
Prostate Margin (OD04720-02)	9.1	3.4	Breast Cancer 1024	5.9	2.7
Normal Lung 061010	15.7	6.5	Breast Cancer 9100266	0.1	0.1
Lung Met to Muscle (ODO4286)	6.0	2.2	Breast Margin 9100265	1.0	0.4
Muscle Margin (ODO4286)	0.0	0.0	Breast Cancer A209073	47.0	56.6
Lung Malignant Cancer (OD03126)	24.0	11.5	Breast Margin A209073	7.0	3.4
Lung Margin (OD03126)	7.6	1.9	Normal Liver	0.0	0.1
Lung Cancer (OD04404)	0.5	0.4	Liver Cancer 064003	0.0	0.0
Lung Margin (OD04404)	4.8	2.8	Liver Cancer 1025	0.0	0.0

Lung Cancer (OD04565)	2.0	0.5	Liver Cancer 1026	0.0	0.0
Lung Margin (OD04565)	1.9	1.2	Liver Cancer 6004-T	0.1	0.0
Lung Cancer (OD04237-01)	1.0	1.1	Liver Tissue 6004-N	0.9	0.1
Lung Margin (OD04237-02)	3.0	0.4	Liver Cancer 6005-T	0.5	0.2
Ocular Mel Met to Liver (ODO4310)	0.3	0.0	Liver Tissue 6005-N	0.0	0.0
Liver Margin (ODO4310)	0.0	0.1	Normal Bladder	2.9	0.6
Melanoma Mets to Lung (OD04321)	6.5	2.9	Bladder Cancer 1023	1.7	37.9
Lung Margin (OD04321)	5.9	2.0	Bladder Cancer A302173	0.0	0.1
Normal Kidney	100.0	57.0	Bladder Cancer (OD04718-01)	0.0	0.3
Kidney Ca, Nuclear grade 2 (OD04338)	3.3	2.6	Bladder Normal Adjacent (OD04718-03)	1.7	0.8
Kidney Margin (OD04338)	64.6	39.0	Normal Ovary	2.2	0.8
Kidney Ca Nuclear grade 1/2 (OD04339)	0.5	0.1	Ovarian Cancer 064008	2.9	1.2
Kidney Margin (OD04339)	65.5	35.4	Ovarian Cancer (OD04768-07)	1.2	2.8
Kidney Ca, Clear cell type (OD04340)	0.0	0.3	Ovary Margin (OD04768-08)	4.1	2.2
Kidney Margin (OD04340)	62.9	33.2	Normal Stomach	41.8	20.3
Kidney Ca, Nuclear grade 3 (OD04348)	13.4	5.7	Gastric Cancer 9060358	1.0	0.6
Kidney Margin (OD04348)	49.0	21.9	Stomach Margin 9060359	29.5	12.8
Kidney Cancer	25.9	14.2	Gastric Cancer	2.0	1.6

(OD04622-01)			9060395		
Kidney Margin (OD04622-03)	8.1	3.1	Stomach Margin 9060394	4.5	2.6
Kidney Cancer (OD04450-01)	0.1	0.1	Gastric Cancer 9060397	0.9	0.1
Kidney Margin (OD04450-03)	72.2	42.9	Stomach Margin 9060396	2.7	2.7
Kidney Cancer 8120607	88.3	44.1	Gastric Cancer 064005	1.3	0.7

Table BI. Panel 3D

Tissue Name	Rel. Exp.(%) Ag2797, Run 165032015	Tissue Name	Rel. Exp.(%) Ag2797, Run 165032015
Daoy- Medulloblastoma	0.7	Ca Ski- Cervical epidermoid carcinoma (metastasis)	5.0
TE671- Medulloblastoma	0.0	ES-2- Ovarian clear cell carcinoma	5.4
D283 Med- Medulloblastoma	0.2	Ramos- Stimulated with PMA/ionomycin 6h	0.0
PFSK-1- Primitive Neuroectodermal	0.0	Ramos- Stimulated with PMA/ionomycin 14h	0.0
XF-498- CNS	1.8	MEG-01- Chronic myelogenous leukemia (megokaryoblast)	0.0
SNB-78- Glioma	0.3	Raji- Burkitt's lymphoma	0.0
SF-268- Glioblastoma	1.8	Daudi- Burkitt's lymphoma	0.0
T98G- Glioblastoma	0.1	U266- B-cell plasmacytoma	0.0
SK-N-SH- Neuroblastoma (metastasis)	0.2	CA46- Burkitt's lymphoma	0.0
SF-295- Glioblastoma	6.3	RL- non-Hodgkin's B-cell lymphoma	0.0
Cerebellum	58.6	JM1- pre-B-cell lymphoma	0.0
Cerebellum	92.7	Jurkat- T cell leukemia	0.0
NCI-H292- Mucoepidermoid lung carcinoma	1.2	TF-1- Erythroleukemia	0.0
DMS-114- Small cell lung cancer	0.0	HUT 78- T-cell lymphoma	0.0
DMS-79- Small cell lung cancer	100.0	U937- Histiocytic lymphoma	0.0



NCI-H146- Small cell lung cancer	35.8	KU-812- Myelogenous leukemia	0.0
NCI-H526- Small cell lung cancer	0.0	769-P- Clear cell renal carcinoma	0.0
NCI-N417- Small cell lung cancer	0.0	Caki-2- Clear cell renal carcinoma	5.2
NCI-H82- Small cell lung cancer	0.1	SW 839- Clear cell renal carcinoma	0.0
NCI-H157- Squamous cell lung cancer (metastasis)	41.8	G401- Wilms' tumor	0.1
NCI-H1155- Large cell lung cancer	1.4	Hs766T- Pancreatic carcinoma (LN metastasis)	0.9
NCI-H1299- Large cell lung cancer	1.5	CAPAN-1- Pancreatic adenocarcinoma (liver metastasis)	0.0
NCI-H727- Lung carcinoid	3.0	SU86.86- Pancreatic carcinoma (liver metastasis)	4.5
NCI-UMC-11- Lung carcinoid	17.3	BxPC-3- Pancreatic adenocarcinoma	0.0
LX-1- Small cell lung cancer	0.0	HPAC- Pancreatic adenocarcinoma	0.8
Colo-205- Colon cancer	0.0	MIA PaCa-2- Pancreatic carcinoma	0.0
KM12- Colon cancer	0.1	CFPAC-1- Pancreatic ductal adenocarcinoma	1.3
KM20L2- Colon cancer	0.0	PANC-1- Pancreatic epithelioid ductal carcinoma	0.1
NCI-H716- Colon cancer	0.8	T24- Bladder carcinma (transitional cell)	0.3
SW-48- Colon adenocarcinoma	0.0	5637- Bladder carcinoma	1.5
SW1116- Colon adenocarcinoma	0.0	HT-1197- Bladder carcinoma	0.0
LS 174T- Colon adenocarcinoma	0.1	UM-UC-3- Bladder carcinma (transitional cell)	1.5
SW-948- Colon adenocarcinoma	0.0	A204- Rhabdomyosarcoma	95.9
SW-480- Colon adenocarcinoma	0.0	HT-1080- Fibrosarcoma	13.5
NCI-SNU-5- Gastric carcinoma	0.0	MG-63- Osteosarcoma	10.4
KATO III- Gastric carcinoma	0.0	SK-LMS-1- Leiomyosarcoma (vulva)	5.3
NCI-SNU-16- Gastric	1.6	SJRH30-	0.0

carcinoma		Rhabdomyosarcoma (met to bone marrow)	
NCI-SNU-1- Gastric carcinoma	0.0	A431- Epidermoid carcinoma	0.0
RF-1- Gastric adenocarcinoma	0.0	WM266-4- Melanoma	0.3
RF-48- Gastric adenocarcinoma	0.0	DU 145- Prostate carcinoma (brain metastasis)	0.0
MKN-45- Gastric carcinoma	0.0	MDA-MB-468- Breast adenocarcinoma	0.1
NCI-N87- Gastric carcinoma	0.3	SCC-4- Squamous cell carcinoma of tongue	0.0
OVCAR-5- Ovarian carcinoma	0.1	SCC-9- Squamous cell carcinoma of tongue	0.0
RL95-2- Uterine carcinoma	0.4	SCC-15- Squamous cell carcinoma of tongue	0.0
HelaS3- Cervical adenocarcinoma	5.3	CAL 27- Squamous cell carcinoma of tongue	0.4

Table BJ. Panel 4.1D

Tissue Name	Rel. Exp.(%) Ag3606, Run 169943525	Tissue Name	Rel. Exp.(%) Ag3606, Run 169943525
Secondary Th1 act	0.0	HUVEC IL-1beta	0.7
Secondary Th2 act	0.0	HUVEC IFN gamma	0.0
Secondary Tr1 act	0.0	HUVEC TNF alpha + IFN gamma	0.8
Secondary Th1 rest	0.0	HUVEC TNF alpha + IL4	1.0
Secondary Th2 rest	0.3	HUVEC IL-11	0.0
Secondary Tr1 rest	0.0	Lung Microvascular EC none	11.0
Primary Th1 act	0.0	Lung Microvascular EC TNFalpha + IL-1beta	14.4
Primary Th2 act	0.0	Microvascular Dermal EC none	1.0
Primary Tr1 act	0.2	Microvascular Dermal EC TNFalpha + IL-1beta	0.0
Primary Th1 rest	0.0	Bronchial epithelium TNFalpha + IL1beta	48.0
Primary Th2 rest	0.0	Small airway epithelium none	14.8
Primary Tr1 rest	0.0	Small airway epithelium TNFalpha + IL-1beta	7.6
CD45RA CD4	0.7	Coronary artery SMC rest	8.5

lymphocyte act			
CD45RO CD4 lymphocyte act	0.0	Coronary artery SMC TNFalpha + IL-1beta	15.9
CD8 lymphocyte act	0.0	Astrocytes rest	7.9
Secondary CD8 lymphocyte rest	0.0	Astrocytes TNFalpha + IL-1beta	8.4
Secondary CD8 lymphocyte act	0.0	KU-812 (Basophil) rest	0.0
CD4 lymphocyte none	0.0	KU-812 (Basophil) PMA/ionomycin	0.0
2ry Th1/Th2/Tr1_anti-CD95 CH11	0.2	CCD1106 (Keratinocytes) none	45.1
LAK cells rest	0.0	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	49.3
LAK cells IL-2	0.0	Liver cirrhosis	0.8
LAK cells IL-2+IL-12	0.3	NCI-H292 none	1.8
LAK cells IL-2+IFN gamma	0.0	NCI-H292 IL-4	2.8
LAK cells IL-2+ IL-18	0.7	NCI-H292 IL-9	2.5
LAK cells PMA/ionomycin	0.0	NCI-H292 IL-13	4.2
NK Cells IL-2 rest	0.0	NCI-H292 IFN gamma	3.2
Two Way MLR 3 day	0.4	HPAEC none	0.3
Two Way MLR 5 day	0.0	HPAEC TNF alpha + IL-1 beta	100.0
Two Way MLR 7 day	0.4	Lung fibroblast none	0.7
PBMC rest	0.4	Lung fibroblast TNF alpha + IL-1 beta	88.3
PBMC PWM	0.0	Lung fibroblast IL-4	1.2
PBMC PHA-L	0.0	Lung fibroblast IL-9	2.2
Ramos (B cell) none	0.2	Lung fibroblast IL-13	1.4
Ramos (B cell) ionomycin	0.0	Lung fibroblast IFN gamma	2.4
B lymphocytes PWM	0.0	Dermal fibroblast CCD1070 rest	0.2
B lymphocytes CD40L and IL-4	1.7	Dermal fibroblast CCD1070 TNF alpha	1.9
EOL-1 dbcAMP	0.3	Dermal fibroblast CCD1070 IL-1 beta	7.5
EOL-1 dbcAMP PMA/ionomycin	0.0	Dermal fibroblast IFN gamma	0.4
Dendritic cells none	0.0	Dermal fibroblast IL-4	0.8
Dendritic cells LPS	0.0	Dermal Fibroblasts rest	0.0
Dendritic cells anti-	0.2	Neutrophils TNFa+LPS	0.0

CD40			
Monocytes rest	0.0	Neutrophils rest	0.0
Monocytes LPS	36.9	Colon	5.5
Macrophages rest	0.4	Lung	1.9
Macrophages LPS	0.0	Thymus	1.2
HUVEC none	0.2	Kidney	36.3
HUVEC starved	0.0		

Table BK. Panel 4D

Tissue Name	Rel. Exp.(%) Ag2797, Run 162291414	Tissue Name	Rel. Exp.(%) Ag2797, Run 162291414
Secondary Th1 act	0.0	HUVEC IL-1beta	0.0
Secondary Th2 act	0.0	HUVEC IFN gamma	0.1
Secondary Tr1 act	0.0	HUVEC TNF alpha + IFN gamma	0.3
Secondary Th1 rest	0.0	HUVEC TNF alpha + IL4	0.0
Secondary Th2 rest	0.0	HUVEC IL-11	0.0
Secondary Tr1 rest	0.0	Lung Microvascular EC none	1.3
Primary Th1 act	0.0	Lung Microvascular EC TNFalpha + IL-1beta	2.7
Primary Th2 act	0.0	Microvascular Dermal EC none	1.0
Primary Tr1 act	0.0	Microvascular Dermal EC TNFalpha + IL-1beta	0.0
Primary Th1 rest	0.0	Bronchial epithelium TNFalpha + IL1beta	27.4
Primary Th2 rest	0.0	Small airway epithelium none	4.8
Primary Tr1 rest	0.0	Small airway epithelium TNFalpha + IL-1beta	6.7
CD45RA CD4 lymphocyte act	0.2	Coronary artery SMC rest	0.0
CD45RO CD4 lymphocyte act	0.0	Coronary artery SMC TNFalpha + IL-1beta	3.3
CD8 lymphocyte act	0.0	Astrocytes rest	1.8
Secondary CD8 lymphocyte rest	0.0	Astrocytes TNFalpha + IL-1beta	2.5
Secondary CD8 lymphocyte act	0.0	KU-812 (Basophil) rest	0.0
CD4 lymphocyte none	0.0	KU-812 (Basophil) PMA/ionomycin	0.0

2ry Th1/Th2/Tr1_anti-CD95 CH11	0.0	CCD1106 (Keratinocytes) none	15.8
LAK cells rest	0.0	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	13.3
LAK cells IL-2	0.0	Liver cirrhosis	0.0
LAK cells IL-2+IL-12	0.0	Lupus kidney	2.1
LAK cells IL-2+IFN gamma	0.0	NCI-H292 none	1.3
LAK cells IL-2+ IL-18	0.0	NCI-H292 IL-4	1.2
LAK cells PMA/ionomycin	0.0	NCI-H292 IL-9	100.0
NK Cells IL-2 rest	0.0	NCI-H292 IL-13	2.0
Two Way MLR 3 day	0.0	NCI-H292 IFN gamma	1.0
Two Way MLR 5 day	0.0	HPAEC none	1.2
Two Way MLR 7 day	0.0	HPAEC TNF alpha + IL-1 beta	28.7
PBMC rest	0.0	Lung fibroblast none	0.3
PBMC PWM	0.1	Lung fibroblast TNF alpha + IL-1 beta	29.9
PBMC PHA-L	0.0	Lung fibroblast IL-4	0.7
Ramos (B cell) none	0.0	Lung fibroblast IL-9	0.9
Ramos (B cell) ionomycin	0.0	Lung fibroblast IL-13	0.7
B lymphocytes PWM	0.0	Lung fibroblast IFN gamma	0.7
B lymphocytes CD40L and IL-4	0.0	Dermal fibroblast CCD1070 rest	0.5
EOL-1 dbcAMP	0.0	Dermal fibroblast CCD1070 TNF alpha	2.0
EOL-1 dbcAMP PMA/ionomycin	0.0	Dermal fibroblast CCD1070 IL-1 beta	3.3
Dendritic cells none	0.0	Dermal fibroblast IFN gamma	0.0
Dendritic cells LPS	0.0	Dermal fibroblast IL-4	0.3
Dendritic cells anti-CD40	0.0	IBD Colitis 2	0.0
Monocytes rest	0.2	IBD Crohn's	0.1
Monocytes LPS	5.4	Colon	2.4
Macrophages rest	0.0	Lung	0.4
Macrophages LPS	0.0	Thymus	21.9
HUVEC none	0.2	Kidney	0.0
HUVEC starved	0.1		

Table BL. Panel CNS\_1

Tissue Name	Rel. Exp.(%) Ag2797, Run 171664308	Tissue Name	Rel. Exp.(%) Ag2797, Run 171664308
BA4 Control	14.1	BA17 PSP	16.0
BA4 Control2	27.5	BA17 PSP2	6.4
BA4 Alzheimer's2	2.4	Sub Nigra Control	61.6
BA4 Parkinson's	28.1	Sub Nigra Control2	68.8
BA4 Parkinson's2	33.4	Sub Nigra Alzheimer's2	25.3
BA4 Huntington's	28.5	Sub Nigra Parkinson's2	73.7
BA4 Huntington's2	3.3	Sub Nigra Huntington's	100.0
BA4 PSP	6.6	Sub Nigra Huntington's2	39.2
BA4 PSP2	15.5	Sub Nigra PSP2	15.1
BA4 Depression	7.3	Sub Nigra Depression	8.8
BA4 Depression2	3.9	Sub Nigra Depression2	7.9
BA7 Control	24.1	Glob Palladus Control	17.0
BA7 Control2	27.4	Glob Palladus Control2	8.6
BA7 Alzheimer's2	4.1	Glob Palladus Alzheimer's	24.8
BA7 Parkinson's	7.2	Glob Palladus Alzheimer's2	5.5
BA7 Parkinson's2	16.6	Glob Palladus Parkinson's	54.0
BA7 Huntington's	23.3	Glob Palladus Parkinson's2	16.2
BA7 Huntington's2	18.6	Glob Palladus PSP	7.9
BA7 PSP	21.8	Glob Palladus PSP2	8.6
BA7 PSP2	12.9	Glob Palladus Depression	4.6
BA7 Depression	4.6	Temp Pole Control	8.3
BA9 Control	15.0	Temp Pole Control2	36.3
BA9 Control2	43.5	Temp Pole Alzheimer's	3.3
BA9 Alzheimer's	3.1	Temp Pole Alzheimer's2	3.3
BA9	5.5	Temp Pole	13.2

Alzheimer's2		Parkinson's	
BA9 Parkinson's	18.2	Temp Pole Parkinson's2	15.0
BA9 Parkinson's2	28.9	Temp Pole Huntington's	22.4
BA9 Huntington's	37.6	Temp Pole PSP	1.9
BA9 Huntington's2	8.7	Temp Pole PSP2	2.2
BA9 PSP	9.3	Temp Pole Depression2	4.3
BA9 PSP2	2.6	Cing Gyr Control	33.7
BA9 Depression	1.5	Cing Gyr Control2	24.1
BA9 Depression2	3.5	Cing Gyr Alzheimer's	16.4
BA17 Control	16.4	Cing Gyr Alzheimer's2	8.7
BA17 Control2	28.9	Cing Gyr Parkinson's	27.9
BA17 Alzheimer's2	3.0	Cing Gyr Parkinson's2	27.0
BA17 Parkinson's	20.2	Cing Gyr Huntington's	54.3
BA17 Parkinson's2	17.1	Cing Gyr Huntington's2	18.6
BA17 Huntington's	24.0	Cing Gyr PSP	17.1
BA17 Huntington's2	8.2	Cing Gyr PSP2	4.6
BA17 Depression	7.5	Cing Gyr Depression	6.0
BA17 Depression2	12.3	Cing Gyr Depression2	8.6

- CNS\_neurodegeneration\_v1.0 Summary:** Ag3606 This panel does not show differential expression of the CG59843-01 gene in Alzheimer's disease. However, this expression profile confirms the presence of this gene in the brain, with highest expression in the temporal cortex of an Alzheimer's patient (CT=26.3). Please see Panel 1.4 for discussion of utility of this gene
- 5 in the central nervous system. Results from a second experiment using the probe and primer set Ag2797 are not included. The amp plot indicates that there were experimental difficulties with this run.

**General\_screening\_panel\_v1.4 Summary:** Ag3606 Highest expression of the CG59843-01 gene is seen in a brain cancer cell line (CT=24). In addition, this gene also shows highly brain preferential expression, with high levels of expression in all CNS regions represented on this panel. Therefore, expression of this gene could be used to differentiate between brain derived samples and other samples on this panel. Furthermore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurologic disorders, such as Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, stroke and epilepsy.

High levels of expression are also seen in samples derived from melanoma, lung and brain cancer cell lines. Thus, expression of this gene could be used as a marker for these types of cancers. This gene encodes a fibropellin-like molecule. Fibropellins are glycoproteins that may be involved in cell adhesion. Therefore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of melanoma, lung and brain cancers.

*See, generally,*

Burke RD, Lail M, Nakajima Y. The apical lamina and its role in cell adhesion in sea urchin embryos. *Cell Adhes Commun* 1998 Mar;5(2):97-108. PMID: 9638331

**Panel 1 Summary:** Ag221 Expression in this panel is in agreement with the profile seen in Panel 1.4. The CG59843-01 gene shows highly brain preferential expression, with highest expression in the cerebellum (CT=21.4). Please see Panel 1.4 for discussion of utility of this gene in the central nervous system.

**Panel 1.3D Summary:** Ag2797 Two experiments with the same probe and primer set produce results that are in excellent agreement, with highest expression in the thalamus (CTs=24.5-25.5).

High levels of expression are also seen in samples derived from melanoma, lung and brain cancer cell lines. Please see Panel 1.4 for further discussion of utility of this gene in the CNS and cancer.

Moderate to low levels of expression are also seen in the adrenal, pituitary, fetal heart, and fetal skeletal muscle. This expression in metabolic tissues suggests that this gene product may



be involved in the pathogenesis and/or treatment of metabolic disorders, including obesity and diabetes.

**Panel 2D Summary:** Ag2797 Two experiments with the same probe and primer set produce results that are in excellent agreement. Highest expression of the CG59843-01 gene is seen in kidney (CTs=28). The expression of this gene is down-regulated in kidney cancers (CTs=31-38), gastric cancer and colon cancer as compared to control margin (CTs=28-31). Therefore, expression of this gene could be used to distinguish between normal kidney, stomach and colon tissue from cancer samples.

In addition significant expression of this gene is also seen in breast cancer, bladder cancer, lung malignant cancer, and prostate cancer samples. Thus, therapeutic modulation of this gene, through the use of small molecule drugs, and antibodies could be of benefit in the treatment of bladder, breast, kidney or lung cancer.

**Panel 3D Summary:** Ag2797 Highest expression of the CG59843-01 gene is seen in a small cell lung cancer cell line (CT=25). Significant levels of expression are also seen in the cerebellum. This is in agreement with the highly brain preferential expression profiles seen in the previous panels. Thus, expression of this gene could be used to differentiate between these samples and other samples on this panel. In addition, significant expression of this gene is associated with squamous cell lung cancer, large cell lung cancer, lung carcinoid, rhabdomyosarcoma, fibrosarcoma, osteosarcoma, medulloblastoma, leiomyosarcoma, cervical and pancreatic cancers. Therefore, therapeutic modulation of this gene or its product, through the use of small molecule drugs, and antibodies could be of benefit in the treatment of these cancers.

**Panel 4.1D Summary:** Ag3606/2797 The CG59843-01 gene was reproducibly expressed, as displayed on Panels 4D and 4.1D, across several activated cell types that model lung inflammatory diseases. These include cytokine-activated lung fibroblasts, cytokine-activated pulmonary aortic endothelial cells, and cytokine-activated bronchial epithelial cells (CTs=28-31). Therefore, therapeutic modulation of this gene or its product, through the use of small molecule drugs, and antibodies, may reduce or eliminate the symptoms of inflammatory lung diseases, such as, but not limited to, asthma, emphysema, and chronic obstructive pulmonary disease.

**Panel 4D Summary:** See annotation for Panel 4.1D for relevant comments.

**Panel CNS\_1 Summary:** Ag3606 This panel confirms the presence of this gene in the brain. Please see Panel 1.4 for discussion of utility of this gene in the central nervous system.

**C. NOV3a (CG59845-01: butyrophillin )**

- 5 Expression of gene CG59845-01 was assessed using the primer-probe set Ag3607, described in Table CA. Results of the RTQ-PCR runs are shown in Table CB.

Table CA. Probe Name Ag3607

Primers	Sequences	Length	Start Position	SEQ ID No
Forward	5'-attccaagtcaatggtcaaaca-3'	22	46	111
Probe	TET-5'-actcgcatctctcacatcaccactt-3'- TAMRA	26	72	112
Reverse	5'-cgaaaggatgagaagaggaagt-3'	22	120	113

Table CB. Panel 4.1D

Tissue Name	Rel. Exp.(%) Ag3607, Run 169943563	Tissue Name	Rel. Exp.(%) Ag3607, Run 169943563
Secondary Th1 act	0.0	HUVEC IL-1beta	0.0
Secondary Th2 act	0.0	HUVEC IFN gamma	0.0
Secondary Tr1 act	0.0	HUVEC TNF alpha + IFN gamma	0.0
Secondary Th1 rest	0.0	HUVEC TNF alpha + IL4	0.0
Secondary Th2 rest	0.0	HUVEC IL-11	0.0
Secondary Tr1 rest	0.0	Lung Microvascular EC none	0.0
Primary Th1 act	0.0	Lung Microvascular EC TNFalpha + IL-1beta	0.0
Primary Th2 act	0.0	Microvascular Dermal EC none	0.0
Primary Tr1 act	0.0	Microvascular Dermal EC TNFalpha + IL-1beta	0.0
Primary Th1 rest	0.0	Bronchial epithelium TNFalpha + IL1beta	0.0
Primary Th2 rest	0.0	Small airway epithelium none	0.0
Primary Tr1 rest	0.0	Small airway epithelium	0.0

		TNFalpha + IL-1beta	
CD45RA CD4 lymphocyte act	0.0	Coronary artery SMC rest	0.0
CD45RO CD4 lymphocyte act	0.0	Coronary artery SMC TNFalpha + IL-1beta	0.0
CD8 lymphocyte act	0.0	Astrocytes rest	0.0
Secondary CD8 lymphocyte rest	0.0	Astrocytes TNFalpha + IL-1beta	0.0
Secondary CD8 lymphocyte act	0.0	KU-812 (Basophil) rest	0.0
CD4 lymphocyte none	0.0	KU-812 (Basophil) PMA/ionomycin	0.0
2ry Th1/Th2/Tr1_anti-CD95 CH11	0.0	CCD1106 (Keratinocytes) none	0.0
LAK cells rest	0.0	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	0.0
LAK cells IL-2	0.0	Liver cirrhosis	0.0
LAK cells IL-2+IL-12	0.0	NCI-H292 none	0.0
LAK cells IL-2+IFN gamma	0.0	NCI-H292 IL-4	0.0
LAK cells IL-2+ IL-18	0.0	NCI-H292 IL-9	0.0
LAK cells PMA/ionomycin	100.0	NCI-H292 IL-13	0.0
NK Cells IL-2 rest	0.0	NCI-H292 IFN gamma	0.0
Two Way MLR 3 day	0.0	HPAEC none	0.0
Two Way MLR 5 day	0.0	HPAEC TNF alpha + IL-1 beta	0.0
Two Way MLR 7 day	0.0	Lung fibroblast none	0.0
PBMC rest	0.0	Lung fibroblast TNF alpha + IL-1 beta	0.0
PBMC PWM	0.0	Lung fibroblast IL-4	0.0
PBMC PHA-L	0.0	Lung fibroblast IL-9	0.0
Ramos (B cell) none	0.0	Lung fibroblast IL-13	0.0
Ramos (B cell) ionomycin	0.0	Lung fibroblast IFN gamma	0.0
B lymphocytes PWM	0.0	Dermal fibroblast CCD1070 rest	0.0
B lymphocytes CD40L and IL-4	0.0	Dermal fibroblast CCD1070 TNF alpha	0.0
EOL-1 dbcAMP	0.0	Dermal fibroblast CCD1070 IL-1 beta	0.0
EOL-1 dbcAMP PMA/ionomycin	0.0	Dermal fibroblast IFN gamma	0.0
Dendritic cells none	0.0	Dermal fibroblast IL-4	0.0

Dendritic cells LPS	0.0	Dermal Fibroblasts rest	0.0
Dendritic cells anti-CD40	0.0	Neutrophils TNFa+LPS	0.0
Monocytes rest	0.0	Neutrophils rest	0.0
Monocytes LPS	0.0	Colon	0.0
Macrophages rest	0.0	Lung	0.0
Macrophages LPS	0.0	Thymus	0.0
HUVEC none	0.0	Kidney	0.0
HUVEC starved	0.0		

**CNS\_neurodegeneration\_v1.0 Summary:** Ag3607 Expression of the CG59845-01 gene is low/undetectable (CTs > 35) across all of the samples on this panel.

**General\_screening\_panel\_v1.4 Summary:** Ag3607 Expression of the CG59845-01 gene is low/undetectable (CTs > 35) across all of the samples on this panel.

- 5 **Panel 4.1D Summary:** Ag3607 Highest expression of the CG59845-01 gene is seen exclusively in PMA/ionomycin treated LAK cells (CT=33.5). Therefore, expression of this gene can be used in distinguishing this sample from other samples in this panel. LAK cells are involved in tumor immunology and cell clearance of virally and bacterial infected cells as well as tumors. Therefore, modulation of the function of the protein encoded by this gene
- 10 through the application of a small molecule drug or antibody may alter the functions of these cells and lead to improvement of symptoms associated with these conditions

#### D. NOV4a (CG59871-01: CVB3 BINDING PROTEIN )

- Expression of gene CG59871-01 was assessed using the primer-probe sets Ag3806 and Ag3808, described in Tables DA and DB. Results of the RTQ-PCR runs are shown in Tables
- 15 DC, DD and DE.

Table DA. Probe Name Ag3806

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-agtggatttcgccagaagtt-3'	20	460	114
Probe	TET-5'-tgagtatcactactcctgaagagatgattg-3'-TAMRA	30	480	115
Reverse	5'-atggcagataggcagtttcc-3'	20	523	116

Table DB. Probe Name Ag3808

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-gtggatttcgccagaagttt-3'	20	461	117
Probe	TET-5'-aaaagccaaaggggaaactgcctatc-3'- TAMRA	26	511	118
Reverse	5'-taagcgtaaatttgcatggc-3'	20	538	119

Table DC. CNS\_neurodegeneration\_v1.0

Tissue Name	Rel. Exp.(%) Ag3806, Run 211292375	Tissue Name	Rel. Exp.(%) Ag3806, Run 211292375
AD 1 Hippo	8.8	Control (Path) 3 Temporal Ctx	2.1
AD 2 Hippo	27.4	Control (Path) 4 Temporal Ctx	29.5
AD 3 Hippo	4.9	AD 1 Occipital Ctx	18.0
AD 4 Hippo	11.4	AD 2 Occipital Ctx (Missing)	0.0
AD 5 Hippo	57.8	AD 3 Occipital Ctx	3.7
AD 6 Hippo	100.0	AD 4 Occipital Ctx	17.1
Control 2 Hippo	30.6	AD 5 Occipital Ctx	38.4
Control 4 Hippo	9.5	AD 6 Occipital Ctx	34.4
Control (Path) 3 Hippo	9.0	Control 1 Occipital Ctx	3.0
AD 1 Temporal Ctx	15.2	Control 2 Occipital Ctx	49.0
AD 2 Temporal Ctx	32.5	Control 3 Occipital Ctx	17.1
AD 3 Temporal Ctx	4.1	Control 4 Occipital Ctx	7.4
AD 4 Temporal Ctx	13.2	Control (Path) 1 Occipital Ctx	82.9
AD 5 Inf Temporal Ctx	66.9	Control (Path) 2 Occipital Ctx	6.0
AD 5 Sup Temporal Ctx	36.9	Control (Path) 3 Occipital Ctx	1.3
AD 6 Inf Temporal Ctx	73.7	Control (Path) 4 Occipital Ctx	14.0
AD 6 Sup Temporal Ctx	71.2	Control 1 Parietal Ctx	5.1
Control 1 Temporal Ctx	3.0	Control 2 Parietal Ctx	28.9
Control 2 Temporal Ctx	28.9	Control 3 Parietal Ctx	12.7
Control 3 Temporal	16.2	Control (Path) 1	73.7

Ctx		Parietal Ctx	
Control 3 Temporal Ctx	4.8	Control (Path) 2 Parietal Ctx	18.2
Control (Path) 1 Temporal Ctx	56.6	Control (Path) 3 Parietal Ctx	2.3
Control (Path) 2 Temporal Ctx	75.8	Control (Path) 4 Parietal Ctx	36.3

Table DD. General\_screening\_panel\_v1.4

Tissue Name	Rel. Exp.(%) Ag3808, Run 218667401	Tissue Name	Rel. Exp.(%) Ag3808, Run 218667401
Adipose	4.9	Renal ca. TK-10	30.4
Melanoma* Hs688(A).T	0.0	Bladder	40.6
Melanoma* Hs688(B).T	0.0	Gastric ca. (liver met.) NCI-N87	25.3
Melanoma* M14	0.1	Gastric ca. KATO III	54.7
Melanoma* LOXIMVI	0.4	Colon ca. SW-948	19.6
Melanoma* SK-MEL-5	17.7	Colon ca. SW480	63.7
Squamous cell carcinoma SCC-4	8.7	Colon ca.* (SW480 met) SW620	12.5
Testis Pool	12.8	Colon ca. HT29	13.7
Prostate ca.* (bone met) PC-3	0.7	Colon ca. HCT-116	15.2
Prostate Pool	11.4	Colon ca. CaCo-2	100.0
Placenta	0.1	Colon cancer tissue	29.9
Uterus Pool	3.1	Colon ca. SW1116	6.9
Ovarian ca. OVCAR-3	53.6	Colon ca. Colo-205	0.1
Ovarian ca. SK-OV-3	1.7	Colon ca. SW-48	14.8
Ovarian ca. OVCAR-4	31.6	Colon Pool	3.7
Ovarian ca. OVCAR-5	22.7	Small Intestine Pool	3.7
Ovarian ca. IGROV-1	14.8	Stomach Pool	4.8
Ovarian ca. OVCAR-8	14.5	Bone Marrow Pool	3.5
Ovary	3.5	Fetal Heart	14.3
Breast ca. MCF-7	0.1	Heart Pool	6.0

Breast ca. MDA-MB-231	10.4	Lymph Node Pool	5.1
Breast ca. BT 549	95.9	Fetal Skeletal Muscle	0.1
Breast ca. T47D	49.7	Skeletal Muscle Pool	0.1
Breast ca. MDA-N	0.1	Spleen Pool	0.8
Breast Pool	4.8	Thymus Pool	3.4
Trachea	8.1	CNS cancer (glio/astro) U87-MG	0.9
Lung	0.2	CNS cancer (glio/astro) U-118-MG	0.1
Fetal Lung	25.3	CNS cancer (neuro;met) SK-N-AS	10.3
Lung ca. NCI-N417	3.2	CNS cancer (astro) SF-539	1.2
Lung ca. LX-1	14.4	CNS cancer (astro) SNB-75	0.9
Lung ca. NCI-H146	6.5	CNS cancer (glio) SNB-19	17.1
Lung ca. SHP-77	0.0	CNS cancer (glio) SF-295	12.9
Lung ca. A549	10.2	Brain (Amygdala) Pool	9.5
Lung ca. NCI-H526	10.5	Brain (cerebellum)	2.2
Lung ca. NCI-H23	60.7	Brain (fetal)	74.7
Lung ca. NCI-H460	10.9	Brain (Hippocampus) Pool	9.3
Lung ca. HOP-62	26.2	Cerebral Cortex Pool	11.0
Lung ca. NCI-H522	59.0	Brain (Substantia nigra) Pool	9.3
Liver	3.8	Brain (Thalamus) Pool	16.0
Fetal Liver	27.4	Brain (whole)	14.7
Liver ca. HepG2	51.8	Spinal Cord Pool	10.7
Kidney Pool	6.7	Adrenal Gland	2.4
Fetal Kidney	18.2	Pituitary gland Pool	4.9
Renal ca. 786-0	0.5	Salivary Gland	6.0
Renal ca. A498	2.0	Thyroid (female)	13.1
Renal ca. ACHN	0.0	Pancreatic ca. CAPAN2	9.0
Renal ca. UO-31	1.6	Pancreas Pool	10.7

Table DE. Panel 4.1D

Tissue Name	Rel. Exp.(%) Ag3806, Run 169997727	Tissue Name	Rel. Exp.(%) Ag3806, Run 169997727
-------------	--	-------------	--

Secondary Th1 act	2.6	HUVEC IL-1beta	14.0
Secondary Th2 act	5.3	HUVEC IFN gamma	12.6
Secondary Tr1 act	15.7	HUVEC TNF alpha + IFN gamma	3.5
Secondary Th1 rest	0.4	HUVEC TNF alpha + IL4	14.1
Secondary Th2 rest	0.2	HUVEC IL-11	11.1
Secondary Tr1 rest	0.3	Lung Microvascular EC none	5.8
Primary Th1 act	0.4	Lung Microvascular EC TNFalpha + IL-1beta	0.3
Primary Th2 act	1.1	Microvascular Dermal EC none	47.3
Primary Tr1 act	0.2	Microvascular Dermal EC TNFalpha + IL-1beta	1.4
Primary Th1 rest	0.4	Bronchial epithelium TNFalpha + IL1beta	72.7
Primary Th2 rest	0.4	Small airway epithelium none	54.7
Primary Tr1 rest	0.3	Small airway epithelium TNFalpha + IL-1beta	69.7
CD45RA CD4 lymphocyte act	0.7	Coronary artery SMC rest	0.0
CD45RO CD4 lymphocyte act	1.5	Coronary artery SMC TNFalpha + IL-1beta	0.0
CD8 lymphocyte act	1.5	Astrocytes rest	18.6
Secondary CD8 lymphocyte rest	0.6	Astrocytes TNFalpha + IL-1beta	9.6
Secondary CD8 lymphocyte act	0.0	KU-812 (Basophil) rest	10.2
CD4 lymphocyte none	0.9	KU-812 (Basophil) PMA/ionomycin	9.9
2ry Th1/Th2/Tr1_anti-CD95 CH11	0.0	CCD1106 (Keratinocytes) none	17.8
LAK cells rest	1.5	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	20.7
LAK cells IL-2	0.4	Liver cirrhosis	69.7
LAK cells IL-2+IL-12	1.8	NCI-H292 none	31.2
LAK cells IL-2+IFN gamma	1.9	NCI-H292 IL-4	63.7
LAK cells IL-2+ IL-18	1.3	NCI-H292 IL-9	85.3
LAK cells PMA/ionomycin	0.0	NCI-H292 IL-13	72.2
NK Cells IL-2 rest	0.2	NCI-H292 IFN gamma	74.7
Two Way MLR 3 day	0.7	HPAEC none	8.1



Two Way MLR 5 day	1.5	HPAEC TNF alpha + IL-1 beta	1.5
Two Way MLR 7 day	0.4	Lung fibroblast none	10.0
PBMC rest	0.9	Lung fibroblast TNF alpha + IL-1 beta	3.7
PBMC PWM	1.1	Lung fibroblast IL-4	9.3
PBMC PHA-L	0.0	Lung fibroblast IL-9	14.6
Ramos (B cell) none	12.0	Lung fibroblast IL-13	8.9
Ramos (B cell) ionomycin	8.4	Lung fibroblast IFN gamma	5.0
B lymphocytes PWM	0.4	Dermal fibroblast CCD1070 rest	0.4
B lymphocytes CD40L and IL-4	0.7	Dermal fibroblast CCD1070 TNF alpha	0.9
EOL-1 dbcAMP	8.8	Dermal fibroblast CCD1070 IL-1 beta	0.0
EOL-1 dbcAMP PMA/ionomycin	3.0	Dermal fibroblast IFN gamma	0.3
Dendritic cells none	0.0	Dermal fibroblast IL-4	0.4
Dendritic cells LPS	0.0	Dermal Fibroblasts rest	0.6
Dendritic cells anti-CD40	0.0	Neutrophils TNFa+LPS	0.0
Monocytes rest	0.0	Neutrophils rest	0.0
Monocytes LPS	0.0	Colon	100.0
Macrophages rest	5.5	Lung	39.0
Macrophages LPS	0.0	Thymus	24.1
HUVEC none	39.5	Kidney	50.7
HUVEC starved	45.4		

**CNS\_neurodegeneration\_v1.0 Summary:** Ag3806 This panel confirms the expression of the CG59871-01 gene at low levels in the brains of an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer's diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 5 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.

**General\_screening\_panel\_v1.4 Summary:** Ag3806 Highest expression of the CG59871-01 gene is detected in colon cancer CaCo-2 cell line (CT=26.3). In addition high expression of this gene is also seen in cluster of colon cancer, CNS cancer, gastric cancer, lung cancer, 10 breast and ovarian cancers, squamous cell line carcinoma and a melanoma cell lines.

Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, might be beneficial in the treatment of these cancers.

Among tissues with metabolic or endocrine function, this gene is expressed at high to moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

Interestingly, this gene is expressed at much higher levels in fetal (CTs=28) when compared to adult lung and liver samples (CTs=33-35). This observation suggests that expression of this gene can be used to distinguish fetal lung and liver from corresponding adult tissues.

In addition, this gene is expressed at high to moderate levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression. Furthermore, expression of this gene is higher in fetal (CT=26) as compared to the adult whole brain (CT=29). Therefore, expression of this gene can be used to distinguish fetal from adult brain.

**Panel 4.1D Summary:** Ag3806 Highest expression of the CG59871-01 gene is detected in colon sample(CT=30). In addition, significant expression of this gene is seen in normal lung, thymus and kidney tissues. Therefore, antibody or small molecule therapies designed with the protein encoded for by this gene could modulate these tissue function and be important in the treatment of inflammatory or autoimmune diseases that affect these tissues such as, lupus and glomerulonephritis, inflammatory bowel diseases, asthma, allergy, COPD and emphysema.

High expression of this gene is also seen in NCI-H292, small airway epithelium, microvascular dermal EC, TNFalpha + IL1beta treated bronchial epithelium, HUVEC, EOL-1 dbcAMP, Ramos (B cells) and activated secondary Tr1 cells. The expression of this gene in cells derived from or within the lung, in activated T and B cells suggests that this gene may be involved in normal conditions, as well as, pathological and inflammatory lung disorders that include chronic obstructive pulmonary disease, asthma, allergy and emphysema.

**E. NOV5a (CG59883-01: CVB3 BINDING PROTEIN )**

Expression of gene CG59883-01 was assessed using the primer-probe set Ag3625, described in Table EA. Results of the RTQ-PCR runs are shown in Tables EB, and EC.

Table EA. Probe Name Ag3625

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-tcatccctgggatccatc-3'	20	1069	120
Probe	TET-5'-tccttccaacatggaaggatattcca-3'-TAMRA	26	1089	121
Reverse	5'-gtgcgttcaaagtcttcacttg-3'	22	1136	122

Table EB. General\_screening\_panel\_v1.4

Tissue Name	Rel. Exp.(%) Ag3625, Run 218211650	Tissue Name	Rel. Exp.(%) Ag3625, Run 218211650
Adipose	0.0	Renal ca. TK-10	0.0
Melanoma* Hs688(A).T	0.0	Bladder	0.0
Melanoma* Hs688(B).T	0.0	Gastric ca. (liver met.) NCI-N87	0.0
Melanoma* M14	0.0	Gastric ca. KATO III	0.8
Melanoma* LOXIMVI	0.0	Colon ca. SW-948	0.0
Melanoma* SK-MEL-5	0.0	Colon ca. SW480	0.0
Squamous cell carcinoma SCC-4	0.0	Colon ca.* (SW480 met) SW620	0.0
Testis Pool	100.0	Colon ca. HT29	0.0
Prostate ca.* (bone met) PC-3	0.3	Colon ca. HCT-116	0.0
Prostate Pool	1.6	Colon ca. CaCo-2	0.0
Placenta	0.0	Colon cancer tissue	0.3
Uterus Pool	0.0	Colon ca. SW1116	0.0
Ovarian ca. OVCAR-3	0.0	Colon ca. Colo-205	0.0
Ovarian ca. SK-OV-3	1.6	Colon ca. SW-48	0.0
Ovarian ca. OVCAR-4	0.2	Colon Pool	0.4
Ovarian ca. OVCAR-5	0.0	Small Intestine Pool	0.1
Ovarian ca. IGROV-1	1.3	Stomach Pool	0.3

Ovarian ca. OVCAR-8	0.4	Bone Marrow Pool	0.0
Ovary	0.2	Fetal Heart	0.0
Breast ca. MCF-7	0.0	Heart Pool	0.0
Breast ca. MDA-MB-231	0.0	Lymph Node Pool	0.5
Breast ca. BT 549	0.0	Fetal Skeletal Muscle	0.0
Breast ca. T47D	0.5	Skeletal Muscle Pool	0.0
Breast ca. MDA-N	0.2	Spleen Pool	0.0
Breast Pool	0.2	Thymus Pool	1.1
Trachea	0.2	CNS cancer (glio/astro) U87-MG	0.0
Lung	0.0	CNS cancer (glio/astro) U-118-MG	0.4
Fetal Lung	0.0	CNS cancer (neuro;met) SK-N-AS	0.0
Lung ca. NCI-N417	0.0	CNS cancer (astro) SF-539	2.0
Lung ca. LX-1	0.0	CNS cancer (astro) SNB-75	26.1
Lung ca. NCI-H146	0.0	CNS cancer (glio) SNB-19	0.4
Lung ca. SHP-77	0.0	CNS cancer (glio) SF-295	0.2
Lung ca. A549	0.0	Brain (Amygdala) Pool	0.0
Lung ca. NCI-H526	0.0	Brain (cerebellum)	0.0
Lung ca. NCI-H23	0.4	Brain (fetal)	0.0
Lung ca. NCI-H460	0.3	Brain (Hippocampus) Pool	0.4
Lung ca. HOP-62	0.0	Cerebral Cortex Pool	0.7
Lung ca. NCI-H522	0.0	Brain (Substantia nigra) Pool	0.2
Liver	0.0	Brain (Thalamus) Pool	0.5
Fetal Liver	0.0	Brain (whole)	0.0
Liver ca. HepG2	0.0	Spinal Cord Pool	0.2
Kidney Pool	0.1	Adrenal Gland	0.3
Fetal Kidney	0.0	Pituitary gland Pool	0.1
Renal ca. 786-0	0.0	Salivary Gland	0.0
Renal ca. A498	1.8	Thyroid (female)	0.0
Renal ca. ACHN	0.0	Pancreatic ca. CAPAN2	0.0
Renal ca. UO-31	0.1	Pancreas Pool	0.8

Table ED. Panel 4.1D

Tissue Name	Rel. Exp.(%) Ag3625, Run 169946001	Tissue Name	Rel. Exp.(%) Ag3625, Run 169946001
Secondary Th1 act	0.0	HUVEC IL-1beta	0.0
Secondary Th2 act	0.0	HUVEC IFN gamma	0.0
Secondary Tr1 act	0.0	HUVEC TNF alpha + IFN gamma	0.0
Secondary Th1 rest	0.0	HUVEC TNF alpha + IL4	0.0
Secondary Th2 rest	0.0	HUVEC IL-11	0.0
Secondary Tr1 rest	0.0	Lung Microvascular EC none	0.9
Primary Th1 act	0.0	Lung Microvascular EC TNFalpha + IL-1beta	0.0
Primary Th2 act	0.0	Microvascular Dermal EC none	0.0
Primary Tr1 act	0.0	Microvascular Dermal EC TNFalpha + IL-1beta	0.0
Primary Th1 rest	0.0	Bronchial epithelium TNFalpha + IL1beta	0.0
Primary Th2 rest	0.0	Small airway epithelium none	0.0
Primary Tr1 rest	0.0	Small airway epithelium TNFalpha + IL-1beta	0.0
CD45RA CD4 lymphocyte act	0.0	Coronary artery SMC rest	0.0
CD45RO CD4 lymphocyte act	3.1	Coronary artery SMC TNFalpha + IL-1beta	0.0
CD8 lymphocyte act	0.0	Astrocytes rest	0.0
Secondary CD8 lymphocyte rest	0.0	Astrocytes TNFalpha + IL-1beta	0.0
Secondary CD8 lymphocyte act	0.0	KU-812 (Basophil) rest	0.0
CD4 lymphocyte none	0.0	KU-812 (Basophil) PMA/ionomycin	0.0
2ry Th1/Th2/Tr1_anti- CD95 CH11	0.0	CCD1106 (Keratinocytes) none	4.8
LAK cells rest	0.7	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	4.4
LAK cells IL-2	0.0	Liver cirrhosis	2.4
LAK cells IL-2+IL-12	0.0	NCI-H292 none	72.7
LAK cells IL-2+IFN gamma	0.0	NCI-H292 IL-4	93.3
LAK cells IL-2+ IL-18	2.4	NCI-H292 IL-9	100.0

LAK cells PMA/ionomycin	0.0	NCI-H292 IL-13	94.0
NK Cells IL-2 rest	0.0	NCI-H292 IFN gamma	74.7
Two Way MLR 3 day	2.1	HPAEC none	0.0
Two Way MLR 5 day	0.0	HPAEC TNF alpha + IL-1 beta	0.0
Two Way MLR 7 day	0.0	Lung fibroblast none	0.0
PBMC rest	0.0	Lung fibroblast TNF alpha + IL-1 beta	0.0
PBMC PWM	0.0	Lung fibroblast IL-4	0.0
PBMC PHA-L	0.0	Lung fibroblast IL-9	0.0
Ramos (B cell) none	0.0	Lung fibroblast IL-13	0.0
Ramos (B cell) ionomycin	0.0	Lung fibroblast IFN gamma	0.0
B lymphocytes PWM	0.0	Dermal fibroblast CCD1070 rest	0.0
B lymphocytes CD40L and IL-4	0.0	Dermal fibroblast CCD1070 TNF alpha	0.0
EOL-1 dbcAMP	0.0	Dermal fibroblast CCD1070 IL-1 beta	0.0
EOL-1 dbcAMP PMA/ionomycin	0.0	Dermal fibroblast IFN gamma	0.0
Dendritic cells none	2.6	Dermal fibroblast IL-4	0.0
Dendritic cells LPS	0.0	Dermal Fibroblasts rest	0.0
Dendritic cells anti- CD40	1.7	Neutrophils TNFa+LPS	2.3
Monocytes rest	0.0	Neutrophils rest	0.0
Monocytes LPS	0.0	Colon	0.0
Macrophages rest	0.0	Lung	1.1
Macrophages LPS	0.0	Thymus	6.3
HUVEC none	0.0	Kidney	0.0
HUVEC starved	0.0		

**CNS\_neurodegeneration\_v1.0 Summary:** Ag3625 Expression of the CG59883-01 gene is low/undetectable in all samples on this panel (CTs>35).

**General\_screening\_panel\_v1.4 Summary:** Ag3625 Expression of the CG59883-01 gene is restricted to the testis and a brain cancer cell line (CTs=30-32). Thus, expression of this gene could be used to differentiate between these samples and other samples on this panel and as a marker of testicular tissue. Furthermore, therapeutic modulation of the expression or function of this gene product may be useful in the treatment of male infertility and hypogonadism.

- Panel 4.1D Summary:** Ag3625 Expression of the CG59883-01 gene is restricted to a cluster of treated and untreated NCI-H292 mucoepidermoid cells (CTs=32-33). Treatment of these cells does not seem to significantly alter expression of this transcript in this cell line. Thus, the protein could be used to identify certain lung tumors similar to NCI-H292. The encoded
- 5 protein may also contribute to the normal function of the goblet cells within the lung. Therefore, designing therapeutics to this protein may be important for the treatment of emphysema and asthma as well as other lung diseases in which goblet cells or the mucus they produce have pathological consequences.

#### F. NOV6a (CG59901-01: Scavenger receptor)

- 10 Expression of gene CG59901-01 was assessed using the primer-probe set Ag3627, described in Table FA.

Table FA. Probe Name Ag3627

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-ggagcagtgactgctgtagaga-3'	22	331	123
Probe	TET-5'-caccctctctggactaccctggtctg-3'-TAMRA	26	356	124
Reverse	5'-agcattcacacgacgtaaattgt-3'	22	388	125

**CNS\_neurodegeneration\_v1.0 Summary:** Ag3627 Expression of the CG59901-01 gene is low/undetectable in all samples on this panel (CTs>35).

- 15 **General\_screening\_panel\_v1.4 Summary:** Ag3627 Expression of the CG59901-01 gene is low/undetectable in all samples on this panel (CTs>35).

**Panel 4.1D Summary:** Ag3627 Expression of the CG59901-01 gene is low/undetectable in all samples on this panel (CTs>35).

#### G. NOV7a (CG88748-01: cyclic nucleotide-gated channel protein)

- 20 Expression of gene CG88748-01 was assessed using the primer-probe set Ag3677, described in Table GA. Results of the RTQ-PCR runs are shown in Tables GB.

Table GA. Probe Name Ag3677

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-acagtggatgagcgagaaatt-3'	21	1328	126
Probe	TET-5'-ctcaagaatctgccagccaagctcag-3'- TAMRA	26	1349	127
Reverse	5'-caagtggacattgatggctatc-3'	22	1381	128

Table GB. General\_screening\_panel\_v1.4

Tissue Name	Rel. Exp.(%) Ag3677, Run 218952040	Tissue Name	Rel. Exp.(%) Ag3677, Run 218952040
Adipose	0.0	Renal ca. TK-10	0.0
Melanoma* Hs688(A).T	0.0	Bladder	0.0
Melanoma* Hs688(B).T	0.0	Gastric ca. (liver met.) NCI-N87	0.0
Melanoma* M14	0.0	Gastric ca. KATO III	0.0
Melanoma* LOXIMVI	0.0	Colon ca. SW-948	0.0
Melanoma* SK- MEL-5	0.0	Colon ca. SW480	0.0
Squamous cell carcinoma SCC-4	0.0	Colon ca.* (SW480 met) SW620	0.0
Testis Pool	100.0	Colon ca. HT29	0.0
Prostate ca.* (bone met) PC-3	0.0	Colon ca. HCT-116	0.0
Prostate Pool	0.0	Colon ca. CaCo-2	0.0
Placenta	0.0	Colon cancer tissue	0.0
Uterus Pool	0.0	Colon ca. SW1116	0.0
Ovarian ca. OVCAR-3	0.0	Colon ca. Colo-205	0.0
Ovarian ca. SK-OV- 3	0.0	Colon ca. SW-48	0.0
Ovarian ca. OVCAR-4	0.0	Colon Pool	7.9
Ovarian ca. OVCAR-5	0.0	Small Intestine Pool	0.0
Ovarian ca. IGROV- 1	0.0	Stomach Pool	0.0
Ovarian ca. OVCAR-8	0.0	Bone Marrow Pool	0.0
Ovary	0.0	Fetal Heart	0.0
Breast ca. MCF-7	0.0	Heart Pool	6.6
Breast ca. MDA- MB-231	0.0	Lymph Node Pool	0.0



Breast ca. BT 549	0.0	Fetal Skeletal Muscle	0.0
Breast ca. T47D	8.2	Skeletal Muscle Pool	0.0
Breast ca. MDA-N	9.7	Spleen Pool	0.0
Breast Pool	0.0	Thymus Pool	16.7
Trachea	0.0	CNS cancer (glio/astro) U87-MG	0.0
Lung	0.0	CNS cancer (glio/astro) U-118-MG	0.0
Fetal Lung	0.0	CNS cancer (neuro;met) SK-N-AS	0.0
Lung ca. NCI-N417	0.0	CNS cancer (astro) SF- 539	0.0
Lung ca. LX-1	9.1	CNS cancer (astro) SNB-75	0.0
Lung ca. NCI-H146	0.0	CNS cancer (glio) SNB-19	0.0
Lung ca. SHP-77	0.0	CNS cancer (glio) SF- 295	0.0
Lung ca. A549	0.0	Brain (Amygdala) Pool	0.0
Lung ca. NCI-H526	0.0	Brain (cerebellum)	0.0
Lung ca. NCI-H23	0.0	Brain (fetal)	0.0
Lung ca. NCI-H460	0.0	Brain (Hippocampus) Pool	0.0
Lung ca. HOP-62	0.0	Cerebral Cortex Pool	0.0
Lung ca. NCI-H522	0.0	Brain (Substantia nigra) Pool	0.0
Liver	0.0	Brain (Thalamus) Pool	0.0
Fetal Liver	0.0	Brain (whole)	0.0
Liver ca. HepG2	0.0	Spinal Cord Pool	0.0
Kidney Pool	33.7	Adrenal Gland	13.0
Fetal Kidney	9.6	Pituitary gland Pool	0.0
Renal ca. 786-0	0.0	Salivary Gland	0.0
Renal ca. A498	0.0	Thyroid (female)	0.0
Renal ca. ACHN	0.0	Pancreatic ca. CAPAN2	0.0
Renal ca. UO-31	0.0	Pancreas Pool	5.6

Table GD. Panel 4.1D

CNS\_neurodegeneration\_v1.0 Summary: Ag3677 Expression of the CG88748-01 gene is low/undetectable in all samples on this panel (CTs>35).

- General\_screening\_panel\_v1.4 Summary:** Ag3677 Expression of the CG88748-01 gene is restricted to the testis (CT=33.8). Therefore, expression of this gene could be used to differentiate between this sample and other samples on this panel and as a marker of testicular tissue. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of male infertility or hypogonadism.

**Panel 4.1D Summary:** Ag3677 Expression of the CG88748-01 gene is low/undetectable in all samples on this panel (CTs>35).

**H. NOV8a (CG90021-01: Testicular Metalloprotease-Like, Disintegrin-Like.)**

- 10 Expression of gene CG90021-01 was assessed using the primer-probe set Ag3701, described in Table HA. Results of the RTQ-PCR runs are shown in Tables HB and HC.

Table HA. Probe Name Ag3701

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5' -caatataaaaaggccacgttcaa-3'	22	665	129
Probe	TET-5' -tccaattcatattatcgcatatatggca-3' - TAMRA	28	690	130
Reverse	5' -gaccacctctttggaacaagtt-3'	22	725	131

Table HB. General\_screening\_panel\_v1.4

Tissue Name	Rel. Exp.(%) Ag3701, Run 218253707	Tissue Name	Rel. Exp.(%) Ag3701, Run 218253707
Adipose	0.0	Renal ca. TK-10	0.0
Melanoma* Hs688(A).T	0.0	Bladder	0.0
Melanoma* Hs688(B).T	0.0	Gastric ca. (liver met.) NCI-N87	0.0
Melanoma* M14	0.0	Gastric ca. KATO III	0.0
Melanoma* LOXIMVI	0.0	Colon ca. SW-948	0.0
Melanoma* SK- MEL-5	0.0	Colon ca. SW480	0.0
Squamous cell carcinoma SCC-4	0.0	Colon ca.* (SW480 met) SW620	0.0
Testis Pool	100.0	Colon ca. HT29	0.0
Prostate ca.* (bone	0.0	Colon ca. HCT-116	0.0

met) PC-3			
Prostate Pool	0.0	Colon ca. CaCo-2	0.0
Placenta	0.0	Colon cancer tissue	0.0
Uterus Pool	0.0	Colon ca. SW1116	0.0
Ovarian ca. OVCAR-3	0.0	Colon ca. Colo-205	0.0
Ovarian ca. SK-OV-3	0.0	Colon ca. SW-48	0.0
Ovarian ca. OVCAR-4	0.0	Colon Pool	0.0
Ovarian ca. OVCAR-5	0.0	Small Intestine Pool	0.0
Ovarian ca. IGROV-1	0.0	Stomach Pool	0.0
Ovarian ca. OVCAR-8	0.0	Bone Marrow Pool	0.0
Ovary	0.0	Fetal Heart	0.0
Breast ca. MCF-7	0.0	Heart Pool	0.0
Breast ca. MDA-MB-231	0.0	Lymph Node Pool	0.0
Breast ca. BT 549	0.0	Fetal Skeletal Muscle	0.0
Breast ca. T47D	0.0	Skeletal Muscle Pool	0.0
Breast ca. MDA-N	0.0	Spleen Pool	0.0
Breast Pool	0.0	Thymus Pool	0.0
Trachea	0.0	CNS cancer (glio/astro) U87-MG	0.0
Lung	0.0	CNS cancer (glio/astro) U-118-MG	0.0
Fetal Lung	0.0	CNS cancer (neuro;met) SK-N-AS	0.0
Lung ca. NCI-N417	0.0	CNS cancer (astro) SF-539	0.0
Lung ca. LX-1	0.0	CNS cancer (astro) SNB-75	0.0
Lung ca. NCI-H146	0.0	CNS cancer (glio) SNB-19	0.0
Lung ca. SHP-77	0.0	CNS cancer (glio) SF-295	0.0
Lung ca. A549	0.0	Brain (Amygdala) Pool	0.0
Lung ca. NCI-H526	0.0	Brain (cerebellum)	0.0
Lung ca. NCI-H23	0.0	Brain (fetal)	0.0
Lung ca. NCI-H460	0.0	Brain (Hippocampus) Pool	0.0
Lung ca. HOP-62	0.0	Cerebral Cortex Pool	0.0

Lung ca. NCI-H522	0.0	Brain (Substantia nigra) Pool	0.0
Liver	0.0	Brain (Thalamus) Pool	0.0
Fetal Liver	0.0	Brain (whole)	0.0
Liver ca. HepG2	0.0	Spinal Cord Pool	0.0
Kidney Pool	0.0	Adrenal Gland	0.0
Fetal Kidney	0.0	Pituitary gland Pool	0.0
Renal ca. 786-0	0.0	Salivary Gland	0.0
Renal ca. A498	0.0	Thyroid (female)	0.0
Renal ca. ACHN	0.0	Pancreatic ca. CAPAN2	0.0
Renal ca. UO-31	0.0	Pancreas Pool	0.0

Table HC. Panel 4.1D

Tissue Name	Rel. Exp.(%) Ag3701, Run 169987419	Tissue Name	Rel. Exp.(%) Ag3701, Run 169987419
Secondary Th1 act	100.0	HUVEC IL-1beta	0.0
Secondary Th2 act	0.0	HUVEC IFN gamma	0.0
Secondary Tr1 act	0.3	HUVEC TNF alpha + IFN gamma	0.0
Secondary Th1 rest	0.0	HUVEC TNF alpha + IL4	0.0
Secondary Th2 rest	0.3	HUVEC IL-11	0.0
Secondary Tr1 rest	0.0	Lung Microvascular EC none	0.0
Primary Th1 act	0.0	Lung Microvascular EC TNFalpha + IL-1beta	0.0
Primary Th2 act	0.0	Microvascular Dermal EC none	0.0
Primary Tr1 act	0.0	Microvascular Dermal EC TNFalpha + IL-1beta	0.2
Primary Th1 rest	0.0	Bronchial epithelium TNFalpha + IL1beta	0.0
Primary Th2 rest	0.0	Small airway epithelium none	0.0
Primary Tr1 rest	0.0	Small airway epithelium TNFalpha + IL-1beta	0.0
CD45RA CD4 lymphocyte act	0.4	Coronary artery SMC rest	0.0
CD45RO CD4 lymphocyte act	0.0	Coronary artery SMC TNFalpha + IL-1beta	0.0
CD8 lymphocyte act	0.0	Astrocytes rest	0.0
Secondary CD8	0.0	Astrocytes TNFalpha +	0.0

lymphocyte rest		IL-1beta	
Secondary CD8 lymphocyte act	0.0	KU-812 (Basophil) rest	0.0
CD4 lymphocyte none	0.0	KU-812 (Basophil) PMA/ionomycin	0.0
2ry Th1/Th2/Tr1_anti-CD95 CH11	0.0	CCD1106 (Keratinocytes) none	0.0
LAK cells rest	0.0	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	0.0
LAK cells IL-2	0.0	Liver cirrhosis	0.0
LAK cells IL-2+IL-12	0.0	NCI-H292 none	0.0
LAK cells IL-2+IFN gamma	0.0	NCI-H292 IL-4	0.0
LAK cells IL-2+ IL-18	0.0	NCI-H292 IL-9	0.0
LAK cells PMA/ionomycin	0.0	NCI-H292 IL-13	0.0
NK Cells IL-2 rest	0.0	NCI-H292 IFN gamma	0.0
Two Way MLR 3 day	0.0	HPAEC none	0.0
Two Way MLR 5 day	0.0	HPAEC TNF alpha + IL-1 beta	0.0
Two Way MLR 7 day	0.0	Lung fibroblast none	0.0
PBMC rest	0.0	Lung fibroblast TNF alpha + IL-1 beta	0.0
PBMC PWM	0.0	Lung fibroblast IL-4	0.0
PBMC PHA-L	0.0	Lung fibroblast IL-9	0.0
Ramos (B cell) none	0.0	Lung fibroblast IL-13	0.0
Ramos (B cell) ionomycin	0.0	Lung fibroblast IFN gamma	0.0
B lymphocytes PWM	0.0	Dermal fibroblast CCD1070 rest	0.0
B lymphocytes CD40L and IL-4	0.0	Dermal fibroblast CCD1070 TNF alpha	0.0
EOL-1 dbcAMP	0.0	Dermal fibroblast CCD1070 IL-1 beta	0.0
EOL-1 dbcAMP PMA/ionomycin	0.0	Dermal fibroblast IFN gamma	0.0
Dendritic cells none	0.0	Dermal fibroblast IL-4	0.0
Dendritic cells LPS	0.0	Dermal Fibroblasts rest	0.0
Dendritic cells anti-CD40	0.0	Neutrophils TNFa+LPS	0.0
Monocytes rest	0.0	Neutrophils rest	0.0
Monocytes LPS	0.0	Colon	0.3
Macrophages rest	0.0	Lung	0.0

Macrophages LPS	0.0	Thymus	0.0
HUVEC none	0.0	Kidney	0.0
HUVEC starved	0.0		

**CNS\_neurodegeneration\_v1.0 Summary:** Ag3701 Expression of the CG90021-01 gene is low/undetectable in all samples on this panel (CTs>35).

- General\_screening\_panel\_v1.4 Summary:** Ag3701 Expression of the CG90021-01 gene is restricted to the testis (CT=33). This expression agrees with the characterization of this protein as a putative testicular protein. Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel and as a marker for testicular tissue. Furthermore, therapeutic modulation of the expression or function of this gene product may be useful in the treatment of male infertility and hypogonadism.

- Panel 4.1D Summary:** Ag3701 Expression of the CG90021-01 gene is restricted to a sample of activated secondary Th1 cells (CT=30.4). Thus, expression of this gene could be used to distinguish this sample from other samples on this panel and as a marker to identify activated Th1 cells. Furthermore, this gene product may be involved in diseases where T cells are chronically stimulated.

#### I. NOV9a (CG90709-01: Ion Transport Protein)

- Expression of gene CG90709-01 was assessed using the primer-probe set Ag3712, described in Table IA.

Table IA. Probe Name Ag3712

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-gttacacattctgtggctggat-3'	22	1217	132
Probe	TET-5'-tgtcttaggaccataccatctacagtttga-3'-TAMRA	30	1239	133
Reverse	5'-acactcagcaactgtgttcaga-3'	22	1272	134

- CNS\_neurodegeneration\_v1.0 Summary:** Ag3712 Expression of the CG90709-01 gene is low/undetectable (CTs > 35) across all of the samples on this panel.

**General\_screening\_panel\_v1.4 Summary:** Ag3712 Results from one experiment with the CG90709-01 gene are not included. The amp plot indicates that there were experimental difficulties with this run.

**Panel 4.1D Summary:** Ag3712 Expression of the CG90709-01 gene is low/undetectable (CTs > 35) across all of the samples on this panel.

**J. NOV9c and NOV9d (CG90709-03 and CG90709-04: Ion Transport Protein)**

Expression of gene CG90709-03 and CG90709-04 was assessed using the primer-probe sets Ag5864 and Ag5941, described in Tables JA and JB. Results of the RTQ-PCR runs are shown in Tables JC, JD, JE and JF.

Table JA. Probe Name Ag5864

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-gaaagagtcctcagccttct-3'	21	1712	135
Probe	TET-5'-cacttcttttctcctccgacagcag-3'-TAMRA	26	1742	136
Reverse	5'-tagcagaacttttagctaataaggtatcaagt-3'	30	1774	137

Table JB. Probe Name Ag5941

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-gagagaggatcaggtgttttcag-3'	23	135	138
Probe	TET-5'-taaccgtcagaaatgcaatggcacat-3'-TAMRA	26	160	139
Reverse	5'-cttagacattcttctttcatctcagaat-3'	28	190	140

Table JC. AI comprehensive panel\_v1.0

Tissue Name	Rel. Exp.(%) Ag5864, Run 247947740	Rel. Exp.(%) Ag5941, Run 247756614	Tissue Name	Rel. Exp.(%) Ag5864, Run 247947740	Rel. Exp.(%) Ag5941, Run 247756614
110967 COPD-F	0.6	0.0	112427 Match Control Psoriasis-F	12.8	10.0
110980 COPD-F	0.3	0.5	112418 Psoriasis-M	0.0	0.3
110968 COPD-	0.0	0.5	112723 Match	0.0	0.0

M			Control Psoriasis-M		
110977 COPD-M	4.0	2.1	112419 Psoriasis-M	0.9	0.0
110989 Emphysema-F	36.3	21.6	112424 Match Control Psoriasis-M	1.3	0.0
110992 Emphysema-F	4.9	4.6	112420 Psoriasis-M	11.9	7.4
110993 Emphysema-F	2.5	0.5	112425 Match Control Psoriasis-M	3.5	10.4
110994 Emphysema-F	1.0	1.7	104689 (MF) OA Bone- Backus	23.3	15.9
110995 Emphysema-F	11.6	9.2	104690 (MF) Adj "Normal" Bone-Backus	11.3	10.0
110996 Emphysema-F	0.4	1.6	104691 (MF) OA Synovium- Backus	11.5	8.8
110997 Asthma-M	5.5	1.4	104692 (BA) OA Cartilage- Backus	80.7	100.0
111001 Asthma-F	2.5	0.7	104694 (BA) OA Bone- Backus	5.8	3.9
111002 Asthma-F	3.3	1.5	104695 (BA) Adj "Normal" Bone-Backus	27.2	19.8
111003 Atopic Asthma-F	7.0	4.2	104696 (BA) OA Synovium- Backus	5.0	6.9
111004 Atopic Asthma-F	10.9	7.4	104700 (SS) OA Bone- Backus	10.8	2.6
111005 Atopic Asthma-F	7.9	5.8	104701 (SS) Adj "Normal" Bone-Backus	22.2	19.3
111006 Atopic Asthma-F	0.0	0.9	104702 (SS) OA Synovium- Backus	11.5	8.5
111417 Allergy-M	2.7	2.3	117093 OA Cartilage Rep7	2.9	4.2
112347 Allergy-M	0.0	0.2	112672 OA Bone5	4.2	1.5



112349 Normal Lung-F	0.0	0.0	112673 OA Synovium5	1.9	1.1
112357 Normal Lung-F	4.5	2.2	112674 OA Synovial Fluid cells5	3.3	1.0
112354 Normal Lung-M	1.0	0.8	117100 OA Cartilage Rep14	0.5	0.7
112374 Crohns-F	2.2	0.0	112756 OA Bone9	0.8	0.5
112389 Match Control Crohns-F	2.8	2.3	112757 OA Synovium9	0.6	0.0
112375 Crohns-F	1.9	0.6	112758 OA Synovial Fluid Cells9	1.5	0.3
112732 Match Control Crohns-F	59.9	36.1	117125 RA Cartilage Rep2	0.0	0.5
112725 Crohns-M	0.0	0.0	113492 Bone2 RA	27.4	11.8
112387 Match Control Crohns-M	5.0	4.4	113493 Synovium2 RA	9.9	4.1
112378 Crohns-M	0.4	0.0	113494 Syn Fluid Cells RA	12.7	7.5
112390 Match Control Crohns-M	23.3	15.8	113499 Cartilage4 RA	27.0	8.7
112726 Crohns-M	3.7	2.0	113500 Bone4 RA	31.2	15.9
112731 Match Control Crohns-M	4.9	2.1	113501 Synovium4 RA	24.5	10.4
112380 Ulcer Col-F	10.1	8.8	113502 Syn Fluid Cells4 RA	20.4	6.4
112734 Match Control Ulcer Col-F	100.0	61.1	113495 Cartilage3 RA	21.2	9.7
112384 Ulcer Col-F	9.2	7.0	113496 Bone3 RA	16.4	9.7
112737 Match Control Ulcer Col-F	2.7	0.8	113497 Synovium3 RA	7.4	5.6
112386 Ulcer	0.3	0.0	113498 Syn	26.6	15.8

Col-F			Fluid Cells3 RA		
112738 Match Control Ulcer Col-F	16.0	5.3	117106 Normal Cartilage Rep20	0.0	0.3
112381 Ulcer Col-M	0.5	0.6	113663 Bone3 Normal	0.0	0.3
112735 Match Control Ulcer Col-M	1.3	0.7	113664 Synovium3 Normal	0.0	0.0
112382 Ulcer Col-M	6.7	2.3	113665 Syn Fluid Cells3 Normal	0.7	0.3
112394 Match Control Ulcer Col-M	0.0	0.5	117107 Normal Cartilage Rep22	0.6	0.7
112383 Ulcer Col-M	6.4	4.2	113667 Bone4 Normal	0.9	1.8
112736 Match Control Ulcer Col-M	1.6	0.6	113668 Synovium4 Normal	2.3	1.9
112423 Psoriasis-F	1.3	1.8	113669 Syn Fluid Cells4 Normal	6.7	1.7

Table JD. CNS\_neurodegeneration\_v1.0

Tissue Name	Rel. Exp.(%) Ag5864, Run 247189534	Tissue Name	Rel. Exp.(%) Ag5864, Run 247189534
AD 1 Hippo	17.6	Control (Path) 3 Temporal Ctx	0.0
AD 2 Hippo	100.0	Control (Path) 4 Temporal Ctx	17.0
AD 3 Hippo	0.0	AD 1 Occipital Ctx	0.0
AD 4 Hippo	87.1	AD 2 Occipital Ctx (Missing)	0.0
AD 5 Hippo	25.9	AD 3 Occipital Ctx	0.0
AD 6 Hippo	80.1	AD 4 Occipital Ctx	17.7
Control 2 Hippo	6.2	AD 5 Occipital Ctx	17.4
Control 4 Hippo	47.3	AD 6 Occipital Ctx	0.0
Control (Path) 3 Hippo	17.4	Control 1 Occipital Ctx	13.7
AD 1 Temporal Ctx	0.0	Control 2 Occipital Ctx	16.6

AD 2 Temporal Ctx	29.3	Control 3 Occipital Ctx	41.5
AD 3 Temporal Ctx	33.7	Control 4 Occipital Ctx	0.0
AD 4 Temporal Ctx	12.2	Control (Path) 1 Occipital Ctx	43.8
AD 5 Inf Temporal Ctx	32.8	Control (Path) 2 Occipital Ctx	16.4
AD 5 Sup Temporal Ctx	56.3	Control (Path) 3 Occipital Ctx	0.0
AD 6 Inf Temporal Ctx	15.2	Control (Path) 4 Occipital Ctx	24.5
AD 6 Sup Temporal Ctx	66.4	Control 1 Parietal Ctx	27.4
Control 1 Temporal Ctx	0.0	Control 2 Parietal Ctx	61.1
Control 2 Temporal Ctx	0.0	Control 3 Parietal Ctx	0.0
Control 3 Temporal Ctx	15.9	Control (Path) 1 Parietal Ctx	19.2
Control 3 Temporal Ctx	43.8	Control (Path) 2 Parietal Ctx	14.7
Control (Path) 1 Temporal Ctx	12.3	Control (Path) 3 Parietal Ctx	0.0
Control (Path) 2 Temporal Ctx	13.4	Control (Path) 4 Parietal Ctx	43.8

Table JE. General\_screening\_panel\_v1.5

Tissue Name	Rel. Exp.(%) Ag5864, Run 246287340	Tissue Name	Rel. Exp.(%) Ag5864, Run 246287340
Adipose	9.0	Renal ca. TK-10	77.9
Melanoma* Hs688(A).T	0.2	Bladder	21.3
Melanoma* Hs688(B).T	0.0	Gastric ca. (liver met.) NCI-N87	0.0
Melanoma* M14	48.6	Gastric ca. KATO III	0.0
Melanoma* LOXIMVI	37.1	Colon ca. SW-948	0.0
Melanoma* SK-MEL-5	100.0	Colon ca. SW480	97.3
Squamous cell carcinoma SCC-4	17.9	Colon ca. * (SW480 met) SW620	0.0
Testis Pool	6.8	Colon ca. HT29	0.5
Prostate ca. * (bone	14.3	Colon ca. HCT-116	72.7

met) PC-3			
Prostate Pool	7.7	Colon ca. CaCo-2	1.7
Placenta	0.4	Colon cancer tissue	27.9
Uterus Pool	2.3	Colon ca. SW1116	22.1
Ovarian ca. OVCAR-3	2.4	Colon ca. Colo-205	0.4
Ovarian ca. SK-OV-3	13.4	Colon ca. SW-48	14.5
Ovarian ca. OVCAR-4	0.7	Colon Pool	1.7
Ovarian ca. OVCAR-5	19.3	Small Intestine Pool	9.9
Ovarian ca. IGROV-1	11.3	Stomach Pool	6.0
Ovarian ca. OVCAR-8	13.6	Bone Marrow Pool	4.1
Ovary	0.0	Fetal Heart	0.9
Breast ca. MCF-7	20.6	Heart Pool	0.6
Breast ca. MDA-MB-231	12.3	Lymph Node Pool	6.8
Breast ca. BT 549	5.9	Fetal Skeletal Muscle	0.5
Breast ca. T47D	10.4	Skeletal Muscle Pool	1.2
Breast ca. MDA-N	56.6	Spleen Pool	48.3
Breast Pool	1.7	Thymus Pool	18.8
Trachea	10.3	CNS cancer (glio/astro) U87-MG	13.7
Lung	0.3	CNS cancer (glio/astro) U-118-MG	0.0
Fetal Lung	15.9	CNS cancer (neuro;met) SK-N-AS	0.0
Lung ca. NCI-N417	0.5	CNS cancer (astro) SF-539	1.9
Lung ca. LX-1	0.0	CNS cancer (astro) SNB-75	5.3
Lung ca. NCI-H146	0.0	CNS cancer (glio) SNB-19	6.9
Lung ca. SHP-77	0.0	CNS cancer (glio) SF-295	77.9
Lung ca. A549	12.2	Brain (Amygdala) Pool	0.5
Lung ca. NCI-H526	14.8	Brain (cerebellum)	0.0
Lung ca. NCI-H23	33.4	Brain (fetal)	0.0
Lung ca. NCI-H460	17.7	Brain (Hippocampus) Pool	0.2
Lung ca. HOP-62	0.7	Cerebral Cortex Pool	0.0

Lung ca. NCI-H522	2.5	Brain (Substantia nigra) Pool	0.0
Liver	0.0	Brain (Thalamus) Pool	0.7
Fetal Liver	1.0	Brain (whole)	0.2
Liver ca. HepG2	0.0	Spinal Cord Pool	3.1
Kidney Pool	2.5	Adrenal Gland	28.9
Fetal Kidney	2.3	Pituitary gland Pool	0.7
Renal ca. 786-0	27.9	Salivary Gland	1.8
Renal ca. A498	5.0	Thyroid (female)	0.3
Renal ca. ACHN	5.8	Pancreatic ca. CAPAN2	0.0
Renal ca. UO-31	12.6	Pancreas Pool	6.9

Table JF. Panel 4.1D

Tissue Name	Rel. Exp.(%) Ag5864, Run 246733832	Rel. Exp.(%) Ag5941, Run 247582900	Tissue Name	Rel. Exp.(%) Ag5864, Run 246733832	Rel. Exp.(%) Ag5941, Run 247582900
Secondary Th1 act	21.9	39.2	HUVEC IL-1beta	0.0	0.0
Secondary Th2 act	43.2	61.6	HUVEC IFN gamma	0.0	0.0
Secondary Tr1 act	5.6	9.2	HUVEC TNF alpha + IFN gamma	0.0	0.0
Secondary Th1 rest	0.1	0.8	HUVEC TNF alpha + IL4	0.0	0.0
Secondary Th2 rest	0.2	0.0	HUVEC IL-11	0.0	0.0
Secondary Tr1 rest	0.1	0.0	Lung Microvascular EC none	0.0	0.0
Primary Th1 act	0.3	0.5	Lung Microvascular EC TNFalpha + IL-1beta	0.0	0.0
Primary Th2 act	2.0	2.4	Microvascular Dermal EC none	0.0	0.0
Primary Tr1 act	5.1	10.2	Microvascular Dermal EC TNFalpha + IL-1beta	0.0	0.0
Primary Th1 rest	0.1	0.0	Bronchial epithelium TNFalpha +	0.3	0.5

			IL1beta		
Primary Th2 rest	0.3	0.4	Small airway epithelium none	0.2	0.4
Primary Tr1 rest	0.0	0.2	Small airway epithelium TNFalpha + IL-1beta	0.4	0.7
CD45RA CD4 lymphocyte act	8.5	18.2	Coronary artery SMC rest	0.0	0.0
CD45RO CD4 lymphocyte act	12.2	30.4	Coronary artery SMC TNFalpha + IL-1beta	0.0	0.0
CD8 lymphocyte act	3.1	5.8	Astrocytes rest	0.1	0.0
Secondary CD8 lymphocyte rest	11.5	23.8	Astrocytes TNFalpha + IL-1beta	0.1	0.0
Secondary CD8 lymphocyte act	2.7	6.6	KU-812 (Basophil) rest	0.0	0.0
CD4 lymphocyte none	0.1	0.3	KU-812 (Basophil) PMA/ionomycin	0.0	0.0
2ry Th1/Th2/Tr1_anti-CD95 CH11	0.7	0.5	CCD1106 (Keratinocytes) none	0.3	0.0
LAK cells rest	2.9	6.2	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	0.2	0.2
LAK cells IL-2	2.9	7.7	Liver cirrhosis	0.4	1.9
LAK cells IL-2+IL-12	0.7	1.2	NCI-H292 none	2.1	3.7
LAK cells IL-2+IFN gamma	3.8	7.4	NCI-H292 IL-4	2.5	5.4
LAK cells IL-2+IL-18	1.3	4.6	NCI-H292 IL-9	2.9	4.5
LAK cells PMA/ionomycin	8.8	18.6	NCI-H292 IL-13	3.0	3.2
NK Cells IL-2 rest	14.0	21.9	NCI-H292 IFN gamma	1.2	2.0
Two Way MLR 3 day	3.4	6.1	HPAEC none	0.0	0.0
Two Way MLR 5 day	0.6	1.0	HPAEC TNF alpha + IL-1 beta	0.0	0.0
Two Way MLR 7 day	2.8	4.6	Lung fibroblast none	0.2	0.6

PBMC rest	0.3	0.3	Lung fibroblast TNF alpha + IL-1 beta	0.2	0.6
PBMC PWM	2.7	5.0	Lung fibroblast IL-4	0.3	0.3
PBMC PHA-L	2.7	2.8	Lung fibroblast IL-9	0.3	0.6
Ramos (B cell) none	2.1	4.6	Lung fibroblast IL-13	0.3	0.4
Ramos (B cell) ionomycin	22.5	52.5	Lung fibroblast IFN gamma	0.4	1.0
B lymphocytes PWM	11.3	33.0	Dermal fibroblast CCD1070 rest	0.8	1.7
B lymphocytes CD40L and IL-4	15.9	37.1	Dermal fibroblast CCD1070 TNF alpha	5.8	12.5
EOL-1 dbcAMP	0.9	3.4	Dermal fibroblast CCD1070 IL-1 beta	0.5	0.4
EOL-1 dbcAMP PMA/ionomycin	0.1	0.0	Dermal fibroblast IFN gamma	0.1	0.1
Dendritic cells none	2.0	3.1	Dermal fibroblast IL-4	0.0	0.5
Dendritic cells LPS	10.6	12.2	Dermal Fibroblasts rest	0.1	0.0
Dendritic cells anti- CD40	0.5	0.9	Neutrophils TNFa+LPS	0.2	0.3
Monocytes rest	0.1	0.0	Neutrophils rest	0.0	0.1
Monocytes LPS	100.0	100.0	Colon	0.2	0.2
Macrophages rest	0.8	1.1	Lung	0.4	0.2
Macrophages LPS	9.7	9.8	Thymus	0.3	0.9
HUVEC none	0.0	0.0	Kidney	0.5	0.8
HUVEC starved	0.0	0.0			

AI\_comprehensive panel\_v1.0 Summary: Ag5864 Two experiments with different probe and primer sets are in excellent agreements with highest expression of the CG90709-03 gene in matched control ulcerative colitis sample and OA cartilage (CTs=30). Interestingly, expression of this gene is higher in matched control ulcerative colitis and Crohn's sample as compared the sample of corresponding diseased tissue. In addition, significant expression of this gene is also observed in synovium, bone and cartilage samples derived from orthoarthritis and rheumatoid arthritis patient. Therefore, therapeutic modulation of the

activity of this gene may prove useful in the treatment of inflammatory bowel diseases and arthritis.

**CNS\_neurodegeneration\_v1.0 Summary:** Ag5864 Expression of the CG90709-03 gene is low/undetectable (CTs > 34) across all of the samples on this panel.

- 5 **General\_screening\_panel\_v1.5 Summary:** Ag5864 Highest expression of the CG90709-03 gene is detected in melanoma SK-MEL-5 cell line (CT=28.2). High to moderate expression of this gene is also seen in melanoma, renal cancer, squamous cell carcinoma, ovarian and breast cancer, colon cancer and CNS cancer cell lines. Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, or antibodies, might be beneficial in the treatment of these cancers.
- 10

Among tissues with metabolic or endocrine function, this gene is expressed at moderate levels in pancreas, adipose, adrenal gland, and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

- 15 The CG90709-03 gene codes for an ion transport protein. Ion transport proteins are responsible for the movement of cations through the membrane. This family contains sodium, potassium and calcium ion channels. The physiologic function of an ion transport protein is determined, in part, by its subcellular localization and by the cellular mechanisms that modulate its activity (Ref.1). Recently, mutations of a gene encoding an ion transport protein, has been shown to be involved in the development of chronic pancreatitis including cystic fibrosis of the pancreas (Ref.2). The CG90709-03 gene is expressed in pancreas at a moderate levels (CT=33). Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of pancreatitis.
- 20

In addition, significant expression of this gene is also observed in spleen and thymus.

- 25 Therefore, antibodies or small molecule therapeutics that block the function of this gene product may be useful as anti-inflammatory therapeutics for the treatment of allergies, autoimmune diseases, and inflammatory diseases.

*See, generally,*



Dunbar LA, Caplan MJ. (2001) Ion pumps in polarized cells: sorting and regulation of the Na<sup>+</sup>, K<sup>+</sup>- and H<sup>+</sup>, K<sup>+</sup>-ATPases. J Biol Chem 2001 Aug 10;276(32):29617-20. PMID: 11404365

Bornstein JD, Cohn JA. (1999) Cystic fibrosis in the pancreas: recent advances provide new insights. Curr Gastroenterol Rep 1(2):161-5. PMID: 10980944

**Panel 4.1D Summary:** Ag5864 Highest expression of the CG90709-03 gene is detected in LPS treated monocytes (CT=27). In addition, expression of this gene is low or undetectable in resting monocytes (CT=37). Therefore, expression of this gene can be used to distinguish between the treated and resting monocytes. Furthermore, the expression of this gene in LPS treated monocytes, cells that play a crucial role in linking innate immunity to adaptive immunity, suggests a role for this gene product in initiating inflammatory reactions. Therefore, modulation of the expression or activity of this gene through the application of monoclonal antibodies or small molecule may reduce or prevent early stages of inflammation and reduce the severity of inflammatory diseases such as psoriasis, asthma, inflammatory bowel disease, rheumatoid arthritis, osteoarthritis and other lung inflammatory diseases.

Expression of this gene is stimulated in activated primary and secondary Th1, Th2 and Tr1 cells, TNF alpha treated Dermal fibroblast CCD1070 cells, LPS treated macrophages, ionomycin treated Ramos B cells, PWM/CD40L and IL-4 treated B lymphocytes, and PWM/PHA treated PMBC. Therefore, the putative protein encoded by this gene could potentially be used diagnostically to identify activated B or T cells. In addition, the gene product could also potentially be used therapeutically in the treatment of asthma, emphysema, IBD, lupus or arthritis and in other diseases in which T cells and B cells are activated.

Expression of this gene is also stimulated in TNF alpha treated dermal fibroblast CCD1070 (CT=31) as compared to the resting cells (CT=34). Therefore, expression of this gene can be used to distinguish between these treated and resting fibroblast cells. Also, therapeutic modulation of this gene product could be useful in the treatment of skin disorder such as psoriasis.

#### **K. NOV10a (CG90739-01: Neuronal thread protein like)**

Expression of gene CG90739-01 was assessed using the primer-probe set Ag3796, described in Table KA. Results of the RTQ-PCR runs are shown in Tables KB, KC, and KD.

**Table KA.** Probe Name Ag3796

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-aatttggtgtccgaagtgcag-3'	20	465	141
Probe	TET-5'-tggcagtaacctcaagcttcgaagg-3'-TAMRA	26	514	142
Reverse	5'-tatggatctgcaggcatctc-3'	20	542	143

**Table KB.** CNS\_neurodegeneration\_v1.0

Tissue Name	Rel. Exp.(%) Ag3796, Run 211176632	Tissue Name	Rel. Exp.(%) Ag3796, Run 211176632
AD 1 Hippo	0.0	Control (Path) 3 Temporal Ctx	19.9
AD 2 Hippo	0.0	Control (Path) 4 Temporal Ctx	11.6
AD 3 Hippo	0.0	AD 1 Occipital Ctx	0.0
AD 4 Hippo	0.0	AD 2 Occipital Ctx (Missing)	0.0
AD 5 hippo	100.0	AD 3 Occipital Ctx	0.0
AD 6 Hippo	53.6	AD 4 Occipital Ctx	7.9
Control 2 Hippo	31.2	AD 5 Occipital Ctx	33.7
Control 4 Hippo	10.3	AD 6 Occipital Ctx	41.8
Control (Path) 3 Hippo	0.0	Control 1 Occipital Ctx	0.0
AD 1 Temporal Ctx	3.7	Control 2 Occipital Ctx	55.5
AD 2 Temporal Ctx	5.5	Control 3 Occipital Ctx	11.0
AD 3 Temporal Ctx	7.2	Control 4 Occipital Ctx	0.0
AD 4 Temporal Ctx	0.0	Control (Path) 1 Occipital Ctx	18.9
AD 5 Inf Temporal Ctx	82.4	Control (Path) 2 Occipital Ctx	23.2
AD 5 SupTemporal Ctx	12.0	Control (Path) 3 Occipital Ctx	1.5
AD 6 Inf Temporal Ctx	77.9	Control (Path) 4 Occipital Ctx	0.0
AD 6 Sup Temporal Ctx	58.2	Control 1 Parietal Ctx	0.0
Control 1 Temporal Ctx	0.0	Control 2 Parietal Ctx	1.9
Control 2 Temporal	47.3	Control 3 Parietal	0.0

Ctx		Ctx	
Control 3 Temporal Ctx	9.7	Control (Path) 1 Parietal Ctx	25.9
Control 4 Temporal Ctx	0.0	Control (Path) 2 Parietal Ctx	18.3
Control (Path) 1 Temporal Ctx	46.0	Control (Path) 3 Parietal Ctx	7.0
Control (Path) 2 Temporal Ctx	32.1	Control (Path) 4 Parietal Ctx	7.6

Table KC. General\_screening\_panel\_v1.5

Tissue Name	Rel. Exp.(%) Ag3796, Run 258082161	Tissue Name	Rel. Exp.(%) Ag3796, Run 258082161
Adipose	0.2	Renal ca. TK-10	0.4
Melanoma* Hs688(A).T	0.3	Bladder	2.3
Melanoma* Hs688(B).T	0.5	Gastric ca. (liver met.) NCI-N87	4.8
Melanoma* M14	2.5	Gastric ca. KATO III	5.0
Melanoma* LOXIMVI	0.6	Colon ca. SW-948	0.2
Melanoma* SK- MEL-5	1.0	Colon ca. SW480	0.2
Squamous cell carcinoma SCC-4	0.1	Colon ca.* (SW480 met) SW620	0.6
Testis Pool	100.0	Colon ca. HT29	0.2
Prostate ca.* (bone met) PC-3	0.7	Colon ca. HCT-116	1.8
Prostate Pool	0.3	Colon ca. CaCo-2	1.2
Placenta	0.1	Colon cancer tissue	0.7
Uterus Pool	0.4	Colon ca. SW1116	0.0
Ovarian ca. OVCAR-3	1.1	Colon ca. Colo-205	0.4
Ovarian ca. SK-OV- 3	3.7	Colon ca. SW-48	0.0
Ovarian ca. OVCAR-4	0.2	Colon Pool	0.9
Ovarian ca. OVCAR-5	1.9	Small Intestine Pool	0.6
Ovarian ca. IGROV- 1	0.1	Stomach Pool	0.6
Ovarian ca. OVCAR-8	0.1	Bone Marrow Pool	0.5

Ovary	0.2	Fetal Heart	0.4
Breast ca. MCF-7	1.7	Heart Pool	0.6
Breast ca. MDA-MB-231	1.1	Lymph Node Pool	0.8
Breast ca. BT 549	0.3	Fetal Skeletal Muscle	0.5
Breast ca. T47D	1.1	Skeletal Muscle Pool	0.4
Breast ca. MDA-N	0.4	Spleen Pool	1.1
Breast Pool	0.0	Thymus Pool	0.8
Trachea	0.2	CNS cancer (glio/astro) U87-MG	1.5
Lung	0.7	CNS cancer (glio/astro) U-118-MG	0.4
Fetal Lung	0.6	CNS cancer (neuro;met) SK-N-AS	0.2
Lung ca. NCI-N417	0.3	CNS cancer (astro) SF-539	0.1
Lung ca. LX-1	0.1	CNS cancer (astro) SNB-75	0.9
Lung ca. NCI-H146	0.0	CNS cancer (glio) SNB-19	0.7
Lung ca. SHP-77	0.8	CNS cancer (glio) SF-295	1.8
Lung ca. A549	3.3	Brain (Amygdala) Pool	0.3
Lung ca. NCI-H526	1.0	Brain (cerebellum)	0.7
Lung ca. NCI-H23	2.4	Brain (fetal)	0.6
Lung ca. NCI-H460	0.8	Brain (Hippocampus) Pool	0.8
Lung ca. HOP-62	0.1	Cerebral Cortex Pool	1.2
Lung ca. NCI-H522	0.6	Brain (Substantia nigra) Pool	0.3
Liver	0.0	Brain (Thalamus) Pool	1.2
Fetal Liver	0.6	Brain (whole)	0.2
Liver ca. HepG2	1.0	Spinal Cord Pool	0.8
Kidney Pool	0.6	Adrenal Gland	0.2
Fetal Kidney	0.6	Pituitary gland Pool	0.3
Renal ca. 786-0	1.2	Salivary Gland	0.3
Renal ca. A498	0.0	Thyroid (female)	0.2
Renal ca. ACHN	0.0	Pancreatic ca. CAPAN2	0.4
Renal ca. UO-31	1.4	Pancreas Pool	0.5

Table KD. Panel 4.1D

Tissue Name	Rel. Exp.(%) Ag3796, Run 169997344	Tissue Name	Rel. Exp.(%) Ag3796, Run 169997344
Secondary Th1 act	83.5	HUVEC IL-1beta	4.9
Secondary Th2 act	30.8	HUVEC IFN gamma	0.0
Secondary Tr1 act	74.7	HUVEC TNF alpha + IFN gamma	4.9
Secondary Th1 rest	13.4	HUVEC TNF alpha + IL4	12.1
Secondary Th2 rest	42.9	HUVEC IL-11	5.9
Secondary Tr1 rest	37.1	Lung Microvascular EC none	0.0
Primary Th1 act	28.1	Lung Microvascular EC TNFalpha + IL-1beta	0.0
Primary Th2 act	21.5	Microvascular Dermal EC none	0.0
Primary Tr1 act	11.3	Microvascular Dermal EC TNFalpha + IL-1beta	2.2
Primary Th1 rest	42.6	Bronchial epithelium TNFalpha + IL1beta	0.0
Primary Th2 rest	55.9	Small airway epithelium none	6.5
Primary Tr1 rest	33.2	Small airway epithelium TNFalpha + IL-1beta	8.4
CD45RA CD4 lymphocyte act	26.4	Coronary artery SMC rest	4.7
CD45RO CD4 lymphocyte act	40.9	Coronary artery SMC TNFalpha + IL-1beta	0.0
CD8 lymphocyte act	55.5	Astrocytes rest	0.0
Secondary CD8 lymphocyte rest	17.1	Astrocytes TNFalpha + IL-1beta	2.9
Secondary CD8 lymphocyte act	26.4	KU-812 (Basophil) rest	17.1
CD4 lymphocyte none	9.5	KU-812 (Basophil) PMA/ionomycin	10.4
2ry Th1/Th2/Tr1 _anti- CD95 CH11	100.0	CCD1106 (Keratinocytes) none	7.2
LAK cells rest	12.0	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	7.8
LAK cells IL-2	49.3	Liver cirrhosis	0.0
LAK cells IL-2+IL-12	20.7	NCI-H292 none	1.8
LAK cells IL-2+IFN gamma	36.6	NCI-H292 IL-4	0.0
LAK cells IL-2+ IL-18	14.7	NCI-H292 IL-9	3.3
LAK cells	10.8	NCI-H292 IL-13	4.9

PMA/ionomycin			
NK Cells IL-2 rest	37.1	NCI-H292 IFN gamma	0.0
Two Way MLR 3 day	19.2	HPAEC none	0.0
Two Way MLR 5 day	18.4	HPAEC TNF alpha + IL-1 beta	0.0
Two Way MLR 7 day	24.0	Lung fibroblast none	3.3
PBMC rest	4.9	Lung fibroblast TNF alpha + IL-1 beta	9.6
PBMC PWM	15.0	Lung fibroblast IL-4	3.1
PBMC PHA-L	27.4	Lung fibroblast IL-9	4.2
Ramos (B cell) none	4.1	Lung fibroblast IL-13	12.9
Ramos (B cell) ionomycin	5.5	Lung fibroblast IFN gamma	0.0
B lymphocytes PWM	31.4	Dermal fibroblast CCD1070 rest	2.3
B lymphocytes CD40L and IL-4	31.2	Dermal fibroblast CCD1070 TNF alpha	27.2
EOL-1 dbcAMP	10.4	Dermal fibroblast CCD1070 IL-1 beta	0.0
EOL-1 dbcAMP PMA/ionomycin	55.5	Dermal fibroblast IFN gamma	0.0
Dendritic cells none	65.5	Dermal fibroblast IL-4	14.9
Dendritic cells LPS	39.0	Dermal Fibroblasts rest	0.5
Dendritic cells anti-CD40	33.9	Neutrophils TNFa+LPS	11.5
Monocytes rest	15.9	Neutrophils rest	62.0
Monocytes LPS	17.6	Colon	9.1
Macrophages rest	16.5	Lung	2.6
Macrophages LPS	13.1	Thymus	23.5
HUVEC none	0.0	Kidney	5.3
HUVEC starved	4.9		

- CNS\_neurodegeneration\_v1.0 Summary: Ag3796 This panel does not show differential expression of the CG56153-01 gene in Alzheimer's disease. However, this expression profile confirms the presence of this gene in the brain, with highest expression in the hippocampus of an Alzheimer's patient (CT=33). Therefore, therapeutic modulation of the expression or
- 5 function of this gene may be useful in the treatment of neurologic disorders, such as Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, stroke and epilepsy.

**General\_screening\_panel\_v1.4 Summary:** Ag3796 Results from one experiment with the CG90739-01 gene are not included. The amp plot indicates that there were experimental difficulties with this run.

**General\_screening\_panel\_v1.5 Summary:** Ag3796 Highest expression of the CG90739-01 gene is seen in the testis (CT=27). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel and as a marker of testicular tissue. Furthermore, therapeutic modulation of the expression or function of this protein may be effective in the treatment of male infertility or hypogonadism.

In addition, low but significant expression of this gene is seen in many regions of the central nervous system examined, including hippocampus, thalamus, cerebellum, cerebral cortex, and spinal cord. This gene codes for variant of neuronal thread protein-like protein. Neuronal thread protein is a thread protein identified in AD and Down's syndrome brain tissue. The AD-associated neuronal thread protein (AD7c-NTP), a ~41 kD membrane-spanning phosphoprotein, is shown to cause apoptosis and neuritic sprouting in transfected neuronal cells (Ref. 1, 2). Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurologic disorders, such as Alzheimer's disease, Parkinson's disease, and Down's syndrome.

*See, generally,*

de la Monte SM. (1999) Molecular abnormalities of the brain in Down syndrome: relevance to Alzheimer's neurodegeneration. J Neural Transm Suppl;57:1-19. PMID: 10666665

Suzanne M. de la Monte, Jack R. Wands (2001) The AD7C-NTP neuronal thread protein biomarker for detecting Alzheimer's disease. Journal of Alzheimer's Disease Volume 3 (3), 345-353.

**Oncology\_cell\_line\_screening\_panel\_v3.2 Summary:** Ag3796 Expression of the CG90739-01 gene is low/undetectable (CTs > 35) across all of the samples on this panel.

**Panel 4.1D Summary:** Ag3796 Expression of the CG90739-01 gene is highest in secondary Th1/TH2/Tr1 cells treated with anti-CD95 (CT=31.7). Expression of this gene in this panel appears to be mainly associated with hematopoietic cells, including T cells, particularly chronically activated Th1, Th2 and Tr1 cells, LAK cells, macrophages and dendritic cells.

Thus, this transcript or the protein it encodes could be used to detect hematopoietically-derived cells. Furthermore, therapeutics designed with the protein encoded by this transcript could be important in the regulation the function of antigen presenting cells (macrophages and dendritic cells) or T cells and be important in the treatment of asthma, emphysema, psoriasis, arthritis, and IBD.

#### L. NOV11a and NOV11b (CG91667-01 and CG91667-02: dlk1)

Expression of gene CG91667-01 and CG91667-02 was assessed using the primer-probe set Ag3009, described in Table LA. Results of the RTQ-PCR runs are shown in Tables LB, LC, LD, LE and LF. Please note that CG91667-02 represents a full-length physical clone of the CG91667-01 gene, validating the prediction of the gene sequence.

Table LA. Probe Name Ag3009

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-gggtatcgtcttctcaacaag-3'	22	966	144
Probe	TET-5'-ctacaaccacatgctgcggaagaaga-3'-TAMRA	26	1014	145
Reverse	5'-ttgtactgaagcagcaggttct-3'	22	1040	146

Table LB. AI\_comprehensive panel\_v1.0

Tissue Name	Rel. Exp.(%) Ag3009, Run 228157490	Tissue Name	Rel. Exp.(%) Ag3009, Run 228157490
110967 COPD-F	0.1	112427 Match Control Psoriasis-F	0.8
110980 COPD-F	0.0	112418 Psoriasis-M	0.1
110968 COPD-M	0.1	112723 Match Control Psoriasis-M	0.0
110977 COPD-M	0.0	112419 Psoriasis-M	0.1
110989 Emphysema-F	1.1	112424 Match Control Psoriasis-M	0.0
110992 Emphysema-F	0.3	112420 Psoriasis-M	0.8
110993 Emphysema-F	0.0	112425 Match Control Psoriasis-M	0.6
110994 Emphysema-F	0.0	104689 (MF) OA Bone-Backus	0.0
110995 Emphysema-	1.0	104690 (MF) Adj	0.0



F		"Normal" Bone-Backus	
110996 Emphysema-F	0.1	104691 (MF) OA Synovium-Backus	0.0
110997 Asthma-M	0.0	104692 (BA) OA Cartilage-Backus	0.0
111001 Asthma-F	0.0	104694 (BA) OA Bone-Backus	0.0
111002 Asthma-F	0.0	104695 (BA) Adj "Normal" Bone-Backus	0.0
111003 Atopic Asthma-F	0.0	104696 (BA) OA Synovium-Backus	0.0
111004 Atopic Asthma-F	0.1	104700 (SS) OA Bone-Backus	0.0
111005 Atopic Asthma-F	0.0	104701 (SS) Adj "Normal" Bone-Backus	0.0
111006 Atopic Asthma-F	0.1	104702 (SS) OA Synovium-Backus	0.0
111417 Allergy-M	0.0	117093 OA Cartilage Rep7	0.2
112347 Allergy-M	1.6	112672 OA Bone5	0.0
112349 Normal Lung-F	1.8	112673 OA Synovium5	0.0
112357 Normal Lung-F	19.8	112674 OA Synovial Fluid cells5	0.0
112354 Normal Lung-M	37.4	117100 OA Cartilage Rep14	0.2
112374 Crohns-F	0.8	112756 OA Bone9	100.0
112389 Match Control Crohns-F	0.0	112757 OA Synovium9	1.9
112375 Crohns-F	2.2	112758 OA Synovial Fluid Cells9	0.0
112732 Match Control Crohns-F	0.0	117125 RA Cartilage Rep2	0.1
112725 Crohns-M	11.9	113492 Bone2 RA	0.4
112387 Match Control Crohns-M	0.0	113493 Synovium2 RA	0.1
112378 Crohns-M	5.1	113494 Syn Fluid Cells RA	0.2
112390 Match Control Crohns-M	0.1	113499 Cartilage4 RA	0.1
112726 Crohns-M	0.1	113500 Bone4 RA	0.1
112731 Match Control Crohns-M	1.8	113501 Synovium4 RA	0.1
112380 Ulcer Col-F	0.2	113502 Syn Fluid Cells4 RA	0.0

112734 Match Control Ulcer Col-F	0.3	113495 Cartilage3 RA	0.0
112384 Ulcer Col-F	0.4	113496 Bone3 RA	0.0
112737 Match Control Ulcer Col-F	0.1	113497 Synovium3 RA	0.0
112386 Ulcer Col-F	0.0	113498 Syn Fluid Cells3 RA	0.0
112738 Match Control Ulcer Col-F	0.0	117106 Normal Cartilage Rep20	0.3
112381 Ulcer Col-M	0.0	113663 Bone3 Normal	0.8
112735 Match Control Ulcer Col-M	17.0	113664 Synovium3 Normal	0.3
112382 Ulcer Col-M	0.0	113665 Syn Fluid Cells3 Normal	0.7
112394 Match Control Ulcer Col-M	0.0	117107 Normal Cartilage Rep22	0.0
112383 Ulcer Col-M	0.0	113667 Bone4 Normal	0.1
112736 Match Control Ulcer Col-M	0.0	113668 Synovium4 Normal	0.0
112423 Psoriasis-F	0.2	113669 Syn Fluid Cells4 Normal	0.1

Table LC. Panel 1.3D

Tissue Name	Rel. Exp.(%) Ag3009, Run 161701362	Rel. Exp.(%) Ag3009, Run 163728052	Tissue Name	Rel. Exp.(%) Ag3009, Run 161701362	Rel. Exp.(%) Ag3009, Run 163728052
Liver adenocarcinoma	0.0	0.0	Kidney (fetal)	2.7	4.1
Pancreas	0.0	0.0	Renal ca. 786- 0	0.0	0.0
Pancreatic ca. CAPAN 2	0.0	0.0	Renal ca. A498	0.0	0.0
Adrenal gland	4.9	4.5	Renal ca. RFX 393	0.0	0.0
Thyroid	0.0	0.0	Renal ca. ACHN	0.0	0.0
Salivary gland	0.0	0.1	Renal ca. UO- 31	0.0	0.0
Pituitary gland	4.5	9.0	Renal ca. TK- 10	0.0	0.0
Brain (fetal)	0.0	22.7	Liver	0.0	0.0
Brain (whole)	0.0	0.0	Liver (fetal)	7.7	9.4
Brain (amygdala)	0.0	0.0	Liver ca. (hepatoblast)	4.3	5.5

			HepG2		
Brain (cerebellum)	0.0	0.0	Lung	0.0	0.0
Brain (hippocampus)	0.0	0.0	Lung (fetal)	0.1	0.1
Brain (substantia nigra)	0.1	0.1	Lung ca. (small cell) LX-1	0.0	0.0
Brain (thalamus)	0.0	0.0	Lung ca. (small cell) NCI-H69	0.0	0.0
Cerebral Cortex	0.0	0.0	Lung ca. (s.cell var.) SHP-77	0.2	0.3
Spinal cord	0.0	0.0	Lung ca. (large cell) NCI-H460	0.0	0.0
glio/astro U87-MG	0.0	0.0	Lung ca. (non-sm. cell) A549	0.0	0.0
glio/astro U-118-MG	0.0	0.0	Lung ca. (non-s.cell) NCI-H23	0.1	0.1
astrocytoma SW1783	0.0	0.0	Lung ca. (non-s.cell) HOP-62	0.0	0.0
neuro*; met SK-N-AS	0.0	0.0	Lung ca. (non-s.cl) NCI-H522	0.0	0.0
astrocytoma SF-539	0.0	0.0	Lung ca. (squam.) SW 900	0.0	0.0
astrocytoma SNB-75	0.0	0.0	Lung ca. (squam.) NCI-H596	0.1	0.1
glioma SNB-19	0.0	0.0	Mammary gland	0.4	0.4
glioma U251	0.0	0.0	Breast ca.* (pl.ef) MCF-7	0.0	0.0
glioma SF-295	0.0	0.0	Breast ca.* (pl.ef) MDA-MB-231	0.0	0.0
Heart (fetal)	1.8	2.5	Breast ca.* (pl.ef) T47D	0.0	0.0
Heart	0.3	0.4	Breast ca. BT-549	0.0	0.0
Skeletal muscle (fetal)	100.0	100.0	Breast ca. MDA-N	0.0	0.0

Skeletal muscle	0.4	0.5	Ovary	1.7	2.3
Bone marrow	0.0	0.0	Ovarian ca. OVCAR-3	0.0	0.0
Thymus	0.1	0.1	Ovarian ca. OVCAR-4	0.0	0.0
Spleen	0.0	0.0	Ovarian ca. OVCAR-5	0.0	0.0
Lymph node	0.0	0.0	Ovarian ca. OVCAR-8	0.0	0.0
Colorectal	0.0	0.0	Ovarian ca. IGROV-1	0.0	0.0
Stomach	0.0	0.0	Ovarian ca.* (ascites) SK- OV-3	0.0	0.0
Small intestine	0.0	0.0	Uterus	0.0	0.0
Colon ca. SW480	0.0	0.0	Placenta	7.1	9.3
Colon ca.* SW620(SW480 met)	0.0	0.0	Prostate	0.0	0.0
Colon ca. HT29	0.1	0.0	Prostate ca.* (bone met)PC- 3	0.0	0.0
Colon ca. HCT- 116	0.0	0.0	Testis	0.4	0.6
Colon ca. CaCo-2	0.0	0.0	Melanoma Hs688(A).T	0.0	0.0
Colon ca. tissue(ODO3866)	0.0	0.0	Melanoma* (met) Hs688(B).T	0.0	0.0
Colon ca. HCC- 2998	0.0	0.0	Melanoma UACC-62	0.0	0.0
Gastric ca.* (liver met) NCI-N87	0.0	0.0	Melanoma M14	0.0	0.0
Bladder	0.1	0.2	Melanoma LOX IMVI	0.0	0.0
Trachea	0.0	0.0	Melanoma* (met) SK- MEL-5	0.1	0.1
Kidney	0.0	0.0	Adipose	0.0	0.0

Table LD. Panel 2D

Tissue Name	Rel. Exp.(%) Ag3009, Run 161701534	Rel. Exp.(%) Ag3009, Run 163578214	Tissue Name	Rel. Exp.(%) Ag3009, Run 161701534	Rel. Exp.(%) Ag3009, Run 163578214
-------------	--	--	-------------	--	--

Normal Colon	0.9	0.5	Kidney Margin 8120608	1.1	1.1
CC Well to Mod Diff (ODO3866)	0.0	0.0	Kidney Cancer 8120613	0.0	0.0
CC Margin (ODO3866)	0.0	0.1	Kidney Margin 8120614	0.1	0.0
CC Gr.2 rectosigmoid (ODO3868)	0.0	0.0	Kidney Cancer 9010320	100.0	100.0
CC Margin (ODO3868)	0.0	0.0	Kidney Margin 9010321	0.3	0.2
CC Mod Diff (ODO3920)	0.0	0.0	Normal Uterus	0.0	0.1
CC Margin (ODO3920)	0.0	0.0	Uterus Cancer 064011	1.8	1.3
CC Gr.2 ascend colon (ODO3921)	0.0	0.0	Normal Thyroid	0.5	0.5
CC Margin (ODO3921)	0.0	0.1	Thyroid Cancer 064010	0.0	0.0
CC from Partial Hepatectomy (ODO4309) Mets	0.2	0.2	Thyroid Cancer A302152	0.0	0.0
Liver Margin (ODO4309)	0.2	0.1	Thyroid Margin A302153	0.0	0.0
Colon mets to lung (OD04451- 01)	0.0	0.0	Normal Breast	5.4	5.1
Lung Margin (OD04451-02)	0.0	0.0	Breast Cancer (OD04566)	0.0	0.0
Normal Prostate 6546-1	0.2	0.8	Breast Cancer (OD04590-01)	0.1	0.1
Prostate Cancer (OD04410)	0.0	0.0	Breast Cancer Mets (OD04590-03)	0.0	0.0
Prostate Margin (OD04410)	0.0	0.0	Breast Cancer Metastasis (OD04655-05)	0.1	0.0
Prostate Cancer	0.1	0.0	Breast Cancer	0.2	0.2

(OD04720-01)			064006		
Prostate Margin (OD04720-02)	0.2	0.1	Breast Cancer 1024	12.9	6.5
Normal Lung 061010	0.6	0.7	Breast Cancer 9100266	8.7	10.0
Lung Met to Muscle (ODO4286)	0.0	0.0	Breast Margin 9100265	4.4	4.6
Muscle Margin (ODO4286)	15.1	10.9	Breast Cancer A209073	4.9	5.5
Lung Malignant Cancer (OD03126)	0.0	0.1	Breast Margin A209073	13.4	9.0
Lung Margin (OD03126)	0.0	0.0	Normal Liver	0.0	0.0
Lung Cancer (OD04404)	0.0	0.0	Liver Cancer 064003	0.0	0.1
Lung Margin (OD04404)	0.1	0.0	Liver Cancer 1025	0.0	0.0
Lung Cancer (OD04565)	0.0	0.0	Liver Cancer 1026	70.7	74.7
Lung Margin (OD04565)	0.0	0.0	Liver Cancer 6004-T	0.0	0.0
Lung Cancer (OD04237-01)	0.0	0.0	Liver Tissue 6004-N	0.0	0.0
Lung Margin (OD04237-02)	0.2	0.3	Liver Cancer 6005-T	77.4	70.2
Ocular Mel Met to Liver (ODO4310)	0.1	0.2	Liver Tissue 6005-N	0.2	0.0
Liver Margin (ODO4310)	2.6	2.2	Normal Bladder	7.9	3.0
Melanoma Mets to Lung (OD04321)	1.9	2.2	Bladder Cancer 1023	0.1	0.1
Lung Margin (OD04321)	0.0	0.0	Bladder Cancer A302173	0.0	0.0
Normal Kidney	0.1	0.0	Bladder Cancer (OD04718-01)	0.0	0.1
Kidney Ca, Nuclear grade 2 (OD04338)	0.0	0.0	Bladder Normal Adjacent (OD04718-03)	0.5	0.5
Kidney Margin	0.1	0.0	Normal Ovary	22.4	19.8

(OD04338)					
Kidney Ca Nuclear grade 1/2 (OD04339)	0.0	0.0	Ovarian Cancer 064008	2.0	1.3
Kidney Margin (OD04339)	0.5	0.3	Ovarian Cancer (OD04768-07)	0.0	0.0
Kidney Ca, Clear cell type (OD04340)	0.0	0.0	Ovary Margin (OD04768-08)	0.0	0.0
Kidney Margin (OD04340)	1.0	0.7	Normal Stomach	0.0	0.0
Kidney Ca, Nuclear grade 3 (OD04348)	0.0	0.0	Gastric Cancer 9060358	0.1	0.1
Kidney Margin (OD04348)	0.0	0.0	Stomach Margin 9060359	0.0	0.1
Kidney Cancer (OD04622-01)	0.0	0.0	Gastric Cancer 9060395	0.0	0.0
Kidney Margin (OD04622-03)	0.1	0.4	Stomach Margin 9060394	0.0	0.0
Kidney Cancer (OD04450-01)	0.0	0.0	Gastric Cancer 9060397	0.0	0.2
Kidney Margin (OD04450-03)	0.7	0.3	Stomach Margin 9060396	0.0	0.0
Kidney Cancer 8120607	0.0	0.0	Gastric Cancer 064005	0.0	0.1

Table LE. Panel 3D

Tissue Name	Rel. Exp.(%) Ag3009, Run 163482997	Tissue Name	Rel. Exp.(%) Ag3009, Run 163482997
Daoy- Medulloblastoma	0.1	Ca Ski- Cervical epidermoid carcinoma (metastasis)	0.0
TE671- Medulloblastoma	0.0	ES-2- Ovarian clear cell carcinoma	0.0
D283 Med- Medulloblastoma	0.0	Ramos- Stimulated with PMA/ionomycin 6h	0.0
PFSK-1- Primitive Neuroectodermal	12.5	Ramos- Stimulated with PMA/ionomycin 14h	0.0
XF-498- CNS	0.0	MEG-01- Chronic myelogenous leukemia	0.0

		(megokaryoblast)	
SNB-78- Glioma	0.0	Raji- Burkitt's lymphoma	0.0
SF-268- Glioblastoma	0.0	Daudi- Burkitt's lymphoma	0.0
T98G- Glioblastoma	0.0	U266- B-cell plasmacytoma	0.0
SK-N-SH- Neuroblastoma (metastasis)	2.3	CA46- Burkitt's lymphoma	0.0
SF-295- Glioblastoma	0.0	RL- non-Hodgkin's B-cell lymphoma	0.0
Cerebellum	0.0	JM1- pre-B-cell lymphoma	0.0
Cerebellum	0.0	Jurkat- T cell leukemia	0.0
NCI-H292- Mucoepidermoid lung carcinoma	0.0	TF-1- Erythroleukemia	0.1
DMS-114- Small cell lung cancer	0.1	HUT 78- T-cell lymphoma	0.0
DMS-79- Small cell lung cancer	2.4	U937- Histiocytic lymphoma	0.0
NCI-H146- Small cell lung cancer	29.1	KU-812- Myelogenous leukemia	4.8
NCI-H526- Small cell lung cancer	0.0	769-P- Clear cell renal carcinoma	0.0
NCI-N417- Small cell lung cancer	0.0	Caki-2- Clear cell renal carcinoma	0.0
NCI-H82- Small cell lung cancer	3.0	SW 839- Clear cell renal carcinoma	0.0
NCI-H157- Squamous cell lung cancer (metastasis)	0.0	G401- Wilms' tumor	1.0
NCI-H1155- Large cell lung cancer	18.8	Hs766T- Pancreatic carcinoma (LN metastasis)	0.0
NCI-H1299- Large cell lung cancer	0.0	CAPAN-1- Pancreatic adenocarcinoma (liver metastasis)	0.0
NCI-H727- Lung carcinoid	0.3	SU86.86- Pancreatic carcinoma (liver metastasis)	0.0
NCI-UMC-11- Lung carcinoid	0.0	BxPC-3- Pancreatic adenocarcinoma	0.0
LX-1- Small cell lung cancer	0.0	HPAC- Pancreatic adenocarcinoma	0.0
Colo-205- Colon cancer	0.0	MIA PaCa-2- Pancreatic carcinoma	0.0
KM12- Colon cancer	0.0	CFPAC-1- Pancreatic ductal adenocarcinoma	0.0
KM20L2- Colon cancer	0.0	PANC-1- Pancreatic	0.2



		epithelioid ductal carcinoma	
NCI-H716- Colon cancer	0.0	T24- Bladder carcinoma (transitional cell)	0.0
SW-48- Colon adenocarcinoma	0.0	5637- Bladder carcinoma	0.0
SW1116- Colon adenocarcinoma	0.1	HT-1197- Bladder carcinoma	0.0
LS 174T- Colon adenocarcinoma	0.0	UM-UC-3- Bladder carcinoma (transitional cell)	0.0
SW-948- Colon adenocarcinoma	0.0	A204- Rhabdomyosarcoma	100.0
SW-480- Colon adenocarcinoma	0.0	HT-1080- Fibrosarcoma	0.0
NCI-SNU-5- Gastric carcinoma	0.0	MG-63- Osteosarcoma	0.0
KATO III- Gastric carcinoma	0.0	SK-LMS-1- Leiomyosarcoma (vulva)	0.0
NCI-SNU-16- Gastric carcinoma	0.0	SJRH30- Rhabdomyosarcoma (met to bone marrow)	0.0
NCI-SNU-1- Gastric carcinoma	0.1	A431- Epidermoid carcinoma	0.0
RF-1- Gastric adenocarcinoma	0.0	WM266-4- Melanoma	0.0
RF-48- Gastric adenocarcinoma	0.0	DU 145- Prostate carcinoma (brain metastasis)	0.0
MKN-45- Gastric carcinoma	0.0	MDA-MB-468- Breast adenocarcinoma	0.0
NCI-N87- Gastric carcinoma	0.0	SCC-4- Squamous cell carcinoma of tongue	0.0
OVCAR-5- Ovarian carcinoma	0.0	SCC-9- Squamous cell carcinoma of tongue	0.0
RL95-2- Uterine carcinoma	0.0	SCC-15- Squamous cell carcinoma of tongue	0.0
HelaS3- Cervical adenocarcinoma	0.0	CAL 27- Squamous cell carcinoma of tongue	0.0

Table LF. Panel 4D

Tissue Name	Rel. Exp.(%) Ag3009, Run 161701540	Rel. Exp.(%) Ag3009, Run 164043473	Rel. Exp.(%) Ag3009, Run 168033531	Tissue Name	Rel. Exp.(%) Ag3009, Run 161701540	Rel. Exp.(%) Ag3009, Run 164043473	Rel. Exp.(%) Ag3009, Run 168033531
Secondary Th1 act	0.0	0.0	0.9	HUVEC IL-1beta	0.0	0.0	0.0

Secondary Th2 act	0.0	0.0	0.0	HUVEC IFN gamma	0.0	0.0	0.0
Secondary Tr1 act	0.0	0.6	0.0	HUVEC TNF alpha + IFN gamma	0.0	0.0	0.0
Secondary Th1 rest	0.0	0.0	0.0	HUVEC TNF alpha + IL4	0.0	0.0	0.0
Secondary Th2 rest	0.0	0.0	0.0	HUVEC IL-11	0.0	0.0	0.0
Secondary Tr1 rest	0.0	0.0	0.0	Lung Microvascular EC none	0.0	0.0	0.0
Primary Th1 act	0.0	0.0	0.0	Lung Microvascular EC TNFalpha + IL-1beta	0.0	0.4	0.0
Primary Th2 act	0.0	0.0	0.0	Microvascular Dermal EC none	0.1	0.0	0.0
Primary Tr1 act	0.0	0.0	0.0	Microvascular Dermal EC TNFalpha + IL-1beta	0.0	0.0	0.0
Primary Th1 rest	0.0	0.0	0.0	Bronchial epithelium TNFalpha + IL1beta	0.0	0.0	0.0
Primary Th2 rest	0.0	0.0	0.0	Small airway epithelium none	0.0	0.0	0.0
Primary Tr1 rest	0.0	0.0	0.0	Small airway epithelium TNFalpha + IL-1beta	0.0	0.0	0.0
CD45RA CD4 lymphocyte act	0.0	0.0	0.0	Coronary artery SMC rest	0.0	0.0	0.0
CD45RO CD4 lymphocyte act	0.0	0.4	0.0	Coronary artery SMC TNFalpha + IL-1beta	0.0	0.0	0.0
CD8 lymphocyte act	0.0	0.0	0.5	Astrocytes rest	1.1	16.0	17.9
Secondary CD8 lymphocyte rest	0.0	0.0	0.0	Astrocytes TNFalpha + IL-1beta	0.7	0.7	2.1
Secondary CD8 lymphocyte act	0.0	0.0	0.0	KU-812 (Basophil) rest	6.5	100.0	88.3
CD4 lymphocyte none	0.0	0.0	0.0	KU-812 (Basophil) PMA/ionomycin	6.8	91.4	100.0
2ry Th1/Th2/Tr1_anti-CD95 CH11	0.0	0.0	0.0	CCD1106 (Keratinocytes) none	0.0	0.0	0.0
LAK cells rest	0.0	0.0	0.0	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	0.0	0.0	0.0
LAK cells IL-2	0.0	0.0	0.0	Liver cirrhosis	0.1	1.4	1.9

LAK cells IL-2+IL-12	0.0	0.5	0.0	Lupus kidney	0.0	0.0	0.0
LAK cells IL-2+IFN gamma	0.0	0.0	0.0	NCI-H292 none	0.0	0.0	0.0
LAK cells IL-2+IL-18	0.0	0.0	0.0	NCI-H292 IL-4	0.0	0.0	0.0
LAK cells PMA/ionomycin	0.0	0.4	0.0	NCI-H292 IL-9	100.0	0.0	0.0
NK Cells IL-2 rest	0.0	0.0	0.0	NCI-H292 IL-13	0.0	0.0	0.0
Two Way MLR 3 day	0.0	0.0	0.0	NCI-H292 IFN gamma	0.0	0.0	0.0
Two Way MLR 5 day	0.0	0.0	0.0	HPAEC none	0.0	0.0	0.0
Two Way MLR 7 day	0.0	0.0	0.0	HPAEC TNF alpha + IL-1 beta	0.0	0.0	0.0
PBMC rest	0.0	0.0	0.0	Lung fibroblast none	0.0	0.0	0.0
PBMC PWM	0.0	0.0	0.0	Lung fibroblast TNF alpha + IL-1 beta	0.0	0.0	0.0
PBMC PHA-L	0.0	0.0	0.0	Lung fibroblast IL-4	0.0	0.0	0.0
Ramos (B cell) none	0.0	0.0	0.0	Lung fibroblast IL-9	0.0	0.0	0.9
Ramos (B cell) ionomycin	0.0	0.0	0.0	Lung fibroblast IL-13	0.0	0.0	0.0
B lymphocytes PWM	0.0	0.0	0.0	Lung fibroblast IFN gamma	0.0	0.0	0.0
B lymphocytes CD40L and IL-4	0.0	0.0	0.0	Dermal fibroblast CCD1070 rest	0.0	0.0	0.0
EOL-1 dbcAMP	0.0	0.0	0.0	Dermal fibroblast CCD1070 TNF alpha	0.0	0.0	0.5
EOL-1 dbcAMP PMA/ionomycin	0.0	0.0	0.0	Dermal fibroblast CCD1070 IL-1 beta	0.0	0.0	0.0
Dendritic cells none	0.0	0.0	0.0	Dermal fibroblast IFN gamma	0.0	0.0	0.0
Dendritic cells LPS	0.0	0.0	0.0	Dermal fibroblast IL-4	0.0	0.0	0.0
Dendritic cells anti-CD40	0.0	0.0	0.0	IBD Colitis 2	0.0	0.0	0.0
Monocytes rest	0.0	0.0	0.0	IBD Crohn's	0.0	0.0	1.4
Monocytes LPS	0.0	0.0	0.0	Colon	0.2	2.2	4.6
Macrophages rest	0.0	0.0	0.0	Lung	0.1	3.2	2.4
Macrophages LPS	0.0	0.0	0.0	Thymus	0.2	5.1	6.7
HUVEC none	0.0	0.0	0.0	Kidney	0.8	12.3	10.4

HUVEC starved	0.0	0.0	0.0			
---------------	-----	-----	-----	--	--	--

**AI\_comprehensive panel\_v1.0 Summary:** Ag3009 Highest expression of the CG91667-01 gene is seen in bone from an osteoarthritis patient (CT=24.8).

**Panel 1.3D Summary:** Ag3009 Two experiments with the same probe and primer set produce results that are in excellent agreement, with highest expression of the CG91667-01 gene, a DLK1 homolog, in fetal skeletal muscle (CTs=21-22). This expression is in agreement with published data that shows preferential expression of this gene in skeletal muscle.

In addition, this gene is expressed at much higher levels in fetal skeletal muscle when compared to expression in the adult counterpart (CTs=29). Thus, expression of this gene may be used to differentiate between the fetal and adult source of this tissue. Furthermore, the relative overexpression of this gene in fetal skeletal muscle suggests that the protein product may enhance muscular growth or development in the fetus and thus may also act in a regenerative capacity in the adult. Therefore, therapeutic modulation of the protein encoded by this gene could be useful in treatment of muscle related diseases. More specifically, treatment of weak or dystrophic muscle with the protein encoded by this gene could restore muscle mass or function.

This gene is also expressed at much higher levels in fetal liver (CT=25), lung (CT=32) and heart and kidney (CTs=27) when compared to expression in the adult heart (CT=30), lung, liver, and kidney (CTs=40). Thus, expression of this gene could be used to differentiate between the fetal and adult forms of lung, liver, kidney and heart. Dlk1 has been implicated in the cells response to growth and differentiation signals (Ref.1, 2). The prominent expression of this gene in fetal tissues suggests that this Dlk1 homolog may also be involved in cellular growth and proliferation.

There are also high levels of expression of this gene in a liver cancer cell line. In addition, low but significant expression of this gene is associated with lung and CNS cancer. Earlier DLK1 gene has been shown to be differentially expressed in small cell lung carcinoma and neuroendocrine tumor cell line (Ref.3). Therefore, therapeutic modulation of this gene, through the use of small molecule drugs, or antibodies could be of benefit in the treatment of liver, lung and CNS cancers.

*See, generally,*

Charlier C, Segers K, Wagenaar D, Karim L, Berghmans S, Jaillon O, Shay T, Weissenbach J, Cockett N, Gyapay G, Georges M. Human-ovine comparative sequencing of a 250-kb imprinted domain encompassing the callipyge (clpg) locus and identification of six imprinted  
5 transcripts: DLK1, DAT, GTL2, PEG11, antiPEG11, and MEG8. *Genome Res* 2001 May;11(5):850-62. PMID: 11337479

Baladron V, Jose Ruiz-Hidalgo M, Bonvini E, Gubina E, Notario V, Laborda J. The EGF-like Homeotic Protein dlk Affects Cell Growth and Interacts with Growth-Modulating Molecules in the Yeast Two-Hybrid System. *Biochem Biophys Res Commun* 2002 Feb 22;291(2):193-  
10 204. PMID: 11846389

Laborda J, Sausville EA, Hoffman T, Notario V. (1993) dlk, a putative mammalian homeotic gene differentially expressed in small cell lung carcinoma and neuroendocrine tumor cell line. *J Biol Chem* 268(6):3817-20. PMID: 8095043

**Panel 2D Summary:** Ag3009 Two experiments with the same probe and primer set produce  
15 results that are in excellent agreement, with highest expression of the CG91667-01 gene in kidney cancer (CTs=25). In addition, this gene is more highly expressed in liver and kidney tumors than in the corresponding matched normal tissue. Thus, expression of this gene could be used to differentiate between these samples and other samples on this panel and as a marker for these cancers. This expression in kidney and liver cancers is in agreement with  
20 published reports that Dlk1 may be involved in the cells response to growth and differentiation signals. Therefore, therapeutic targeting of this gene product with a human monoclonal antibody is anticipated to limit or block the extent of tumor cell growth and metastasis, particularly in kidney and liver tumors.

**Panel 3D Summary:** Ag3009 Highest expression of the CG91667-01 gene is seen in a  
25 rhabdomyosarcoma cell line (CT=25). Significant levels of expression are also seen in cell lines derived from lung cancer, myelogenous leukemia, neuroblastoma, and neuroectodermal tissue. Thus, expression of this gene could be used to differentiate between a rhabdomyosarcoma cell line and other samples on this panel.

This gene codes for delta like protein precursor (DLK), belonging to NOTCH family.  
30 Recently, a similar protein DLL4 belonging to NOTCH family has been shown to induces T-

cell leukemia/lymphoma when overexpressed in mice by retroviral-mediated gene transfer (ref.1). Therefore, therapeutic modulation of this gene, through the use of small molecule drugs, or antibodies could be of benefit in the treatment of leukemia, lymphomas, blastomas and sarcomas.

5 *See, generally,*

Yan XQ, Sarmiento U, Sun Y, Huang G, Guo J, Juan T, Van G, Qi MY, Scully S, Senaldi G, Fletcher FA. (2001) A novel Notch ligand, Dll4, induces T-cell leukemia/lymphoma when overexpressed in mice by retroviral-mediated gene transfer. Blood 98(13):3793-9. PMID: 11739188

- 10 **Panel 4D Summary:** Ag3009 Two experiments with the same probe and primer set produce results that are in excellent agreement, with highest expression of the CG91667-01 gene in treated or untreated samples derived from the KU-812 basophil cell line (CTs=29-30). Low but significant levels of expression are also seen in resting astrocytes, colon, thymus, and kidney. Data from a third experiment with this probe and primer are not included because the
- 15 amp plot indicates there were experimental difficulties with this run (Run 161701540).

Basophils release histamines and other biological modifiers in response to allergens and play an important role in the pathology of asthma and hypersensitivity reactions. Therefore, therapeutics designed against the putative protein encoded by this gene may reduce or inhibit inflammation by blocking basophil function in these diseases. In addition, these cells are a

20 reasonable model for the inflammatory cells that take part in various inflammatory lung and bowel diseases, such as asthma, Crohn's disease, and ulcerative colitis. Therefore, therapeutics that modulate the function of this gene product may reduce or eliminate the symptoms of patients suffering from asthma, Crohn's disease, and ulcerative colitis.

25 **M. NOV12a and NOV12b (CG92293-01 and CG92293-02: Polyprotein (ovochymase))**

Expression of gene CG92293-01 and CG92293-02 was assessed using the primer-probe sets Ag3775 and Ag5273, described in Tables MA and MB. Results of the RTQ-PCR runs are shown in Tables MC, MD, ME and MF.

Table MA. Probe Name Ag3775

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-gcagattcaagtgcattgtgta-3'	22	2032	147
Probe	TET-5'-ttactattctgccatccaggagga-3'- TAMRA	26	2077	148
Reverse	5'-gcacagatcatcttctctgtga-3'	22	2103	149

Table MB. Probe Name Ag5273

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-tgctctgaagcagagctagaaa-3'	22	2417	150
Probe	TET-5'-tttccacaccacggtatctactgga-3'- TAMRA	26	2453	151
Reverse	5'-acccaagaacattccagtcttc-3'	22	2487	152

Table MC. AI\_comprehensive panel\_v1.0

Tissue Name	Rel. Exp.(%) Ag5273, Run 233667801	Tissue Name	Rel. Exp.(%) Ag5273, Run 233667801
110967 COPD-F	1.9	112427 Match Control Psoriasis-F	21.5
110980 COPD-F	15.7	112418 Psoriasis-M	4.8
110968 COPD-M	12.6	112723 Match Control Psoriasis-M	6.0
110977 COPD-M	48.0	112419 Psoriasis-M	21.8
110989 Emphysema-F	24.3	112424 Match Control Psoriasis-M	12.1
110992 Emphysema-F	3.8	112420 Psoriasis-M	28.5
110993 Emphysema-F	14.3	112425 Match Control Psoriasis-M	19.3
110994 Emphysema-F	11.3	104689 (MF) OA Bone-Backus	18.0
110995 Emphysema-F	5.9	104690 (MF) Adj "Normal" Bone-Backus	2.9
110996 Emphysema-F	6.2	104691 (MF) OA Synovium-Backus	17.7
110997 Asthma-M	6.9	104692 (BA) OA Cartilage-Backus	7.7
111001 Asthma-F	11.0	104694 (BA) OA Bone-Backus	13.0
111002 Asthma-F	15.9	104695 (BA) Adj	17.0

		"Normal" Bone-Backus	
111003 Atopic Asthma-F	15.3	104696 (BA) OA Synovium-Backus	10.2
111004 Atopic Asthma-F	3.1	104700 (SS) OA Bone-Backus	11.8
111005 Atopic Asthma-F	5.6	104701 (SS) Adj "Normal" Bone-Backus	36.6
111006 Atopic Asthma-F	1.6	104702 (SS) OA Synovium-Backus	23.3
111417 Allergy-M	4.5	117093 OA Cartilage Rep7	19.8
112347 Allergy-M	0.0	112672 OA Bone5	48.3
112349 Normal Lung-F	0.0	112673 OA Synovium5	23.3
112357 Normal Lung-F	25.2	112674 OA Synovial Fluid cells5	16.2
112354 Normal Lung-M	15.3	117100 OA Cartilage Rep14	0.0
112374 Crohns-F	5.7	112756 OA Bone9	0.0
112389 Match Control Crohns-F	13.1	112757 OA Synovium9	6.0
112375 Crohns-F	2.7	112758 OA Synovial Fluid Cells9	8.1
112732 Match Control Crohns-F	38.2	117125 RA Cartilage Rep2	9.5
112725 Crohns-M	5.8	113492 Bone2 RA	24.8
112387 Match Control Crohns-M	0.0	113493 Synovium2 RA	21.2
112378 Crohns-M	1.3	113494 Syn Fluid Cells RA	61.1
112390 Match Control Crohns-M	12.7	113499 Cartilage4 RA	85.9
112726 Crohns-M	9.7	113500 Bone4 RA	97.9
112731 Match Control Crohns-M	11.5	113501 Synovium4 RA	97.9
112380 Ulcer Col-F	7.4	113502 Syn Fluid Cells4 RA	62.9
112734 Match Control Ulcer Col-F	100.0	113495 Cartilage3 RA	47.0
112384 Ulcer Col-F	21.8	113496 Bone3 RA	70.7
112737 Match Control Ulcer Col-F	5.4	113497 Synovium3 RA	20.7
112386 Ulcer Col-F	0.0	113498 Syn Fluid Cells3 RA	63.3



112738 Match Control Ulcer Col-F	0.0	117106 Normal Cartilage Rep20	0.0
112381 Ulcer Col-M	0.0	113663 Bone3 Normal	1.6
112735 Match Control Ulcer Col-M	25.3	113664 Synovium3 Normal	0.0
112382 Ulcer Col-M	31.4	113665 Syn Fluid Cells3 Normal	0.0
112394 Match Control Ulcer Col-M	6.4	117107 Normal Cartilage Rep22	16.2
112383 Ulcer Col-M	8.7	113667 Bone4 Normal	13.9
112736 Match Control Ulcer Col-M	2.9	113668 Synovium4 Normal	7.6
112423 Psoriasis-F	20.7	113669 Syn Fluid Cells4 Normal	20.7

Table MD. CNS\_neurodegeneration\_v1.0

Tissue Name	Rel. Exp.(%) Ag3775, Run 211176610	Rel. Exp.(%) Ag3775, Run 224339887	Rel. Exp.(%) Ag5273, Run 230512547	Tissue Name	Rel. Exp.(%) Ag3775, Run 211176610	Rel. Exp.(%) Ag3775, Run 224339887	Rel. Exp.(%) Ag5273, Run 230512547
AD 1 Hippo	34.2	29.1	28.3	Control (Path) 3 Temporal Ctx	4.4	2.1	6.3
AD 2 Hippo	33.4	25.7	30.4	Control (Path) 4 Temporal Ctx	37.1	21.5	27.9
AD 3 Hippo	25.7	9.7	18.4	AD 1 Occipital Ctx	24.7	19.9	26.4
AD 4 Hippo	9.0	8.1	13.9	AD 2 Occipital Ctx (Missing)	0.0	0.0	0.0
AD 5 hippo	100.0	61.6	94.0	AD 3 Occipital Ctx	8.1	9.0	9.4
AD 6 Hippo	88.9	100.0	100.0	AD 4 Occipital Ctx	12.2	16.0	23.2
Control 2 Hippo	10.7	20.9	24.7	AD 5 Occipital Ctx	29.5	11.3	25.5

Control 4 Hippo	12.2	5.9	10.8	AD 6 Occipital Ctx	29.9	29.9	20.3
Control (Path) 3 Hippo	4.7	2.8	5.3	Control 1 Occipital Ctx	1.8	0.9	1.6
AD 1 Temporal Ctx	24.0	26.8	18.7	Control 2 Occipital Ctx	21.9	23.3	17.6
AD 2 Temporal Ctx	22.2	21.5	47.3	Control 3 Occipital Ctx	8.9	3.3	9.2
AD 3 Temporal Ctx	15.9	5.0	26.8	Control 4 Occipital Ctx	3.3	3.5	4.8
AD 4 Temporal Ctx	16.2	21.9	18.9	Control (Path) 1 Occipital Ctx	46.0	36.1	37.1
AD 5 Inf Temporal Ctx	79.0	36.1	90.8	Control (Path) 2 Occipital Ctx	3.9	3.3	3.8
AD 5 Sup Temporal Ctx	73.2	47.3	64.6	Control (Path) 3 Occipital Ctx	4.6	1.3	2.9
AD 6 Inf Temporal Ctx	70.2	33.9	76.8	Control (Path) 4 Occipital Ctx	3.3	3.2	6.5
AD 6 Sup Temporal Ctx	74.2	51.1	88.3	Control 1 Parietal Ctx	3.7	3.3	3.3
Control 1 Temporal Ctx	1.4	3.7	5.2	Control 2 Parietal Ctx	26.8	34.9	42.9
Control 2 Temporal Ctx	18.7	12.9	29.1	Control 3 Parietal Ctx	9.3	3.1	13.4
Control 3 Temporal Ctx	8.4	6.5	6.6	Control (Path) 1 Parietal Ctx	44.4	27.7	50.7
Control 4 Temporal Ctx	14.2	2.9	8.4	Control (Path) 2 Parietal Ctx	13.1	17.7	12.6

				Ctx			
Control (Path) 1 Temporal Ctx	53.6	29.5	42.9	Control (Path) 3 Parietal Ctx	1.4	4.5	3.8
Control (Path) 2 Temporal Ctx	43.2	21.8	44.8	Control (Path) 4 Parietal Ctx	32.8	23.3	40.1

Table ME. General\_screening\_panel\_v1.4

Tissue Name	Rel. Exp.(%) Ag3775, Run 219514534	Tissue Name	Rel. Exp.(%) Ag3775, Run 219514534
Adipose	17.1	Renal ca. TK-10	0.0
Melanoma* Hs688(A).T	0.0	Bladder	3.9
Melanoma* Hs688(B).T	0.0	Gastric ca. (liver met.) NCI-N87	0.0
Melanoma* M14	21.6	Gastric ca. KATO III	0.0
Melanoma* LOXIMVI	0.0	Colon ca. SW-948	0.0
Melanoma* SK- MEL-5	5.2	Colon ca. SW480	0.0
Squamous cell carcinoma SCC-4	0.0	Colon ca.* (SW480 met) SW620	0.0
Testis Pool	40.1	Colon ca. HT29	0.0
Prostate ca.* (bone met) PC-3	6.0	Colon ca. HCT-116	0.0
Prostate Pool	5.7	Colon ca. CaCo-2	0.0
Placenta	0.0	Colon cancer tissue	12.8
Uterus Pool	6.1	Colon ca. SW1116	0.0
Ovarian ca. OVCAR-3	100.0	Colon ca. Colo-205	0.0
Ovarian ca. SK-OV- 3	5.4	Colon ca. SW-48	0.0
Ovarian ca. OVCAR-4	0.0	Colon Pool	13.6
Ovarian ca. OVCAR-5	0.0	Small Intestine Pool	12.2
Ovarian ca. IGROV- 1	12.5	Stomach Pool	15.6
Ovarian ca.	11.3	Bone Marrow Pool	10.5

OVCAR-8			
Ovary	12.1	Fetal Heart	3.7
Breast ca. MCF-7	10.4	Heart Pool	17.2
Breast ca. MDA-MB-231	0.0	Lymph Node Pool	24.5
Breast ca. BT 549	56.3	Fetal Skeletal Muscle	14.7
Breast ca. T47D	0.0	Skeletal Muscle Pool	61.1
Breast ca. MDA-N	6.2	Spleen Pool	90.8
Breast Pool	9.9	Thymus Pool	40.3
Trachea	11.2	CNS cancer (glio/astro) U87-MG	54.3
Lung	9.7	CNS cancer (glio/astro) U-118-MG	0.0
Fetal Lung	3.8	CNS cancer (neuro;met) SK-N-AS	2.3
Lung ca. NCI-N417	0.0	CNS cancer (astro) SF-539	3.0
Lung ca. LX-1	0.0	CNS cancer (astro) SNB-75	35.1
Lung ca. NCI-H146	0.0	CNS cancer (glio) SNB-19	3.8
Lung ca. SHP-77	12.3	CNS cancer (glio) SF-295	39.5
Lung ca. A549	0.0	Brain (Amygdala) Pool	21.5
Lung ca. NCI-H526	0.0	Brain (cerebellum)	6.4
Lung ca. NCI-H23	0.0	Brain (fetal)	45.1
Lung ca. NCI-H460	30.4	Brain (Hippocampus) Pool	25.7
Lung ca. HOP-62	23.0	Cerebral Cortex Pool	34.4
Lung ca. NCI-H522	0.0	Brain (Substantia nigra) Pool	12.9
Liver	3.8	Brain (Thalamus) Pool	36.3
Fetal Liver	3.1	Brain (whole)	33.7
Liver ca. HepG2	1.2	Spinal Cord Pool	21.5
Kidney Pool	27.7	Adrenal Gland	20.3
Fetal Kidney	49.0	Pituitary gland Pool	6.1
Renal ca. 786-0	0.0	Salivary Gland	6.6
Renal ca. A498	0.0	Thyroid (female)	0.0
Renal ca. ACHN	1.9	Pancreatic ca. CAPAN2	0.0
Renal ca. UO-31	0.0	Pancreas Pool	18.9

Table MF. Panel 4.1D

Tissue Name	Rel. Exp.(%) Ag3775, Run 170129781	Rel. Exp.(%) Ag5273, Run 230500481	Tissue Name	Rel. Exp.(%) Ag3775, Run 170129781	Rel. Exp.(%) Ag5273, Run 230500481
Secondary Th1 act	0.0	0.0	HUVEC IL-1beta	5.1	5.8
Secondary Th2 act	51.4	40.3	HUVEC IFN gamma	4.8	24.3
Secondary Tr1 act	29.1	7.8	HUVEC TNF alpha + IFN gamma	1.4	0.0
Secondary Th1 rest	4.0	0.0	HUVEC TNF alpha + IL4	4.7	1.1
Secondary Th2 rest	20.0	10.2	HUVEC IL-11	1.8	4.4
Secondary Tr1 rest	14.9	0.0	Lung Microvascular EC none	0.0	2.3
Primary Th1 act	6.7	2.3	Lung Microvascular EC TNFalpha + IL- 1beta	0.0	0.0
Primary Th2 act	10.4	7.6	Microvascular Dermal EC none	0.0	0.0
Primary Tr1 act	8.8	13.5	Microvascular Dermal EC TNFalpha + IL- 1beta	0.0	0.0
Primary Th1 rest	0.9	0.0	Bronchial epithelium TNFalpha + IL1beta	4.2	1.9
Primary Th2 rest	2.1	0.0	Small airway epithelium none	0.0	2.4
Primary Tr1 rest	13.4	3.2	Small airway epithelium TNFalpha + IL- 1beta	0.0	0.0
CD45RA CD4 lymphocyte act	7.8	10.7	Coronary artery SMC rest	2.8	4.9
CD45RO CD4 lymphocyte act	2.8	8.5	Coronary artery SMC TNFalpha + IL-1beta	2.0	5.1
CD8 lymphocyte act	6.6	1.7	Astrocytes rest	15.3	6.0
Secondary CD8 lymphocyte rest	3.5	3.1	Astrocytes TNFalpha + IL-	9.1	5.4

			1beta		
Secondary CD8 lymphocyte act	0.0	0.0	KU-812 (Basophil) rest	4.3	0.0
CD4 lymphocyte none	3.9	6.7	KU-812 (Basophil) PMA/ionomycin	0.0	0.0
2ry Th1/Th2/Tr1_anti-CD95 CH11	10.7	4.0	CCD1106 (Keratinocytes) none	0.0	0.0
LAK cells rest	7.8	2.5	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	2.2	0.0
LAK cells IL-2	5.8	0.0	Liver cirrhosis	1.5	0.0
LAK cells IL-2+IL-12	11.2	0.0	NCI-H292 none	0.0	0.0
LAK cells IL-2+IFN gamma	11.2	0.0	NCI-H292 IL-4	0.0	0.0
LAK cells IL-2+IL-18	14.9	0.0	NCI-H292 IL-9	0.0	0.0
LAK cells PMA/ionomycin	13.5	14.8	NCI-H292 IL-13	0.0	0.0
NK Cells IL-2 rest	3.8	15.8	NCI-H292 IFN gamma	0.0	2.0
Two Way MLR 3 day	14.3	0.9	HPAEC none	0.0	0.9
Two Way MLR 5 day	2.5	2.2	HPAEC TNF alpha + IL-1 beta	8.0	6.8
Two Way MLR 7 day	2.0	0.0	Lung fibroblast none	13.0	17.9
PBMC rest	0.0	0.0	Lung fibroblast TNF alpha + IL-1 beta	2.3	17.1
PBMC PWM	3.8	0.0	Lung fibroblast IL-4	32.1	21.0
PBMC PHA-L	17.6	5.3	Lung fibroblast IL-9	56.6	25.2
Ramos (B cell) none	0.0	0.0	Lung fibroblast IL-13	45.4	13.5
Ramos (B cell) ionomycin	0.0	0.0	Lung fibroblast IFN gamma	18.2	49.0
B lymphocytes PWM	1.9	0.0	Dermal fibroblast CCD1070 rest	9.0	0.0
B lymphocytes CD40L and IL-4	10.1	28.5	Dermal fibroblast CCD1070 TNF	4.7	7.5

			alpha		
EOL-1 dbcAMP	0.0	0.0	Dermal fibroblast CCD1070 IL-1 beta	0.0	5.9
EOL-1 dbcAMP PMA/ionomycin	0.0	0.0	Dermal fibroblast IFN gamma	38.4	20.3
Dendritic cells none	8.3	3.8	Dermal fibroblast IL-4	100.0	100.0
Dendritic cells LPS	0.0	0.0	Dermal Fibroblasts rest	5.3	9.8
Dendritic cells anti- CD40	15.4	8.0	Neutrophils TNFa+LPS	4.0	35.4
Monocytes rest	1.1	2.7	Neutrophils rest	2.1	28.7
Monocytes LPS	9.4	11.2	Colon	0.0	0.0
Macrophages rest	7.2	0.0	Lung	21.8	4.0
Macrophages LPS	5.6	0.0	Thymus	57.4	14.7
HUVEC none	0.0	2.5	Kidney	2.2	0.0
HUVEC starved	0.0	2.7			

**AI\_comprehensive\_panel\_v1.0 Summary:** Ag5273 The CG92293-01 gene appears to be slightly overexpressed in a cluster of samples derived from bone, cartilage, and synovium of rheumatoid arthritis patients (CTs=33-34). This expression profile suggests that therapeutic modulation of this gene product may reduce or eliminate the symptoms of patients suffering from rheumatoid arthritis.

**CNS\_neurodegeneration\_v1.0 Summary:** Ag3775 Two experiments with two probe and primer sets produce results that are in excellent agreement. This panel does not show differential expression of the CG92152-01 gene in Alzheimer's disease. However, this expression profile confirms the presence of this gene in the brain, with highest expression in the hippocampus of an Alzheimer's patient (CTs=31-32). Please see Panel 1.4 for discussion of utility of this gene in the central nervous system.

**General\_screening\_panel\_v1.4 Summary:** Ag3775 Highest expression of the CG92152-01 gene is seen in an ovarian cancer cell line (CT=32). significant levels of expression are seen in a cluster of samples derived from breast and lung cancer cell lines. Thus, expression of this gene could be used to differentiate between these samples and other samples on this panel and as a marker to detect the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of ovarian, breast and lung cancers.

This gene is also expressed at low levels in the CNS, including the hippocampus, thalamus, substantia nigra, amygdala, cerebellum and cerebral cortex. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurologic disorders, such as Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, stroke and epilepsy.

Among tissues with metabolic function, this gene is expressed at low but significant levels in adipose, adrenal gland, pancreas, heart and adult and fetal skeletal muscle. This expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic and that dysregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.

**Panel 4.1D Summary:** Ag3775 Highest expression of the CG92152-01 gene in IL-4 treated with dermal fibroblasts (CTs=32.5). Low, but significant levels of expression are also seen in treated and untreated lung and dermal fibroblasts, and chronically activated Th2 cells. The expression of this gene in lung and skin derived fibroblasts suggests that this gene may be involved in normal conditions as well as pathological and inflammatory lung disorders that include chronic obstructive pulmonary disease, asthma, allergy, psoriasis, and emphysema.

#### N. NOV15a (CG92531-01: LEUCINE RICH)

Expression of gene CG92531-01 was assessed using the primer-probe set Ag3839, described in Table NA. Results of the RTQ-PCR runs are shown in Tables NB, NC and ND.

20 Table NA. Probe Name Ag3839

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-ccggtacagtgtcttttct-3'	20	5	153
Probe	TET-5'-ataaacccatgctggaacaacccaa-3'-TAMRA	26	26	154
Reverse	5'-ggtaccacacgtaccacaa-3'	20	83	155

Table NB. CNS\_neurodegeneration\_v1.0

Tissue Name	Rel. Exp.(%) Ag3839, Run 212186726	Tissue Name	Rel. Exp.(%) Ag3839, Run 212186726
AD 1 Hippo	11.0	Control (Path) 3 Temporal Ctx	9.3



AD 2 Hippo	25.2	Control (Path) 4 Temporal Ctx	44.4
AD 3 Hippo	17.3	AD 1 Occipital Ctx	37.9
AD 4 Hippo	11.7	AD 2 Occipital Ctx (Missing)	0.0
AD 5 Hippo	90.1	AD 3 Occipital Ctx	13.2
AD 6 Hippo	51.1	AD 4 Occipital Ctx	27.4
Control 2 Hippo	17.0	AD 5 Occipital Ctx	46.0
Control 4 Hippo	14.6	AD 6 Occipital Ctx	20.4
Control (Path) 3 Hippo	5.8	Control 1 Occipital Ctx	0.0
AD 1 Temporal Ctx	22.5	Control 2 Occipital Ctx	68.3
AD 2 Temporal Ctx	30.8	Control 3 Occipital Ctx	34.4
AD 3 Temporal Ctx	15.1	Control 4 Occipital Ctx	3.9
AD 4 Temporal Ctx	22.4	Control (Path) 1 Occipital Ctx	100.0
AD 5 Inf Temporal Ctx	81.2	Control (Path) 2 Occipital Ctx	14.9
AD 5 Sup Temporal Ctx	32.3	Control (Path) 3 Occipital Ctx	4.1
AD 6 Inf Temporal Ctx	45.7	Control (Path) 4 Occipital Ctx	24.8
AD 6 Sup Temporal Ctx	72.7	Control 1 Parietal Ctx	14.8
Control 1 Temporal Ctx	4.1	Control 2 Parietal Ctx	37.4
Control 2 Temporal Ctx	34.4	Control 3 Parietal Ctx	12.5
Control 3 Temporal Ctx	11.6	Control (Path) 1 Parietal Ctx	84.1
Control 3 Temporal Ctx	7.6	Control (Path) 2 Parietal Ctx	27.5
Control (Path) 1 Temporal Ctx	65.5	Control (Path) 3 Parietal Ctx	1.1
Control (Path) 2 Temporal Ctx	31.2	Control (Path) 4 Parietal Ctx	62.9

Table NC. General\_screening\_panel\_v1.4

Tissue Name	Rel. Exp.(%) Ag3839, Run 213604224	Tissue Name	Rel. Exp.(%) Ag3839, Run 213604224
Adipose	12.9	Renal ca. TK-10	28.5

Melanoma* Hs688(A).T	10.4	Bladder	11.3
Melanoma* Hs688(B).T	13.4	Gastric ca. (liver met.) NCI-N87	35.1
Melanoma* M14	16.7	Gastric ca. KATO III	50.0
Melanoma* LOXIMVI	5.4	Colon ca. SW-948	14.8
Melanoma* SK- MEL-5	10.1	Colon ca. SW480	21.3
Squamous cell carcinoma SCC-4	20.9	Colon ca.* (SW480 met) SW620	26.4
Testis Pool	1.4	Colon ca. HT29	6.2
Prostate ca.* (bone met) PC-3	30.8	Colon ca. HCT-116	66.0
Prostate Pool	16.3	Colon ca. CaCo-2	8.8
Placenta	5.5	Colon cancer tissue	6.2
Uterus Pool	14.1	Colon ca. SW1116	6.2
Ovarian ca. OVCAR-3	19.5	Colon ca. Colo-205	3.5
Ovarian ca. SK-OV- 3	33.4	Colon ca. SW-48	2.6
Ovarian ca. OVCAR-4	29.3	Colon Pool	44.4
Ovarian ca. OVCAR-5	49.0	Small Intestine Pool	38.2
Ovarian ca. IGROV- 1	5.8	Stomach Pool	18.4
Ovarian ca. OVCAR-8	3.8	Bone Marrow Pool	16.0
Ovary	27.0	Fetal Heart	3.4
Breast ca. MCF-7	7.6	Heart Pool	19.1
Breast ca. MDA- MB-231	44.1	Lymph Node Pool	50.7
Breast ca. BT 549	23.0	Fetal Skeletal Muscle	5.1
Breast ca. T47D	83.5	Skeletal Muscle Pool	12.2
Breast ca. MDA-N	21.8	Spleen Pool	6.5
Breast Pool	42.6	Thymus Pool	22.2
Trachea	7.7	CNS cancer (glio/astro) U87-MG	25.2
Lung	15.3	CNS cancer (glio/astro) U-118-MG	100.0
Fetal Lung	8.4	CNS cancer (neuro;met) SK-N-AS	18.9
Lung ca. NCI-N417	2.3	CNS cancer (astro) SF-	6.8

		539	
Lung ca. LX-1	20.4	CNS cancer (astro) SNB-75	14.6
Lung ca. NCI-H146	7.3	CNS cancer (glio) SNB-19	5.0
Lung ca. SHP-77	20.6	CNS cancer (glio) SF- 295	67.4
Lung ca. A549	10.5	Brain (Amygdala) Pool	15.3
Lung ca. NCI-H526	1.7	Brain (cerebellum)	34.6
Lung ca. NCI-H23	57.8	Brain (fetal)	32.8
Lung ca. NCI-H460	10.2	Brain (Hippocampus) Pool	6.8
Lung ca. HOP-62	3.6	Cerebral Cortex Pool	19.3
Lung ca. NCI-H522	8.2	Brain (Substantia nigra) Pool	13.3
Liver	0.7	Brain (Thalamus) Pool	14.6
Fetal Liver	9.0	Brain (whole)	24.5
Liver ca. HepG2	6.1	Spinal Cord Pool	6.9
Kidney Pool	98.6	Adrenal Gland	24.0
Fetal Kidney	10.8	Pituitary gland Pool	5.8
Renal ca. 786-0	14.3	Salivary Gland	3.1
Renal ca. A498	0.8	Thyroid (female)	3.3
Renal ca. ACHN	12.9	Pancreatic ca. CAPAN2	12.2
Renal ca. UO-31	13.1	Pancreas Pool	29.1

Table ND. Panel 4.1D

Tissue Name	Rel. Exp.(%) Ag3839, Run 170126776	Tissue Name	Rel. Exp.(%) Ag3839, Run 170126776
Secondary Th1 act	16.3	HUVEC IL-1beta	21.2
Secondary Th2 act	20.7	HUVEC IFN gamma	8.8
Secondary Tr1 act	25.5	HUVEC TNF alpha + IFN gamma	48.6
Secondary Th1 rest	6.0	HUVEC TNF alpha + IL4	73.2
Secondary Th2 rest	20.2	HUVEC IL-11	11.0
Secondary Tr1 rest	14.7	Lung Microvascular EC none	97.9
Primary Th1 act	20.9	Lung Microvascular EC TNFalpha + IL-1beta	100.0
Primary Th2 act	24.3	Microvascular Dermal EC none	17.0
Primary Tr1 act	15.2	Microvascular Dermal EC	50.7

		TNFalpha + IL-1beta	
Primary Th1 rest	13.4	Bronchial epithelium TNFalpha + IL1beta	22.4
Primary Th2 rest	12.4	Small airway epithelium none	12.5
Primary Tr1 rest	23.2	Small airway epithelium TNFalpha + IL-1beta	39.0
CD45RA CD4 lymphocyte act	23.2	Coronary artery SMC rest	18.8
CD45RO CD4 lymphocyte act	23.7	Coronary artery SMC TNFalpha + IL-1beta	3.9
CD8 lymphocyte act	23.7	Astrocytes rest	6.4
Secondary CD8 lymphocyte rest	22.2	Astrocytes TNFalpha + IL-1beta	4.8
Secondary CD8 lymphocyte act	13.0	KU-812 (Basophil) rest	10.3
CD4 lymphocyte none	8.4	KU-812 (Basophil) PMA/ionomycin	9.2
2ry Th1/Th2/Tr1_anti- CD95 CH11	12.4	CCD1106 (Keratinocytes) none	18.7
LAK cells rest	16.0	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	12.4
LAK cells IL-2	9.7	Liver cirrhosis	5.2
LAK cells IL-2+IL-12	8.0	NCI-H292 none	0.8
LAK cells IL-2+IFN gamma	16.4	NCI-H292 IL-4	0.5
LAK cells IL-2+ IL-18	27.7	NCI-H292 IL-9	1.3
LAK cells PMA/ionomycin	16.5	NCI-H292 IL-13	0.7
NK Cells IL-2 rest	25.9	NCI-H292 IFN gamma	1.4
Two Way MLR 3 day	17.2	HPAEC none	10.5
Two Way MLR 5 day	3.3	HPAEC TNF alpha + IL-1 beta	15.6
Two Way MLR 7 day	5.1	Lung fibroblast none	15.7
PBMC rest	3.0	Lung fibroblast TNF alpha + IL-1 beta	3.3
PBMC PWM	12.0	Lung fibroblast IL-4	15.6
PBMC PHA-L	10.7	Lung fibroblast IL-9	32.8
Ramos (B cell) none	11.3	Lung fibroblast IL-13	22.8
Ramos (B cell) ionomycin	21.6	Lung fibroblast IFN gamma	18.9
B lymphocytes PWM	14.0	Dermal fibroblast CCD1070 rest	36.9
B lymphocytes CD40L	16.6	Dermal fibroblast	31.9

and IL-4		CCD1070 TNF alpha	
EOL-1 dbcAMP	15.0	Dermal fibroblast CCD1070 IL-1 beta	5.3
EOL-1 dbcAMP PMA/ionomycin	10.2	Dermal fibroblast IFN gamma	9.5
Dendritic cells none	2.6	Dermal fibroblast IL-4	9.9
Dendritic cells LPS	8.0	Dermal Fibroblasts rest	6.0
Dendritic cells anti- CD40	5.6	Neutrophils TNFa+LPS	0.0
Monocytes rest	16.0	Neutrophils rest	1.6
Monocytes LPS	5.0	Colon	4.4
Macrophages rest	4.6	Lung	4.5
Macrophages LPS	2.6	Thymus	24.0
HUVEC none	3.4	Kidney	5.8
HUVEC starved	23.3		

**CNS\_neurodegeneration\_v1.0 Summary:** Ag3839 This panel confirms the expression of CG92531-01 gene at low levels in the brains of an independent group of individuals.

- However, no differential expression of this gene was detected between Alzheimer's diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 5 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.

- General\_screening\_panel\_v1.4 Summary:** Ag3839 Highest expression of the CG92531-01 gene is detected in CNS cancer (glio/astro) cell line U-118-MG (CT=31.3). Significant expression of this gene is seen in cluster of cancer cell lines (CNS, colon, gastric, lung, 10 breast, ovarian, prostate and melanoma) used in this panel. Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, or antibodies, might be beneficial in the treatment of these cancers.

- Among tissues with metabolic or endocrine function, this gene is expressed at low to moderate levels in pancreas, adipose, adrenal gland, thyroid, skeletal muscle, heart, liver and 15 the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

Interestingly, expression of this gene is higher in adult (CT=33) compared to the fetal heart sample (CT=36). Thus, expression of this gene can be used to distinguish between the adult and fetal heart.

In addition, this gene is expressed at low to moderate levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

**Panel 4.1D Summary:** Ag3839 Highest expression of the CG92531-01 gene is detected TNFalpha + IL-1beta treated lung microvascular EC (CT=32). In addition, this gene is expressed at high to moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General\_screening\_panel\_v1.4 and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.

#### O. NOV16a and NOV16b (CG92715-01 and CG92715-02: LRR protein)

Expression of gene CG92715-01 and CG92715-02 was assessed using the primer-probe set Ag2502, described in Table OA. Results of the RTQ-PCR runs are shown in Tables OB, OC, OD, OE and OF.

Table OA. Probe Name Ag2502

Primers	Sequences	Length	Start Position	SEQ ID No:
---------	-----------	--------	----------------	------------

Forward	5'-ggagtaaccacttcacctcctt-3'	22	1632	156
Probe	TET-5'-ccagctgaagtcactcaccacaaatcg-3'- TAMRA	26	1675	157
Reverse	5'-aggtacaatcccaaggattgtc-3'	22	1709	158

Table OB. CNS\_neurodegeneration\_v1.0

Tissue Name	Rel. Exp.(%) Ag2502, Run 208776914	Tissue Name	Rel. Exp.(%) Ag2502, Run 208776914
AD 1 Hippo	9.9	Control (Path) 3 Temporal Ctx	1.8
AD 2 Hippo	20.4	Control (Path) 4 Temporal Ctx	29.9
AD 3 Hippo	4.9	AD 1 Occipital Ctx	11.8
AD 4 Hippo	4.2	AD 2 Occipital Ctx (Missing)	0.0
AD 5 hippo	100.0	AD 3 Occipital Ctx	4.5
AD 6 Hippo	35.8	AD 4 Occipital Ctx	14.8
Control 2 Hippo	21.5	AD 5 Occipital Ctx	13.3
Control 4 Hippo	4.6	AD 6 Occipital Ctx	36.9
Control (Path) 3 Hippo	2.4	Control 1 Occipital Ctx	0.8
AD 1 Temporal Ctx	10.8	Control 2 Occipital Ctx	53.6
AD 2 Temporal Ctx	30.1	Control 3 Occipital Ctx	13.2
AD 3 Temporal Ctx	3.3	Control 4 Occipital Ctx	2.9
AD 4 Temporal Ctx	15.6	Control (Path) 1 Occipital Ctx	84.7
AD 5 Inf Temporal Ctx	92.7	Control (Path) 2 Occipital Ctx	7.5
AD 5 SupTemporal Ctx	40.9	Control (Path) 3 Occipital Ctx	1.1
AD 6 Inf Temporal Ctx	51.8	Control (Path) 4 Occipital Ctx	17.3
AD 6 Sup Temporal Ctx	50.7	Control 1 Parietal Ctx	2.9
Control 1 Temporal Ctx	2.8	Control 2 Parietal Ctx	37.1
Control 2 Temporal Ctx	31.6	Control 3 Parietal Ctx	17.0
Control 3 Temporal Ctx	16.3	Control (Path) 1 Parietal Ctx	75.3
Control 4 Temporal	5.6	Control (Path) 2	19.6

Ctx		Parietal Ctx	
Control (Path) 1 Temporal Ctx	68.3	Control (Path) 3 Parietal Ctx	2.2
Control (Path) 2 Temporal Ctx	31.6	Control (Path) 4 Parietal Ctx	44.1

Table OC. Panel 1.3D

Tissue Name	Rel. Exp.(%) Ag2502, Run 162431037	Tissue Name	Rel. Exp.(%) Ag2502, Run 162431037
Liver adenocarcinoma	1.6	Kidney (fetal)	0.9
Pancreas	0.6	Renal ca. 786-0	3.3
Pancreatic ca. CAPAN 2	1.3	Renal ca. A498	0.7
Adrenal gland	0.0	Renal ca. RXF 393	0.0
Thyroid	2.8	Renal ca. ACHN	0.3
Salivary gland	3.0	Renal ca. UO-31	1.0
Pituitary gland	0.6	Renal ca. TK-10	1.0
Brain (fetal)	4.8	Liver	0.0
Brain (whole)	9.7	Liver (fetal)	0.0
Brain (amygdala)	8.1	Liver ca. (hepatoblast) HepG2	0.0
Brain (cerebellum)	7.1	Lung	0.2
Brain (hippocampus)	16.5	Lung (fetal)	0.8
Brain (substantia nigra)	0.6	Lung ca. (small cell) LX-1	0.3
Brain (thalamus)	2.9	Lung ca. (small cell) NCI-H69	2.4
Cerebral Cortex	100.0	Lung ca. (s.cell var.) SHP-77	10.7
Spinal cord	7.3	Lung ca. (large cell) NCI-H460	1.4
glio/astro U87-MG	12.5	Lung ca. (non-sm. cell) A549	0.5
glio/astro U-118-MG	2.7	Lung ca. (non-s.cell) NCI-H23	16.8
astrocytoma SW1783	0.3	Lung ca. (non-s.cell) HOP-62	1.4
neuro*; met SK-N-AS	3.4	Lung ca. (non-s.cl) NCI-H522	0.3



astrocytoma SF-539	0.0	Lung ca. (squam.) SW 900	0.7
astrocytoma SNB-75	0.7	Lung ca. (squam.) NCI-H596	4.0
glioma SNB-19	0.2	Mammary gland	0.2
glioma U251	1.4	Breast ca.* (pl.ef) MCF-7	0.0
glioma SF-295	0.2	Breast ca.* (pl.ef) MDA-MB-231	0.0
Heart (fetal)	0.2	Breast ca.* (pl.ef) T47D	0.9
Heart	0.2	Breast ca. BT-549	1.4
Skeletal muscle (fetal)	17.3	Breast ca. MDA-N	0.4
Skeletal muscle	0.4	Ovary	5.0
Bone marrow	0.0	Ovarian ca. OVCAR-3	3.1
Thymus	0.1	Ovarian ca. OVCAR-4	0.2
Spleen	0.0	Ovarian ca. OVCAR-5	0.0
Lymph node	0.0	Ovarian ca. OVCAR-8	8.3
Colorectal	1.4	Ovarian ca. IGROV- 1	0.2
Stomach	0.1	Ovarian ca.* (ascites) SK-OV-3	0.2
Small intestine	0.4	Uterus	0.1
Colon ca. SW480	0.0	Placenta	0.0
Colon ca.* SW620(SW480 met)	0.5	Prostate	0.7
Colon ca. HT29	0.0	Prostate ca.* (bone met)PC-3	0.6
Colon ca. HCT-116	0.0	Testis	0.5
Colon ca. CaCo-2	0.0	Melanoma Hs688(A).T	0.0
Colon ca. tissue(ODO3866)	0.0	Melanoma* (met) Hs688(B).T	0.0
Colon ca. HCC-2998	1.3	Melanoma UACC- 62	0.1
Gastric ca.* (liver met) NCI-N87	0.0	Melanoma M14	0.2
Bladder	0.7	Melanoma LOX IMVI	0.8
Trachea	1.9	Melanoma* (met)	1.3

		SK-MEL-5	
Kidney	0.1	Adipose	1.3

Table OD. Panel 2D

Tissue Name	Rel. Exp.(%) Ag2502, Run 162319639	Rel. Exp.(%) Ag2502, Run 164993363	Tissue Name	Rel. Exp.(%) Ag2502, Run 162319639	Rel. Exp.(%) Ag2502, Run 164993363
Normal Colon	7.1	9.9	Kidney Margin 8120608	0.1	0.1
CC Well to Mod Diff (ODO3866)	0.0	0.1	Kidney Cancer 8120613	0.0	0.1
CC Margin (ODO3866)	0.7	0.3	Kidney Margin 8120614	0.2	0.6
CC Gr.2 rectosigmoid (ODO3868)	0.3	0.0	Kidney Cancer 9010320	1.4	2.1
CC Margin (ODO3868)	0.4	0.8	Kidney Margin 9010321	0.6	0.2
CC Mod Diff (ODO3920)	10.5	11.1	Normal Uterus	0.1	0.1
CC Margin (ODO3920)	1.0	1.5	Uterus Cancer 064011	0.3	0.7
CC Gr.2 ascend colon (ODO3921)	2.8	1.3	Normal Thyroid	14.5	13.5
CC Margin (ODO3921)	0.1	0.2	Thyroid Cancer 064010	0.4	0.3
CC from Partial Hepatectomy (ODO4309) Mets	0.0	0.0	Thyroid Cancer A302152	0.2	0.6
Liver Margin (ODO4309)	0.1	0.1	Thyroid Margin A302153	14.9	12.4
Colon mets to lung (OD04451- 01)	0.9	1.3	Normal Breast	1.7	2.6
Lung Margin (OD04451-02)	0.9	0.4	Breast Cancer (OD04566)	0.1	0.2
Normal Prostate	13.8	7.2	Breast Cancer	5.5	5.1

6546-1			(OD04590-01)		
Prostate Cancer (OD04410)	19.1	15.9	Breast Cancer Mets (OD04590-03)	4.2	2.6
Prostate Margin (OD04410)	7.0	8.5	Breast Cancer Metastasis (OD04655-05)	1.0	0.9
Prostate Cancer (OD04720-01)	33.2	34.9	Breast Cancer 064006	1.3	0.4
Prostate Margin (OD04720-02)	43.5	56.6	Breast Cancer 1024	2.1	1.1
Normal Lung 061010	2.8	3.0	Breast Cancer 9100266	0.1	0.1
Lung Met to Muscle (ODO4286)	15.8	14.3	Breast Margin 9100265	2.5	2.5
Muscle Margin (ODO4286)	0.5	0.6	Breast Cancer A209073	2.4	0.6
Lung Malignant Cancer (OD03126)	0.9	0.7	Breast Margin A209073	3.7	3.3
Lung Margin (OD03126)	1.2	1.9	Normal Liver	0.0	0.1
Lung Cancer (OD04404)	0.3	0.3	Liver Cancer 064003	0.6	1.2
Lung Margin (OD04404)	0.4	0.5	Liver Cancer 1025	0.0	0.0
Lung Cancer (OD04565)	0.1	0.5	Liver Cancer 1026	0.0	0.1
Lung Margin (OD04565)	0.3	1.0	Liver Cancer 6004-T	0.0	0.0
Lung Cancer (OD04237-01)	1.7	1.7	Liver Tissue 6004-N	0.3	0.2
Lung Margin (OD04237-02)	0.1	0.0	Liver Cancer 6005-T	0.1	0.0
Ocular Mel Met to Liver (ODO4310)	0.0	0.0	Liver Tissue 6005-N	0.0	0.0
Liver Margin (ODO4310)	0.2	0.0	Normal Bladder	6.5	4.0
Melanoma Mets to Lung (OD04321)	0.0	0.1	Bladder Cancer 1023	0.0	0.3
Lung Margin (OD04321)	0.4	0.6	Bladder Cancer A302173	24.0	23.5

Normal Kidney	2.3	1.9	Bladder Cancer (OD04718-01)	0.0	0.0
Kidney Ca, Nuclear grade 2 (OD04338)	2.8	2.9	Bladder Normal Adjacent (OD04718-03)	0.1	0.1
Kidney Margin (OD04338)	0.4	0.3	Normal Ovary	2.1	3.9
Kidney Ca Nuclear grade 1/2 (OD04339)	0.4	0.3	Ovarian Cancer 064008	4.9	6.3
Kidney Margin (OD04339)	0.4	0.9	Ovarian Cancer (OD04768-07)	10.4	7.8
Kidney Ca, Clear cell type (OD04340)	27.4	33.2	Ovary Margin (OD04768-08)	0.4	0.2
Kidney Margin (OD04340)	0.2	0.3	Normal Stomach	6.2	5.2
Kidney Ca, Nuclear grade 3 (OD04348)	3.0	3.0	Gastric Cancer 9060358	3.1	7.5
Kidney Margin (OD04348)	0.4	0.0	Stomach Margin 9060359	1.3	0.8
Kidney Cancer (OD04622-01)	100.0	100.0	Gastric Cancer 9060395	4.7	4.3
Kidney Margin (OD04622-03)	0.0	0.5	Stomach Margin 9060394	1.5	1.3
Kidney Cancer (OD04450-01)	0.1	0.8	Gastric Cancer 9060397	1.4	1.2
Kidney Margin (OD04450-03)	0.8	0.7	Stomach Margin 9060396	0.2	0.2
Kidney Cancer 8120607	4.7	3.7	Gastric Cancer 064005	4.7	3.0

Table OE. Panel 3D

Tissue Name	Rel. Exp.(%) Ag2502, Run 164629448	Tissue Name	Rel. Exp.(%) Ag2502, Run 164629448
Daoy- Medulloblastoma	1.6	Ca Ski- Cervical epidermoid carcinoma (metastasis)	1.2

TE671- Medulloblastoma	41.8	ES-2- Ovarian clear cell carcinoma	22.5
D283 Med- Medulloblastoma	63.7	Ramos- Stimulated with PMA/ionomycin 6h	0.0
PFSK-1- Primitive Neuroectodermal	0.0	Ramos- Stimulated with PMA/ionomycin 14h	0.0
XF-498- CNS	22.8	MEG-01- Chronic myelogenous leukemia (megakaryoblast)	13.8
SNB-78- Glioma	11.8	Raji- Burkitt's lymphoma	0.0
SF-268- Glioblastoma	5.1	Daudi- Burkitt's lymphoma	0.0
T98G- Glioblastoma	0.0	U266- B-cell plasmacytoma	8.5
SK-N-SH- Neuroblastoma (metastasis)	0.0	CA46- Burkitt's lymphoma	6.3
SF-295- Glioblastoma	0.8	RL- non-Hodgkin's B-cell lymphoma	0.0
Cerebellum	79.0	JM1- pre-B-cell lymphoma	0.0
Cerebellum	26.4	Jurkat- T cell leukemia	0.0
NCI-H292- Mucoepidermoid lung carcinoma	1.5	TF-1- Erythroleukemia	11.8
DMS-114- Small cell lung cancer	13.2	HUT 78- T-cell lymphoma	0.0
DMS-79- Small cell lung cancer	0.0	U937- Histiocytic lymphoma	0.0
NCI-H146- Small cell lung cancer	28.5	KU-812- Myelogenous leukemia	0.3
NCI-H526- Small cell lung cancer	3.1	769-P- Clear cell renal carcinoma	9.5
NCI-N417- Small cell lung cancer	46.3	Caki-2- Clear cell renal carcinoma	3.1
NCI-H82- Small cell lung cancer	87.1	SW 839- Clear cell renal carcinoma	12.5
NCI-H157- Squamous cell lung cancer (metastasis)	100.0	G401- Wilms' tumor	12.6
NCI-H1155- Large cell lung cancer	35.6	Hs766T- Pancreatic carcinoma (LN metastasis)	0.0
NCI-H1299- Large cell lung cancer	16.5	CAPAN-1- Pancreatic adenocarcinoma (liver metastasis)	0.0
NCI-H727- Lung carcinoid	0.0	SU86.86- Pancreatic carcinoma (liver metastasis)	2.4
NCI-UMC-11- Lung	53.2	BxPC-3- Pancreatic	0.0

carcinoid		adenocarcinoma	
LX-1- Small cell lung cancer	1.2	HPAC- Pancreatic adenocarcinoma	0.0
Colo-205- Colon cancer	5.9	MIA PaCa-2- Pancreatic carcinoma	0.7
KM12- Colon cancer	0.0	CFPAC-1- Pancreatic ductal adenocarcinoma	0.4
KM20L2- Colon cancer	0.0	PANC-1- Pancreatic epithelioid ductal carcinoma	1.3
NCI-H716- Colon cancer	0.0	T24- Bladder carcinoma (transitional cell)	0.0
SW-48- Colon adenocarcinoma	0.0	5637- Bladder carcinoma	7.7
SW1116- Colon adenocarcinoma	0.0	HT-1197- Bladder carcinoma	0.0
LS 174T- Colon adenocarcinoma	0.0	UM-UC-3- Bladder carcinoma (transitional cell)	3.1
SW-948- Colon adenocarcinoma	0.0	A204- Rhabdomyosarcoma	0.0
SW-480- Colon adenocarcinoma	0.0	HT-1080- Fibrosarcoma	2.6
NCI-SNU-5- Gastric carcinoma	0.0	MG-63- Osteosarcoma	4.6
KATO III- Gastric carcinoma	0.0	SK-LMS-1- Leiomyosarcoma (vulva)	0.3
NCI-SNU-16- Gastric carcinoma	6.7	SJRH30- Rhabdomyosarcoma (met to bone marrow)	22.8
NCI-SNU-1- Gastric carcinoma	0.0	A431- Epidermoid carcinoma	0.0
RF-1- Gastric adenocarcinoma	2.4	WM266-4- Melanoma	15.8
RF-48- Gastric adenocarcinoma	2.6	DU 145- Prostate carcinoma (brain metastasis)	0.0
MKN-45- Gastric carcinoma	0.0	MDA-MB-468- Breast adenocarcinoma	0.3
NCI-N87- Gastric carcinoma	0.0	SCC-4- Squamous cell carcinoma of tongue	0.0
OVCAR-5- Ovarian carcinoma	0.0	SCC-9- Squamous cell carcinoma of tongue	0.0
RL95-2- Uterine carcinoma	1.7	SCC-15- Squamous cell carcinoma of tongue	0.0
HelaS3- Cervical adenocarcinoma	14.6	CAL 27- Squamous cell carcinoma of tongue	0.0

Table OF. Panel 4D

Tissue Name	Rel. Exp.(%) Ag2502, Run 162293442	Tissue Name	Rel. Exp.(%) Ag2502, Run 162293442
Secondary Th1 act	1.6	HUVEC IL-1beta	3.5
Secondary Th2 act	0.0	HUVEC IFN gamma	0.0
Secondary Tr1 act	0.0	HUVEC TNF alpha + IFN gamma	0.0
Secondary Th1 rest	0.0	HUVEC TNF alpha + IL4	0.0
Secondary Th2 rest	0.0	HUVEC IL-11	3.7
Secondary Tr1 rest	0.0	Lung Microvascular EC none	2.8
Primary Th1 act	0.0	Lung Microvascular EC TNFalpha + IL-1beta	0.0
Primary Th2 act	0.0	Microvascular Dermal EC none	0.0
Primary Tr1 act	0.0	Microvascular Dermal EC TNFalpha + IL-1beta	0.0
Primary Th1 rest	0.0	Bronchial epithelium TNFalpha + IL1beta	9.7
Primary Th2 rest	0.0	Small airway epithelium none	23.0
Primary Tr1 rest	1.8	Small airway epithelium TNFalpha + IL-1beta	0.0
CD45RA CD4 lymphocyte act	0.0	Coronary artery SMC rest	0.0
CD45RO CD4 lymphocyte act	0.0	Coronary artery SMC TNFalpha + IL-1beta	0.0
CD8 lymphocyte act	0.0	Astrocytes rest	21.6
Secondary CD8 lymphocyte rest	0.0	Astrocytes TNFalpha + IL-1beta	4.1
Secondary CD8 lymphocyte act	0.0	KU-812 (Basophil) rest	0.0
CD4 lymphocyte none	3.1	KU-812 (Basophil) PMA/ionomycin	46.3
2ry Th1/Th2/Tr1_anti- CD95 CH11	1.1	CCD1106 (Keratinocytes) none	2.5
LAK cells rest	4.1	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	6.9
LAK cells IL-2	6.6	Liver cirrhosis	16.6
LAK cells IL-2+IL-12	0.0	Lupus kidney	2.6
LAK cells IL-2+IFN gamma	2.4	NCI-H292 none	57.8
LAK cells IL-2+ IL-18	4.4	NCI-H292 IL-4	26.8

LAK cells PMA/ionomycin	0.0	NCI-H292 IL-9	54.3
NK Cells IL-2 rest	2.4	NCI-H292 IL-13	24.0
Two Way MLR 3 day	0.0	NCI-H292 IFN gamma	20.7
Two Way MLR 5 day	0.0	HPAEC none	0.0
Two Way MLR 7 day	0.0	HPAEC TNF alpha + IL-1 beta	0.0
PBMC rest	7.8	Lung fibroblast none	5.8
PBMC PWM	6.7	Lung fibroblast TNF alpha + IL-1 beta	0.0
PBMC PHA-L	0.0	Lung fibroblast IL-4	31.4
Ramos (B cell) none	6.6	Lung fibroblast IL-9	7.6
Ramos (B cell) ionomycin	8.8	Lung fibroblast IL-13	3.0
B lymphocytes PWM	0.0	Lung fibroblast IFN gamma	5.3
B lymphocytes CD40L and IL-4	0.0	Dermal fibroblast CCD1070 rest	9.5
EOL-1 dbcAMP	100.0	Dermal fibroblast CCD1070 TNF alpha	0.0
EOL-1 dbcAMP PMA/ionomycin	18.2	Dermal fibroblast CCD1070 IL-1 beta	0.0
Dendritic cells none	0.0	Dermal fibroblast IFN gamma	0.0
Dendritic cells LPS	0.0	Dermal fibroblast IL-4	0.0
Dendritic cells anti- CD40	0.0	IBD Colitis 2	6.0
Monocytes rest	3.5	IBD Crohn's	1.3
Monocytes LPS	0.0	Colon	31.4
Macrophages rest	0.0	Lung	56.3
Macrophages LPS	0.0	Thymus	25.3
HUVEC none	0.0	Kidney	12.2
HUVEC starved	23.3		

**CNS\_neurodegeneration\_v1.0 Summary:** Ag2502 This panel does not show differential expression of the CG92715-01 gene in Alzheimer's disease. However, this expression profile confirms the presence of this gene in the brain, with highest expression in the hippocampus from an Alzheimer's patient (CT=26.9). Please see Panel 1.3D for discussion of utility of this

5 gene in the central nervous system.

**Panel 1.3D Summary:** Ag2502 Highest expression of the CG92715-01 gene is seen in the cerebral cortex (CT=27). In addition, low levels of expression are seen in all CNS regions



- examined in this panel. This gene encodes a leucine-rich repeat protein. Leucine rich repeats (LRR) mediate reversible protein-protein interactions and have diverse cellular functions, including cellular adhesion and signaling. Several of these proteins, such as connectin, slit, chaptin, and Toll have pivotal roles in neuronal development in *Drosophila* and may play significant but distinct roles in neural development and in the adult nervous system of humans (Ref. 1). In *Drosophila*, the LRR region of axon guidance proteins has been shown to be critical for their function (especially in axon repulsion). Since the leucine-rich-repeat protein encoded by this gene shows high expression in the cerebral cortex, it is an excellent candidate neuronal guidance protein for axons, dendrites and/or growth cones in general.
- Therefore, therapeutic modulation of the levels of this protein, or possible signaling via this protein, may be of utility in enhancing/directing compensatory synaptogenesis and fiber growth in the CNS in response to neuronal death (stroke, head trauma), axon lesion (spinal cord injury), or neurodegeneration (Alzheimer's, Parkinson's, Huntington's, vascular dementia or any neurodegenerative disease).
- Moderate levels of expression are also seen in cell lines derived from ovarian cancer, lung cancer, and brain cancer. Therefore, therapeutic modulation of the expression or function of this gene product may be effective in the treatment of these cancers.

- Among metabolically relevant tissues, this gene expression is seen in fetal skeletal muscle, thyroid, and pituitary gland. This observation suggests that therapeutic modulation may aid the treatment of metabolic diseases such as obesity and diabetes as well as neuroendocrine disorders. Glycoprotein hormones influence the development and function of the ovary, testis and thyroid by binding to specific high-affinity receptors. Interestingly, the extracellular domains of these receptors are members of the leucine-rich repeat (LRR) protein superfamily and are responsible for the high-affinity binding.

- Results from a second experiment with the same probe and primer set are not included (Run 165518160). The amp plot indicates that there were experimental difficulties with this run.

*See, generally,*

Jiang X., Dreano M., Buckler D.R., Cheng S., Ythier A., Wu H., Hendrickson W.A., el Tayar N. (1995) Structural predictions for the ligand-binding region of glycoprotein hormone

receptors and the nature of hormone-receptor interactions. Structure 3: 1341-1353. PMID: 8747461

Battye R., Stevens A., Perry R.L., Jacobs J.R. (2001) Repellent signaling by Slit requires the leucine-rich repeats. J. Neurosci. 21: 4290-4298. PMID: 11404414

- 5 Itoh A., Miyabayashi T., Ohno M., Sakano S. 1998 Cloning and expressions of three mammalian homologues of *Drosophila* slit suggest possible roles for Slit in the formation and maintenance of the nervous system. Brain Res. Mol. Brain Res. 62: 175-186. PMID: 9813312

**Panel 2D Summary:** Ag2502 Two experiments with the same probe and primer set produce  
10 results that are in excellent agreement. Highest expression of the CG92715-01 gene is seen in kidney cancer (CTs=27.7). In addition, expression is significantly higher in the kidney cancer when compared to expression in the normal adjacent tissue, suggesting a role in renal cancer progression. There is also moderate to low expression in bladder, gastric, colon and ovarian cancers. Thus, expression of this gene could be used to differentiate the kidney cancer  
15 samples from other samples on this panel and as a marker for kidney cancer. Furthermore, therapeutic targeting of the CG92715-01 gene with a human monoclonal antibody is anticipated to limit or block the extent of tumor cell migration, invasion, and metastasis, specifically in kidney, ovarian, bladder, gastric, and colon tumors.

**Panel 3D Summary:** Ag2502 Highest expression of the CG92715-01 gene is seen in a lung  
20 cancer cell line (CT=28). In addition, moderate levels of expression are seen in a cluster of lung and brain cancer cell lines. Prominent expression is also seen in cerebellum, in agreement with expression seen in Panel 1.3D. Low, but significant expression is also seen in kidney cancer and ovarian cancer cell lines. Thus, expression of this gene could be used to differentiate lung and brain cancer cell lines and normal brain from other samples on this  
25 panel and as a marker for lung and brain cancer. In addition, moderate expression of this gene is also seen in melanoma, rhabdomyosarcoma, osteosarcoma, renal and bladder carcinoma, lymphoma, ovarian and cervical cancer and gastric cancer cell lines. Therefore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of these cancers.

**Panel 4D Summary:** Ag2502 Ag2502 Highest expression of the CG92715-01 gene is seen in eosinophils (CT=32). Furthermore, differential gene expression is observed in the eosinophil cell line EOL-1 under resting conditions over that in EOL-1 cells stimulated by phorbol ester and ionomycin (CT=34.4). Thus, this gene may be involved in eosinophil function. Antibodies raised against this protein that stimulate its activity may be useful in reduction of eosinophil activation and may therefore be useful therapeutic antibodies for asthma and allergy and as an anti-inflammatory therapeutics for T cell-mediated autoimmune and inflammatory diseases. Low but significant levels of expression are also seen in a cluster of treated and untreated NCI-H292 mucoepidermoid cells and in normal colon, lung and thymus. This pattern of restricted expression suggests that this gene may be involved in the normal homeostasis of these tissues and/or pathological/inflammatory conditions of the lung.

**P. NOV17a (CG92813-01: Cadherin-related tumor suppressor precursor (FAT))**

Expression of gene CG92813-01 was assessed using the primer-probe sets Ag1350, Ag1413, Ag1414, Ag1515, Ag3085, Ag693, Ag694, Ag740 and Ag3819, described in Tables PA, PB, PC, PD, PE, PF, PG, PH and PI. Results of the RTQ-PCR runs are shown in Tables PJ, PK, PL, PM, PN, PO, PP, PQ and PR.

Table PA. Probe Name Ag1350

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-tggtggcattaatcctgaaata-3'	22	8897	159
Probe	TET-5'-aaaacacttgccatttgatccctca-3'-TAMRA	26	8848	160
Reverse	5'-tcaggatattgcaacagatcct-3'	22	8824	161

Table PB. Probe Name Ag1413

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-aggattctggtgttcctcaaata-3'	22	10908	162
Probe	TET-5'-tcttccacaggaactgtgcatatcaca-3'-TAMRA	27	10931	251
Reverse	5'-cgagactgtgaaggattgtcat-3'	22	10971	163

20 Table PC. Probe Name Ag1414

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-gaattctctcaaagccacatga-3'	22	9410	164
Probe	TET-5'-aaccatccctgagagccatagcattg-3'- TAMRA	26	9436	165
Reverse	5'-tgcagaaacagttctgacaatg-3'	22	9466	166

Table PD. Probe Name Ag1515

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-ggatggttccatatacgtgaac-3'	22	2078	167
Probe	TET-5'-ctcgtgaccactgggtcctctgg-3'- TAMRA	23	2108	168
Reverse	5'-agaacaatctgggaagcaagtt-3'	22	2145	169

Table PE. Probe Name Ag3085

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-cttcacctgtagctgcca-3'	19	13801	170
Probe	TET-5'-acacgggaaggacctgtgagatggt-3'- TAMRA	25	13827	171
Reverse	5'-acagaggacgccaagacag-3'	19	13858	172

Table PF. Probe Name Ag693

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-tggtggcattaatcctgaaat-3'	21	8898	173
Probe	TET-5'-aaaacacttgctcatttgatccctca-3'- TAMRA	26	8848	174
Reverse	5'-tcaggatatttgcaacagatcct-3'	22	8824	175

Table PG. Probe Name Ag694

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-cggtagatgagaatgctcaagt-3'	22	1614	176
Probe	TET-5'-ctcaccgtgacggacgcagattct-3'- TAMRA	24	1655	177
Reverse	5'-agaatttgacggagatgttc-3'	21	1693	178

5 Table PH. Probe Name Ag740

Primers	Sequences	Length	Start Position	SEQ ID No:
---------	-----------	--------	----------------	------------

Forward	5'-gagggatattgtcagggatc-3'	22	14126	179
Probe	TET-5'-aaaagcaacgttctcacttcctttt-3'- TAMRA	26	14100	180
Reverse	5'-aatcccaaagaggagaagaa-3'	22	14062	181

Table PI. Probe Name Ag3819

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-agtcacatcaatggctcgata-3'	20	2523	182
Probe	TET-5'-tcttctggatataaatgataacagccctg-3'- TAMRA	29	2551	183
Reverse	5'-aagtattggaccgggtagaaga-3'	22	2580	184

Table PJ. CNS\_neurodegeneration\_v1.0

Tissue Name	Rel. Exp.(%) Ag1413, Run 206231509	Rel. Exp.(%) Ag3819, Run 211292463	Rel. Exp.(%) Ag693, Run 224758513	Tissue Name	Rel. Exp.(%) Ag1413, Run 206231509	Rel. Exp.(%) Ag3819, Run 211292463	Rel. Exp.(%) Ag693, Run 224758513
AD 1 Hippo	21.0	37.4	25.2	Control (Path) 3 Temporal Ctx	8.6	14.0	11.3
AD 2 Hippo	45.1	30.6	34.2	Control (Path) 4 Temporal Ctx	26.2	25.9	5.6
AD 3 Hippo	11.0	24.1	8.2	AD 1 Occipital Ctx	9.7	25.5	18.6
AD 4 Hippo	16.3	8.8	10.4	AD 2 Occipital Ctx (Missing)	0.0	0.0	0.0
AD 5 hippo	88.3	58.2	15.9	AD 3 Occipital Ctx	12.2	12.6	3.8
AD 6 Hippo	58.6	100.0	67.8	AD 4 Occipital Ctx	28.3	16.7	30.4
Control 2 Hippo	27.0	45.7	42.6	AD 5 Occipital Ctx	4.3	36.9	39.0
Control 4 Hippo	12.9	28.1	3.5	AD 6 Occipital	45.7	27.0	24.8

				Ctx			
Control (Path) 3 Hippo	8.7	14.3	19.6	Control 1 Occipital Ctx	14.5	11.1	10.7
AD 1 Temporal Ctx	10.7	40.6	41.8	Control 2 Occipital Ctx	51.1	34.4	26.6
AD 2 Temporal Ctx	69.7	39.5	10.3	Control 3 Occipital Ctx	10.8	21.2	23.3
AD 3 Temporal Ctx	10.3	10.0	15.0	Control 4 Occipital Ctx	3.8	17.3	3.4
AD 4 Temporal Ctx	23.5	26.1	29.7	Control (Path) 1 Occipital Ctx	100.0	60.3	100.0
AD 5 Inf Temporal Ctx	56.3	90.1	52.5	Control (Path) 2 Occipital Ctx	9.2	17.4	25.3
AD 5 Sup Temporal Ctx	88.3	67.8	73.2	Control (Path) 3 Occipital Ctx	8.9	14.1	4.5
AD 6 Inf Temporal Ctx	66.9	68.8	37.4	Control (Path) 4 Occipital Ctx	23.2	19.9	1.0
AD 6 Sup Temporal Ctx	53.2	73.7	67.8	Control 1 Parietal Ctx	10.2	9.8	13.7
Control 1 Temporal Ctx	9.6	8.1	8.0	Control 2 Parietal Ctx	47.3	55.1	3.8
Control 2 Temporal Ctx	33.4	21.3	25.7	Control 3 Parietal Ctx	10.9	17.4	17.4
Control 3 Temporal Ctx	14.5	20.3	11.8	Control (Path) 1 Parietal Ctx	57.4	55.9	12.7
Control 4 Temporal Ctx	13.2	10.9	3.1	Control (Path) 2 Parietal Ctx	31.0	26.2	30.4
Control	50.7	46.0	71.7	Control	6.4	16.5	12.2

(Path) 1 Temporal Ctx				(Path) 3 Parietal Ctx			
Control (Path) 2 Temporal Ctx	15.5	21.5	27.0	Control (Path) 4 Parietal Ctx	61.6	35.6	5.4

Table PK. General\_screening\_panel\_v1.4

Tissue Name	Rel. Exp.(%) Ag1413, Run 213323517	Rel. Exp.(%) Ag3819, Run 218713598	Tissue Name	Rel. Exp.(%) Ag1413, Run 213323517	Rel. Exp.(%) Ag3819, Run 218713598
Adipose	11.3	5.8	Renal ca. TK-10	6.4	4.6
Melanoma* Hs688(A).T	84.1	68.8	Bladder	6.4	4.5
Melanoma* Hs688(B).T	29.7	20.7	Gastric ca. (liver met.) NCI-N87	0.9	0.5
Melanoma* M14	0.0	0.0	Gastric ca. KATO III	0.0	0.0
Melanoma* LOXIMVI	17.7	14.6	Colon ca. SW- 948	0.0	0.0
Melanoma* SK-MEL-5	0.7	1.2	Colon ca. SW480	0.0	0.0
Squamous cell carcinoma SCC-4	2.2	2.2	Colon ca.* (SW480 met) SW620	0.0	0.0
Testis Pool	4.5	4.1	Colon ca. HT29	0.0	0.0
Prostate ca.* (bone met) PC-3	5.0	3.5	Colon ca. HCT- 116	1.3	1.2
Prostate Pool	10.6	7.7	Colon ca. CaCo- 2	0.1	0.0
Placenta	2.5	3.7	Colon cancer tissue	7.4	4.0
Uterus Pool	4.6	5.8	Colon ca. SW1116	0.0	0.0
Ovarian ca. OVCAR-3	3.6	2.9	Colon ca. Colo- 205	42.3	0.0
Ovarian ca. SK-OV-3	46.0	7.7	Colon ca. SW-48	0.0	0.0

Ovarian ca. OVCAR-4	10.4	7.9	Colon Pool	14.9	11.9
Ovarian ca. OVCAR-5	5.8	3.7	Small Intestine Pool	17.8	16.6
Ovarian ca. IGROV-1	1.8	1.5	Stomach Pool	48.0	15.0
Ovarian ca. OVCAR-8	3.7	3.3	Bone Marrow Pool	6.3	7.2
Ovary	25.2	13.6	Fetal Heart	12.7	8.0
Breast ca. MCF-7	0.4	0.2	Heart Pool	7.9	6.8
Breast ca. MDA-MB- 231	54.3	40.1	Lymph Node Pool	21.6	19.1
Breast ca. BT 549	32.5	28.7	Fetal Skeletal Muscle	9.7	11.2
Breast ca. T47D	7.2	5.6	Skeletal Muscle Pool	5.0	3.9
Breast ca. MDA-N	0.1	0.1	Spleen Pool	14.8	16.3
Breast Pool	48.6	15.9	Thymus Pool	16.3	16.2
Trachea	8.8	11.3	CNS cancer (glio/astro) U87- MG	6.4	6.1
Lung	6.0	5.9	CNS cancer (glio/astro) U- 118-MG	48.0	14.8
Fetal Lung	70.7	59.5	CNS cancer (neuro;met) SK- N-AS	50.0	28.3
Lung ca. NCI- N417	42.9	0.3	CNS cancer (astro) SF-539	22.7	16.5
Lung ca. LX- 1	0.0	0.0	CNS cancer (astro) SNB-75	38.7	38.7
Lung ca. NCI- H146	0.5	0.2	CNS cancer (glio) SNB-19	2.7	2.4
Lung ca. SHP-77	2.8	2.5	CNS cancer (glio) SF-295	27.9	16.8
Lung ca. A549	1.4	1.7	Brain (Amygdala) Pool	7.1	4.1
Lung ca. NCI- H526	0.0	0.0	Brain (cerebellum)	0.7	0.5
Lung ca. NCI- H23	100.0	100.0	Brain (fetal)	75.3	52.5
Lung ca. NCI-	44.1	6.5	Brain	7.9	6.2



H460			(Hippocampus) Pool		
Lung ca. HOP-62	29.9	20.6	Cerebral Cortex Pool	4.7	4.2
Lung ca. NCI-H522	1.1	1.6	Brain (Substantia nigra) Pool	4.4	3.2
Liver	1.4	0.6	Brain (Thalamus) Pool	9.0	5.4
Fetal Liver	16.7	13.5	Brain (whole)	44.4	4.1
Liver ca. HepG2	0.4	0.6	Spinal Cord Pool	6.8	4.5
Kidney Pool	35.8	24.7	Adrenal Gland	2.3	2.1
Fetal Kidney	48.6	25.7	Pituitary gland Pool	1.2	0.9
Renal ca. 786-0	37.6	30.8	Salivary Gland	0.9	0.8
Renal ca. A498	7.6	6.0	Thyroid (female)	7.8	4.7
Renal ca. ACHN	5.6	3.4	Pancreatic ca. CAPAN2	5.3	4.5
Renal ca. UO-31	37.4	22.7	Pancreas Pool	20.2	14.0

Table PL. Panel 1.2

Tissue Name	Rel. Exp.(%) Ag693, Run 114253177	Rel. Exp.(%) Ag694, Run 114254448	Rel. Exp.(%) Ag694, Run 116352614	Tissue Name	Rel. Exp.(%) Ag693, Run 114253177	Rel. Exp.(%) Ag694, Run 114254448	Rel. Exp.(%) Ag694, Run 116352614
Endothelial cells	46.0	42.3	10.5	Renal ca. 786-0	0.0	36.1	20.0
Heart (Fetal)	0.0	10.5	3.3	Renal ca. A498	0.0	17.6	9.3
Pancreas	0.0	5.8	5.0	Renal ca. RXF 393	0.0	0.7	0.5
Pancreatic ca. CAPAN 2	0.0	4.0	2.1	Renal ca. ACHN	0.0	6.0	8.2
Adrenal Gland	0.0	20.6	3.2	Renal ca. UO-31	0.0	37.9	15.1
Thyroid	0.0	9.0	9.2	Renal ca. TK-10	0.0	12.9	10.2
Salivary gland	0.0	2.6	3.3	Liver	11.0	4.7	7.0
Pituitary gland	0.0	4.5	2.9	Liver (fetal)	0.0	1.5	2.5
Brain (fetal)	100.0	8.9	14.6	Liver ca. (hepatoblast) HepG2	0.0	0.9	0.7

Brain (whole)	13.3	5.8	4.5	Lung	0.0	2.9	2.9
Brain (amygdala)	14.7	3.7	2.5	Lung (fetal)	0.0	7.8	8.0
Brain (cerebellum)	0.0	2.8	1.3	Lung ca. (small cell) LX-1	0.0	0.0	0.0
Brain (hippocampus)	81.8	3.7	4.8	Lung ca. (small cell) NCI-H69	0.0	20.0	6.3
Brain (thalamus)	0.0	2.2	2.3	Lung ca. (s.cell var.) SHP-77	0.0	4.5	1.4
Cerebral Cortex	10.3	20.6	18.7	Lung ca. (large cell) NCI-H460	0.0	13.4	9.5
Spinal cord	0.0	3.3	2.9	Lung ca. (non-sm. cell) A549	0.0	7.1	7.0
glio/astro U87-MG	0.0	9.5	9.2	Lung ca. (non-s.cell) NCI-H23	31.6	69.7	76.8
glio/astro U-118-MG	0.0	22.2	27.2	Lung ca. (non-s.cell) HOP-62	0.0	56.3	100.0
astrocytoma SW1783	0.0	7.1	6.5	Lung ca. (non-s.cl) NCI-H522	0.0	6.1	7.1
neuro*; met SK-N-AS	0.0	100.0	94.6	Lung ca. (squam.) SW 900	0.0	11.3	10.0
astrocytoma SF-539	0.0	8.8	9.9	Lung ca. (squam.) NCI-H596	0.0	25.9	2.9
astrocytoma SNB-75	0.0	10.7	9.0	Mammary gland	0.0	2.6	3.7
glioma SNB-19	0.0	16.7	7.9	Breast ca.* (pl.ef) MCF-7	0.0	0.5	0.1
glioma U251	0.0	20.4	9.7	Breast ca.* (pl.ef) MDA-MB-231	0.0	29.3	31.6
glioma SF-295	0.0	16.3	16.6	Breast ca.* (pl. ef) T47D	0.0	1.2	2.2
Heart	0.0	21.9	21.2	Breast ca. BT-549	0.0	9.7	9.2
Skeletal Muscle	0.0	7.5	10.8	Breast ca. MDA-N	0.0	0.8	0.5
Bone marrow	0.0	0.1	0.1	Ovary	0.0	25.2	7.0

Thymus	0.0	0.3	0.1	Ovarian ca. OVCA-3	0.0	6.0	4.5
Spleen	0.0	2.4	2.8	Ovarian ca. OVCA-4	0.0	10.8	8.4
Lymph node	0.0	2.4	2.4	Ovarian ca. OVCA-5	0.0	14.5	13.5
Colorectal Tissue	0.0	3.8	1.5	Ovarian ca. OVCA-8	0.0	16.8	7.5
Stomach	0.0	4.6	5.2	Ovarian ca. IGROV-1	0.0	6.1	3.7
Small intestine	0.0	5.6	6.0	Ovarian ca. (ascites) SK-OV-3	0.0	12.9	9.9
Colon ca. SW480	0.0	0.0	0.0	Uterus	0.0	2.4	2.8
Colon ca.* SW620 (SW480 met)	0.0	0.0	0.0	Placenta	0.0	5.9	9.2
Colon ca. HT29	0.0	0.5	0.6	Prostate	0.0	1.1	1.2
Colon ca. HCT-116	0.0	1.7	1.2	Prostate ca.* (bone met) PC-3	0.0	9.5	5.4
Colon ca. CaCo-2	0.0	0.1	0.2	Testis	0.0	2.3	2.8
Colon ca. Tissue (ODO3866)	0.0	3.9	2.5	Melanoma Hs688(A).T	0.0	19.6	25.7
Colon ca. HCC-2998	0.0	0.7	1.0	Melanoma* (met) Hs688(B).T	0.0	9.7	11.3
Gastric ca.* (liver met) NCI-N87	0.0	0.8	1.2	Melanoma UACC-62	0.0	1.0	0.5
Bladder	18.7	16.4	15.3	Melanoma M14	0.0	0.2	0.0
Trachea	0.0	1.2	2.5	Melanoma LOX IMVI	0.0	13.6	9.5
Kidney	0.0	25.0	11.0	Melanoma* (met) SK-MEL-5	0.0	1.4	1.8
Kidney (fetal)	0.0	20.7	32.3				

Table PM. Panel 1.3D

Tissue Name	Rel. Exp.(%) Ag3085, Run 165673584	Tissue Name	Rel. Exp.(%) Ag3085, Run 165673584
Liver adenocarcinoma	5.6	Kidney (fetal)	22.2

Pancreas	3.0	Renal ca. 786-0	28.3
Pancreatic ca. CAPAN 2	3.5	Renal ca. A498	25.7
Adrenal gland	2.8	Renal ca. RXF 393	0.0
Thyroid	11.3	Renal ca. ACHN	3.7
Salivary gland	1.7	Renal ca. UO-31	64.2
Pituitary gland	6.8	Renal ca. TK-10	1.6
Brain (fetal)	100.0	Liver	5.5
Brain (whole)	23.2	Liver (fetal)	6.3
Brain (amygdala)	13.1	Liver ca. (hepatoblast) HepG2	0.5
Brain (cerebellum)	2.4	Lung	27.9
Brain (hippocampus)	17.6	Lung (fetal)	21.0
Brain (substantia nigra)	11.5	Lung ca. (small cell) LX-1	0.0
Brain (thalamus)	15.9	Lung ca. (small cell) NCI-H69	0.0
Cerebral Cortex	4.4	Lung ca. (s.cell var.) SHP-77	1.4
Spinal cord	12.0	Lung ca. (large cell) NCI-H460	9.0
glio/astro U87-MG	5.5	Lung ca. (non-sm. cell) A549	1.2
glio/astro U-118-MG	49.3	Lung ca. (non-s.cell) NCI-H23	40.3
astrocytoma SW1783	21.0	Lung ca. (non-s.cell) HOP-62	53.6
neuro*; met SK-N-AS	75.8	Lung ca. (non-s.cl) NCI-H522	0.7
astrocytoma SF-539	11.4	Lung ca. (squam.) SW 900	4.9
astrocytoma SNB-75	27.9	Lung ca. (squam.) NCI-H596	0.0
glioma SNB-19	4.4	Mammary gland	25.2
glioma U251	42.0	Breast ca.* (pl.ef) MCF-7	0.0
glioma SF-295	12.6	Breast ca.* (pl.ef) MDA-MB-231	68.3
Heart (fetal)	3.5	Breast ca.* (pl.ef) T47D	0.0
Heart	10.4	Breast ca. BT-549	14.2
Skeletal muscle (fetal)	7.0	Breast ca. MDA-N	0.0
Skeletal muscle	12.1	Ovary	5.6
Bone marrow	1.1	Ovarian ca.	3.7

		OVCAR-3	
Thymus	1.8	Ovarian ca. OVCAR-4	6.6
Spleen	14.0	Ovarian ca. OVCAR-5	0.9
Lymph node	7.2	Ovarian ca. OVCAR-8	4.6
Colorectal	24.8	Ovarian ca. IGROV-1	0.0
Stomach	22.5	Ovarian ca.* (ascites) SK-OV-3	7.7
Small intestine	35.6	Uterus	25.7
Colon ca. SW480	0.0	Placenta	6.9
Colon ca.* SW620(SW480 met)	0.8	Prostate	4.5
Colon ca. HT29	0.0	Prostate ca.* (bone met)PC-3	3.5
Colon ca. HCT-116	0.5	Testis	3.8
Colon ca. CaCo-2	0.6	Melanoma Hs688(A).T	26.1
Colon ca. tissue(ODO3866)	7.3	Melanoma* (met) Hs688(B).T	9.2
Colon ca. HCC-2998	1.1	Melanoma UACC-62	0.8
Gastric ca.* (liver met) NCI-N87	0.5	Melanoma M14	0.9
Bladder	4.3	Melanoma LOX IMVI	1.6
Trachea	4.5	Melanoma* (met) SK-MEL-5	0.0
Kidney	10.3	Adipose	20.7

Table PN. Panel 2.2

Tissue Name	Rel. Exp.(%) Ag3085, Run 174284805	Tissue Name	Rel. Exp.(%) Ag3085, Run 174284805
Normal Colon	47.0	Kidney Margin (OD04348)	84.1
Colon cancer (OD06064)	19.1	Kidney malignant cancer (OD06204B)	1.4
Colon Margin (OD06064)	34.9	Kidney normal adjacent tissue (OD06204E)	10.8
Colon cancer (OD06159)	5.8	Kidney Cancer (OD04450-01)	15.4

Colon Margin (OD06159)	37.6	Kidney Margin (OD04450-03)	19.8
Colon cancer (OD06297-04)	15.6	Kidney Cancer 8120613	0.0
Colon Margin (OD06297-05)	76.8	Kidney Margin 8120614	6.3
CC Gr.2 ascend colon (ODO3921)	15.8	Kidney Cancer 9010320	5.2
CC Margin (ODO3921)	20.3	Kidney Margin 9010321	0.7
Colon cancer metastasis (OD06104)	1.5	Kidney Cancer 8120607	4.8
Lung Margin (OD06104)	11.4	Kidney Margin 8120608	1.0
Colon mets to lung (OD04451-01)	17.6	Normal Uterus	100.0
Lung Margin (OD04451-02)	48.3	Uterine Cancer 064011	16.6
Normal Prostate	5.0	Normal Thyroid	8.8
Prostate Cancer (OD04410)	3.8	Thyroid Cancer 064010	9.7
Prostate Margin (OD04410)	24.3	Thyroid Cancer A302152	21.3
Normal Ovary	20.0	Thyroid Margin A302153	32.1
Ovarian cancer (OD06283-03)	4.7	Normal Breast	36.6
Ovarian Margin (OD06283-07)	43.8	Breast Cancer (OD04566)	0.0
Ovarian Cancer 064008	19.2	Breast Cancer 1024	15.4
Ovarian cancer (OD06145)	4.5	Breast Cancer (OD04590-01)	16.0
Ovarian Margin (OD06145)	30.8	Breast Cancer Mets (OD04590-03)	21.2
Ovarian cancer (OD06455-03)	3.3	Breast Cancer Metastasis (OD04655-05)	8.5
Ovarian Margin (OD06455-07)	41.2	Breast Cancer 064006	6.5
Normal Lung	26.8	Breast Cancer 9100266	6.1
Invasive poor diff. lung adeno (ODO4945-01)	0.9	Breast Margin 9100265	10.8
Lung Margin (ODO4945-03)	38.2	Breast Cancer A209073	3.3
Lung Malignant Cancer	12.5	Breast Margin	21.0

(OD03126)		A2090734	
Lung Margin (OD03126)	12.4	Breast cancer (OD06083)	11.7
Lung Cancer (OD05014A)	10.3	Breast cancer node metastasis (OD06083)	5.4
Lung Margin (OD05014B)	19.9	Normal Liver	27.7
Lung cancer (OD06081)	4.5	Liver Cancer 1026	1.6
Lung Margin (OD06081)	27.2	Liver Cancer 1025	16.0
Lung Cancer (OD04237-01)	0.0	Liver Cancer 6004-T	12.2
Lung Margin (OD04237-02)	84.1	Liver Tissue 6004-N	2.2
Ocular Melanoma Metastasis	1.4	Liver Cancer 6005-T	8.8
Ocular Melanoma Margin (Liver)	10.4	Liver Tissue 6005-N	27.7
Melanoma Metastasis	1.2	Liver Cancer 064003	25.0
Melanoma Margin (Lung)	53.6	Normal Bladder	8.0
Normal Kidney	31.4	Bladder Cancer 1023	0.0
Kidney Ca, Nuclear grade 2 (OD04338)	65.1	Bladder Cancer A302173	5.4
Kidney Margin (OD04338)	13.8	Normal Stomach	87.1
Kidney Ca Nuclear grade 1/2 (OD04339)	35.1	Gastric Cancer 9060397	8.2
Kidney Margin (OD04339)	24.5	Stomach Margin 9060396	5.0
Kidney Ca, Clear cell type (OD04340)	16.7	Gastric Cancer 9060395	23.0
Kidney Margin (OD04340)	37.6	Stomach Margin 9060394	27.2
Kidney Ca, Nuclear grade 3 (OD04348)	2.1	Gastric Cancer 064005	6.8

Table PQ. Panel 2D

Tissue Name	Rel. Exp.(%) Ag1413, Run 169477489	Rel. Exp.(%) Ag740, Run 169590466	Tissue Name	Rel. Exp.(%) Ag1413, Run 169477489	Rel. Exp.(%) Ag740, Run 169590466
Normal Colon	68.3	100.0	Kidney Margin 8120608	2.9	1.0

CC Well to Mod Diff (ODO3866)	6.3	5.0	Kidney Cancer 8120613	0.2	0.5
CC Margin (ODO3866)	7.9	25.7	Kidney Margin 8120614	6.3	2.0
CC Gr.2 rectosigmoid (ODO3868)	4.6	12.6	Kidney Cancer 9010320	23.0	2.4
CC Margin (ODO3868)	11.0	38.2	Kidney Margin 9010321	11.7	1.7
CC Mod Diff (ODO3920)	1.4	9.7	Normal Uterus	13.8	4.6
CC Margin (ODO3920)	12.1	54.3	Uterus Cancer 064011	17.8	9.3
CC Gr.2 ascend colon (ODO3921)	20.3	61.6	Normal Thyroid	13.6	10.4
CC Margin (ODO3921)	10.9	12.9	Thyroid Cancer 064010	12.9	6.4
CC from Partial Hepatectomy (ODO4309) Mets	4.9	3.3	Thyroid Cancer A302152	8.1	5.4
Liver Margin (ODO4309)	10.4	9.0	Thyroid Margin A302153	29.1	11.0
Colon mets to lung (OD04451-01)	2.9	1.4	Normal Breast	21.0	13.5
Lung Margin (OD04451-02)	10.2	11.5	Breast Cancer (OD04566)	1.8	1.2
Normal Prostate 6546-1	2.7	5.1	Breast Cancer (OD04590-01)	17.3	1.1
Prostate Cancer (OD04410)	18.4	12.2	Breast Cancer Mets (OD04590-03)	23.3	3.7
Prostate Margin (OD04410)	36.1	44.4	Breast Cancer Metastasis (OD04655-05)	4.2	0.8
Prostate Cancer (OD04720-01)	17.3	28.9	Breast Cancer 064006	5.2	3.9
Prostate Margin (OD04720-02)	28.5	39.5	Breast Cancer 1024	12.8	1.8



Normal Lung 061010	48.0	38.4	Breast Cancer 9100266	3.9	1.7
Lung Met to Muscle (ODO4286)	3.6	3.0	Breast Margin 9100265	10.2	5.0
Muscle Margin (ODO4286)	5.9	3.5	Breast Cancer A209073	12.2	10.1
Lung Malignant Cancer (OD03126)	11.7	9.7	Breast Margin A209073	11.7	9.0
Lung Margin (OD03126)	40.3	24.7	Normal Liver	7.1	4.4
Lung Cancer (OD04404)	18.0	2.7	Liver Cancer 064003	10.3	8.0
Lung Margin (OD04404)	32.8	9.0	Liver Cancer 1025	5.0	5.1
Lung Cancer (OD04565)	2.9	2.7	Liver Cancer 1026	3.0	1.5
Lung Margin (OD04565)	8.0	10.2	Liver Cancer 6004-T	5.4	0.7
Lung Cancer (OD04237-01)	4.5	4.0	Liver Tissue 6004-N	1.4	0.3
Lung Margin (OD04237-02)	31.4	17.9	Liver Cancer 6005-T	5.2	0.5
Ocular Mel Met to Liver (ODO4310)	0.9	0.3	Liver Tissue 6005-N	3.3	3.5
Liver Margin (ODO4310)	8.1	10.8	Normal Bladder	7.1	7.7
Melanoma Mets to Lung (OD04321)	2.8	1.5	Bladder Cancer 1023	1.0	4.1
Lung Margin (OD04321)	33.9	19.2	Bladder Cancer A302173	3.0	3.6
Normal Kidney	100.0	28.5	Bladder Cancer (OD04718-01)	6.0	4.4
Kidney Ca, Nuclear grade 2 (OD04338)	14.1	9.8	Bladder Normal Adjacent (OD04718-03)	27.5	25.2
Kidney Margin (OD04338)	24.0	7.1	Normal Ovary	6.7	4.8
Kidney Ca Nuclear grade	14.3	6.7	Ovarian Cancer	27.0	21.9

1/2 (OD04339)			064008		
Kidney Margin (OD04339)	22.8	4.5	Ovarian Cancer (OD04768-07)	0.7	0.2
Kidney Ca, Clear cell type (OD04340)	53.2	16.0	Ovary Margin (OD04768-08)	12.4	6.7
Kidney Margin (OD04340)	26.6	10.5	Normal Stomach	27.4	12.3
Kidney Ca, Nuclear grade 3 (OD04348)	8.9	3.6	Gastric Cancer 9060358	6.9	2.1
Kidney Margin (OD04348)	14.1	10.0	Stomach Margin 9060359	7.2	10.9
Kidney Cancer (OD04622-01)	27.4	27.4	Gastric Cancer 9060395	29.9	21.0
Kidney Margin (OD04622-03)	3.5	4.4	Stomach Margin 9060394	13.7	16.3
Kidney Cancer (OD04450-01)	8.4	2.6	Gastric Cancer 9060397	23.2	18.3
Kidney Margin (OD04450-03)	23.8	7.5	Stomach Margin 9060396	3.7	2.6
Kidney Cancer 8120607	1.3	0.4	Gastric Cancer 064005	18.3	26.8

Table PP. Panel 4.1D

Tissue Name	Rel. Exp.(%) Ag1413, Run 169827815	Rel. Exp.(%) Ag3819, Run 170127253	Rel. Exp.(%) Ag740, Run 169827863	Tissue Name	Rel. Exp.(%) Ag1413, Run 169827815	Rel. Exp.(%) Ag3819, Run 170127253	Rel. Exp.(%) Ag740, Run 169827863
Secondary Th1 act	0.0	0.1	0.0	HUVEC IL-1beta	21.3	24.5	21.2
Secondary Th2 act	0.0	0.0	0.0	HUVEC IFN gamma	100.0	100.0	100.0
Secondary Tr1 act	0.0	0.1	0.0	HUVEC TNF alpha + IFN gamma	10.0	19.2	11.8
Secondary Th1 rest	0.0	0.1	0.0	HUVEC TNF alpha + IL4	4.0	5.2	3.1
Secondary Th2 rest	0.2	0.0	0.0	HUVEC IL-11	22.5	29.5	28.1
Secondary Tr1	0.0	0.1	0.0	Lung	48.6	91.4	59.5

rest				Microvascular EC none			
Primary Th1 act	0.0	0.0	0.0	Lung Microvascular EC TNFalpha + IL-1beta	12.5	18.8	8.6
Primary Th2 act	0.0	0.0	0.0	Microvascular Dermal EC none	62.9	58.6	62.4
Primary Tr1 act	0.0	0.0	0.0	Microvascular Dermal EC TNFalpha + IL- 1beta	8.8	9.9	9.7
Primary Th1 rest	0.0	0.0	0.0	Bronchial epithelium TNFalpha + IL1beta	3.8	4.2	2.7
Primary Th2 rest	0.0	0.0	0.0	Small airway epithelium none	1.8	2.1	1.2
Primary Tr1 rest	0.0	0.0	0.0	Small airway epithelium TNFalpha + IL- 1beta	3.4	1.9	2.5
CD45RA CD4 lymphocyte act	3.4	4.1	3.0	Coronary artery SMC rest	4.2	3.4	4.4
CD45RO CD4 lymphocyte act	0.0	0.0	0.0	Coronary artery SMC TNFalpha + IL-1beta	2.0	3.3	4.1
CD8 lymphocyte act	0.0	0.0	0.0	Astrocytes rest	7.0	6.3	6.0
Secondary CD8 lymphocyte rest	0.0	0.0	0.0	Astrocytes TNFalpha + IL- 1beta	3.7	4.2	6.5
Secondary CD8 lymphocyte act	0.0	0.0	0.0	KU-812 (Basophil) rest	1.1	1.5	2.0
CD4 lymphocyte none	0.2	0.1	0.0	KU-812 (Basophil) PMA/ionomycin	4.2	3.9	4.9
2ry Th1/Th2/Tr1_anti- CD95 CH11	0.1	0.0	0.0	CCD1106 (Keratinocytes) none	1.0	3.0	1.7
LAK cells rest	0.3	0.0	0.0	CCD1106 (Keratinocytes) TNFalpha + IL- 1beta	1.6	1.3	0.0
LAK cells IL-2	0.5	0.5	0.0	Liver cirrhosis	4.5	7.0	6.4
LAK cells IL- 2+IL-12	0.0	0.1	0.0	NCI-H292 none	0.3	0.9	1.1
LAK cells IL- 2+IFN gamma	0.1	0.3	0.0	NCI-H292 IL-4	0.9	1.3	2.3
LAK cells IL-2+	0.5	0.2	0.0	NCI-H292 IL-9	2.0	2.9	2.8

IL-18							
LAK cells PMA/ionomycin	0.1	0.1	0.0	NCI-H292 IL-13	1.1	1.0	1.5
NK Cells IL-2 rest	3.3	2.4	2.2	NCI-H292 IFN gamma	2.6	2.3	4.2
Two Way MLR 3 day	0.7	0.3	0.0	HPAEC none	27.0	41.5	52.9
Two Way MLR 5 day	0.0	0.1	0.0	HPAEC TNF alpha + IL-1 beta	6.0	7.0	4.0
Two Way MLR 7 day	0.0	0.0	0.0	Lung fibroblast none	10.2	14.4	6.7
PBMC rest	0.2	0.2	0.0	Lung fibroblast TNF alpha + IL-1 beta	11.6	10.8	8.9
PBMC PWM	0.1	0.0	0.0	Lung fibroblast IL-4	9.1	13.9	4.2
PBMC PHA-L	0.1	0.0	0.0	Lung fibroblast IL-9	17.3	26.4	12.2
Ramos (B cell) none	0.0	0.0	0.0	Lung fibroblast IL-13	6.3	13.2	5.4
Ramos (B cell) ionomycin	0.0	0.0	0.0	Lung fibroblast IFN gamma	11.2	9.4	6.6
B lymphocytes PWM	0.0	0.0	0.0	Dermal fibroblast CCD1070 rest	11.1	15.9	23.2
B lymphocytes CD40L and IL-4	0.0	0.2	0.0	Dermal fibroblast CCD1070 TNF alpha	4.6	6.3	6.3
EOL-1 dbcAMP	0.0	0.0	0.0	Dermal fibroblast CCD1070 IL-1 beta	2.1	3.4	5.9
EOL-1 dbcAMP PMA/ionomycin	0.0	0.0	0.0	Dermal fibroblast IFN gamma	6.9	8.4	4.7
Dendritic cells none	0.0	0.0	0.0	Dermal fibroblast IL-4	15.5	17.2	21.8
Dendritic cells LPS	0.0	0.0	0.0	Dermal Fibroblasts rest	17.6	14.0	12.8
Dendritic cells anti-CD40	0.2	0.0	0.0	Neutrophils TNFa+LPS	0.0	0.0	0.0
Monocytes rest	0.0	0.0	0.0	Neutrophils rest	0.0	0.0	0.0
Monocytes LPS	0.0	0.0	0.0	Colon	6.0	5.2	5.5
Macrophages rest	0.0	0.0	0.0	Lung	17.1	15.1	25.3
Macrophages LPS	0.0	0.0	0.0	Thymus	3.6	2.6	5.3
HUVEC none	16.2	17.9	19.5	Kidney	11.4	12.1	14.9
HUVEC starved	37.1	38.7	49.0				

Table PQ. Panel 4D

Tissue Name	Rel. Exp.(%) Ag1515, Run 163478545	Rel. Exp.(%) Ag3085, Run 164682194	Tissue Name	Rel. Exp.(%) Ag1515, Run 163478545	Rel. Exp.(%) Ag3085, Run 164682194
Secondary Th1 act	0.0	0.0	HUVEC IL-1beta	17.8	8.5
Secondary Th2 act	0.0	0.0	HUVEC IFN gamma	100.0	100.0
Secondary Tr1 act	0.0	0.2	HUVEC TNF alpha + IFN gamma	18.2	16.2
Secondary Th1 rest	0.1	0.0	HUVEC TNF alpha + IL4	5.4	4.2
Secondary Th2 rest	0.0	0.0	HUVEC IL-11	31.4	35.1
Secondary Tr1 rest	0.0	0.2	Lung Microvascular EC none	50.3	50.7
Primary Th1 act	0.0	0.0	Lung Microvascular EC TNFalpha + IL- 1beta	9.0	6.8
Primary Th2 act	0.0	0.0	Microvascular Dermal EC none	71.7	83.5
Primary Tr1 act	0.0	0.0	Microvascular Dermal EC TNFalpha + IL- 1beta	16.2	14.1
Primary Th1 rest	0.0	0.0	Bronchial epithelium TNFalpha + IL1beta	6.7	5.6
Primary Th2 rest	0.0	0.0	Small airway epithelium none	2.0	2.1
Primary Tr1 rest	0.0	0.0	Small airway epithelium TNFalpha + IL- 1beta	12.9	8.8
CD45RA CD4 lymphocyte act	3.8	4.6	Coronary artery SMC rest	5.4	4.8
CD45RO CD4 lymphocyte act	0.0	0.3	Coronary artery SMC TNFalpha + IL-1beta	2.2	2.6
CD8 lymphocyte act	0.1	0.0	Astrocytes rest	5.1	8.9

Secondary CD8 lymphocyte rest	0.0	0.0	Astrocytes TNFalpha + IL-1beta	5.8	5.8
Secondary CD8 lymphocyte act	0.0	0.0	KU-812 (Basophil) rest	1.2	0.7
CD4 lymphocyte none	0.0	0.0	KU-812 (Basophil) PMA/ionomycin	6.7	4.7
2ry Th1/Th2/Tr1_anti-CD95 CH11	0.1	0.0	CCD1106 (Keratinocytes) none	2.0	4.4
LAK cells rest	0.3	0.1	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	1.1	0.7
LAK cells IL-2	0.5	0.4	Liver cirrhosis	4.8	4.9
LAK cells IL-2+IL-12	0.3	0.2	Lupus kidney	1.9	4.7
LAK cells IL-2+IFN gamma	0.4	0.4	NCI-H292 none	2.1	1.5
LAK cells IL-2+IL-18	0.5	0.0	NCI-H292 IL-4	3.1	2.3
LAK cells PMA/ionomycin	0.0	0.4	NCI-H292 IL-9	3.7	3.1
NK Cells IL-2 rest	2.2	1.8	NCI-H292 IL-13	1.5	1.7
Two Way MLR 3 day	0.4	0.5	NCI-H292 IFN gamma	3.6	1.6
Two Way MLR 5 day	0.1	0.1	HPAEC none	29.3	40.1
Two Way MLR 7 day	0.1	0.0	HPAEC TNF alpha + IL-1 beta	4.5	5.3
PBMC rest	0.4	0.6	Lung fibroblast none	12.7	19.1
PBMC PWM	0.4	0.0	Lung fibroblast TNF alpha + IL-1 beta	10.0	15.3
PBMC PHA-L	0.1	0.1	Lung fibroblast IL-4	16.4	20.2
Ramos (B cell) none	0.0	0.0	Lung fibroblast IL-9	19.1	21.5
Ramos (B cell) ionomycin	0.0	0.0	Lung fibroblast IL-13	7.5	14.5
B lymphocytes PWM	0.0	0.0	Lung fibroblast IFN gamma	17.2	19.6
B lymphocytes	0.1	0.0	Dermal fibroblast	30.6	27.0

CD40L and IL-4			CCD1070 rest		
EOL-1 dbcAMP	0.0	0.0	Dermal fibroblast CCD1070 TNF alpha	8.4	10.1
EOL-1 dbcAMP PMA/ionomycin	0.0	0.0	Dermal fibroblast CCD1070 IL-1 beta	6.5	8.5
Dendritic cells none	0.0	0.0	Dermal fibroblast IFN gamma	7.0	11.0
Dendritic cells LPS	0.0	0.0	Dermal fibroblast IL-4	17.6	15.7
Dendritic cells anti- CD40	0.0	0.0	IBD Colitis 2	0.5	2.2
Monocytes rest	0.0	0.0	IBD Crohn's	1.8	3.0
Monocytes LPS	0.0	0.0	Colon	14.6	15.6
Macrophages rest	0.0	0.1	Lung	17.9	21.0
Macrophages LPS	0.0	0.0	Thymus	22.1	22.2
HUVEC none	22.8	30.4	Kidney	6.7	5.2
HUVEC starved	97.9	88.9			

Table PR. Panel CNS\_1

Tissue Name	Rel. Exp.(%) Ag693, Run 171791037	Tissue Name	Rel. Exp.(%) Ag693, Run 171791037
BA4 Control	10.2	BA17 PSP	13.5
BA4 Control2	53.6	BA17 PSP2	4.5
BA4 Alzheimer's2	5.0	Sub Nigra Control	58.6
BA4 Parkinson's	40.3	Sub Nigra Control2	47.0
BA4 Parkinson's2	59.5	Sub Nigra Alzheimer's2	14.3
BA4 Huntington's	19.5	Sub Nigra Parkinson's2	71.7
BA4 Huntington's2	5.0	Sub Nigra Huntington's	80.7
BA4 PSP	11.0	Sub Nigra Huntington's2	92.0
BA4 PSP2	13.1	Sub Nigra PSP2	31.2
BA4 Depression	15.7	Sub Nigra Depression	35.4
BA4 Depression2	5.7	Sub Nigra Depression2	15.6
BA7 Control	32.5	Glob Palladus Control	37.6

BA7 Control2	16.8	Glob Palladus Control2	6.3
BA7 Alzheimer's2	9.6	Glob Palladus Alzheimer's	9.2
BA7 Parkinson's	14.8	Glob Palladus Alzheimer's2	10.3
BA7 Parkinson's2	39.5	Glob Palladus Parkinson's	91.4
BA7 Huntington's	46.0	Glob Palladus Parkinson's2	39.5
BA7 Huntington's2	54.7	Glob Palladus PSP	5.1
BA7 PSP	36.3	Glob Palladus PSP2	2.4
BA7 PSP2	14.2	Glob Palladus Depression	11.5
BA7 Depression	10.6	Temp Pole Control	6.6
BA9 Control	12.9	Temp Pole Control2	29.1
BA9 Control2	81.2	Temp Pole Alzheimer's	9.7
BA9 Alzheimer's	5.3	Temp Pole Alzheimer's2	4.8
BA9 Alzheimer's2	12.2	Temp Pole Parkinson's	39.8
BA9 Parkinson's	36.1	Temp Pole Parkinson's2	19.5
BA9 Parkinson's2	35.1	Temp Pole Huntington's	46.3
BA9 Huntington's	40.6	Temp Pole PSP	5.9
BA9 Huntington's2	18.2	Temp Pole PSP2	3.4
BA9 PSP	7.3	Temp Pole Depression2	6.3
BA9 PSP2	7.7	Cing Gyr Control	43.8
BA9 Depression	10.4	Cing Gyr Control2	19.1
BA9 Depression2	5.1	Cing Gyr Alzheimer's	20.9
BA17 Control	36.6	Cing Gyr Alzheimer's2	7.7
BA17 Control2	47.0	Cing Gyr Parkinson's	40.1
BA17 Alzheimer's2	8.2	Cing Gyr Parkinson's2	49.0
BA17 Parkinson's	45.4	Cing Gyr Huntington's	100.0



BA17 Parkinson's2	43.2	Cing Gyr Huntington's2	56.6
BA17 Huntington's	39.8	Cing Gyr PSP	22.2
BA17 Huntington's2	17.1	Cing Gyr PSP2	10.2
BA17 Depression	44.1	Cing Gyr Depression	23.8
BA17 Depression2	26.6	Cing Gyr Depression2	23.0

**CNS\_neurodegeneration\_v1.0 Summary:** Ag1413/Ag3819/Ag693 Three experiment with different primer and probe sets are in excellent agreement. This panel confirms the expression of the CG92813-01 gene at low levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer's diseased

5 postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.

**General\_screening\_panel\_v1.4 Summary:** Ag1413/Ag3819 Two experiment with different primer and probe sets are in excellent agreement, with highest expression of the

10 CG92813-01 gene in lung cancer cell line NCI-H23 (CT=26-28). High to moderate levels of expression of this gene is also seen in cluster of CNS cancer, renal cancer, lung cancer, breast cancer, ovarian cancer and melanoma cell lines. Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, protein

15 therapeutics or antibodies, might be beneficial in the treatment of lung cancer or ovarian cancer. The CG92813-01 gene codes for cadherin-related tumor suppressor precursor. E-cadherin, a related protein is used as a prognostic marker for breast cancer detection (Ref. 1). Therefore, expression of CG92813-01 gene can also be used as diagnostic marker in the above mentioned cancers.

Among tissues with metabolic or endocrine function, this gene is expressed at high to

20 moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes. In addition, E cadherin, a related protein is shown to be reduced in small intestinal mucosa of coeliac sprue disease (Ref.1), a sample not used in this panel. In

analogy to E cadherin, we predict that expression of the CG92813-01 gene may also be reduced in this tissue of coeliac sprue disease. Coeliac sprue is a chronic disease, in which there is a characteristic mucosal lesion of the small intestine and impaired nutrient absorption, which improves upon the withdrawal of wheat gliadins and related grain proteins from the diet. Biopsy specimens demonstrate diffuse enteritis with pronounced atrophy or total loss of villi. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of coeliac sprue disease.

In addition, this gene is expressed at low to moderate levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. This gene product is a transmembrane glycoproteins belonging to the cadherin superfamily of molecules, which are involved in many biological processes such as cell adhesion, cytoskeletal organization and morphogenesis. Cadherins can act as axon guidance and cell adhesion proteins, specifically during development and in the response to injury (ref 2). Therefore, manipulation of levels of this protein may be of use in inducing a compensatory synaptogenic response to neuronal death in Alzheimer's disease, Parkinson's disease, Huntington's disease, spinocerebellar ataxia, progressive supranuclear palsy, ALS, head trauma, stroke, or any other disease/condition associated with neuronal loss.

Ag740 Results from one experiment with this gene are not included. The amp plot indicates that there were experimental difficulties with this run.

*See, generally,*

Barshack I, Goldberg I, Chowers Y, Weiss B, Horowitz A, Kopolovic J. (2001) Immunohistochemical analysis of candidate gene product expression in the duodenal epithelium of children with coeliac sprue. J Clin Pathol 54(9):684-8. PMID: 11533074

25 Ranscht B. (2000) Cadherins: molecular codes for axon guidance and synapse formation. Int. J. Dev. Neurosci. 18: 643-651. PMID: 10978842

**Panel 1.2 Summary:** Ag694 Two experiment with same primer and probe sets are in excellent agreement, with high expression of the CG92813-01 gene in neuroblastoma metastasis SK-N-AS, and two of the lung cancer (NCI-H23, HOP-62) cell lines (CT=26-28). High to moderate levels of expression of this gene is also seen in cluster of CNS cancer, renal

cancer, lung cancer, breast cancer, ovarian cancer and melanoma cell lines. Significant expression of this gene is also seen in tissues with metabolic or endocrine function and all regions of the central nervous system examined. Please see Panel 1.4 for a discussion of the potential utility of this gene.

- 5 Ag693 Highest expression of this gene is detected in fetal brain (CT=28.5). Expression of this gene is restricted to some of the brain region, endothelial cells, bladder, liver, and a lung cancer NCI-H23 cell line (CTs=28-32). Thus, expression of this gene can be used to distinguish these samples from other samples used in this panel. Please note that this primer and probe set recognizes a different region of the gene and shows a different expression  
10 pattern.

**Panel 1.3D Summary:** Ag3085 Highest expression of the CG92813-01 gene is detected in fetal brain (CT=28). High to moderate levels of expression of this gene is also seen in cluster of CNS cancer, renal cancer, lung cancer, breast cancer, ovarian cancer and melanoma cell lines. Significant expression of this gene is also seen in tissues with metabolic or endocrine  
15 function and all regions of the central nervous system examined. Please see Panel 1.4 for a discussion of the potential utility of this gene.

**Panel 2.2 Summary:** Ag3085 Highest expression of the CG92813-01 gene is detected in normal uterus (CT=30). High to moderate levels of expression of this gene is also seen in both normal and cancer tissues. Interestingly, expression of this gene is higher in control  
20 margin samples of colon, ovary, lung (OD04237-02), liver (ODO4310), kidney (OD04348; 8120614) as compared to their corresponding cancer tissue. Please see Panel 1.4 for a discussion of the potential utility of this gene.

**Panel 2D Summary:** Ag1413/Ag740 Highest expression of the CG92813-01 gene is detected in normal Kidney and colon (CTs=29-30). Two experiments with different primer  
25 and probe sets are in good agreement, with significant expression of this gene in both normal and cancer tissues. Interestingly, expression of this gene is higher in control margin samples of colon (ODO3920), liver (ODO4310), and ovary (OD04768-08) as compared to their corresponding cancer tissue. Please see Panel 1.4 for a discussion of the potential utility of this gene.

**Panel 4.1D Summary:** Ag1413/Ag3819/Ag740 Three experiments with different probe and primer sets are in excellent agreement, with highest expression of the CG92813-01 gene in IFN gamma treated HUVEC cells (CT=25-27). In addition, high to moderate expression of this gene is seen in treated and untreated HUVEC, lung microvascular EC, microvascular dermal EC, Bronchial epithelium, small airway epithelium, NCI-H292, HPAEC, lung fibroblasts, and dermal fibroblasts. The expression of this gene in cells derived from or within the lung suggests that this gene may be involved in normal conditions as well as pathological and inflammatory lung disorders that include chronic obstructive pulmonary disease, asthma, allergy and emphysema.

10 In addition, high expression of this gene is also detected in normal tissues represented by colon, lung, thymus and kidney. Therefore, therapeutic modulation of the activity of the protein encoded by this gene may be useful in the treatment of inflammatory disease affecting these tissues such as inflammatory bowel disease, chronic obstructive pulmonary disease, asthma, allergy, emphysema, lupus and glomerulonephritis.

15 **Panel 4D Summary:** Ag1515/Ag3085 Two experiments with different probe and primer sets are in excellent agreement, with highest expression of the CG92813-01 gene in IFN gamma treated HUVEC cells (CT=25-27). In addition, high to moderate expression of this gene is seen in treated and untreated HUVEC, lung microvascular EC, microvascular dermal EC, Bronchial epithelium, small airway epithelium, NCI-H292, HPAEC, lung fibroblasts, and dermal fibroblasts. The expression of this gene in cells derived from or within the lung suggests that this gene may be involved in normal conditions as well as pathological and inflammatory lung disorders that include chronic obstructive pulmonary disease, asthma, allergy and emphysema.

25 Interestingly, expression of this gene is higher in untreated HPAEC (CTs=27-28) as compared to TNF alpha + IL-1 beta treated cells (CTs=30-31). Thus, expression of this gene can be used to distinguish the treated from untreated HPAEC samples.

In addition, high expression of this gene is also detected in normal tissues represented by colon, lung, thymus and kidney. Interestingly, expression of this gene is much lower in colon samples from patients with IBD colitis and Crohn's disease relative CTs=31-33) to normal colon (CTs=28-29). Therefore, therapeutic modulation of the activity of the protein encoded by this gene may be useful in the treatment of inflammatory bowel disease.

**Panel CNS\_1 Summary:** Ag693 This panel confirms the expression of the CG92813-01 gene at low levels in the brains of an independent group of individuals. Please see panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.

5 **Q. NOV19a (CG93088-01: monocarboxylate transporter)**

Expression of gene CG93088-01 was assessed using the primer-probe set Ag3841, described in Table QA. Results of the RTQ-PCR runs are shown in Tables QB, QC, and QD.

Table QA. Probe Name Ag3841

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-ttcctatggcattgttgtaggt-3'	22	583	185
Probe	TET-5'-tggtttattatactgcaacagtgacca-3'-TAMRA	29	613	186
Reverse	5'-atcgtcaaaatactggcacgta-3'	22	643	187

Table QB. CNS\_neurodegeneration\_v1.0

Tissue Name	Rel. Exp.(%) Ag3841, Run 206873281	Rel. Exp.(%) Ag3841, Run 224339890	Tissue Name	Rel. Exp.(%) Ag3841, Run 206873281	Rel. Exp.(%) Ag3841, Run 224339890
AD 1 Hippo	59.5	60.7	Control (Path) 3 Temporal Ctx	11.8	9.9
AD 2 Hippo	91.4	77.4	Control (Path) 4 Temporal Ctx	26.4	19.1
AD 3 Hippo	15.8	13.0	AD 1 Occipital Ctx	35.1	39.0
AD 4 Hippo	15.0	19.3	AD 2 Occipital Ctx (Missing)	0.0	0.0
AD 5 Hippo	43.2	52.5	AD 3 Occipital Ctx	16.8	16.0
AD 6 Hippo	92.7	100.0	AD 4 Occipital	31.9	28.1

			Ctx		
Control 2 Hippo	25.5	32.3	AD 5 Occipital Ctx	23.8	13.4
Control 4 Hippo	45.7	54.7	AD 6 Occipital Ctx	15.2	28.1
Control (Path) 3 Hippo	16.6	14.8	Control 1 Occipital Ctx	7.0	6.1
AD 1 Temporal Ctx	55.1	54.3	Control 2 Occipital Ctx	35.4	32.3
AD 2 Temporal Ctx	61.6	62.0	Control 3 Occipital Ctx	20.6	18.0
AD 3 Temporal Ctx	12.9	16.4	Control 4 Occipital Ctx	16.8	22.7
AD 4 Temporal Ctx	42.9	44.1	Control (Path) 1 Occipital Ctx	52.5	50.0
AD 5 Inf Temporal Ctx	96.6	92.0	Control (Path) 2 Occipital Ctx	9.2	12.2
AD 5 Sup Temporal Ctx	100.0	83.5	Control (Path) 3 Occipital Ctx	5.1	5.3
AD 6 Inf Temporal Ctx	51.4	48.3	Control (Path) 4 Occipital Ctx	6.3	6.2
AD 6 Sup Temporal Ctx	56.3	49.0	Control 1 Parietal Ctx	14.4	15.9
Control 1 Temporal Ctx	18.4	15.9	Control 2 Parietal Ctx	63.7	76.3
Control 2 Temporal Ctx	23.0	27.4	Control 3 Parietal Ctx	14.3	14.9
Control 3 Temporal Ctx	12.4	17.9	Control (Path) 1 Parietal Ctx	24.0	28.3

Control 3 Temporal Ctx	19.9	25.5	Control (Path) 2 Parietal Ctx	25.5	24.8
Control (Path) 1 Temporal Ctx	22.2	20.7	Control (Path) 3 Parietal Ctx	8.8	7.9
Control (Path) 2 Temporal Ctx	29.1	26.6	Control (Path) 4 Parietal Ctx	27.7	21.2

Table QC. General\_screening\_panel\_v1.4

Tissue Name	Rel. Exp.(%) Ag3841, Run 213604526	Tissue Name	Rel. Exp.(%) Ag3841, Run 213604526
Adipose	1.6	Renal ca. TK-10	5.6
Melanoma* Hs688(A).T	0.0	Bladder	3.1
Melanoma* Hs688(B).T	0.1	Gastric ca. (liver met.) NCI-N87	2.6
Melanoma* M14	0.0	Gastric ca. KATO III	0.0
Melanoma* LOXIMVI	0.0	Colon ca. SW-948	0.8
Melanoma* SK- MEL-5	0.4	Colon ca. SW480	1.7
Squamous cell carcinoma SCC-4	5.7	Colon ca.* (SW480 met) SW620	2.4
Testis Pool	2.3	Colon ca. HT29	0.0
Prostate ca.* (bone met) PC-3	10.2	Colon ca. HCT-116	8.7
Prostate Pool	2.3	Colon ca. CaCo-2	0.6
Placenta	0.0	Colon cancer tissue	0.2
Uterus Pool	3.8	Colon ca. SW1116	0.3
Ovarian ca. OVCAR-3	3.0	Colon ca. Colo-205	0.0
Ovarian ca. SK-OV- 3	1.9	Colon ca. SW-48	0.0
Ovarian ca. OVCAR-4	1.3	Colon Pool	9.9
Ovarian ca. OVCAR-5	19.9	Small Intestine Pool	3.8
Ovarian ca. IGROV- 1	0.4	Stomach Pool	2.9
Ovarian ca.	1.6	Bone Marrow Pool	2.7

OVCAR-8			
Ovary	30.6	Fetal Heart	0.8
Breast ca. MCF-7	2.4	Heart Pool	1.9
Breast ca. MDA-MB-231	0.0	Lymph Node Pool	8.8
Breast ca. BT 549	3.8	Fetal Skeletal Muscle	1.4
Breast ca. T47D	33.9	Skeletal Muscle Pool	0.7
Breast ca. MDA-N	0.0	Spleen Pool	22.4
Breast Pool	9.7	Thymus Pool	3.1
Trachea	8.2	CNS cancer (glio/astro) U87-MG	0.0
Lung	5.2	CNS cancer (glio/astro) U-118-MG	0.0
Fetal Lung	3.0	CNS cancer (neuro;met) SK-N-AS	3.0
Lung ca. NCI-N417	0.7	CNS cancer (astro) SF-539	2.5
Lung ca. LX-1	0.3	CNS cancer (astro) SNB-75	2.6
Lung ca. NCI-H146	0.5	CNS cancer (glio) SNB-19	0.5
Lung ca. SHP-77	0.0	CNS cancer (glio) SF-295	0.4
Lung ca. A549	0.1	Brain (Amygdala) Pool	1.0
Lung ca. NCI-H526	0.0	Brain (cerebellum)	5.5
Lung ca. NCI-H23	3.8	Brain (fetal)	4.7
Lung ca. NCI-H460	2.0	Brain (Hippocampus) Pool	2.9
Lung ca. HOP-62	0.2	Cerebral Cortex Pool	2.1
Lung ca. NCI-H522	2.4	Brain (Substantia nigra) Pool	1.8
Liver	0.1	Brain (Thalamus) Pool	2.6
Fetal Liver	8.0	Brain (whole)	3.1
Liver ca. HepG2	3.1	Spinal Cord Pool	3.8
Kidney Pool	8.7	Adrenal Gland	100.0
Fetal Kidney	12.9	Pituitary gland Pool	2.1
Renal ca. 786-0	0.1	Salivary Gland	1.1
Renal ca. A498	0.5	Thyroid (female)	5.2
Renal ca. ACHN	0.7	Pancreatic ca. CAPAN2	0.2
Renal ca. UO-31	1.8	Pancreas Pool	5.2

Table QD. Panel 4.1D



Tissue Name	Rel. Exp.(%) Ag3841, Run 170126778	Tissue Name	Rel. Exp.(%) Ag3841, Run 170126778
Secondary Th1 act	0.3	HUVEC IL-1beta	0.2
Secondary Th2 act	0.3	HUVEC IFN gamma	1.3
Secondary Tr1 act	0.3	HUVEC TNF alpha + IFN gamma	0.1
Secondary Th1 rest	0.0	HUVEC TNF alpha + IL4	0.3
Secondary Th2 rest	0.1	HUVEC IL-11	1.0
Secondary Tr1 rest	0.0	Lung Microvascular EC none	2.3
Primary Th1 act	2.4	Lung Microvascular EC TNFalpha + IL-1beta	1.4
Primary Th2 act	1.0	Microvascular Dermal EC none	0.6
Primary Tr1 act	1.0	Microvascular Dermal EC TNFalpha + IL-1beta	0.1
Primary Th1 rest	0.0	Bronchial epithelium TNFalpha + IL1beta	4.9
Primary Th2 rest	0.0	Small airway epithelium none	2.9
Primary Tr1 rest	0.1	Small airway epithelium TNFalpha + IL-1beta	3.1
CD45RA CD4 lymphocyte act	0.2	Coronary artery SMC rest	3.7
CD45RO CD4 lymphocyte act	0.3	Coronary artery SMC TNFalpha + IL-1beta	2.3
CD8 lymphocyte act	0.2	Astrocytes rest	4.4
Secondary CD8 lymphocyte rest	0.1	Astrocytes TNFalpha + IL-1beta	2.9
Secondary CD8 lymphocyte act	0.1	KU-812 (Basophil) rest	18.6
CD4 lymphocyte none	0.0	KU-812 (Basophil) PMA/ionomycin	16.4
2ry Th1/Th2/Tr1_anti- CD95 CH11	0.0	CCD1106 (Keratinocytes) none	3.5
LAK cells rest	0.1	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	2.5
LAK cells IL-2	0.1	Liver cirrhosis	0.1
LAK cells IL-2+IL-12	0.3	NCI-H292 none	0.0
LAK cells IL-2+IFN gamma	0.2	NCI-H292 IL-4	0.2
LAK cells IL-2+ IL-18	0.5	NCI-H292 IL-9	0.2
LAK cells	0.0	NCI-H292 IL-13	0.1

PMA/ionomycin			
NK Cells IL-2 rest	0.1	NCI-H292 IFN gamma	0.4
Two Way MLR 3 day	0.0	HPAEC none	0.1
Two Way MLR 5 day	0.0	HPAEC TNF alpha + IL-1 beta	1.5
Two Way MLR 7 day	0.0	Lung fibroblast none	0.1
PBMC rest	0.0	Lung fibroblast TNF alpha + IL-1 beta	0.0
PBMC PWM	0.7	Lung fibroblast IL-4	0.0
PBMC PHA-L	0.1	Lung fibroblast IL-9	0.0
Ramos (B cell) none	0.0	Lung fibroblast IL-13	0.0
Ramos (B cell) ionomycin	0.0	Lung fibroblast IFN gamma	0.0
B lymphocytes PWM	0.9	Dermal fibroblast CCD1070 rest	0.0
B lymphocytes CD40L and IL-4	0.2	Dermal fibroblast CCD1070 TNF alpha	0.0
EOL-1 dbcAMP	0.0	Dermal fibroblast CCD1070 IL-1 beta	0.0
EOL-1 dbcAMP PMA/ionomycin	0.0	Dermal fibroblast IFN gamma	0.0
Dendritic cells none	0.0	Dermal fibroblast IL-4	0.0
Dendritic cells LPS	0.1	Dermal Fibroblasts rest	0.0
Dendritic cells anti-CD40	0.2	Neutrophils TNFa+LPS	0.0
Monocytes rest	0.0	Neutrophils rest	0.0
Monocytes LPS	0.0	Colon	0.3
Macrophages rest	0.1	Lung	0.2
Macrophages LPS	0.0	Thymus	0.3
HUVEC none	0.0	Kidney	100.0
HUVEC starved	0.0		

- CNS\_neurodegeneration\_v1.0 Summary:** Ag3841 Two experiments with same probe and primer sets are in excellent agreements. It confirms the expression of the CG93088-01 gene at low levels in the brain in an independent group of individuals. This gene is upregulated in the temporal cortex of Alzheimer's disease patients when compared with non-demented controls (p = 0.02 when analyzed by Ancova, estimate of total cDNA loaded per well used as a covariate). This gene may therefore be a small molecule target, and blockade of this transporter may slow or stop the progression of Alzheimer's disease.

**General\_screening\_panel\_v1.4 Summary:** Ag3841 Highest expression of the CG93088-01 gene is detected in adrenal gland (CT=25). In addition, this gene is also expressed at high to moderate levels in other tissues with metabolic or endocrine function, such as pancreas, adipose, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract.

- 5 The CG93088-01 gene codes for monocarboxylate transporter, a transporter belonging to sugar transporter family. Recently, a protein belonging to this family was shown to be associated with non-insulin-dependent diabetes mellitus (NIDDM) (Ref.1). Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes including NIDDM.
- 10 Interestingly, this gene is expressed at much higher levels in fetal (CT=28.7) when compared to adult liver (CT=35.6). This observation suggests that expression of this gene can be used to distinguish fetal from adult liver.

- In addition, this gene is expressed at high to moderate levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.
- 15

*See, generally,*

- McVie-Wylie AJ, Lamson DR, Chen YT. (2001) Molecular cloning of a novel member of the GLUT family of transporters, SLC2a10 (GLUT10), localized on chromosome 20q13.1: a candidate gene for NIDDM susceptibility. *Genomics* 72(1):113-7. PMID: 11247674
- 20

**Panel 2.2 Summary:** Ag3841 Results from one experiment with the CG93088-01 gene are not included. The amp plot indicates that there were experimental difficulties with this run.

- Panel 4.1D Summary:** Ag3841 Highest expression of the CG93088-01 gene is detected in kidney sample (CT=26). Therefore, antibody or small molecule therapies designed with the protein encoded for by this gene could modulate kidney function and be important in the treatment of inflammatory or autoimmune diseases that affect the kidney, including lupus and glomerulonephritis.
- 25

In addition, low to moderate expression of this gene is also seen in TNF alpha + IL-1 beta treated HPAEC, keratinocytes, basophils, astrocytes, coronary artery SMC, small airway epithelium, lung microvascular EC, microvascular dermal EC and PWM treated B lymphocytes. Interestingly, expression of this gene is stimulated in TNF alpha + IL-1 beta treated HPAEC, IFN gamma/IL-11 treated HUVEC cells, PWM treated PBMC cells, IL-2+ IL-18 treated LAK cells, activated primary and secondary Th1, Th2, Tr1 cells as compared to their corresponding untreated or resting cells. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.

#### R. NOV21a (CG93345-01: GPCR)

Expression of gene CG93345-01 was assessed using the primer-probe set Ag3850, described in Table RA. Results of the RTQ-PCR runs are shown in Tables RB.

15 Table RA. Probe Name Ag3850

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-taatcctgcaggcagtattgag-3'	22	737	188
Probe	TET-5'-attgcttcccaggaagacaggctcaa-3'-TAMRA	26	760	189
Reverse	5'-tgagagagacacaggtgttgag-3'	22	790	190

Table RB. General\_screening\_panel\_v1.4

Tissue Name	Rel. Exp.(%) Ag3850, Run 218998898	Tissue Name	Rel. Exp.(%) Ag3850, Run 218998898
Adipose	0.0	Renal ca. TK-10	0.0
Melanoma* Hs688(A).T	0.0	Bladder	0.6
Melanoma* Hs688(B).T	0.0	Gastric ca. (liver met.) NCI-N87	0.0
Melanoma* M14	0.0	Gastric ca. KATO III	0.0
Melanoma* LOXIMVI	0.0	Colon ca. SW-948	0.0
Melanoma* SK-MEL-5	0.0	Colon ca. SW480	0.0
Squamous cell	0.0	Colon ca.* (SW480	0.4

carcinoma SCC-4		met) SW620	
Testis Pool	1.8	Colon ca. HT29	0.0
Prostate ca.* (bone met) PC-3	0.0	Colon ca. HCT-116	0.0
Prostate Pool	1.7	Colon ca. CaCo-2	0.0
Placenta	0.0	Colon cancer tissue	0.0
Uterus Pool	0.0	Colon ca. SW1116	0.0
Ovarian ca. OVCAR-3	0.0	Colon ca. Colo-205	0.0
Ovarian ca. SK-OV-3	0.6	Colon ca. SW-48	0.0
Ovarian ca. OVCAR-4	0.0	Colon Pool	0.0
Ovarian ca. OVCAR-5	0.0	Small Intestine Pool	0.3
Ovarian ca. IGROV-1	0.0	Stomach Pool	0.0
Ovarian ca. OVCAR-8	0.0	Bone Marrow Pool	0.0
Ovary	0.0	Fetal Heart	0.0
Breast ca. MCF-7	0.0	Heart Pool	0.0
Breast ca. MDA-MB-231	0.0	Lymph Node Pool	0.0
Breast ca. BT 549	0.0	Fetal Skeletal Muscle	0.4
Breast ca. T47D	0.0	Skeletal Muscle Pool	0.0
Breast ca. MDA-N	0.0	Spleen Pool	0.0
Breast Pool	0.2	Thymus Pool	0.0
Trachea	0.0	CNS cancer (glio/astro) U87-MG	0.0
Lung	0.0	CNS cancer (glio/astro) U-118-MG	0.0
Fetal Lung	0.0	CNS cancer (neuro;met) SK-N-AS	0.0
Lung ca. NCI-N417	0.0	CNS cancer (astro) SF-539	0.0
Lung ca. LX-1	0.0	CNS cancer (astro) SNB-75	0.0
Lung ca. NCI-H146	4.7	CNS cancer (glio) SNB-19	0.0
Lung ca. SHP-77	100.0	CNS cancer (glio) SF-295	0.5
Lung ca. A549	0.0	Brain (Amygdala) Pool	0.0
Lung ca. NCI-H526	0.0	Brain (cerebellum)	0.0
Lung ca. NCI-H23	0.0	Brain (fetal)	0.3

Lung ca. NCI-H460	0.0	Brain (Hippocampus) Pool	0.0
Lung ca. HOP-62	0.0	Cerebral Cortex Pool	0.0
Lung ca. NCI-H522	0.0	Brain (Substantia nigra) Pool	0.0
Liver	0.0	Brain (Thalamus) Pool	0.0
Fetal Liver	0.0	Brain (whole)	0.0
Liver ca. HepG2	0.0	Spinal Cord Pool	0.0
Kidney Pool	1.1	Adrenal Gland	0.0
Fetal Kidney	3.1	Pituitary gland Pool	0.0
Renal ca. 786-0	0.0	Salivary Gland	0.0
Renal ca. A498	0.0	Thyroid (female)	0.0
Renal ca. ACHN	0.0	Pancreatic ca. CAPAN2	0.0
Renal ca. UO-31	0.0	Pancreas Pool	0.0

**CNS\_neurodegeneration\_v1.0 Summary:** Ag3850 Expression of the CG93345-01 gene is low/undetectable in all samples on this panel (CTs>35).

- General\_screening\_panel\_v1.4 Summary:** Ag3850 Expression of the CG93345-01 gene is restricted to a sample derived from a lung cancer cell line (CT=31.1). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel and as a marker to detect the presence of lung cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of lung cancer.

**Panel 4.1D Summary:** Ag3850 Expression of the CG93345-01 gene is low/undetectable in all samples on this panel (CTs>35).

#### 10 S. NOV22a (CG93400-01: GPCR)

Expression of gene CG93400-01 was assessed using the primer-probe set Ag3853, described in Table SA. Results of the RTQ-PCR runs are shown in Tables SB, and SC.

**Table SA.** Probe Name Ag3853

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-acgatgctgagaatcttcttgt-3'	22	274	191
Probe	TET-5'-tacatgcattgccaggaattcttca-3'-TAMRA	26	321	192
Reverse	5'-aagactccatgtctgtgaatcc-3'	22	352	193

Table SB. General\_screening\_panel\_v1.4

Tissue Name	Rel. Exp.(%) Ag3853, Run 218998963	Tissue Name	Rel. Exp.(%) Ag3853, Run 218998963
Adipose	0.0	Renal ca. TK-10	0.0
Melanoma* Hs688(A).T	0.0	Bladder	0.8
Melanoma* Hs688(B).T	0.0	Gastric ca. (liver met.) NCI-N87	0.0
Melanoma* M14	0.0	Gastric ca. KATO III	0.0
Melanoma* LOXIMVI	0.0	Colon ca. SW-948	0.4
Melanoma* SK- MEL-5	0.0	Colon ca. SW480	0.0
Squamous cell carcinoma SCC-4	0.4	Colon ca.* (SW480 met) SW620	0.0
Testis Pool	1.0	Colon ca. HT29	0.0
Prostate ca.* (bone met) PC-3	0.0	Colon ca. HCT-116	0.0
Prostate Pool	1.8	Colon ca. CaCo-2	0.0
Placenta	0.0	Colon cancer tissue	0.6
Uterus Pool	0.0	Colon ca. SW1116	0.0
Ovarian ca. OVCAR-3	0.0	Colon ca. Colo-205	0.0
Ovarian ca. SK-OV- 3	0.0	Colon ca. SW-48	0.0
Ovarian ca. OVCAR-4	0.0	Colon Pool	0.0
Ovarian ca. OVCAR-5	0.0	Small Intestine Pool	0.0
Ovarian ca. IGROV- 1	0.0	Stomach Pool	0.0
Ovarian ca. OVCAR-8	0.0	Bone Marrow Pool	0.0
Ovary	0.0	Fetal Heart	0.0
Breast ca. MCF-7	0.0	Heart Pool	0.0
Breast ca. MDA- MB-231	0.0	Lymph Node Pool	0.4
Breast ca. BT 549	0.0	Fetal Skeletal Muscle	0.0
Breast ca. T47D	0.0	Skeletal Muscle Pool	0.6
Breast ca. MDA-N	0.0	Spleen Pool	0.0
Breast Pool	0.0	Thymus Pool	0.0
Trachea	0.0	CNS cancer (glio/astro) U87-MG	0.0

Lung	0.0	CNS cancer (glio/astro) U-118-MG	0.0
Fetal Lung	0.0	CNS cancer (neuro;met) SK-N-AS	0.0
Lung ca. NCI-N417	0.0	CNS cancer (astro) SF- 539	0.0
Lung ca. LX-1	0.0	CNS cancer (astro) SNB-75	0.0
Lung ca. NCI-H146	2.8	CNS cancer (glio) SNB-19	0.0
Lung ca. SHP-77	100.0	CNS cancer (glio) SF- 295	0.0
Lung ca. A549	0.0	Brain (Amygdala) Pool	0.0
Lung ca. NCI-H526	0.8	Brain (cerebellum)	0.0
Lung ca. NCI-H23	0.0	Brain (fetal)	0.0
Lung ca. NCI-H460	0.0	Brain (Hippocampus) Pool	0.0
Lung ca. HOP-62	0.0	Cerebral Cortex Pool	0.0
Lung ca. NCI-H522	0.0	Brain (Substantia nigra) Pool	0.0
Liver	0.0	Brain (Thalamus) Pool	0.0
Fetal Liver	0.0	Brain (whole)	0.0
Liver ca. HepG2	0.0	Spinal Cord Pool	0.0
Kidney Pool	0.3	Adrenal Gland	0.0
Fetal Kidney	3.1	Pituitary gland Pool	0.0
Renal ca. 786-0	0.0	Salivary Gland	0.0
Renal ca. A498	0.0	Thyroid (female)	0.0
Renal ca. ACHN	0.0	Pancreatic ca. CAPAN2	0.0
Renal ca. UO-31	0.0	Pancreas Pool	0.4

Table SC. Panel 4.1D

Tissue Name	Rel. Exp.(%) Ag3853, Run 170121471	Tissue Name	Rel. Exp.(%) Ag3853, Run 170121471
Secondary Th1 act	0.0	HUVEC IL-1beta	0.0
Secondary Th2 act	0.0	HUVEC IFN gamma	0.0
Secondary Tr1 act	0.0	HUVEC TNF alpha + IFN gamma	0.0
Secondary Th1 rest	0.0	HUVEC TNF alpha + IL4	0.0
Secondary Th2 rest	0.0	HUVEC IL-11	0.0



Secondary Tr1 rest	0.0	Lung Microvascular EC none	0.0
Primary Th1 act	0.0	Lung Microvascular EC TNFalpha + IL-1beta	0.0
Primary Th2 act	0.0	Microvascular Dermal EC none	0.0
Primary Tr1 act	0.0	Microvascular Dermal EC TNFalpha + IL-1beta	0.0
Primary Th1 rest	0.0	Bronchial epithelium TNFalpha + IL1beta	0.0
Primary Th2 rest	0.0	Small airway epithelium none	0.0
Primary Tr1 rest	0.0	Small airway epithelium TNFalpha + IL-1beta	0.0
CD45RA CD4 lymphocyte act	0.0	Coronary artery SMC rest	0.0
CD45RO CD4 lymphocyte act	0.0	Coronary artery SMC TNFalpha + IL-1beta	0.0
CD8 lymphocyte act	0.0	Astrocytes rest	0.0
Secondary CD8 lymphocyte rest	0.0	Astrocytes TNFalpha + IL-1beta	0.0
Secondary CD8 lymphocyte act	0.0	KU-812 (Basophil) rest	1.5
CD4 lymphocyte none	0.0	KU-812 (Basophil) PMA/ionomycin	0.0
2ry Th1/Th2/Tr1_anti-CD95 CH11	0.0	CCD1106 (Keratinocytes) none	0.0
LAK cells rest	0.0	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	0.0
LAK cells IL-2	0.0	Liver cirrhosis	0.0
LAK cells IL-2+IL-12	0.0	NCI-H292 none	0.0
LAK cells IL-2+IFN gamma	0.0	NCI-H292 IL-4	0.0
LAK cells IL-2+ IL-18	0.0	NCI-H292 IL-9	0.0
LAK cells PMA/ionomycin	0.0	NCI-H292 IL-13	0.0
NK Cells IL-2 rest	100.0	NCI-H292 IFN gamma	0.0
Two Way MLR 3 day	0.0	HPAEC none	0.0
Two Way MLR 5 day	0.0	HPAEC TNF alpha + IL-1 beta	0.0
Two Way MLR 7 day	0.0	Lung fibroblast none	0.0
PBMC rest	0.0	Lung fibroblast TNF alpha + IL-1 beta	0.0
PBMC PWM	0.0	Lung fibroblast IL-4	0.0

PBMC PHA-L	0.0	Lung fibroblast IL-9	0.0
Ramos (B cell) none	0.0	Lung fibroblast IL-13	0.0
Ramos (B cell) ionomycin	0.0	Lung fibroblast IFN gamma	0.0
B lymphocytes PWM	0.0	Dermal fibroblast CCD1070 rest	0.0
B lymphocytes CD40L and IL-4	0.0	Dermal fibroblast CCD1070 TNF alpha	0.0
EOL-1 dbcAMP	0.0	Dermal fibroblast CCD1070 IL-1 beta	0.0
EOL-1 dbcAMP PMA/ionomycin	0.0	Dermal fibroblast IFN gamma	0.0
Dendritic cells none	0.0	Dermal fibroblast IL-4	0.0
Dendritic cells LPS	0.0	Dermal Fibroblasts rest	0.0
Dendritic cells anti-CD40	0.0	Neutrophils TNFa+LPS	0.0
Monocytes rest	0.0	Neutrophils rest	0.0
Monocytes LPS	0.0	Colon	0.0
Macrophages rest	0.0	Lung	0.0
Macrophages LPS	0.0	Thymus	0.0
HUVEC none	0.0	Kidney	0.0
HUVEC starved	0.0		

**CNS\_neurodegeneration\_v1.0 Summary:** Ag3853 Expression of the CG93400-01 gene is low/undetectable in all samples on this panel (CTs>35).

**General\_screening\_panel\_v1.4 Summary:** Ag3853 Expression of the CG93400-01 gene is restricted to a sample derived from a lung cancer cell line (CT=31). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel and as a marker to detect the presence of lung cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of lung cancer.

**Panel 4.1D Summary:** Ag3853 Expression of the CG93400-01 gene is restricted to a sample derived from IL-2 treated NK cells (CT=31.5). Thus, expression of this gene may be used to differentiate between this sample and other samples on this panel and as a marker of activated NK cells.

#### **T. NOV23a (CG93410-01: GLUTAMATE RECEPTOR 5)**

Expression of gene CG93410-01 was assessed using the primer-probe set Ag1682, described in Table TA. Results of the RTQ-PCR runs are shown in Tables TB and TC.

Table TA. Probe Name Ag1682

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-cattgagtatgtgacgcagaga-3'	22	471	194
Probe	TET-5'-aactgcaacctcactcagatcgggg-3'-TAMRA	25	446	195
Reverse	5'-taggtgttcccactccgtaac-3'	21	407	196

Table TB. Panel 1.3D

Tissue Name	Rel. Exp.(%) Ag1682, Run 146581572	Rel. Exp.(%) Ag1682, Run 148168380	Tissue Name	Rel. Exp.(%) Ag1682, Run 146581572	Rel. Exp.(%) Ag1682, Run 148168380
Liver adenocarcinoma	0.8	0.6	Kidney (fetal)	0.7	0.3
Pancreas	0.2	0.0	Renal ca. 786-0	0.2	0.5
Pancreatic ca. CAPAN 2	0.8	0.8	Renal ca. A498	1.8	1.6
Adrenal gland	1.7	2.5	Renal ca. RXF 393	0.4	0.4
Thyroid	0.2	0.3	Renal ca. ACHN	0.1	0.2
Salivary gland	1.4	0.4	Renal ca. UO-31	0.0	0.0
Pituitary gland	0.1	0.4	Renal ca. TK-10	0.1	0.4
Brain (fetal)	5.7	4.5	Liver	0.0	0.1
Brain (whole)	15.1	18.3	Liver (fetal)	0.5	0.8
Brain (amygdala)	13.6	12.1	Liver ca. (hepatoblast) HepG2	0.4	0.9
Brain (cerebellum)	3.5	3.9	Lung	0.8	0.0
Brain (hippocampus)	20.4	17.7	Lung (fetal)	1.0	1.0
Brain (substantia nigra)	3.7	4.5	Lung ca. (small cell) LX-1	1.0	0.5
Brain (thalamus)	19.2	17.6	Lung ca. (small cell) NCI-H69	2.8	2.2

Cerebral Cortex	30.1	31.4	Lung ca. (s.cell var.) SHP-77	100.0	100.0
Spinal cord	2.2	1.4	Lung ca. (large cell)NCI- H460	1.1	1.0
glio/astro U87-MG	3.8	1.6	Lung ca. (non- sm. cell) A549	0.3	0.6
glio/astro U-118- MG	4.0	3.3	Lung ca. (non- s.cell) NCI- H23	1.1	1.0
astrocytoma SW1783	0.1	0.0	Lung ca. (non- s.cell) HOP-62	1.4	1.1
neuro*; met SK-N- AS	2.0	1.1	Lung ca. (non- s.cl) NCI- H522	0.0	0.0
astrocytoma SF- 539	0.7	0.9	Lung ca. (squam.) SW 900	0.2	0.0
astrocytoma SNB- 75	3.4	3.7	Lung ca. (squam.) NCI- H596	0.3	0.3
glioma SNB-19	0.3	0.8	Mammary gland	6.1	2.8
glioma U251	0.2	0.2	Breast ca.* (pl.ef) MCF-7	0.7	0.4
glioma SF-295	0.2	0.0	Breast ca.* (pl.ef) MDA- MB-231	1.7	1.1
Heart (fetal)	1.3	2.1	Breast ca.* (pl.ef) T47D	10.6	9.3
Heart	0.5	0.0	Breast ca. BT- 549	3.1	2.4
Skeletal muscle (fetal)	7.2	8.0	Breast ca. MDA-N	0.5	0.6
Skeletal muscle	0.1	0.0	Ovary	0.4	0.8
Bone marrow	0.7	0.5	Ovarian ca. OVCAR-3	0.2	0.5
Thymus	0.3	0.7	Ovarian ca. OVCAR-4	0.0	0.0
Spleen	0.7	0.8	Ovarian ca. OVCAR-5	1.8	1.0
Lymph node	0.6	1.2	Ovarian ca. OVCAR-8	0.3	0.2
Colorectal	0.4	0.5	Ovarian ca.	0.1	0.0

			IGROV-1		
Stomach	1.6	1.4	Ovarian ca.* (ascites) SK- OV-3	0.6	0.8
Small intestine	2.8	2.4	Uterus	0.7	0.3
Colon ca. SW480	0.0	0.1	Placenta	3.2	2.2
Colon ca.* SW620(SW480 met)	0.4	0.1	Prostate	0.8	0.8
Colon ca. HT29	0.0	0.2	Prostate ca.* (bone met)PC- 3	0.1	0.9
Colon ca. HCT- 116	0.0	0.2	Testis	5.6	3.9
Colon ca. CaCo-2	0.7	0.0	Melanoma Hs688(A).T	0.8	0.3
Colon ca. tissue(ODO3866)	0.9	0.6	Melanoma* (met) Hs688(B).T	0.5	0.9
Colon ca. HCC- 2998	0.4	0.7	Melanoma UACC-62	0.3	0.0
Gastric ca.* (liver met) NCI-N87	0.8	0.7	Melanoma M14	0.4	0.2
Bladder	1.3	0.8	Melanoma LOX IMVI	0.3	0.2
Trachea	1.3	0.7	Melanoma* (met) SK- MEL-5	0.2	0.1
Kidney	0.0	0.3	Adipose	0.6	0.2

Table TC. Panel 2D

Tissue Name	Rel. Exp.(%) Ag1682, Run 148168595	Rel. Exp.(%) Ag1682, Run 148399984	Tissue Name	Rel. Exp.(%) Ag1682, Run 148168595	Rel. Exp.(%) Ag1682, Run 148399984
Normal Colon	21.2	39.2	Kidney Margin 8120608	0.0	2.6
CC Well to Mod Diff (ODO3866)	2.0	2.9	Kidney Cancer 8120613	1.4	1.7
CC Margin (ODO3866)	2.5	2.0	Kidney Margin 8120614	0.0	7.4
CC Gr.2 rectosigmoid	10.3	15.2	Kidney Cancer	8.2	20.3

(ODO3868)			9010320		
CC Margin (ODO3868)	2.3	0.9	Kidney Margin 9010321	5.9	9.9
CC Mod Diff (ODO3920)	12.6	11.7	Normal Uterus	3.2	2.2
CC Margin (ODO3920)	4.3	8.8	Uterus Cancer 064011	8.0	14.9
CC Gr.2 ascend colon (ODO3921)	11.7	17.8	Normal Thyroid	4.3	9.8
CC Margin (ODO3921)	1.9	3.4	Thyroid Cancer 064010	3.2	3.0
CC from Partial Hepatectomy (ODO4309) Mets	4.6	15.6	Thyroid Cancer A302152	7.2	5.2
Liver Margin (ODO4309)	2.3	6.9	Thyroid Margin A302153	3.3	8.7
Colon mets to lung (OD04451- 01)	5.7	5.4	Normal Breast	26.6	39.5
Lung Margin (OD04451-02)	3.9	10.2	Breast Cancer (OD04566)	2.0	4.5
Normal Prostate 6546-1	8.3	18.9	Breast Cancer (OD04590-01)	7.3	10.5
Prostate Cancer (OD04410)	27.7	52.9	Breast Cancer Mets (OD04590-03)	6.9	20.7
Prostate Margin (OD04410)	47.6	84.7	Breast Cancer Metastasis (OD04655-05)	9.7	18.7
Prostate Cancer (OD04720-01)	14.8	35.8	Breast Cancer 064006	21.9	26.8
Prostate Margin (OD04720-02)	24.7	50.0	Breast Cancer 1024	7.1	15.8
Normal Lung 061010	25.3	50.7	Breast Cancer 9100266	4.5	8.5
Lung Met to Muscle (ODO4286)	1.6	4.9	Breast Margin 9100265	9.4	16.5
Muscle Margin (ODO4286)	7.3	10.5	Breast Cancer A209073	12.2	12.0
Lung Malignant	100.0	100.0	Breast Margin	14.6	30.4

Cancer (OD03126)			A209073		
Lung Margin (OD03126)	21.6	49.7	Normal Liver	3.2	2.8
Lung Cancer (OD04404)	10.6	13.6	Liver Cancer 064003	11.9	28.3
Lung Margin (OD04404)	9.3	9.7	Liver Cancer 1025	4.7	5.9
Lung Cancer (OD04565)	11.5	11.7	Liver Cancer 1026	2.6	0.7
Lung Margin (OD04565)	6.1	11.7	Liver Cancer 6004-T	7.7	11.3
Lung Cancer (OD04237-01)	12.6	27.2	Liver Tissue 6004-N	8.7	25.0
Lung Margin (OD04237-02)	11.0	24.0	Liver Cancer 6005-T	0.9	3.0
Ocular Mel Met to Liver (ODO4310)	0.4	3.4	Liver Tissue 6005-N	0.8	1.0
Liver Margin (ODO4310)	2.5	3.2	Normal Bladder	34.2	76.8
Melanoma Mets to Lung (OD04321)	8.0	8.4	Bladder Cancer 1023	4.2	4.2
Lung Margin (OD04321)	12.2	10.9	Bladder Cancer A302173	6.0	15.0
Normal Kidney	24.3	42.9	Bladder Cancer (OD04718-01)	15.6	27.7
Kidney Ca, Nuclear grade 2 (OD04338)	27.0	15.9	Bladder Normal Adjacent (OD04718-03)	7.8	20.9
Kidney Margin (OD04338)	7.3	25.7	Normal Ovary	0.9	5.1
Kidney Ca Nuclear grade 1/2 (OD04339)	23.7	42.0	Ovarian Cancer 064008	13.8	34.2
Kidney Margin (OD04339)	17.3	29.1	Ovarian Cancer (OD04768-07)	5.9	16.3
Kidney Ca, Clear cell type (OD04340)	20.6	25.9	Ovary Margin (OD04768-08)	3.6	9.1
Kidney Margin	18.6	27.0	Normal	14.0	17.7

(OD04340)			Stomach		
Kidney Ca, Nuclear grade 3 (OD04348)	3.9	10.6	Gastric Cancer 9060358	0.4	1.0
Kidney Margin (OD04348)	16.3	31.6	Stomach Margin 9060359	6.7	13.3
Kidney Cancer (OD04622-01)	5.0	10.4	Gastric Cancer 9060395	1.5	6.8
Kidney Margin (OD04622-03)	0.9	0.9	Stomach Margin 9060394	6.2	9.7
Kidney Cancer (OD04450-01)	4.7	8.0	Gastric Cancer 9060397	6.5	16.0
Kidney Margin (OD04450-03)	4.5	9.9	Stomach Margin 9060396	1.5	4.0
Kidney Cancer 8120607	0.7	0.9	Gastric Cancer 064005	8.4	30.1

**Panel 1.3D Summary:** Ag1682 Two experiments with same probe and primer set are in excellent agreement with highest expression of this gene in lung cancer SHP-77 cell line (CTs=26). In addition, low to moderate expression of this gene is also observed in number of cancer cell lines (melanoma, ovarian, breast, lung, renal, colon, CNS and liver  
5 adenocarcinoma). Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, protein therapeutics or antibodies, might be beneficial in the treatment of these cancers.

In addition, this gene is expressed at high to moderate levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus,  
10 cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression. CG93410-01 codes for a splice variant of glutamate receptor 5 (GluR5). Mutation or allelic variation in GluR5 has been shown to be associated  
15 (JAE)(Ref.2). Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of ALS and JAE.

Among tissues with metabolic or endocrine function, this gene is expressed at high to moderate levels in pancreas, adrenal gland, fetal skeletal muscle, fetal heart, fetal liver and



the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

- 5 Interestingly, this gene is expressed at much higher levels in fetal (CT = 30-33) when compared to adult skeletal muscle, heart and liver (CT > 35). This observation suggests that expression of this gene can be used to distinguish these fetal from adult tissue.

*See, generally,*

- Eubanks JH, Puranam RS, Kleckner NW, Bettler B, Heinemann SF, McNamara JO. (1993) The gene encoding the glutamate receptor subunit GluR5 is located on human chromosome  
10 21q21.1-22.1 in the vicinity of the gene for familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 90(1):178-82. PMID: 8419920

Sander T, Hildmann T, Kretz R, Furst R, Sailer U, Bauer G, Schmitz B, Beck-Mannagetta G, Wienker TF, Janz D. (1997). PMID: 9259378

- Panel 2D Summary:** Ag1682 Two experiments with same probe and primer set are in  
15 excellent agreement with highest expression of this gene in lung malignant cancer (OD03126) (CTs=28-31). In addition, expression of this gene is seen in both normal, control margin and cancer tissue. Please see Panel 1.4 for a discussion of the potential utility of this gene.

#### U. NOV24a (CG93722-01: SERINE PROTEASE HEPsin)

- 20 Expression of gene CG93722-01 was assessed using the primer-probe sets Ag1299, Ag897, Ag898 and Ag228, described in Tables UA, UB, UC and UD. Results of the RTQ-PCR runs are shown in Tables UE, and UF.

Table UA. Probe Name Ag1299

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-gcctatttgccctaccttttgat-3'	22	766	197
Probe	TET-5'-ccaaatcctggacggaaacacaaagt-3'-TAMRA	26	793	198
Reverse	5'-cttccccagccacttataaaac-3'	22	819	199

Table UB. Probe Name Ag897

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-gcctatttgctaccttttga-3'	21	766	200
Probe	TET-5'-ccaaatcctggacggaacacaaaagt-3'- TAMRA	26	793	201
Reverse	5'-gttcttcccagccacttat-3'	20	824	202

Table UC. Probe Name Ag898

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-gcctatttgctaccttttga-3'	21	766	203
Probe	TET-5'-ccaaatcctggacggaacacaaaagt-3'- TAMRA	26	793	204
Reverse	5'-gttcttcccagccacttat-3'	20	824	205

Table UD. Probe Name Ag228

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-tgtggaacagcaccgcttaag-3'	21	365	206
Probe	TET-5'-ccctataatccgagacccttgcaacaca-3'- TAMRA	28	388	207
Reverse	5'-atgcgcagcttgtgctt-3'	18	423	208

Table UE. Panel 1

Tissue Name	Rel. Exp.(%) Ag228, Run 87590239	Tissue Name	Rel. Exp.(%) Ag228, Run 87590239
Endothelial cells	0.0	Renal ca. 786-0	0.0
Endothelial cells (treated)	0.0	Renal ca. A498	0.0
Pancreas	0.0	Renal ca. RXF 393	0.0
Pancreatic ca. CAPAN 2	0.0	Renal ca. ACHN	0.0
Adrenal gland	0.0	Renal ca. UO-31	0.0
Thyroid	0.0	Renal ca. TK-10	0.0
Salivary gland	0.0	Liver	0.0
Pituitary gland	0.0	Liver (fetal)	0.0
Brain (fetal)	0.0	Liver ca. (hepatoblast) HepG2	0.0
Brain (whole)	0.0	Lung	0.0
Brain (amygdala)	0.0	Lung (fetal)	0.0

Brain (cerebellum)	0.0	Lung ca. (small cell) LX-1	0.0
Brain (hippocampus)	0.0	Lung ca. (small cell) NCI-H69	0.0
Brain (substantia nigra)	0.0	Lung ca. (s.cell var.) SHP-77	0.0
Brain (thalamus)	0.0	Lung ca. (large cell)NCI-H460	0.0
Brain (hypothalamus)	0.0	Lung ca. (non-sm. cell) A549	0.0
Spinal cord	0.0	Lung ca. (non-s.cell) NCI-H23	0.0
glio/astro U87-MG	0.0	Lung ca. (non-s.cell) HOP-62	0.0
glio/astro U-118-MG	0.0	Lung ca. (non-s.cl) NCI-H522	0.0
astrocytoma SW1783	0.0	Lung ca. (squam.) SW 900	0.0
neuro*; met SK-N-AS	0.0	Lung ca. (squam.) NCI-H596	0.0
astrocytoma SF-539	0.0	Mammary gland	0.0
astrocytoma SNB-75	0.0	Breast ca.* (pl.ef) MCF-7	0.0
glioma SNB-19	0.0	Breast ca.* (pl.ef) MDA-MB-231	0.0
glioma U251	0.0	Breast ca.* (pl. ef) T47D	0.0
glioma SF-295	0.0	Breast ca. BT-549	0.0
Heart	0.0	Breast ca. MDA-N	0.0
Skeletal muscle	0.0	Ovary	0.0
Bone marrow	0.0	Ovarian ca. OVCAR- 3	0.0
Thymus	0.0	Ovarian ca. OVCAR- 4	0.0
Spleen	0.0	Ovarian ca. OVCAR- 5	0.0
Lymph node	0.0	Ovarian ca. OVCAR- 8	0.0
Colon (ascending)	0.0	Ovarian ca. IGROV-1	0.0
Stomach	0.0	Ovarian ca. (ascites) SK-OV-3	0.0
Small intestine	0.0	Uterus	0.0
Colon ca. SW480	0.0	Placenta	0.0
Colon ca.* SW620	0.0	Prostate	0.0

(SW480 met)			
Colon ca. HT29	0.0	Prostate ca. * (bone met) PC-3	0.0
Colon ca. HCT-116	0.0	Testis	100.0
Colon ca. CaCo-2	0.0	Melanoma Hs688(A).T	0.0
Colon ca. HCT-15	0.0	Melanoma* (met) Hs688(B).T	0.0
Colon ca. HCC-2998	0.0	Melanoma UACC-62	0.0
Gastric ca. * (liver met) NCI-N87	0.0	Melanoma M14	0.0
Bladder	0.0	Melanoma LOX IMVI	0.0
Trachea	0.0	Melanoma* (met) SK-MEL-5	0.0
Kidney	0.0	Melanoma SK-MEL-28	0.0
Kidney (fetal)	0.0		

Table UF. Panel 1.3D

Tissue Name	Rel. Exp.(%) Ag898, Run 153559338	Tissue Name	Rel. Exp.(%) Ag898, Run 153559338
Liver adenocarcinoma	0.2	Kidney (fetal)	0.1
Pancreas	0.3	Renal ca. 786-0	0.0
Pancreatic ca. CAPAN 2	0.0	Renal ca. A498	0.0
Adrenal gland	0.2	Renal ca. RXF 393	0.0
Thyroid	0.4	Renal ca. ACHN	0.0
Salivary gland	0.0	Renal ca. UO-31	0.0
Pituitary gland	0.2	Renal ca. TK-10	0.2
Brain (fetal)	0.2	Liver	0.0
Brain (whole)	0.2	Liver (fetal)	0.3
Brain (amygdala)	0.5	Liver ca. (hepatoblast) HepG2	0.0
Brain (cerebellum)	0.1	Lung	0.0
Brain (hippocampus)	0.0	Lung (fetal)	0.5
Brain (substantia nigra)	0.0	Lung ca. (small cell) LX-1	0.0
Brain (thalamus)	0.2	Lung ca. (small cell) NCI-H69	0.0
Cerebral Cortex	0.0	Lung ca. (s.cell var.) SHP-77	0.0
Spinal cord	0.0	Lung ca. (large	0.3

		cell)NCI-H460	
glio/astro U87-MG	0.0	Lung ca. (non-sm. cell) A549	0.0
glio/astro U-118-MG	0.0	Lung ca. (non-s.cell) NCI-H23	0.2
astrocytoma SW1783	0.2	Lung ca. (non-s.cell) HOP-62	0.0
neuro*; met SK-N-AS	0.0	Lung ca. (non-s.cl) NCI-H522	0.0
astrocytoma SF-539	0.2	Lung ca. (squam.) SW 900	0.0
astrocytoma SNB-75	0.2	Lung ca. (squam.) NCI-H596	0.0
glioma SNB-19	0.0	Mammary gland	0.0
glioma U251	0.0	Breast ca.* (pl.ef) MCF-7	0.0
glioma SF-295	0.2	Breast ca.* (pl.ef) MDA-MB-231	0.0
Heart (fetal)	0.2	Breast ca.* (pl.ef) T47D	0.2
Heart	0.0	Breast ca. BT-549	0.1
Skeletal muscle (fetal)	1.0	Breast ca. MDA-N	0.0
Skeletal muscle	0.2	Ovary	0.3
Bone marrow	0.0	Ovarian ca. OVCAR-3	0.0
Thymus	0.0	Ovarian ca. OVCAR-4	0.0
Spleen	0.0	Ovarian ca. OVCAR-5	0.0
Lymph node	0.0	Ovarian ca. OVCAR-8	0.0
Colorectal	0.0	Ovarian ca. IGROV-1	0.0
Stomach	0.2	Ovarian ca.* (ascites) SK-OV-3	0.1
Small intestine	0.0	Uterus	0.2
Colon ca. SW480	0.0	Placenta	0.6
Colon ca.* SW620(SW480 met)	0.0	Prostate	0.5
Colon ca. HT29	0.0	Prostate ca.* (bone met)PC-3	0.2
Colon ca. HCT-116	0.0	Testis	100.0
Colon ca. CaCo-2	0.0	Melanoma Hs688(A).T	0.0

Colon ca. tissue(ODO3866)	0.0	Melanoma* (met) Hs688(B).T	0.0
Colon ca. HCC-2998	0.2	Melanoma UACC-62	0.0
Gastric ca.* (liver met) NCI-N87	0.0	Melanoma M14	0.0
Bladder	0.0	Melanoma LOX IMVI	0.0
Trachea	0.0	Melanoma* (met) SK-MEL-5	0.0
Kidney	0.0	Adipose	0.0

**Panel 1 Summary:** Ag228 Expression of the CG93722-01 gene is detected exclusively in testis. Thus, expression of this gene can be used to distinguish testis from other samples used in this panel. Therefore, therapeutic modulation of the activity of the serine protease encoded by this gene may be useful in the treatment of fertility and hypogonadism.

- 5 **Panel 1.3D Summary:** Ag898 Expression of the CG93722-01 gene is detected exclusively in testis. Thus, expression of this gene can be used to distinguish testis from other samples used in this panel. Therefore, therapeutic modulation of the activity of the serine protease encoded by this gene may be useful in the treatment of fertility and hypogonadism.

- 10 **Panel 4D Summary:** Ag1299 Expression of the CG93722-01 gene is low/undetectable (CTs > 35) across all of the samples on this panel.

**V. NOV25a, NOV25b, and NOV25c (CG93858-01 and CG93858-02 and CG56914-03: Fibulin 6 like)**

- 15 Expression of gene CG93858-01 and variants CG93858-02 and CG56914-03 was assessed using the primer-probe sets Ag1315b, Ag1316b, Ag1924, Ag900, Ag3960, and Ag4338. In addition expression of gene CG93858-02 was also assessed using the primer-probe sets Ag343, Ag3108, Ag771, Ag772, Ag3899 with CG56914-03 corresponding to Ag3108 and Ag3899 only. The probes are described in Tables VA, VB, VC, VD, VE, VF, VG, VH, VI, VJ and VK. Results of the RTQ-PCR runs are shown in Tables VL, VM, VN, VO, VP, VQ, and VR.

- 20 **Table VA. Probe Name Ag1315b**

Primers	Sequences	Length	Start Position	SEQ ID No:
---------	-----------	--------	----------------	------------

Forward	5'-catcagaggttcttcgaaagc-3'	21	6744	209
Probe	TET-5'-cacaacggaccacacagcgataagat-3'- TAMRA	26	6712	210
Reverse	5'-aggactgtgacaatacgaattgg-3'	22	6690	211

Table VB. Probe Name Ag1316b

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-aatgccatggggacttactact-3'	22	6572	212
Probe	TET-5'-cctaaaggcctcaccatagctgcaga-3'- TAMRA	26	6602	213
Reverse	5'-cccaaagcacactcatcaatat-3'	22	6645	214

Table VC. Probe Name Ag1924

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-ctatgggagcagggattcc-3'	19	6546	215
Probe	TET-5'-ctgcacattcatcctcatcagcaca-3'- TAMRA	26	6517	216
Reverse	5'-ccgggtttaccttagactcagt-3'	22	6486	217

Table VD. Probe Name Ag3108

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-attccattgccaaattaaca-3'	21	4061	218
Probe	TET-5'-ccttcaataacaatattattccagccca-3'- TAMRA	28	4086	219
Reverse	5'-actgtgtccattcacactgtca-3'	22	4117	220

Table VE. Probe Name Ag771

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-gtttcgagcaacacattcaa-3'	22	4723	221
Probe	TET-5'-tcagaggtatcttctttctgagcatcagca-3'- TAMRA	30	4693	222
Reverse	5'-taacgtgtgtgtccaacaactca-3'	22	4663	223

5 Table VF. Probe Name Ag772

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-gtttcgagcaacacattcaa-3'	22	4723	224

Probe	TET-5'-tcagaggtatcttctttctgagcatcagca-3'- TAMRA	30	4693	225
Reverse	5'-taacgtgttggtccaacaactca-3'	22	4663	226

Table VG. Probe Name Ag900

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-aatgccatggggacttactact-3'	22	6572	227
Probe	TET-5'-cctaaaggcctcaccatagctgcaga-3'- TAMRA	26	6602	228
Reverse	5'-cccaaagcacactcatcaatat-3'	22	6645	229

Table VH. Probe Name Ag3899

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-ccattgcccaaattaacatg-3'	20	4064	230
Probe	TET-5'-ccttcaataacaatattattccagccca-3'- TAMRA	28	4086	231
Reverse	5'-actgtgtccattcacactgtca-3'	22	4117	232

Table VI. Probe Name Ag3960

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-aaacacttcatgcatcctctgt-3'	22	6375	233
Probe	TET-5'-cactgggtttttaaattcatgcttca-3'- TAMRA	26	6426	234
Reverse	5'-ttactgcatctcctttggata-3'	22	6453	235

5 Table VJ. Probe Name Ag4338

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-tcatgcatcctctgtggaat-3'	20	6382	236
Probe	TET-5'-cactgggtttttaaattcatgcttca-3'- TAMRA	26	6426	237
Reverse	5'-ctgattactgcatctcctttg-3'	22	6457	238

Table VK. Probe Name Ag343

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-attgcacctgggtcacctgagt-3'	21	5777	239



Probe	TET-5'-tgccgtccctgtcccga-3'-TAMRA	19	5752	240
Reverse	5'-gctgtgcgaccatcctgtg-3'	19	5722	241

Table VL General\_screening\_panel\_v1.4

Tissue Name	Rel. Exp.(%) Ag3899, Run 219166475	Rel. Exp.(%) Ag3960, Run 217310662	Rel. Exp.(%) Ag4338, Run 222550860	Tissue Name	Rel. Exp.(%) Ag3899, Run 219166475	Rel. Exp.(%) Ag3960, Run 217310662	Rel. Exp.(%) Ag4338, Run 222550860
Adipose	1.0	1.9	2.6	Renal ca. TK-10	0.0	0.0	0.0
Melanoma* Hs688(A).T	33.9	72.7	79.0	Bladder	0.6	1.2	1.1
Melanoma* Hs688(B).T	8.4	22.4	28.9	Gastric ca. (liver met.) NCI-N87	0.0	0.0	0.1
Melanoma* M14	12.9	24.0	25.3	Gastric ca. KATO III	0.0	0.1	0.1
Melanoma* LOXIMVI	0.1	0.2	0.4	Colon ca. SW-948	0.0	0.0	0.0
Melanoma* SK-MEL-5	58.6	58.2	77.4	Colon ca. SW480	0.0	0.1	0.2
Squamous cell carcinoma SCC-4	0.0	0.0	0.1	Colon ca.* (SW480 met) SW620	0.0	0.0	0.0
Testis Pool	0.6	0.9	0.9	Colon ca. HT29	0.0	0.0	0.0
Prostate ca.* (bone met) PC-3	0.2	0.6	0.8	Colon ca. HCT-116	0.0	0.1	0.1
Prostate Pool	0.4	1.4	2.1	Colon ca. CaCo-2	0.0	0.0	0.1
Placenta	0.1	0.3	0.5	Colon cancer tissue	1.2	2.1	3.8
Uterus Pool	0.1	0.2	0.6	Colon ca. SW1116	0.0	0.0	0.0
Ovarian ca. OVCAR-3	0.4	1.2	1.2	Colon ca. Colo-205	0.0	0.0	0.0
Ovarian ca. SK-OV-3	0.1	0.8	0.5	Colon ca. SW-48	0.0	0.0	0.0
Ovarian ca. OVCAR-4	0.1	0.1	0.2	Colon Pool	0.2	1.5	1.8
Ovarian ca. OVCAR-5	0.2	0.4	0.6	Small Intestine Pool	0.2	1.2	1.0
Ovarian ca. IGROV-1	0.1	0.1	0.0	Stomach Pool	0.1	0.9	0.8
Ovarian ca.	0.1	0.2	0.1	Bone Marrow	0.2	0.4	0.6

OVCAR-8				Pool			
Ovary	3.6	4.3	5.6	Fetal Heart	1.0	1.3	1.9
Breast ca. MCF-7	0.5	2.0	2.7	Heart Pool	0.3	0.8	0.7
Breast ca. MDA-MB- 231	0.1	0.2	0.1	Lymph Node Pool	0.4	1.8	2.2
Breast ca. BT 549	2.6	10.0	7.1	Fetal Skeletal Muscle	0.1	0.5	0.7
Breast ca. T47D	0.2	0.4	0.7	Skeletal Muscle Pool	0.2	0.8	0.6
Breast ca. MDA-N	2.2	15.1	20.3	Spleen Pool	1.1	2.3	2.8
Breast Pool	0.1	1.1	1.9	Thymus Pool	0.6	1.0	1.3
Trachea	1.0	2.8	2.9	CNS cancer (glio/astro) U87-MG	0.8	1.9	2.4
Lung	0.0	0.5	0.7	CNS cancer (glio/astro) U- 118-MG	3.0	10.0	10.5
Fetal Lung	5.6	21.9	23.7	CNS cancer (neuro;met) SK-N-AS	0.0	0.0	0.0
Lung ca. NCI-N417	0.0	0.1	0.1	CNS cancer (astro) SF-539	18.8	37.1	37.1
Lung ca. LX-1	0.0	0.0	0.0	CNS cancer (astro) SNB-75	100.0	100.0	100.0
Lung ca. NCI-H146	0.0	0.1	0.1	CNS cancer (glio) SNB-19	0.0	0.1	0.0
Lung ca. SHP-77	0.0	0.0	0.0	CNS cancer (glio) SF-295	0.8	2.4	3.1
Lung ca. A549	0.0	0.0	0.0	Brain (Amygdala) Pool	0.0	0.0	0.0
Lung ca. NCI-H526	0.0	0.0	0.0	Brain (cerebellum)	0.0	0.0	0.0
Lung ca. NCI-H23	0.3	0.2	0.3	Brain (fetal)	0.0	0.2	0.3
Lung ca. NCI-H460	0.1	2.3	1.3	Brain (Hippocampus) Pool	0.0	0.1	0.3
Lung ca. HOP-62	0.6	1.7	2.6	Cerebral Cortex Pool	0.0	0.1	0.1
Lung ca. NCI-H522	0.0	0.1	0.0	Brain (Substantia nigra) Pool	0.0	0.1	0.1
Liver	0.0	0.1	0.2	Brain (Thalamus) Pool	0.0	0.2	0.2

Fetal Liver	1.3	1.7	2.4	Brain (whole)	0.0	0.2	0.2
Liver ca. HepG2	0.0	0.0	0.0	Spinal Cord Pool	0.1	0.3	0.2
Kidney Pool	0.2	0.7	0.6	Adrenal Gland	0.1	0.4	0.4
Fetal Kidney	1.4	2.4	3.6	Pituitary gland Pool	0.1	0.2	0.5
Renal ca. 786-0	0.2	0.8	0.4	Salivary Gland	0.2	0.6	0.7
Renal ca. A498	0.0	0.2	0.2	Thyroid (female)	0.1	0.2	0.7
Renal ca. ACHN	0.0	0.0	0.0	Pancreatic ca. CAPAN2	0.0	0.0	0.0
Renal ca. UO-31	4.6	4.8	1.3	Pancreas Pool	0.4	1.4	1.4

Table VM. Panel 1

Tissue Name	Rel. Exp.(%) Ag343, Run 87586142	Tissue Name	Rel. Exp.(%) Ag343, Run 87586142
Endothelial cells	0.0	Renal ca. 786-0	0.9
Endothelial cells (treated)	0.0	Renal ca. A498	0.0
Pancreas	0.3	Renal ca. RXF 393	0.0
Pancreatic ca. CAPAN 2	0.0	Renal ca. ACHN	0.0
Adrenal gland	1.3	Renal ca. UO-31	4.3
Thyroid	4.2	Renal ca. TK-10	0.0
Salivary gland	6.1	Liver	14.6
Pituitary gland	2.6	Liver (fetal)	3.7
Brain (fetal)	0.0	Liver ca. (hepatoblast) HepG2	0.0
Brain (whole)	0.0	Lung	12.4
Brain (amygdala)	0.0	Lung (fetal)	29.1
Brain (cerebellum)	0.2	Lung ca. (small cell) LX-1	0.0
Brain (hippocampus)	0.0	Lung ca. (small cell) NCI-H69	0.0
Brain (substantia nigra)	0.0	Lung ca. (s.cell var.) SHP-77	0.0
Brain (thalamus)	0.0	Lung ca. (large cell) NCI-H460	15.7
Brain (hypothalamus)	6.5	Lung ca. (non-sm. cell) A549	0.0
Spinal cord	2.9	Lung ca. (non-s.cell)	0.0

		NCI-H23	
glio/astro U87-MG	6.3	Lung ca. (non-s.cell) HOP-62	7.2
glio/astro U-118-MG	10.6	Lung ca. (non-s.cl) NCI-H522	0.0
astrocytoma SW1783	1.6	Lung ca. (squam.) SW 900	9.2
neuro*; met SK-N-AS	0.0	Lung ca. (squam.) NCI-H596	0.0
astrocytoma SF-539	54.7	Mammary gland	72.2
astrocytoma SNB-75	29.7	Breast ca.* (pl.ef) MCF-7	13.7
glioma SNB-19	0.0	Breast ca.* (pl.ef) MDA-MB-231	0.0
glioma U251	0.6	Breast ca.* (pl. ef) T47D	0.0
glioma SF-295	1.8	Breast ca. BT-549	2.6
Heart	18.4	Breast ca. MDA-N	100.0
Skeletal muscle	1.7	Ovary	24.0
Bone marrow	0.0	Ovarian ca. OVCAR-3	0.0
Thymus	7.1	Ovarian ca. OVCAR-4	0.0
Spleen	20.3	Ovarian ca. OVCAR-5	0.6
Lymph node	8.8	Ovarian ca. OVCAR-8	0.0
Colon (ascending)	7.9	Ovarian ca. IGROV-1	0.0
Stomach	20.3	Ovarian ca. (ascites) SK-OV-3	0.0
Small intestine	13.7	Uterus	10.3
Colon ca. SW480	0.0	Placenta	10.7
Colon ca.* SW620 (SW480 met)	0.0	Prostate	7.4
Colon ca. HT29	0.0	Prostate ca.* (bone met) PC-3	3.0
Colon ca. HCT-116	0.0	Testis	45.7
Colon ca. CaCo-2	0.0	Melanoma Hs688(A).T	45.7
Colon ca. HCT-15	0.0	Melanoma* (met) Hs688(B).T	62.9
Colon ca. HCC-2998	0.0	Melanoma UACC-62	97.3
Gastric ca. * (liver met) NCI-N87	0.0	Melanoma M14	90.1

Bladder	5.0	Melanoma LOX IMVI	0.5
Trachea	10.6	Melanoma* (met) SK-MEL-5	95.9
Kidney	7.2	Melanoma SK-MEL- 28	72.7
Kidney (fetal)	29.9		

Table VN. Panel 1.2

Tissue Name	Rel. Exp.(%) Ag771, Run 116423907	Rel. Exp.(%) Ag772, Run 117131093	Tissue Name	Rel. Exp.(%) Ag771, Run 116423907	Rel. Exp.(%) Ag772, Run 117131093
Endothelial cells	1.4	1.4	Renal ca. 786- 0	0.3	0.3
Heart (Fetal)	0.7	1.0	Renal ca. A498	0.0	0.0
Pancreas	0.7	2.0	Renal ca. RXF 393	0.0	0.0
Pancreatic ca. CAPAN 2	0.0	0.0	Renal ca. ACHN	0.0	0.0
Adrenal Gland	2.0	1.9	Renal ca. UO- 31	4.0	1.4
Thyroid	0.7	2.4	Renal ca. TK- 10	0.0	0.0
Salivary gland	1.8	3.6	Liver	5.6	8.7
Pituitary gland	1.1	2.8	Liver (fetal)	1.2	2.6
Brain (fetal)	0.0	0.2	Liver ca. (hepatoblast) HepG2	0.0	0.0
Brain (whole)	0.0	0.3	Lung	3.3	6.2
Brain (amygdala)	0.0	0.0	Lung (fetal)	2.4	7.0
Brain (cerebellum)	0.0	0.0	Lung ca. (small cell) LX-1	0.0	0.0
Brain (hippocampus)	0.0	0.1	Lung ca. (small cell) NCI-H69	0.3	0.2
Brain (thalamus)	0.1	0.2	Lung ca. (s.cell var.) SHP-77	0.0	0.0
Cerebral Cortex	0.0	0.0	Lung ca. (large cell) NCI-H460	3.2	8.9
Spinal cord	0.5	1.2	Lung ca. (non- sm. cell) A549	0.0	0.0
glio/astro U87-	1.3	1.2	Lung ca. (non-	0.1	0.2

MG			s.cell) NCI-H23		
glio/astro U-118-MG	1.9	2.9	Lung ca. (non-s.cell) HOP-62	2.5	5.9
astrocytoma SW1783	0.3	0.5	Lung ca. (non-s.cl) NCI-H522	0.0	0.1
neuro*; met SK-N-AS	0.0	0.0	Lung ca. (squam.) SW 900	1.0	1.1
astrocytoma SF-539	9.5	11.1	Lung ca. (squam.) NCI-H596	0.1	0.3
astrocytoma SNB-75	4.5	3.6	Mammary gland	7.3	12.6
glioma SNB-19	0.0	0.0	Breast ca.* (pl.ef) MCF-7	0.7	1.0
glioma U251	1.0	0.8	Breast ca.* (pl.ef) MDA-MB-231	0.0	0.0
glioma SF-295	1.0	0.1	Breast ca.* (pl.ef) T47D	0.0	0.1
Heart	7.8	12.3	Breast ca. BT-549	0.1	0.2
Skeletal Muscle	4.4	7.7	Breast ca. MDA-N	27.2	24.3
Bone marrow	0.0	0.0	Ovary	0.8	1.3
Thymus	0.1	0.2	Ovarian ca. OVCAR-3	0.4	0.9
Spleen	1.3	2.7	Ovarian ca. OVCAR-4	0.0	0.0
Lymph node	0.4	1.3	Ovarian ca. OVCAR-5	0.4	0.6
Colorectal Tissue	0.0	0.1	Ovarian ca. OVCAR-8	0.0	0.0
Stomach	1.0	2.7	Ovarian ca. IGROV-1	0.1	0.2
Small intestine	2.7	5.6	Ovarian ca. (ascites) SK-OV-3	0.2	0.4
Colon ca. SW480	0.0	0.0	Uterus	0.5	0.8
Colon ca.* SW620 (SW480 met)	0.0	0.0	Placenta	2.2	5.0

Colon ca. HT29	0.0	0.0	Prostate	0.2	0.9
Colon ca. HCT-116	0.0	0.0	Prostate ca.* (bone met) PC-3	0.6	2.0
Colon ca. CaCo-2	0.0	0.0	Testis	1.9	3.6
Colon ca. Tissue (ODO3866)	0.8	0.5	Melanoma Hs688(A).T	5.2	7.8
Colon ca. HCC-2998	0.0	0.0	Melanoma* (met) Hs688(B).T	10.4	14.1
Gastric ca.* (liver met) NCI-N87	0.0	0.0	Melanoma UACC-62	100.0	100.0
Bladder	0.8	1.8	Melanoma M14	29.3	14.6
Trachea	1.1	2.5	Melanoma LOX IMVI	0.0	0.0
Kidney	0.9	1.6	Melanoma* (met) SK-MEL-5	30.4	30.4
Kidney (fetal)	4.2	4.8			

Table VO. Panel 1.3D

Tissue Name	Rel. Exp.(%) Ag3108, Run 167985250	Tissue Name	Rel. Exp.(%) Ag3108, Run 167985250
Liver adenocarcinoma	0.2	Kidney (fetal)	4.2
Pancreas	0.1	Renal ca. 786-0	0.5
Pancreatic ca. CAPAN 2	0.0	Renal ca. A498	7.7
Adrenal gland	0.0	Renal ca. RXF 393	0.5
Thyroid	0.3	Renal ca. ACHN	0.0
Salivary gland	0.0	Renal ca. UO-31	7.9
Pituitary gland	0.3	Renal ca. TK-10	0.0
Brain (fetal)	0.1	Liver	0.2
Brain (whole)	0.3	Liver (fetal)	0.7
Brain (amygdala)	0.0	Liver ca. (hepatoblast) HepG2	0.0
Brain (cerebellum)	0.0	Lung	0.4
Brain (hippocampus)	0.0	Lung (fetal)	5.7
Brain (substantia nigra)	0.2	Lung ca. (small cell)	0.0

		LX-1	
Brain (thalamus)	0.0	Lung ca. (small cell) NCI-H69	0.1
Cerebral Cortex	0.0	Lung ca. (s.cell var.) SHP-77	0.1
Spinal cord	0.5	Lung ca. (large cell)NCI-H460	0.6
glio/astro U87-MG	1.2	Lung ca. (non-sm. cell) A549	0.0
glio/astro U-118-MG	3.1	Lung ca. (non-s.cell) NCI-H23	0.4
astrocytoma SW1783	1.4	Lung ca. (non-s.cell) HOP-62	1.9
neuro*; met SK-N-AS	0.0	Lung ca. (non-s.cl) NCI-H522	0.1
astrocytoma SF-539	25.2	Lung ca. (squam.) SW 900	1.7
astrocytoma SNB-75	30.8	Lung ca. (squam.) NCI-H596	0.3
glioma SNB-19	0.0	Mammary gland	1.2
glioma U251	2.4	Breast ca.* (pl.ef) MCF-7	1.0
glioma SF-295	1.1	Breast ca.* (pl.ef) MDA-MB-231	0.0
Heart (fetal)	0.8	Breast ca.* (pl.ef) T47D	0.1
Heart	1.2	Breast ca. BT-549	0.2
Skeletal muscle (fetal)	0.1	Breast ca. MDA-N	28.7
Skeletal muscle	0.7	Ovary	1.0
Bone marrow	0.0	Ovarian ca. OVCAR-3	0.8
Thymus	0.1	Ovarian ca. OVCAR-4	0.1
Spleen	0.6	Ovarian ca. OVCAR-5	0.8
Lymph node	0.2	Ovarian ca. OVCAR-8	0.0
Colorectal	0.0	Ovarian ca. IGROV- 1	0.2
Stomach	0.2	Ovarian ca.* (ascites) SK-OV-3	0.5
Small intestine	0.4	Uterus	0.4
Colon ca. SW480	0.0	Placenta	0.2
Colon ca.*	0.0	Prostate	0.2



SW620(SW480 met)			
Colon ca. HT29	0.0	Prostate ca.* (bone met)PC-3	0.7
Colon ca. HCT-116	0.0	Testis	0.3
Colon ca. CaCo-2	0.0	Melanoma Hs688(A).T	12.4
Colon ca. tissue(ODO3866)	4.2	Melanoma* (met) Hs688(B).T	2.2
Colon ca. HCC-2998	0.0	Melanoma UACC-62	100.0
Gastric ca.* (liver met) NCI-N87	0.0	Melanoma M14	14.6
Bladder	0.3	Melanoma LOX IMVI	0.2
Trachea	0.4	Melanoma* (met) SK-MEL-5	20.3
Kidney	0.4	Adipose	3.3

Table VP. Panel 2.1

Tissue Name	Rel. Exp.(%) Ag3108, Run 170686074	Tissue Name	Rel. Exp.(%) Ag3108, Run 170686074
Normal Colon	0.7	Kidney Cancer 9010320	0.9
Colon cancer (OD06064)	1.3	Kidney margin 9010321	9.5
Colon cancer margin (OD06064)	0.0	Kidney Cancer 8120607	0.6
Colon cancer (OD06159)	0.5	Kidney margin 8120608	0.7
Colon cancer margin (OD06159)	1.8	Normal Uterus	1.7
Colon cancer (OD06298-08)	1.6	Uterus Cancer	1.2
Colon cancer margin (OD06298-018)	0.3	Normal Thyroid	0.1
Colon Cancer Gr.2 ascend colon (ODO3921)	1.6	Thyroid Cancer	0.9
Colon Cancer margin (ODO3921)	4.6	Thyroid Cancer A302152	1.2
Colon cancer metastasis (OD06104)	2.1	Thyroid margin A302153	0.9
Lung margin (OD06104)	2.8	Normal Breast	12.4
Colon mets to lung	4.5	Breast Cancer	0.9

(OD04451-01)			
Lung margin (OD04451-02)	10.7	Breast Cancer	4.3
Normal Prostate	0.8	Breast Cancer (OD04590-01)	0.6
Prostate Cancer (OD04410)	0.7	Breast Cancer Mets (OD04590-03)	6.6
Prostate margin (OD04410)	13.6	Breast Cancer Metastasis	2.1
Normal Lung	34.2	Breast Cancer	3.3
Invasive poor diff. lung adeno 1 (ODO4945-01)	9.2	Breast Cancer 9100266	4.6
Lung margin (ODO4945-03)	6.2	Breast margin 9100265	1.5
Lung Malignant Cancer (OD03126)	11.1	Breast Cancer A209073	2.5
Lung margin (OD03126)	34.9	Breast margin A2090734	9.9
Lung Cancer (OD05014A)	25.2	Normal Liver	4.2
Lung margin (OD05014B)	5.6	Liver Cancer 1026	1.8
Lung Cancer (OD04237-01)	1.5	Liver Cancer 1025	6.1
Lung margin (OD04237-02)	63.3	Liver Cancer 6004-T	3.5
Ocular Mel Met to Liver (ODO4310)	24.3	Liver Tissue 6004-N	0.8
Liver margin (ODO4310)	7.6	Liver Cancer 6005-T	14.2
Melanoma Mets to Lung (OD04321)	100.0	Liver Tissue 6005-N	14.8
Lung margin (OD04321)	20.2	Liver Cancer	1.4
Normal Kidney	3.6	Normal Bladder	1.7
Kidney Ca, Nuclear grade 2 (OD04338)	6.9	Bladder Cancer	1.8
Kidney margin (OD04338)	2.1	Bladder Cancer	2.4
Kidney Ca Nuclear grade 1/2 (OD04339)	1.1	Normal Ovary	7.7
Kidney margin (OD04339)	0.2	Ovarian Cancer	13.6
Kidney Ca, Clear cell type (OD04340)	8.8	Ovarian cancer (OD06145)	0.6
Kidney margin	4.5	Ovarian cancer	2.2

(OD04340)		margin (OD06145)	
Kidney Ca, Nuclear grade 3 (OD04348)	1.3	Normal Stomach	4.1
Kidney margin (OD04348)	1.8	Gastric Cancer 9060397	1.2
Kidney Cancer (OD04450-01)	0.6	Stomach margin 9060396	0.5
Kidney margin (OD04450-03)	4.6	Gastric Cancer 9060395	7.4
Kidney Cancer 8120613	0.3	Stomach margin 9060394	2.6
Kidney margin 8120614	0.5	Gastric Cancer 064005	4.3

Table VQ. Panel 4.1D

Tissue Name	Rel. Exp.(%) Ag3899, Run 170120166	Rel. Exp.(%) Ag3960, Run 170739794	Rel. Exp.(%) Ag4338, Run 184798156	Rel. Exp.(%) Ag772, Run 170188028
Secondary Th1 act	0.0	0.0	0.0	0.0
Secondary Th2 act	0.0	0.0	0.0	0.0
Secondary Tr1 act	0.0	0.0	0.0	0.0
Secondary Th1 rest	0.0	0.0	0.0	0.0
Secondary Th2 rest	0.0	0.0	0.6	0.9
Secondary Tr1 rest	0.0	0.0	0.0	0.0
Primary Th1 act	0.0	0.0	0.0	0.0
Primary Th2 act	0.0	0.0	0.0	0.0
Primary Tr1 act	0.0	0.0	0.0	0.0
Primary Th1 rest	0.0	0.0	0.0	0.0
Primary Th2 rest	0.0	0.0	0.0	0.0
Primary Tr1 rest	0.0	0.4	0.6	0.0
CD45RA CD4 lymphocyte act	0.3	2.2	2.4	2.5
CD45RO CD4 lymphocyte act	0.0	0.0	0.0	0.0
CD8 lymphocyte act	0.0	0.0	0.0	0.0
Secondary CD8 lymphocyte rest	0.0	0.0	0.0	0.0
Secondary CD8 lymphocyte act	0.0	0.0	0.0	0.0
CD4 lymphocyte none	0.0	0.4	0.0	0.0
2ry Th1/Th2/Tr1_anti-CD95 CH11	0.0	0.0	1.1	0.0
LAK cells rest	0.0	0.0	0.0	0.0

LAK cells IL-2	0.0	0.0	0.0	0.0
LAK cells IL-2+IL-12	0.0	0.4	0.0	0.0
LAK cells IL-2+IFN gamma	0.0	0.0	0.0	0.0
LAK cells IL-2+ IL-18	0.0	0.0	0.0	0.0
LAK cells PMA/ionomycin	0.0	0.0	0.0	0.0
NK Cells IL-2 rest	0.0	0.0	0.0	0.0
Two Way MLR 3 day	0.0	0.0	0.0	0.0
Two Way MLR 5 day	0.0	0.0	0.0	0.0
Two Way MLR 7 day	0.0	0.0	0.0	0.0
PBMC rest	0.0	0.0	0.0	0.0
PBMC PWM	0.0	0.0	1.9	0.0
PBMC PHA-L	0.0	0.0	0.0	0.0
Ramos (B cell) none	0.0	0.0	0.0	85.3
Ramos (B cell) ionomycin	0.0	0.0	0.0	100.0
B lymphocytes PWM	0.0	0.0	0.7	0.0
B lymphocytes CD40L and IL-4	0.0	0.0	0.9	0.0
EOL-1 dbcAMP	0.0	0.0	0.0	0.0
EOL-1 dbcAMP PMA/ionomycin	0.0	0.0	0.0	0.0
Dendritic cells none	0.0	0.0	0.0	0.0
Dendritic cells LPS	0.0	0.0	0.0	0.0
Dendritic cells anti-CD40	0.0	0.0	0.0	0.0
Monocytes rest	0.0	0.0	0.0	0.0
Monocytes LPS	0.0	0.0	0.0	0.0
Macrophages rest	0.0	0.0	0.0	0.0
Macrophages LPS	0.0	0.0	0.0	0.0
HUVEC none	3.2	7.8	10.5	4.5
HUVEC starved	8.1	15.4	14.6	16.5
HUVEC IL-1beta	4.1	3.9	7.4	6.3
HUVEC IFN gamma	15.8	22.8	22.4	16.4
HUVEC TNF alpha + IFN gamma	1.0	8.0	8.8	6.0
HUVEC TNF alpha + IL4	2.9	4.7	8.0	5.9
HUVEC IL-11	4.2	10.2	10.4	13.4
Lung Microvascular EC none	1.5	8.1	8.4	4.6
Lung Microvascular EC	0.0	2.7	3.3	0.0

TNFalpha + IL-1beta				
Microvascular Dermal EC none	0.0	1.0	1.6	2.0
Microvascular Dermal EC TNFalpha + IL- 1beta	0.0	0.0	1.5	0.0
Bronchial epithelium TNFalpha + IL1beta	0.4	7.7	5.0	3.6
Small airway epithelium none	0.0	0.0	0.6	0.0
Small airway epithelium TNFalpha + IL-1beta	0.0	0.5	0.0	0.0
Coronary artery SMC rest	8.5	12.7	8.2	14.0
Coronary artery SMC TNFalpha + IL-1beta	1.8	10.6	9.8	19.5
Astrocytes rest	0.0	0.5	0.8	0.0
Astrocytes TNFalpha + IL-1beta	0.5	1.3	2.3	1.0
KU-812 (Basophil) rest	1.0	3.1	3.4	6.3
KU-812 (Basophil) PMA/ionomycin	8.0	27.9	28.9	30.8
CCD1106 (Keratinocytes) none	0.0	1.6	4.0	1.0
CCD1106 (Keratinocytes) TNFalpha + IL-1beta	0.0	1.1	2.0	1.3
Liver cirrhosis	7.6	18.6	14.2	17.1
NCI-H292 none	0.0	0.0	0.0	0.0
NCI-H292 IL-4	0.0	0.0	0.0	0.0
NCI-H292 IL-9	0.0	0.0	0.0	0.0
NCI-H292 IL-13	0.0	0.5	0.5	0.0
NCI-H292 IFN gamma	0.0	0.0	0.0	0.0
HPAEC none	17.9	21.8	13.2	13.9
HPAEC TNF alpha + IL-1 beta	11.3	14.6	13.4	6.3
Lung fibroblast none	3.4	3.3	5.8	5.2
Lung fibroblast TNF alpha + IL-1 beta	2.7	2.0	5.3	6.7
Lung fibroblast IL-4	4.4	1.8	7.1	9.3
Lung fibroblast IL-9	2.2	3.6	5.2	5.6
Lung fibroblast IL-13	3.9	6.4	6.4	7.7
Lung fibroblast IFN	7.2	6.5	7.8	14.2

gamma				
Dermal fibroblast CCD1070 rest	5.5	11.4	9.3	13.8
Dermal fibroblast CCD1070 TNF alpha	1.9	8.4	9.5	5.9
Dermal fibroblast CCD1070 IL-1 beta	1.5	6.7	6.8	4.1
Dermal fibroblast IFN gamma	29.5	41.8	17.7	27.5
Dermal fibroblast IL-4	75.8	69.3	51.8	68.8
Dermal Fibroblasts rest	21.5	36.9	29.5	22.1
Neutrophils TNFa+LPS	0.0	2.2	0.0	1.6
Neutrophils rest	0.0	6.6	0.4	0.0
Colon	2.0	5.6	2.3	7.1
Lung	100.0	100.0	100.0	79.6
Thymus	0.5	4.4	4.5	4.2
Kidney	3.4	8.4	8.8	9.6

Table VR. Panel 4D

Tissue Name	Rel. Exp.(%) Ag3108, Run 164529436	Tissue Name	Rel. Exp.(%) Ag3108, Run 164529436
Secondary Th1 act	0.0	HUVEC IL-1beta	3.1
Secondary Th2 act	0.0	HUVEC IFN gamma	7.9
Secondary Tr1 act	0.0	HUVEC TNF alpha + IFN gamma	3.5
Secondary Th1 rest	0.0	HUVEC TNF alpha + IL4	7.1
Secondary Th2 rest	0.2	HUVEC IL-11	4.6
Secondary Tr1 rest	0.3	Lung Microvascular EC none	2.3
Primary Th1 act	0.0	Lung Microvascular EC TNFalpha + IL-1beta	0.3
Primary Th2 act	0.0	Microvascular Dermal EC none	1.2
Primary Tr1 act	0.0	Microvascular Dermal EC TNFalpha + IL-1beta	0.6
Primary Th1 rest	0.0	Bronchial epithelium TNFalpha + IL1beta	3.2
Primary Th2 rest	0.3	Small airway epithelium none	0.2
Primary Tr1 rest	0.0	Small airway epithelium	0.3

		TNFalpha + IL-1beta	
CD45RA CD4 lymphocyte act	1.5	Coronary artery SMC rest	11.7
CD45RO CD4 lymphocyte act	0.0	Coronary artery SMC TNFalpha + IL-1beta	3.6
CD8 lymphocyte act	0.0	Astrocytes rest	0.2
Secondary CD8 lymphocyte rest	0.0	Astrocytes TNFalpha + IL-1beta	3.7
Secondary CD8 lymphocyte act	0.0	KU-812 (Basophil) rest	0.6
CD4 lymphocyte none	0.0	KU-812 (Basophil) PMA/ionomycin	25.7
2ry Th1/Th2/Tr1_anti-CD95 CH11	0.0	CCD1106 (Keratinocytes) none	0.6
LAK cells rest	0.1	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	0.4
LAK cells IL-2	0.3	Liver cirrhosis	12.2
LAK cells IL-2+IL-12	0.0	Lupus kidney	0.2
LAK cells IL-2+IFN gamma	0.0	NCI-H292 none	0.3
LAK cells IL-2+ IL-18	0.0	NCI-H292 IL-4	0.0
LAK cells PMA/ionomycin	0.0	NCI-H292 IL-9	0.0
NK Cells IL-2 rest	0.0	NCI-H292 IL-13	0.0
Two Way MLR 3 day	0.2	NCI-H292 IFN gamma	0.0
Two Way MLR 5 day	0.0	HPAEC none	11.2
Two Way MLR 7 day	0.0	HPAEC TNF alpha + IL-1 beta	6.3
PBMC rest	0.0	Lung fibroblast none	1.1
PBMC PWM	0.9	Lung fibroblast TNF alpha + IL-1 beta	3.0
PBMC PHA-L	0.0	Lung fibroblast IL-4	4.2
Ramos (B cell) none	0.0	Lung fibroblast IL-9	3.5
Ramos (B cell) ionomycin	0.0	Lung fibroblast IL-13	5.0
B lymphocytes PWM	0.5	Lung fibroblast IFN gamma	6.9
B lymphocytes CD40L and IL-4	0.0	Dermal fibroblast CCD1070 rest	9.0
EOL-1 dbcAMP	0.0	Dermal fibroblast CCD1070 TNF alpha	10.9
EOL-1 dbcAMP PMA/ionomycin	0.0	Dermal fibroblast CCD1070 IL-1 beta	3.6
Dendritic cells none	0.0	Dermal fibroblast IFN	22.8

		gamma	
Dendritic cells LPS	0.0	Dermal fibroblast IL-4	34.2
Dendritic cells anti-CD40	0.0	IBD Colitis 2	0.2
Monocytes rest	0.0	IBD Crohn's	3.2
Monocytes LPS	0.0	Colon	13.0
Macrophages rest	0.0	Lung	100.0
Macrophages LPS	0.0	Thymus	16.2
HUVEC none	6.0	Kidney	3.7
HUVEC starved	19.3		

**CNS\_neurodegeneration\_v1.0 Summary:** Ag3899/Ag3960/Ag4338/Ag772 Expression of the CG94013-01 gene is low/undetectable (CTs > 34) across all of the samples on this panel.

**General\_screening\_panel\_v1.4 Summary:** Ag3899/Ag3960/Ag4338 Results of three experiments with two different primer and probe sets are in excellent agreement, with highest expression of the CG94013-01 gene in CNS cancer (astro) SNB-75 cell line (CTs=23-26). In addition, high expression of this gene is seen in CNS cancer cell lines, colon cancer tissue, renal cancer cell line UO-31, breast cancer and melanoma cell lines. Therefore, expression of this gene can be used to distinguish these samples from other samples in the panel and also as marker for detection of these cancers. In addition, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, protein therapeutics or antibodies, might be beneficial in the treatment of these cancers.

Among tissues with metabolic or endocrine function, this gene is expressed at low to moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

Interestingly, this gene is expressed at much higher levels in fetal liver (CTs=31-32) and lung (CTs=28) when compared to corresponding adult tissue(CTs=33-35). This observation suggests that expression of this gene can be used to distinguish these fetal tissues from corresponding adult tissues.

**Panel 1 Summary:** Ag343 Highest expression of the CG94013-01 gene is detected in breast cancer MDA-N cell line (CTs=26). In addition high expression of this gene is also observed



in melanoma, astrocytoma, and lung cancer cell lines. Please see panel 1.4 for the utility of this gene.

**Panel 1.2 Summary:** Ag771/Ag772 Two experiments produce results that are in excellent agreement, with highest expression of this gene in a melanoma cell line (CTs=25). High levels of expression are also seen in clusters of samples from melanoma, breast and brain cancer cell lines. Thus, expression of this gene could be used to differentiate between the melanoma sample and other samples on this panel and as a marker to detect the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of melanoma, breast and brain cancers. Data from a third experiment with Ag772 are not included. The results suggest that there were experimental difficulties with this run.

**Panel 1.3D Summary:** Ag3108 Highest expression of the CG94013-01 gene is detected in melanoma (met) Hs688(B).T cell line (CT=27). In addition, expression of this gene is also seen in melanoma, breast cancer, lung cancer, astrocytoma cell lines and colon cancer well to moderately differentiated (ODO3866) tissue. Please see panel 1.4 for the utility of this gene.

**Panel 2.1 Summary:** Ag3108 Highest expression of the CG94013-01 gene is detected in melanoma metastasis sample (CT=29). In addition, expression of this gene is higher in metastasis breast cancer (OD04590-03) (CT=33) as compared to breast cancer (OD04590-01) (CT=36.7). Thus, expression of this gene can be used to distinguish these two samples from each other and also as marker for cancer metastasis. Please see panel 1.4 for further utility of this gene.

**Panel 4.1D Summary:** Ag3899/Ag3960/Ag4338 Results of three experiments with two different primer and probe sets are in excellent agreement, with highest expression of the CG94013-01 gene in lung (CT=30-31). In addition, significant expression of this gene is seen in HUVEC cells, lung fibroblast and dermal fibroblasts. Therefore, antibody or small molecule therapies designed with the protein encoded for by this gene could be important in the treatment of inflammatory lung disorders such as chronic obstructive pulmonary disease, asthma, allergy and emphysema and skin disorders including psoriasis.

In addition, low expression of this gene is also seen in kidney. Therefore, antibody or small molecule therapies designed with the protein encoded for by this gene could modulate kidney

function and be important in the treatment of inflammatory or autoimmune diseases that affect the kidney, including lupus and glomerulonephritis.

Results from one experiment with probe and primer set Ag772 are not included. The amp plot suggests that there were experimental difficulties with this run.

- 5 **Panel 4D Summary:** Ag3108 Highest expression of the CG94013-01 gene in lung (CT=28.6). In addition, significant expression of this gene is seen in HPAEC cells, HUVEC cells, lung fibroblast, TNFalpha + IL1beta treated bronchial epithelium and dermal fibroblasts. Therefore, antibody or small molecule therapies designed with the protein encoded for by this gene could be important in the treatment of inflammatory lung disorders  
10 such as chronic obstructive pulmonary disease, asthma, allergy and emphysema and skin disorders including psoriasis.

- In addition, low expression of this gene is also seen in kidney and colon. Therefore, antibody or small molecule therapies designed with the protein encoded for by this gene be important in the treatment of inflammatory or autoimmune diseases that affect the kidney, including  
15 lupus and glomerulonephritis, as well as, inflammatory bowel diseases such as Crohns.

- Interestingly, expression of this gene is stimulated in PMA/ionomycin treated basophils (CT=30) as compared to resting basophils (CT=36). Basophils release histamines and other biological modifiers in reponse to allergens and play an important role in the pathology of asthma and hypersensitivity reactions. Therefore, therapeutics designed against the putative  
20 protein encoded by this gene may reduce or inhibit inflammation by blocking basophil function in these diseases. In addition, these cells are a reasonable model for the inflammatory cells that take part in various inflammatory lung and bowel diseases, such as asthma, Crohn's disease, and ulcerative colitis. Therefore, therapeutics that modulate the function of this gene product may reduce or eliminate the symptoms of patients suffering  
25 from asthma, Crohn's disease, and ulcerative colitis.

Ag1924 Results from one experiment with the CG94013-01 gene are not included. The amp plot indicates that there were experimental difficulties with this run.

**W. NOV26a (CG93871-01: Fibullin)**

Expression of gene CG93871-01 was assessed using the primer-probe sets Ag1294b, Ag746 and Ag905, described in Tables WA, WB and WC. Results of the RTQ-PCR runs are shown in Tables WD, WE, WF, WG, WH and WI.

Table WA. Probe Name Ag1294b

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-cattggcagctacaagtgttc-3'	21	688	242
Probe	TET-5'-ctgtcgaactggcttccaccttcacat-3'-TAMRA	25	709	243
Reverse	5'-cctccgacactcgtttacatc-3'	21	755	244

5 Table WB. Probe Name Ag746

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-gcattggcagctacaagtgt-3'	20	687	245
Probe	TET-5'-ctgtcgaactggcttccaccttcacat-3'-TAMRA	25	709	246
Reverse	5'-cctccgacactcgtttacatc-3'	21	755	247

Table WC. Probe Name Ag905

Primers	Sequences	Length	Start Position	SEQ ID No:
Forward	5'-cattggcagctacaagtgttc-3'	21	688	248
Probe	TET-5'-ctgtcgaactggcttccaccttcacat-3'-TAMRA	25	709	249
Reverse	5'-cctccgacactcgtttacatc-3'	21	755	250

Table WD. AI\_comprehensive panel\_v1.0

Tissue Name	Rel. Exp.(%) Ag1294b, Run 249007981	Tissue Name	Rel. Exp.(%) Ag1294b, Run 249007981
110967 COPD-F	6.6	112427 Match Control Psoriasis-F	30.8
110980 COPD-F	16.6	112418 Psoriasis-M	4.6
110968 COPD-M	3.9	112723 Match Control Psoriasis-M	23.8

110977 COPD-M	31.6	112419 Psoriasis-M	2.7
110989 Emphysema-F	45.1	112424 Match Control Psoriasis-M	1.9
110992 Emphysema-F	7.2	112420 Psoriasis-M	4.9
110993 Emphysema-F	5.8	112425 Match Control Psoriasis-M	25.9
110994 Emphysema-F	3.3	104689 (MF) OA Bone-Backus	12.9
110995 Emphysema-F	2.0	104690 (MF) Adj "Normal" Bone-Backus	3.7
110996 Emphysema-F	3.1	104691 (MF) OA Synovium-Backus	6.9
110997 Asthma-M	3.7	104692 (BA) OA Cartilage-Backus	21.3
111001 Asthma-F	2.8	104694 (BA) OA Bone-Backus	6.6
111002 Asthma-F	5.3	104695 (BA) Adj "Normal" Bone-Backus	2.3
111003 Atopic Asthma-F	6.1	104696 (BA) OA Synovium-Backus	5.7
111004 Atopic Asthma-F	3.4	104700 (SS) OA Bone-Backus	6.2
111005 Atopic Asthma-F	3.9	104701 (SS) Adj "Normal" Bone-Backus	3.8
111006 Atopic Asthma-F	2.4	104702 (SS) OA Synovium-Backus	15.4
111417 Allergy-M	6.6	117093 OA Cartilage Rep7	18.0
112347 Allergy-M	3.3	112672 OA Bone5	90.1
112349 Normal Lung-F	3.2	112673 OA Synovium5	63.7
112357 Normal Lung-F	100.0	112674 OA Synovial Fluid cells5	32.3
112354 Normal Lung-M	58.6	117100 OA Cartilage Rep14	3.3
112374 Crohns-F	7.5	112756 OA Bone9	7.0
112389 Match Control Crohns-F	3.5	112757 OA Synovium9	12.2
112375 Crohns-F	5.1	112758 OA Synovial Fluid Cells9	3.9
112732 Match	0.5	117125 RA Cartilage	4.6

Control Crohns-F		Rep2	
112725 Crohns-M	10.6	113492 Bone2 RA	2.4
112387 Match Control Crohns-M	3.5	113493 Synovium2 RA	1.1
112378 Crohns-M	1.7	113494 Syn Fluid Cells RA	1.4
112390 Match Control Crohns-M	55.5	113499 Cartilage4 RA	1.4
112726 Crohns-M	3.6	113500 Bone4 RA	0.5
112731 Match Control Crohns-M	13.9	113501 Synovium4 RA	1.7
112380 Ulcer Col-F	13.7	113502 Syn Fluid Cells4 RA	1.8
112734 Match Control Ulcer Col-F	5.6	113495 Cartilage3 RA	1.6
112384 Ulcer Col-F	3.9	113496 Bone3 RA	1.1
112737 Match Control Ulcer Col-F	3.3	113497 Synovium3 RA	0.0
112386 Ulcer Col-F	0.0	113498 Syn Fluid Cells3 RA	0.6
112738 Match Control Ulcer Col-F	0.0	117106 Normal Cartilage Rep20	4.5
112381 Ulcer Col-M	4.2	113663 Bone3 Normal	6.7
112735 Match Control Ulcer Col-M	18.2	113664 Synovium3 Normal	1.2
112382 Ulcer Col-M	4.2	113665 Syn Fluid Cells3 Normal	0.9
112394 Match Control Ulcer Col-M	0.0	117107 Normal Cartilage Rep22	1.3
112383 Ulcer Col-M	12.2	113667 Bone4 Normal	11.8
112736 Match Control Ulcer Col-M	2.0	113668 Synovium4 Normal	12.0
112423 Psoriasis-F	3.9	113669 Syn Fluid Cells4 Normal	10.7

Table WE. CNS\_neurodegeneration\_v1.0

Tissue Name	Rel. Exp.(%) Ag1294b, Run 206231468	Tissue Name	Rel. Exp.(%) Ag1294b, Run 206231468
AD 1 Hippo	11.2	Control (Path) 3 Temporal Ctx	1.5
AD 2 Hippo	22.5	Control (Path) 4 Temporal Ctx	19.2
AD 3 Hippo	4.7	AD 1 Occipital Ctx	15.8

AD 4 Hippo	8.7	AD 2 Occipital Ctx (Missing)	0.0
AD 5 hippo	37.6	AD 3 Occipital Ctx	1.2
AD 6 Hippo	100.0	AD 4 Occipital Ctx	17.8
Control 2 Hippo	28.7	AD 5 Occipital Ctx	8.7
Control 4 Hippo	30.4	AD 6 Occipital Ctx	12.3
Control (Path) 3 Hippo	6.9	Control 1 Occipital Ctx	0.0
AD 1 Temporal Ctx	16.3	Control 2 Occipital Ctx	27.4
AD 2 Temporal Ctx	31.6	Control 3 Occipital Ctx	5.4
AD 3 Temporal Ctx	3.8	Control 4 Occipital Ctx	6.7
AD 4 Temporal Ctx	10.9	Control (Path) 1 Occipital Ctx	56.3
AD 5 Inf Temporal Ctx	34.6	Control (Path) 2 Occipital Ctx	10.4
AD 5 Sup Temporal Ctx	19.6	Control (Path) 3 Occipital Ctx	1.2
AD 6 Inf Temporal Ctx	73.7	Control (Path) 4 Occipital Ctx	6.3
AD 6 Sup Temporal Ctx	81.2	Control 1 Parietal Ctx	6.4
Control 1 Temporal Ctx	1.2	Control 2 Parietal Ctx	39.5
Control 2 Temporal Ctx	15.5	Control 3 Parietal Ctx	4.4
Control 3 Temporal Ctx	5.9	Control (Path) 1 Parietal Ctx	17.6
Control 4 Temporal Ctx	7.9	Control (Path) 2 Parietal Ctx	17.6
Control (Path) 1 Temporal Ctx	41.8	Control (Path) 3 Parietal Ctx	0.0
Control (Path) 2 Temporal Ctx	26.2	Control (Path) 4 Parietal Ctx	26.4

Table WF. Panel 1.2

Tissue Name	Rel. Exp.(%) Ag746, Run 115163442	Rel. Exp.(%) Ag746, Run 119442272	Tissue Name	Rel. Exp.(%) Ag746, Run 115163442	Rel. Exp.(%) Ag746, Run 119442272
Endothelial cells	12.3	5.9	Renal ca. 786-0	0.0	0.0
Heart (Fetal)	0.0	0.0	Renal ca. A498	0.0	0.0

Pancreas	0.0	0.0	Renal ca. RXF 393	0.0	0.0
Pancreatic ca. CAPAN 2	0.0	0.0	Renal ca. ACHN	0.0	0.0
Adrenal Gland	0.0	0.2	Renal ca. UO-31	0.0	0.0
Thyroid	0.1	0.0	Renal ca. TK-10	0.0	0.0
Salivary gland	0.0	0.0	Liver	32.8	53.2
Pituitary gland	0.2	0.1	Liver (fetal)	72.7	100.0
Brain (fetal)	2.4	16.0	Liver ca. (hepatoblast) HepG2	100.0	94.0
Brain (whole)	0.0	0.3	Lung	0.0	0.0
Brain (amygdala)	0.0	0.0	Lung (fetal)	0.0	0.0
Brain (cerebellum)	0.0	0.0	Lung ca. (small cell) LX-1	0.0	0.0
Brain (hippocampus)	0.0	0.0	Lung ca. (small cell) NCI-H69	0.0	0.0
Brain (thalamus)	0.0	0.0	Lung ca. (s.cell var.) SHP-77	0.0	0.0
Cerebral Cortex	0.0	0.0	Lung ca. (large cell) NCI-H460	0.0	0.0
Spinal cord	0.0	0.0	Lung ca. (non-sm. cell) A549	0.0	0.0
glio/astro U87-MG	0.0	0.0	Lung ca. (non-s.cell) NCI-H23	0.0	0.0
glio/astro U-118-MG	0.0	0.0	Lung ca. (non-s.cell) HOP-62	0.0	0.0
astrocytoma SW1783	0.0	0.0	Lung ca. (non-s.cl) NCI-H522	63.7	90.1
neuro*; met SK-N-AS	0.0	0.2	Lung ca. (squam.) SW 900	0.0	0.0
astrocytoma SF-539	0.0	0.0	Lung ca. (squam.) NCI-H596	0.0	0.0
astrocytoma SNB-75	0.0	0.0	Mammary gland	0.7	3.6
glioma SNB-19	0.0	0.0	Breast ca.*	0.0	0.0

			(pl.ef) MCF-7		
glioma U251	0.0	0.0	Breast ca.* (pl.ef) MDA-MB-231	0.0	0.0
glioma SF-295	0.0	0.0	Breast ca.* (pl.ef) T47D	0.0	0.0
Heart	0.0	0.0	Breast ca. BT-549	0.0	0.0
Skeletal Muscle	0.0	0.0	Breast ca. MDA-N	0.0	0.0
Bone marrow	0.0	0.0	Ovary	0.5	11.7
Thymus	1.2	2.8	Ovarian ca. OVCAR-3	0.0	0.0
Spleen	0.0	0.0	Ovarian ca. OVCAR-4	0.0	0.0
Lymph node	0.0	0.0	Ovarian ca. OVCAR-5	0.0	0.0
Colorectal Tissue	0.0	0.0	Ovarian ca. OVCAR-8	0.0	0.0
Stomach	0.0	0.0	Ovarian ca. IGROV-1	0.0	0.0
Small intestine	0.0	0.0	Ovarian ca. (ascites) SK-OV-3	0.0	0.0
Colon ca. SW480	0.0	0.0	Uterus	0.0	0.0
Colon ca.* SW620 (SW480 met)	1.1	1.9	Placenta	34.4	39.5
Colon ca. HT29	0.0	0.0	Prostate	0.0	0.0
Colon ca. HCT-116	0.0	0.0	Prostate ca.* (bone met) PC-3	0.0	0.0
Colon ca. CaCo-2	46.3	56.6	Testis	1.0	3.5
Colon ca. Tissue (ODO3866)	0.0	0.0	Melanoma Hs688(A).T	0.0	0.0
Colon ca. HCC-2998	0.0	0.0	Melanoma* (met) Hs688(B).T	0.0	0.0
Gastric ca.* (liver met) NCI-N87	0.0	0.0	Melanoma UACC-62	0.0	0.0
Bladder	0.0	0.0	Melanoma M14	0.0	0.0



Trachea	0.0	0.0	Melanoma LOX IMVI	0.0	0.0
Kidney	0.0	0.0	Melanoma* (met) SK- MEL-5	0.0	0.0
Kidney (fetal)	0.1	0.9			

Table WG. Panel 2D

Tissue Name	Rel. Exp.(%) Ag746, Run 147127131	Rel. Exp.(%) Ag746, Run 148019631	Tissue Name	Rel. Exp.(%) Ag746, Run 147127131	Rel. Exp.(%) Ag746, Run 148019631
Normal Colon	18.3	21.8	Kidney Margin 8120608	6.5	6.4
CC Well to Mod Diff (ODO3866)	16.5	23.7	Kidney Cancer 8120613	2.2	0.7
CC Margin (ODO3866)	3.1	0.0	Kidney Margin 8120614	6.3	3.0
CC Gr.2 rectosigmoid (ODO3868)	0.0	0.8	Kidney Cancer 9010320	10.9	16.5
CC Margin (ODO3868)	0.5	2.0	Kidney Margin 9010321	9.0	11.3
CC Mod Diff (ODO3920)	1.2	2.3	Normal Uterus	4.3	6.3
CC Margin (ODO3920)	1.3	2.6	Uterus Cancer 064011	13.4	17.7
CC Gr.2 ascend colon (ODO3921)	3.4	4.4	Normal Thyroid	9.1	14.9
CC Margin (ODO3921)	1.3	0.0	Thyroid Cancer 064010	6.4	5.9
CC from Partial Hepatectomy (ODO4309) Mets	8.4	1.9	Thyroid Cancer A302152	4.4	5.1
Liver Margin (ODO4309)	49.7	41.5	Thyroid Margin A302153	12.0	22.1
Colon mets to lung (OD04451- 01)	0.3	5.3	Normal Breast	9.9	14.3

Lung Margin (OD04451-02)	0.0	1.8	Breast Cancer (OD04566)	0.4	0.2
Normal Prostate 6546-1	9.1	12.1	Breast Cancer (OD04590-01)	5.3	3.9
Prostate Cancer (OD04410)	2.0	9.7	Breast Cancer Mets (OD04590-03)	4.0	10.4
Prostate Margin (OD04410)	16.8	20.3	Breast Cancer Metastasis (OD04655-05)	7.2	4.4
Prostate Cancer (OD04720-01)	13.5	14.4	Breast Cancer 064006	5.2	3.3
Prostate Margin (OD04720-02)	14.0	22.4	Breast Cancer 1024	12.1	18.6
Normal Lung 061010	6.8	11.7	Breast Cancer 9100266	2.7	5.3
Lung Met to Muscle (ODO4286)	1.8	0.7	Breast Margin 9100265	5.0	5.8
Muscle Margin (ODO4286)	11.5	13.1	Breast Cancer A209073	0.5	1.8
Lung Malignant Cancer (OD03126)	1.5	6.0	Breast Margin A209073	1.7	0.4
Lung Margin (OD03126)	4.8	2.4	Normal Liver	39.5	47.0
Lung Cancer (OD04404)	4.2	2.3	Liver Cancer 064003	4.2	0.6
Lung Margin (OD04404)	9.0	10.4	Liver Cancer 1025	66.4	74.2
Lung Cancer (OD04565)	0.3	0.0	Liver Cancer 1026	36.1	42.6
Lung Margin (OD04565)	0.4	0.3	Liver Cancer 6004-T	100.0	100.0
Lung Cancer (OD04237-01)	10.7	11.1	Liver Tissue 6004-N	22.8	34.4
Lung Margin (OD04237-02)	4.9	5.4	Liver Cancer 6005-T	39.2	35.4
Ocular Mel Met to Liver (ODO4310)	10.5	11.9	Liver Tissue 6005-N	33.2	38.2
Liver Margin (ODO4310)	22.4	32.8	Normal Bladder	6.6	4.9
Melanoma Mets to Lung (OD04321)	0.0	0.0	Bladder Cancer 1023	1.0	4.8

Lung Margin (OD04321)	0.6	0.0	Bladder Cancer A302173	2.6	0.7
Normal Kidney	5.3	5.3	Bladder Cancer (OD04718-01)	0.0	0.7
Kidney Ca, Nuclear grade 2 (OD04338)	39.8	43.8	Bladder Normal Adjacent (OD04718-03)	3.5	14.4
Kidney Margin (OD04338)	4.8	6.4	Normal Ovary	50.7	47.3
Kidney Ca Nuclear grade 1/2 (OD04339)	3.0	0.3	Ovarian Cancer 064008	10.2	7.4
Kidney Margin (OD04339)	5.4	10.0	Ovarian Cancer (OD04768-07)	73.7	80.7
Kidney Ca, Clear cell type (OD04340)	18.2	19.2	Ovary Margin (OD04768-08)	2.6	0.8
Kidney Margin (OD04340)	9.0	10.4	Normal Stomach	2.9	2.9
Kidney Ca, Nuclear grade 3 (OD04348)	5.2	8.3	Gastric Cancer 9060358	0.0	1.1
Kidney Margin (OD04348)	6.9	4.7	Stomach Margin 9060359	2.4	0.3
Kidney Cancer (OD04622-01)	41.8	45.4	Gastric Cancer 9060395	0.5	1.1
Kidney Margin (OD04622-03)	1.9	1.4	Stomach Margin 9060394	5.2	2.0
Kidney Cancer (OD04450-01)	9.2	6.2	Gastric Cancer 9060397	3.4	7.0
Kidney Margin (OD04450-03)	10.2	9.0	Stomach Margin 9060396	1.4	0.0
Kidney Cancer 8120607	2.2	1.7	Gastric Cancer 064005	1.3	6.0

Table WH. Panel 4.1D

Tissue Name	Rel. Exp.(%) Ag1294b, Run	Tissue Name	Rel. Exp.(%) Ag1294b, Run
-------------	------------------------------	-------------	------------------------------

	200065765		200065765
Secondary Th1 act	15.3	HUVEC IL-1beta	5.6
Secondary Th2 act	7.2	HUVEC IFN gamma	21.9
Secondary Tr1 act	5.5	HUVEC TNF alpha + IFN gamma	3.5
Secondary Th1 rest	6.7	HUVEC TNF alpha + IL4	31.2
Secondary Th2 rest	1.0	HUVEC IL-11	17.7
Secondary Tr1 rest	1.3	Lung Microvascular EC none	65.1
Primary Th1 act	26.6	Lung Microvascular EC TNFalpha + IL-1beta	34.4
Primary Th2 act	34.2	Microvascular Dermal EC none	42.3
Primary Tr1 act	40.3	Microvascular Dermal EC TNFalpha + IL-1beta	16.7
Primary Th1 rest	0.3	Bronchial epithelium TNFalpha + IL1beta	2.4
Primary Th2 rest	0.5	Small airway epithelium none	1.7
Primary Tr1 rest	0.0	Small airway epithelium TNFalpha + IL-1beta	2.5
CD45RA CD4 lymphocyte act	7.7	Coronary artery SMC rest	9.0
CD45RO CD4 lymphocyte act	10.9	Coronary artery SMC TNFalpha + IL-1beta	5.2
CD8 lymphocyte act	11.0	Astrocytes rest	2.1
Secondary CD8 lymphocyte rest	11.8	Astrocytes TNFalpha + IL-1beta	2.2
Secondary CD8 lymphocyte act	4.7	KU-812 (Basophil) rest	10.2
CD4 lymphocyte none	0.0	KU-812 (Basophil) PMA/ionomycin	11.1
2ry Th1/Th2/Tr1_anti-CD95 CH11	1.7	CCD1106 (Keratinocytes) none	0.0
LAK cells rest	0.0	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	0.6
LAK cells IL-2	3.1	Liver cirrhosis	6.8
LAK cells IL-2+IL-12	2.9	NCI-H292 none	21.3
LAK cells IL-2+IFN gamma	0.5	NCI-H292 IL-4	11.5
LAK cells IL-2+ IL-18	0.5	NCI-H292 IL-9	13.8
LAK cells PMA/ionomycin	1.0	NCI-H292 IL-13	19.9
NK Cells IL-2 rest	1.4	NCI-H292 IFN gamma	7.3

Two Way MLR 3 day	3.1	HPAEC none	20.4
Two Way MLR 5 day	5.0	HPAEC TNF alpha + IL-1 beta	21.5
Two Way MLR 7 day	4.7	Lung fibroblast none	23.5
PBMC rest	0.6	Lung fibroblast TNF alpha + IL-1 beta	8.8
PBMC PWM	11.5	Lung fibroblast IL-4	21.2
PBMC PHA-L	7.2	Lung fibroblast IL-9	16.8
Ramos (B cell) none	1.8	Lung fibroblast IL-13	33.2
Ramos (B cell) ionomycin	3.4	Lung fibroblast IFN gamma	19.1
B lymphocytes PWM	20.2	Dermal fibroblast CCD1070 rest	2.9
B lymphocytes CD40L and IL-4	12.2	Dermal fibroblast CCD1070 TNF alpha	0.0
EOL-1 dbcAMP	1.5	Dermal fibroblast CCD1070 IL-1 beta	1.5
EOL-1 dbcAMP PMA/ionomycin	1.1	Dermal fibroblast IFN gamma	45.1
Dendritic cells none	8.5	Dermal fibroblast IL-4	100.0
Dendritic cells LPS	6.4	Dermal Fibroblasts rest	53.6
Dendritic cells anti-CD40	8.7	Neutrophils TNFa+LPS	1.5
Monocytes rest	0.0	Neutrophils rest	10.2
Monocytes LPS	1.1	Colon	1.5
Macrophages rest	8.8	Lung	1.7
Macrophages LPS	0.0	Thymus	40.1
HUVEC none	10.1	Kidney	1.5
HUVEC starved	7.6		

Table WI. Panel 4D

Tissue Name	Rel. Exp.(%) Ag1294b, Run 138944262	Rel. Exp.(%) Ag1294b, Run 139408252	Tissue Name	Rel. Exp.(%) Ag1294b, Run 138944262	Rel. Exp.(%) Ag1294b, Run 139408252
Secondary Th1 act	10.9	7.7	HUVEC IL-1beta	4.1	1.7
Secondary Th2 act	6.4	8.0	HUVEC IFN gamma	21.0	13.7
Secondary Tr1 act	11.3	9.3	HUVEC TNF alpha + IFN gamma	2.8	0.6
Secondary Th1 rest	3.4	2.7	HUVEC TNF	30.8	25.7

			alpha + IL4		
Secondary Th2 rest	1.5	2.5	HUVEC IL-11	11.6	7.3
Secondary Tr1 rest	1.4	2.0	Lung Microvascular EC none	24.1	20.0
Primary Th1 act	48.0	46.0	Lung Microvascular EC TNFalpha + IL- 1beta	8.0	12.2
Primary Th2 act	38.7	27.7	Microvascular Dermal EC none	64.6	45.7
Primary Tr1 act	72.2	55.5	Microvascular Dermal EC TNFalpha + IL- 1beta	18.4	11.7
Primary Th1 rest	3.1	2.3	Bronchial epithelium TNFalpha + IL1beta	5.2	5.4
Primary Th2 rest	1.0	0.8	Small airway epithelium none	4.0	3.2
Primary Tr1 rest	1.1	0.5	Small airway epithelium TNFalpha + IL- 1beta	8.2	4.5
CD45RA CD4 lymphocyte act	2.9	1.8	Coronary artery SMC rest	5.8	6.3
CD45RO CD4 lymphocyte act	18.6	12.2	Coronary artery SMC TNFalpha + IL-1beta	4.5	5.1
CD8 lymphocyte act	17.8	6.8	Astrocytes rest	0.8	0.5
Secondary CD8 lymphocyte rest	6.8	6.0	Astrocytes TNFalpha + IL- 1beta	3.6	1.9
Secondary CD8 lymphocyte act	5.5	4.1	KU-812 (Basophil) rest	16.0	11.1
CD4 lymphocyte none	0.0	0.2	KU-812 (Basophil) PMA/ionomycin	12.3	9.5
2ry Th1/Th2/Tr1_anti- CD95 CH11	2.9	3.1	CCD1106 (Keratinocytes) none	0.0	0.5
LAK cells rest	1.4	0.3	CCD1106 (Keratinocytes) TNFalpha + IL-	0.7	0.4

			1 beta		
LAK cells IL-2	3.8	2.2	Liver cirrhosis	8.4	3.8
LAK cells IL-2+IL-12	3.0	0.8	Lupus kidney	2.0	3.2
LAK cells IL-2+IFN gamma	2.0	1.7	NCI-H292 none	21.9	25.7
LAK cells IL-2+IL-18	0.5	0.2	NCI-H292 IL-4	15.7	12.3
LAK cells PMA/ionomycin	0.7	1.3	NCI-H292 IL-9	20.6	14.7
NK Cells IL-2 rest	0.7	0.7	NCI-H292 IL-13	8.3	5.7
Two Way MLR 3 day	1.1	2.5	NCI-H292 IFN gamma	5.1	8.2
Two Way MLR 5 day	2.5	2.8	HPAEC none	18.7	23.8
Two Way MLR 7 day	4.5	5.0	HPAEC TNF alpha + IL-1 beta	11.9	12.9
PBMC rest	0.0	0.0	Lung fibroblast none	15.7	13.5
PBMC PWM	41.8	29.1	Lung fibroblast TNF alpha + IL-1 beta	6.9	4.7
PBMC PHA-L	34.4	21.8	Lung fibroblast IL-4	25.0	16.6
Ramos (B cell) none	4.7	2.4	Lung fibroblast IL-9	14.7	15.8
Ramos (B cell) ionomycin	9.2	5.8	Lung fibroblast IL-13	40.3	32.5
B lymphocytes PWM	51.8	51.4	Lung fibroblast IFN gamma	15.4	17.4
B lymphocytes CD40L and IL-4	10.2	12.3	Dermal fibroblast CCD1070 rest	0.5	0.9
EOL-1 dbcAMP	0.3	0.2	Dermal fibroblast CCD1070 TNF alpha	0.9	0.8
EOL-1 dbcAMP PMA/ionomycin	0.4	1.8	Dermal fibroblast CCD1070 IL-1 beta	0.6	0.6
Dendritic cells none	6.7	3.8	Dermal fibroblast IFN gamma	32.1	18.4
Dendritic cells LPS	4.7	3.1	Dermal fibroblast IL-4	100.0	100.0
Dendritic cells anti-CD40	6.0	5.6	IBD Colitis 2	0.0	0.0
Monocytes rest	0.0	0.0	IBD Crohn's	0.3	0.8

Monocytes LPS	0.7	0.8	Colon	1.4	0.5
Macrophages rest	19.8	9.9	Lung	0.5	0.8
Macrophages LPS	0.7	0.5	Thymus	2.9	4.3
HUVEC none	9.3	10.2	Kidney	65.5	47.3
HUVEC starved	19.2	13.1			

**AI\_comprehensive panel\_v1.0 Summary:** Ag1294b Expression of the CG93871-01 gene in this panel confirms expression of this gene in cells involved in the immune response. Highest expression of this gene is seen in normal lung (CT=30.5). Please see Panel 4D for discussion of utility of this gene in inflammation.

- 5 **CNS\_neurodegeneration\_v1.0 Summary:** Ag1294b This panel does not show differential expression of the CG56153-01 gene in Alzheimer's disease. However, this expression profile confirms the presence of this gene in the brain. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurologic disorders, such as Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, stroke and
- 10 epilepsy.

**Panel 1.2 Summary:** Ag746 Two experiments with the same probe and primer set produce results that are in excellent agreement, with highest expression of the CG93871-01 gene in a liver cancer cell line (CTs=27). High levels of expression are also seen in fetal and adult liver tissue, a colon cancer cell line and a lung cancer cell line. Thus, expression of this gene could

15 be used to differentiate liver derived samples, the colon cancer cell line and the lung cancer cell line from other samples on this panel. Expression of this gene could also be used as a diagnostic marker to detect the presence of colon and lung cancers.

Moderate expression is also seen in the fetal brain, placenta, and endothelial cells.

**Panel 2D Summary:** Ag746 Two experiments with the same probe and primer set produce

20 results that are in excellent agreement, with highest expression of the CG93871-01 gene in liver cancer (CTs=31). The prominent expression in liver derived tissue is consistent with the results in Panel 1.2. Moderate levels of expression are also evident in samples from ovarian cancer and kidney cancer. Furthermore, expression of this gene is higher in these cancers than in the normal adjacent tissue. Thus, expression of this gene could be used to differentiate

25 between liver derived samples and other samples on this panel and as a marker to detect the presence of liver, kidney, and ovarian cancer. Furthermore, therapeutic modulation of the



expression or function of this gene may be effective in the treatment of liver, kidney, and ovarian cancers.

**Panel 4.1D Summary:** Ag1294b Results from this experiment are in agreement with the expression profile in Panel 4D, with highest expression of the CG93871-01 gene in this experiment in IL-4 treated dermal fibroblasts (CT=29.9). In addition, this experiment shows low but significant levels of expression in resting neutrophils (CT=33.2), a sample absent in Panel 4D. Please see Panel 4D for discussion of utility of this gene in inflammation.

**Panel 4D Summary:** Ag1294b Two experiments with the same probe and primer set produce results that are in excellent agreement, with highest expression of the CG93871-01 gene in IL-4 treated dermal fibroblasts (CTs=30). In addition, this gene is expressed at moderate levels in IFN gamma stimulated dermal fibroblasts, activated lung fibroblasts, HPAECs, lung and dermal microvasculature, activated small airway and bronchial epithelium, activated NCI-H292 cells, acutely activated T cells, and activated B cells.

Based on these levels of expression in T cells, activated B cells and cells in lung and skin, therapeutics that block the function of this gene product may be useful as therapeutics that reduce or eliminate the symptoms in patients with autoimmune and inflammatory diseases in which activated B cells present antigens in the generation of the aberrant immune response and in treating T-cell mediated diseases, including Crohn's disease, ulcerative colitis, multiple sclerosis, chronic obstructive pulmonary disease, asthma, allergy, emphysema, rheumatoid arthritis, or psoriasis.

#### **Example D: Identification of Single Nucleotide Polymorphisms in NOVX nucleic acid sequences**

Variant sequences are also included in this application. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a "cSNP" to denote that the nucleotide sequence containing the SNP originates as a cDNA. A SNP can arise in several ways. For example, a SNP may be due to a substitution of one nucleotide for another at the polymorphic site. Such a substitution can be either a transition or a transversion. A SNP can also arise from a deletion of a nucleotide or an insertion of a nucleotide, relative to a reference allele. In this case, the polymorphic site is a site at which one allele bears a gap with respect to a particular nucleotide in another allele. SNPs occurring within genes may result in an alteration of the amino acid encoded by the

gene at the position of the SNP. Intragenic SNPs may also be silent, when a codon including a SNP encodes the same amino acid as a result of the redundancy of the genetic code. SNPs occurring outside the region of a gene, or in an intron within a gene, do not result in changes in any amino acid sequence of a protein but may result in altered regulation of the expression pattern. Examples include alteration in temporal expression, physiological response regulation, cell type expression regulation, intensity of expression, and stability of transcribed message.

SeqCalling assemblies produced by the exon linking process were selected and extended using the following criteria. Genomic clones having regions with 98% identity to all or part of the initial or extended sequence were identified by BLASTN searches using the relevant sequence to query human genomic databases. The genomic clones that resulted were selected for further analysis because this identity indicates that these clones contain the genomic locus for these SeqCalling assemblies. These sequences were analyzed for putative coding regions as well as for similarity to the known DNA and protein sequences. Programs used for these analyses include Grail, Genscan, BLAST, HMMER, FASTA, Hybrid and other relevant programs.

Some additional genomic regions may have also been identified because selected SeqCalling assemblies map to those regions. Such SeqCalling sequences may have overlapped with regions defined by homology or exon prediction. They may also be included because the location of the fragment was in the vicinity of genomic regions identified by similarity or exon prediction that had been included in the original predicted sequence. The sequence so identified was manually assembled and then may have been extended using one or more additional sequences taken from CuraGen Corporation's human SeqCalling database. SeqCalling fragments suitable for inclusion were identified by the CuraTools™ program SeqExtend or by identifying SeqCalling fragments mapping to the appropriate regions of the genomic clones analyzed.

The regions defined by the procedures described above were then manually integrated and corrected for apparent inconsistencies that may have arisen, for example, from miscalled bases in the original fragments or from discrepancies between predicted exon junctions, EST locations and regions of sequence similarity, to derive the final sequence disclosed herein. When necessary, the process to identify and analyze SeqCalling assemblies and genomic clones was reiterated to derive the full length sequence (Alderborn et al., Determination of Single Nucleotide Polymorphisms by Real-time Pyrophosphate DNA Sequencing. Genome Research. 10 (8) 1249-1265, 2000).

Variants are reported individually but any combination of all or a select subset of variants are also included as contemplated NOVX embodiments of the invention.

### RESULTS:

#### 5 **NOV2a SNP Data**

Two polymorphic variants of NOV2a have been identified and are shown in Table 28A.

Table 28A						
Variant No.	Nucleotides			Amino Acids		
	Base Position of SNP	Wild-type	Variant	Base Position of SNP	Wild-type	Variant
13374244	1115	G	A	363	Ser	Asn
13377677	1895	A	G	623	Lys	Arg

#### **NOV11a SNP Data**

10 Two polymorphic variants of NOV11a have been identified and are shown in Table 28B.

Table 28B						
Variant No.	Nucleotides			Amino Acids		
	Base Position of SNP	Wild-type	Variant	Base Position of SNP	Wild-type	Variant
13377547	564	T	C	188	Ile	Ile
13375667	779	G	A	260	Ser	Asn

#### 15 **NOV12a SNP Data**

Eleven polymorphic variants of NOV12a have been identified and are shown in Table 28C.

Table 28C						
-----------	--	--	--	--	--	--

Variant No.	Nucleotides			Amino Acids		
	Base Position of SNP	Wild-type	Variant	Base Position of SNP	Wild-type	Variant
13376026	1212	C	T	402	Thr	Ile
13376027	1459	C	T	484	Ala	Ala
13376028	1575	C	T	523	Pro	Leu
13376020	1699	C	T	564	Asn	Asn
13376021	1733	C	T	576	Gln	End
13376029	1826	C	T	607	His	Tyr
13376022	1859	A	C	618	Ser	Arg
13376019	1896	C	T	630	Ser	Phe
13376023	1984	C	T	659	Thr	Thr
13376024	2522	C	G	839	Pro	Ala
13376025	2865	G	A	953	Arg	Gln

**NOV17a SNP Data**

Eleven polymorphic variants of NOV17a have been identified and are shown in Table 28D.

5

Table 28D						
Variant No.	Nucleotides			Amino Acids		
	Base Position of SNP	Wild-type	Variant	Base Position of SNP	Wild-type	Variant
13377723	612	C	T	32	Ser	Leu
13377722	774	G	A	86	Ser	Asn
13377727	1875	A	T	453	Gln	Leu
13377716	8402	T	C	2629	Ser	Pro
13377717	8502	C	T	2662	Ser	Phe
13377718	8520	T	C	2668	Val	Ala
13377719	8676	T	C	2720	Ile	Thr
13377720	9006	T	C	2830	Val	Ala

13377724	10626	G	A	3370	Ser	Asn
13377725	10719	G	A	3401	Gly	Asp
13377721	15055	A	G	4846	Arg	Arg

**NOV19a SNP Data**

Three polymorphic variants of NOV19a have been identified and are shown in Table 28E.

Table 28E						
Variant No.	Nucleotides			Amino Acids		
	Base Position of SNP	Wild-type	Variant	Base Position of SNP	Wild-type	Variant
13377733	1458	C	T	399	Ala	Val
13377732	1987	T	C	0		
13377731	2121	T	C	0		

5

**NOV20a SNP Data**

Two polymorphic variants of NOV20a have been identified and are shown in Table 28F.

10

Table 28F						
Variant No.	Nucleotides			Amino Acids		
	Base Position of SNP	Wild-type	Variant	Base Position of SNP	Wild-type	Variant
13377737	436	A	G	99	Asn	Asp
13377736	591	T	C	150	Ala	Ala

**OTHER EMBODIMENTS**

- 5 Although particular embodiments have been disclosed herein in detail, this has been done by way of example for purposes of illustration only, and is not intended to be limiting with respect to the scope of the appended claims, which follow. In particular, it is contemplated by the inventors that various substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the
- 10 claims. The choice of nucleic acid starting material, clone of interest, or library type is believed to be a matter of routine for a person of ordinary skill in the art with knowledge of the embodiments described herein. The claims presented are representative of the inventions disclosed herein. Other, unclaimed inventions are also contemplated. Applicants reserve the right to pursue such inventions in later claims.

## CLAIMS

## We claim:

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
  - a) a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO:2 $n$ , wherein  $n$  is an integer between 1-46;
  - b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO:2 $n$ , wherein  $n$  is an integer between 1-46, wherein any amino acid in the mature form is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed;
  - c) the amino acid sequence selected from the group consisting of SEQ ID NO:2 $n$ , wherein  $n$  is an integer between 1-46;
  - d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO:2 $n$ , wherein  $n$  is an integer between 1-46, wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; and
  - e) a fragment of any of a) through d).
2. The polypeptide of claim 1 that is a naturally occurring allelic variant of the sequence selected from the group consisting of SEQ ID NO:2 $n$ , wherein  $n$  is an integer between 1-46.
3. The polypeptide of claim 2, wherein said allelic variant comprises an amino acid sequence that is the translation of a nucleic acid sequence differing by a single nucleotide from a nucleic acid sequence selected from the group consisting of SEQ ID NO:2 $n$ -1, wherein  $n$  is an integer between 1-46.
4. The polypeptide of claim 1 that is a variant polypeptide described therein, wherein any amino acid specified in the chosen sequence is changed to provide a conservative substitution.

5. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.
6. A kit comprising in one or more containers, the pharmaceutical composition of claim 5.
7. The use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a human disease, the disease selected from a pathology associated with the polypeptide of claim 1, wherein said therapeutic is the polypeptide of claim 1.
8. A method for determining the presence or amount of the polypeptide of claim 1 in a sample, the method comprising:
  - (a) providing said sample;
  - (b) introducing said sample to an antibody that binds immunospecifically to the polypeptide; and
  - (c) determining the presence or amount of antibody bound to said polypeptide, thereby determining the presence or amount of polypeptide in said sample.
9. A method for determining the presence of or predisposition to a disease associated with altered levels of the polypeptide of claim 1 in a first mammalian subject, the method comprising:
  - a) measuring the level of expression of the polypeptide in a sample from the first mammalian subject; and
  - b) comparing the amount of said polypeptide in the sample of step (a) to the amount of the polypeptide present in a control sample from a second mammalian subject known not to have, or not to be predisposed to, said disease,wherein an alteration in the expression level of the polypeptide in the first subject as compared to the control sample indicates the presence of or predisposition to said disease.



10. A method for modulating the activity of the polypeptide of claim 1, the method comprising introducing a cell sample expressing the polypeptide of said claim with an antibody that binds to said polypeptide in an amount sufficient to modulate the activity of the polypeptide.
11. The method of claim 10, wherein said subject is a human.
12. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of:
  - a) a mature form of the amino acid sequence of SEQ ID NO:2 $n$ , wherein  $n$  is an integer between 1-46;
  - b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO:2 $n$ , wherein  $n$  is an integer between 1-46, wherein any amino acid in the mature form of the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed;
  - c) the amino acid sequence selected from the group consisting of SEQ ID NO:2 $n$ , wherein  $n$  is an integer between 1-46;
  - d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO:2 $n$ , wherein  $n$  is an integer between 1-46, in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed;
  - e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:2 $n$ , wherein  $n$  is an integer between 1-46, or any variant of said polypeptide wherein any amino acid of the chosen sequence is changed to a different amino acid, provided that no more than 10% of the amino acid residues in the sequence are so changed; and
  - f) the complement of any of said nucleic acid molecules.
13. The nucleic acid molecule of claim 12, wherein the nucleic acid molecule comprises the nucleotide sequence of a naturally occurring allelic nucleic acid variant.

14. The nucleic acid molecule of claim 12 that encodes a variant polypeptide, wherein the variant polypeptide has the polypeptide sequence of a naturally occurring polypeptide variant.
15. The nucleic acid molecule of claim 12, wherein the nucleic acid molecule differs by a single nucleotide from a nucleic acid sequence selected from the group consisting of SEQ ID NO:2 $n$ -1, wherein  $n$  is an integer between 1-46.
16. The nucleic acid molecule of claim 12, wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of
  - a) the nucleotide sequence selected from the group consisting of SEQ ID NO:2 $n$ -1, wherein  $n$  is an integer between 1-46;
  - b) a nucleotide sequence wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO:2 $n$ -1, wherein  $n$  is an integer between 1-46, is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed;
  - c) a nucleic acid fragment of the sequence selected from the group consisting of SEQ ID NO:2 $n$ -1, wherein  $n$  is an integer between 1-46; and
  - d) a nucleic acid fragment wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO:2 $n$ -1, wherein  $n$  is an integer between 1-46, is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed.
17. The nucleic acid molecule of claim 12, wherein said nucleic acid molecule hybridizes under stringent conditions to the nucleotide sequence selected from the group consisting of SEQ ID NO:2 $n$ -1, wherein  $n$  is an integer between 1-46, or a complement of said nucleotide sequence.
18. The nucleic acid molecule of claim 12, wherein the nucleic acid molecule comprises a nucleotide sequence in which any nucleotide specified in the coding sequence of the chosen nucleotide sequence is changed from that selected from the group consisting

of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides in the chosen coding sequence are so changed, an isolated second polynucleotide that is a complement of the first polynucleotide, or a fragment of any of them.

19. A vector comprising the nucleic acid molecule of claim 12.
20. The vector of claim 19, further comprising a promoter operably linked to said nucleic acid molecule.
21. A cell comprising the vector of claim 20.
22. A method for determining the presence or amount of the nucleic acid molecule of claim 12 in a sample, the method comprising:
  - (a) providing said sample;
  - (b) introducing said sample to a probe that binds to said nucleic acid molecule;  
and
  - (c) determining the presence or amount of said probe bound to said nucleic acid molecule,  
thereby determining the presence or amount of the nucleic acid molecule in said sample.
23. The method of claim 22 wherein presence or amount of the nucleic acid molecule is used as a marker for cell or tissue type.
24. The method of claim 23 wherein the cell or tissue type is cancerous.
25. A method for determining the presence of or predisposition to a disease associated with altered levels of the nucleic acid molecule of claim 12 in a first mammalian subject, the method comprising:
  - a) measuring the amount of the nucleic acid in a sample from the first mammalian subject; and

- b) comparing the amount of said nucleic acid in the sample of step (a) to the amount of the nucleic acid present in a control sample from a second mammalian subject known not to have or not be predisposed to, the disease; wherein an alteration in the level of the nucleic acid in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.
26. An antibody that binds immunospecifically to the polypeptide of claim 1.
27. The antibody of claim 26, wherein said antibody is a monoclonal antibody.
28. The antibody of claim 26, wherein the antibody is a humanized antibody.
29. The antibody of claim 26, wherein the antibody is a fully human antibody
30. The antibody of claim 26, wherein the dissociation constant for the binding of the polypeptide to the antibody is less than  $1 \times 10^{-9}$  M.
31. The antibody of claim 26, wherein the antibody neutralizes an activity of the polypeptide.
32. A pharmaceutical composition comprising the antibody of claim 26 and a pharmaceutically acceptable carrier.
33. A kit comprising in one or more containers, the pharmaceutical composition of claim 29.
34. The use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a human disease, the disease selected from a pathology associated with the polypeptide of claim 1, wherein said therapeutic is a NOVX antibody.
35. A method of treating or preventing a NOVX-associated disorder, said method comprising administering to a subject in which such treatment or prevention is desired the antibody of claim 26 in an amount sufficient to treat or prevent said NOVX-associated disorder in said subject.

36. A method of treating a pathological state in a mammal, the method comprising administering to the mammal the antibody of claim 26 in an amount sufficient to alleviate the pathological state.
37. A method of treating or preventing a pathology associated with the polypeptide of claim 1, said method comprising administering to a subject in which such treatment or prevention is desired a NOVX antibody in an amount sufficient to treat or prevent said pathology in said subject.
38. The method of claim 37, wherein the subject is a human.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
17 October 2002 (17.10.2002)

PCT

(10) International Publication Number  
**WO 02/081625 A3**

(51) International Patent Classification <sup>7</sup> :	<b>A61K 38/16</b>	US	60/283,512 (CIP)
		Filed on	12 April 2001 (12.04.2001)
(21) International Application Number:	PCT/US02/10366	US	60/283,444 (CIP)
		Filed on	12 April 2001 (12.04.2001)
(22) International Filing Date:	3 April 2002 (03.04.2002)	US	60/283,657 (CIP)
		Filed on	13 April 2001 (13.04.2001)
(25) Filing Language:	English	US	60/283,710 (CIP)
		Filed on	13 April 2001 (13.04.2001)
(26) Publication Language:	English	US	60/283,678 (CIP)
		Filed on	13 April 2001 (13.04.2001)
(30) Priority Data:		US	60/284,234 (CIP)
60/281,086	3 April 2001 (03.04.2001)	US	60/284,234 (CIP)
60/281,906	5 April 2001 (05.04.2001)	Filed on	17 April 2001 (17.04.2001)
60/282,020	6 April 2001 (06.04.2001)	US	60/285,325 (CIP)
60/282,930	10 April 2001 (10.04.2001)	Filed on	19 April 2001 (19.04.2001)
60/283,512	12 April 2001 (12.04.2001)	US	60/285,381 (CIP)
60/283,444	12 April 2001 (12.04.2001)	Filed on	20 April 2001 (20.04.2001)
60/283,657	13 April 2001 (13.04.2001)	US	60/286,068 (CIP)
60/283,710	13 April 2001 (13.04.2001)	Filed on	24 April 2001 (24.04.2001)
60/283,678	13 April 2001 (13.04.2001)	US	60/286,292 (CIP)
60/284,234	17 April 2001 (17.04.2001)	Filed on	25 April 2001 (25.04.2001)
60/285,325	19 April 2001 (19.04.2001)	US	60/296,692 (CIP)
60/285,381	20 April 2001 (20.04.2001)	Filed on	7 June 2001 (07.06.2001)
60/286,068	24 April 2001 (24.04.2001)	US	60/300,883 (CIP)
60/286,292	25 April 2001 (25.04.2001)	Filed on	26 June 2001 (26.06.2001)
60/296,692	7 June 2001 (07.06.2001)	US	60/311,003 (CIP)
60/300,883	26 June 2001 (26.06.2001)	Filed on	8 August 2001 (08.08.2001)
60/311,003	8 August 2001 (08.08.2001)	US	60/311,973 (CIP)
60/311,973	13 August 2001 (13.08.2001)	Filed on	13 August 2001 (13.08.2001)
60/312,901	16 August 2001 (16.08.2001)	US	60/312,901 (CIP)
60/322,283	14 September 2001 (14.09.2001)	Filed on	16 August 2001 (16.08.2001)
60/327,448	5 October 2001 (05.10.2001)	US	60/322,283 (CIP)
60/345,734	31 December 2001 (31.12.2001)	Filed on	14 September 2001 (14.09.2001)
60/345,755	3 January 2002 (03.01.2002)	US	60/327,448 (CIP)
60/354,391	4 February 2002 (04.02.2002)	Filed on	5 October 2001 (05.10.2001)
10/114,153	2 April 2002 (02.04.2002)	US	60/345,755 (CIP)
		Filed on	3 January 2002 (03.01.2002)
(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:		US	60/354,391 (CIP)
US	60/281,086 (CIP)	Filed on	2 February 2002 (02.02.2002)
Filed on	3 April 2001 (03.04.2001)	US	Not furnished (CIP)
US	60/281,906 (CIP)	Filed on	31 December 2001 (31.12.2001)
Filed on	5 April 2001 (05.04.2001)	US	Not furnished (CIP)
US	60/282,020 (CIP)	Filed on	2 April 2002 (02.04.2002)
Filed on	6 April 2001 (06.04.2001)		
US	60/282,930 (CIP)		
Filed on	10 April 2001 (10.04.2001)		
(71) Applicant (for all designated States except US):	<b>CURA-GEN CORPORATION</b> [US/US]; 11th Floor, 555 Long Wharf Drive, New Haven, CT 06511 (US).		

[Continued on next page]

(54) Title: NOVEL ANTIBODIES THAT BIND TO ANTIGENIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING THE ANTIGENS, AND METHODS OF USE

(57) Abstract: Disclosed herein are nucleic acid sequences that encode polypeptides. Also disclosed are antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids, polypeptides, or antibodies, or fragments thereof.

WO 02/081625 A3



## (72) Inventors; and

(75) Inventors/Applicants (for US only): **PADIGARU, Murallidhara** [IN/US]; 71 Hampton Park, Branford, CT 06405 (US). **SHENOY, Suresh, G.** [IN/US]; 15 Millwood Drive, Branford, CT 06405 (US). **KEKUDA, Ramesh** [IN/US]; 1213 Avalon Valley Drive, Danbury, CT 06810 (US). **RASTELLI, Luca** [IT/US]; 52 Pepperbush Lane, Guilford, CT 06437 (US). **MEZES, Peter, S.** [CA/US]; 7 Clark's lane, Old Lyme, CT 06371 (US). **SMITHSON, Glennnda** [US/US]; 125 Michael Drive, Guilford, CT 06435 (US). **GUO, Xiaojia** [CN/US]; 713 Robert Frost Drive, Branford, CT 06405 (US). **GERLACH, Valerie** [US/US]; 18 Rock Pasture Road, Branford, CT 06405 (US). **CASMAN, Stacie, J.** [US/US]; 17 Peck Street, North Haven, CT 06473 (US). **BOLDOG, Ferenc, L.** [HU/US]; 1687 Hartford Turnpike, North Haven, CT 06473 (US). **LI, Li** [CN/US]; 56 Jerimoth Drive, Branford, CT 06405 (US). **ZERHUSEN, Bryan, D.** [US/US]; 337 Monticello Drive, Branford, CT 06405 (US). **TCHERNEV, Velizar, T.** [BG/US]; 45 Jefferson Road #3-12, Branford, CT 06405 (US). **GANGOLLI, Esha, A.** [IN/US]; 31 Strawberry Hill Road, Madison, CT 06443 (US). **VERNET, Corine, A., M.** [FR/US]; 1739 Foxon Road, Apartment L6, Branford, CT 06471 (US). **SPYTEK, Kimberly, A.** [US/US]; 28 Court Street, Number 1, New Haven, CT 06511 (US). **MALYANKAR, Uriel, M.** [IN/US]; 229 Branford Road, Number 330, Branford, CT 06405 (US). **PATTURAJAN, Meera** [IN/US]; 45 Harrison Avenue, Apartment 1C, Branford, CT 06405 (US). **MILLER, Charles, E.** [US/US]; 98 Saddle Hill Drive, Guilford, CT 06437 (US). **TAUPIER, Raymond, J., Jr.** [US/US]; 34 Pardee Place Extension, East Haven, CT 06512 (US). **HEYES, Melvyn, P.** [GB/US]; 183 Townsend Avenue, Number 3, New Haven, CT 06512 (US). **JU, Jingfang** [US/US]; 391 Roschud Lane, Orange, CT 06477 (US). **PEYMAN, John, A.** [US/US]; 336 West Rock Avenue, New Haven, CT 06515 (US). **CATTERTON, Elina** [FI/US]; 584 Boston Post Road, Madison, CT 06443 (US). **MACDOUGALL, John, R.** [CA/US]; 117 Russell Street, Hamden, CT 06517 (US). **EDINGER, Shlomit, R.** [US/US]; 766 Edgewood

Avenue, New Haven, CT 06515 (US). **STONE, David, J.** [US/US]; 223 Whitethorn Drive, Guilford, CT 06437 (US). **MAZUR, Ann** [US/US]; 35 Burr Road, Bloomfield, CT 06002 (US).

(74) Agent: **ELRIFI, Ivor, R.**; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).

(81) Designated States (national): AE, AG, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:  
22 May 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/10366

**A. CLASSIFICATION OF SUBJECT MATTER**IPC(7) : A61K 38/16  
US CL : 530/300; 514/02

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**Minimum documentation searched (classification system followed by classification symbols)  
U.S. : 530/300; 514/02

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Sequence Search**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database SwissProt 40. Assession Number P70549. Sequence of Sodium/Calcium exchanger precursor. 01 November 1997. See sequence alignment.	1-4
---		5-7
Y		

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

07 March 2003 (07.03.2003)

Date of mailing of the international search report

20 MAR 2003

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Michael Borin

Telephone No. (703) 308-0196



# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/10366

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:  
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-7

Remark on Protest

☐  
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

PCT/US02/10366

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

Group I, claims 1-6, drawn to polypeptides.

Group II, claim 7, drawn to method of use of polypeptide for manufacturing medicament.

Group III, claim 9, drawn to method of use of polypeptide for determining presence of disease.

Group IV, claims 12-18, drawn to nucleic acids, vectors, host cells, method of making recombinant cell using said nucleic acids.

Group V, claims 22-24, drawn to method of use of a probe to determine presence of a polynucleotide of Group IV.

Group VI, claim 25, drawn to method of use of polynucleotide for determining presence of a disease.

Group VII, claims 26-33, drawn to antibody.

Group VIII, claim 34, drawn to method of use of antibody for manufacturing medicament.

Group IX, claim 35, drawn to method of use of antibody for treating disorder.

Group X, claim 36, drawn to method of use of antibody for treating a pathological state.

Group XI, claims 37,38, drawn to method of use of antibody for preventing pathology.

method of use of antibody for determining presence of polypeptide of Group I.

method of use of antibody for modulating activity of polypeptide of Group I.

### *Sequence Election Requirement Applicable to All Groups*

In addition, each Group detailed above reads on distinct Groups drawn to multiple sequences which do not have common core structure (sequences ID Nos 2,4,6,8,...92 for polypeptides; sequences SEQ ID Nos. 1,3,5,7,9...91 for polynucleotides). Thus, each of the above group is further divided into 46 independent groups. The lack of unity is partially waived and the Applicants must further elect one sequence for examination in the elected Group detailed above. Payment of fees for an additional invention will entitle the Applicants to examination of four additional sequences.

The inventions listed as Groups I-X do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The inventions listed as Groups I, IV, VII are drawn to different products which lack the same or corresponding special technical features. Groups II, III are different methods of use of polypeptide of Group I. Groups V, VII are different methods of use of polynucleotide of Group IV. Groups VIII-XIII are different methods of use of antibodies of Group VII.

For the product elected, the first method of making/use will be examined together with the product.